(A) O
HEK293 O
cells O
were O
transfected O
with O
DAPKΔCaM B-proteingene
or O
with O
a O
control O
vector O
(pcDNA3-luciferase, O
LUC), O
together O
with O
shRNAs O
targeting O
beclin B-proteingene
1 I-proteingene
or O
HcRed, B-proteingene
and O
with O
GFP-LC3 B-proteingene
plasmid O
. O

After O
72 O
h, O
cells O
were O
counted O
and O
lysates O
were O
prepared O
. O

(A) O
The O
percentage O
of O
cells O
with O
punctate O
GFP-LC3 B-proteingene
fluorescence O
per O
total O
GFP-LC3-positive B-proteingene
cells O
was O
quantified O
. O

Data O
presented O
are O
the O
mean±s.d O
. O

from O
a O
triplicate O
of O
100 O
transfected O
cells O
. O

The O
asterisks O
denote O
a O
significance O
level O
of O
P=0.001 O
. O

(B) O
Western O
blot O
analysis O
was O
performed O
using O
the O
indicated O
antibodies O
. O

(C) O
Representative O
GFP-LC3 B-proteingene
staining O
of O
cells O
transfected O
with O
the O
control O
shRNA O
(HcRed) B-proteingene
together O
with O
pcDNA3‐luciferase O
or O
DAPKΔCaM. B-proteingene
CaM, B-proteingene
calmodulin; B-proteingene
DAPK, B-proteingene
death‐associated O
protein O
kinase; O
GFP, O
green O
fluorescent O
protein; O
HEK, O
human O
embryonic O
kidney; O
shRNA, O
short O
hairpin O
RNA O
. O

(A) O
Flag‐tagged B-proteingene
DAPK B-proteingene
(100 O
ng) O
was O
incubated O
with O
GST B-proteingene
(900 O
ng) O
or O
GST-beclin‐1 B-proteingene
(750 O
ng) O
in O
the O
presence O
of O
Ca2+, O
calmodulin B-proteingene
and O
[γ‐33P]ATP O
for O
30 O
min O
or O
60 O
min O
. O

Phosphorylated O
proteins O
were O
visualized O
by O
X‐ray O
film O
exposure, O
and O
GST/GST-beclin‐1 B-proteingene
levels O
were O
visualized O
by O
Ponceau O
S O
staining O
. O

The O
autophosphorylation O
of O
DAPK B-proteingene
indicates O
that O
its O
catalytic O
activity O
was O
intact O
in O
all O
samples O
. O

(B) O
Flag‐tagged B-proteingene
DAPK B-proteingene
(60 O
ng) O
was O
incubated O
with O
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
(250 O
ng), O
which O
was O
purified O
from O
HEK293T O
cells, O
and O
a O
kinase O
assay O
was O
performed O
for O
60 O
min O
. O

Where O
indicated O
(+LiCl), O
beclin‐1‐bound B-proteingene
beads O
were O
first O
washed O
stringently O
in O
0.5 O
M O
LiCl O
and O
0.5 O
M O
KCl O
. O

Phosphorylated O
proteins O
were O
visualized O
by O
X‐ray O
film O
exposure, O
and O
the O
levels O
of O
beclin B-proteingene
1 I-proteingene
were O
visualized O
by O
Western O
blot O
analysis O
using O
beclin B-proteingene
1 I-proteingene
antibodies O
. O

DAPK, B-proteingene
death‐associated O
protein O
kinase; O
GST, O
glutathione O
S‐transferase; O
HEK, O
human O
embryonic O
kidney O
. O

(Aa) O
Protein O
extracts O
from O
COS7 O
cells, O
HEK293T O
cells, O
or O
no O
extracts O
were O
added O
to O
bacterially O
produced O
GST B-proteingene
or O
GST-beclin‐1 B-proteingene
. O

The O
pulled‐down O
proteins, O
as O
well O
as O
the O
total O
cell O
extracts, O
were O
blotted O
with O
the O
indicated O
antibodies O
. O

(Ab) O
Ponceau O
S O
staining O
of O
GST B-proteingene
and O
GST-beclin‐1 B-proteingene
to O
which O
the O
extracts O
were O
added O
. O

(B) O
HEK293 O
cells O
were O
co‐transfected O
with O
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
or O
with O
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
lacking O
the O
Bcl‐2‐binding B-proteingene
domain O
(ΔBD) O
together O
with O
Bcl‐XL B-proteingene
and O
HA‐tagged B-proteingene
DAPK. B-proteingene
Beclin B-proteingene
1 I-proteingene
was O
immunoprecipitated O
using O
Flag B-proteingene
antibodies, O
and O
the O
co‐immunoprecipitated O
proteins, O
as O
well O
as O
the O
total O
cell O
extracts, O
were O
blotted O
with O
DAPK, B-proteingene
Bcl‐XL B-proteingene
and O
beclin B-proteingene
1 I-proteingene
antibodies O
. O

(C) O
HEK293 O
cells O
were O
transfected O
with O
Flag-beclin‐1 B-proteingene
or O
Flag-GFP, B-proteingene
and O
the O
Flag‐tagged B-proteingene
proteins O
were O
immunoprecipitated O
using O
Flag B-proteingene
antibodies, O
and O
eluted O
with O
an O
excess O
of O
Flag B-proteingene
peptides O
. O

The O
blot O
was O
reacted O
with O
DAPK B-proteingene
antibodies O
or O
with O
Flag B-proteingene
antibodies O
at O
different O
time O
exposures O

(A) O
A O
bacterially O
purified O
catalytic O
domain O
of O
DAPK B-proteingene
was O
incubated O
for O
15 O
min O
at O
30°C O
with O
increasing O
concentrations O
(5-10 O
nmol) O
of O
a O
peptide O
corresponding O
to O
the O
BH3 O
domain O
of O
beclin B-proteingene
1 I-proteingene
(aa O
108-127) O
and O
with O
the O
same O
peptide O
in O
which O
Thr O
119 O
was O
substituted O
by O
alanine O
. O

An O
in O
vitro O
kinase O
assay O
was O
performed, O
and O
the O
reactions O
were O
applied O
to O
Whatman O
filters O
. O

Total O
levels O
of O
TCA‐insoluble O
counts O
were O
measured O
and O
plotted O
against O
substrate O
concentration O
. O

Data O
are O
the O
mean±s.d O
. O

of O
three O
experiments O
. O

(C) O
Flag‐tagged B-proteingene
DAPK B-proteingene
(60 O
ng) O
was O
incubated O
with O
GST-WT B-proteingene
beclin B-proteingene
1 I-proteingene
or O
with O
GST-T119A B-proteingene
beclin B-proteingene
1 I-proteingene
(1000 O
ng) O
in O
the O
presence O
of O
Ca2+, O
calmodulin B-proteingene
and O
ATP O
for O
30 O
min O
. O

GST‐beclin B-proteingene
1 I-proteingene
levels O
were O
visualized O
by O
Ponceau O
S O
staining, O
and O
phosphorylation O
on O
Thr O
119 O
was O
detected O
by O
a O
phosphoThr O
119 O
antibody O
(Western O
blot) O
. O

(D) O
HEK293 O
cells O
were O
co‐transfected O
with O
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
with O
or O
without O
ΔCaMDAPK. B-proteingene
After O
24 O
h, O
beclin B-proteingene
1 I-proteingene
was O
immunoprecipitated O
from O
cells, O
using O
Flag B-proteingene
antibodies, O
and O
the O
immunoprecipitates O
were O
reacted O
with O
phosphoThr O
119 O
antibodies O
. O

The O
Ponceau O
staining O
shows O
equal O
amounts O
of O
immunoprecipitatedbeclin B-proteingene
1 I-proteingene
. O

The O
cell O
extract O
blots O
were O
reacted O
with O
haemagglutinin O
antibodies O
or O
with O
beclin B-proteingene
1 I-proteingene
antibodies O
. O

CaM, B-proteingene
calmodulin; O
DAPK, O
death‐associated O
protein O
kinase; O
GST, B-proteingene
glutathione O
S‐transferase; O
HEK, O
human O
embryonic O
kidney; O
TCA, O
trichloro‐acetic O
acid O
. O

(A) O
HEK293 O
cells O
were O
transfected O
with O
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
and O
Bcl‐XL B-proteingene
with O
or O
without O
haemagglutinin‐tagged B-proteingene
DAPK. B-proteingene
Beclin B-proteingene
1 I-proteingene
was O
immunoprecipitated O
using O
Flag B-proteingene
antibodies, O
and O
the O
co‐immunoprecipitated O
proteins, O
as O
well O
as O
the O
total O
cell O
extracts, O
were O
blotted O
using O
the O
indicated O
antibodies O
. O

(B) O
HEK293 O
cells O
were O
co‐transfected O
with O
Flag‐tagged B-proteingene
T119A O
or O
T119Ebeclin B-proteingene
1 I-proteingene
mutants O
and O
Bcl‐XL. B-proteingene
Beclin B-proteingene
1 I-proteingene
was O
immunoprecipitated O
using O
Flag B-proteingene
antibodies, O
and O
the O
co‐immunoprecipitated O
proteins, O
as O
well O
as O
the O
total O
cell O
extracts, O
were O
blotted O
using O
the O
indicated O
antibodies O
. O

(C) O
HEK293 O
cells O
were O
transfected O
with O
5 O
or O
10 O
μg O
T119A O
or O
T119E O
beclin B-proteingene
1 I-proteingene
mutants O
together O
with O
GFP-LC3 B-proteingene
plasmid O
. O

After O
24 O
h, O
cells O
were O
counted O
and O
lysates O
were O
prepared O
. O

(a) O
Representative O
GFP-LC3 B-proteingene
staining O
. O

(b) O
The O
percentage O
of O
cells O
with O
punctate O
GFP-LC3 B-proteingene
fluorescence O
per O
total O
GFP-LC3‐positive B-proteingene
cells O
was O
quantified O
. O

Data O
presented O
are O
the O
mean±s.d O
. O

from O
a O
triplicate O
experiment O
with O
100 O
transfected O
cells O
. O

The O
asterisks O
denote O
significance O
level: O
*P=0.01; O
**P=0.005 O
. O

(c) O
Western O
blot O
analysis O
was O
performed O
using O
the O
indicated O
antibodies O
. O

(D) O
HEK293 O
cells O
were O
transfected O
with O
Bcl‐XL, B-proteingene
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
(WT) O
or O
Flag‐tagged B-proteingene
T119A O
beclin B-proteingene
1 I-proteingene
mutant O
with O
or O
without O
haemagglutinin‐tagged B-proteingene
activated O
DAPK B-proteingene
(ΔCaM) B-proteingene
. O

Beclin B-proteingene
1 I-proteingene
was O
immunoprecipitated O
using O
Flag B-proteingene
antibodies, O
and O
the O
co‐immunoprecipitated O
proteins, O
as O
well O
as O
the O
total O
cell O
extracts, O
were O
blotted O
using O
the O
indicated O
antibodies O
. O

Levels O
of O
Bcl‐XL B-proteingene
were O
quantified O
using O
NIH O
image O
software, O
and O
the O
ratio O
between O
immunoprecipitated O
and O
expressed O
Bcl‐XL B-proteingene
was O
calculated O
. O

(E) O
Transmission O
electron O
micrographs O
of O
HEK293 O
cells24 O
h O
after O
they O
were O
transfected O
with O
Bcl‐XL, B-proteingene
Flag‐tagged B-proteingene
beclin B-proteingene
1 I-proteingene
and O
ΔCaM B-proteingene
or O
pcDNA3‐luciferase O
as O
a O
control O
. O

The O
images O
in O
(c) O
and O
(d) O
were O
taken O
at O
higher O
magnifications O
of O
the O
ΔCaM B-proteingene
treatment O
(see O
the O
scale O
bars) O
. O

'AV' O
indicates O
autophagic O
vacuoles O
. O

CaM, B-proteingene
calmodulin; B-proteingene
DAPK, B-proteingene
death‐associated O
protein O
kinase; O
GFP, O
green O
fluorescent O
protein; O
GST, O
glutathione O
S‐transferase; O
HEK, O
human O
embryonic O
kidney; O
NIH, O
National O
Institutes O
of O
Health O
. O

(a) O
Knockdown O
of O
dRagA B-proteingene
and O
dRagC B-proteingene
decreased O
dS6K B-proteingene
phosphorylation O
(Thr O
398) O
. O

Drosophila O
S2 O
cells O
untreated O
(lane O
2) O
or O
treated O
with O
the O
indicated O
RNAi O
were O
starved O
of O
amino O
acids O
for O
1 O
h O
followed O
by O
amino O
acid O
stimulation O
for O
30 O
min O
Phosphorylation O
and O
protein O
levels O
of O
dS6K B-proteingene
were O
determined O
by O
immunoblotting O
with O
the O
indicated O
antibodies O
. O

(b) O
dRagA B-proteingene
and O
dRagC B-proteingene
are O
not O
required O
for O
dAkt B-proteingene
phosphorylation O
. O

Drosophila O
S2 O
cells O
untreated O
(lanes O
1-3) O
or O
treated O
with O
the O
indicated O
RNAi O
were O
starved O
of O
amino O
acids O
for O
1 O
h O
and O
stimulated O
with O
amino O
acids O
for O
30 O
min O
. O

Phosphorylation O
and O
protein O
levels O
of O
dAkt B-proteingene
were O
determined O
by O
immunoblotting O
with O
appropriate O
antibodies O
as O
indicated O
. O

NC, O
negative O
control O
RNAi O
. O

(c) O
dRagA B-proteingene
and O
dRagC B-proteingene
function O
in O
parallel O
with O
TSC2 B-proteingene
and O
PTEN. B-proteingene
dRagA B-proteingene
and/or O
dRagC B-proteingene
RNAi O
was O
added O
to O
S2 O
cells O
in O
combination O
with O
dTSC2 B-proteingene
or O
dPTEN B-proteingene
RNAi, O
as O
indicated O
. O

dTSC2 B-proteingene
or O
dPTEN B-proteingene
RNAi O
treatment O
increased O
pdS6K B-proteingene
(Thr O
398) O
and O
this O
increase O
was O
compromised O
by O
dRagA B-proteingene
or/and O
dRagC B-proteingene
RNAi O
. O

Full O
scans O
of O
blots O
are O
provided O
in O
Supplementary O
Information, O
Fig O
. O

S6 O
. O

(a) O
Constitutively O
active O
RagA B-proteingene
and O
RagB B-proteingene
stimulate O
S6K B-proteingene
phosphorylation O
. O

200 O
ng O
of O
each O
mammalian O
RagA, B-proteingene
RagB, B-proteingene
RagC B-proteingene
or O
RagD B-proteingene
construct O
was O
co-transfected O
with O
HA-S6K B-proteingene
(20 O
ng) O
into O
HEK293 O
cells O
. O

Their O
corresponding O
dominant-negative O
mutants O
(RagAT21N, B-proteingene
RagBT54N, B-proteingene
RagCS75N, B-proteingene
RagDS76N) B-proteingene
and O
constitutively O
active O
mutants O
(RagAQ66L, O
RagBQ99L, B-proteingene
RagCQ120L, O
RagDQ121L) O
were O
also O
tested O
. O

Phosphorylation O
and O
protein O
levels O
were O
determined O
by O
immunoblotting O
with O
the O
appropriate O
antibodies, O
as O
indicated O
. O

(b) O
RagA B-proteingene
has O
a O
dominant O
role O
over O
RagC B-proteingene
in O
regulating O
S6K B-proteingene
phosphorylation O
. O

Each O
Rag O
construct O
(200 O
ng) O
indicated O
was O
co-transfected O
with O
HA-S6K B-proteingene
(20 O
ng) O
. O

The O
different O
Rag O
mutants O
used O
in O
the O
transfection O
are O
indicated O
at O
the O
top O
of O
each O
lane O
. O

(c) O
Rag O
regulates O
TORC1 O
but O
not O
TORC2 O
activity O
. O

Each O
indicated O
Rag O
construct O
(200 O
ng) O
was O
co-transfected O
with O
either O
HA-S6K B-proteingene
(20 O
ng), O
Myc-4EBP1 B-proteingene
(20 O
ng) O
or O
of O
GST-Akt B-proteingene
(100 O
ng) O
. O

Phosphorylation O
and O
protein O
levels O
were O
determined O
by O
immunoblotting O
with O
the O
appropriate O
antibodies, O
as O
indicated O
. O

Full O
scans O
of O
blots O
are O
provided O
in O
Supplementary O
Information, O
Fig O
. O

S6 O
. O

(a) O
RagAQ66L B-proteingene
and O
RagCS75N B-proteingene
activate O
TORC1 O
in O
the O
absence O
of O
amino O
acids O
. O

Each O
Rag O
construct O
(200 O
ng) O
indicated O
was O
co-transfected O
with O
HA-S6K B-proteingene
(20 O
ng) O
into O
HEK293 O
cells O
. O

Cells O
were O
starved O
of O
amino O
acids O
for O
1 O
h O
before O
collection O
. O

Phosphorylation O
and O
protein O
levels O
were O
determined O
by O
immunoblotting O
with O
the O
appropriate O
antibodies, O
as O
indicated O
. O

(b) O
RagAT21N B-proteingene
and O
RagCQ120L B-proteingene
block O
S6K B-proteingene
phosphorylation O
in O
response O
to O
amino O
acid O
(AA) O
stimulation O
. O

pcDNA3 O
(200 O
ng, O
lanes O
1 O
and O
2) O
or O
each O
indicated O
Rag O
construct O
was O
co-transfected O
with O
HA-S6K B-proteingene
into O
HEK293 O
cells O
. O

Cells O
were O
starved O
of O
amino O
acids O
for O
1 O
h O
(-AA) O
and O
either O
remained O
in O
the O
starvation O
medium O
or O
were O
stimulated O
with O
amino-acid-containing-medium O
(+AA) O
for O
30 O
min O
before O
collection O
. O

Phosphorylation O
and O
protein O
levels O
were O
determined O
by O
immunoblotting O
with O
the O
appropriate O
antibodies, O
as O
indicated O
. O

(c) O
RagAT21N B-proteingene
and O
RagCQ120L B-proteingene
suppress O
insulin-induced O
stimulation O
of O
S6K B-proteingene
phosphorylation O
. O

pcDNA3 O
(200 O
ng, O
lanes O
1 O
and O
2) O
or O
each O
indicated O
Rag O
construct O
was O
co-transfected O
with O
HA-S6K B-proteingene
(20 O
ng) O
or O
GST-Akt B-proteingene
(100 O
ng) O
into O
HeLa O
cells O
. O

Cells O
were O
serum-starved O
overnight O
and O
stimulated O
with O
insulin O
(400 O
nM) O
for O
30 O
min O
. O

Phosphorylation O
and O
protein O
levels O
were O
determined O
by O
immunoblotting O
with O
the O
appropriate O
antibodies, O
as O
indicated O
. O

Full O
scans O
of O
blots O
are O
provided O
in O
Supplementary O
Information, O
Fig O
. O

S6 O
. O

(a) O
dRagA B-proteingene
positively O
regulates O
wing O
compartment O
size O
. O

Wild-type O
or O
mutant O
dRagA B-proteingene
transgenes O
were O
expressed O
in O
posterior O
compartments O
with O
the O
en-GAL4 B-proteingene
driver O
. O

The O
ratios O
of O
representative O
posterior O
to O
anterior O
compartment O
areas O
are O
shown O
. O

Posterior O
compartment O
area O
was O
significantly O
increased O
in O
response O
to O
dRagAQ61L B-proteingene
expression O
and O
decreased O
in O
response O
to O
dRagAT61N B-proteingene
expression O
. O

Data O
are O
mean O
± O
s.d., O
*P O
= O
7.32 O
× O
10−4 O
(n O
= O
7), O
**P O
= O
6.18 O
× O
10−4 O
(n O
= O
12), O
Student O
's O
two-tailed O
t-test, O
(n O
is O
the O
number O
of O
adult O
wings O
analysed) O
. O

(b) O
dRagA B-proteingene
positively O
regulates O
wing O
cell O
size O
. O

The O
average O
area O
of O
posterior O
compartment O
cells O
from O
en-GAL4 B-proteingene
UAS-dRagA B-proteingene
adult O
wings O
is O
shown O
. O

Cells O
expressing O
dRagAQ61L B-proteingene
are O
significantly O
larger O
and O
dRagAT61N-expressing B-proteingene
cells O
are O
smaller O
than O
controls O
. O

Data O
are O
mean O
± O
s.d., O
*P O
= O
1.15 O
× O
10−3 O
(n O
= O
7), O
**P O
= O
0.025 O
(n O
= O
12), O
Student O
's O
2-tailed O
t-test O
(n O
represents O
number O
of O
adult O
wings O
analysed) O
. O

(c, O
d) O
dRag O
GTPases O
positively O
regulate O
larval O
fat O
body O
cell O
size O
. O

(c) O
Cell O
area O
of O
clonally-induced O
dRagA-expressing B-proteingene
cells O
or O
dRagC B-proteingene
homozygous O
mutant O
cells O
relative O
to O
neighbouring O
wild-type O
control O
cells O
is O
shown O
. O

Cell O
area O
was O
determined O
from O
phalloidin-stained O
fixed O
fat O
body O
samples O
from O
fed O
or O
48 O
h O
starved O
larvae O
. O

Expression O
of O
dRagAWT B-proteingene
or O
dRagAQ61L B-proteingene
significantly O
increased O
relative O
cell O
area O
under O
starvation O
but O
not O
fed O
conditions O
. O

Cells O
expressing O
dRagAT61N B-proteingene
and O
dRagC B-proteingene
loss-of-function O
cells O
were O
significantly O
smaller O
than O
control O
cells O
only O
under O
nutrient O
replete O
conditions O
. O

Data O
are O
means O
± O
s.d., O
*P O
= O
2.04 O
× O
10−3 O
(n O
= O
5), O
**P O
= O
2.94 O
× O
10−6 O
(n O
= O
14), O
***P O
= O
3.79 O
× O
10−7 O
(n O
= O
14), O
****P O
= O
1.36 O
× O
10−5 O
(n O
= O
30), O
Student O
's O
two-tailed O
t-test O
. O

(d) O
Representative O
examples O
of O
fat O
body O
cells O
with O
altered O
dRagA B-proteingene
activity O
. O

Cells O
expressing O
dRagA B-proteingene
transgenes O
are O
marked O
by O
the O
expression O
of O
GFP B-proteingene
in O
the O
left O
and O
middle O
panels, O
and O
dRagC B-proteingene
homozygous O
mutant O
cells O
are O
marked O
by O
absence O
of O
GFP B-proteingene
in O
the O
right O
panel O
. O

Scale O
bar O
represents O
50 O
μm O
. O

(a) O
Rag O
acts O
through O
TORC1 O
to O
regulate O
S6K B-proteingene
phosphorylation O
. O

HEK293 O
cells O
were O
transfected O
with O
constructs O
as O
indicated O
. O

Co-expression O
of O
of O
mTORKD B-proteingene
construct O
(600 O
ng) O
or O
rapamycin O
treatment O
(rapa, O
20 O
nM, O
30 O
min) O
abolished O
the O
effect O
of O
RagAQ66L B-proteingene
and O
RagCS75N B-proteingene
on O
S6K B-proteingene
phosphorylation O
. O

The O
protein O
level O
of O
mTORKD B-proteingene
was O
determined O
by O
immunoblotting O
with O
anti-mTOR B-proteingene
antibody O
. O

(b) O
RagA/RagC B-proteingene
and O
TSC1/TSC2 B-proteingene
independently O
regulate O
S6K B-proteingene
phosphorylation O
. O

HEK293 O
cells O
were O
transfected O
with O
200 O
ng O
of O
each O
Rag O
and/or O
′ O
constructs O
as O
indicated O
. O

Amino O
acid O
starvation O
for O
1 O
h O
(-AA) O
is O
indicated O
. O

Phosphorylation O
and O
protein O
levels O
of O
the O
transfected O
proteins O
were O
determined O
by O
immunoblotting O
with O
appropriate O
antibodies, O
as O
indicated O
. O

(c) O
TSC2 B-proteingene
and O
RagA/B B-proteingene
independently O
affect O
S6K B-proteingene
phosphorylation O
. O

HA-S6K B-proteingene
(20 O
ng) O
was O
transfected O
into O
HeLa O
cells O
with O
or O
without O
RNAi O
against O
human O
TSC2, B-proteingene
RagA B-proteingene
and O
RagB B-proteingene
as O
indicated O
. O

(d) O
RagAT21N B-proteingene
and O
RagCQ120L B-proteingene
do O
not O
block O
Rheb-induced B-proteingene
S6K B-proteingene
phosphorylation O
. O

RagAT21N B-proteingene
and O
RagCQ120L B-proteingene
(200 O
ng O
each) O
were O
transfected O
into O
HEK293 O
cells O
with O
or O
without O
Rheb B-proteingene
construct O
(20 O
ng) O
. O

S6K B-proteingene
was O
included O
in O
the O
co-transfection O
. O

Phosphorylation O
and O
protein O
levels O
of O
the O
transfected O
proteins O
were O
determined O
by O
immunoblotting O
with O
appropriate O
antibodies, O
as O
indicated O
. O

Full O
scans O
of O
blots O
are O
provided O
in O
Supplementary O
Information, O
Fig O
. O

S6 O
. O

(a, O
b) O
dRagC B-proteingene
is O
not O
required O
for O
Rheb-induced B-proteingene
cell O
growth O
. O

(a) O
The O
area O
of O
Rheb-overexpressing B-proteingene
cells O
in O
control O
or O
dRagC B-proteingene
mutant O
(dRagC−/−) B-proteingene
backgrounds O
under O
fed O
conditions, O
relative O
to O
that O
of O
neighbouring O
control O
cells O
which O
were O
assigned O
a O
value O
of O
1 O
. O

Overexpression O
of O
Rheb B-proteingene
led O
to O
a O
significant O
increase O
in O
cell O
area O
in O
both O
control O
and O
dRagC B-proteingene
mutant O
backgrounds O
. O

Data O
are O
mean O
± O
s.d., O
*P O
= O
0.034 O
(n O
= O
5), O
**P O
= O
6.1 O
× O
10−3 O
(n O
= O
5), O
Student O
's O
two-tailed O
t-test O
(n O
represents O
number O
of O
experimental O
samples) O
. O

(b) O
A O
representative O
example O
of O
a O
clone O
of O
Rheb-overexpressing B-proteingene
cells O
in O
a O
dRagC−/− B-proteingene
animal O
. O

Rheb B-proteingene
transgene-expressing O
cells O
are O
marked O
by O
co-expression O
of O
GFP. B-proteingene
Cell O
boundaries O
are O
labelled O
by O
phalloidin O
staining O
in O
red; O
nuclei O
are O
labelled O
by O
DAPI O
in O
blue O
. O

Scale O
bar O
represents O
50 O
μm O
. O

(c, O
d) O
Expression O
of O
dRagAQ61L B-proteingene
fails O
to O
rescue O
the O
growth O
impairment O
of O
Rheb B-proteingene
mutant O
cells O
. O

(c) O
Relative O
area O
of O
clonally-induced O
Rheb26.2 O
homozygous O
mutant O
cells O
in O
a O
control O
background O
and O
in O
animals O
expressing O
dRagAQ61L B-proteingene
throughout O
the O
fat O
body O
. O

Clonally O
induced O
Rheb26.2 B-proteingene
homozygous O
mutant O
cells O
were O
significantly O
smaller O
than O
neighbouring O
control O
cells O
both O
in O
wild-type O
and O
in O
dRagAQ61L O
expressing O
backgrounds O
. O

Data O
are O
mean O
±s.d., O
*P O
= O
2.91 O
× O
10−4 O
(n O
= O
7), O
**P O
= O
2.59 O
× O
10−8 O
(n O
= O
5), O
Student O
's O
two-tailed O
t-test O
(fed O
conditions O
where O
n O
represents O
number O
of O
experimental O
samples) O
. O

(d) O
A O
representative O
example O
of O
Rheb B-proteingene
homozygous O
mutant O
cells O
(marked O
by O
lack O
of O
GFP, B-proteingene
arrows) O
in O
fat O
body O
ubiquitously O
expressing O
UAS-dRagAQ61L. O
GFP-positive B-proteingene
control O
cells O
in O
this O
experiment O
are O
a O
mixture O
of O
Rheb+/− B-proteingene
and O
Rheb+/+ B-proteingene
. O

Scale O
bar O
represents O
50 O
μm O
. O

(a-d) O
dRagAQ61L B-proteingene
suppresses O
autophagy O
. O

(a) O
Drosophila O
fat O
body O
cells O
clonally O
expressing O
dRagAQ61L B-proteingene
(marked O
in O
green O
by O
GFP B-proteingene
expression) O
failed O
to O
accumulate O
autolysosomes O
(shown O
in O
surrounding O
control O
cells O
by O
punctate O
Lysotracker O
Red O
staining) O
in O
response O
to O
starvation O
for O
4 O
h. O
Nuclei O
are O
marked O
in O
blue O
by O
DAPI O
. O

(b-d) O
Induction O
of O
autophagosomes O
in O
response O
to O
4-h O
starvation O
is O
shown O
by O
the O
punctate O
pattern O
of O
GFP-Atg8a B-proteingene
expression O
in O
control O
fat O
body O
cells O
(b), O
but O
not O
in O
cells O
expressing O
dRagAQ61L O
(c) O
. O

The O
average O
number O
of O
GFP-Atg8a-marked B-proteingene
autophagosomes O
per O
cell O
in O
control O
and O
dRagAQ61L-expressing B-proteingene
clones O
is O
shown O
(d) O
. O

Data O
are O
mean O
± O
s.d., O
*P O
= O
2.91 O
× O
10−6, O
Students O
two-tailed O
t-test O
(n O
= O
33 O
fat O
body O
samples O
imaged O
per O
genotype) O
. O

Scale O
bars O
represent O
25 O
μm O
in O
each O
panel O
. O

(e) O
RagA B-proteingene
regulates O
LC3 B-proteingene
conversion O
in O
mammalian O
cells O
. O

Myc-LC3 B-proteingene
was O
co-transfected O
with O
RagAQL B-proteingene
and O
RagCSN B-proteingene
or O
RagATN B-proteingene
and O
RagCQL B-proteingene
into O
HEK293 O
cells O
as O
indicated O
. O

One O
day O
after O
transfection, O
cells O
were O
cultured O
in O
amino-acid-sufficienct O
medium O
(+AA) O
or O
amino-acid-depleted O
medium O
(−AA) O
for O
4 O
h O
before O
collection O
. O

Western O
blotting O
for O
Myc-LC3 B-proteingene
and O
HA-Rag B-proteingene
were O
performed O
. O

Autophagic O
conversion O
of O
LC3I O
into O
the O
lipidated O
LC3II O
form O
was O
blocked O
by O
active O
RagA B-proteingene
and O
stimulated O
by O
dominant-negative O
RagA. B-proteingene
Full O
scans O
of O
blots O
are O
provided O
in O
Supplementary O
Information, O
Fig O
. O

S6 O
. O

(a, O
b) O
dRagA B-proteingene
activation O
increases O
sensitivity O
to O
starvation O
. O

Expression O
of O
dRagAQ61L B-proteingene
using O
the O
fat-body-specific O
Cg-GAL4 B-proteingene
driver O
significantly O
decreased O
survival O
of O
adult O
female O
flies O
under O
starvation O
(b) O
but O
not O
fed O
(a) O
conditions, O
relative O
to O
controls O
(Cg-GAL4 B-proteingene
alone) O
. O

Asterisks O
indicate O
significant O
difference, O
compared O
with O
controls O
. O

Data O
are O
mean O
± O
s.d., O
*P O
0.05, O
Students O
two-tailed O
t-test O
(n O
= O
150 O
flies/genotype/treatment) O
. O

(A) O
Wild‐type O
and O
rho0 B-proteingene
cells O
harbouring O
prATG8‐GFP‐ATG8 B-proteingene
(upper O
panels) O
or O
prATG8‐GFP B-proteingene
(lower O
panels) O
were O
exposed O
to O
amino‐acid O
or O
nitrogen O
starvation O
(‐N) O
medium O
supplemented O
with O
indicated O
carbon O
sources O
. O

Cells O
were O
analysed O
at O
indicated O
time O
points O
by O
whole O
cell O
extraction O
and O
western O
blot O
analysis O
using O
α‐GFP B-proteingene
and O
α‐Cdc11 B-proteingene
antibodies O
. O

Quantification O
of O
ATG8 B-proteingene
induction O
is O
shown O
in O
the O
lower O
left O
panel O
. O

Total O
GFP B-proteingene
signals O
(GFP‐Atg8 B-proteingene
and O
free O
GFP) B-proteingene
were O
quantified O
and O
normalized O
to O
Cdc11 B-proteingene
signals O
. O

Normalized O
values O
at O
0 O
h O
were O
set O
as O
one O
and O
relative O
changes O
are O
shown O
after O
6 O
h O
starvation O
. O

Quantification O
of O
autophagic O
flux O
is O
shown O
in O
the O
lower O
right O
panel O
as O
ratio O
of O
free O
GFP B-proteingene
to O
total O
GFP B-proteingene
signals O
(GFP‐Atg8 B-proteingene
and O
free O
GFP) B-proteingene
after O
6 O
h O
starvation O
. O

The O
means O
and O
s.d O
. O

of O
four O
(n=4) O
independent O
experiments O
are O
indicated O
. O

(B) O
Fluorescence O
microscopical O
analysis O
. O

Wild‐type, O
rho0, B-proteingene
and O
Δatg7 B-proteingene
cells O
expressing O
prATG8‐GFP‐ATG8 B-proteingene
were O
grown O
as O
described O
in O
(A) O
and O
exposed O
to O
amino‐acid O
(left O
panel, O
galactose) O
or O
nitrogen O
starvation O
(right O
panel, O
glucose O
(‐N)) O
for O
6 O
h. O
Vacuoles O
were O
visualized O
by O
over O
night O
FM4‐64 O
(1 O
μM) O
staining O
(red) O
. O

Arrowhead O
indicates O
a O
punctate O
GFP‐Atg8 B-proteingene
structure O
. O

Transmission O
and O
fluorescence O
light O
microscopy O
images O
were O
superimposed O
to O
visualize O
cellular O
boundaries O
. O

Cellular O
localization O
of O
GFP B-proteingene
signal O
was O
analysed O
in O
at O
least O
150 O
cells O
(n⩾150) O
for O
each O
strain O
and O
condition O
. O

Scale O
bars O
represent O
1.5 O
μm O
. O

Autophagic O
response O
in O
cells O
with O
compromised O
respiratory O
chain O
complex O
III, O
IV, O
or O
V O
activity O
during O
amino‐acid O
starvation O
. O

Wild‐type, O
rho0, B-proteingene
atg7 B-proteingene
cells O
and O
mutants O
that O
are O
selectively O
inhibited O
in O
the O
biogenesis O
of O
respiratory O
chain O
complex O
III O
(CIII: O
cbs1), B-proteingene
complex O
IV O
(CIV: O
mss51, B-proteingene
pet111, B-proteingene
pet122), B-proteingene
or O
the O
F1Fo‐ATP O
synthase O
(complex O
V; O
CV: O
atp10) B-proteingene
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
acetate O
(A) O
or O
galactose O
(B) O
. O

When O
indicated, O
wild‐type O
cells O
were O
exposed O
to O
antimycin O
A O
(AA) O
or O
oligomycin O
(O) O
during O
the O
amino‐acid O
starvation O
period O
. O

All O
strains O
expressed O
prATG8‐GFP‐ATG8 B-proteingene
(upper O
panels) O
or O
prATG8‐GFP B-proteingene
(lower O
panels) O
. O

Samples O
were O
analysed O
as O
described O
in O
Figure O
1A. O
The O
means O
and O
s.d O
. O

of O
five O
(n=5) O
independent O
experiments O
are O
indicated O
. O

(A, O
B) O
Wild‐type, O
rho0, B-proteingene
and O
Δatg7 B-proteingene
cells O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
acetate O
(A) O
or O
galactose O
(B) O
. O

When O
indicated, O
wild‐type O
cells O
were O
exposed O
to O
antimycin O
A O
(AA) O
or O
oligomycin O
(O) O
during O
the O
amino‐acid O
starvation O
period O
. O

ATP O
and O
protein O
from O
total O
cells O
(upper O
panels) O
or O
isolated O
mitochondria O
(lower O
panels) O
were O
determined O
at O
indicated O
time O
points O
. O

(C) O
Wild‐type O
and O
Δatg7 B-proteingene
cells O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
acetate O
or O
galactose O
for O
3 O
h. O
Wild‐type O
cells O
were O
exposed O
to O
antimycin O
A O
(AA), O
oligomycin O
(O), O
or O
CCCP O
(50 O
μM) O
during O
the O
amino‐acid O
starvation O
period O
when O
indicated O
. O

Cells O
were O
treated O
with O
the O
mitochondrial O
membrane O
potential‐dependent O
dye O
DiOC6(3) O
and O
examined O
by O
fluorescence O
microscopy O
. O

Average O
pixel O
intensities O
for O
at O
least O
10 O
mitochondrial O
tubules O
(n=10) O
in O
5 O
representative O
cells O
were O
determined O
for O
each O
condition O
. O

Values O
for O
wild‐type O
mitochondria O
in O
the O
presence O
of O
acetate O
were O
defined O
as O
100% O
and O
relative O
values O
were O
calculated O
accordingly O
. O

The O
means O
and O
s.d O
. O

are O
shown O
. O

(A) O
Wild‐type, O
rho0, B-proteingene
Δnpr2, B-proteingene
and O
Δnpr2 B-proteingene
rho0 B-proteingene
cells O
expressing O
prATG8‐GFP‐ATG8 B-proteingene
(upper O
panel) O
or O
prATG8‐GFP B-proteingene
(lower O
panel) O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
galactose O
in O
the O
absence O
or O
presence O
of O
rapamycin O
. O

Samples O
were O
analysed O
as O
described O
in O
Figure O
1A. O
The O
means O
and O
s.d O
. O

of O
four O
(n=4) O
independent O
experiments O
are O
indicated O
. O

(B) O
Wild‐type, O
rho0, B-proteingene
Δnpr2, B-proteingene
and O
Δatg7 B-proteingene
cells O
expressing O
prNPR1‐NPR1‐HA B-proteingene
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
galactose O
in O
the O
absence O
(upper O
panels) O
or O
presence O
(lower O
panels) O
of O
rapamycin O
. O

The O
hyperphosphorylated O
(Npr1‐P) B-proteingene
and O
dephosphorylated O
(Npr1) B-proteingene
forms O
of O
Npr1 B-proteingene
are O
indicated O
. O

Cells O
were O
analysed O
at O
indicated O
time O
points O
by O
whole O
cell O
extraction O
and O
western O
blot O
analysis O
using O
α‐HA B-proteingene
and O
α‐Cdc11 B-proteingene
antibodies O
. O

(C) O
Wild‐type, O
rho0, B-proteingene
Δnpr2, B-proteingene
and O
Δatg7 B-proteingene
cells O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
galactose O
. O

Additionally, O
wild‐type O
cells O
were O
treated O
with O
rapamycin O
during O
starvation O
(left O
panel) O
. O

Phosphorylated O
(Atg13‐P) B-proteingene
and O
dephosphorylated O
(Atg13) B-proteingene
Atg13 B-proteingene
was O
monitored O
at O
indicated O
time O
points O
by O
whole O
cell O
extraction O
and O
western O
blot O
analysis O
using O
α‐Atg13 B-proteingene
and O
α‐Cdc11 B-proteingene
antibodies O
. O

(A) O
PKA‐dependent O
regulation O
of O
the O
autophagic O
response O
under O
amino‐acid O
starvation O
. O

Wild‐type, O
rho0, B-proteingene
pka, B-proteingene
and O
ras2G19V‐expressing B-proteingene
cells O
harbouring O
prATG8‐GFP‐ATG8 B-proteingene
(upper O
panels) O
or O
prATG8‐GFP B-proteingene
(lower O
panels) O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
galactose O
. O

PKA O
activity O
in O
pka O
was O
inhibited O
by O
addition O
of O
1NM‐PP1 O
(PP1; O
1 O
μg/ml) O
. O

Samples O
were O
analysed O
as O
described O
in O
Figure O
1A; O
autophagic O
flux O
was O
determined O
after O
3 O
and O
6 O
h O
. O

(B)In O
vivo O
activity O
of O
PKA. O
Wild‐type, O
rho0, B-proteingene
pka, B-proteingene
and O
ras2G19V‐expressing B-proteingene
cells O
harbouring O
6xMYC‐cki12−200(S125/130A) B-proteingene
(Cki1) B-proteingene
were O
grown O
in O
galactose O
medium O
. O

When O
indicated, O
wild‐type O
cells O
were O
grown O
in O
galactose O
medium O
in O
the O
presence O
of O
antimycin O
A O
(AA) O
or O
oligomycin O
(O) O
for O
6 O
h. O
PKA‐dependent O
phosphorylation O
of O
Cki1 B-proteingene
was O
analysed O
by O
whole O
cell O
extraction O
and O
western O
blot O
analysis O
using O
a O
α‐Myc B-proteingene
antibody O
(upper O
panels) O
. O

Ratio O
of O
phosphorylated O
(Cki1‐P) B-proteingene
and O
non‐phosphorylated O
(Cki1) B-proteingene
forms O
of O
Cki1 B-proteingene
relative O
to O
wild‐type O
cells O
(wt=1) O
(lower O
panels) O
. O

(C) O
PKA O
inhibition O
restores O
autophagic O
flux, O
but O
not O
ATG8 B-proteingene
induction O
in O
the O
presence O
of O
mitochondrial O
dysfunction O
. O

Wild‐type, O
rho0, B-proteingene
pka, B-proteingene
and O
pkarho0 B-proteingene
cells O
expressing O
prATG8‐GFP‐ATG8 B-proteingene
were O
treated O
as O
described O
in O
(A) O
. O

Samples O
were O
analysed O
as O
described O
in O
Figure O
1A. O
The O
means O
and O
s.d O
. O

of O
four O
(n=4) O
independent O
experiments O
are O
indicated O
in O
(A-C) O
. O

(A)ATG8 B-proteingene
induction O
is O
independent O
of O
the O
Atg1-Atg13 B-proteingene
complex O
and O
autophagic O
flux O
. O

Wild‐type, O
rho0, B-proteingene
Δatg1, B-proteingene
Δatg7, B-proteingene
Δatg9, B-proteingene
and O
Δatg11 B-proteingene
cells O
harbouring O
prATG8‐GFP‐ATG8 B-proteingene
were O
analysed O
as O
described O
in O
Figure O
1A. O
The O
means O
and O
s.d O
. O

of O
four O
(n=4) O
independent O
experiments O
are O
indicated O
. O

(B) O
Atg1 B-proteingene
and O
Atg13 B-proteingene
recruitment O
to O
the O
PAS O
depends O
on O
mitochondrial O
function O
. O

Wild‐type O
and O
rho0 B-proteingene
cells O
harbouring O
prATG8‐GFP‐ATG8 B-proteingene
and O
prATG1‐ATG1‐mCherry B-proteingene
(upper O
panels) O
or O
prATG13‐ATG13‐mCherry B-proteingene
(lower O
panels) O
were O
exposed O
to O
amino‐acid O
starvation O
medium O
supplemented O
with O
galactose O
for O
3 O
h. O
Wild‐type O
cells O
were O
treated O
with O
antimycin O
A O
(AA O
30′) O
after O
2.5 O
h O
of O
starvation O
for O
30 O
min O
or O
with O
oligomycin O
(O) O
for O
3 O
h O
of O
starvation O
. O

Arrowheads O
indicate O
the O
position O
of O
GFP‐Atg8 B-proteingene
puncta O
. O

Transmission O
and O
fluorescence O
light O
microscopy O
images O
were O
superimposed O
to O
visualize O
cellular O
boundaries O
. O

Scale O
bar O
represents O
1.5 O
μm O
. O

(C) O
Steady‐state O
levels O
of O
Atg1‐ B-proteingene
and O
Atg13‐mCherry B-proteingene
during O
amino‐acid O
starvation O
. O

Wild‐type, O
rho0, B-proteingene
and O
Δatg7 B-proteingene
cells O
expressing O
prATG1‐ATG1‐mCherry B-proteingene
(upper O
panels) O
or O
prATG13‐ATG13‐mCherry B-proteingene
(lower O
panels) O
were O
exposed O
and O
treated O
as O
described O
in O
(B) O
and O
analysed O
by O
whole O
cell O
extraction O
and O
western O
blot O
analysis O
using O
α‐dsRed B-proteingene
and O
α‐Cdc11 B-proteingene
antibodies O
. O

A. O
Relative O
mRNA O
expression O
in O
skeletal O
muscle O
from O
SBMA O
patients O
(white O
bars, O
n O
= O
3) O
and O
controls O
(black O
bars, O
n O
= O
3) O
(mean O
+/− O
SEM) O
. O

* O
p<0.05, O
** O
p<0.01 O
by O
Student O
's O
t O
test O
. O

B. O
Splicing O
of O
XBP1 B-proteingene
mRNA O
was O
assessed O
by O
RT-PCR. O
Products O
from O
unspliced O
(XBP1u) B-proteingene
and O
spliced O
(XBP1s) B-proteingene
transcripts O
were O
resolved O
on O
a O
nondenaturing O
polyacrylamide O
gel O
and O
stained O
with O
SYBR O
green O
. O

C. O
Relative O
mRNA O
expression O
in O
proximal O
hind O
limb O
muscle O
(mean O
+/− O
SEM) O
. O

Mice O
evaluated O
were O
littermate O
WT O
(n O
= O
6), O
AR113Q B-proteingene
(n O
= O
6), O
castrated O
WT O
(C-WT, O
n O
= O
6) O
and O
castrated O
AR113Q B-proteingene
males O
(C-AR113Q, B-proteingene
n O
= O
5) O
on O
a O
mixed O
C57BL/6J-129 O
genetic O
background O
. O

*p<0.05 O
by O
ANOVA O
. O

D. O
Western O
blot O
of O
BiP B-proteingene
and O
PDI B-proteingene
expression O
in O
proximal O
hind O
limb O
muscle O
. O

Right O
panels O
show O
quantification O
of O
signal O
relative O
to O
loading O
control O
(mean O
+/− O
SEM) O
. O

* O
p<0.05 O
by O
Student O
's O
t O
test O
. O

E. O
Relative O
mRNA O
expression O
in O
proximal O
hind O
limb O
muscle O
of O
AR21Q B-proteingene
(n O
= O
5) B-proteingene
and O
AR113Q O
(n O
= O
3) O
males O
backcrossed O
to O
C57BL/6J. O
** O
p<0.01, O
***p<0.001 O
by O
Student O
's O
t O
test O
. O

F. O
Relative O
mRNA O
expression O
in O
spinal O
cord O
of O
AR21Q B-proteingene
(n O
= O
5) O
and O
AR113Q O
(n O
= O
3) O
males O
(mean O
+/− O
SEM) O
. O

n. O
s. O
= O
not O
significant O
by O
Student O
's O
t O
test O
. O

A. O
Muscle O
fiber O
size O
(100 O
fibers/mouse) O
was O
quantified O
from O
proximal O
hind O
limb O
muscle O
of O
AR113Q B-proteingene
(black) O
or O
AR113Q, O
CHOP B-proteingene
−/− O
mice O
(white) O
at O
12 O
wks O
. O

Left O
panel O
shows O
fiber O
size O
distribution, O
middle O
panel O
shows O
cumulative O
percent O
of O
fibers O
as O
a O
function O
of O
fiber O
area, O
and O
right O
panel O
shows O
relative O
fiber O
cross O
sectional O
area O
(mean O
+/− O
SEM) O
. O

Left, O
middle O
panels, O
p<0.0001 O
by O
Mann-Whitney O
test O
. O

Right O
panel, O
p<0.001 O
by O
Student O
's O
t O
test O
. O

B. O
Representative O
image O
of O
muscle O
fibers O
following O
NADH O
stain O
. O

Bar O
= O
20 O
µM O
. O

C. O
Distribution O
of O
proximal O
hind O
limbmuscle O
fiber O
size O
from O
wt O
(black) O
and O
CHOP B-proteingene
−/− O
(white) O
mice O
at O
12 O
wks O
. O

Difference O
not O
significant O
by O
Mann-Whitney O
test O
. O

A. O
Relative O
expression O
of O
MurRF1 B-proteingene
and O
MAFbx B-proteingene
mRNAs O
in O
proximal O
hind O
limbmuscle O
of O
12 O
wk O
mice O
(n O
= O
5-6/genotype) O
. O

*p<0.05 O
by O
ANOVA, O
n. O
s. O
= O
not O
significant O
. O

B. O
LC3 B-proteingene
and O
p62 B-proteingene
expression O
in O
proximal O
hind O
limbmuscle O
of O
12 O
wk O
mice O
was O
assessed O
by O
western O
blot O
. O

Right O
panels O
show O
quantification O
of O
signal O
relative O
to O
GAPDH. B-proteingene
**p<0.01 O
by O
Student O
's O
t O
test O
. O

C. O
Relative O
expression O
of O
mRNAs O
encoding O
autophagy O
regulators O
in O
proximal O
hind O
limbmuscle O
. O

*p<0.05 O
by O
Student O
's O
t O
test O
. O

Androgen B-proteingene
receptor I-proteingene
protein O
expression O
in O
skeletal O
muscle O
of O
12 O
wk O
mice O
. O

Hsp90 B-proteingene
serves O
as O
a O
loading O
control O
. O

Right O
panel O
shows O
quantification O
of O
relative O
signal O
intensity O
(n O
= O
3/genotype) O
. O

D. O
Proximal O
hind O
limb O
muscles O
stained O
for O
the O
androgen B-proteingene
receptor I-proteingene
(in O
red) O
exhibit O
intranuclear O
inclusions O
. O

Nuclei O
are O
stained O
by O
DAPI O
(in O
blue) O
. O

E. O
P-JNK B-proteingene
and O
P-eIF2 B-proteingene
alpha O
expression O
(top, O
middle) O
and O
XBP1 B-proteingene
mRNA O
splicing O
(bottom) O
in O
proximal O
hind O
limbmuscle O
of O
12 O
wk O
mice O
. O

Right O
panels O
show O
quantification O
of O
signal O
relative O
to O
loading O
control O
. O

**p<0.01 O
by O
Student O
's O
t O
test O
. O

n. O
s. O
= O
not O
significant O
. O

Denervated O
gastrocnemius O
muscles O
or O
contralateral O
intact O
controls O
were O
harvested O
at O
the O
indicated O
times O
following O
unilateral O
sciatic O
nerve O
transection O
in O
6 O
wk O
male O
mice O
. O

A. O
Western O
blot O
shows O
enhanced O
eIF2 B-proteingene
alpha O
phosphorylation O
(top) O
and O
RT-PCR O
demonstrates O
increased O
XBP1 B-proteingene
mRNA O
splicing O
(bottom) O
in O
denervated O
muscle O
. O

Right O
panels O
show O
relative O
quantification O
of O
signal O
intensity O
. O

*p<0.05 O
by O
Student O
's O
t O
test O
. O

. O

B. O
Relative O
expression O
of O
BiP, B-proteingene
ATF4 B-proteingene
and O
CHOP B-proteingene
mRNA O
(n O
= O
3) O
. O

*p<0.05 O
by O
Student O
's O
t O
test O
. O

C. O
Following O
surgical O
denervation O
of O
wild O
type O
or O
CHOP−/− B-proteingene
mice, O
LC3 B-proteingene
and O
p62 B-proteingene
expression O
was O
assessed O
by O
western O
blot O
. O

Right O
panels O
show O
quantification O
of O
signal O
relative O
to O
GAPDH. B-proteingene
***p<0.001 O
by O
ANOVA, O
n. O
s. O
= O
not O
significant O
. O

D. O
Muscle O
fiber O
size O
(100 O
fibers/mouse) O
was O
quantified O
from O
wild O
type O
(black, O
n O
= B-proteingene
5), O
CHOP O
−/− O
(white, O
n B-proteingene
= O
3) O
and O
Beclin-1 O
+/− O
(grey, O
n O
= O
3) O
mice O
7 O
days O
post O
sciatic O
nerve O
transection O
. O

Shown O
is O
relative O
fiber O
cross O
sectional O
area O
(mean O
+/− O
SEM) O
. O

***p<0.001 O
by O
ANOVA O
. O

E. O
Muscle O
fiber O
size O
(100 O
fibers/mouse) O
was O
quantified O
from O
CHOP B-proteingene
−/− O
(black, O
n O
= O
6) B-proteingene
or O
CHOP B-proteingene
−/−, O
Beclin-1 O
+/− O
mice O
(white, O
n O
= O
6) O
7 O
days O
post O
sciatic O
nerve O
transection O
. O

Left O
panel O
shows O
fiber O
size O
distribution, O
middle O
panel O
shows O
cumulative O
percent O
of O
fibers O
as O
a O
function O
of O
fiber O
area, O
and O
right O
panel O
shows O
relative O
fiber O
cross O
sectional O
area O
(mean O
+/− O
SEM) O
. O

Left, O
middle O
panels, O
p<0.0001 O
by O
Mann-Whitney O
test O
. O

Right O
panel, O
p<0.001 O
by O
Student O
's O
t O
test O
. O

A. O
Muscle O
fiber O
size O
(100 O
fibers/mouse) O
was O
quantified O
from O
proximal O
hind O
limbmuscle O
of O
AR113Q B-proteingene
(red, O
n O
= O
6) B-proteingene
or B-proteingene
AR113Q, O
Beclin-1 O
+/− O
(blue, O
n O
= O
6) O
mice O
at O
16 O
wks O
. O

Left O
panel O
shows O
fiber O
size O
distribution, O
and O
right O
panel O
shows O
relative O
fiber O
cross O
sectional O
area O
(mean O
+/− O
SEM) O
. O

Left O
panel, O
p<0.0001 O
by O
Mann-Whitney O
test O
. O

Right O
panel, O
p<0.0001 O
by O
Student O
's O
t O
test O
. O

B. O
AR B-proteingene
expression O
in O
skeletal O
muscle O
of O
16 O
wk O
mice O
was O
assessed O
by O
western O
blot O
. O

GAPDH B-proteingene
controls O
for O
loading O
. O

Right O
panel O
shows O
quantification O
of O
signal O
relative O
to O
GAPDH B-proteingene
(mean O
+/− O
SEM) O
. O

Differences O
not O
significant O
(n. O
s.) O
. O

A. O
Left O
panel, O
Kaplan-Meyer O
survival O
curve O
of O
AR113Q B-proteingene
males O
(red O
line, O
n O
= O
12) B-proteingene
and B-proteingene
AR113Q, O
Beclin-1 O
+/− O
males O
(blue O
line, O
n O
= O
15) O
. O

*p<0.05 O
by O
log-rank O
analysis O
. O

Right O
panel, O
mean O
survival O
+/− O
SEM. O
*p<0.05 O
by O
Student O
's O
t-test O
. O

B, O
C. O
Body O
weight O
(panel O
B) O
and O
grip O
strength O
(panel O
C) O
at O
different O
ages O
for O
wild O
type O
(wt, O
green O
line, O
n O
= B-proteingene
7), O
Beclin-1 O
+/− O
(yellow O
line B-proteingene
n O
= O
9), O
AR113Q O
(red B-proteingene
line, B-proteingene
n O
= O
12), O
and O
AR113Q, O
Beclin-1 O
+/− O
(blue O
line, O
n O
= O
15) O
male O
mice O
. O

B, O
C. O
Body O
weight O
(panel O
B) O
and O
grip O
strength O
(panel O
C) O
at O
different O
ages O
for O
wild O
type O
(wt, O
green O
line, O
n O
= B-proteingene
7), O
Beclin-1 O
+/− O
(yellow O
line B-proteingene
n O
= O
9), O
AR113Q O
(red O
line, B-proteingene
n O
= O
12), O
and O
AR113Q, O
Beclin-1 O
+/− O
(blue O
line, O
n O
= O
15) O
male O
mice O
. O

D. O
Age O
of O
disease O
onset O
as O
measured O
by O
a O
decrease O
of O
5% O
or O
more O
in O
forelimb O
grip O
strength O
(not O
significant O
by O
log O
rank O
analysis) O
. O

a, O
Correlative O
light O
and O
electron O
microscopy O
of O
HeLa/GFP-LC3 B-proteingene
cell O
infected O
with O
SIN/mCherry.capsid B-proteingene
virus O
. O

Top O
left, O
deconvolved O
image O
of O
red O
and O
green O
fluorescence O
channels; O
middle, O
three-dimensional O
surface O
reconstruction O
of O
red O
and O
green O
channels; O
right, O
yellow O
(red O
+ O
green) O
colocalization O
channel O
. O

Arrows O
denote O
yellow O
puncta O
that O
correspond O
to O
'1' O
and O
'2' O
in O
electron O
microscopy O
images O
below O
. O

Bottom O
left, O
electron O
microscopy O
of O
identical O
cell; O
middle O
and O
right, O
high O
magnification O
images O
of O
insets O
'1' O
and O
'2' O
. O

Scale O
bars, O
left, O
10 O
µm; O
middle O
and O
right, O
200 O
nm O
. O

a, O
Electron O
microscopy O
analysis O
of O
wild-type O
(WT) O
and O
Smurf1-/- B-proteingene
(KO) O
MEFs O
grown O
in O
normal O
media O
or O
EBSS O
(starvation) O
for O
4 O
h. O
Arrowheads, O
representative O
autophagosomes; O
arrows, O
representative O
autolysosomes O
. O

Scale O
bars, O
500 O
nm O
. O

b, O
Western O
blot O
analyses O
of O
LC3-I/II B-proteingene
(non-lipidated O
and O
lipidated O
forms O
of O
MAP1LC3, B-proteingene
respectively) O
and O
p62 B-proteingene
levels O
in O
MEFs O
of O
indicated O
genotype O
. O

c, O
Quantification O
of O
colocalization O
of O
SIN/mCherry.capsid B-proteingene
and O
GFP-LC3 B-proteingene
in O
indicated O
MEFs O
16 O
h O
after O
SIN/mCherry.capsid/GFP-LC3 B-proteingene
infection O
. O

Data O
shown O
represent O
mean O
± O
s.e.m O
. O

number O
of O
colocalized O
red O
and O
green O
puncta O
per O
cell O
for O
50 O
cells O
per O
well O
in O
triplicate O
samples O
. O

*P<0.001 O
against O
wild-type, O
Students O
t-test O
. O

d, O
Representative O
confocal O
micrographs O
of O
colocalization O
of O
SIN/mCherry.capsid B-proteingene
and O
GFP-LC3 B-proteingene
in O
indicated O
MEFs16 O
h O
after B-proteingene
SIN/mCherry.capsid/GFP-LC3 O
infection O
images O
used O
for O
quantification O
in O
c. O
Arrows, O
colocalized O
red O
and O
green O
puncta O
. O

Scale O
bar, O
15 O
&mgr;m O
. O

e, O
Representative O
electron O
microscopy O
images O
of O
indicated O
MEFs O
infected O
with O
HSV-1 O
(strain O
17termA) O
. O

White O
arrowheads, O
partially O
degraded O
viral O
nucleocapsids O
inside O
autolysosomes; O
black O
arrowheads, O
intact O
viral O
nucleocapsids O
inside O
viral O
vesicles O
. O

Scale O
bar, O
0.5 O
µm O
. O

For O
a-e, O
similar O
results O
were O
obtained O
in O
3-5 O
independent O
experiments O
. O

a, O
Representative O
mitochondrial O
morphology O
in O
Smurf1+/+ B-proteingene
(wild-type) O
and O
Smurf1−/− B-proteingene
(KO) O
MEFs O
transfected O
with O
indicated O
construct O
and O
treated O
with O
DMSO O
or O
10 O
µM O
CCCP O
for O
24 O
h. O
b, O
Quantification O
of O
percentage O
of O
total O
cells O
with O
a O
diffuse O
accumulation O
of O
abnormal O
fragmented O
mitochondria O
and O
lack O
of O
mitochondrial O
clearance O
. O

Results O
shown O
represent O
combined O
data O
from O
3-5 O
experiments O
per O
condition O
with O
triplicate O
wells O
(of O
at O
least O
100 O
cells O
per O
well) O
analysed O
for O
each O
condition O
per O
experiment O
. O

Shown O
are O
mean O
± O
s.e.m O
. O

for O
average O
values O
from O
each O
experiment O
. O

Similar O
results O
were O
observed O
in O
each O
independent O
experiment O
. O

*P O
0.001, O
Students O
t-test O
. O

c, O
Measurement O
of O
mitochondrial O
fractional O
area O
(percentage O
of O
total O
cellular O
area) O
in O
MEFs O
treated O
as O
in O
a O
. O

Results O
shown O
represent O
mean O
± O
s.e.m O
. O

for O
50 O
cells O
per O
condition O
. O

d, O
Representative O
confocal O
micrographs O
of O
KO O
MEFs O
transfected O
with O
YFP-SMURF1 B-proteingene
wild-type O
or O
YFP-SMURF1Dgr;C2 B-proteingene
(Dgr;C2) O
and O
treated O
for O
4 O
h O
with O
DMSO O
or O
CCCP O
. O

e, O
Representative O
confocal O
micrographs O
of O
KO O
MEFs O
transfected O
with O
GFP-LC3 B-proteingene
and O
wild-type O
mCherry-SMURF1 B-proteingene
(WT) O
or O
mCherry-SMURF1Dgr;C2 B-proteingene
(Dgr;C2) O
and O
treated O
for O
4 O
h O
with O
CCCP. O
Inset, O
upper O
right, O
formation O
of O
completed O
autophagosome O
around O
a O
damaged O
mitochondrion O
associated O
with O
wild-type B-proteingene
SMURF1; O
insets, O
lower O
right, O
incomplete O
autophagosomes O
or O
absence O
of B-proteingene
LC3 O
signal O
around O
mitochondria O
associated O
with O
SMURF1Dgr;C2 O
. O

See O
also O
Supplementary O
Figs O
10 O
and O
11 O
for O
enlarged O
images O
. O

f, O
Representative O
electron O
microscopy O
images O
of O
indicated O
tissues O
from O
10-month-oldSmurf1+/+ B-proteingene
(WT) O
or O
Smurf1-/- B-proteingene
(KO) O
mice O
. O

Arrows, O
representative O
abnormal O
mitochondria O
. O

Scale O
bars, O
1 O
µm O
. O

Similar O
abnormalities O
were O
observed O
throughout O
entire O
electron O
microscopy O
tissue O
section O
for O
each O
mouse O
and O
in O
tissue O
samples O
from O
three O
different O
mice O
for O
each O
genotype O
. O

(A) O
Atg5fl/fl B-proteingene
Cre− B-proteingene
and O
Atg5fl/fl B-proteingene
Cre+bone O
marrow‐derived O
macrophages O
(BMMs), O
pretreated O
overnight O
with O
100 O
ng/ml O
LPS, O
were O
stimulated O
for O
1 O
h O
with O
the O
inflammasome O
agonist O
nigericin O
(20 O
μM) O
with O
(Starvation; O
EBSS) O
or O
without O
(Full; O
full O
medium) O
autophagic O
induction O
. O

Cell O
culture O
supernatants O
were O
assayed O
for O
murine O
IL‐1β B-proteingene
by O
ELISA. O
Data O
represent O
mean O
values±s.d O
. O

(n≥3); O
*P0.05 O
. O

(B) O
LPS‐pretreated O
Atg5fl/flCre− B-proteingene
and O
Atg5fl/flCre+BMMs B-proteingene
were O
stimulated O
with O
20 O
μM O
nigericin O
for O
1 O
h O
in O
OptiMEM O
and O
the O
release O
of O
active O
caspase‐1 B-proteingene
and O
IL‐1β B-proteingene
was O
determined O
by O
immunoblotting O
. O

(C) O
As O
in O
(A), O
assayed O
for O
IL‐18 B-proteingene
. O

Data O
represent O
mean O
values±s.d O
. O

(n≥3); O
*P0.05 O
. O

(D) O
LPS‐pretreated O
BMMs O
were O
exposed O
to O
alum O
(250 O
μg/ml) O
for O
1 O
h O
with O
or O
without O
autophagic O
induction O
by O
starvation O
. O

Secreted O
IL‐1β B-proteingene
was O
measured O
as O
in O
(A) O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(E) O
LPS‐pretreated O
BMMs O
were O
exposed O
to O
silica O
(250 O
μg/ml) O
for O
1 O
h O
with O
or O
without O
autophagic O
induction O
by O
starvation O
. O

Secreted O
IL‐1β B-proteingene
was O
measured O
as O
in O
(A) O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(F) O
BMMs O
were O
transfected O
with O
scramble O
(Scr) O
control O
siRNA O
or O
siRNAs O
against O
ASC B-proteingene
and O
NLRP3 B-proteingene
. O

After O
48 O
h O
following O
transfection, O
cells O
were O
treated O
overnight O
with O
LPS O
and O
subjected O
to O
nigericin O
(20 O
μM) O
and O
starvation O
for O
1 O
h. O
Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(G) O
Immunoblot O
analysis O
of O
ASC B-proteingene
and O
NLRP3 B-proteingene
knockdowns O
. O

(H) O
BMMs O
were O
transfected O
with O
scramble O
(Scr) O
control O
siRNA O
or O
siRNAs O
against O
ASC B-proteingene
and O
NLRP3 B-proteingene
. O

After O
48 O
h O
following O
transfection, O
cells O
were O
treated O
overnight O
with O
LPS O
and O
subjected O
to O
silica O
(250 O
μg/ml) O
and O
starvation O
for O
1 O
h. O
Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(I) O
Colocalization O
of O
IL‐1β B-proteingene
with O
the O
basal O
autophagic O
machinery O
factor O
LC3 B-proteingene
. O

Fluorescence: O
LC3 B-proteingene
(green, O
Alexa488); O
IL‐1β B-proteingene
(red, O
Alexa568) O
. O

BMMs O
were O
from O
GFP-LC3 B-proteingene
knock‐in O
mice, O
treated O
with O
LPS O
then O
prepared O
for O
immunofluorescence O
microscopy O
using O
fluorescently O
labelled O
antibodies O
against O
GFP B-proteingene
and O
IL‐1β B-proteingene
. O

(L) O
Pearson O
's O
colocalization O
coefficient O
for O
IL‐1β B-proteingene
and O
LC3 B-proteingene
. O

Pearson O
's O
coefficient O
was O
derived O
from O
three O
independent O
experiments O
with O
five O
fields O
per O
experiment, O
for O
a O
total O
of O
15 O
fields O
contributing O
to O
the O
cumulative O
result O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

(A, O
B) O
LPS‐pretreated O
BMMs O
were O
treated O
with O
20 O
μM O
nigericin O
(Nig) O
and O
100 O
nM O
bafilomycin O
A1 O
(Baf) O
with O
(Starvation) O
or O
without O
(Full) O
autophagic O
induction O
for O
1 O
h O
and O
secreted O
IL‐1β B-proteingene
(A) O
and O
IL‐18 B-proteingene
(B) O
were O
measured O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(C) O
LPS‐pretreated O
BMMs O
were O
treated O
with O
250 O
μg/ml O
of O
silica O
and O
100 O
nM O
bafilomycin O
A1 O
(Baf) O
with O
(Starvation) O
or O
without O
(Full) O
autophagic O
induction O
for O
1 O
h O
and O
secreted O
IL‐1β B-proteingene
were O
measured O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(D) O
Colocalization O
of O
cathepsin B-proteingene
B I-proteingene
with O
the O
basal O
autophagic O
machinery O
factor O
LC3 B-proteingene
and O
IL‐1β B-proteingene
. O

Fluorescence; O
LC3 B-proteingene
(green, O
Alexa488), O
IL‐1β B-proteingene
(red, O
Alexa568), O
and O
cathepsin B-proteingene
B I-proteingene
(blue, O
Alexa633) O
. O

BMMs O
from O
GFP-LC3 B-proteingene
knock‐in O
mice O
were O
treated O
with O
LPS O
and O
then O
analysed O
for O
immunofluorescence O
. O

(F) O
LPS‐pretreated O
BMMs O
were O
treated O
with O
20 O
μM O
nigericin O
and O
cathepsin B-proteingene
B I-proteingene
inhibitor O
CA‐074 O
Me O
(10 O
μM), O
with O
(Starvation) O
or O
without O
(Full) O
autophagic O
induction, O
for O
1 O
h O
and O
secreted O
IL‐1β B-proteingene
was O
measured O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(G) O
LPS‐pretreated O
Atg5fl/flCre− B-proteingene
and O
Atg5fl/flCre+BMMs B-proteingene
were O
stimulated O
with O
20 O
μM O
nigericin O
for O
1 O
h O
in O
OptiMEM O
and O
release O
of O
cathepsin B-proteingene
B I-proteingene
was O
determined O
by O
immunoblotting O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

(A) O
Colocalization O
of O
Rab8a B-proteingene
with O
the O
basal O
autophagic O
machinery O
factor O
LC3 B-proteingene
and O
IL‐1β B-proteingene
. O

Fluorescence; O
LC3 B-proteingene
(green, O
Alexa488), O
IL‐1β B-proteingene
(red, O
Alexa568), O
Rab8a B-proteingene
(blue, O
Alexa633) O
. O

BMMs O
from O
GFP-LC3 B-proteingene
knock‐in O
mice O
were O
pretreated O
with O
LPS O
and O
analysed O
by O
immunofluorescence O
microscopy O
. O

Arrows O
indicate O
triple O
colocalization O
. O

(C) O
Pearson O
's O
colocalization O
coefficient O
for O
IL‐1β B-proteingene
and O
Rab8a B-proteingene
. O

Pearson O
's O
coefficients O
were O
derived O
from O
three O
completely O
independent O
experiments O
with O
>5 O
fields O
per O
experiment, O
for O
a O
total O
of O
⩾15 O
fields O
contributing O
to O
the O
cumulative O
result O
. O

(D) O
BMMs O
were O
transfected O
with O
siRNAs O
against O
Rab8a B-proteingene
or O
scramble O
(Scr) O
control O
. O

At O
24 O
h O
after O
the O
first O
transfection, O
cells O
were O
transfected O
again O
with O
siRNA, O
treated O
with O
LPS O
and O
the O
day O
after O
subjected O
to O
nigericin O
in O
full O
medium O
for O
1 O
h, O
and O
IL‐1β B-proteingene
secretion O
measured O
. O

(E) O
Immunoblot O
analysis O
of O
Rab8a B-proteingene
knockdown O
in O
BMMs O
. O

(F) O
RAW O
264.7 O
macrophages O
were O
transfected O
with O
GFP‐tagged B-proteingene
Rab8a B-proteingene
constructs O
(WT, O
wild O
type; O
S22N, O
dominant‐negative O
mutant), O
treated O
overnight O
with O
LPS O
and O
stimulated O
for O
1 O
h O
with O
20 O
μM O
nigericin O
along O
with O
induction O
of O
autophagy O
by O
starvation O
. O

IL‐1β B-proteingene
secretion O
was O
measured O
by O
ELISA. O
Data O
represent O
mean O
values±s.d O
. O

(n≥3); O
*P0.05 O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

(A) O
BMM O
cells O
were O
transfected O
with O
scramble O
(Scr) O
control O
siRNA O
or O
siRNA O
against O
GRASP55 B-proteingene
. O

After O
48 O
h O
of O
transfection, O
cells O
were O
treated O
with O
LPS O
and O
the O
day O
after O
subjected O
to O
20 O
μM O
nigericin O
in O
EBSS, O
and O
secreted O
IL‐1β B-proteingene
was O
measured O
by O
ELISA. O
Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

Inset: O
Immunoblot O
analysis O
of O
GRASP55 B-proteingene
knockdown O
. O

(B) O
Immunofluorescence O
confocal O
microscopy O
analysis O
of O
LC3 B-proteingene
and O
GRASP55 B-proteingene
distribution O
. O

LC3 B-proteingene
(green, O
Alexa488), O
GRASP55 B-proteingene
(red, O
Alexa568) O
. O

BMMs O
were O
pretreated O
overnight O
with O
100 O
ng/ml O
LPS O
and O
either O
not O
stimulated O
(Ctrl) O
or O
stimulated O
(Nig) O
for O
30 O
min O
with O
the O
inflammasome O
agonist O
nigericin O
(20 O
μM) O
in O
full O
medium O
. O

(D) O
Pearson O
's O
coefficients O
for O
LC3 B-proteingene
and O
GRASP55 B-proteingene
were O
quantified O
using O
SlideBook O
morphometric O
analysis O
software O
as O
a O
measure O
of O
adjacency O
between O
GRASP55 B-proteingene
and O
LC3 B-proteingene
profiles O
. O

Pearson O
's O
coefficients O
were O
derived O
from O
three O
independent O
experiments O
with O
five O
fields O
per O
experiment, O
for O
a O
total O
of O
15 O
fields O
contributing O
to O
the O
cumulative O
result O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

(A, O
B) O
Effect O
of O
GRASP55 B-proteingene
on O
autophagy O
induction O
by O
measuring O
LC3‐II. B-proteingene
BMM O
cells O
were O
transfected O
with O
GRASP55 B-proteingene
siRNAs O
or O
scramble O
(Scr) O
control O
. O

At O
72 O
h O
post O
transfection, O
cells O
were O
induced O
for O
autophagy, O
treated O
or O
not O
with O
Bafilomycin O
A1 O
(Baf) O
to O
inhibit O
autophagic O
degradation O
and O
LC3‐II/actin B-proteingene
ratios O
determined O
by O
immunoblotting O
(A) O
followed O
by O
densitometry O
(B) O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

(C, O
D) O
RAW O
264.7 O
was O
transfected O
with O
GRASP55 B-proteingene
siRNAs O
or O
scramble O
(Scr) O
siRNA O
control O
. O

Following O
48 O
h O
of O
siRNA O
treatment, O
cells O
were O
transfected O
with O
RFP-GFP-LC3 B-proteingene
plasmid O
(GFP B-proteingene
is O
sensitive O
to O
acidification, O
whereas O
RFP B-proteingene
is O
not), O
after O
24 O
h O
induced O
for O
autophagy O
in O
EBSS O
for O
1 O
h O
and O
autophagic O
induction O
and O
flux O
quantified O
(graph O
in O
D) O
by O
determining O
the O
number O
of O
early O
autophagic O
organelles O
(GFP+RFP+ B-proteingene
puncta) O
and O
autolysosomal O
organelles O
(GFP−RFP+ B-proteingene
puncta) O
per O
cell O
as O
illustrated O
in O
fluorescent O
images O
(yellow O
arrows, O
GFP+RFP+; B-proteingene
red O
arrows, O
GFP−RFP+) B-proteingene
. O

Total, O
yellow+red O
puncta O
per O
cell O
. O

Data O
represent O
mean O
values±s.d O
. O

(n⩾3); O
*P0.05 O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

(B) O
LPS‐pretreated O
Atg5fl/flCre− B-proteingene
and O
Atg5fl/flCre+BMMs B-proteingene
were O
stimulated O
with O
20 O
μM O
nigericin O
for O
1 O
h O
in O
OptiMEM O
and O
the O
release O
of O
HMGB1 B-proteingene
was O
determined O
by O
immunoblotting O
. O

Figure O
source O
data O
can O
be O
found O
in O
Supplementary O
data O
. O

a, O
b, O
Analysis O
of O
HeLa O
cells O
stably O
expressing O
YFP B-proteingene
fused O
to O
the O
indicated O
galectins O
and O
infected O
with O
S. O
Typhimurium O
for O
1 O
h. O
a, O
Percentage O
of O
bacteria O
coated O
by O
the O
indicated O
galectins O
. O

YFP-positive B-proteingene
bacteria O
were O
counted O
by O
microscopy O
. O

Mean O
and O
standard O
deviation O
(s.d.) O

of O
triplicate O
HeLa O
cultures, O
n O
> O
100 O
bacteria O
per O
coverslip O
. O

b, O
Confocal O
microscopy O
. O

Arrowheads, O
bacteria O
shown O
in O
insets O
. O

DAPI, O
4′,6-diamidino-2-phenylindole O
. O

c, O
Kinetics O
of O
fold O
replication O
for O
S. O
Typhimurium O
in O
HeLa O
cells O
transfected O
with O
the O
indicated O
siRNAs O
. O

Bacteria O
were O
counted O
on O
the O
basis O
of O
their O
ability O
to O
form O
colonies O
on O
agar O
plates O
. O

Mean O
and O
s.d O
. O

of O
triplicate O
HeLa O
cultures O
and O
duplicate O
colony O
counts O
. O

siRNAs O
are O
further O
characterized O
in O
Supplementary O
Fig O
. O

2a-c. O
**P O
0.01, O
Student O
's O
t-test O
. O

Scale O
bar, O
10 O
µm O
. O

a, O
LUMIER O
binding O
assay: O
normalized O
ratio O
between O
luciferase B-proteingene
activity O
bound O
to O
beads O
and O
present O
in O
lysates O
. O

Lysates O
of O
293ET O
cells O
expressing O
NDP52, B-proteingene
p62 B-proteingene
or O
optineurin B-proteingene
each O
fused O
to O
luciferase, B-proteingene
and O
the O
indicated O
Flag-tagged B-proteingene
galectins O
were O
incubated O
with O
anti-Flag B-proteingene
beads O
. O

Flag-tagged B-proteingene
proteins O
are O
further O
characterized O
in O
Supplementary O
Fig O
. O

4a O

b, O
Lysates O
of O
293ET O
cells, O
expressing O
Flag-tagged B-proteingene
proteins O
as O
indicated, O
were O
immunoprecipitated O
with O
anti-Flag B-proteingene
beads O
. O

Lysates O
and O
immunoprecipitates O
(IP) O
were O
blotted O
for O
the O
presence O
of O
Flag-tagged B-proteingene
proteins O
and O
endogenous O
NDP52 B-proteingene
. O

c, O
Confocal O
images O
of O
HeLa O
cells O
infected O
with O
S. O
Typhimurium O
for O
1 O
h O
and O
stained O
with O
antisera O
against O
NDP52 B-proteingene
and O
galectin B-proteingene
8 I-proteingene
. O

Arrowheads, O
bacteria O
shown O
in O
insets O
. O

d, O
Co-localization O
of O
NDP52 B-proteingene
with O
galectin-positive O
bacteria O
in O
HeLa O
cells O
stably O
expressing O
YFP B-proteingene
fused O
to O
the O
indicated O
galectins, O
infected O
with O
S. O
Typhimurium O
and O
stained O
with O
NDP52 B-proteingene
antiserum O
1 O
h O
after O
infection O
. O

Mean O
and O
s.d O
. O

of O
duplicate O
HeLa O
cultures, O
n O
> O
100 O
bacteria O
per O
coverslip, O
representative O
of O
two O
independent O
experiments O
. O

Scale O
bar, O
10 O
µm O
. O

a, O
Percentage O
of O
S. O
Typhimurium O
coated O
by O
the O
indicated O
galectins O
. O

HeLa O
cells O
stably O
expressing O
YFP-tagged B-proteingene
galectins O
were O
treated O
with O
the O
indicated O
siRNAs O
. O

YFP-positive B-proteingene
bacteria O
were O
counted O
by O
microscopy O
at O
1 O
h O
p.i O
. O

siRNAs O
are O
further O
characterized O
in O
Supplementary O
Fig O
. O

2 O
. O

b, O
Analysis O
of O
HeLa O
cells O
treated O
with O
the O
indicated O
siRNAs O
and O
stained O
with O
NDP52 B-proteingene
antiserum O
. O

NDP52-positive B-proteingene
bacteria O
were O
counted O
by O
microscopy O
1 O
h O
after O
infection O
with O
S. O
Typhimurium O
. O

siRNAs O
are O
further O
characterized O
in O
Supplementary O
Fig O
. O

2 O
. O

c, O
Percentage O
of O
bacteria O
coated O
by O
the O
indicated O
galectin B-proteingene
8 I-proteingene
alleles O
. O

HeLa O
cells O
stably O
expressing O
the O
indicated O
galectin B-proteingene
8 I-proteingene
alleles O
fused O
to O
YFP B-proteingene
were O
infected O
with O
S. O
Typhimurium O
. O

YFP-positive B-proteingene
S. O
Typhimurium O
were O
counted O
by O
microscopy O
at O
75 O
min O
p.i O
. O

WT, O
wild O
type O
. O

d, O
Binding O
of O
galectin B-proteingene
8 I-proteingene
to O
bacteria O
and O
HeLa O
cells O
. O

The O
indicated O
bacteria O
and O
HeLa O
cells O
were O
incubated O
with O
His-GST-ubiquitin B-proteingene
(Ub), O
His-GST-galectin B-proteingene
8 O
or O
buffer O
as O
indicated, O
followed O
by O
murine O
anti-His B-proteingene
antibody O
and O
PE-labelled O
anti-mouse O
serum O
. O

e, O
Percentage O
of O
S. O
Typhimurium O
coated O
by O
the O
indicated O
galectins O
. O

Wild-type O
CHO O
cells O
and O
mutant O
Lec3.2.8.1 O
cells O
stably O
expressing O
YFP-tagged B-proteingene
galectins O
were O
infected O
with O
S. O
Typhimurium O
. O

YFP-positive B-proteingene
bacteria O
were O
counted O
by O
microscopy O
at O
1 O
h O
p.i O
. O

f, O
Confocal O
images O
of O
HeLa O
cells O
expressing O
the O
indicated O
YFP-tagged B-proteingene
galectins O
. O

Cells O
were O
left O
untreated O
or O
were O
exposed O
to O
hypertonic O
conditions, O
with O
or O
without O
(w/o) O
PEG O
as O
indicated, O
followed O
by O
hypotonic O
shock O
. O

g, O
Fold O
replication O
of O
S. O
Typhimurium O
in O
HeLa O
cells O
expressing O
the O
indicated O
galectin B-proteingene
3 I-proteingene
variants O
and O
transfected O
with O
the O
indicated O
siRNAs O
. O

At O
2 O
h O
and O
6 O
h O
after O
infection, O
cells O
were O
lysed O
and O
bacteria O
counted O
on O
the O
basis O
of O
their O
ability O
to O
form O
colonies O
on O
agar O
plates O
. O

Galectin B-proteingene
3 I-proteingene
proteins O
are O
further O
characterized O
in O
Supplementary O
Fig O
. O

4b O
. O

Mean O
and O
s.d O
. O

of O
duplicate O
coverslips>100 O
bacteria O
counted O
per O
coverslip O
. O

Data O
are O
representative O
of O
at O
least O
two O
repeats O
. O

*P< O
0.05, O
Student O
's O
t-test O
. O

Scale O
bar, O
10 O
µm O
. O

a, O
Confocal O
micrograph O
of O
HeLa O
cells O
expressing O
GFP-LC3 B-proteingene
and O
mCherry-galectin-8, B-proteingene
stained O
for O
NDP521 B-proteingene
h O
after O
infection O
with O
S. O
Typhimurium O
. O

The O
lower O
right O
panel O
contains O
a O
fluorescence O
line O
scan O
along O
the O
yellow O
line O
in O
the O
merge O
inset O
. O

Arrowheads, O
bacteria O
shown O
in O
insets O
. O

b, O
Percentage O
of O
GFP-LC3-positive B-proteingene
S. O
Typhimurium O
at O
1 O
h O
p.i O
. O

in O
HeLa O
cells O
treated O
with O
the O
indicated O
siRNAs O
. O

c, O
Percentage O
of O
bacteria O
positive O
for O
NDP52 B-proteingene
. O

HeLa O
cells O
expressing O
the O
indicated O
NDP52 B-proteingene
variants O
fused O
to O
YFP B-proteingene
were O
infected O
with O
S. O
Typhimurium O
. O

d, O
Percentage O
of O
bacteria O
positive O
for O
the O
indicated O
markers O
. O

HeLa O
cells, O
either O
wild O
type O
or O
expressing O
YFP-galectin-8 B-proteingene
as O
indicated, O
were O
infected O
with O
S. O
Typhimurium O
. O

Ubiquitin B-proteingene
was O
detected O
by O
antibody O
staining O
. O

e, O
HeLa O
cells O
treated O
with O
the O
indicated O
siRNAs O
were O
infected O
with O
S. O
Typhimurium O
and O
stained O
for O
NDP52 B-proteingene
at O
the O
indicated O
time O
points O
. O

Fluorescent O
bacteria O
were O
counted O
by O
microscopy O
at O
the O
indicated O
time O
points O
. O

Graphs, O
representing O
at O
least O
two O
independent O
repeats, O
show O
mean O
and O
s.d O
. O

of O
duplicate O
coverslips O
for O
which O
>200 O
bacteria O
were O
counted O
. O

*P O
0.05, O
Student O
's O
t-test O
. O

Scale O
bar, O
10 O
µm O
. O

(a,b) O
Changes O
in O
HEK293T O
cell O
cytoplasmic O
(a) O
and O
mitochondrial O
(b) O
[Ca2+] O
in O
response O
to O
ionomycin O
(2.5 O
μM) O
were O
simultaneously O
measured O
by O
fluo-4 O
and O
rhod-2 O
imaging, O
respectively O
. O

Each O
bar O
represents O
one O
target O
gene O
silenced O
with O
pooled O
siRNA O
. O

(c) O
qrtPCR O
of O
MCU, B-proteingene
MCUR1 B-proteingene
and O
MICU1 B-proteingene
mRNA O
from O
mouse O
tissues O
(n O
= O
3; O
mean O
± O
s.e.m O
. O

) O
. O

(d) O
qrtPCR O
of O
MCUR1 B-proteingene
mRNA O
from O
HEK293T O
cell O
clones O
(n O
= O
3; O
mean O
± O
s.e.m.) O
. O

KD, O
knockdown O
. O

Neg O
shRNA, O
negative O
shRNA O
. O

(e) O
qrtPCR O
of O
MCUR1 B-proteingene
mRNA O
from O
HeLa O
cell O
clones O
and O
of O
rescued O
MCUR1 B-proteingene
mRNA O
levels O
in O
shHe2 O
clone O
cells O
(n O
= O
3; O
mean O
± O
s.e.m.) O
. O

The O
same O
lentiviral O
shRNAs O
were O
used O
to O
generate O
shHK4 O
and O
shHe1 O
and O
shHK5 O
and O
shHe2, O
respectively O
. O

(f) O
MCUR1 B-proteingene
protein O
expression O
levels O
(top) O
and O
densitometric O
analysis O
(bottom O
left) O
(n O
= O
3; O
± O
s.e.m.) O
. O

Bottom O
right, O
Flag-tagged B-proteingene
MCUR1 B-proteingene
protein O
expression O
in O
clone O
shHe2 O
cells O
reconstituted O
with O
shRNA-resistant O
MCUR1 B-proteingene
cDNA O
plasmid O
. O

WB, O
western O
blot O
. O

(g,h) O
Representative O
images O
from O
movies O
of O
HEK293T O
negative O
shRNA O
or O
shHK5 O
cells O
showing O
cytosolic O
(green) O
and O
mitochondrial O
(red) O
[Ca2+] O
before, O
during O
and O
after O
ionomycin O
exposure O
. O

Scale O
bar, O
20 O
μm O
. O

(i-p) O
Cytoplasmic O
(green) O
and O
mitochondrial O
matrix O
(red) O
[Ca2+] O
responses O
in O
HEK293T O
(i-l) O
cells O
challenged O
with O
ionomycin O
or O
histamine O
(100 O
μM), O
respectively O
. O

(n O
= O
3) O
. O

(i) O
Wild-type O
HEK293T O
cells O
. O

(j) O
Cells O
expressing O
negative O
shRNA O
. O

(k) O
Clone O
shHK5 O
(n O
= O
4) O
. O

(l) O
Quantification O
of O
peak O
rhod-2 O
fluorescence O
. O

**P0.01 O
(mean±s.e.m O
. O

) O
. O

(i-p) O
Cytoplasmic O
(green) O
and O
mitochondrial O
matrix O
(red) O
[Ca2+] O
responses O
in O
HeLa O
(m-p) O
cells O
challenged O
with O
ionomycin O
or O
histamine O
(100 O
μM), O
respectively O
. O

(n O
= O
3) O
. O

(m) O
HeLa O
cells O
expressing O
negative O
shRNA O
. O

(n) O
Clone O
shHe2 O
. O

(o) O
Clone O
shHe2 O
re-expressing O
MCUR1 B-proteingene
(n O
= O
3) O
. O

(p) O
Quantification O
of O
peak O
rhod-2 O
fluorescence O
. O

*P0.05, O
**P0.01 O
(mean±s.e.m O
. O

) O
. O

(q) O
[Ca2+]c O
and O
[Ca2+]m O
signals O
evoked O
by O
ATP O
(100 O
μM) O
and O
thapsigargin O
(Tg, O
2 O
μM) O
were O
monitored O
simultaneously O
using O
fura-2/AM O
and O
mitopericam O
(ipcam490), O
respectively O
in O
control O
(left) B-proteingene
and O
MCUR1-knockdown O
(right) O
HeLa O
cells O
. O

[Ca2+]c O
is O
calibrated O
in O
nanomolar O
concentrations O
(black), O
whereas O
mitopericam O
fluorescence O
is O
inversely O
normalized O
to O
baseline O
(F0/F; O
red) O
. O

(r) O
Summary O
mean O
[Ca2+]c O
and O
[Ca2+]m O
peaks O
during O
ATP O
stimulation O
(negative O
shRNA O
n O
= B-proteingene
29; O
MCUR1 O
knockdown O
n O
= O
36 O
cells) O
. O

*P0.05 O
(mean±s.e.m O
. O

) O
. O

(s) O
Increase O
in O
bath O
[Ca2+](Rfura2) O
and O
[Ca2+]m O
(Ripcam) O
signals O
in O
response O
to O
CaCl2 O
(1 O
μM) O
and O
InsP3 O
(IP3, O
7.5 O
μM) O
addition O
in O
permeabilized O
cells O
. O

Uncropped O
images O
of O
blots/gels O
are O
shown O
in O
Supplementary O
Fig O
. O

S6 O
. O

Digitonin-permeabilized O
HeLa O
cells O
bathed O
in O
intracellular-like O
solution O
containing O
thapsigargin O
(Tg) O
were O
loaded O
with O
the O
ΔΨm O
indicator O
JC-1 O
and O
the O
Ca2+ O
indicator O
Fura2FF, O
to O
which O
pulses O
of O
10 O
μM O
Ca2+ O
were O
added O
before O
the O
addition O
of O
the O
mitochondrial O
uncoupler O
CCCP O
(carbonyl O
cyanide O
m-chloro O
phenyl O
hydrazone) O
. O

(a-e) O
Representative O
traces O
from O
three O
independent O
experiments O
depict O
simultaneous O
changes O
of O
bath O
[Ca2+] O
and O
ΔΨm O
in O
cells O
expressing O
negative O
shRNA O
(Neg O
shRNA; O
a), O
clone O
shHe1 O
(b), O
clone O
shHe2 O
(c), O
clone O
shHe2 O
re-expressing O
MCUR1 B-proteingene
(d) O
and O
HeLa O
cells O
stably O
overexpressing O
MCUR1 B-proteingene
(e) O
. O

Under O
similar O
conditions, O
1 O
μM O
Ru360 O
was O
added O
before O
10 O
μM O
Ca2+ O
pulses O
until O
the O
addition O
of O
CCCP O
. O

(f-i) O
Representative O
traces O
from O
three O
independent O
experiments O
depict O
simultaneous O
changes O
of O
bath O
[Ca2+] O
and O
ΔΨm O
in O
negative O
shRNA O
cells O
(f), O
MCUR1-knockdown B-proteingene
clone O
shHe1 O
(g) O
and O
shHe2 O
(h), O
and O
in O
control O
cells O
overexpressing O
MCUR1 B-proteingene
(i) O
. O

(j,k) O
Negative O
shRNA O
(j) O
and O
MCUR1-overexpressing B-proteingene
(k) O
HEK293T O
cells O
were O
permeabilized O
with O
digitonin O
in O
intracellular-like O
medium O
containing O
thapsigargin O
and O
bath O
[Ca2+] O
indicator O
Fura2FF, O
and O
then O
pulsed O
with O
10 O
μM O
Ca2+ O
. O

After O
mitochondrial O
clearance O
of O
bath O
Ca2+, O
Ru360 O
caused O
an O
elevation O
of O
bath O
[Ca2+], O
indicating O
that O
steady-state O
bath O
[Ca2+] O
after O
the O
pulse O
was O
maintained O
by O
a O
balance O
of O
MCU-mediated B-proteingene
Ca2+ O
uptake O
and O
CGP37157 O
(10 O
μM)-sensitive O
Na+-Ca2+ O
exchanger-mediated O
extrusion O
. O

CCCP O
was O
added O
as O
indicated O
. O

The O
solid O
line O
is O
the O
mean; O
shaded O
areas O
are O
±s.e.m O
. O

(n O
= O
3) O
. O

(l) O
[Ca2+]m O
efflux O
rate O
derived O
from O
j O
and O
k O
during O
the O
initial O
60 O
s O
following O
Ru360 O
addition O
(NS; O
not O
significant; O
n O
= O
3) O
. O

(a,b) O
Confocal O
images O
of O
HeLa O
cells O
transiently O
co-transfected O
for O
48 O
h O
with B-proteingene
GFP-tagged B-proteingene
MCUR1 O
and B-proteingene
DsRed-Mito O
plasmids O
(a) O
or B-proteingene
mRFP-tagged B-proteingene
MCUR1 O
and B-proteingene
EYFP-Mito O
(b) O
. O

Scale O
bar, O
20 O
μm O
. O

(c) O
Immunoblot O
analysis O
of O
Flag-tagged B-proteingene
MCUR1 B-proteingene
in O
the O
HeLa O
cell O
crude O
mitochondrial O
fraction, O
outer O
mitochondrial O
membrane O
(OMM) O
and O
mitoplasts, O
using O
antibodies O
against O
VDAC1 B-proteingene
(outer O
mitochondrial O
membrane O
protein), O
COII B-proteingene
(integral O
membrane O
marker) O
and O
Flag B-proteingene
. O

(d) O
Immunoblot O
analyses O
of O
mitochondria-containing O
pellet O
and O
cytosolic O
fractions O
from O
plasma-membrane-permeabilized O
HeLa O
cells O
. O

Permeabilized O
cells O
were O
treated O
with O
or O
without O
tBid B-proteingene
(50 O
nM) O
for O
outer O
mitochondrial O
membrane O
permeabilization O
and O
the O
appearance O
of O
cytosolic O
cytochrome B-proteingene
c I-proteingene
was O
verified O
. O

Intact O
and O
outer O
mitochondrial O
membrane O
permeabilized O
samples O
were O
exposed O
to O
proteinase O
K O
for O
10 O
min O
. O

These O
samples O
were O
probed O
using O
antibodies O
against O
HSP60, B-proteingene
OXA1, B-proteingene
Flag B-proteingene
and O
MCUR1 B-proteingene
. O

(e) O
Reciprocal O
co-immunoprecipitation O
(IP) O
of O
MCU-GFP B-proteingene
and O
MCUR1-Flag B-proteingene
transiently O
expressed O
in O
COS7 O
cells O
. O

Representative O
of O
four O
independent O
experiments O
. O

WB, O
western O
blot O
. O

(f) O
Co-immunoprecipitation O
of O
MICU1-Flag B-proteingene
with O
MCU-GFP B-proteingene
but O
not O
with O
MCUR1-GFP B-proteingene
transiently O
expressed O
in O
COS7 O
cells O
. O

Representative O
of O
four O
independent O
experiments O
. O

(g) O
Immunoprecipitation O
of O
LETM1-GFP B-proteingene
with O
anti-LETM1 B-proteingene
failed O
to O
pull O
down O
MCUR1-Flag B-proteingene
in O
transiently O
transfected O
COS7 O
cells O
. O

(h) O
Immunoprecipitation O
with O
Flag B-proteingene
antibody O
pulled O
down O
LETM1-Flag B-proteingene
or O
MCU-Flag B-proteingene
transiently O
expressed O
in O
COS7 O
cells O
(immunoprecipitation O
lanes O
2 O
and O
3, O
lower O
panel), O
but O
only O
co-immunoprecipitatedMCUR1-V5 B-proteingene
in O
the O
MCU-Flag-expressing B-proteingene
cells O
(immunoprecipitation O
lanes O
4 O
versus O
5, O
upper O
panel), O
despite O
lower O
expression O
of O
MCU-Flag B-proteingene
in O
MCUR1-co-transfected B-proteingene
cells O
(compare O
MCU-Flag B-proteingene
and O
LETM1-Flag B-proteingene
expression O
in O
MCUR1-co-transfected B-proteingene
cells O
in O
lysate O
lanes O
4 O
and O
5, O
bottom O
panel) O
. O

Representative O
of O
three O
independent O
experiments O
. O

Uncropped O
images O
of O
blots/gels O
are O
shown O
in O
Supplementary O
Fig O
. O

S6 O
. O

(a) O
qrtPCR O
of O
MCU B-proteingene
mRNA O
from O
wild-type O
and O
stable O
MCUR1-overexpressing B-proteingene
HeLa O
cells O
that O
were O
transiently O
transfected O
with O
scrambled O
siRNA O
or O
siRNA O
against O
MCU. B-proteingene
***P0.001 O
(mean±s.e.m O
. O

) O
. O

(b) O
[Ca2+]m O
responses O
to O
histamine O
(100 O
μM) O
in O
HeLa O
cells O
stably O
overexpressing B-proteingene
MCUR1 O
and O
in O
cells O
transiently O
transfected O
with O
scrambled O
siRNA O
or B-proteingene
MCU O
siRNA, O
and O
in O
stable B-proteingene
MCUR1-overexpressing O
HeLa O
cells O
transfected O
with B-proteingene
MCU O
siRNA. O
After O
48 O
h O
of O
siRNA O
transfection, O
cells O
were O
loaded O
with O
rhod-2 O
and O
[Ca2+]m O
responses O
were O
visualized O
by O
confocal O
microscopy O
. O

Solid O
lines O
are O
mean; O
shaded O
regions O
are O
±s.e.m O
. O

; O
n O
= O
3 O
. O

(c) O
Quantification O
of O
peak O
rhod-2 O
fluorescence O
following O
histamine O
stimulation O
. O

*P0.05, O
***P0.001 O
(mean±s.e.m O
. O

; O
NS, O
not O
significant; O
n O
= O
3) O
. O

(d) O
qrtPCR O
of O
MCU B-proteingene
mRNA O
from O
wild-type O
and O
MCUR1-knockdown B-proteingene
HeLa O
cells O
that O
were O
transiently O
transfected O
with O
MCU B-proteingene
cDNA. O
**P0.01, O
***P0.001 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(e) O
[Ca2+]m O
responses O
to O
histamine O
(100 O
μM) O
in O
wild-type O
and B-proteingene
MCUR1 O
(shHe2)-knockdown O
HeLa O
cells O
overexpressing B-proteingene
MCU. O
Negative O
shRNA O
(Neg O
shRNA) O
and B-proteingene
MCUR1-shHe2 O
cells O
were O
used O
as O
controls O
. O

Solid O
lines O
are O
mean; O
shaded O
regions O
are O
±s.e.m O
. O

; O
n O
= O
3 O
. O

(f) O
Quantification O
of O
peak O
rhod-2 O
fluorescence O
following O
histamine O
stimulation O
. O

***P0.001 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(a) O
AMP/ATP O
ratios O
in O
stable O
HeLa O
cell O
lines O
stably O
expressing O
negative O
shRNA O
(Neg O
shRNA), O
MCUR1 B-proteingene
shRNA O
(clone O
shHe2) O
or O
shHe2 O
with O
MCUR1 B-proteingene
re-expressed O
. O

**P0.01 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(b) O
O2 O
consumption O
rates O
(OCR) O
in O
stable O
HeLa O
cells O
expressing O
irrelevant O
shRNA, O
clone O
shHe2, O
and O
clone O
shHe2 O
re-expressing O
MCUR1, B-proteingene
exposed O
sequentially O
to O
oligomycin O
(i), O
FCCP O
(ii) O
and O
rotenone O
plus O
myzothiazol O
(iii) O
. O

(c) O
Basal O
and O
maximal O
O2 O
consumption O
rates O
in O
cells O
as O
described O
in O
b O
. O

*P0.05 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(d) O
Western O
blot O
of O
phosphorylated O
and O
total O
AMPK B-proteingene
(top) O
and O
densitometric O
analysis O
(bottom) O
in O
stable O
HeLa O
lines O
expressing O
negative O
shRNA O
or O
MCUR1 B-proteingene
shRNA O
(clone O
shHe2) O
and O
clone O
shHe2 O
re-expressing O
MCUR1 B-proteingene
. O

*P0.05, O
**P0.01 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(e) O
Western O
blot O
of O
LC3 B-proteingene
or O
tubulin B-proteingene
in O
stable O
HeLa O
lines O
expressing O
negative O
shRNA O
or O
MCUR1 B-proteingene
shRNA O
(clone O
shHe2) O
and O
clone O
shHe2 O
re-expressing O
MCUR1 B-proteingene
(top) O
and O
quantification O
of O
LC3-II/(LC3-I B-proteingene
+ O
LC3-II) B-proteingene
(bottom) O
expressed O
as O
fold O
increase O
over O
levels O
in O
cells O
expressing O
irrelevant O
shRNA. O
*P0.05, O
**P0.01 O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

(f,g), O
The O
same O
as O
in O
d O
and O
e. O
Activation O
of O
AMPK B-proteingene
(f) O
and O
autophagy O
(**P0.001; O
mean±s.e.m O
. O

; O
n O
= O
3) O
(g) O
in O
the O
absence O
and O
presence B-proteingene
of O
InsP3R O
inhibitor O
xestospongin O
B O
(XeB) O
. O

*P0.05, O
**P0.001, O
NS, O
not O
significant O
(mean±s.e.m O
. O

; O
n O
= O
3) O
. O

Uncropped O
images O
of O
blots/gels O
are O
shown O
in O
Supplementary O
Fig O
. O

S6 O
. O

(A) O
Ribbon O
representation O
of O
the O
Atg12-Atg5 B-proteingene
conjugate O
bound O
to O
Atg16N. B-proteingene
Atg12, B-proteingene
Atg5 B-proteingene
and O
Atg6 B-proteingene
are O
coloured O
salmon O
pink, O
green O
and O
orange, O
respectively O
. O

Atg12 B-proteingene
Phe O
185 O
and O
Gly O
186 O
and O
Atg5 B-proteingene
Lys O
149 O
are O
shown O
with O
a O
stick O
model O
. O

The O
disordered O
C‐terminal O
region O
of O
Atg12 B-proteingene
(residues O
182-184) O
is O
indicated O
with O
a O
broken O
line O
. O

The O
left O
figure O
was O
obtained O
by O
a O
90° O
rotation O
of O
the O
right O
figure O
along O
the O
vertical O
axis O
. O

The O
amino‐ O
and O
carboxy‐termini O
are O
denoted O
as O
N O
and O
C, O
respectively O
. O

All O
of O
the O
figures O
representing O
the O
molecular O
structures O
were O
generated O
with O
PyMOL O
[ O
26] O
. O

(B) O
Stereo O
view O
of O
the O
detailed O
interactions O
between O
Atg12 B-proteingene
and O
Atg5 B-proteingene
. O

The O
side O
chains O
of O
the O
residues O
involved O
in O
the O
Atg12-Atg5 B-proteingene
interaction O
are O
shown O
with O
a O
stick O
model, O
in O
which O
nitrogen O
and O
oxygen O
atoms O
are O
coloured O
red O
and O
blue, O
respectively O
. O

(C) O
Electron O
density O
map O
of O
the O
isopeptide O
linkage O
between O
Atg12 B-proteingene
Gly O
186 O
and B-proteingene
Atg5 O
Lys O
149 O
. O

The O
simulated O
annealing O
Fo-Fc O
difference O
Fourier O
map O
was O
calculated O
by O
omitting O
Atg12 B-proteingene
Phe O
185 O
and O
Gly O
186 B-proteingene
and O
Atg5 O
Lys O
149, O
and O
is O
shown O
with O
black O
meshes O
at O
5.0σ O
. O

(D) O
Superimposition O
of O
the O
Atg5‐Atg16N B-proteingene
complex O
structure O
(PDB O
ID O
2DYM) O
on O
that O
of O
the O
Atg12-Atg5‐Atg16N B-proteingene
complex O
. O

The O
Atg12-Atg5‐Atg16N B-proteingene
complex O
is O
coloured O
red, O
while O
the O
Atg5‐Atg16N B-proteingene
complex O
is O
coloured O
grey O
. O

Atg12 B-proteingene
Phe O
185 O
and O
Gly O
186 O
and O
the O
side O
chain O
of O
Atg5 B-proteingene
Lys O
149 O
are O
shown O
with O
a O
stick O
model O
. O

(E) O
In O
vivo O
analyses O
of O
the O
Atg12 B-proteingene
and O
Atg5 B-proteingene
mutants O
for O
studying O
the O
functional O
significance O
of O
the O
non‐covalent O
Atg12‐Atg5 B-proteingene
interactions O
. O

Yeast O
cells O
with O
or O
without O
starvation O
were O
lysed O
and O
subjected O
to O
ureaSDS-polyacrylamide O
gel O
electrophoresis O
(PAGE) O
followed O
by O
western O
blotting O
. O

Ape1, B-proteingene
aminopeptidase B-proteingene
I; I-proteingene
mApe1, B-proteingene
mature O
form O
of O
Ape1; B-proteingene
PE, O
phosphatidylethanolamine; O
prApe1, B-proteingene
preform O
of O
Ape1; B-proteingene
WT, O
wild‐type O
. O

(A) O
In O
vitro O
pull‐down O
assay O
using O
recombinant O
plant O
Atg O
homologues O
. O

CBB, O
Coomassie O
Brilliant O
Blue O
staining; O
GST, O
S; B-proteingene
HA, O
haemagglutinin; B-proteingene
PE, O
phosphatidylethanolamine; O
WT, O
wild‐type O
. O

(B) O
Mapping O
of O
the O
mutated O
residues O
on O
the O
Atg12-Atg5‐Atg16N B-proteingene
complex O
structure O
. O

Atg5 B-proteingene
and O
Atg16N B-proteingene
are O
shown O
with O
a O
ribbon O
model, O
whereas O
Atg12 B-proteingene
is O
shown O
with O
both O
surface O
and O
ribbon O
models O
. O

The O
side O
chains O
of O
Tyr O
147, O
Tyr O
149 O
and O
Phe O
154 O
of O
Atg12 B-proteingene
are O
shown O
with O
a O
stick O
model O
and O
coloured O
grey O
(Tyr O
147) O
or O
blue O
(Tyr O
149 O
and O
Phe O
154) O
. O

Corresponding O
AtAtg12b O
residues O
are O
indicated O
in O
parentheses O
. O

Atg12 B-proteingene
Phe O
185 O
and O
Gly O
186 O
and O
the O
side O
chain O
of O
Atg5 B-proteingene
Lys O
149 O
are O
shown O
with O
a O
stick O
model O
. O

Mutations O
in O
epg-7 B-proteingene
cause O
defective O
degradation O
of O
SQST-1 B-proteingene
aggregates O
. O

(A O
and O
B) O
In O
wild-type O
embryos, O
SQST-1::GFP B-proteingene
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
the O
cytoplasm O
. O

(A) O
DIC O
image O
of O
the O
embryo O
shown O
in O
B O
. O

(C) O
Elevated O
expression O
level O
and O
accumulation O
of O
many O
SQST-1::GFP B-proteingene
aggregates O
in O
epg-7 B-proteingene
mutant O
embryos O
. O

(D) O
Compared O
with O
wild O
type O
and O
epg-2 B-proteingene
mutants, O
levels O
of O
SQST-1 B-proteingene
are O
dramatically O
elevated O
in O
atg-3 B-proteingene
and O
epg-7 B-proteingene
mutant O
embryos O
in O
an O
immunoblotting O
assay O
. O

(E-G) O
Compared O
with O
wild-type O
embryos O
(E O
and O
F), O
endogenous O
SQST-1 B-proteingene
shows O
dramatically O
elevated O
levels O
and O
accumulates O
into O
a O
large O
number O
of O
aggregates O
in O
epg-7 B-proteingene
mutant O
embryos O
(G) O
. O

∼200-cell O
stage O
embryos O
are O
shown O
in O
E-G. O
(E) O
DAPI O
image O
of O
the O
embryo O
shown O
in O
F O
. O

(H) O
Number O
of O
SQST-1 B-proteingene
aggregates O
per O
focal O
plane O
in O
wild O
type, O
atg-3 B-proteingene
mutants, O
and O
epg-7 B-proteingene
mutants O
. O

(I-L) O
At O
the O
∼100-cell O
stage, O
far O
fewer O
SQST-1 B-proteingene
aggregates O
are O
formed O
in O
epg-7 B-proteingene
mutants O
than O
in O
atg-3 B-proteingene
mutants O
. O

(I O
and O
K) O
DAPI O
images O
of O
the O
embryos O
shown O
in O
J O
and O
L, O
respectively O
. O

(M) O
SQST-1 B-proteingene
directly O
interacts O
with O
ZK1053.4 B-proteingene
in O
a O
GST B-proteingene
pull-down O
assay O
. O

(N) O
Compared O
with O
wild-type O
animals, O
levels O
of O
ZK1053.4::GFP B-proteingene
are O
dramatically O
elevated O
in O
atg-3 B-proteingene
and O
epg-7 B-proteingene
mutants O
. O

(O-R) O
ZK1053.4::GFP B-proteingene
is O
weakly O
expressed O
in O
wild-type O
embryos O
(O-P) O
and O
sqst-1 B-proteingene
mutants O
(R), O
but O
forms O
a O
large O
number O
of O
aggregates O
in O
epg-7 B-proteingene
mutants O
(Q) O
. O

(O) O
DIC O
image O
of O
the O
embryo O
shown O
in O
P O
. O

(S) O
Survival O
curve O
of O
L1 O
larvae O
under O
food O
depletion O
conditions O
in O
wild O
type, O
epg-1 B-proteingene
mutants, O
and O
epg-7 B-proteingene
mutants O
. O

This O
experiment O
was O
completed O
once O
(wild O
type: O
n O
= O
2,964; O
epg-7: B-proteingene
n O
= O
602; O
epg-1: B-proteingene
n O
= O
215) O
. O

Statistical O
analysis O
of O
L1 O
survival O
shows O
that O
epg-7 B-proteingene
mutants O
exhibit O
significant O
difference O
to O
wild O
type O
and O
also O
to O
epg-1 B-proteingene
mutants O
(log-rank O
test, O
P O
= O
0.000) O
. O

(T) O
Loss O
of O
function O
of O
epg-7 B-proteingene
does O
not O
ameliorate O
the O
degeneration O
of O
mec-4::gfp-labeled B-proteingene
touch O
neurons O
caused O
by O
mec-4(u231) B-proteingene
. O

(U) O
Survival O
curves O
of O
wild O
type O
and O
various O
mutants O
. O

sqst-1;epg-7 B-proteingene
mutants O
have O
a O
shortened O
mean O
and O
maximum O
life O
span O
. O

(P O
= O
0.000 O
for O
epg-7 B-proteingene
or O
wild O
type O
vs. O
sqst-1;epg-7 B-proteingene
in O
all O
three O
repeats; O
log-rank O
test) O
. O

(V) O
Survival O
of O
hydrogen O
peroxide-treated O
animals O
. O

(In O
all O
three O
repeats, O
P O
= O
0.000 O
for O
epg-7 B-proteingene
vs. O
sqst-1;epg-7; B-proteingene
P O
> O
0.2 O
for O
wild O
type O
vs. O
sqst-1;epg-7; B-proteingene
log-rank O
test) O
. O

(W) O
Survival O
of O
animals O
at O
the O
indicated O
time O
after O
heat O
shock O
treatment O
. O

(P O
< O
0.05 O
for O
wild O
type O
vs. O
epg-7 B-proteingene
or O
epg-7 B-proteingene
vs. O
sqst-1;epg-7 B-proteingene
at O
5, O
6, O
and O
7 O
h) O
. O

(X) O
Dauer O
formation O
of O
daf-2(e1370) B-proteingene
mutants O
in O
different O
backgrounds O
. O

(D) O
A O
large O
number O
of O
SQST-1::GFP B-proteingene
aggregates O
accumulate O
in O
epg-7 B-proteingene
mutant O
embryos O
carrying O
an O
epg-7(del B-proteingene
Atg11) B-proteingene
transgene O
. O

(E O
and O
F) O
No O
SQST-1 B-proteingene
aggregates O
are O
detected O
in O
epg-7 B-proteingene
mutants O
carrying O
an O
epg-7::gfp B-proteingene
reporter O
. O

(E) O
DAPI O
image O
of O
the O
embryo O
shown O
in O
F O
. O

(G) O
EPG-7::GFP B-proteingene
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
the O
cytoplasm O
in O
wild-type O
embryos O
. O

(H-I) O
EPG-7::GFP B-proteingene
is O
expressed O
in O
pharyngeal O
muscles O
(H, O
arrow) O
and O
cells O
in O
the O
tail O
region O
(I) O
at O
larval O
stages O
. O

(J) O
Compared O
with O
wild-type O
animals, O
levels O
of O
EPG-7::GFP B-proteingene
are O
dramatically O
elevated O
in O
epg-4 B-proteingene
mutants, O
but O
remain O
unchanged O
in O
sqst-1 B-proteingene
mutants O
. O

(K) O
The O
expression O
level O
of O
EPG-7::GFP B-proteingene
is O
dramatically O
elevated O
and O
many O
EPG-7::GFP B-proteingene
aggregates O
are O
formed O
in O
lgg-1 B-proteingene
mutant O
embryos O
. O

(L O
and O
M) O
No O
EPG-7 B-proteingene
aggregates, O
detected O
by O
anti-EPG-7 B-proteingene
antibody, O
are O
formed O
in O
wild-type O
embryos O
. O

(L) O
DAPI O
image O
of O
the O
embryo O
shown O
in O
M. O
(N) O
Levels O
of O
EPG-7 B-proteingene
are O
dramatically O
elevated O
and O
a O
large O
number O
of O
EPG-7 B-proteingene
aggregates O
are O
formed O
in O
atg-3 B-proteingene
mutants O
. O

(O) O
No O
EPG-7 B-proteingene
aggregates O
are O
formed O
in O
sqst-1 B-proteingene
mutant O
embryos O
. O

(A) O
EPG-7 B-proteingene
colocalizes O
with O
SQST-1 B-proteingene
aggregates O
in O
epg-8 B-proteingene
mutant O
embryos O
. O

Colocalization O
was O
defined O
as O
two O
aggregates O
showing O
>70% O
overlap O
in O
their O
fluorescence O
signals O
. O

Insets O
show O
a O
magnified O
view O
. O

(B) O
Percentage O
of O
EPG-7 B-proteingene
aggregates O
colocalized O
with O
SQST-1 B-proteingene
in O
indicated O
autophagy O
mutants O
. O

(C) O
A O
coimmunoprecipitation O
assay O
reveals O
that O
EPG-7 B-proteingene
associates O
with O
SQST-1 B-proteingene
. O

(D) O
EPG-7 B-proteingene
interacts O
with O
SQST-1 B-proteingene
in O
a O
pull-down O
assay O
. O

(E) O
EPG-7 B-proteingene
self-associates O
in O
a O
pull-down O
assay O
. O

(F) O
SDS-PAGE O
and O
blue-native O
PAGE O
of O
purified O
EPG-7(520-714) B-proteingene
proteins O
. O

Lane O
M O
shows O
molecular O
weight O
marker O
. O

Lanes O
1, O
2, O
3, O
and O
4 O
contain O
10, O
5, O
2.5, O
and O
1.25 O
µg O
of O
proteins, O
respectively O
. O

(G) O
An O
EPG-7 B-proteingene
fragment O
containing O
amino O
acids O
531-631 O
self-interacts O
. O

(H O
and O
I) O
SQST-1 B-proteingene
aggregates O
accumulate O
in O
epg-7 B-proteingene
mutant O
embryos O
carrying O
an O
epg-7(del B-proteingene
531-631)::gfp B-proteingene
transgene O
. O

(H) O
DAPI O
image O
of O
the O
embryo O
shown O
in O
I O
. O

(J O
and O
K) O
EPG-7(del B-proteingene
531-631)::GFP B-proteingene
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
epg-7(tm2508) B-proteingene
embryos O
. O

Its O
expression O
is O
not O
elevated O
in O
lgg-1(RNAi) B-proteingene
animals O
. O

H-K O
show O
embryos O
carrying O
the O
same O
transgene O
. O

Images O
in O
J O
and O
K O
were O
taken O
using O
the O
same O
exposure O
time O
. O

(L O
and O
M) O
SQST-1 B-proteingene
self-interacts O
(L) O
and O
the O
self-interaction O
is O
mediated O
by O
a O
fragment O
containing O
amino O
acids O
26-181 O
(M) O
. O

(N) O
Levels O
of O
SQST-1(del B-proteingene
26-181)::GFP B-proteingene
are O
dramatically O
elevated O
in O
epg-7 B-proteingene
and O
atg-3 B-proteingene
mutants O
. O

(O O
and O
P) O
SQST-1(del B-proteingene
26-181)::GFP B-proteingene
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
sqst-1(ok2892) B-proteingene
mutant O
embryos O
. O

(O) O
DIC O
image O
of O
the O
embryo O
shown O
in O
P O
. O

(Q O
and O
R) O
SQST-1(del B-proteingene
26-181)::GFP B-proteingene
is O
expressed O
at O
dramatically O
elevated O
levels O
and O
accumulates O
into O
a O
large O
number O
of O
aggregates O
in O
lgg-1 B-proteingene
(Q) O
and O
epg-7 B-proteingene
(R) O
mutants O
. O

(A-D) O
Expression O
of O
LGG-1 B-proteingene
in O
wild-type O
embryos O
at O
the O
∼100-cell O
(A O
and O
B), O
the O
∼200-cell O
(C), O
and O
the O
fourfold O
(D) O
stages O
. O

(A) O
DAPI O
image O
of O
the O
embryo O
shown O
in O
B O
. O

(E) O
Loss O
of O
function O
of O
epg-7 B-proteingene
does O
not O
increase O
levels O
of O
LGG-1 B-proteingene
and O
also O
does O
not O
suppress O
accumulation O
of O
LGG-1 B-proteingene
in O
epg-3 B-proteingene
mutant O
embryos O
. O

(F-H) O
Expression O
of O
LGG-1 B-proteingene
in O
epg-7 B-proteingene
mutant O
embryos O
before O
the O
∼100-cell O
stage O
(F), O
at O
the O
∼200-cell O
stage O
(G), O
and O
at O
the O
fourfold O
stage O
(H) O
. O

Images O
in O
B-D O
and O
F-H O
were O
taken O
using O
the O
same O
exposure O
time O
. O

(I) O
SQST-1 B-proteingene
aggregates O
are O
separable O
from O
LGG-1 B-proteingene
puncta O
in O
epg-7 B-proteingene
mutant O
embryos O
. O

Insets O
show O
a O
magnified O
view O
. O

(J) O
In O
epg-6 B-proteingene
mutant O
embryos, O
LGG-1 B-proteingene
puncta O
and O
SQST-1 B-proteingene
aggregates O
are O
enlarged O
and O
colocalized O
. O

(K) O
LGG-1 B-proteingene
and O
SQST-1 B-proteingene
aggregates O
are O
smaller O
in O
size O
and O
largely O
separable O
in O
epg-6;epg-7 B-proteingene
double O
mutants O
. O

(I-K) O
DAPI O
images O
of O
the O
embryos O
shown O
in O
the O
same O
row O
. O

(L-O) O
Enlarged O
LGG-1 B-proteingene
and O
SQST-1 B-proteingene
aggregates O
are O
colocalized O
in O
epg-4 B-proteingene
mutants O
(L O
and O
M) O
. O

Simultaneously O
depleting O
epg-7 B-proteingene
reduces O
the O
size O
of O
LGG-1 B-proteingene
puncta O
and O
SQST-1 B-proteingene
aggregates, O
which O
become O
largely O
separable O
(N O
and O
O) O
. O

(L O
and O
N) O
DAPI O
images O
of O
the O
embryos O
shown O
in O
M O
and O
O, O
respectively O
. O

(P) O
In O
atg-9 B-proteingene
mutant O
embryos, O
LGG-1 B-proteingene
puncta O
largely O
colocalize O
with O
SQST-1 B-proteingene
aggregates O
at O
the O
comma O
stage O
. O

Notably, O
there O
are O
more O
SQST-1 B-proteingene
aggregates O
than O
LGG-1 B-proteingene
puncta O
. O

(Q) O
SQST-1 B-proteingene
aggregates O
are O
separable O
from O
LGG-1 B-proteingene
puncta O
in O
atg-9;epg-7 B-proteingene
mutants O
at O
the O
comma O
stage O
. O

(R) O
Percentage O
of O
LGG-1 B-proteingene
puncta O
colocalized O
with O
SQST-1 B-proteingene
aggregates O
in O
indicated O
autophagy O
mutants O
. O

Comma-stage O
embryos O
were O
examined O
for O
atg-9 B-proteingene
and O
atg-9;epg-7 B-proteingene
mutants O
. O

∼200-cell O
stage O
embryos O
were O
examined O
for O
other O
autophagy O
mutants O
. O

(A) O
EPG-7 B-proteingene
coimmunoprecipitates O
with O
ATG-9::HA B-proteingene
. O

(B) O
EPG-7 B-proteingene
directly O
interacts O
with O
ATG-9 B-proteingene
in O
a O
GST B-proteingene
pull-down O
assay O
. O

(C O
and O
D) O
Coimmunoprecipitation O
reveals O
that O
EPG-7 B-proteingene
associates O
with O
LGG-3 B-proteingene
(C) O

(C O
and O
D) O
Coimmunoprecipitation O
reveals O
that O
EPG-7 B-proteingene
associates O
with O
LGG-1 B-proteingene
(D) O
. O

(E) O
EPG-7 B-proteingene
directly O
interacts O
with O
LGG-3 B-proteingene
. O

(F) O
EPG-7 B-proteingene
fragments O
containing O
amino O
acids O
852-1003 O
or O
1004-1142, O
but O
not O
762-851, O
interact O
with O
LGG-1 B-proteingene
. O

(G) O
Fragments O
of O
EPG-7 B-proteingene
containing O
amino O
acids O
762-851 O
or O
852-1003 O
directly O
interact O
with O
ATG-18 B-proteingene
. O

(H) O
Fragments O
of O
EPG-7 B-proteingene
containing O
amino O
acids O
1-704 O
or O
1143-1330 O
directly O
interact O
with O
UNC-51 B-proteingene
. O

(I) O
SQST-1 B-proteingene
associates O
with O
LGG-1 B-proteingene
in O
vivo O
. O

Embryonic O
extracts O
from O
epg-7 B-proteingene
mutants O
show O
that O
interaction O
of O
SQST-1 B-proteingene
with O
LGG-1 B-proteingene
is O
EPG-7 B-proteingene
independent O
. O

(J) O
Fragments O
of O
SQST-1 B-proteingene
containing O
amino O
acids O
351-499 O
and O
604-693, O
but O
not O
500-603, O
interact O
with O
LGG-1 B-proteingene
. O

(K) O
Fragments O
of O
SQST-1-containing B-proteingene
amino O
acids O
418-499 O
and O
604-630 O
bind O
to O
LGG-1 B-proteingene
. O

Mutating O
the O
putative O
LIR O
in O
the O
604-630 O
fragment O
(605YPDL608 O
to O
APDA) O
does O
not O
affect O
the O
binding O
. O

(L O
and O
M) O
SQST-1(del B-proteingene
LGG-1-1+2)::GFP, B-proteingene
in O
which O
the O
two O
LGG-1-binding B-proteingene
fragments O
(amino O
acids O
418-499 O
and O
604-630) O
are O
deleted, O
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
the O
cytoplasm O
in O
sqst-1(ok2892) B-proteingene
mutants O
. O

(N O
and O
O) O
Loss O
of O
function O
of O
lgg-1 B-proteingene
dramatically O
elevates O
the O
expression O
level O
of O
SQST-1(del B-proteingene
LGG-1-1+2)::GFP, B-proteingene
which O
forms O
a O
large O
number O
of O
aggregates O
. O

(L O
and O
N) O
DIC O
images O
of O
the O
embryos O
shown O
in O
M O
and O
O, O
respectively O

(P) O
SQST-1(del B-proteingene
LGG-1-1+2)::GFP B-proteingene
aggregates O
colocalize O
with O
EPG-7 B-proteingene
in O
lgg-1;sqst-1 B-proteingene
mutants O
. O

Insets O
show O
a O
magnified O
view O
. O

Formation O
of O
ATG-9 B-proteingene
puncta O
in O
various O
autophagy O
mutants O
. O

(A O
and O
B) O
In O
wild-type O
embryos, O
ATG-9::GFP B-proteingene
is O
diffusely O
localized O
in O
the O
cytoplasm O
. O

(A) O
DIC O
image O
of O
the O
embryo O
shown O
in O
B. O
Insets O
show O
a O
magnified O
view O
. O

(C) O
ATG-9::GFP B-proteingene
forms O
a O
large O
number O
of O
small, O
intense O
puncta O
in O
epg-1 B-proteingene
mutants O
. O

(D O
and O
E) O
Accumulation O
of O
ATG-9::GFP B-proteingene
puncta O
in O
unc-51(D) B-proteingene
and O
epg-1 B-proteingene
(E) O
mutants O
is O
independent O
of O
lgg-1 B-proteingene
. O

(F) O
The O
ATG-9::GFP B-proteingene
puncta O
largely O
disappear O
in O
epg-1;epg-7 B-proteingene
mutants O
. O

(G) O
ATG-9::GFP B-proteingene
accumulates O
into O
large O
punctate O
structures O
in O
epg-6 B-proteingene
mutants O
. O

(H) O
Loss O
of O
function O
of O
lgg-1 B-proteingene
suppresses O
the O
accumulation O
of O
ATG-9::GFP B-proteingene
puncta O
in O
epg-6 B-proteingene
mutants O
. O

(I) O
Loss O
of O
function O
of O
epg-7 B-proteingene
has O
no O
effect O
on O
the O
formation O
of O
ATG-9::GFP B-proteingene
puncta O
in O
epg-6 B-proteingene
mutants O
. O

The O
ATG-9::GFP B-proteingene
puncta O
are O
smaller O
in O
epg-6;epg-7 B-proteingene
mutants O
than O
those O
in O
epg-6 B-proteingene
single O
mutants O
. O

(J-L) O
ATG-9::GFP B-proteingene
accumulates O
into O
large O
punctate O
structures O
in O
epg-4 B-proteingene
mutants O
(J) O
and O
the O
accumulation O
is O
suppressed O
by O
simultaneously O
depleting O
the O
activity O
of O
lgg-1 B-proteingene
(K) O
or O
epg-7 B-proteingene
(L) O
. O

(M O
and O
N) O
In O
epg-8 B-proteingene
mutants, O
ATG-9 B-proteingene
accumulates O
into O
aggregates O
(M) O
that O
are O
suppressed O
by O
loss O
of O
lgg-1 B-proteingene
activity O
(N) O
. O

(O) O
epg-7 B-proteingene
mutants O
exhibit O
the O
same O
distribution O
pattern O
of O
ATG-9::GFP B-proteingene
as O
wild-type O
embryos O
. O

(P) O
Percentage O
of O
ATG-9::GFP B-proteingene
puncta O
colocalized O
with O
EPG-7 B-proteingene
and O
SQST-1 B-proteingene
aggregates O
in O
indicated O
autophagy O
mutants O
. O

(Q-T) O
The O
ATG-9::GFP B-proteingene
puncta O
in O
epg-6 B-proteingene
(Q), O
epg-8 B-proteingene
(R), O
unc-51 B-proteingene
(S), O
and O
atg-18 B-proteingene
(T) O
mutants O
colocalize O
with O
EPG-7 B-proteingene
aggregates O
. O

(U O
and O
V) O
ATG-9::GFP B-proteingene
puncta O
in O
epg-6 B-proteingene
(U) O
and O
epg-8 B-proteingene
(V) O
mutants O
colocalize O
with O
SQST-1 B-proteingene
aggregates O
. O

(W O
and O
X) O
In O
unc-51 B-proteingene
(W) O
and O
atg-18 B-proteingene
(X) O
mutants, O
ATG-9::GFP B-proteingene
partially O
colocalizes O
with O
SQST-1 B-proteingene
aggregates O
. O

(A2) O
Levels O
of O
W07G4.5::GFP B-proteingene
in O
wild O
type, O
epg-7 B-proteingene
mutants, O
and O
atg-3 B-proteingene
L1 O
larvae O
before O
and O
after O
6 O
h O
starvation O
treatment O
. O

(B2) O
Model O
for O
the O
role O
of O
epg-7 B-proteingene
in O
degradation O
of O
SQST-1 O
aggregates O
. O

SQST-1 O
directly O
interacts O
with O
EPG-7 O
and O
is O
recruited O
into O
EPG-7 O
aggregates O
. O

EPG-7 O
also O
associates O
with O
multiple O
Atg O
proteins, O
which O
may O
be O
recruited O
to O
the O
SQST-1-EPG-7 O
complex O
in O
a O
hierarchical O
order O
. O

IM, O
isolation O
membrane O
. O

(C2) O
Hierarchical O
relationship O
of O
the O
scaffold O
proteins O
EPG-2 O
and O
EPG-7 O
and O
other O
essential O
ATG O
and O
EPG O
proteins O
in O
the O
aggrephagy O
pathway O

(A O
and O
B) O
C17E4.2::GFP B-proteingene
is O
weakly O
expressed O
and O
diffusely O
localized O
in O
a O
wild-type O
embryo O
. O

(A) O
DIC O
image O
of O
the O
embryo O
shown O
in O
B O
. O

(C O
and O
D) O
C17E4.2::GFP B-proteingene
is O
expressed O
at O
dramatically O
elevated O
levels O
and O
accumulates O
into O
many O
aggregates O
in O
lgg-1 B-proteingene
(C) O
and O
epg-7 B-proteingene
(D) O
mutant O
embryos O
. O

(E O
and O
F) O
W07G4.5::GFP B-proteingene
is O
expressed O
in O
the O
intestine O
and O
a O
few O
aggregates O
are O
formed O
in O
a O
wild-type O
embryo O
at O
the O
fourfold O
stage O
. O

(E) O
DIC O
image O
of O
the O
embryo O
shown O
in O
F. O
(G O
and O
H) O
W07G4.5::GFP B-proteingene
is O
expressed O
at O
dramatically O
elevated O
levels O
and O
accumulates O
into O
a O
large O
number O
of O
aggregates O
in O
atg-3 B-proteingene
(G) O
and O
epg-7 B-proteingene
(H) O
mutants O
. O

(I) O
Levels O
of O
C33D9.6::GFP B-proteingene
and O
W07G4.5::GFP B-proteingene
are O
dramatically O
elevated O
in O
atg-3 B-proteingene
and O
epg-7 B-proteingene
mutant O
embryos O
. O

(J O
and O
K) O
C17E4.2 B-proteingene
aggregates O
in O
atg-3 B-proteingene
mutants O
overlap O
with O
EPG-7 B-proteingene
aggregates O
(J), O
but O
are O
separable O
from O
SQST-1 B-proteingene
aggregates O
(K) O
. O

Insets O
show O
a O
magnified O
view O
. O

(L) O
Colocalization O
frequency O
of O
C17E4.2, B-proteingene
C33D9.6, B-proteingene
and O
W07G4.5 B-proteingene
aggregates O
with O
EPG-7 B-proteingene
and O
SQST-1 B-proteingene
aggregates O
in O
atg-3 B-proteingene
mutants O
. O

(M) O
SQST-1::GFP B-proteingene
accumulates O
in O
hypodermal O
cells O
in O
epg-7 B-proteingene
mutants O
at O
the O
larval O
stage O
. O

(N) O
SQST-1::GFP B-proteingene
aggregates O
disappear O
in O
rheb-1(RNAi);epg-7 B-proteingene
mutant O
larvae O
. O

(O) O
Dramatic O
accumulation O
of O
SQST-1::GFP B-proteingene
aggregates O
in O
hypodermal O
cells O
in O
atg-3 B-proteingene
mutant O
larvae O
. O

(P) O
SQST-1::GFP B-proteingene
aggregates O
persist O
in O
rheb-1(RNAi);atg-3 B-proteingene
mutant O
larvae O
. O

(Q-T) O
At O
larval O
stages, O
W07G4.5::GFP B-proteingene
forms O
aggregates O
in O
intestinal O
cells O
(Q O
and O
R) O
. O

These O
aggregates O
disappear O
upon O
RNAi O
knockdown O
of O
let-363 B-proteingene
(S O
and O
T) O
. O

(U-X) O
W07G4.5::GFP B-proteingene
aggregates O
accumulate O
in O
intestinal O
cells O
in O
epg-7 B-proteingene
mutant O
larvae O
(U O
and O
V) O
. O

These O
aggregates O
disappear O
when O
let-363 B-proteingene
is O
simultaneously O
depleted O
(W O
and O
X) O
. O

(Y O
and O
Z) O
In O
atg-3 B-proteingene
mutants, O
W07G4.5::GFP B-proteingene
aggregates O
accumulate O
in O
intestinal O
cells O
(Y) O
and O
persist O
after O
RNAi O
knockdown O
of O
let-363 B-proteingene
(Z) O
. O

(a) O
Representative O
differential O
interference O
contrast O
microscopy O
images O
of O
midgut O
cells O
from O
wild-type O
animals O
at O
the O
early O
third O
instar O
larval O
(Early O
3rd), O
late O
third O
instar O
larval O
(Late O
3rd) O
and O
at O
puparium O
formation O
(white O
prepupal, O
WPP) O
stages O
. O

(b) O
Autophagy O
detected O
by O
formation O
of O
mCherry-Atg8a B-proteingene
punctate O
spots O
in O
midgut O
cells O
from O
wild-type O
animals O
at O
indicated O
stages O
. O

Representative O
images O
are O
shown O
. O

(c) O
Midguts O
from O
control O
Atg18KG03090/wild-type B-proteingene
(Atg18/+), B-proteingene
n O
= O
14, B-proteingene
and O
Atg18KG03090/Df(3L)6112 B-proteingene
mutant O
(Atg18/Df), O
n O
= O
11, O
animals O
at O
puparium O
formation O
analysed O
by O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(d) O
Wild-type, O
control O
(Atg18KG03090/+) B-proteingene
and O
Atg18 B-proteingene
mutant O
(Atg18/Df) B-proteingene
midgut O
cell O
size O
quantification O
(μm2) O
at O
indicated O
stages; O
n O
= O
10 O
animal O
intestines O
per O
genotype O
with O
5 O
cells O
measured O
per O
intestine O
per O
stage O
. O

(e) O
Differential O
interference O
contrast O
images O
of O
midgut O
cells O
from O
Atg2EP3697/wild-type B-proteingene
control O
(Atg2/+) B-proteingene
and O
Atg2EP3697/Df(3L)6091 B-proteingene
mutant O
(Atg2/Df) B-proteingene
animals O
at O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(f) O
Cell O
size O
quantification O
(μm2) O
from O
e, O
n O
= B-proteingene
12 O
(Atg2/+) O
and B-proteingene
n O
= O
7 O
(Atg2/Df) O
animal O
intestines O
per O
genotype O
with O
5 O
cells O
measured O
per O
intestine O
. O

(g-j) O
Representative O
TEM O
images O
of O
intestine O
cells O
2 O
h O
after O
puparium O
formation O
. O

(g,i) O
Control O
Atg18KG03090/wild-type B-proteingene
(Atg18/+, B-proteingene
g) O
and O
control O
Atg2EP3697/wild-type B-proteingene
(Atg2/+, B-proteingene
i) O
cells O
with O
an O
enlarged O
image O
showing O
a O
double-membrane O
structure O
(arrowhead) O
that O
surrounds O
a O
mitochondrion O
and O
endoplasmic O
reticulum O
. O

Arrows O
indicate O
autolysosomes O
. O

(h,j) O
Atg18KG03090/Df(3L)6112mutant B-proteingene
(Atg18/Df, B-proteingene
h) O
and O
Atg2EP3697/Df B-proteingene
(Atg2/Df, B-proteingene
j) O
mutant O
cells O
lacking O
autophagic O
structures O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

Scale O
bars, O
20 O
μm O
(a-c O
and O
e) O
and O
1 O
μm O
(g-j) O
. O

(a) O
Midguts O
dissected O
from O
animals O
expressing O
Atg18IR B-proteingene
specifically O
in O
DsRed-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
(DIC) O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(b) O
Quantification O
(μm2) O
from O
a, O
n O
= O
12 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(c) O
Midguts O
expressing O
mCherry-Atg8a B-proteingene
in O
all O
cells, O
and O
expressing O
Atg18IR B-proteingene
specifically O
in O
GFP-marked B-proteingene
cell O
clones O
dissected O
from O
animals O
at O
2 O
h O
after O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(d) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
an O
Atg1Δ3D B-proteingene
loss-of-function O
mutant O
cell O
clone O
(lacking O
GFP) B-proteingene
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Wild-type O
(+/+) O
control O
cell O
possesses O
stronger O
GFP B-proteingene
and O
heterozygous O
Atg1Δ3D/wild-type B-proteingene
(Δ3D/+) O
cells O
have O
weaker O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(e) O
Quantification O
(μm2) O
from O
d, O
n O
= O
7 O
(+/+), O
n O
= O
8 O
(Δ3D/+) O
and O
n O
= O
8 O
(Δ3D/Δ3D) O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(f) O
Midguts O
dissected O
from O
animals O
expressing O
mCherry-Atg8a B-proteingene
in O
all O
cells, O
and O
expressing O
Atg1IR B-proteingene
specifically O
in O
GFP-marked B-proteingene
clones O
of O
cells O
at O
2 O
h O
after O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(g-j) O
Representative O
cut O
views O
from O
three-dimensional O
reconstitution O
images O
from O
wild-type O
(g,h) O
and O
Atg1 B-proteingene
knockdown O
(i,j) O
cells O
at O
early O
third O
instar O
larval O
stage O
(g,i) O
and O
at O
puparium O
formation O
(h,j) O
. O

(k) O
Quantification O
of O
cell O
volume O
(μm3) O
from O
g-j, O
n O
= O
5 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
per O
stage O
. O

Black O
columns: O
early O
third O
instar O
larval O
stage O
. O

White O
columns: O
puparium O
formation O
stage O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

NS, O
not O
significant O
. O

Scale O
bars, O
20 O
μm O
. O

(a) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
Vps34Δm22 B-proteingene
loss-of-function O
mutant O
cell O
clones O
(lacking O
GFP) B-proteingene
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
(DIC) O
microscopy O
. O

Wild-type O
(+/+) O
control O
cells O
possess O
stronger O
GFP B-proteingene
and O
heterozygous O
Vps34Δm22/wild-type B-proteingene
(Δm22/+) O
cells O
have O
weaker O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(b) O
Quantification O
(μm2) O
from O
a, O
n O
= O
14 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(c) O
Midguts O
dissected O
from O
animals O
expressing O
Atg8aIR B-proteingene
specifically O
in O
GFP-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(d) O
Cell O
size O
quantification O
(μm2) O
from O
c, O
n O
= O
10 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(e) O
Midguts O
dissected O
from O
animals O
expressing O
Atg12IR B-proteingene
specifically O
in O
DsRed-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(f) O
Cell O
size O
quantification O
(μm2) O
from O
e, O
n O
= O
14 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(g-i) O
Midguts O
dissected O
from O
early O
third O
instar O
larvae O
that O
mis-express O
Atg1GS10797 B-proteingene
(Atg1; B-proteingene
g, O
GFP B-proteingene
in O
nucleus O
and O
cytoplasm), O
both O
Atg1 B-proteingene
+Atg8aIR B-proteingene
(h), O
or O
both O
Atg1 B-proteingene
+Atg7IR B-proteingene
(i) O
and O
stained O
to O
detect O
Discs B-proteingene
large I-proteingene
(green) O
on O
the O
cortex O
of O
all O
cells O
. O

Representative O
images O
are O
shown O
. O

(g' O
and O
i') O
DIC O
images O
of O
midguts O
expressing O
mCherry-Atg8a B-proteingene
in O
all O
cells, O
Atg1 B-proteingene
(g'), O
and O
Atg1+Atg7IR B-proteingene
(i') O
in O
GFP-marked B-proteingene
clones O
of O
cells O
. O

mCherry-Atg8a B-proteingene
puncta O
are O
shown O
in O
insets O
. O

Representative O
images O
are O
shown O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

Scale O
bars, O
20 O
μm O
. O

(a) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
Atg7d4 B-proteingene
loss-of-function O
mutant O
cell O
clones O
(lacking O
GFP) B-proteingene
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
(DIC) O
microscopy O
. O

Wild-type O
(+/+) O
control O
cells O
possess O
stronger O
GFP B-proteingene
and O
heterozygous O
Atg7d4/wild-type B-proteingene
(d4/+) O
cells O
have O
weaker O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(b) O
Cell O
size O
quantification O
(μm2) O
from O
a, O
n O
= O
8 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(c) O
Midguts O
expressing O
mCherry-Atg8a B-proteingene
in O
all O
cells, O
and O
with O
Atg7d4 B-proteingene
loss-of-function O
clone O
cells O
(lacking O
GFP) B-proteingene
at O
2 O
h O
after O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(f) O
Midguts O
expressing O
GFP-Atg5 B-proteingene
in O
enterocytes O
(larger O
nuclei) O
with O
an O
Atg7d4 B-proteingene
loss-of-function O
clone O
cell O
(lacking O
RFP) B-proteingene
at O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(g,h) O
Representative O
TEM O
images O
of O
intestine O
cells O
2 O
h O
after O
puparium O
formation O
. O

Arrows O
indicate O
autolysosomes O
. O

(g,h) O
Control O
(Atg7d30/d14; B-proteingene
g) O
and O
Atg7 B-proteingene
mutant O
(Atg7d77/d14; B-proteingene
h) O
cells O
both O
contain O
autophagic O
structures O
. O

(h, O
right) O
Enlarged O
Atg7 B-proteingene
mutant O
cell O
image O
of O
a O
double-membrane O
autophagosome O
(arrowhead) O
surrounding O
a O
mitochondrion O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

NS, O
not O
significant O
. O

Scale O
bars, O
20 O
μm O
(a,c,d O
and O
f) O
and O
1 O
μm O
(g,h) O
. O

(a) O
Quantification O
of O
mitochondria O
numbers O
from O
Atg18 B-proteingene
control O
(Atg18KG03090/wild B-proteingene
type) O
and O
mutant O
(Atg18KG03090/Df(3L)6112) B-proteingene
or O
Atg7 B-proteingene
control O
(Atg7d30/d14) B-proteingene
and O
mutant O
(Atg7d77/d14) B-proteingene
TEM O
images O
. O

Mitochondria O
were O
quantified O
from O
2 O
distinct O
25 O
μm2 O
regions O
per O
cell O
from O
2 O
cells O
per O
animal O
from O
at O
least O
3 O
different O
animals O
per O
genotype O
. O

(b,c) O
Midguts O
dissected O
from O
either O
early O
third O
instar O
larvae O
(b) O
or O
at O
puparium O
formation O
(c) O
that O
express O
GFP-labelled B-proteingene
mitochondria O
in O
all O
cells O
and O
contain O
an O
Atg1Δ3D B-proteingene
loss-of-function O
mutant O
cell O
clone O
(lacking O
RFP) B-proteingene
. O

Wild-type O
control O
cells O
possess O
stronger O
RFP B-proteingene
and O
heterozygous O
cells O
have O
weaker O
RFP. B-proteingene
Representative O
images O
are O
shown O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

NS, O
not O
significant O
. O

Scale O
bars, O
0 O
μm O
. O

(a) O
Midguts O
dissected O
from O
animals O
expressing O
Uba1IR B-proteingene
specifically O
in O
GFP-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
(DIC) O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(b) O
Cell O
size O
quantification O
(μm2) O
from O
a; O
n O
= O
16 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(c) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
Uba1H33 B-proteingene
loss-of-function O
mutant O
cell O
clones O
(lacking O
RFP) B-proteingene
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Wild-type O
(+/+) O
control O
cells O
possess O
stronger O
RFP B-proteingene
and O
heterozygous O
Uba1H33/wild-type B-proteingene
(H33/+) O
cells O
have O
weaker O
RFP. B-proteingene
Representative O
images O
are O
shown O
. O

(d) O
Quantification O
(μm2) O
from O
c, O
n O
= O
8 O
(+/+), O
n O
= O
11 O
(H33/+) O
and O
n O
= O
11 O
(H33/H33) O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(e) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
Uba1H33 B-proteingene
loss-of-function O
MARCM O
mutant O
cell O
clones O
(GFP-positive) B-proteingene
that O
also O
have O
mCherry-Atg8a B-proteingene
expressed O
in O
all O
cells O
and O
analysed O
by O
fluorescence O
microscopy O
. O

Control O
wild-type O
and O
heterozygous O
cells O
have O
no O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(f) O
Midguts O
expressing O
GFP-Atg5 B-proteingene
in O
enterocytes O
(larger O
nuclei), O
and O
with O
an O
Uba1H33 B-proteingene
loss-of-function O
clone O
cell O
(lacking O
RFP) B-proteingene
at O
puparium O
formation O
analysed O
by O
fluorescence O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(g) O
Midguts O
dissected O
from O
animals O
at O
puparium O
formation O
that O
contain O
Uba1H33 B-proteingene
loss-of-function O
MARCM O
mutant O
cell O
clones O
(GFP-positive) B-proteingene
that O
are O
stained O
with O
p62 B-proteingene
antibody O
and O
analysed O
by O
fluorescence O
microscopy O
. O

Control O
wild-type O
and O
heterozygous O
cells O
have O
no O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(h) O
Midguts O
dissected O
from O
animals O
expressing O
Dts7, B-proteingene
a O
dominant O
temperature-sensitive O
mutant O
of O
the O
β2 O
subunit O
of O
the O
proteasome, O
specifically O
in O
GFP-marked B-proteingene
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(i) O
Cell O
size O
quantification O
(μm2) O
from O
h, O
n O
= O
6 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

NS, O
not O
significant O
. O

Scale O
bars, O
20 O
μm O
. O

(a,b) O
E1-charging O
assay O
for O
Uba1 B-proteingene
and O
Atg7 B-proteingene
with O
either O
Atg8a B-proteingene
(a) O
or O
ubiquitin B-proteingene
(Ub; O
b), O
n O
= O
2 O
experiments O
with O
independently O
isolated O
proteins O
and O
analyses O
. O

Flag-tagged B-proteingene
baculoviral-expressed O
E1s O
were O
incubated O
with O
either O
His-tagged B-proteingene
Atg8a B-proteingene
or O
Ub O
in O
the O
presence O
or O
absence O
of O
β-mercaptoethanol, O
separated O
by O
electrophoresis O
and O
blotted O
. O

Band O
shift O
was O
detected O
with O
anti-Flag B-proteingene
antibody O
. O

Relative O
molecular O
mass O
(Mr O
K) O
ladders O
are O
indicated O
. O

Representative O
images O
are O
shown O
. O

Relative O
molecular O
masses: O
Flag-Uba1, B-proteingene
135K; O
Flag-Atg7, B-proteingene
81K; O
His-Atg8a, B-proteingene
29K; O
Ub, O
9K O
. O

(c) O
Midgut O
protein O
extracts O
at O
puparium O
formation O
from O
wild-type, O
Atg7 B-proteingene
mutant O
(Atg7d77/d14) B-proteingene
and O
Atg8 B-proteingene
(Atg8KG07569) B-proteingene
mutant O
animals O
blotted O
with O
anti-Atg8 B-proteingene
and O
anti-Tubulin, B-proteingene
n O
= O
3 O
independent O
biological O
experiments O
. O

Representative O
images O
are O
shown O
. O

(d) O
Midguts O
from O
control O
Atg310/wild-type B-proteingene
(Atg3/+) B-proteingene
and O
Atg310/Df(3L)cat B-proteingene
mutant O
(Atg3/Df) B-proteingene
animals O
at O
puparium O
formation O
analysed O
by O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(e) O
Cell O
size O
quantification O
(μm2) O
from O
d, O
n O
= B-proteingene
11 O
(Atg3/+) O
and B-proteingene
n O
= O
9 O
(Atg3/Df) O
animal O
intestines O
per O
genotype O
with O
5 O
cells O
measured O
per O
intestine O
. O

(f) O
Midguts O
dissected O
from O
early O
third O
instar O
larvae O
that O
mis-express O
Atg1GS10797 B-proteingene
(Atg1) B-proteingene
and O
Atg3IR B-proteingene
only O
in O
the O
DsRed-marked B-proteingene
cell O
clone O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
(DIC) O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(g) O
Midguts O
dissected O
from O
animals O
expressing O
Atg4DN B-proteingene
specifically O
in O
DsRed-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(h) O
Cell O
size O
quantification O
(μm2) O
from O
g, O
n O
= O
10 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(i) O
Midguts O
dissected O
from O
animals O
expressing O
mCherry-Atg8a B-proteingene
in O
all O
cells, O
and O
expressing O
UbIR B-proteingene
specifically O
in O
GFP-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
. O

Representative O
images O
are O
shown O
. O

(j) O
Midguts O
dissected O
from O
animals O
expressing O
UbIR B-proteingene
specifically O
in O
GFP-marked B-proteingene
clones O
of O
cells O
at O
puparium O
formation O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Representative O
images O
are O
shown O
. O

(k) O
Cell O
size O
quantification O
(μm2) O
from O
(j), O
n O
= O
12 O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

(l,m) O
Midguts O
dissected O
from O
early O
third O
instar O
larvae O
that O
exhibit O
Atg1GS10797 B-proteingene
(Atg1) B-proteingene
mis-expression O
in O
either O
a O
wild-type O
GFP-positive B-proteingene
cell O
clone O
(l) O
or O
a O
Uba1H33 B-proteingene
loss-of-function O
MARCM O
mutant O
cell O
clone O
(GFP-positive; B-proteingene
m) O
and O
analysed O
by O
fluorescence O
and O
differential O
interference O
contrast O
microscopy O
. O

Control O
wild-type O
and O
heterozygous O
Uba1H33/wild-type B-proteingene
cells O
have O
no O
GFP. B-proteingene
Representative O
images O
are O
shown O
. O

(n) O
Quantification O
(μm2) O
from O
l O
and O
m, O
n O
= O
22 O
(control), B-proteingene
n O
= O
16 B-proteingene
(Atg1) B-proteingene
and O
n O
= O
6 O
(Atg1 O
+Uba1H33) O
animal O
intestines O
per O
genotype O
with O
1-5 O
cells O
measured O
per O
intestine O
. O

Quantification O
data O
for O
control O
cells O
(l,m) O
were O
pooled O
because O
they O
are O
genetically O
identical O
. O

Quantification O
is O
shown O
as O
mean O
± O
s.d O
. O

NS, O
not O
significant O
. O

Scale O
bars, O
20 O
μm O
. O

(a,b) O
Midguts O
dissected O
from O
either O
early O
third O
instar O
larvae O
(a) O
or O
at O
puparium O
formation O
(b) O
that O
express O
GFP-labelled B-proteingene
mitochondria O
in O
enterocytes O
(larger O
nuclei) O
and O
contain O
Uba1H33 B-proteingene
loss-of-function O
mutant O
cell O
clones O
(lacking O
RFP) B-proteingene
. O

Wild-type O
control O
cells O
possess O
stronger O
RFP B-proteingene
and O
heterozygous O
cells O
have O
weaker O
RFP. B-proteingene
Representative O
images O
are O
shown O
. O

(c) O
Midguts O
dissected O
at O
puparium O
formation O
that O
express O
Uba1IR B-proteingene
(GFP B-proteingene
in O
nucleus O
and O
cytoplasm) O
and O
stained O
with O
ATP O
synthase O
complex O
V O
(ATPV) O
to O
detect O
mitochondria O
in O
all O
cells O
. O

Representative O
images O
are O
shown O
. O

(d-f) O
Representative O
immuno-TEM O
images O
of O
Uba1IRclone B-proteingene
cells O
at O
puparium O
formation O
. O

Uba1IR-expressing B-proteingene
cells O
possess O
gold O
particles; O
control O
cells O
lack O
gold O
particles O
(d) O
. O

Control O
cells O
possess O
numerous O
autolysosomes O
in O
the O
cytoplasm O
(arrowheads) O
and O
few O
mitochondria O
(asterisks); O
Uba1IR-expressing B-proteingene
cells O
possess O
numerous O
mitochondria O
and O
few O
autophagic O
structures O
. O

Scale O
bars, O
20 O
μm O
(a-c) O
and O
1 O
μm O
(d-f) O
. O

(A) O
Proteins O
detected O
in O
Vps34-TAPimmunoprecipitations B-proteingene
by O
MS O
analysis O
are O
listed O
. O

The O
number O
of O
identified O
peptides O
of O
each O
protein O
and O
the O
peptide O
coverage O
are O
also O
shown O
. O

(B) O
Cells O
expressing O
TAP-tagged O
Atg38 B-proteingene
and O
the O
indicated O
HA-tagged B-proteingene
proteins O
were O
grown O
in O
YPD. O
The O
extracts O
were O
prepared O
and O
were O
immunoprecipitated O
by O
IgG-Dynabeads O
as O
described O
in O
Materials O
and O
methods O
. O

The O
whole-cell O
extract O
(left, O
"input") O
and O
the O
precipitated O
proteins O
(right) O
were O
analyzed O
by O
immunoblotting O
with O
the O
indicated O
antibodies O
. O

(C) O
Relative O
abundances O
of O
proteins O
identified O
by O
LC-MS/MS O
of O
Atg14-TAP B-proteingene
and O
Atg38-TAP B-proteingene
purifications O
from O
YPD-grown O
cells O
. O

Relative O
abundances O
are O
defined O
as O
emPAIprey/emPAIbait O
and O
are O
shown O
as O
mean O
± O
SD O
of O
two O
independent O
experiments O
. O

(D) O
Cell O
extracts O
were O
prepared O
from O
wild-type O
and O
atg14Δ B-proteingene
cells O
expressing O
Atg38-TAP B-proteingene
as O
well O
as O
HA-tagged B-proteingene
proteins O
of O
complex O
I O
components O
. O

The O
IgG O
Dynabead-precipitated O
proteins O
(bottom), O
together O
with O
the O
whole-cell O
extracts O
(top), O
were O
immunoblotted O
with O
the O
indicated O
antibodies O
. O

(E) O
ATG38-2GFPATG17-2mCherrycells B-proteingene
in O
wild-type O
and O
atg14Δ B-proteingene
were O
cultured O
at O
30°C O
with O
or O
without O
rapamycin O
. O

After O
180 O
min, O
cells O
were O
analyzed O
by O
fluorescence O
microscopy O
. O

Bar, O
5 O
µm O
. O

(A) O
Cells O
expressing O
Pho8Δ60 B-proteingene
were O
grown O
in O
YPD O
and O
shifted O
to O
SD(-N) O
medium O
for O
3 O
h O
at O
30°C. O
Lysates O
from O
each O
group O
of O
cells O
were O
tested O
for O
ALP B-proteingene
activity O
. O

ALP B-proteingene
activity O
is O
shown O
as O
mean O
± O
SD O
of O
three O
independent O
experiments O
with O
the O
activity O
of O
wild-type O
cells O
normalized O
to O
1 O
. O

(B) O
Cells O
with O
the O
indicated O
genotypes O
were O
grown O
in O
YPD O
and O
treated O
with O
rapamycin O
for O
3 O
h O
at O
30°C. O
Total O
protein O
was O
separated O
by O
SDS-PAGE O
and O
detected O
by O
immunoblotting O
with O
anti-API B-proteingene
. O

(C) O
Cells O
were O
grown O
in O
YPD O
medium O
for O
1 O
h O
at O
30°C O
and O
separated O
to O
the O
intracellular O
(I; O
cells) O
and O
extracellular O
(E; O
medium) O
fractions O
by O
centrifugation O
. O

The O
fractions O
were O
treated O
as O
detailed O
in O
Materials O
and O
methods O
and O
aliquots O
of O
each O
were O
separated O
by O
SDS-PAGE. O
The O
positions O
of O
the O
precursor O
(p2-CPY) B-proteingene
and O
mature O
(m-CPY) B-proteingene
forms O
of O
CPY B-proteingene
are O
indicated O
. O

(A) O
Wild-type O
and O
atg38Δ B-proteingene
cells O
expressing O
the O
indicated O
GFP B-proteingene
fusion O
proteins O
and O
Ape1-mRFP B-proteingene
were O
cultured O
at O
30°C O
in O
the O
presence O
of O
rapamycin O
. O

After O
60 O
min, O
cells O
were O
analyzed O
by O
fluorescence O
microscopy O
. O

Of O
the O
total O
pool O
of O
Ape1-mRFP B-proteingene
signal, O
the O
percentage O
of O
Ape1-mRFP B-proteingene
colocalizing O
with O
GFP B-proteingene
was O
calculated O
. O

This O
percentage O
is O
shown O
as O
mean O
± O
SD O
of O
two O
independent O
experiments, O
with O
the O
number O
of O
cells O
counted O
indicated O
at O
the O
bottom O
of O
the O
graph O
. O

(B) O
Examples O
of O
wild-type O
and O
atg38Δ B-proteingene
cells O
expressing O
either O
Atg14-3 B-proteingene
× O
GFP B-proteingene
or O
Vps34-3 B-proteingene
× O
GFP B-proteingene
in O
A. O
Bar, O
5 O
µm O
. O

(C) O
Cell O
extracts O
were O
prepared O
from O
the O
cells O
in O
A, O
then O
analyzed O
by O
immunoblotting O
with O
anti-GFP B-proteingene
and O
anti-Pgk1 B-proteingene
antibodies O
. O

(A) O
Cell O
extracts O
were O
prepared O
from O
wild-type O
and O
atg38Δ B-proteingene
strains O
expressing O
TAP-tagged B-proteingene
Atg38 B-proteingene
and O
the O
indicated O
HAproteins B-proteingene
. O

The O
extracts O
were O
immunoprecipitated O
by O
IgG-Dynabeads O
. O

The O
whole-cell O
extracts O
(top, O
"input") O
and O
the O
precipitates O
(bottom) O
were O
analyzed O
by O
immunoblotting O
with O
the O
indicated O
antibodies O
. O

Relative O
binding O
efficiency O
was O
determined O
as O
described O
in O
Materials O
and O
methods O
. O

To O
compare O
results O
from O
multiple O
experiments, O
the O
value O
for O
the O
reference O
sample O
(wild-type O
cells) O
was O
normalized O
to O
1.0 O
. O

Relative O
binding O
efficiency O
is O
shown O
as O
mean O
± O
SD O
of O
three O
independent O
experiments O
. O

(B) O
Relative O
abundances O
of O
proteins O
identified O
in O
TAP B-proteingene
purifications O
from O
the O
indicated O
strains O
were O
analyzed O
as O
described O
in O
Fig O
. O

1 O
C O
and O
are O
shown O
as O
mean O
± O
SD O
of O
two O
independent O
experiments O
. O

(C) O
Cells O
expressing O
Pho8Δ60 B-proteingene
were O
grown O
in O
YPD O
and O
shifted O
to O
SD(-N) O
medium O
for O
3 O
h O
at O
30°C. O
Cell O
lysates O
from O
each O
group O
of O
cells O
were O
tested O
for O
ALP B-proteingene
activity O
. O

ALP B-proteingene
activity O
is O
shown O
as O
mean O
± O
SD O
of O
three O
independent O
experiments O
with O
the O
activity O
of O
wild-type O
cells O
normalized O
to O
1 O
. O

(D) O
Cells O
expressing O
Vps34-6HA, B-proteingene
Vps30-9myc, B-proteingene
Atg38-3FLAG, B-proteingene
and O
Atg14-TAP B-proteingene
were O
lysed O
in O
a O
buffer O
containing O
150 O
mM O
NaCl O
. O

The O
Atg14-TAPimmunoprecipitate B-proteingene
with O
IgG-Dynabeads O
from O
this O
lysate O
was O
split O
into O
eight O
fractions O
and O
washed O
with O
lysis O
buffer O
containing O
the O
indicated O
concentrations O
of O
NaCl O
. O

The O
resulting O
precipitates O
were O
analyzed O
by O
immunoblotting O
with O
the O
indicated O
antibodies O
. O

Relative O
binding O
efficiency O
was O
determined O
as O
described O
in O
Materials O
and O
methods, O
although O
a O
150-mM O
NaCl O
sample O
was O
used O
as O
a O
control O
and O
normalized O
to O
1.0 O
. O

Relative O
binding O
efficiency O
is O
shown O
as O
mean O
± O
SD O
of O
three O
independent O
experiments O
. O

(A) O
AH109 O
cells O
containing O
the O
indicated O
GAL4 B-proteingene
activation O
domain O
fusions O
(bait) O
and O
GAL4 B-proteingene
DNA-binding O
domain O
fusions O
(prey) O
were O
selected O
on O
SD-Leu-Trp O
plates O
at O
30°C O
(−LW, O
left) O
. O

The O
interaction O
of O
fusion O
proteins O
was O
examined O
by O
plating O
cells O
on O
SD-Leu-Trp-His O
(−LWH, O
middle) O
and O
SD-Leu-Trp-Ade O
(−LWA, O
right) O
plates O
at O
30°C O
for O
3 O
d O
. O

(B) O
Interactions O
between O
the O
indicated O
fusion O
proteins O
were O
analyzed O
as O
in O
A. O
AH109 O
cells O
containing O
the O
indicated O
GAL4 B-proteingene
activation O
domain O
fusions O
(bait) O
and O
GAL4 B-proteingene
DNA-binding O
domain O
fusions O
(prey) O
were O
selected O
on O
SD-Leu-Trp O
plates O
at O
30°C O
(−LW, O
left) O
. O

The O
interaction O
of O
fusion O
proteins O
was O
examined O
by O
plating O
cells O
on O
SD-Leu-Trp-His O
(−LWH, O
middle) O
and O
SD-Leu-Trp-Ade O
(−LWA, O
right) O
plates O
at O
30°C O
for O
3 O
d O
. O

(C) O
The O
TAP-tagged B-proteingene
Vps34 B-proteingene
protein O
complex O
was O
purified O
from O
the O
vps30Δ B-proteingene
atg14Δ B-proteingene
vps38Δ B-proteingene
cells O
. O

The O
purified O
proteins O
were O
separated O
on O
SDS-PAGE O
and O
visualized O
by O
Coomassie O
staining O
. O

Recombinant O
GST-Atg38 B-proteingene
(WT), O
GST-Atg381-120 B-proteingene
(N), O
and O
GST-Atg38121-226 B-proteingene
(C) O
were O
incubated O
with O
Vps15-Vps34-TAP B-proteingene
complex O
bound O
to O
IgG-Dynabeads O
. O

The O
eluted O
proteins O
were O
analyzed O
by O
immunoblotting O
. O

(B) O
Analysis O
of O
Atg38 B-proteingene
by O
gel O
filtration O
. O

Recombinant O
Atg38 B-proteingene
protein O
was O
fractionated O
over O
a O
gel O
filtration O
column O
. O

Each O
fraction O
was O
subjected O
to O
SDS-PAGE O
and O
visualized O
by O
Coomassie O
staining O
. O

(A) O
Cell O
extracts O
were O
prepared O
from O
atg38Δ B-proteingene
strains O
expressing O
Atg14-TAP B-proteingene
and O
either O
Vps34-6HA B-proteingene
or O
Vps15-6HA B-proteingene
with O
Atg381-120 B-proteingene
fused O
with O
GFP B-proteingene
and O
either O
GBP B-proteingene
or O
GBP3A. O
The O
cell O
extracts O
were O
immunoprecipitated O
with O
IgG-Dynabeads O
. O

The O
precipitated O
proteins, O
together O
with O
the O
whole-cell O
extracts, O
were O
immunoblotted O
with O
the O
indicated O
antibodies O
(left) O
. O

Relative O
binding O
efficiency O
was O
determined O
as O
described O
in O
Fig O
. O

3 O
A O
and O
was O
shown O
as O
mean O
± O
SD O
of O
three O
independent O
experiments O
. O

a, O
Wild-type O
(WT) O
and O
Park2-/- B-proteingene
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
(Mtb) O
for O
4 O
h O
and O
immunostained O
using O
anti-parkin B-proteingene
antibodies O
. O

b, O
Wild-type O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
4 O
h O
and O
immunostained O
for O
polyubiquitin B-proteingene
. O

b, O
Wild-type O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
4 O
h O
and O
immunostained O
for O
polyubiquitin B-proteingene
. O

c, O
Quantification O
of O
ubiquitin-positive B-proteingene
M. O
tuberculosis O
from O
b O
. O

Results O
are O
means O
± O
s.e.m O
. O

of O
three O
independent O
experiments O
(**P O
< O
0.001, O
paired O
Student O
's O
t-test) O
. O

d, O
U937human O
macrophages O
expressing O
a O
scrambled O
shRNA O
(Control) O
or O
one O
of O
two O
different O
shRNAs O
targeting O
PARK2 B-proteingene
(shRNA O
no O
. O

1, O
shRNA O
no O
. O

2) O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
12 O
h O
and O
immunostained O
for O
polyubiquitin B-proteingene
. O

d, O
U937human O
macrophages O
expressing O
a O
scrambled O
shRNA O
(Control) O
or O
one O
of O
two O
different O
shRNAs O
targeting O
PARK2 B-proteingene
(shRNA O
no O
. O

1, O
shRNA O
no O
. O

2) O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
12 O
h O
and O
immunostained O
for B-proteingene
polyubiquitin O
. O

e, O
Quantification O
of O
ubiquitin B-proteingene
positive O
M. O
tuberculosis O
from O
d, O
results O
are O
means O
± O
s.e.m O
. O

of O
three O
independent O
experiments O
(**P O
0.005, O
Student O
's O
t-test) O
. O

f, O
The O
parkin B-proteingene
and O
actin B-proteingene
expression O
in O
cells O
from O
e O
was O
determined O
by O
western O
blotting O
. O

g, O
Park2−/− B-proteingene
BMDMs O
were O
transduced O
with O
lentivirus O
expressing O
BFP B-proteingene
(−), O
wild-type O
parkin, B-proteingene
or O
two O
separate O
mutant O
parkin B-proteingene
alleles O
(T240R, O
P437L) O
. O

Cells O
were O
infected O
with O
M. O
tuberculosis O
for O
4 O
h O
and B-proteingene
ubiquitin O
and O
M. O
tuberculosis O
co-localization O
was O
quantified O
and O
expressed O
relative O
to O
control O
BMDMs O
. O

Results O
are O
means O
± O
s.e.m O
. O

of O
three O
independent O
experiments O
(**P O
0.005, O
paired O
Student O
's O
t-test) O
. O

h, O
The O
parkin B-proteingene
and O
actin B-proteingene
expression O
in O
cells O
from O
g O
was O
determined O
by O
western O
blotting O
. O

a, O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
4 O
h O
and O
immunostained O
using O
linkage-specific B-proteingene
ubiquitin O
antibodies O
. O

b, O
Quantification O
of O
K63 O
and O
K48 O
ubiquitin-positive B-proteingene
M. O
tuberculosis O
from O
a O
. O

c, O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
for O
4 O
h O
and O
immunostained O
for B-proteingene
NDP52, B-proteingene
p62, B-proteingene
phospho-TBK1 O
or B-proteingene
NBR1 O
. O

d, O
Quantification O
of O
co-localization O
from O
c O
(n O
= O
3 O
per O
group, O
**P O
0.001) O
. O

All O
errors, O
s.e.m O
. O

a, O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
(arrows) O
for O
4 O
h O
and O
immunostained O
for B-proteingene
LC3 B-proteingene
(LC3B O
antibody) O
or B-proteingene
ATG12 O
. O

b, O
Quantification O
of O
results O
from O
a O
(n O
= O
3 O
per O
group, O
**P O
0.001) O
. O

c, O
Western O
blot O
analysis O
of O
LC3 B-proteingene
(LC3B B-proteingene
antibody) O
from O
cell O
lysates O
from O
a O
. O

d, O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
(arrows) O
for O
6 O
h O
and O
immunostained O
for O
LAMP1 B-proteingene
. O

d, O
BMDMs O
were O
infected O
with O
mCherry-expressing B-proteingene
M. O
tuberculosis O
(arrows) O
for O
6 O
h O
and O
immunostained O
for B-proteingene
LAMP1 O
. O

e, O
Quantification O
of O
results O
from O
d O
expressed O
relative O
to O
control O
BMDMs O
(n O
= O
3 O
per O
group, O
**P O
0.001) O
. O

f, O
BMDMs O
were O
infected O
with O
M. O
tuberculosis O
and O
colony-forming O
units O
(c.f.u.) O

at O
t O
= O
0 O
and O
t O
= O
16 O
h O
were O
determined O
by O
plating O
. O

Results O
were O
normalized O
to O
t O
= O
0 O
(n O
= O
3 O
per O
group, O
*P O
< O
0.02) O
. O

g, O
RAW264.7 O
macrophages O
transduced O
with O
lentivirus O
expressing O
green O
fluorescent O
protein O
(GFP) B-proteingene
or O
parkin B-proteingene
were O
infected O
with O
M. O
tuberculosis O
and O
c.f.u O
. O

were O
determined O
after O
16 O
h. O
Results O
were O
normalized O
to O
GFP-expressing B-proteingene
cells O
(n O
= O
3 O
per O
group, O
**P O
< O
0.0076) O
. O

h, O
U937 O
human O
macrophages O
expressing O
either O
scrambled O
or O
PARK2 B-proteingene
shRNAs O
were O
infected O
with O
M. O
tuberculosis O
for O
36 O
h O
and O
c.f.u O
were O
determined O
. O

Results O
were O
normalized O
to O
t O
= O
0 O
(N O
= O
3 O
per O
group, O
*P< O
0.02) O
. O

All O
errors, O
s.e.m O
. O

a, O
WT O
and O
Park2-/- B-proteingene
mice O
were O
infected O
with O
wild-type O
M. O
tuberculosis O
by O
aerosol O
and O
lung O
bacterial O
burdens O
were O
determined O
by O
plating O
(means O
± O
s.d., O
n O
= O
5 O
per O
group, O
*P O
< O
0.02 O
by O
Student O
's O
t-test) O
. O

b, O
Enumeration O
of O
liver O
and O
spleenc.f.u O
. O

from O
mice O
infected O
in O
a, O
21 O
days O
post-infection O
(means O
± O
s.d, O
n O
= O
5 O
per O
group, O
*P O
< O
0.03 O
by O
Student O
's O
t-test) O
. O

c, O
Survival O
of O
M. O
tuberculosis-infected O
wild-type O
and O
Park2-/- B-proteingene
mice O
(n O
= O
10, O
**P O
< O
0.001 O
by O
log-rank O
test) O
. O

d, O
Immunohistochemistry O
staining O
of O
lung O
sections O
from O
infected O
mice21 O
days O
post-infection, O
scale O
bar, O
50 O
µm O
. O

e, O
Immunohistochemistry O
staining O
of O
lung O
sections O
from O
a O
human O
patient O
with O
active O
tuberculosis O
. O

Scale O
bars, O
500 O
µm O
(×4), O
50 O
µm O
(×40) O
. O

f, O
Confocal O
microscopy O
images O
of O
humanlung O
sections O
from O
e O
immunostained O
for O
M. O
tuberculosis O
and O
parkin; B-proteingene
DNA O
was O
visualized O
using O
DAPI O
(4′,6-diamidino-2-phenylindole) O
. O

Scale O
bars, O
25 O
µm O
. O

g, O
Mice O
were O
infected O
with O
wild-type O
L. O
monocytogenes O
by O
i.p O
. O

injection O
and O
bacterial O
burdens O
in O
livers O
and O
spleens O
were O
determined O
by O
plating O
(means O
± O
s.d., O
n O
= O
7 O
per O
group, O
*P O
< O
0.04 O
by O
Student O
's O
t-test) O
. O

a, O
Wild-type O
and O
two O
independent O
parkin-deficient B-proteingene
D. O
melanogaster O
lines O
(parkc00062, O
parkf01950) O
were O
infected O
with O
L. O
monocytogenes O
by O
anterior O
abdomen O
injection O
. O

Atg8 B-proteingene
processing O
was O
monitored O
in O
whole-fly O
protein O
lysates O
by O
western O
blotting O
. O

b, O
L. O
monocytogenes O
c.f.u O
. O

from O
a O
were O
determined O
by O
plating O
(means O
± O
s.d., O
n O
= O
3-5, O
**P O
< O
0.001 O
by O
Student O
's O
t-test) O
. O

c, O
Survival O
of O
D. O
melanogaster O
was O
determined O
(n O
= O
33, O
**P O
< O
0.001 O
by O
log-rank O
test) O
. O

d, O
e, O
Flies O
were O
infected O
with O
S. O
enterica O
serovar O
Typhimurium O
and O
bacterial O
c.f.u O
. O

(d) O
(means O
± O
s.d., O
n O
= O
3-5 O
per O
group, O
**P O
0.009 O
by O
Student O
's O
t-test) O
and O
flysurvival O
(e) O
were O
determined O
(n O
= O
59, O
**P O
0.001 O
by O
log-rank O
test) O
. O

f, O
Survival O
of O
flies O
infected O
with O
M. O
marinum O
(n O
= O
37, O
**P O
0.0045 O
by O
log-rank O
test) O
. O

(A) O
EM O
analysis O
of O
KMnO4-fixed O
pex3atg1 B-proteingene
and O
WT O
cells O
grown O
for O
16 O
h O
on O
MM-M/G. O
The O
inset O
shows O
a O
cluster O
of O
vesicles O
(enlarged O
from O
the O
boxed O
region) O
. O

(B) O
iEM O
analysis O
of O
pex3atg1 B-proteingene
cells O
using O
α-Pex14 B-proteingene
antibodies O
. O

(C O
and O
D) O
FM O
images O
of O
pex3atg1 B-proteingene
cells O
producing O
Pex14-mCherry B-proteingene
and O
the O
ER O
marker O
BiPN30-eGFP-HDEL B-proteingene
(C), O
or O
Pex14-mGFP B-proteingene
complemented O
with O
Mitotracker O
orange O
staining O
(D) O
. O

(E) O
Electron O
tomography O
analysis O
of O
a O
serial-sectioned O
pex3atg1 B-proteingene
cell O
(a) O
containing O
a O
perinuclear O
membrane O
cluster O
(b, O
arrows) O
. O

(d-f) O
10-nm-thin O
digital O
slices O
through O
the O
tomogram O
reconstruction O
(viewing O
direction O
indicated O
in O
c) O
revealed O
vesicles O
(black O
arrows) O
and O
reticular O
structures O
(red O
arrows) O
. O

The O
surface-rendered O
reconstruction O
in O
g O
shows O
the O
reticulovesicular O
structures O
in O
3D O
viewed O
at O
right O
angles O
from O
d. O
CW, O
cell O
wall; O
M, O
mitochondrion; O
N, O
nucleus; O
P, O
peroxisome; O
V, O
vacuole O
. O

Bars: O
(A) O
500 O
nm; O
(A, O
inset; O
and O
B) O
100 O
nm; O
(C O
and O
D) O
2.5 O
µm; O
(E) O
250 O
nm O
. O

(A) O
iEM O
analysis O
of O
pex3 B-proteingene
cells O
using O
α-Pex14 B-proteingene
antibodies, O
identifying O
structures O
(arrows) O
in O
the O
vicinity O
of O
mitochondria O
. O

CW, O
cell O
wall; O
M, O
mitochondrion O
. O

(B) O
Quantification O
of O
Pex14-mGFP B-proteingene
spots O
in O
pex3 B-proteingene
and O
pex3atg1 B-proteingene
cells O
. O

(C) O
FM O
images O
of O
pex3atg1 B-proteingene
or O
pex3 B-proteingene
cells, O
producing O
Pex14-mGFP B-proteingene
complemented O
with O
FM4-64vacuolar O
staining O
. O

The O
inset O
(enlarged O
from O
the O
boxed O
region) O
shows O
optimized O
intensities O
for O
pex3 B-proteingene
cells, O
highlighting O
the O
Pex14-mGFP B-proteingene
spot O
and O
vacuolarmGFP B-proteingene
. O

(D) O
WB O
analysis O
of O
cells O
grown O
for O
16 O
h O
on O
MM-M/G O
using O
α-Pex11 B-proteingene
or O
α-Pex14 B-proteingene
antibodies O
. O

Pyruvate B-proteingene
carboxylase I-proteingene
1 I-proteingene
(Pyc1) B-proteingene
was O
used O
as O
a O
loading O
control O
. O

Error O
bars O
indicate O
SEM. O
Bars: O
(A) O
100 O
nm; O
(C) O
1 O
µm O
. O

(A) O
FM O
images O
of O
pex3atg1 B-proteingene
cells O
grown O
for O
16 O
h O
on O
MM-M/G. O
Cells O
produced O
Pex14-mCherry B-proteingene
and O
C-terminal O
mGFP B-proteingene
fusions O
of O
the O
indicated O
proteins O
. O

(B) O
WB O
analysis O
of O
WT O
(1) O
and O
pex3atg1 B-proteingene
cells O
(2), O
grown O
for O
6 O
or O
16 O
h O
on O
MM-M/G O
. O

(C) O
FM O
images O
showing O
mGFP-fluorescence B-proteingene
in O
pex3atg1 B-proteingene
cells O
producing O
Pex14-mCherry B-proteingene
(control) O
or O
Pex14-mCherry B-proteingene
together O
with O
the O
indicated O
mGFP B-proteingene
fusion O
protein O
. O

Cells O
were O
grown O
for O
6 O
h O
on O
MM-M/G O
. O

(D O
and O
E) O
iEM O
of O
pex3atg1 B-proteingene
cells O
using O
α-Pex5 B-proteingene
(D) O
or O
α-alcohol B-proteingene
oxidase I-proteingene
antibodies O
(E) O
. O

(H) O
Colocalization O
of O
Pex8-GFP B-proteingene
and O
Pex14-mCherry B-proteingene
in O
pex10 B-proteingene
cells O
. O

(A) O
FM O
images O
of O
pex3 B-proteingene
cells O
with O
Pex14-mCherry B-proteingene
upon O
Pex3-eGFP B-proteingene
reintroduction O
after O
shifting O
cells O
from O
MM-Glu O
with O
ammonium O
sulfate O
to O
MM-M/G O
with O
methylamine O
. O

(B-E) O
Live O
cell O
FM O
images O
of O
pex3atg1 B-proteingene
cells O
upon O
Pex3 B-proteingene
reintroduction O
. O

Shown O
are O
pex3atg1 B-proteingene
cells O
producing O
Pex14-mCherry B-proteingene
and O
PAMOPEX3-eGFP B-proteingene
(B), O
PAMOPEX3.PEX10-GFP B-proteingene
(C), O
PAMOPEX3.PMP47-GFP B-proteingene
(D), O
or O
PAMOPEX3.PTEFGFP-SKL B-proteingene
(E) O
. O

Cells O
were O
grown O
similar O
to O
the O
method O
in O
A. O
The O
arrows O
in O
B-D O
indicate O
the O
first O
detectable O
GFP B-proteingene
signal O
. O

Bars, O
2.5 O
µm O
. O

(A O
and O
B) O
WB O
analysis O
(A) O
and O
protein O
quantification O
(B) O
in O
WT O
(lane O
1; O
blue), O
pex3atg1 B-proteingene
(lane O
2; O
red), O
and O
pex3atg1-PAOXPEX19 B-proteingene
(lane O
3; O
green) O
cells O
grown O
for O
6 O
h O
on O
MM-M/G. O
The O
protein O
levels O
in O
WT O
were O
set O
to O
100% O
. O

(C O
and O
D) O
FM O
images O
(C) O
and O
quantification O
(D) O
of O
Pmp47-mGFP B-proteingene
and O
Pex10-mGFP B-proteingene
in O
pex3atg1 B-proteingene
(1; O
red) O
and O
pex3atg1-PAOXPex19 B-proteingene
(2; O
green) O
cells O
grown O
for O
6 O
h O
on O
MM-M/G. O
Control O
cells O
in O
D O
did O
not O
produce O
mGFP. B-proteingene
Significance O
indications: O
n.s., O
P O
< O
0.10; O
*, O
0.10 O
> O
P O
> O
0.05; O
**, O
0.05 O
> O
P O
> O
0.01; O
***, O
P O
< O
0.01 O
. O

Error O
bars O
indicate O
SD O
. O

(E O
and O
F) O
iEM O
analysis O
of O
pex19 B-proteingene
(E) O
and O
pex19atg1 B-proteingene
(F) O
cells O
using O
α-Pex14 B-proteingene
antibodies O
. O

(G) O
EM O
analysis O
of O
KMnO4-fixed O
pex3atg1pex25 B-proteingene
cells O
grown O
for O
16 O
h O
on O
MM-M/G-showing O
membranevesicles O
(arrows) O
. O

(H) O
FM O
image O
of O
pex3atg1pex25 B-proteingene
cells O
producing O
Pex14-mGFP. B-proteingene
CW, O
cell O
wall; O
M, O
mitochondrion; O
N, O
nucleus; O
V, O
vacuole O
. O

(a) O
H3R B-proteingene
expression O
in O
cultured O
ratcortical O
neurons O
at O
DIV7 O
after O
OGD/R O
injury O
(2 O
h O
OGD O
and O
24 O
h O
reperfusion) O
shown O
by O
western O
blot O
(n=6 O
per O
condition; O
**P0.01 O
versus O
control O
with O
Student O
's O
t-test) O
. O

Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

9 O
. O

(b) O
When O
the O
H3R B-proteingene
antagonist O
thioperamide O
(THIO, O
10−6 O
mol O
l−1 O
at O
reperfusion) O
and O
the O
agonist O
immepip O
(IMME, O
10−6 O
mol O
l−1 O
at O
reperfusion) O
were O
administered, O
viability O
was O
tested O
in O
cultured O
neurons O
by O
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium O
bromide(MTT) O
assay O
after O
OGD/R O
(n=7 O
per O
condition; O
***P0.001 O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(c) O
2,3,5-triphenyltetrazolium O
chloride-stainedbrain O
sections O
showing O
the O
infarct O
area O
in O
WT O
and O
H3R−/− B-proteingene
mice O
receiving O
saline, O
the O
H3R B-proteingene
antagonists O
A331440, O
clobenpropit O
(CLOB) O
and O
thioperamide, O
(THIO; O
5 O
mg O
kg−1, O
i.p., O
immediately O
at O
reperfusion O
and O
6 O
h O
later), O
and O
the O
H3R B-proteingene
agonist O
immepip O
(IMME, O
1 O
μg, O
i.c.v., O
at O
reperfusion) O
after O
I/R O
(1 O
h O
MCAO O
followed O
by O
24 O
h O
reperfusion; O
scale O
bar, O
5 O
mm) O
. O

The O
bar O
graphs O
show O
infarct O
volume O
(d) O
and O
neurological O
score O
(e) O
(n=6-8 O
mice O
per O
condition, O
*P0.05, O
**P0.01, O
***P0.001 O
versus O
WT O
saline O
group O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Data O
are O
presented O
as O
mean±s.e.m O
. O

(a) O
TUNEL O
staining O
of O
apoptotic O
cells O
in O
penumbral O
brain O
slices O
in O
vivo O
(scale O
bar, O
100 O
μm) O
when B-proteingene
H3R O
was O
inhibited O
with O
thioperamide O
(scale O
bar, O
50 O
μm) O
after O
tMCAO. O
TUNEL-positive O
cells O
are O
green, O
and O
all O
cells O
are O
stained O
with O
4',6-diamidino-2-phenylindole O
(blue) O
. O

(b,d) O
H3R B-proteingene
was O
inhibited O
by O
thioperamide, O
and O
cleaved O
caspase-3 B-proteingene
protein O
expression O
is O
shown O
by O
western O
blot O
in O
WT O
and O
H3R−/−mice O
after O
tMCAO O
(b) O
(n=6-7 O
per O
condition; O
**P0.01, O
***P0.001 O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
Bonferroni/Dunn O
post O
hoc O
test) O

(c) O
TUNEL O
staining O
of O
apoptotic O
cells O
in O
cultured O
neurons O
when O
H3R B-proteingene
was O
inhibited O
with O
thioperamide O
(scale O
bar, O
50 O
μm) O
after O
OGD/R. O
TUNEL-positive O
cells O
are O
green, O
and O
all O
cells O
are O
stained O
with O
4',6-diamidino-2-phenylindole O
(blue) O
. O

(b,d) O
H3R B-proteingene
was O
inhibited O
by O
thioperamide, O
and O
cleaved O
caspase-3 B-proteingene
protein O
expression O
is O
shown O
by O
western O
blot O
in O
WT O
and O
H3R−/−mice O
in O
cultured O
neurons O
subjected O
to O
OGD/R O
(d) O
(n=8 O
per O
condition; O
*P0.05, O
***P0.001 O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Data O
are O
presented O
as O
mean±s.e.m O
. O

Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

10 O
. O

(a) O
2,3,5-Triphenyltetrazolium O
chloride O
(TTC)-stainedbrain O
sections O
from O
WT O
and O
HDC−/− B-proteingene
mice O
showing O
the O
infarct O
area O
in O
those O
receiving O
saline, O
the O
H3R B-proteingene
antagonist O
thioperamide O
(THIO), O
the O
H1R B-proteingene
antagonist O
pyrilamine O
(PYRI; O
10 O
mg O
kg−1, O
i.p., O
at O
reperfusion), B-proteingene
the O
H2R O
antagonist O
cimetidine O
(CIME; O
10 O
mg O
kg−1, O
i.p., O
at O
reperfusion) O
and O
α-FMH O
(50 O
mg O
kg−1, O
i.p., O
2 O
h O
before O
ischemia) O
after O
24 O
h O
reperfusion O
(n=6 O
per O
condition; O
scale O
bar, O
5 O
mm) O
. O

(b) O
Infarct O
volumes O
and O
(c) O
neurological O
deficit O
scores O
(*P0.05, O
**P0.01, O
***P0.001 O
with O
analysis O
of O
variances O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Data O
are O
presented O
as O
mean±s.e.m O
. O

(a) O
Akt/GSK-3β/mTOR/P70S6K B-proteingene
phosphorylation O
assessed O
by O
western O
blots O
after O
thioperamide O
administration O
and O
OGD/R. O
LiCl O
(5 O
mmol O
l−1 O
immediately O
at O
reperfusion) O
was O
used O
to B-proteingene
rephosphorylate O
GSK-3β/mTOR/P70S6K. O
The O
digits O
below O
represent O
the O
semiquantified O
optidensity O
of O
the O
bands, O
the O
control O
bands O
were O
defined O
as O
1.00 O
. O

(b) O
Representative O
western O
blots O
showing O
the O
phosphorylation O
of O
Akt/GSK-3β/mTOR/P70S6K B-proteingene
signaling O
in O
H3R−/− B-proteingene
mice O
after O
OGD/R O
injury O
. O

The O
digits O
below O
represent O
the O
semiquantified O
optidensity O
of O
the O
bands, O
the O
control O
bands O
were O
defined O
as O
1.00 O
. O

(c) O
Representative O
images O
showing O
LC3-positive B-proteingene
autophagic O
vacuoles O
(red) O
with O
4',6-diamidino-2-phenylindole O
staining O
(blue) O
after O
administration O
of O
thioperamide O
and O
LiCl O
with O
OGD/R O
(scale O
bar, O
10 O
μm) O
. O

(d) O
Cell O
viability O
assessed O
by O
MTT O
when O
thioperamide O
and O
LiCl O
were O
administered O
after O
OGD/R O
(n=7, O
**P0.01, O
***P0.001 O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(e) O
Representative O
western O
blots O
and O
bar O
graph O
showing O
the O
expression O
of O
LC3-I B-proteingene
and O
LC3-II B-proteingene
in O
steady-state O
autophagy O
and O
autophagic O
flux O
under O
OGD/R O
injury O
when O
thioperamide O
(THIO) O
and O
immepip O
(IMME) O
were O
administered O
(n=6; O
**P0.01, O
***P0.001 O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Data O
are O
presented O
as O
mean±s.e.m O
. O

Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

11 O
. O

(a) O
Representative O
immunohistochemical O
staining O
of O
LC3 B-proteingene
(green) O
along O
with O
NeuN B-proteingene
staining O
(red) O
in O
WT O
and O
H3R−/− B-proteingene
mice O
(scale O
bar, O
25 O
μm) O
. O

(b,c) O
When O
thioperamide O
was O
administered O
in O
vivo, O
LC3 B-proteingene
expression O
was O
assessed O
by O
western O
blot O
after O
I/R O
in O
WT O
mice O
(b) O
(*P0.05, O
***P0.001; O
n=6 O
mice O
per O
condition, O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test), O
and O
in O
H3R−/− B-proteingene
mice O
(c) O
(***P0.001 O
versus O
H3R−/− B-proteingene
sham O
group; O
n=5-6 O
mice O
per O
condition, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test.) O

Data O
are O
presented O
as O
mean±s.e.m O
. O

Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

12 O
. O

(a) O
Western O
blots O
showing O
the O
inhibitory O
effect O
of O
3-MA O
on O
autophagy O
in O
I/R. O
Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

13 O
. O

(b) O
TTC-stained O
sections O
showing O
the O
infarct O
area O
after O
administration O
of O
3-MA O
(100 O
nmol, O
i.c.v., O
at O
reperfusion) O
in O
WT O
and B-proteingene
H3R−/− O
mice O
(scale O
bar, O
5 O
mm), O
and O
(c) O
bar O
graph O
showing O
infarct O
volume O
(n=6-8 O
mice O
per O
condition; O
*P0.05, O
***P0.001, O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(d) O
TTC-stained O
sections O
(scale O
bar, O
5 O
mm) O
and O
bar O
graph O
showing O
the O
infarct O
area O
after O
administration O
of O
thioperamide O
in O
Atg5+/−mice O
(n=4-6 O
mice O
per O
condition) O
. O

(e) O
In O
cultured O
neurons, O
viability O
was O
tested O
by O
MTT O
assay O
after O
3-MA O
(2.5 O
mmol O
l−1 O
at O
reperfusion) O
and O
thioperamide O
was O
administered O
in O
OGD/R O
(n=7 O
per O
condition; O
***P0.001, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(f) O
In O
cultured O
neurons, O
viability O
was O
tested O
by O
MTT O
after O
siRNA O
for O
Atg7 B-proteingene
and O
OGD/R O
(n=7 O
per O
condition; O
***P0.001, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(g) O
Viability O
was O
tested O
by O
MTT O
assay O
on O
Atg5+/+and B-proteingene
Atg5−/− B-proteingene
MEFs O
after O
thioperamide O
administration O
after O
OGD/R O
(n=7 O
per O
condition; O
**P0.01, O
***P0.001, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Data O
are O
presented O
as O
mean±s.e.m O
. O

(a) O
Representative O
co-immunoprecipitation O
results O
showing O
the O
effect O
of O
thioperamide O
on O
the O
interaction O
of O
H3R B-proteingene
with O
CLIC4 B-proteingene
during O
OGD/R. O
Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

14 O
. O

(b) O
Cell O
viability O
was O
tested O
by O
MTT O
assay O
after O
administration O
of O
Tat-H3RCT414-436 B-proteingene
(10−6 O
mol O
l−1 O
at O
reperfusion) O
under O
OGD/R O
(data O
are O
presented O
as O
mean±s.e.m O
. O

; O
n=7 O
per O
condition; O
*P0.05, O
**P0.01, O
with O
analysis O
of O
variances O
(ANOVAs) O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

(c) O
Representative O
western O
blots O
showing O
the O
effect O
of O
Tat-H3RCT414-436 B-proteingene
on O
phosphorylation O
of O
Akt/GSK-3β/mTOR/P70S6K B-proteingene
signalling O
and O
LC3 B-proteingene
expression O
in O
OGD/R. O
Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

14 O
. O

(d) O
Representative O
images O
of O
the O
effect O
of O
Tat-H3RCT414-436 B-proteingene
on O
LC3-positive B-proteingene
autophagic O
puncta O
(red) O
in O
4',6-diamidino-2-phenylindole-stained O
(blue) O
neurons O
after O
OGD/R O
(scale O
bar,10 O
μm) O
. O

(e) O
Western O
blots O
showing O
the O
effect O
of O
siRNA O
for O
CLIC4 B-proteingene
on O
phosphorylation O
of O
Akt/GSK-3β/mTOR/P70S6K B-proteingene
signalling O
and O
LC3 B-proteingene
expression O
in O
OGD/R. O
Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

14 O
. O

(f) O
Representative O
western O
blots O
and O
bar O
graph O
showing O
the O
expression O
of O
LC3-I B-proteingene
and O
LC3-II B-proteingene
on O
steady-state O
autophagy O
and O
autophagic O
flux O
under O
OGD/R O
when O
CLIC4 B-proteingene
was O
knocked O
down O
(data O
are O
presented O
as O
mean±s.e.m O
. O

; O
n=6; O
*P0.05, O
**P0.01; O
, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

Full-size O
blots O
are O
shown O
in O
Supplementary O
Fig O
. O

14 O
. O

(g) O
Cell O
viability O
was O
assessed O
by O
MTT O
assay O
after O
siRNA O
for O
CLIC4 B-proteingene
under O
OGD/R O
(data O
are O
presented O
as O
mean±s.e.m O
. O

; O
n=8 O
per O
condition; O
***P0.001, O
with O
ANOVAs O
followed O
by O
the O
Bonferroni/Dunn O
post O
hoc O
test) O
. O

a, O
Hierarchical O
cluster O
analysis O
of O
predicted O
REST B-proteingene
targets, O
based O
on O
the O
presence O
of O
the O
canonical O
RE1 B-proteingene
motif, O
shows O
relatively O
high O
expression O
in O
young O
adults O
(red) O
and O
lower O
expression O
(blue) O
in O
the O
ageing O
population O
. O

Each O
lane O
represents O
an O
individual O
prefrontal O
cortical O
brain O
sample O
. O

b, O
qRT-PCR O
shows O
age-dependent O
induction O
of O
REST B-proteingene
mRNA O
in O
the O
PFC. O
Values O
represent O
the O
mean O
± O
s.d., O
n O
= O
3 O
. O

Shown O
are O
P O
values O
indicating O
significance O
for O
the O
mean O
of O
aged O
(71-95 O
years) O
versus O
young O
(24-29 O
years) O
cases O
for O
each O
primer O
. O

c, O
Age-dependent O
increase O
in O
total O
REST B-proteingene
protein O
level O
in O
the O
PFC O
of O
controls O
but O
not O
AD O
patients O
. O

REST B-proteingene
levels O
were O
also O
measured O
in O
isolated O
nuclear O
(Nuc O
REST; B-proteingene
lower O
right O
panel, O
upper O
blot) O
and O
cytoplasmic O
(Cyt O
REST; B-proteingene
lower O
right O
panel, O
lower O
blot) O
fractions O
. O

Each O
lane O
represents O
an O
individual O
case O
. O

Young, O
n O
= O
12; O
Aged, O
n O
= O
15; O
AD, O
n O
= O
10 O
. O

d, O
Confocal O
immunofluorescence O
labelling O
for O
REST B-proteingene
(green), O
the O
neuronal O
marker O
MAP2 B-proteingene
(red) O
and O
DNA O
(DAPI, O
blue) O
in O
the O
PFC O
of O
young O
adult, O
aged O
and O
AD O
cases O
. O

Scale O
bar, O
25 O
µm O
. O

e, O
Quantitative O
analysis O
of O
nuclearREST B-proteingene
levels O
by O
in O
situ O
imaging O
(left O
panel: O
Young, O
n O
= O
11; O
Aged, O
n O
= O
77; O
AD, O
n O
= O
72; O
MCI O
= O
11) O
or O
FACS O
analysis O
of O
isolated O
PFC O
neuronalnuclei O
(right O
panel: O
Young, O
n O
= O
11; O
Aged, O
n O
= O
22; O
AD, O
n O
= O
11; O
MCI O
n O
= O
12) O
. O

For O
c O
and O
e, O
values O
are O
expressed O
as O
fold O
change O
relative O
to O
the O
young O
adult O
group, O
and O
represent O
the O
mean O
± O
s.e.m O
. O

*P O
0.05, O
**P O
0.01, O
***P O
0.001 O
by O
Student O
's O
unpaired O
t-test O
. O

f, O
ChIP O
analysis O
shows O
induction O
of O
REST-RE1 B-proteingene
site O
binding O
in O
normal O
ageing O
PFC O
neurons O
but O
not O
in O
AD O
. O

a, O
ChIP-qPCR O
analysis O
of O
REST B-proteingene
binding O
to O
target O
genes O
in O
isolated O
PFCneuronalnuclei O
. O

Shown O
are O
young O
adult O
(Young), O
normal O
aged O
(Aged) O
and O
AD O
cases, O
which O
were O
stratified O
as O
AD1 O
(MMSE O
score O
> O
18) O
and O
AD2 O
(MMSE O
score O
8) O
. O

Also O
shown O
are O
control O
ChIP O
assays O
with O
non-specific O
IgG, O
and O
a O
RESTChIP B-proteingene
with O
PCR O
primers O
directed O
10 O
kb O
3′ O
to O
the O
SNAP25 B-proteingene
RE1 B-proteingene
site O
(SNAP25-10K B-proteingene
down) O
. O

Values O
represent O
fold O
change O
relative O
to O
the O
mean O
young O
adult O
value, O
and O
represent O
the O
mean O
± O
s.e.m., O
n O
= O
7 O
. O

*P O
0.05 O
by O
the O
Mann-Whitney O
test O
. O

b, O
mRNA O
expression O
of O
REST B-proteingene
target O
genes O
determined O
by O
qRT-PCR O
of O
PFC. O
Shown O
are O
REST B-proteingene
target O
genes O
related O
to O
cell O
death O
pathways O
and O
AD O
pathology O
(left), O
and O
neurotransmission O
(right) O
. O

Values O
are O
normalized O
to O
the O
mean O
young O
adult O
expression O
level O
(100%) O
and O
represent O
the O
mean O
± O
s.e.m O
. O

Young, O
n O
= O
9; O
Aged, O
n O
= O
10; O
AD1, O
n O
= O
10; O
AD2, O
n O
= O
10 O
. O

Asterisks O
above O
the O
'Aged' O
bars O
indicate O
significance O
relative O
to O
young O
adults; O
brackets O
indicate O
significance O
of O
Aged O
versus O
AD1 O
or O
AD2 O
. O

*P O
0.05 O
by O
the O
Mann-Whitney O
test O
. O

c, O
Linear O
regression O
analysis O
of O
nuclear O
REST B-proteingene
versus O
levels O
of O
protein O
targets O
or O
histone O
H3K9ac B-proteingene
in O
double-labelled O
PFCneurons O
. O

d, O
Representative O
images O
showing O
inverse O
relationships O
between O
nuclear O
REST B-proteingene
and O
H3K9ac, B-proteingene
PS2, B-proteingene
DAXX B-proteingene
and O
BAX B-proteingene
in O
AD1 O
neurons O
. O

Scale O
bar, O
20 O
µm O
. O

e, O
Global O
epigenetic O
regulation O
in O
ageing O
and O
AD. O
Histone O
modification O
H3K9ac B-proteingene
was O
determined O
in O
isolated O
PFCneuronalnuclei O
. O

Values O
are O
normalized O
to O
the O
mean O
of O
the O
young O
adult O
group O
(100%), O
and O
represent O
the O
mean O
± O
s.e.m., O
**P O
0.005 O
by O
Student O
's O
unpaired O
t-test O
. O

Young, O
n O
= O
8; O
Aged, O
n O
= O
11; O
AD1, O
n O
= O
4; O
AD2, O
n O
= O
4 O
. O

a, O
REST-deficient B-proteingene
cortical O
neurons O
cultured O
from O
REST B-proteingene
cKO O
mouse O
embryos O
show O
increased O
vulnerability O
to O
H2O2 O
and O
oligomeric O
Aβ42 O
toxicity O
. O

Cell O
viability O
is O
expressed O
as O
percentage O
of O
the O
value O
in O
untreated O
cultures O
. O

Values O
represent O
the O
mean O
± O
s.e.m., O
n O
= O
6-8 O
. O

*P O
0.05, O
**P O
0.01 O
by O
Student O
's O
unpaired O
t-test O
. O

b, O
Reduced O
nuclear O
translocation O
of O
the O
ΔREST B-proteingene
mutant O
. O

c, O
REST B-proteingene
cKO O
mice O
show O
age-related O
neurodegeneration O
. O

Shown O
are O
sections O
of O
the O
hippocampal O
CA1 O
subfield O
from O
8-month-old O
REST B-proteingene
cKO O
mice O
labelled O
for O
TUNEL, O
cleaved O
caspase B-proteingene
3 I-proteingene
(cl-CASP3) O
and O
GFAP, B-proteingene
or O
stained O
with O
haematoxylin O
and O
eosin O
(HE) O
. O

d, O
Neurodegeneration O
in O
8-months O
but O
not O
1-month-old O
REST B-proteingene
cKO O
mice O
in O
the O
cortex, O
and O
in O
hippocampal O
CA1 O
and O
dentate O
gyrus O
(DG) O
regions O
. O

Values O
represent O
the O
mean O
± O
s.e.m., O
n O
= O
6 O
mice; O
**P O
0.001 O
relative O
to O
control O
by O
Student O
's O
unpaired O
t-test O
. O

Scale O
bars, O
20 O
µm O
. O

a, O
spr-4(by105) B-proteingene
worms O
incubated O
continuously O
with O
paraquat O
(5 O
mM) O
exhibit O
increased O
mortality O
rescued O
by O
wild-type O
SPR-4 B-proteingene
or O
human O
REST. B-proteingene
Shown O
is O
a O
representative O
experiment O
replicated O
three O
times O
. O

b, O
Quantitative O
analysis O
of O
survival O
in O
wild-type O
worms O
expressing O
mCherry B-proteingene
or O
SPR-4 B-proteingene
(WT+mCherry B-proteingene
and O
WT+SPR-4), B-proteingene
spr-4(by105) B-proteingene
mutants, O
and O
spr-4(by105) B-proteingene
mutants O
expressing O
SPR-4 B-proteingene
or O
human O
REST B-proteingene
(spr4(by105)+SPR4 B-proteingene
and O
spr4(by105)+REST) B-proteingene
. O

Shown O
is O
the O
percentage O
change O
in O
mean O
survival O
relative O
to O
wild-type O
. O

Values O
represent O
the O
mean O
± O
s.d., O
n O
= O
3 O
independent O
replicates O
of O
at O
least O
30 O
animals O
per O
genotype; O
**P O
0.01 O
relative O
to O
wild O
type O
by O
the O
log-rank O
test O
. O

c, O
REST B-proteingene
and O
SPR-4 B-proteingene
reduce O
levels O
of O
reactive O
oxygen O
species O
(ROS) O
. O

Shown O
are O
representative O
confocal O
images O
of O
paraquat-treated O
worms O
labelled O
with O
the O
ROS-sensitive O
dye O
DCFDA. O
WT, O
wild O
type O
. O

Scale O
bar, O
30 O
µm O
. O

d, O
Quantitation O
of O
ROS O
levels O
by O
DCFDA O
labelling O
. O

Horizontal O
bars O
indicate O
the O
median; O
boxed O
areas O
represent O
the O
second O
and O
third O
quartiles O
. O

*P O
0.05 O
relative O
to O
wild O
type O
by O
analysis O
of O
variance O
with O
post-hoc O
Tukey O
test; O
n O
= O
30 O
worms O
. O

AFU, O
arbitrary O
fluorescence O
units O
. O

e, O
SPR-4 B-proteingene
protects O
against O
Aβ O
neurotoxicity O
. O

Shown O
are O
Aβ O
worms O
(expressing O
a O
stably O
integrated O
Aβ1-42 O
transgene) O
and O
Aβ O
spr4(by105) B-proteingene
worms O
. O

Neuronal O
degeneration O
does O
not O
occur O
in O
wild-type O
worms O
or O
spr4(by105) B-proteingene
mutants O
in O
the O
absence O
of O
the O
Aβ O
transgene O
. O

Values O
represent O
the O
percentage O
of O
worms O
that O
retain O
five O
glutamatergic O
tail O
neurons O
at O
the O
indicated O
age O
(days), O
and O
are O
the O
mean O
± O
s.d., O
n O
= O
3 O
. O

*P O
0.05 O
by O
unpaired O
t-test O
. O

a, O
Loss O
of O
nuclear O
REST B-proteingene
in O
DLB O
and O
FTD. O
Left, O
immunofluorescence O
microscopy O
with O
labelling O
for O
REST B-proteingene
(green), O
the O
neuronal O
marker O
MAP2 B-proteingene
(red) O
and O
DNA O
(DAPI, O
blue) O
. O

Right, O
quantitative O
analysis O
of O
immunofluorescence O
. O

Values O
(AFU) O
represent O
the O
mean O
± O
s.e.m O
. O

; O
Young, O
n O
= O
11; O
Aged, O
n O
= O
21; O
DLB, O
n O
= O
18; O
FTD, O
n O
= O
16 O
. O

**P O
0.001 O
by O
Student O
's O
unpaired O
t-test O
. O

b, O
Colocalization O
of O
REST B-proteingene
with O
disease-associated O
misfolded O
proteins O
in O
autophagosomes O
. O

Cortical O
sections O
were O
triple-labelled O
for O
REST, B-proteingene
LC3, B-proteingene
and O
either O
Aβ B-proteingene
in O
AD, O
α-synuclein B-proteingene
(α-syn) O
in O
DLB, O
or O
phosphorylated O
tau B-proteingene
(PHF1 B-proteingene
epitope) O
or O
TDP-43 B-proteingene
in O
FTD. O
Two O
different O
representative O
cases O
are O
shown O
for O
each O
disease O
. O

Scale O
bars, O
20 O
µm O
. O

a, O
Linear O
regression O
analysis O
of O
nuclearREST O
levels O
in O
PFCneurons O
and O
cognitive O
test O
scores O
. O

Nuclear O
REST B-proteingene
was O
imaged O
by O
anti-RESTimmunofluorescence B-proteingene
and O
quantified O
by O
MetaMorph O
. O

Each O
point O
represents O
an O
individual O
case O
. O

n O
= O
111 O
cases O
(59 O
females, O
52 O
males), O
age O
range O
71-90 O
years O
. O

b, O
Nuclear O
REST B-proteingene
levels O
are O
inversely O
correlated O
with O
Braak O
stage O
(extent O
of O
neurofibrillary O
tangle O
formation) O
. O

c, O
Nuclear O
REST B-proteingene
levels O
in O
PFC O
from O
cases O
with O
neuropathological O
AD O
(moderate/frequent O
plaques O
by O
CERAD O
score O
and O
intermediate/high O
likelihood O
AD O
by O
NIA-Reagan O
criteria) O
that O
had O
mild O
or O
no O
cognitive O
impairment O
(NCI/MCI), O
or O
AD O
dementia O
. O

Values O
are O
the O
mean O
± O
s.e.m O
. O

*P O
0.01 O
by O
Student O
's O
unpaired O
t-test; O
NCI/MCI O
n O
= O
30, O
AD O
dementia O
n O
= O
21 O
. O

d, O
Nuclear O
REST B-proteingene
levels O
in O
ageing O
neurons O
correlate O
positively O
with O
longevity O
. O

REST B-proteingene
levels O
were O
quantified O
by O
FACS O
analysis O
of O
isolated O
PFCneuronalnuclei O
in O
61 O
individuals O
without O
AD O
(age O
range O
67-104 O
years) O
. O

(a) O
Kinetics O
of O
the O
appearance O
of O
P14 O
cells O
in O
spleens O
of O
C57BL/6mice O
given O
adoptive O
transfer O
of O
1 O
× O
104 O
P14 O
cells, O
monitored O
after O
infection O
of O
recipients O
with O
LCMV O
Armstrong O
strain O
. O

(b) O
Flow O
cytometry O
of O
cell O
size O
at O
various O
stages O
of O
P14 O
differentiation, O
assessed O
by O
forward O
scatter O
(FSC) O
. O

(c) O
Immunoblot O
analysis O
of O
LC3b B-proteingene
and O
p62 B-proteingene
at O
various O
stages O
of O
P14 O
differentiation O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
with O
samples O
pooled O
from O
5-20 O
mice O
for O
each O
time O
point O
. O

(b) O
Flow O
cytometry O
of O
P14 O
cells O
from O
the O
spleens O
of O
recipient O
mice O
given O
adoptive O
transfer O
of O
P14 O
cells O
transduced O
with O
retrovirus O
as O
in O
a, O
assessed O
on O
days O
5, O
8 O
and O
30 O
after O
infection O
of O
recipients O
with O
LCMV. O
Numbers O
in O
blue O
outlined O
areas O
indicate O
percent O
GFP− B-proteingene
cells O
among O
transduced O
(Thy-1.1+) B-proteingene
P14 O
cells O
. O

(c) O
Summary O
of O
results O
in O
b, O
showing O
autophagy O
activity O
as O
percent O
GFP− B-proteingene
cells O
. O

*P O
≤ O
0.0005 O
(unpaired O
t-test) O
. O

(d) O
Multispectral-imaging O
flow O
cytometry O
of O
P14 O
cells O
from O
the O
spleens O
of O
recipient O
mice O
given O
adoptive O
transfer O
of O
P14 O
cells O
transduced O
with O
retrovirus O
as O
in O
a, O
assessed O
on O
day O
8 O
after O
infection, O
showing O
GFP B-proteingene
signals O
from O
GFP+ B-proteingene
transduced O
(CD45.1+ B-proteingene
Thy-1.1+) B-proteingene
P14 O
cells O
. O

Original O
magnification, O
×60 O
. O

(e) O
Summary O
of O
results O
in O
d, O
presented O
as O
the O
frequency O
of O
cells O
with O
more O
than O
one O
GFP+ B-proteingene
punctum O
among O
vector O
transduced O
Thy-1.1+ B-proteingene
P14 O
cells O
. O

Each O
symbol O
represents O
an O
individual O
mouse; O
small O
horizontal O
lines O
indicate O
the O
mean O
(±s.e.m.) O
. O

Data O
are O
representative O
of O
three O
independent O
experiments O
(b,d) O
or O
three O
independent O
experiments O
with O
three O
or O
more O
mice O
per O
group O
(e; O
error O
bars, O
s.e.m.) O

or O
six O
mice O
per O
group O
(c; O
error O
bars, O
s.e.m O
. O

) O
. O

(b) O
Flow O
cytometry O
of O
splenocytes O
from O
recipient O
mice O
(n O
= O
6) O
given O
adoptive O
transfer O
of O
P14 O
cells O
transduced O
with O
retrovirus O
as O
in O
a, O
assessed O
on O
days O
5 O
and O
8 O
after O
infection O
of O
recipients O
with O
LCMV O
(left), O
and O
quantification O
of O
P14 O
cells O
per O
spleen O
(right) O
. O

Numbers O
adjacent O
to O
outlined O
areas O
(left) O
indicate O
percent O
P14 O
(CD45.1+) B-proteingene
cells O
. O

*P O
≤ O
0.0005 O
(unpaired O
t-test) O
. O

(c) O
Flow O
cytometry O
of O
the O
size O
of O
P14 O
cells O
transduced O
with O
wild-type O
mCherry-GFP-LC3bretrovirus O
(assessed O
as O
in O
Fig O
. O

1b) O
in O
mice O
treated O
as O
in O
b, O
assessed O
at O
days O
5 O
and O
8 O
after O
infection O
. O

(d) O
Efficiency O
of O
retroviral O
transduction O
(left) O
and O
expression O
of O
GFP B-proteingene
and O
mCherry B-proteingene
(right) O
in O
retrovirus-transduced O
P14 O
cells, O
assessed O
by O
flow O
cytometry O
gated O
on O
CD45.1+ B-proteingene
P14 O
cells O
(left) O
or O
CD45.1+Thy-1.1+ B-proteingene
P14 O
cells O
(right) O
. O

Numbers O
in O
quadrants O
indicate O
percent O
CD45.1+Thy-1.1− B-proteingene
(untransduced) O
P14 O
cells O
(top O
left) O
or O
CD45.1+Thy-1.1+ B-proteingene
(transduced) O
P14 O
cells O
(top O
right; O
magenta) O
(left) O
or O
percent O
cells O
in O
each O
(right) O
. O

(e) O
Ratio O
of O
the O
geometric O
mean O
fluorescence O
intensity O
(gMFI) O
of O
GFP B-proteingene
to O
that O
of O
mCherry B-proteingene
(GFP/mCherry) B-proteingene
for O
the O
cells O
in O
d; O
each O
symbol O
represents O
an O
individual O
mouse; O
numbers O
above O
lines O
connecting O
groups O
indicate O
difference O
in O
ratio O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
with O
three O
or O
more O
mice O
per O
group O
(error O
bars O
(b), O
s.e.m O
. O

) O
. O

(a) O
Genomic O
deletion O
of O
Atg7 B-proteingene
in O
H-2Db-gp33+ B-proteingene
T O
cells O
and O
in O
total O
activated O
(CD44hiCD62Llo) B-proteingene
CD8+ B-proteingene
T O
cells O
from O
Atg7fl/fl B-proteingene
mice O
(Cre B-proteingene
−) O
and O
Atg7fl/flGzmb-Cremice O
(Cre B-proteingene
+) O
at O
day O
8 O
after O
infection O
with O
LCMV O
Armstrong O
strain; O
results O
are O
presented O
relative O
to O
those O
of O
Atg7fl/fl B-proteingene
mice, O
set O
as O
100% O
. O

Each O
symbol O
represents O
an O
individual O
mouse; O
small O
horizontal O
lines O
indicate O
the O
mean O
(±s.e.m O
. O

) O
. O

(b) O
Immunoblot O
analysis O
of O
Atg7 B-proteingene
and O
the O
products O
of O
its O
enzymatic O
activity O
(left O
margin) O
in O
CD44hiCD62Llo B-proteingene
CD8+ B-proteingene
T O
cells O
isolated O
at O
day O
8 O
after O
infection O
as O
in O
a; O
β-actin B-proteingene
serves O
as O
a O
loading O
control O
. O

(c) O
Flow O
cytometry O
of O
T O
cells O
in O
the O
peripheral O
blood O
at O
day O
8 O
after O
infection O
as O
in O
a, O
gated O
on O
CD8+ B-proteingene
T O
cells O
(left), O
and O
of O
the O
H-2Db-gp33+ B-proteingene
T O
cells O
identified O
at O
left, O
identifying O
terminal O
effector O
(KLRG1hiCD127lo) B-proteingene
and O
memory O
precursor O
(KLRG1loCD127hi) O
populations O
(right) O
. O

Numbers O
adjacent O
to O
outlined O
areas O
(left) O
indicate O
percent O
H-2Db-gp33+ B-proteingene
T O
cells; O
numbers O
in O
quadrants O
(right) O
indicate O
percent O
cells O
in O
each O
. O

(d) O
Total O
antigen-specific O
CD8+ B-proteingene
T O
cells O
in O
the O
spleen, O
liver O
and O
lungs O
at O
day O
8 O
after O
infection O
as O
in O
a O
. O

(e) O
Production O
of O
IFN-γ B-proteingene
and O
TNF B-proteingene
in O
cells O
obtained O
8 O
d O
after O
infection O
and O
stimulated O
ex O
vivo O
with O
various O
peptides O
(above O
plots), O
gated O
on O
total O
CD8+ B-proteingene
T O
cells O
. O

Numbers O
in O
quadrants O
indicate O
percent O
cells O
in O
each O
. O

(f) O
Flow O
cytometry O
of O
CD8+ B-proteingene
T O
cells O
in O
the O
peripheral O
blood O
of O
mice O
at O
day O
15 O
after O
infection O
as O
in O
a O
(numbers O
in O
plots O
as O
in O
c, O
left) O
. O

(g) O
Quantification O
of O
tetramer-positive O
cells O
in O
spleens O
at O
day O
15 O
after O
infection O
as O
in O
a O
. O

(h) O
Kinetics O
of O
the O
appearance O
H-2Db-gp33+ B-proteingene
CD8+ B-proteingene
T O
cells O
among O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
after O
infection O
as O
in O
a O
(left); O
each O
line O
represents O
one O
mouse O
. O

Right, O
frequency O
of O
H-2Db-gp33+ B-proteingene
CD8+ B-proteingene
T O
cells O
remaining O
on O
day O
15 O
relative O
to O
that O
on O
day O
8, O
set O
as O
100% O
. O

(i) O
Quantification O
of O
tetramer-positive O
cells O
at O
day O
30 O
after O
infection O
as O
in O
a. O
Horizontal O
dashed O
lines O
(g,h) O
indicate O
the O
limit O
of O
detection O
. O

*P O
≤ O
0.05, O
**P O
≤ O
0.005 O
and O
***P O
≤ O
0.0005 O
(unpaired O
t-test) O
. O

Data O
were O
pooled O
from O
two O
independent O
experiments O
(a) O
or O
at O
least O
two O
independent O
experiments O
(c-i) O
with O
three O
to O
seven O
mice O
per O
group O
(error O
bars, O
s.e.m.) O

or O
are O
from O
one O
experiment O
with O
samples O
obtained O
from O
two O
independent O
experiments O
(b) O
. O

(a) O
Flow O
cytometry O
of O
circulating O
LCMV-specific O
CD8+ B-proteingene
T O
cells O
among O
peripheral O
blood O
mononuclear O
cells O
from O
Atg5fl/fl B-proteingene
and O
Atg5fl/flGzmb-Cremice B-proteingene
on O
days O
8, O
15 O
and O
50 O
after O
infection O
with O
LCMV O
Armstrong O
strain O
. O

Numbers O
adjacent O
to O
outlined O
areas O
indicate O
percent O
H-2Db-gp33+ B-proteingene
T O
cells, O
gated O
on O
CD8+ B-proteingene
T O
cells O
. O

(b) O
Longitudinal O
kinetics O
of O
the O
appearance O
of O
H-2Db-gp33+ B-proteingene
T O
cells O
in O
the O
peripheral O
blood O
of O
mice O
as O
in O
a O
(left), O
and O
percent O
H-2Db-gp33+ B-proteingene
CD8+ B-proteingene
T O
cells O
remaining O
on O
day O
15 O
(right) O
(all O
presented O
as O
in O
Fig O
. O

4h) O
. O

(c) O
Flow O
cytometry O
of O
T O
cells O
in O
tissues O
on O
day O
279 O
after O
infection O
as O
in O
a O
(numbers O
in O
plots O
as O
in O
a, O
among O
total O
gated O
CD8+ B-proteingene
T O
cells) O
. O

(d) O
Total O
T O
cells O
specific O
for O
H-2Db-gp33 B-proteingene
(left) O
or O
H-2Db-NP396 B-proteingene
(right) O
in O
the O
spleen, O
liver O
and O
lungs O
of O
mice O
as O
in O
a O
. O

*P O
≤ O
0.05, O
**P O
≤ O
0.005 O
and O
***P O
≤ O
0.0005 O
(unpaired O
t-test) O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
with O
three O
to O
seven O
mice O
per O
group O
(error O
bars O
(d), O
s.e.m O
. O

) O
. O

(a,b) O
Flow O
cytometry O
of O
CD8+ B-proteingene
T O
cell O
obtained O
from O
chimeras O
generated O
(as O
in O
Supplementary O
Fig O
. O

5a) O
by O
reconstitution O
of O
wild-type O
mice O
with O
a O
mixture O
of O
bone O
marrow O
cells O
from O
Atg7fl/fl B-proteingene
C57BL/6 O
and O
wild-type O
C57BL/6C57BL/6 O
(Atg7fl/fl B-proteingene
vs O
C57BL/6) O
or O
from O
Atg7fl/flGzmb-Cremice O
and O
wild-type O
C57BL/6mice O
and O
(Atg7fl/flGzmb-Cre B-proteingene
vs O
C57BL/6), O
gated O
(far O
left) O
as O
populations O
specific O
for O
H-2Db-gp33 B-proteingene
(a) O
or O
H-2Db-NP396 B-proteingene
(b) O
and O
then O
assessed, O
on O
days O
8, O
15 O
and O
30 O
after O
infection O
of O
recipients O
with O
LCMV O
Armstrong O
infection, O
as O
CD45.2+ B-proteingene
(Atg7fl/fl B-proteingene
or O
Atg7fl/flGzmb-Cre) B-proteingene
donor O
cells O
or O
CD45.1+ B-proteingene
(C57BL/6) O
donor O
cells O
(middle) O
. O

Far O
right, O
appearance O
of O
tetramer-positive O
T O
cells O
(key, O
donor O
source) O
in O
the O
peripheral O
blood O
of O
chimeras O
from O
day O
8 O
to O
day O
30 O
after O
infection, O
presented O
relative O
to O
that O
at O
day O
8 O
after O
infection, O
set O
as O
100% O
. O

(c) O
Frequency O
of O
CD45.2+ B-proteingene
antigen-specific O
CD8+ B-proteingene
T O
cells O
in O
the O
spleen, O
liver O
and O
lungs O
on O
day O
30 O
after O
infectionwith O
LCMV O
Armstrongas O
in O
a,b O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
with O
three O
to O
four O
mice O
per O
group O
(error O
bars, O
s.e.m O
. O

) O
. O

(a) O
Kinetics O
of O
the O
appearance O
of O
H-2Db-gp276+ B-proteingene
T O
cells O
in O
the O
peripheral O
blood O
of O
Atg7fl/fl B-proteingene
and O
Atg7fl/flGzmb-Cremice O
at O
various O
times O
(horizontal O
axis) O
after O
infection O
with O
LCMV O
clone O
13 O
. O

(b) O
Total O
IFN-γ-secreting B-proteingene
cells O
in O
spleens O
obtained O
from O
mice O
at O
day O
8 O
or O
day O
15 O
after O
infection O
as O
in O
a, O
assessed O
after O
5 O
h O
of O
stimulation O
ex O
vivo O
with O
various O
peptides O
(horizontal O
axes) O
. O

(c) O
Viral O
titers O
in O
serum O
of O
mice O
at O
various O
times O
(horizontal O
axis) O
after O
infection O
with O
LCMV O
clone O
13 O
as O
in O
a O
. O

Each O
symbol O
represents O
an O
individual O
mouse; O
small O
horizontal O
lines O
indicate O
the O
mean O
(±s.e.m.) O
. O

*P O
≤ O
0.05, O
**P O
≤ O
0.005 O
and O
***P O
≤ O
0.0005 O
(unpaired O
t-test) O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
with O
three O
to O
five O
mice O
per O
group O
(error O
bars, O
s.e.m O
. O

) O
. O

RNAi O
was O
induced O
with O
an O
empty O
vector O
as O
a O
negative O
control O
(panel O
I), O
whereas O
a O
smg-2 B-proteingene
clone O
(panel O
II) O
was O
used O
as O
a O
positive O
control O
. O

Panels O
i O
and O
ii O
show O
brightfield O
images O
of O
the O
PTCxi O
strain O
treated O
with O
the O
negative O
and O
positive O
controls, O
respectively O
. O

Depletion O
of O
five O
genes O
(panels O
III O
to O
VII) O
resulted O
in O
increased O
GFP B-proteingene
expression O
. O

Panels O
iii O
to O
vii O
show O
brightfield O
images O
of O
the O
phenotypes O
of O
the O
affected O
worms O
. O

The O
scale O
bars O
correspond O
to O
100 O
μm O
. O

Depletion O
of O
the O
novel O
NMD O
genes O
in O
C. O
elegans O
leads O
to O
upregulation O
of O
the O
PTCx O
NMD O
reporter O
mRNA, O
which O
was O
monitored O
by O
quantitative O
RT-PCR O
relative O
to O
the O
expression O
of O
ama-1 B-proteingene
reference O
gene O
. O

The O
values O
shown O
are O
the O
average O
fold-change O
(mean O
± O
SEM) O
from O
at O
least O
three O
independent O
experiments O
relative O
to O
empty O
vector-depleted O
worms O
. O

Statistical O
analysis O
was O
performed O
using O
the O
Mann-Whitney O
U-test O
for O
non-parametric O
distributions O
. O

*P O
< O
0.05 O
. O

A-C O
Embryos O
expressing O
a O
GFP-NMD B-proteingene
sensor O
(green) O
under O
the O
control O
of O
nompA B-proteingene
regulatory O
sequences O
show O
signal O
in O
support O
cells O
linked O
to O
the O
embryonic O
peripheral O
nervous O
system O
(PNS) O
[labeled O
by O
22C10 O
signal O
(magenta)] O
. O

DAPI O
signal O
is O
shown O
in O
blue O
. O

Expression O
of O
UAS-RNAi B-proteingene
constructs O
against O
Upf1 B-proteingene
(B) O
or O
nompA B-proteingene
(C) O
genes O
using O
a O
nompA-Gal4 B-proteingene
driver O
leads O
to O
upregulation O
of O
the O
GFP-NMD B-proteingene
sensor O
when O
compared O
to O
wild-type O
(no O
RNAi) O
(A), O
revealing O
a O
reduction O
in O
NMD O
activity O
in O
the O
knockdown O
conditions O
. O

Scale O
bars O
represent O
100 O
μm O
. O

D-F O
Higher O
magnification O
(40×) O
of O
the O
areas O
marked O
by O
a O
rectangle O
in O
(A-C) O
further O
illustrates O
the O
upregulation O
of O
the O
GFP-NMD B-proteingene
sensor O
in O
Upf1- B-proteingene
(E) O
and O
NompA-depleted B-proteingene
cells O
(F) O
. O

Optical O
fields O
include O
embryonic O
abdominal O
segments O
A4-A5 O
. O

Scale O
bars O
represent O
10 O
μm O
. O

G O
Quantification O
of O
GFP B-proteingene
signal O
in O
cells O
marked O
by O
an O
arrow O
in O
panels O
(D-F) O
shows O
a O
significant O
upregulation O
of O
NMD O
sensor O
expression O
upon O
downregulation O
of O
Upf1 B-proteingene
(dark O
gray) O
and O
NompA B-proteingene
(black) O
compared O
to O
wild-type O
(no O
RNAi) O
(light O
gray) O
. O

Results O
represent O
the O
average O
of O
five O
biological O
replicates O
(mean O
± O
SEM) O
. O

Pair-wise O
comparisons O
were O
performed O
using O
a O
one-tailed O
t-test O
(non-parametric) O
between O
treatments O
and O
wild-type O
. O

***P O
< O
0.001 O
. O

A, O
B O
HeLa O
cells O
stably O
expressing O
a O
wild-type O
β-globin B-proteingene
reporter O
(A) O
or O
a O
β-globin B-proteingene
NS39 O
NMD O
reporter O
(B) O
were O
mock-depleted O
or O
depleted O
of O
UPF2, B-proteingene
GNL2, B-proteingene
SEC13 B-proteingene
, O
RAB27A, B-proteingene
RAB27B B-proteingene
or O
both O
RAB27A B-proteingene
and O
RAB27B. B-proteingene
The O
level O
of O
the O
β-globin B-proteingene
mRNA O
was O
monitored O
by O
quantitative O
RT-PCR O
relative O
to O
two O
reference O
genes O
(POLR2J B-proteingene
and O
ACTB) B-proteingene
. O

The O
values O
shown O
are O
the O
average O
fold-change O
(mean O
± O
SEM) O
from O
four O
independent O
experiments O
relative O
to O
mock-depleted O
cells O
(control) O
. O

Statistical O
analysis O
was O
performed O
using O
the O
Mann-Whitney O
U-test O
for O
non-parametric O
distributions O
. O

*P O
< O
0.05 O
. O

The O
level O
of O
depletion O
of O
NMD O
factors O
is O
shown O
in O
Supplementary O
Fig O
S3C O
. O

C, O
D O
Analysis O
of O
the O
half-life O
of O
β-globin B-proteingene
reporters O
. O

Samples O
were O
collected O
at O
the O
indicated O
time O
points, O
and O
the O
mRNA O
levels O
of O
the O
HBB B-proteingene
reporters O
were O
monitored O
by O
qRT-PCR O
and O
normalized O
to O
POLR2J B-proteingene
and O
ACTB B-proteingene
reference O
genes O
. O

The O
values O
shown O
are O
the O
average O
fold-change O
(mean O
± O
SEM) O
from O
three O
independent O
experiments O
relative O
to O
the O
first O
time O
point O
. O

E O
Depletion O
of O
GNL2 B-proteingene
and O
SEC13 B-proteingene
leads O
to O
a O
significant O
upregulation O
in O
the O
mRNA O
levels O
of O
endogenous O
NMD O
substrates O
. O

Samples O
were O
analyzed O
as O
described O
in O
(A, O
B) O
*P O
< O
0.05; O
***P O
< O
0.01, O
***P O
< O
0.001 O
. O

F O
GNL2 B-proteingene
and O
SEC13 B-proteingene
contribute O
to O
the O
negative O
NMD O
feedback O
loop, O
regulating O
the O
levels O
of O
transcripts O
encoding O
NMD O
factors O
. O

RT-qPCR O
analysis O
of O
total O
cellular O
RNA O
from O
HeLa O
cells O
depleted O
of O
GNL2 B-proteingene
(in O
green) O
and O
SEC13 B-proteingene
(in O
purple) O
is O
shown O
. O

The O
graph O
shows O
distribution O
of O
relative O
fold-change O
from O
eight O
independent O
experiments O
relative O
to O
mock-depleted O
cells O
(control) O
. O

Statistical O
analysis O
was O
performed O
using O
Student O
's O
t-test O
. O

*P O
< O
0.05 O
. O

B O
Phos‐tag O
gel O
following O
complete O
conversion O
of O
Ub B-proteingene
to O
phosphoUb, B-proteingene
using O
GST‐PhPINK1 B-proteingene
. O

A O
Ser65 O
mutant O
Ub B-proteingene
is O
not O
modified O
. O

C O
ESI‐MS O
analysis O
of O
pure O
Ub B-proteingene
(left, O
mass O
8,565.65 O
Da, O
reference O
8,565.80 O
Da) O
and O
purified O
phosphoUb B-proteingene
(right, O
mass O
8,645.61 O
Da, O
reference O
8,645.80 O
Da) O
. O

The O
difference O
of O
80 O
Da O
corresponds O
to O
one O
phosphate O
group O
. O

D O
AQUA O
analysis O
of O
PhPINK1‐phosphorylated O
Lys63‐linked O
hexaUb B-proteingene
. O

The O
Lys63 O
peptide O
(K63) O
is O
modified O
by O
Ser65 O
phosphorylation O
during O
the O
time O
course, O
as O
observed O
by O
rise O
of O
the O
Lys63/pSer65 O
peptide O
(K63pS65) O
. O

E O
AQUA O
analysis O
after O
180 O
min O
as O
in O
(D) O
with O
Lys6‐, O
Lys11‐, O
Lys33‐, O
Lys48‐, O
Lys63‐, O
and O
Met1‐linked O
tetraUb B-proteingene
(K6, O
K11, O
K33, O
K48, O
K63, O
M1) O
. O

For O
all O
tetraUb O
chains, O
Ser65 O
is O
phosphorylated O
to O
greater O
than O
80% O
after O
incubation O
with O
PhPINK1 B-proteingene
for O
180 O
min O
. O

F O
Time O
course O
analysis O
of O
autoubiquitination B-proteingene
reactions O
with O
unphosphorylated O
full‐length O
humanParkin O
(hParkin) B-proteingene
and O
Ub B-proteingene
(left), O
a O
80% O
Ub/20% B-proteingene
phosphoUb B-proteingene
mixture O
(middle) O
and O
100% O
phosphoUb B-proteingene
(right) O
. O

G O
Analysis O
of O
different O
ratios O
of O
Ub:phosphoUb B-proteingene
in O
a O
120‐min O
ubiquitination B-proteingene
reaction O
of O
full‐length O
hParkin B-proteingene
. O

Parkin B-proteingene
is O
activated O
by O
a O
mixture O
of O
Ub B-proteingene
and O
phosphoUb, B-proteingene
and O
is O
much O
less O
active O
in O
a O
reaction O
with O
no O
phosphoUb B-proteingene
as O
well O
as O
with O
100% O
phosphoUb B-proteingene
. O

A O
1H, O
15N‐BEST‐TROSY O
spectrum O
of O
phosphoUb B-proteingene
(shades O
of O
blue) O
overlaid O
with O
wild‐type O
(wt) O
Ub B-proteingene
(orange) O
. O

The O
phosphoUb B-proteingene
spectrum O
contains O
130 O
non‐sidechain O
resonances O
that O
have O
been O
colored O
in O
dark O
blue O
for O
the O
major O
species O
and O
light O
blue O
for O
the O
minor O
species O
based O
on O
the O
assignment O
of O
each O
species O
in O
Supplementary O
Fig O
S2B-D. O
B-D O
Weighted O
chemical O
shift O
perturbation O
(CSP) O
graphs O
for O
(B) O
wt O
Ub B-proteingene
versus O
major O
phosphoUb B-proteingene
species, O
(C) O
wt O
Ub B-proteingene
versus O
minor O
phosphoUb B-proteingene
species, O
(D) O
major O
versus O
minor O
phosphoUb B-proteingene
species O
. O

A O
Structure O
of O
phosphoUb B-proteingene
in O
space O
group O
P1 O
with O
8 O
molecules O
in O
the O
asymmetric O
unit O
(Table O
) O
. O

Ub B-proteingene
molecules O
are O
colored O
differently, O
and O
atoms O
for O
pSer65 O
are O
shown O
as O
spheres O
with O
red O
oxygen O
and O
purple O
phosphorous O
atoms O
. O

B O
Six O
of O
eight O
phosphoUb B-proteingene
molecules O
form O
similar O
dimer O
interactions, O
where O
phosphoUb B-proteingene
molecules O
interact O
via O
their O
Ile44 O
patch O
. O

This O
resembles O
the O
crystal O
structure O
of O
Lys48‐linked O
diUb B-proteingene
[pdb‐id O
1aar O
(Cook O
et O
al, O
)] O
. O

Atoms O
for O
pSer65 O
are O
shown O
as O
in O
(A), O
and O
the O
Ile44 O
side O
chain O
is O
shown O
as O
blue O
sticks O
. O

C O
Representative O
electron O
density, O
contoured O
at O
1 O
σ, O
covering O
the O
phosphorylation O
site O
. O

pSer65 O
is O
shown O
in O
ball‐and‐stick O
representation, O
and O
neighboring O
side O
chains O
are O
shown O
in O
stick O
representation O
with O
red O
oxygen O
and O
blue O
nitrogen O
atoms O
. O

D O
In O
wt O
Ub B-proteingene
(left), O
Ser65 O
forms O
a O
hydrogen O
bond O
with O
the O
backbone O
amide O
of O
Gln62 O
. O

Upon O
phosphorylation O
(right), O
an O
oxygen O
atom O
from O
the O
phosphate O
forms O
the O
same O
backbone O
hydrogen O
bond O
. O

E O
Cartoon O
representation O
and O
electrostatic O
surface O
potential O
of O
Ub B-proteingene
(left) O
and O
phosphoUb O
(right) O
in O
identical O
orientations O
. O

Electrostatics O
were O
calculated O
using O
CHARMM O
(www.charmm-gui.org) O
and O
are O
colored O
from O
red O
(negative O
potential) O
to O
blue O
(positive O
potential) O
. O

A O
Long‐range O
HNCO O
NMR O
experiments O
showing O
differences O
of O
hydrogen O
bonding O
patterns O
for O
major O
and O
minor O
phosphoUb B-proteingene
species O
. O

Through O
H O
bond O
correlations O
(blue) O
recorded O
for O
residue O
Ile44 O
in O
the O
major O
and O
minor O
species O
of O
phosphoUb B-proteingene
with O
reference O
to O
a O
control O
HNCO O
spectrum O
(red) O
. O

In O
the O
major O
form O
of O
phosphoUb B-proteingene
(left), O
the O
HN O
of O
Ile44 O
is O
a O
H O
bond O
donor O
to O
His68, O
as O
seen O
in O
wt O
Ub B-proteingene
. O

In O
the O
minor O
form O
of O
phosphoUb B-proteingene
(right), O
the O
HN O
of O
Ile44 O
does O
not O
have O
a O
cross O
peak O
to O
His68 O
but O
instead O
has O
a O
correlation O
to O
Val70 O
. O

C O
Structure O
of O
the O
major O
form O
of O
phosphoUb, B-proteingene
where O
phosphoUb O
residues O
1-61 O
are O
shown O
under O
a O
surface, O
and O
the O
β5 O
strand O
is O
shown O
in O
stick O
representation O
with O
red O
oxygen, O
blue O
nitrogen O
and O
purple O
phosphorus O
atoms O
. O

The O
four O
core O
Leu O
residues O
are O
shown O
in O
green O
. O

D O
Model O
of O
the O
phosphoUb O
minor O
species O
as O
in O
(C) O
in O
which O
the O
β5 O
strand O
is O
retracted O
into O
the O
protein O
core O
by O
two O
residues O
. O

This O
extends O
the O
β4-β5 O
loop O
and O
significantly O
shortens O
the O
C‐terminal O
tail O
of O
Ub B-proteingene
. O

A O
E1‐mediated O
charging O
of O
E2 O
enzymes O
by O
Ub B-proteingene
and O
phosphoUb B-proteingene
in O
a O
time O
course O
analysis O
. O

Non‐reducing O
Coomassie‐stained O
4-12% O
SDS-PAGE O
gradient O
gels O
are O
shown, O
and O
bands O
are O
labeled O
. O

"˜Ub" B-proteingene
refers O
to O
generation O
of O
a O
thioester, O
while O
"Ub‐"refers B-proteingene
to O
additional O
covalent O
ubiquitination O
of O
the O
E2 O
enzyme O
. O

* O
contaminant O
from O
E2 O
purification O
. O

B O
SAXS‐derived O
ensemble O
of O
UBE2D3 B-proteingene
(Pruneda O
et O
al, O
), O
where O
the O
E2 O
is O
shown O
under O
a O
blue O
surface O
and O
the O
Ub B-proteingene
is O
shown O
as O
a O
green O
ribbon O
. O

Ser65 O
is O
shown O
in O
sphere O
representation O
. O

Ser65 O
does O
not O
contact O
the O
E2 O
enzyme O
in O
any O
orientation O
of O
the O
Ub B-proteingene
at O
the O
E2 O
enzyme O
. O

PDB O
files O
were O
downloaded O
from O
the O
Klevit‐lab O
website O
(http://depts.washington.edu/klvtlab/) O
. O

C O
Quantitative O
mass O
spectrometry O
analysis O
for O
UBE2T, B-proteingene
UBE2E1 B-proteingene
and O
UBE2R1 B-proteingene
with O
Ub B-proteingene
and O
phosphoUb O
using O
UbAQUA B-proteingene
peptides O
reveals O
impaired O
chain O
formation O
with O
phosphoUb B-proteingene
(see O
also O
Supplementary O
Fig O
S10) O
. O

D O
Charging O
of O
UBE2N, B-proteingene
and O
UBE2N/UBE2V1‐mediated B-proteingene
Lys63 O
chain O
assembly O
with O
Ub B-proteingene
and O
phosphoUb B-proteingene
. O

Charging O
of O
UBE2N B-proteingene
as O
in O
(A) O
proceeds O
identically O
with O
both O
Ub B-proteingene
and O
phosphoUb B-proteingene
(left O
6 O
lanes), O
while O
UBE2V1‐mediated B-proteingene
Lys63 O
chain O
assembly O
only O
proceeds O
with O
Ub B-proteingene
but O
not O
phosphoUb B-proteingene
(right O
6 O
lanes O
and O
Western O
blot) O
. O

E O
Structure O
of O
Saccharomyces O
cerevisiae O
Ubc13‐Mms2 B-proteingene
(blue/red, O
Mms2 B-proteingene
is O
a O
homolog O
of O
UBE2V1) B-proteingene
with O
the O
acceptor O
Ub B-proteingene
(cyan) O
bound O
non‐covalently O
to O
Mms2 B-proteingene
[pdb‐id O
2gmi O
(Eddins O
et O
al, O
)] O
. O

Ser65 O
of O
the O
acceptor O
Ub B-proteingene
interacts O
with O
Mms2, B-proteingene
and O
Ser65 O
phosphorylation O
would O
prevent O
binding O
due O
to O
Mms2 B-proteingene
Glu18 O
. O

F O
PhosphoUb B-proteingene
competition O
assays O
for O
UBE2N/UBE2V1‐mediated B-proteingene
Lys63 O
diUb O
formation O
. O

Time O
course O
with O
K63R O
Ub B-proteingene
(donor) O
and O
Ub B-proteingene
ΔGG O
(acceptor) O
generates O
Lys63 O
diUb B-proteingene
and O
is O
not O
inhibited O
upon O
increasing O
concentrations O
of O
phosphoUb, B-proteingene
revealing O
phosphoUb B-proteingene
does O
not O
compete O
with O
Ub B-proteingene
for O
UBE2N/UBE2V1‐mediated B-proteingene
Lys63 O
diUb B-proteingene
formation O
. O

A O
Time O
course O
for O
a O
ligase O
reaction O
with O
GST‐tagged B-proteingene
cIAP1 B-proteingene
(aa O
363-614), O
UBE2D1 B-proteingene
and O
Ub B-proteingene
or O
phosphoUb B-proteingene
. O

See O
Supplementary O
Fig O
S11D O
for O
a O
reaction O
with O
UBE2D3 B-proteingene
. O

B O
Anti‐Ub B-proteingene
Western O
blot O
of O
an O
identical O
reaction O
run O
for O
3 O
h. O
C O
Comparison O
of O
the O
number O
of O
Ub B-proteingene
chain O
linkages O
in O
the O
reaction O
in O
(B) O
. O

D O
Ub B-proteingene
chain O
linkage O
profile O
for O
the O
reaction O
in O
(B) O
. O

E O
Reaction O
of O
GST‐tagged B-proteingene
TRAF6 B-proteingene
(aa O
1-285) O
with O
UBE2D3 B-proteingene
as O
in O
(A) O
. O

See O
Supplementary O
Fig O
S11E O
and O
F O
for O
additional O
TRAF6 B-proteingene
reactions O
. O

F O
Anti‐UbWestern B-proteingene
blot O
of O
GST‐TRAF6/UBE2D1 B-proteingene
run O
for O
3 O
h. O
G O
Comparison O
of O
the O
number O
of O
Ub B-proteingene
chain O
linkages O
in O
the O
reaction O
in O
(F) O
. O

H O
Linkage O
composition O
in O
GST‐TRAF6‐UBE2D1 B-proteingene
reactions O
reveals O
58% O
Lys63 O
chains O
with O
wt O
Ub B-proteingene
and O
UBE2D1 B-proteingene
. O

Significantly O
smaller O
quantities O
of O
linkages O
are O
assembled O
with O
phosphoUb O
. O

I-K O
Chain O
assembly O
as O
in O
(A) O
with O
UBE2L3 B-proteingene
and O
(I) O
GST‐tagged B-proteingene
NEDD4L B-proteingene
(aa O
576-955) O
(Mund O
& O
Pelham, O
), O
(J) O
NleL B-proteingene
(aa O
170-782) O
(Hospenthal O
et O
al, O
) O
and O
(K) O
HOIP B-proteingene
RBR‐LDD O
(aa O
699-1072) O
(Smit O
et O
al, O
) O
. O

While O
the O
HECT O
E3 O
ligases O
NEDD4L B-proteingene
and O
NleL B-proteingene
are O
active O
with O
Ub B-proteingene
and O
phosphoUb, B-proteingene
HOIP B-proteingene
is O
significantly O
less O
active O
with O
phosphoUb B-proteingene
. O

See O
also O
Supplementary O
Fig O
S11G O
and O
H O
. O

A O
Structure O
of O
TAB2 B-proteingene
NZF O
(red) O
in O
complex O
with O
Lys63 O
diUb B-proteingene
(cyan) O
[pdb‐id O
2wwz O
(Kulathu O
et O
al, O
)] O
. O

Ser65 O
for O
both O
Ub B-proteingene
moieties O
is O
shown O
as O
spheres O
and O
highlighted O
with O
a O
blue O
circle O
. O

B O
Pull‐down O
assays O
with O
the O
Lys63‐specific O
TAB2 B-proteingene
NZF O
against O
different O
tetraUb B-proteingene
(Ub4) B-proteingene
species O
are O
shown O
. O

Phosphorylation O
of O
K63 O
Ub4 B-proteingene
does O
not O
prevent O
binding O
to O
TAB2 B-proteingene
NZF. O
Met1‐linked O
tetraUb B-proteingene
does O
not O
interact O
with O
TAB2 B-proteingene
NZF, O
independent O
of O
Ser65 O
phosphorylation O
. O

A O
Structure O
of O
USP2 B-proteingene
(red) O
bound O
to O
Ub B-proteingene
(cyan) O
[pdb‐id O
2hd5 O
(Renatus O
et O
al, O
)], O
with O
a O
close‐up O
on O
Ub B-proteingene
Ser65 O
in O
the O
distal O
Ub B-proteingene
. O

A O
negative O
charge O
at O
the O
USP2 B-proteingene
Asp345 O
position O
is O
conserved O
in O
most O
USP O
enzymes O
(Ye O
et O
al, O
) O
. O

B-H O
Ubiquitination B-proteingene
reactions O
from O
Fig O
A O
were O
used O
as O
input O
for O
deubiquitinase O
(DUB) O
analysis O
. O

Silver O
stainedtime O
course O
gels O
are O
shown O
. O

All O
DUBs O
tested O
(USP2, B-proteingene
USP8, B-proteingene
USP15, B-proteingene
USP30, B-proteingene
Ataxin‐3, B-proteingene
USP21) B-proteingene
hydrolyze O
Ub B-proteingene
chains O
but O
have O
significantly O
lower O
activity O
against O
phosphoUb B-proteingene
chains, O
with O
the O
exception O
of O
vOTU B-proteingene
and O
USP21 B-proteingene
. O

B-H O
Ubiquitination B-proteingene
reactions O
from O
Fig O
A O
were O
used O
as O
input O
for O
deubiquitinase O
(DUB) O
analysis O
. O

Silver‐stainedtime‐course O
gels O
are O
shown O
. O

All O
DUBs O
tested O
(USP2, B-proteingene
USP8, B-proteingene
USP15, B-proteingene
USP30, B-proteingene
Ataxin‐3, B-proteingene
USP21) B-proteingene
hydrolyze O
Ub B-proteingene
chains O
but O
have O
significantly O
lower O
activity O
against O
phosphoUb O
chains, O
with O
the O
exception O
of O
vOTU B-proteingene
and O
USP21 B-proteingene
. O

I O
USP30 B-proteingene
activity O
was O
significantly O
lower O
for O
cIAPpolyUb B-proteingene
as O
compared O
to O
other O
USP O
DUBs O
. O

Cleavage O
assays O
against O
the O
diUb B-proteingene
panel O
reveals O
preference O
for O
Lys6‐linked O
chains O
. O

J O
USP30 B-proteingene
activity O
is O
decreased O
against O
phosphorylated O
Lys6 O
diUb B-proteingene
. O

K-N O
Deubiquitinase O
assays O
against O
phosphorylated O
tetraUb B-proteingene
. O

The O
activity O
of O
AMSH B-proteingene
(K), O
TRABID B-proteingene
(L), O
OTUB1 B-proteingene
(M) O
and O
OTULIN B-proteingene
(N) O
are O
inhibited O
with O
Lys63, O
Lys33, O
Lys48 O
and O
Met1 O
phosphorylated O
tetraUb, B-proteingene
respectively O
. O

A) O
Transmission O
electron O
microscopy O
(TEM) O
of O
MoDCs O
infected O
with O
P. O
gingivalis O
for O
2, O
12 O
and O
24 O
hours O
(left, O
middle O
and O
right O
panels) O
. O

The O
sections O
show O
the O
intra-and O
extra-cellular O
contents O
of O
Cont O
. O

(un-infected), O
Pg381, O
Mfa1+Pg B-proteingene
and O
FimA+Pg B-proteingene
infected O
MoDCs O
for O
the O
different O
time O
points O

B) O
The O
figure O
shows O
the O
intracellular O
content O
of O
P. O
gingivalis O
strains O
after O
24 O
hours O
of O
infection O
. O

MoDCs O
infected O
with O
Pg381 O
or O
isogenic O
mutants O
strains O
were O
lysed O
and O
the O
survived O
intracellular O
bacteria O
were O
re-suspended O
and O
maintained O
in O
anaerobic O
broth O
for O
5 O
days O
. O

The O
data O
represents O
CFU O
within O
MoDCs O
harvested O
from O
three O
healthy O
individuals O
. O

The O
means O
±standard O
deviation O
(in O
triplicates) O
were O
analyzed O
by O
One-way O
ANOVA O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
group O
comparisons O
within O
3 O
different O
experiments O
(* O
statistical O
significance O
at O
the O
p<0.001) O
. O

A) O
Epifluorescence O
microscopy O
images O
of O
MoDCs O
infected O
with O
pre-labeled O
bacteria O
(green-CFSE) O
. O

LAMP1 B-proteingene
detected O
by O
transduction O
of O
red O
fluorescent O
protein O
(RFP) B-proteingene
chimera O
using O
baculovirus O
transgenes O
to O
MoDCs O
. O

B) O
The O
mean O
of O
fluorescent O
intensities O
±standard O
deviation O
of O
LAMP1 B-proteingene
were O
quantified O
in O
three O
different O
experiments O
(* O
p<0.001) O
. O

C) O
The O
upper O
scattered O
plot O
shows O
the O
co-localization O
of O
red O
and O
green O
signals O
in O
sections O
of O
MoDCs O
infected O
with O
Pg381 O
and O
mutants O
strains O
. O

The O
lower O
plot O
shows O
the O
average O
of O
Pearson O
's O
correlation O
measures O
of O
three O
randomly O
selected O
region O
of O
interest O
(ROI) O
within O
each O
field O
within O
3 O
different O
experiments O
(* O
p<0.0001) O
(Table O
4 O
and O
5) O
. O

All O
analysis O
of O
fluorescence O
intensity O
used O
One-way O
ANOVA O
analysis O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
comparisons O
. O

A) O
DC-SIGN B-proteingene
mRNA O
expression O
in O
P. O
gingivalis-infected O
MoDCs O
at O
0.1, O
1 O
and O
10 O
MOIs O
. O

The O
figure O
shows O
the O
gene O
expression O
after O
12 O
hours O
of O
Pg381 O
and O
mutant O
strains O
infections O
. O

The O
target O
gene O
(DC-SIGN) B-proteingene
was O
normalized O
using O
the O
endogenous O
control O
GAPDH B-proteingene
(ΔCt) O
and O
fold O
regulations O
were O
calculated O
using O
2-(ΔΔCt) O
method O
. O

The O
statistical O
analysis O
was O
performed O
using O
the O
t-test, O
which O
accounts O
for O
the O
clustering O
of O
infected O
and O
un-infected O
controls O
within O
3 O
different O
experiments O
(* O
p<0.001) O
. O

B) O
Immuno-electron O
microscopy O
of O
un-infected O
MoDCs O
(Cont.) O

(upper O
panel), O
MoDCs O
infected O
with O
Pg381 O
(middle O
panel) O
and O
Mfa1+Pg B-proteingene
mutants O
(lower O
panel) O
. O

Gold O
particles O
(marked O
with O
red O
rings) O
for O
positive O
DC-SIGN B-proteingene
were O
detected O
in O
the O
cell O
membrane O
and O
cytoplasm O
of O
cells O
infected O
with O
Mfa1+Pg B-proteingene
strains O
. O

Minimal O
positive O
staining O
for O
DC-SIGN B-proteingene
was O
detected O
in O
the O
membranes O
of O
MoDCs O
infected O
with O
Pg381, O
while O
no O
cytoplasmic O
gold O
labeling O
was O
detected O
in O
these O
cells O
. O

C) O
Flow O
cytometry O
analysis O
of O
surface O
DC-SIGN B-proteingene
in O
human O
MoDCs O
after O
infection O
with O
Pg381, O
Mfa1+Pg B-proteingene
and O
FimA+Pg B-proteingene
. O

The O
analysis O
of O
the O
intensity O
used O
Kruskal-Wallis O
test O
analysis O
of O
different O
groups O
and O
Dunn O
's O
test O
for O
multiple O
comparisons O
3 O
different O
experiments O
(* O
p<0.01) O
. O

A) O
Pg381 O
and O
mutant O
strains O
count O
after O
24 O
hr O
incubation O
with O
human O
MoDCs O
with/without O
Rapamycin O
treatment O
. O

The O
survived O
bacteria O
were O
measured O
after O
maintaining O
the O
lysed O
MoDCs O
suspension O
in O
anaerobic O
broth O
for O
5 O
days O
. O

The O
plot O
represents O
the O
means O
±standard O
deviation O
of O
CFU O
within O
MoDCs O
harvested O
from O
three O
healthy O
individuals O
(* O
P<0.001) O
. O

The O
analysis O
of O
readings O
used O
One-way O
AVOVA O
analysis O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
comparisons O
. O

B) O
Epifluorescence O
microscopy O
images O
of O
MoDCs O
treated O
with O
Rapamycin O
1 O
hour O
after O
P. O
gingivalis O
infections O
. O

LC3-II B-proteingene
(red-fluorescent O
dye) O
and O
the O
bacterial O
strains O
(green O
CFSE) O
were O
studied O
in O
MoDCs O
11 O
hours O
after O
Rapamycin O
treatment O
(12 O
hours O
after O
infections) O
. O

C) O
Quantifications O
of O
the O
fluorescent O
intensity O
of O
CFSE-labeled O
P. O
gingivalis O
and O
LC3-II B-proteingene
signals O
within O
infected O
MoDCs O
using O
NIS-Elements O
BR O
software O
. O

One-way O
ANOVA O
analysis O
was O
used O
to O
compare O
the O
means O
of O
intensity O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
comparisons O
(* O
P<0.001) O
. O

A) O
Survival O
of O
P. O
gingivalis O
strains O
within O
MoDCs O
after O
6, O
12, O
24 O
and O
48 O
hours O
. O

Blue O
lines O
show O
P. O
gingivalis O
strains O
survival O
within O
MoDCs O
and O
their O
survival O
in O
anaerobic O
condition O
in O
the O
absence O
of O
DCs O
are O
showed O
in O
black O
lines O
. O

The O
effect O
of O
rapamycin O
on O
Mfa1+Pg, B-proteingene
Pg381 O
and O
FimA+Pg B-proteingene
survival O
within O
MoDCs O
are O
shown O
in O
figures O
B, O
C O
and O
D O
respectively O
. O

A O
three-factor O
repeated O
measures O
ANOVA O
using O
mixed O
models O
was O
used O
to O
test O
the O
effect O
of O
strain O
and O
rapamycin O
treatment O
over O
time O
on O
OD O
reading O
. O

The O
survival O
curves O
for O
the O
strains O
are O
showed O
in O
blue, O
while O
the O
effect O
of O
rapamycin O
treatments O
are O
in O
red O
. O

Bacterial O
survivals O
in O
the O
absence O
of O
MoDCs O
with O
and O
without O
rapamycin O
are O
plotted O
in O
grey O
and O
black, O
respectively O
. O

Statistical O
analysis O
showed O
that O
the O
strain O
by O
rapamycin O
treatment O
overtime O
interaction O
indicates O
the O
pattern O
of O
means O
in O
each O
strain O
(Mfa1+Pg, B-proteingene
Pg381 O
and O
FimA+Pg) B-proteingene
between O
treated O
(rapamycin) O
and O
untreated O
were O
significantly O
different O
overtime O
(p-value O
<0.=001) O
. O

A) O
Epifluorescence O
microscopy O
images O
of O
MoDCs O
infected O
with O
Pg381, O
Mfa1+Pg, B-proteingene
FimA+Pg B-proteingene
and O
MFB O
strains O
after O
12 O
hours O
. O

LC3-II B-proteingene
was O
detected O
in O
red-fluorescent O
(Texas O
red) O
dye O
and O
the O
bacterial O
strains O
were O
pre-labeled O
with O
CFSE O
(green) O
. O

Co-localization O
of O
P. O
gingivalis O
and O
LC3-II B-proteingene
showed O
in O
the O
right O
panels O
. O

B) O
Quantifications O
of O
the O
fluorescent O
intensity O
of O
LC3-II B-proteingene
within O
infected O
MoDCs O
using O
NIS-Elements O
BR O
software O
. O

One-way O
ANOVA O
analysis O
was O
used O
to O
compare O
the O
means O
of O
intensity O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
comparisons O
of O
three O
different O
experiments O
(* O
p<0.001, O
# O
p<0.01) O
. O

C) O
Bacterial O
uptake O
by O
MoDCs O
was O
determined O
by O
CFSE O
fluorescent O
intensity O
(* O
p<0.001, O
# O
p<0.01) O
. O

A) O
Immuno-fluorescence O
images O
of O
LC3-II B-proteingene
and O
P. O
gingivalis O
within O
MoDCs O
pre-treated O
with O
GP120 B-proteingene
(DC-SIGN B-proteingene
blocker) O
after O
12 O
hours O
of O
infection O
. O

LC3-II B-proteingene
was O
detected O
in O
red-fluorescent O
dye O
and O
the O
bacterial O
strains O
were O
pre-labeled O
with O
green O
CFSE O
. O

B) O
Fluorescent O
intensity O
of O
LC3-II B-proteingene
and O
P. O
gingivalis O
strains O
signal O
(in O
triplicates) O
were O
statistically O
analyzed O
(* O
and O
# O
p<0.001) O
. O

C) O
Flow O
cytometry O
of O
MoDCs O
treated O
with O
siRNA O
for O
DC-SIGN B-proteingene
(si-DC-SIGN) B-proteingene
after O
12 O
hours O
. O

Left O
panels O
show O
the O
decrease O
of O
DC-SIGN B-proteingene
in O
Cont O
. O

(un-infected), O
Pg381 O
and O
Mfa1+Pg-infected B-proteingene
MoDCs O
. O

D) O
Epifluorescence O
microscopy O
images O
of O
MoDCs O
(si-DC-SIGN) B-proteingene
infected O
with O
Pg381 O
and O
Mfa1+Pg B-proteingene
. O

LC3-II B-proteingene
was O
detected O
in O
red-fluorescent O
dye O
and O
the O
bacterial O
strains O
were O
pre-labeled O
with O
green O
CFSE O
. O

E) O
The O
figure O
shows O
the O
CFU O
counts O
of O
the O
P. O
gingivalis O
strains O
with O
MoDCs O
that O
lack O
DC-SIGN B-proteingene
(si-DC-SIGN) B-proteingene
. O

The O
analysis O
of O
readings O
used O
One-way O
ANOVA O
analysis O
of O
different O
groups O
and O
Tukey O
's O
test O
for O
multiple O
comparisons O
(* O
p<0.001) O
. O

A) O
Western O
blot O
detection O
of O
LC3 B-proteingene
in O
MoDCs O
infected O
with O
Pg381 O
and O
mutant O
strains O
for O
12 O
hours O
. O

B) O
The O
mean O
±standard O
deviation O
of O
LC3-II B-proteingene
intensity O
represents O
three O
different O
experiments O
and O
the O
values O
were O
analyzed O
using O
Kruskal-Wallis O
test O
analysis O
of O
different O
groups O
and O
Dunn O
's O
test O
for O
multiple O
comparisons O
. O

C) O
Blot O
shows O
the O
autophagy O
flux O
test O
after O
blocking O
the O
lysosomal O
fusion O
with O
Bafilomycin O
in O
MoDCs O
. O

Cells O
were O
treated O
with O
Bafilomycin O
for O
4 O
hours O
at O
4nM. O
D) O
LC3-II B-proteingene
intensity O
in O
MoDCs O
infected O
with O
Pg381 O
strains O
with O
and O
without O
Bafilomycin O
. O

The O
analysis O
of O
the O
intensity O
of O
three O
different O
experiments O
used O
Kruskal-Wallis O
test O
analysis O
of O
different O
groups O
and O
Dunn O
's O
test O
for O
multiple O
comparisons O
. O

A) O
Flow O
cytometry O
of O
CD83 B-proteingene
on O
MoDCs O
after O
incubation O
of O
TLR4 O
ligand O
(E. O
coli O
LPS) O
and O
TLR1 O
and O
2 O
ligand O
(Pam3csk4) O
for O
4 O
hour O
. O

B) O
Immuno-fluorescence O
images O
of O
LC3-II B-proteingene
(red) O
within O
MoDCs O
after O
incubation O
with O
TLR4 O
and O
TLR1&2 O
ligands O
(E. O
coli O
LPS O
and O
Pam3csk4) O

C) O
The O
plot O
represents O
the O
means O
±standard O
deviation O
of O
CFU O
within O
MoDCs O
harvested O
from O
three O
healthy O
individuals O
after O
24 O
hours O
(** O
p<0.001) O
. O

A) O
Scanning O
electron O
microscopy O
(SEM) O
of O
MoDCs O
of O
the O
early O
interaction O
of O
MoDCs O
with O
Pg381 O
and O
Mfa1+Pg B-proteingene
(upper O
panel O
10000x O
and O
lower O
panel O
25000x) O
. O

B) O
SEM O
for O
MoDCs O
interacting O
with O
Pg381 O
(green O
stains O
for O
bacteria O
are O
computer O
generated) O
. O

C) O
Transmission O
electron O
microscopy O
(TEM) O
of O
autophagosome O
like O
structures O
within O
MoDCs O
infected O
with O
Pg381, O
Mfa1+Pg B-proteingene
and O
FimA+Pg B-proteingene
for O
12 O
hours O
(upper, O
middle O
and O
lower O
panels, O
respectively) O
. O

The O
right O
and O
left O
sections O
show O
the O
different O
magnifications O
of O
randomly O
selected O
sections O
. O

Pg381 O
and O
FimA+Pg B-proteingene
strains O
are O
mostly O
enclosed O
in O
the O
characteristics O
double-membrane O
intracellular O
vesicles O
(Orange O
arrows) O
. O

Contrary, O
Mfa1+Pg B-proteingene
escaped O
these O
autophagic O
(double-membrane) O
vesicles O
and O
enclosed O
within O
single O
membrane O
structures O
or O
freely O
occupy O
the O
cytoplasm O
(Green O
arrows) O
. O

D) O
The O
ratio O
of O
bacteria O
included O
in O
the O
double O
membrane O
were O
compared O
to O
total O
number O
of O
bacteria O
within O
MoDCs O
and O
plotted O
as O
percentage O
. O

Counting O
of O
the O
bacteria O
included O
in O
single O
or O
doubled O
membrane O
vesicles O
after O
12 O
hours O
of O
infection O
. O

Each O
strain O
was O
counted O
in O
three O
randomly O
selected O
grids O
for O
each O
sample O
. O

The O
analysis O
of O
the O
bacterial O
counts O
used O
Kruskal-Wallis O
test O
of O
different O
groups O
and O
Dunn O
's O
test O
for O
multiple O
comparisons O
(*p<0.01) O
. O

The O
results O
of O
oligonucleotide O
array O
screens O
of O
EGF- B-proteingene
or O
control-stimulated O
MCF10A O
cells O
(Amit O
et O
al, O
2007) O
were O
re-analyzed, O
and O
genes O
induced O
by O
> O
twofold O
were O
included O
in O
the O
Venn O
diagram O
. O

The O
heatmap O
presents O
a O
time O
series O
of O
genes O
induced O
upon O
EGF B-proteingene
treatment O
. O

siRNAs O
specific O
to O
the O
indicated O
genes O
were O
used O
to O
treat O
MCF10A O
cells, O
and O
migration O
tracks O
were O
subsequently O
quantified O
(see O
Supplementary O
Fig O
S1A) O
. O

Shown O
are O
means O
± O
SEM O
of O
three O
experiments; O
60 O
cells O
were O
analyzed O
in O
each O
case O
. O

The O
results O
of O
statistical O
analyses O
(two-tailed O
Student O
's O
t-test) O
are O
shown O
in O
Supplementary O
Table O
S1 O
. O

Changes O
in O
NAV3 B-proteingene
expression O
levels O
in O
response O
to O
EGF B-proteingene
were O
extracted O
from O
DNA O
arrays O
or O
determined O
by O
means O
of O
quantitative O
PCR O
. O

Serum-starved O
MCF10A O
cells O
were O
treated O
with O
EGF B-proteingene
(10 O
ng/ml) O
for O
the O
indicated O
time O
intervals, O
and O
cell O
extracts O
were O
subjected O
to O
immunoblotting O
(IB), O
as O
indicated O
. O

Shown O
are O
trajectories O
of O
MCF10A O
cells O
expressing O
either O
siCTRL O
or O
siNAV3 B-proteingene
and O
migrated O
on O
collagen O
in O
the O
absence O
or O
presence O
of O
EGF. B-proteingene
Red O
tracks O
indicate O
low O
persistence O
(< O
0.3) O
. O

See O
quantification O
of O
the O
data O
in O
Supplementary O
Fig O
S2D. O
Quantitative O
analysis O
of O
the O
mode O
of O
migration O
of O
NAV3-depleted B-proteingene
cells O
. O

The O
distribution O
of O
step O
sizes O
was O
computed, O
normalized O
and O
presented O
as O
probability O
distribution O
functions O
(left O
panel) O
. O

Log-log O
plots O
indicating O
modes O
of O
migration O
for O
each O
of O
the O
four O
conditions O
are O
shown O
(right O
panel) O
. O

Note O
that O
only O
EGF-treated B-proteingene
siCTRL O
cells O
exhibit O
a O
persistent O
walk O
(diagonal), O
whereas O
the O
other O
three O
asymptote, O
as O
expected O
for O
random O
walks O
. O

MCF10A O
cells, O
pre-transfected O
with O
the O
indicated O
siRNAs, O
were O
assayed O
for O
migration O
or O
invasion O
in O
the O
absence O
or O
presence O
of O
EGF. B-proteingene
Cells O
that O
reached O
the O
filter O
's O
bottom O
were O
stained O
and O
photographed O
. O

Scale O
bars, O
150 O
μm O
(migration) O
and O
100 O
μm O
(invasion) O
. O

The O
results O
from O
(A) O
are O
depicted O
as O
means O
± O
SD O
(four O
experiments) O
. O

Phase O
microscopy O
analysis O
of O
shCTRL O
and O
shNAV3MCF10A O
cells O
(scale O
bars, O
50 O
μm), O
which O
were O
plated O
in O
Matrigel O
and O
grown O
for O
8 O
or O
12 O
days O
in O
the O
presence O
of O
EGF B-proteingene
(20 O
ng/ml) O
. O

Acini O
were O
photographed O
and O
quantified O
for O
their O
volumes O
using O
ImageJ. O
The O
right O
panel O
shows O
analysis O
of O
acinus O
size O
after O
8 O
days O
in O
culture O
(data O
represent O
three O
different O
experiments, O
and O
P-value O
was O
calculated O
using O
t-test) O
. O

shCTRL O
or O
shNAV3acini O
(day O
10) O
were O
immunostained O
for O
activated O
caspase-3 B-proteingene
(red) O
and O
DAPI O
(scale O
bar, O
20 O
μm) O
. O

Clusters O
positive O
for O
activated O
caspase-3 B-proteingene
were O
counted O
and O
quantified O
in O
three O
experiments O
(means O
± O
SD) O
. O

shCTRL- O
and O
shNAV3-MDA-MB-231 B-proteingene
cells O
were O
plated O
in O
invasion O
chambers, O
and O
18 O
h O
later, O
invaded O
cells O
were O
stained O
. O

For O
3D O
growth, O
cells O
were O
seeded O
in O
Matrigel O
and O
photos O
were O
taken O
5 O
days O
later O
(scale O
bars, O
200 O
μm O
and O
50 O
μm) O
. O

Histograms O
(means O
± O
SD) O
of O
the O
results O
presented O
in O
(A) O
(from O
three O
experiments) O
. O

MDA-MB-231 O
derivatives O
were O
plated O
on O
coverslips O
pre-coated O
with O
a O
fluorescent O
gelatin O
. O

Two O
hours O
later, O
cells O
were O
probed O
for O
actin B-proteingene
and O
TKS5 B-proteingene
. O

The O
number O
of O
cells O
with O
invadopodia O
were O
quantified O
in O
three O
experiments O
. O

Shown O
are O
means O
± O
SD. O
Each O
determination O
included O
80 O
cells O
. O

Scale O
bar, O
10 O
μm O
. O

MDA-MB-231 O
derivatives O
were O
monitored O
for O
invasion O
and O
proliferation O
using O
real-time O
impedance O
(xCELLigence) O
. O

The O
indicated O
RFP-expressing B-proteingene
MDA-MB-231 O
derivatives O
were O
injected O
either O
intravenously O
(1.5 O
× O
105 O
per O
mouse; O
tail O
vein), O
or O
into O
the O
mammary O
fat O
pad O
(2.5 O
× O
106 O
cells O
per O
mouse) O
of O
SCIDmice O
. O

Four O
weeks O
later, O
lungs O
from O
the O
tail O
vein-injected O
mice O
were O
photographed O
and O
examined O
for O
RFP B-proteingene
signals O
corresponding O
to O
relatively O
large O
nodules, O
which O
were O
quantified O
. O

Photographs O
and O
numbers O
of O
the O
relatively O
small O
metastases, O
as O
well O
as O
tumor O
size O
from O
mice O
injected O
into O
the O
fat O
pad, O
were O
obtained O
8 O
weeks O
post-implantation O
(right O
panels) O
. O

The O
indicated O
MDA-MB-231 O
derivatives O
were O
transfected O
with O
a O
GFP-EB1 B-proteingene
plasmid O
. O

Time-lapse O
images O
were O
taken O
at O
2-s O
intervals, O
and O
MT O
ends O
were O
tracked O
using O
plusTipTracker O
. O

Overlays O
of O
four O
MT O
subpopulations O
and O
representative O
cells O
are O
shown O
(scale O
bar, O
10 O
μm), O
along O
with O
the O
relative O
proportions O
of O
subpopulations O
(right O
panel) O
. O

Data O
(mean O
± O
SD) O
were O
pooled O
from O
three O
experiments O
. O

P-values O
are O
shown O
for O
two O
groups O
. O

Cells O
from O
(A) O
were O
used O
to O
derive O
representative O
overlays O
of O
MT O
dynamics O
maps, O
depicting O
displacement O
and O
speed O
(scale O
bar, O
10 O
μm) O
. O

Scatter O
plots O
of O
mean O
displacement O
and O
speed O
of O
MT O
tracks O
are O
shown O
. O

Nine O
representative O
cells O
(three O
of O
each O
experiment) O
were O
selected O
for O
analysis O
of O
MT O
's O
mean O
displacement O
and O
speed O
. O

The O
indicated O
derivatives O
of O
MDA-MB-231 O
cells O
were O
photographed, O
either O
directly O
or O
following O
immunofluorescence O
analysis O
using O
the O
indicated O
antibodies O
. O

Nuclei O
were O
stained O
with O
DAPI O
(scale O
bars, O
20 O
μm O
and O
10 O
μm, O
left O
and O
right O
columns, O
respectively) O
. O

The O
indicated O
stable O
derivatives O
of O
MDA-MB-231 O
cells O
were O
analyzed O
using O
RT-PCR O
for O
the O
levels O
of O
NAV3 B-proteingene
expression O
(right O
panel) O
. O

Shown O
are O
means O
± O
SD O
from O
three O
independent O
analyses O
. O

Whole-cell O
extracts O
were O
prepared O
and O
subjected O
to O
immunoblotting O
with O
anti-NAV3, B-proteingene
anti-acetylated O
tubulin B-proteingene
and O
anti-α-tubulin B-proteingene
antibodies O
(left O
panel) O
. O

MDA-MB-231 O
cells, O
pre-treated O
with O
the O
indicated O
siRNAs, O
were O
stimulated O
with O
Alexa O
Fluor O
488-EGF B-proteingene
(20 O
ng/ml) O
and O
imaged O
for O
25 O
min O
. O

Frames O
taken O
at O
2 O
and O
25 O
min O
are O
shown O
(scale O
bars, O
10 O
μm; O
see O
Supplementary O
Movie O
S3) O
. O

Cells O
were O
stimulated O
with O
EGF B-proteingene
(20 O
ng/ml; O
10 O
min) O
as O
in O
(A), O
acid-washed O
and O
incubated O
at O
37°C O
for O
the O
indicated O
intervals O
. O

Thereafter, O
cells O
were O
detached, O
fixed O
and O
analyzed O
using O
imaging O
flow O
cytometry O
(ImageStreamX) O
. O

Shown O
are O
means O
± O
SD O
from O
three O
experiments O
. O

MDA-MB-231 O
derivatives O
were O
serum-starved O
and O
stimulated O
with O
EGF B-proteingene
for O
the O
indicated O
time O
intervals O
. O

Whole O
extracts O
were O
subjected O
to O
immunoblotting O
as O
indicated O
. O

Rose O
plots O
obtained O
with O
MDA-MB-231 O
derivatives O
exposed O
to O
an O
EGF B-proteingene
gradient O
(shown O
as O
a O
blue O
and O
green O
wedge) O
in O
chemotaxis O
chambers O
. O

Blue O
lines O
indicate O
properly O
oriented O
tracks O
. O

Histograms O
(mean O
± O
SEM) O
show O
quantification O
of O
persistence O
and O
chemotactic O
orientation O
from O
three O
experiments O
(45 O
cells) O
. O

A O
MCF10A O
cells O
were O
plated O
on O
collagen, O
and O
24 O
h O
later, O
they O
were O
treated O
with O
EGF B-proteingene
(10 O
ng/ml) O
. O

Shown O
are O
trajectories O
of O
cells O
transiently O
expressing O
the O
indicated O
forms O
of O
NAV3 B-proteingene
. O

Red O
tracks O
indicate O
relatively O
low O
persistence O
(< O
0.6) O
. O

B O
Quantification O
of O
migration O
parameters O
(from O
A) O
is O
shown O
as O
mean O
± O
SEM O
(60 O
cells O
and O
three O
experiments) O
. O

C O
HEK293 O
cells O
previously O
transfected O
with O
EGFP-NAV3 B-proteingene
(WT), O
EGFP-NAV3-D1047N B-proteingene
or O
EGFP-NAV3-A459P B-proteingene
were O
treated O
with O
cycloheximide O
(CHX; O
50 O
μg/ml) O
or O
with O
the O
solvent, O
DMSO, O
for O
the O
indicated O
time O
intervals, O
followed O
by O
cell O
lysis O
and O
immunoblotting O
using O
anti-EGFP B-proteingene
and O
anti-α-tubulin B-proteingene
antibodies O
. O

The O
signals O
obtained O
were O
quantified O
and O
normalized O
to O
time O
zero O
(untreated O
cells; O
right O
panel) O
. O

D, O
E O
The O
indicated O
mCherry-expressing B-proteingene
MDA-MB-231 O
derivatives O
were O
injected O
intravenously O
(1.5 O
× O
105 O
per O
mouse) O
using O
5-week-old O
female O
SCIDmice O
. O

Four O
weeks O
later, O
lungs O
were O
photographed O
and O
the O
numbers O
of O
lungmetastases O
were O
determined O
. O

A O
Representative O
immunohistochemistry O
images O
of O
NAV3 B-proteingene
in O
a O
normal O
breast O
tissue, O
as O
well O
as O
in O
the O
indicated O
molecular O
subtypes O
of O
breast O
cancer O
. O

B O
Tissue O
microarrays O
were O
used O
to O
stratify O
288 O
breast O
cancer O
patients O
for O
overall O
survival O
according O
to O
NAV3 B-proteingene
abundance O
. O

C O
Immunohistochemistry O
was O
used O
to O
score O
NAV3 B-proteingene
expression O
and O
stratify O
323 O
breast O
cancer O
patients O
according O
to O
the O
indicated O
subtypes O
and O
tumor O
parameters O
. O

D, O
E O
Kaplan-Meier O
curves O
depicting O
survival O
of O
1,471 O
estrogen O
receptor-positive O
breast O
cancer O
patients O
(D) O
and O
1,405 O
lung O
cancer O
patients O
(E) O
stratified O
according O
to O
NAV3 B-proteingene
abundance O
. O

A O
CcnomRNA B-proteingene
is O
expressed O
in O
the O
embryonic O
node O
at O
E8 O
as O
shown O
by O
in O
situ O
hybridization O
. O

Occasionally, O
additional O
expression O
is O
observed O
at O
the O
posterior O
tip O
of O
the O
embryo O
(asterisk) O
. O

Double O
labelling O
by O
staining O
for O
LacZ B-proteingene
expression O
from O
the O
CcnoTA B-proteingene
allele O
(shown O
in O
B) O
and O
in O
situ O
hybridization O
for O
Dand5, B-proteingene
marking O
crown O
cells O
at O
the O
circumference O
of O
the O
node O
. O

Ccno B-proteingene
expression O
is O
restricted O
to O
ciliated, O
ventral O
pit O
cells O
of O
the O
node O
as O
detailed O
in O
the O
transverse O
section O
at O
the O
indicated O
plane O
. O

C O
Whole O
embryoX‐Gal O
staining O
of O
E16 O
CcnoTA/+ B-proteingene
and O
wild‐type O
control O
embryos O
and O
indicated O
section O
planes O
of O
(D-F') O
. O

D-F' O
Histological O
sections O
of O
LacZ‐stained B-proteingene
CcnoTA/+embryo B-proteingene
at O
E16 O
reveal O
Ccno B-proteingene
expression O
in O
the O
epithelium O
of O
(D) O
plexus O
choroideus O
and O
ependyme, O
(E) O
snoutepithelium, O
and O
(F, O
F') O
trachea O
and O
bronchi O
. O

pc, O
plexus O
choroideus; O
se, O
snoutepithelium; O
tr, O
trachea; O
and O
br, O
bronchus O
. O

G O
Co‐expression O
of O
Ccno B-proteingene
and O
Foxj1 B-proteingene
in O
multiciliated O
cells O
of O
the O
trachea O
shown O
by O
double O
staining O
for O
X‐Gal O
and O
immunohistochemistry O
using O
a O
FOXJ1‐specific B-proteingene
antibody O
. O

A O
Ccno‐deficient B-proteingene
mice O
develop O
severe O
hydrocephalus O
resulting O
in O
characteristic O
head O
deformation O
at O
P21 O
(arrow) O
. O

B, O
C O
Cranial O
MRI O
analysis O
(B) O
shows O
the O
drastically O
enlarged O
ventricular O
cavity O
(marked O
by O
V) O
and O
diminished O
cerebral O
cortex O
tissue, O
(C) O
also O
seen O
when O
brains O
are O
cut O
in O
coronal O
orientation O
. O

D, O
D' O
Alcian‐blue O
staining O
of O
paranasal O
cavities O
reveals O
mucus O
congestion O
along O
the O
nasal O
epithelium O
(arrows) O
. O

F, O
F' O
Scanning O
electron O
microscopy O
(SEM) O
of O
P21 O
adult O
trachea O
shows O
reduced O
numbers O
of O
cilia O
of O
Ccno‐deficient B-proteingene
MCCs O
. O

Remaining O
cilia O
are O
found O
in O
the O
central O
regions O
of O
the O
cell O
surface, O
and O
cell O
margins O
frequently O
lack O
the O
ciliary O
decoration O
(arrows) O
. O

G O
Transmission O
electron O
microscopy O
(TEM) O
of O
wild‐type O
and O
CcnoRA/RAMCCs O
from O
adult O
trachea O
. O

Ccno‐deficient B-proteingene
MCCs O
show O
reduced O
numbers O
of O
basal O
bodies O
and O
cilia O
that O
correctly O
docked O
to O
the O
apical O
cell O
surface O
(arrows) O
. O

Ectopic O
electron‐dense O
material O
is O
found O
within O
the O
cytoplasm O
of O
Ccno‐deficient B-proteingene
MCCs O
(arrowheads) O
. O

A-H O
X‐Gal‐staining O
of O
(A-C) O
control O
and O
(D-H) O
CcnoTA/+ B-proteingene
embryonic O
lungs O
at O
indicated O
stages O
showing O
onset O
of O
Ccno B-proteingene
expression O
from O
E13 O
in O
the O
proximal O
trachea O
and O
in O
the O
main O
bronchi O
. O

Expression O
is O
extending O
to O
more O
distal O
regions, O
and O
from O
E16 O
staining O
is O
also O
found O
in O
bronchioli O
. O

I O
X‐Gal‐staining O
indicating O
LacZ B-proteingene
expression O
from O
the O
CcnoTA/+ B-proteingene
allele O
in O
mTEC O
cultures O
after O
5 O
days O
of O
differentiation‐onset O
by O
switching O
to O
air-liquid O
interface O
(ALI) O
conditions O
(ALI O
d5) O
. O

J O
Transcript O
levels O
of O
Ccno B-proteingene
and O
indicated O
genes O
with O
known O
functions O
for O
the O
generation O
of O
multiple O
cilia O
during O
mTEC O
differentiation O
. O

mRNA O
levels O
from O
three O
independent O
experiments O
were O
measured O
by O
qRT-PCR O
and O
levels O
of O
expression O
set O
as O
1 O
on O
day O
0 O
of O
ALI O
cultures O
. O

Scales O
for O
Ccno B-proteingene
and O
Deup1 B-proteingene
are O
indicated O
on O
the O
left, O
and O
for O
Cep152, B-proteingene
Cep63 B-proteingene
and O
Ift57 B-proteingene
on O
the O
right O
side O
. O

K O
Relative O
mRNA O
expression O
levels O
for O
indicated O
genes O
were O
measured O
by O
qRT-PCR O
in O
wild‐type O
and O
Ccno‐deficient B-proteingene
mTEC O
cultures O
at O
indicated O
days O
after O
differentiation‐onset O
. O

Relative O
values O
were O
calculated O
as O
in O
(J) O
relative O
to O
day O
0 O
of O
ALI O
cultures O
. O

A-B' O
SEM O
of O
tracheae O
from O
(A, O
A') O
wild‐type O
and O
(B, O
B') O
CcnoRA/RAembryos B-proteingene
at O
E17 O
. O

In O
comparison O
to O
wild‐type O
MCCs, O
Ccno‐deficient B-proteingene
MCCs O
almost O
completely O
lack O
formation O
of O
multiple O
cilia O
and O
only O
single, O
or O
doublet O
(arrow) O
cilia O
are O
observed O
at O
E17 O
. O

C-E O
The O
lack O
of O
multiple O
cilia O
at O
E17 O
stages O
is O
reflected O
by O
the O
almost O
complete O
absence O
of O
acetylated O
α‐tubulin B-proteingene
staining O
as O
marker O
for O
axonemes O
in O
(D) O
Ccno‐deficient B-proteingene
MCCs O
of O
E17 O
embryonic O
trachea O
as O
quantified O
in O
(E) O
. O

FOV, O
field O
of O
view O
. O

F-I O
TEM O
of O
MCCs O
from O
E17 O
embryonic O
tracheae O
shows O
deuterosomes O
with O
forming O
procentrioles O
in O
(F, O
F', O
H) O
Ccno‐proficient B-proteingene
and O
(G, O
G', O
I) O
Ccno‐deficient B-proteingene
MCCs O
. O

Asterisks O
in O
(F, O
G) O
indicate O
microvilli O
that O
extend O
from O
the O
apical O
cell O
surface O
. O

(F', O
G') O
Deuterosomes O
in O
Ccno‐deficient B-proteingene
MCCs O
are O
significantly O
enlarged O
(identical O
size O
bars O
in O
F' O
and O
G') O
and O
show O
irregular O
morphology, O
which O
is O
different O
to O
the O
annular O
shape O
of O
wild‐type O
deuterosomes O
as O
seen O
in O
(F', O
H) O
. O

Procentrioles O
(arrowheads O
in O
F' O
and O
I) O
that O
are O
found O
at O
deuterosomes O
of O
(I) O
Ccno‐deficient B-proteingene
MCCs O
were O
recurrently O
found O
being O
shorter O
and O
appeared O
less O
structured O
in O
comparison O
to O
(F', O
H) O
wild‐type O
cells O
. O

J O
The O
average O
length O
of O
procentrioles O
was O
quantified O
for O
wild‐type O
and O
Ccno‐deficient B-proteingene
MCCs O
of O
E17 O
tracheae O
(49 O
procentrioles O
in O
n O
= O
3 O
independent O
samples O
for O
wild‐types O
and O
47 O
procentrioles O
in O
n O
= O
3 O
independent O
samples O
for O
Ccno‐deficient B-proteingene
MCCs) O
. O

K O
The O
diameter O
of O
deuterosomes O
(41 O
deuterosomes O
in O
n O
= O
3 O
independent O
samples O
for O
wild‐types; O
38 O
deuterosomes O
in O
n O
= O
5 O
independent O
samples O
for O
Ccno‐deficient B-proteingene
MCCs) O
was O
measured O
in O
wild‐type O
and O
Ccno‐deficient B-proteingene
MCCs O
of O
E17 O
tracheae O
. O

Double O
IF O
analysis O
of O
mTEC O
cultures O
at O
early O
stage O
of O
MCC O
differentiation O
and O
centriole O
amplification O
(ALI O
day O
3) O
using O
antibodies O
for O
the O
deuterosome O
protein O
DEUP1 B-proteingene
and O
the O
early O
centriole O
marker O
SAS‐6 B-proteingene
. O

Deuterosome O
numbers O
are O
decreased O
and O
deuterosome O
size O
enlarged O
in O
Ccno‐deficient B-proteingene
MCCs O
as O
quantified O
in O
(C) O
. O

Deuterosome‐dependent O
centriole O
biogenesis O
is O
severely O
reduced O
in O
Ccno‐deficient B-proteingene
MCCs O
as O
shown O
by O
reduced O
staining O
for O
the O
early O
centriole O
marker O
SAS‐6 B-proteingene
. O

IFstaining O
for O
DEUP1 B-proteingene
reveals O
a O
further O
size O
increase O
of O
deuterosomes O
of O
Ccno‐deficient B-proteingene
MCCs O
at O
later O
stages O
of O
centriole O
biogenesis O
(ALI O
day O
7) O
. O

Deuterosome O
number O
and O
size O
were O
quantified O
in O
(C) O
. O

IF O
using O
a O
Centrin B-proteingene
antibody O
shows O
globally O
reduced O
presence O
of O
centrioles O
at O
ALI O
day O
7, O
which O
stay O
localized O
below O
the O
level O
of O
deuterosomes O
and O
fail O
to O
dock O
to O
the O
apical O
cellmembrane O
in O
Ccno‐deficient B-proteingene
MCCs O
as O
seen O
in O
z‐projection O
. O

IFstaining O
for O
DEUP1 B-proteingene
in O
(A, O
B) O
was O
analysed O
by O
Imaris O
7.7.2 O
software O
to O
calculate O
average O
deuterosome O
number O
of O
wild‐type O
(n O
= O
17) O
and O
Ccno‐deficient B-proteingene
(n O
= O
19) O
MCCs O
at O
ALI O
day O
3, O
and O
wild‐type O
(n O
= O
12) O
and O
Ccno‐deficient B-proteingene
(n O
= O
14) O
MCCs O
at O
ALI O
day O
7 O
. O

Deuterosome O
size O
was O
measured O
using O
the O
spot O
measurement O
tool O
in O
n O
= O
10 O
MCCs O
for O
both O
genotypes O
at O
ALI O
day O
3, O
and O
in O
wild‐type O
(n O
= O
12) O
and O
Ccno‐deficient B-proteingene
(n O
= O
14) O
MCCs O
at O
ALI O
day O
7 O
. O

A, O
B O
IF O
analysis O
of O
mTEC O
cultures O
at O
ALI O
day O
7 O
using O
antibodies O
against O
the O
centriole O
marker O
Centrin B-proteingene
and O
CEP164, B-proteingene
which O
marks O
maturing O
centrioles O
. O

At O
ALI O
day O
7, O
centrioles O
of O
wild‐type O
MCCs O
are O
decorated O
with O
CEP164 B-proteingene
and O
are O
mostly O
localized O
to O
the O
apical O
cellmembrane O
. O

The O
fewer O
centrioles O
of O
Ccno‐deficient B-proteingene
MCCs O
do O
not O
colocalize O
with O
CEP164 B-proteingene
and O
fail O
to O
reach O
the O
apical O
cell O
surface O
as O
seen O
in O
z‐projection O
. O

Lack O
of O
CEP164 B-proteingene
indicates O
immature O
centrioles O
in O
Ccno‐deficient B-proteingene
MCCs O
. O

(B) O
Total O
centriole O
numbers O
per O
MCC O
were O
counted O
in O
n O
= O
11 O
MCCs O
for O
both O
genotypes O
using O
Imaris O
7.7.2 O
software O
. O

C, O
D O
Double O
IFstaining O
using O
Centrin‐ B-proteingene
and O
CP110‐specific B-proteingene
antibodies O
shows O
an O
almost O
complete O
absence O
of O
CP110 B-proteingene
from O
Centrin‐positive B-proteingene
centrioles O
in O
the O
majority O
of O
wild‐type O
MCCs O
at O
day O
7 O
of O
ALI O
cultures O
. O

Most O
Ccno‐deficient B-proteingene
MCCs O
exhibit O
pronounced O
CP110 B-proteingene
staining O
that O
colocalizes O
with O
Centrin B-proteingene
as O
seen O
in O
z‐projection O
. O

(D) O
CP110‐positive B-proteingene
MCCs O
were O
counted O
in O
wild‐type O
and O
Ccno‐deficient B-proteingene
MTEC O
cultures O
and O
the O
percentages O
of O
CP110‐positive B-proteingene
MCCs O
from O
total O
MCCs O
calculated O
. O

H&E O
staining O
of O
adult O
head O
sections O
of O
(A) O
repo>GFP.nls B-proteingene
and O
(B) O
repo>Shits1 B-proteingene
at O
29°C O
for O
3 O
days O
. O

Lamina O
degeneration O
was O
identified O
as O
vacuoles O
in O
(B) O
. O

Cryosection O
of O
adult O
(C) O
repo>H2B-RFP B-proteingene
exhibited O
the O
expression O
of O
the O
nuclear O
red O
fluorescent O
protein O
(RFP) B-proteingene
in O
the O
glia O
(epithelialglialnucleus: O
arrowhead) O
and O
(D) O
repo>Shits1 B-proteingene
at O
28°C O
for O
12 O
days O
. O

Vacuoles O
were O
identified O
in O
the O
lamina O
neuropile O
(D) O
. O

Epithelial O
(arrowhead) O
(E), O
marginal O
(arrow) O
and O
distal O
satellite O
(arrowhead) O
glianuclei O
(F) O
are O
labeled O
by O
HisCl-GAL4 B-proteingene
and O
NP2109-GAL4, B-proteingene
respectively O
. O

Note O
that O
HisCl-GAL4 B-proteingene
is O
not O
expressed O
in O
all O
epithelialglia O
. O

(G, O
H) O
Weak O
lamina O
vacuolization O
was O
identified O
in O
HisCl>Shits1 B-proteingene
(G, O
0.92%) O
and O
NP2109>Shits1 B-proteingene
(H, O
1.46%) O
at O
29°C O
for O
14 O
days O
. O

(I, O
J) O
A O
single O
MARCMglia O
clone O
(GFP, B-proteingene
green) O
expressed O
Shits1 B-proteingene
at O
21°C O
(I) O
and O
29°C O
(J) O
. O

(J) O
A O
vacuole O
occurred O
within O
a O
glial O
clone O
. O

DAPI O
(white) O
stains O
the O
nuclei O
(C, O
D, O
and O
G-J) O
. O

(K) O
The O
percentage O
of O
the O
vacuole O
area O
in O
the O
lamina O
of O
the O
repo>Shits1flies B-proteingene
at O
28°C O
progressively O
increased O
. O

n O
indicated O
in O
each O
column O
. O

P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Bonferroni O
's O
post-test O
. O

(L) O
When O
repo>Shits1flies O
were O
shifted O
to O
28°C O
for O
12 O
days O
and O
then O
shifted O
to O
17°C O
for O
9 O
additional O
days, O
the O
vacuolization O
was O
not O
alleviated O
. O

P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Tukey O
's O
post-test O
. O

n O
indicated O
in O
each O
column O
. O

(A) O
repots>Rab5S43N B-proteingene
. O

(B) O
repots>Rab7T22N B-proteingene
. O

(C) O
repots>Rab11S25N B-proteingene
. O

(D-H) O
MARCM O
clones O
labeled O
by O
RFP B-proteingene
or O
GFP B-proteingene
(green) O
of O
control O
(D), O
Rab52 B-proteingene
(E), O
α-Ada3 B-proteingene
(F), O
HrsD28 B-proteingene
(G), O
Rab7KO B-proteingene
(H), O
dor8 B-proteingene
(I) O
and O
carΔ146 B-proteingene
(J) O
. O

The O
penetrance O
(number O
of O
samples O
with O
vacuole O
over O
the O
number O
of O
samples O
examined) O
is O
indicated O
in O
each O
panel O
. O

Adults O
of O
all O
genotypes O
were O
incubated O
at O
28°C O
for O
14 O
days O
. O

DAPI: O
nuclei O
(white O
in O
A-J) O
. O

Scale O
bar: O
20 O
μm O
. O

(K) O
The O
percentage O
of O
the O
vacuole O
area O
in O
(A-C) O
was O
summarized O
. O

Adults O
of O
these O
genotypes O
were O
incubated O
at O
28°C O
for O
12 O
days O
. O

P-values O
were O
calculated O
using O
Kruskal-Wallis O
with O
Dunn O
's O
post-tests O
. O

repots>DERDN B-proteingene
was O
coexpressed O
with O
(A) O
H2B-RFP, B-proteingene
(B) O
Dorwt, O
(C) O
Dor-RNAi, B-proteingene
(D) O
H2B-RFP, B-proteingene
(E) O
Car, B-proteingene
(F) O
Car-RNAi, B-proteingene
(G) O
lacZ, B-proteingene
(H) O
Car-RNAi+Dor-RNAi B-proteingene
and O
(I) O
Car+Dorwt B-proteingene
. O

The O
autophagy O
reporter O
Ref(2)P B-proteingene
(green) O
was O
stained O
(G'-H') O
. O

Scale O
bar: O
20 O
μm O
. O

(J, O
K, O
L) O
The O
percentages O
of O
the O
vacuole O
areas O
in O
the O
lamina O
of O
(A-C, O
D-F, O
G-I) O
were O
summarized, O
respectively O
. O

The O
adults O
were O
shifted O
to O
28°C O
for O
7 O
days O
. O

DAPI: O
nuclei O
(white O
in O
A-I) O
. O

All O
P-values O
were O
calculated O
using O
Kruskal-Wallis O
tests O
with O
Dunn O
's O
post-tests O
. O

(A-E) O
Horizontal O
sections O
of O
the O
adult O
head O
lamina O
cartridge O
. O

(A) O
In O
repo>GFP.nls B-proteingene
flies, O
two O
lamina O
neurons O
L1, O
L2 O
axons O
(L) O
and O
R1-6 O
axons O
(blue O
area) O
were O
surrounded O
by O
the O
electron-dense O
cytoplasm O
of O
the O
epithelial O
glia O
(G) O
. O

The O
section O
was O
examined O
at O
three O
different O
depths, O
and O
the O
size O
of O
a O
single O
cartridge O
is O
not O
significantly O
different O
at O
different O
depths O
. O

(B-D) O
repo>Shits1 B-proteingene
adults O
maintained O
at O
29°C O
for O
4 O
days O
. O

Axons O
were O
enlarged O
but O
intact O
. O

A O
large O
number O
of O
small O
and O
medium O
vacuoles O
were O
identified O
in O
the O
epithelial O
glia O
. O

(C) O
Small O
vacuoles O
in O
the O
glia O
that O
contained O
a O
double-membrane O
structure O
(arrowhead) O
. O

(C') O
Higher O
magnification O
of O
the O
boxed O
area O
in O
(C) O
. O

(D) O
A O
double-membrane O
autophagosome-like O
structure O
(arrowhead) O
in O
the O
glialcytoplasm O
. O

(E) O
In O
repots>DERDN B-proteingene
adults O
maintained O
at O
29°C O
for O
2 O
days, O
large O
vacuoles O
were O
identified O
in O
between O
the O
lamina O
cartridges O
. O

N: O
glialnuclei O
. O

(E') O
Higher O
magnification O
of O
the O
boxed O
area O
in O
(E), O
which O
shows O
autophagosome-like O
vesicles O
(arrowhead) O
in O
the O
gliacytoplasm O
. O

(A) O
Rh1>lacZ+H2B-RFP B-proteingene
exhibited O
nuclearRFP B-proteingene
expression O
in O
the O
R1-6 O
photoreceptors O
(red) O
. O

(B) O
Rh1>lacZ+Shits1 B-proteingene
maintained O
at O
29°C O
for O
14 O
days O
resulted O
in O
lamina O
vacuolization O
. O

(C) O
Pan-Rh7>H2B-RFP B-proteingene
exhibited O
expression O
in O
R7 O
(arrow) O
and O
R8 O
(arrowhead) O
(red) O
. O

(D) O
Pan-Rh7>Shits1 B-proteingene
incubated O
at O
29°C O
for O
14 O
days O
did O
not O
exhibit O
lamina O
degeneration O
. O

(E) O
Lamina O
monopolar O
(L) O
neurons O
(red) O
were O
selectively O
labeled O
by O
the O
Ln-GAL4 B-proteingene
driven O
H2B-RFP B-proteingene
with O
repo-GAL80 B-proteingene
. O

(F) O
Ln>Shits1, B-proteingene
repoGAL80 O
shifted O
to O
29°C O
for O
14 O
days O
did O
not O
exhibit O
lamina O
degeneration O
. O

(G) O
R1-6 O
photoreceptors O
were O
killed O
in O
Rh1ts>lacZ+Hid B-proteingene
shifted O
to O
29°C O
for O
14 O
days O
. O

Rh1ts B-proteingene
indicates O
tubGAL80ts; B-proteingene
Rh1-GAL4 B-proteingene
. O

Degeneration O
was O
induced O
in O
the O
lamina O
in O
addition O
to O
the O
retina O
. O

(H) O
rdgC306/+ B-proteingene
mutant O
exposed O
to O
constant O
light O
for O
14 O
days O
exhibited O
degeneration O
in O
the O
retina, O
as O
well O
as O
the O
lamina O
. O

DAPI: O
nuclei O
(white O
in O
A-H) O
. O

(I, O
K) O
Rh1>lacZ+Shits1 B-proteingene
at O
29°C O
for O
4 O
days O
exhibited O
vacuoles O
in O
the O
electron O
dense O
cytoplasm O
of O
epithelialglia O
or O
near O
the O
glianucleus O
. O

Arrow: O
vacuole O
with O
internal O
debris O
. O

Arrowhead: O
large O
vacuole O
. O

(J) O
Lamina O
cartridge O
of O
Rh1>lacZ+H2B-RFP. B-proteingene
N O
indicates O
glialnuclei O
. O

(L) O
The O
percentage O
of O
the O
vacuole O
area O
in O
the O
lamina O
at O
29°C O
for O
14 O
days O
was O
examined O
. O

All O
P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Tukey O
's O
post-test O
. O

Scale O
bar: O
20 O
μm O
. O

(A) O
repots>Shits1+H2B-RFP, B-proteingene
(B) O
repots>Shits1+Egfrλtop B-proteingene
and O
(C) O
repots>Shits1+RlSem B-proteingene
incubated O
for O
12 O
days O
at O
28°C O
. O

(D) O
repots>DERDN B-proteingene
for O
7 O
days O
at O
28°C O
. O

(E) O
Epithelial O
glia O
MARCM O
clone O
and O
(F) O
Egfrco B-proteingene
mutant O
glia O
MARCM O
clone O
(labeled O
with O
Tomato, B-proteingene
green) O
. O

The O
penetrance O
is O
indicated O
as O
the O
number O
of O
samples O
with O
vacuoles O
over O
the O
total O
number O
of O
samples O
. O

DAPI: O
nuclei O
(white O
in O
A-F) O
. O

(G) O
Percentage O
of O
vacuole O
area O
in O
the O
lamina O
neuropile O
of O
(A-D) O
. O

The O
P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Dunnett O
's O
post-test O
. O

(H) O
Percentage O
of O
vacuole O
area O
in O
the O
lamina O
of O
repots>Shits1 B-proteingene
flies O
in O
the O
indicated O
genetic O
background O
. O

The O
adults O
were O
shifted O
to O
28°C O
for O
12 O
days O
. O

The O
P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Tukey O
's O
post-test O
. O

Scale O
bar: O
20 O
μm O
. O

(A, O
A') O
Anti-Spitz B-proteingene
(red) O
immunostaining O
of O
w1118 O
adult O
head O
. O

Spitz B-proteingene
can O
be O
detected O
in O
the O
retina O
and O
lamina O
. O

(B, O
B') O
The O
full-length O
transmembrane O
form O
of O
Spitz-GFP B-proteingene
(mSpi, O
green) O
expressed O
in O
the O
retina O
in O
GMR>mSpiGFP O
flies O
was O
predominantly O
identified O
in O
the O
photoreceptor O
soma O
and O
terminally O
localized O
in O
the O
lamina O
cartridge O
. O

mSpitz-GFP B-proteingene
requires O
processing O
by O
Rho B-proteingene
and O
Star B-proteingene
to O
become O
a O
secreted O
form O
. O

Overexpressed O
mSpitzGFP B-proteingene
has O
been O
demonstrated O
to O
be O
retained O
in O
the O
perinuclear O
ER O
even O
in O
the O
presence O
of O
endogenous O
Rho/Star B-proteingene
[56] O
(C) O
Knockdown O
of O
both O
EGFR B-proteingene
ligands O
Spi B-proteingene
and O
Krn B-proteingene
in O
R1-6 O
photoreceptors O
in O
Rh1>Dcr2+Spi-RNAi+Krn-RNAi B-proteingene
and O
(D) O
blockade O
of O
Spi B-proteingene
processing O
in O
Rh1>lacZ+iRhom B-proteingene
exhibited O
lamina O
degeneration O
after O
shifting O
to O
29°C O
for O
14 O
days O
. O

(E-E') O
Lamina O
degeneration O
in O
whole O
eye O
rho7M43ru1 B-proteingene
double O
mutant O
clones O
at O
28°C O
for O
12 O
days O
. O

The O
clone O
is O
labeled O
by O
DsRed O
(red) O
. O

(F) O
Spi B-proteingene
secretion O
is O
inhibited O
in O
Rh1>lacZ+Rab11S25N B-proteingene
. O

(G) O
The O
percentages O
of O
the O
vacuole O
areas O
of O
(C, O
D, O
F) O
in O
lamina O
at O
29°C O
for O
14 O
days O
were O
examined O
. O

All O
P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Tukey O
's O
post-test O
. O

DAPI: O
nuclei O
(white O
in O
A', O
B', O
C-F) O
. O

Scale O
bar: O
20 O
μm O
. O

(A, O
A') O
Anti-Spitz B-proteingene
detected O
Spitz B-proteingene
(magenta) O
colocalizing O
(arrowhead) O
with O
epithelialgliacytoplasm O
marked O
by O
anti-Black B-proteingene
(green) O
. O

Scale O
bar: O
5 O
μm O
. O

(B-B') O
EGFR B-proteingene
reporter O
pointed-lacZ B-proteingene
(pnt-lacZ) B-proteingene
exhibited O
expression O
in O
the O
epithelial O
(arrow) O
and O
marginal O
glia O
(arrowhead) O
. O

(C, O
C') O
Dominant-negative O
form O
of O
EGFR B-proteingene
(DERDN) B-proteingene
expressed O
in O
glia O
at O
28°C O
for O
3 O
days O
inhibited O
pnt-lacZ B-proteingene
expression O
. O

(D, O
D') O
pnt-laZ O
expression O
was O
lost O
in O
Shits-expressing B-proteingene
glia O
at O
28°C O
for O
3 O
days O
. O

(E, O
E') O
The O
knockdown O
of O
Spi B-proteingene
in O
R1-6 O
photoreceptors O
at O
28°C O
for O
12 O
days O
also O
inhibited O
pnt-lacZ B-proteingene
expression O
in O
the O
glia O
. O

The O
penetrances O
of O
(B-E) O
are O
shown O
in O
the O
upper O
right O
corner O
of O
each O
panel O
. O

DAPI: O
nuclei O
(white O
in O
B'-E') O
. O

Scale O
bar: O
20 O
μm O
. O

(A-C) O
Immunostaining O
of O
TUNEL O
assay O
(red), O
active O
Caspase-3 O
(magenta, O
A'-C') O
and O
Repo O
(green, O
A"-C") O
. O

(A) O
GMR-wIR; O
repots>lacZ B-proteingene
. O

(B) O
GMR-wIR; O
repots>Shits1 B-proteingene
. O

(C) O
GMR-wIR; O
repots>DERDN. B-proteingene
GMR-wIR O
was O
used O
to O
reduce O
the O
autofluorescence O
of O
the O
eye O
pigments O
. O

Scale O
bar: O
20 O
μm O
. O

(D-F) O
The O
in O
vivo O
fluorescent O
sensor O
of O
caspase B-proteingene
activity O
(Apoliner) B-proteingene
indicated O
there O
was O
no O
active O
caspase B-proteingene
activity O
in O
the O
glia O
. O

(D) O
repots>Apoliner+lacZ B-proteingene
. O

(E) O
repots>Apoliner+Shits1 B-proteingene
. O

(F) O
repots>Apoliner+DERDN. B-proteingene
All O
adults O
were O
shifted O
to O
28°C O
for O
5 O
days O
. O

nls-GFP B-proteingene
(green, O
D-F); O
merge O
of O
GFP B-proteingene
(green) O
and O
mRFP O
(red) O
in O
(D'-F'); O
merge O
of O
nls-GFP B-proteingene
and O
DAPI O
(magenta) O
in O
(D"-F") O
. O

Scale O
bar: O
10 O
μm O
. O

(G) O
Percentage O
of O
vacuole O
area O
in O
the O
lamina O
in O
repots>Shits1flies O
that O
coexpressed O
the O
anti-apoptotic O
factors O
P35 O
and O
Diap1 O
. O

The O
adults O
were O
shifted O
to O
28°C O
for O
21 O
days O
. O

The O
P-values O
were O
calculated O
using O
one-way O
ANOVA O
with O
Tukey O
's O
post-test O
. O

(H) O
The O
cell O
number O
of O
the O
epithelialglia O
was O
not O
reduced O
in O
the O
vacuolated O
lamina O
. O

The O
numbers O
of O
epithelial O
glia O
in O
the O
lamina O
of O
repo>H2B-RFP B-proteingene
and O
repo>H2B-RFP+Shits1 B-proteingene
female O
adults O
incubated O
at O
28°C O
for O
14 O
days O
were O
examined O
by O
counting O
the O
nuclear O
RFP B-proteingene
at O
the O
epithelial O
layer O
from O
the O
entire O
Z-stacks O
of O
confocal O
images O
. O

P-values O
were O
calculated O
via O
Mann-Whitney O
tests O
. O

In O
repots>GFP-LC3+DERDN B-proteingene
shifted O
to O
28°C, O
the O
GFP B-proteingene
signal O
(green) O
was O
weak O
on O
day O
1 O
(A-A") O
and O
progressively O
increased O
on O
days O
2 O
(B-B") O
and O
3 O
(C-C") O
and O
colocalized O
with O
Ref(2)P B-proteingene
(magenta) O
. O

(D) O
Ref(2)P B-proteingene
(magenta) O
accumulated O
within O
the O
Egfrco B-proteingene
mutant O
MARCM O
clone O
(green) O
. O

The O
double-tagged O
GFP-mCherry-Atg8a B-proteingene
is O
used O
to O
distinguish O
the O
autophagosomes O
(GFP B-proteingene
and O
mCherry, B-proteingene
yellow) O
and O
autolysosomes O
(mCherry, B-proteingene
red) O
in O
autophagic O
flux O
. O

(E) O
In O
repots>GFP-mCherry-Atg8a+dAtg1, B-proteingene
autophagosomes O
(arrowhead) O
and O
autolysosomes O
(arrow) O
were O
induced O
in O
the O
glia O
with O
normal O
autophagic O
flux O
. O

(F) O
repots>GFP-mCherry-Atg8a B-proteingene
. O

(G) O
repots>GFP-mCherry-Atg8a+Shits1 B-proteingene
. O

Epithelialglial O
nuclei O
are O
indicated O
(arrow) O
. O

(H) O
repots>GFP-mCherry-Atg8a+DERDN. B-proteingene
The O
adults O
were O
shifted O
to O
28°C O
for O
3 O
days O
. O

GFP: B-proteingene
green O
(E-H); O
mCherry: B-proteingene
red O
(E'-H'); O
merge O
(E"-H") O
. O

Scale O
bar: O
10 O
μm O
. O

(A-C) O
repots>GFP-LAMP1 B-proteingene
. O

(D-F) O
repots>GFP-LAMP1+Shits1 B-proteingene
. O

(G-I) O
repots>GFP-LAMP1+DERDN. B-proteingene
Adults O
were O
incubated O
at O
28°C O
for O
12 O
h O
(A, O
D, O
G), O
24 O
h O
(B, O
E, O
H), O
and O
48 O
h O
(C, O
F, O
I), O
respectively O
. O

The O
GFP-LAMP1 B-proteingene
signal O
(green) O
was O
induced O
at O
12 O
h O
and O
progressively O
enhanced O
in O
(D-F) O
and O
(G-I) O
. O

(J) O
repots>Rab7-mCherry+H2B-RFP B-proteingene
. O

(K) O
repots>Rab7-mCherry+Shits1 B-proteingene
. O

(L) O
repots>Rab7-mCherry+DERDN. B-proteingene
The O
adults O
were O
shifted O
to O
28°C O
for O
2 O
days O
. O

Rab7-mCherry B-proteingene
puncta O
(red) O
were O
increased O
in O
(K, O
L) O
. O

DAPI: O
nuclei O
(white O
in O
J'-L') O
. O

Scale O
bar: O
20 O
μm O
. O

A, O
B O
1 O
× O
105B16F10 O
melanoma O
cells O
were O
intravenously O
injected O
into O
C57BL/6 O
wild-type O
(WT) O
or O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
mice, O
and O
the O
number O
of O
lungmetastases O
was O
determined O
after O
14 O
days O
. O

The O
photographs O
(A) O
show O
two O
representative O
results O
. O

The O
graph O
(B) O
shows O
the O
mean O
± O
SD O
number O
of O
pulmonary O
metastases O
in O
15 O
WT O
and O
14 O
Asm-deficient B-proteingene
animals O
. O

C, O
D O
B16F10 O
melanoma O
grow O
as O
fast O
or O
slightly O
faster O
in O
Asm-deficient B-proteingene
mice O
than O
in O
wild-type O
mice O
after O
subcutaneous O
injection O
at O
the O
flank O
(C) O
or O
transcutaneous O
direct O
intrapulmonary O
injection O
(D), O
excluding O
a O
general O
growth O
defect O
of O
the O
tumor O
in O
Asm-deficient B-proteingene
mice O
. O

The O
size O
of O
tumors O
was O
determined O
14 O
days O
after O
local O
injection O
at O
the O
flank O
or O
10 O
days O
after O
injection O
into O
the O
lung O
. O

E O
The O
number O
of O
lungmetastases O
25 O
days O
after O
intravenous O
injection O
does O
not O
differ O
from O
the O
number O
observed O
after O
14 O
days O
in O
(B) O
. O

F O
5 O
× O
108platelets O
isolated O
from O
wild-type O
(WT) O
or O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
mice O
were O
injected O
intravenously O
into O
Asm-deficient B-proteingene
or O
wild-type O
mice, O
respectively O
. O

After O
120 O
min O
1 O
× O
105, O
B16F10tumor O
cells O
were O
intravenously O
injected O
. O

The O
number O
of O
lungmetastases O
was O
determined O
after O
14 O
days O
. O

Displayed O
are O
the O
mean O
± O
SD O
of O
the O
number O
of O
pulmonary O
metastases, O
n O
= O
3 O
in O
WT O
platelets O
in O
WT O
mice, O
n O
= O
5 O
in O
WT O
platelets O
in O
Asm−/−mice, O
and O
n O
= O
4 O
in O
Asm−/−platelets O
in O
Asm−/−mice O
. O

A O
Platelets O
were O
isolated O
from O
wild-type O
(WT) O
or O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
mice O
by O
density-gradient O
centrifugation, O
and O
1 O
× O
107platelets O
were O
incubated O
with O
1 O
× O
105B16F10 O
cells O
. O

The O
samples O
were O
lysed, O
and O
Asm B-proteingene
activity O
was O
determined O
. O

In O
unstimulated O
samples O
(time O
point O
of O
co-incubation O
0 O
s), O
tumor O
cells O
and O
platelets O
were O
admixed O
after O
lysis O
. O

B O
The O
formation O
of O
ceramide O
was O
determined O
by O
a O
diacylglycerol O
(DAG) O
kinase O
assay O
(upper O
panel) O
and O
mass O
spectrometry O
(lower O
panel) O
. O

In O
unstimulated O
samples O
(time O
point O
of O
co-incubation O
0 O
s), O
tumor O
cells O
and O
platelets O
were O
admixed O
after O
lysis O
. O

C, O
D O
For O
determination O
of O
the O
secretion O
of O
Asm B-proteingene
by O
platelets O
into O
the O
supernatants O
(C), O
tumor O
cells O
and O
wild-type O
(WT) O
or O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
platelets O
were O
co-incubated O
for O
20 O
s, O
the O
samples O
were O
pelleted, O
the O
supernatants O
were O
removed O
and O
acidified, O
and O
the O
Asm B-proteingene
activity O
was O
measured O
in O
the O
presence O
or O
absence O
of O
Zn2+ O
. O

For O
measurement O
of O
surface O
Asm B-proteingene
and O
ceramide, O
samples O
were O
co-incubated O
as O
indicated O
(C, O
D) O
and O
pelleted; O
the O
supernatants O
were O
discarded, O
incubated O
with O
anti-Asm B-proteingene
antibodies, O
washed, O
and O
lysed; O
and O
Asm B-proteingene
immunocomplexes O
were O
immobilized O
and O
subjected O
to O
immunocomplex O
enzyme O
assays O
. O

Surface O
ceramide O
was O
measured O
by O
incubation O
of O
intact O
cells O
with O
DAG B-proteingene
kinase I-proteingene
in O
the O
presence O
of O
[32P]γATP O
followed O
by O
extraction O
and O
measurement O
of O
[32P]-ceramide O
. O

Omission O
of O
one O
cell O
type O
indicated O
by O
"−" O
here O
and O
thereafter O
. O

E O
Treatment O
of O
B16F10tumor O
cells O
for O
2 O
min O
with O
1 O
U/ml O
ASM B-proteingene
or O
10 O
μM O
C16ceramide O
restores O
in O
vivo O
metastasis O
in O
Asm-deficient B-proteingene
mice O
. O

After O
treatment, O
the O
cells O
were O
injected O
intravenously O
into O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
mice O
. O

Controls O
were O
left O
untreated O
prior O
to O
injection O
. O

The O
number O
of O
metastases O
was O
determined O
14 O
days O
after O
tumor O
cell O
injection O
. O

Incubation O
of O
human O
melanoma O
(HM) O
cells O
with O
humanplatelets O
results O
in O
the O
release O
of O
Zn2+-dependent O
ASM B-proteingene
into O
the O
supernatant, O
Zn2+-dependent O
activity O
of O
ASM B-proteingene
on O
cell O
surfaces, O
and O
the O
formation O
of O
ceramide O
. O

The O
assay O
buffer O
contained O
100 O
μM O
Zn2+ O
. O

Addition O
of O
human O
or O
mouse O
recombinant O
ASM B-proteingene
to O
human O
melanoma O
or O
B16F10 O
cells, O
respectively, O
results O
in O
binding O
of O
ASM B-proteingene
to O
the O
tumorcell O
surfaces O
as O
determined O
by O
flow O
cytometry O
. O

Cytochalasin O
B O
was O
added O
to O
control O
for O
internalization O
of O
added O
ASM B-proteingene
. O

Suppression O
of O
Asm B-proteingene
in O
B16F10tumor O
cells O
using O
siRNA O
technology O
reduces O
Asm B-proteingene
activity O
in O
B16F10 O
cells O
(right O
panel), O
but O
does O
not O
alter O
release O
or O
surface O
activity O
of O
the O
Asm B-proteingene
after O
co-incubation O
with O
wild-type O
platelets O
(left O
panels) O
. O

Platelets O
were O
isolated O
from O
wild-type O
(WT) O
or O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
mice O
by O
density-gradient O
centrifugation, O
and O
1 O
× O
107platelets O
were O
incubated O
with O
1 O
× O
105B16F10 O
cells O
or O
left O
untreated O
. O

Co-incubation O
of O
washed O
platelets O
with O
B16F10 O
melanoma O
cells O
resulted O
in O
upregulation O
of O
GPIIb/IIIa B-proteingene
and O
CD62P B-proteingene
on O
both O
wild-type O
and O
Asm-deficient B-proteingene
platelets O
in O
FACS O
analyses O
. O

Platelets O
were O
gated O
in O
FCS/SSC O
. O

Aggregation O
properties O
of O
platelets O
after O
co-incubation O
with O
collagen O
or O
ADP O
are O
independent O
of O
Asm B-proteingene
as O
determined O
by O
aggregometry O
measurements O
. O

Incubation O
of O
tumor O
cells O
with O
platelets O
resulted O
in O
marked O
change O
of O
platelet O
shape O
and O
degranulation O
as O
determined O
by O
FACS O
analysis O
using O
forward O
versus O
side O
scatter O
analysis O
indicating O
global O
activation O
of O
platelets O
. O

4 O
× O
104B16F10tumor O
cells O
were O
incubated O
with O
2 O
× O
107 O
wild-type O
(WT), O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
platelets O
(Plts) O
or O
a O
45:55 O
of O
WT:Asm−/−platelet O
mixture O
in O
the O
presence O
or O
absence O
of O
50 O
ng/ml O
PGE1 O
. O

Controls O
were O
stimulated O
with O
Mn2+ O
. O

Tumor O
cells O
were O
then O
incubated O
for O
60 O
s O
on O
fibronectin-coated O
cover O
slips, O
washed, O
and O
fixed, O
and O
adhesion O
of O
the O
tumor O
cells O
was O
determined O
. O

The O
graph O
displays O
the O
mean O
± O
SD O
of O
tumor O
cells O
adhering O
to O
fibronectin-coated O
cover O
slips, O
n O
= O
7 O
for O
WT-platelets, O
n O
= O
9 O
for O
Asm-deficient-platelets, O
n O
= O
4 O
for O
45:55 O
WT:Asm−/−platelets, O
and O
all O
others O
n O
= O
3 O
. O

Statistical O
significance O
was O
determined O
by O
analysis O
of O
variance O
(ANOVA) O
followed O
by O
Tukey O
's O
multiple O
comparisons O
test O
. O

P-values O
are O
indicated O
. O

A-C O
1 O
× O
105B16F10 O
cells O
were O
incubated O
with O
(A) O
1 O
U/ml O
purified O
acid B-proteingene
sphingomyelinase I-proteingene
(ASM) B-proteingene
or O
(B) O
5 O
× O
107 O
wild-type O
(WT), O
Asm-deficient B-proteingene
(Asm−/−) B-proteingene
platelets O
(Plts), O
or O
a O
mixture O
of O
45:55 O
wild-type:Asm-deficient B-proteingene
platelets O
. O

Cells O
were O
fixed O
with O
2% O
paraformaldehyde O
for O
15 O
min O
and O
stained O
with O
fluorescein O
isothiocyanate O
(FITC)-coupled O
anti-α5 B-proteingene
integrin, I-proteingene
Cy3-labeled O
anti-β1 B-proteingene
integrin, I-proteingene
and O
Cy5-labeled O
anti-ceramide O
antibodies O
. O

Samples O
were O
analyzed O
by O
confocal O
microscopy O
. O

Shown O
are O
representative O
examples O
from O
four O
independent O
experiments O
(A, O
B) O
or O
the O
quantitative O
analysis O
of O
cells O
positive O
for O
ceramide/β1 B-proteingene
integrin I-proteingene
clusters O
from O
at O
least O
100 O
cells/sample O
(C) O
. O

Given O
is O
the O
mean O
± O
SD, O
n O
= O
4, O
ANOVA O
followed O
by O
Tukey O
's O
multiple O
comparisons O
test O
. O

P-values O
are O
indicated O
. O

D O
ASM-induced B-proteingene
B16F10tumorcell O
adhesion O
to O
fibronectin-coated O
cover O
slips O
is O
abrogated O
by O
the O
inhibition O
of O
integrins O
with O
RGD O
peptides O
. O

Shown O
is O
the O
mean O
± O
SD O
of O
the O
number O
of O
cells O
adherent O
to O
the O
cover O
slip O
. O

Statistical O
significance O
was O
determined O
by O
ANOVA O
followed O
by O
Tukey O
's O
multiple O
comparisons O
test O
. O

P-values O
are O
indicated O
. O

E O
Intravenous O
injection O
of O
CFSE-labeled O
B16F10 O
cells O
into O
wild-type O
mice O
results O
in O
formation O
of O
ceramide-enriched O
domains O
that O
contain O
β1 B-proteingene
integrin I-proteingene
clusters O
on O
tumor O
cells O
in O
vivo, O
while O
injection O
of O
tumor O
cells O
into O
Asm-deficient B-proteingene
mice O
does O
not O
result O
in O
ceramide O
and O
integrin O
clustering O
. O

Please O
note O
that O
the O
cell O
in O
the O
lower O
panel O
still O
binds O
a O
platelet O
. O

Shown O
are O
representative O
results O
from O
four O
independent O
experiments O
each O
. O

Human O
melanoma O
cells O
were O
stimulated O
for O
10 O
min O
with O
1 O
U/ml O
purified O
ASM B-proteingene
or O
10 O
μM O
C16 O
ceramide O
(C16-Cer) O
in O
the O
presence O
or O
absence O
of O
500 O
ng O
ceramidase B-proteingene
(CDase) B-proteingene
or O
1 O
μg/ml O
neutralizing O
anti-ceramide O
antibodies O
(anti-Cer), O
and O
lysed O
and O
active O
β1 B-proteingene
integrin I-proteingene
was O
immunoprecipitated O
using O
the O
HUTS-4 O
antibody O
. O

Octylglucopyranoside O
(OGP, O
final O
concentration O
0.01%) O
served O
to O
resuspend O
C16 O
ceramide O
. O

Internalization O
was O
excluded O
by O
addition O
of O
cytochalasin O
B O
(CTB) O
as O
indicated O
. O

Samples O
were O
separated O
by O
SDS-PAGE O
and O
blotted O
with O
an O
activation-independent O
anti-β1 B-proteingene
Integrin I-proteingene
antibody O
to O
detect O
the O
amount O
of O
immunoprecipitated, O
that O
is O
active O
β1 B-proteingene
integrin I-proteingene
. O

Control O
immunoprecipitates O
(control O
Ipt) O
were O
performed O
with O
an O
irrelevant O
isotype O
control O
antibody O
. O

Activation O
of O
β1 B-proteingene
integrin I-proteingene
in O
human O
melanoma O
cells O
by O
incubation O
with O
Asm B-proteingene
or O
C16 O
ceramide O
was O
confirmed O
by O
FACS O
analysis O
upon O
staining O
with O
FITC-labeled O
HUTS-4 O
antibodies O
. O

Incubation O
of O
human O
melanoma O
with O
humanplatelets O
or O
ASM B-proteingene
for O
5 O
min O
triggers O
co-clustering O
of O
ceramide O
and O
activated O
β1 B-proteingene
integrin I-proteingene
on O
the O
surface O
of O
the O
tumor O
cells O
. O

Cells O
were O
stained O
with O
FITC-coupled O
anti-active O
β1 B-proteingene
integrin I-proteingene
(HUTS-4) O
antibodies O
and O
Cy3-coupled O
anti-ceramide O
antibodies O
. O

Shown O
are O
representative O
stainings O
from O
each O
four O
independent O
experiments O
. O

B16F10tumor O
cells O
or O
B16F10 O
transfected O
with O
siRNA O
targeting O
Asm B-proteingene
expression O
or O
with O
scrambled O
control O
siRNA O
were O
labeled O
with O
[3H]thymidine, O
washed, O
and O
treated O
(+) O
for O
10 O
min O
with O
1 O
U/ml O
ASM, B-proteingene
10 O
μM O
C16ceramide, O
10 O
μM O
S1P, O
10 O
μM O
PDMP, O
20 O
μM O
sphingosine B-proteingene
kinase I-proteingene
inhibitor O
SKI O
II, O
and O
10 O
μM O
myriocin, O
or O
left O
untreated O
(−) O
. O

The O
cells O
were O
then O
injected O
intravenously O
into O
wild-type O
or O
Asm-deficient B-proteingene
mice O
as O
indicated O
. O

If O
indicated, O
10 O
μg O
of O
arginine-glycine-aspartic O
acid O
(RGD) O
peptide O
or O
10 O
μg/ml O
neutralizing O
anti-β1 B-proteingene
integrin I-proteingene
antibodies O
were O
added O
to O
B16F10tumor O
cells O
together O
with O
ASM B-proteingene
for O
15 O
min O
prior O
injection O
. O

Mice O
were O
sacrificed O
30 O
min O
after O
tumorcell O
injection, O
the O
lungs O
carefully O
flushed O
via O
the O
right O
heart, O
and O
the O
radioactivity O
in O
the O
lung O
as O
a O
measurement O
for O
adherent O
tumor O
cells O
was O
determined O
. O

Shown O
is O
the O
mean O
± O
SD O
of O
the O
counts O
per O
minute O
(cpm) O
in O
the O
lung O
lysates O
from O
three O
independent O
experiments O
. O

Statistical O
significance O
was O
determined O
by O
analysis O
of O
variance O
(ANOVA) O
followed O
by O
Tukey O
's O
test O
for O
multiple O
comparison O
to O
determine O
P-values O
. O

A O
Amitriptyline O
(2 O
mg/kg, O
Ami) O
was O
intraperitoneally O
injected O
into O
C57BL/6mice O
for O
five O
times O
every O
12 O
h. O
Sixty O
minutes O
after O
the O
last O
injection, O
1 O
× O
105B16F10tumor O
cells O
were O
intravenously O
injected O
. O

Control O
experiments O
confirmed O
that O
amitriptyline O
inhibited O
Asm B-proteingene
activity O
in O
the O
blood O
by O
approximately O
85% O
. O

Asm B-proteingene
heterozygous O
mice O
were O
injected O
with O
1 O
× O
105B16F10tumor O
cells O
. O

The O
number O
of O
lungmetastases O
was O
determined O
after O
14 O
days O
. O

Shown O
is O
the O
mean O
± O
SD O
from O
six O
mice O
each, O
ANOVA O
followed O
by O
Tukey O
's O
test O
for O
multiple O
comparison O
. O

P-values O
are O
indicated O
. O

B, O
C O
MT/ret O
cells O
(105) O
suspended O
in O
200 O
μl O
Matrigel/PBS O
(1:1) O
were O
injected O
s.c. O
in O
the O
left O
and O
right O
flanks O
of O
8-week-old O
Asm-deficient B-proteingene
mice O
or O
wild-type O
mice O
. O

Mice O
were O
sacrificed O
at O
day O
20 O
after O
injection, O
and O
spleens O
were O
inspected O
for O
the O
presence O
of O
metastases O
. O

The O
representative O
photographs O
(B) O
show O
the O
results O
from O
one O
of O
four O
experiments, O
and O
the O
quantitative O
analysis O
is O
displayed O
in O
(C) O
. O

B, O
C O
MT/ret O
cells O
(105) O
suspended O
in O
200 O
μl O
Matrigel/PBS O
(1:1) O
were O
injected O
s.c. O
in O
the O
left O
and O
right O
flanks O
of O
8-week-old O
Asm-deficient B-proteingene
mice O
or O
wild-type O
mice O
. O

Mice O
were O
sacrificed O
at O
day O
20 O
after O
injection, O
and O
spleens O
were O
inspected O
for O
the O
presence O
of O
metastases O
. O

The O
representative O
photographs O
(B) O
show O
the O
results O
from O
one O
of O
four O
experiments, O
and O
the O
quantitative O
analysis O
is O
displayed O
in O
(C) O
. O

D O
Platelets O
were O
isolated O
from O
wild-type O
or O
Asm-deficient B-proteingene
mice O
by O
density-gradient O
centrifugation, O
and O
1 O
× O
107platelets O
were O
incubated O
with O
1 O
× O
105MT/ret O
melanoma O
cells O
. O

The O
samples O
were O
lysed, O
and O
Asm B-proteingene
activity O
in O
cell O
lysates O
was O
determined O
. O

In O
unstimulated O
samples O
(time O
point O
0 O
of O
co-incubation), O
tumorcell O
and O
platelet O
lysates O
were O
admixed O
after O
lysis O
. O

E O
To O
measure O
secretion O
of O
Asm B-proteingene
by O
platelets, O
tumor O
cells O
and O
platelets O
were O
co-incubated O
for O
30 O
s, O
the O
samples O
were O
pelleted, O
the O
supernatants O
were O
acidified, O
and O
the O
Asm B-proteingene
activity O
was O
measured O
. O

All O
Asm B-proteingene
activity O
measurements O
were O
performed O
in O
the O
presence O
of O
100 O
μM O
Zn2+ O
. O

F O
Local O
tumorgrowth O
in O
wild-type O
or O
Asm-deficient B-proteingene
mice O
at O
the O
flank O
was O
measured O
at O
day O
20 O
. O

Phenotypic O
changes O
of O
HSCs O
by O
citral O
. O

Phase-contrast O
images O
(left), O
oil O
red O
O-stained O
images O
(middle), O
and O
autofluorescence O
images O
(right) O
are O
shown O
for O
HSCs O
after O
passage O
1 O
with O
or O
without O
the O
treatment O
of O
citral O
(100 O
μM) O
for O
24 O
h. O
Scale O
bar O
= O
10 O
μm O
. O

Western O
blot O
analysis O
of O
cell O
lysates O
from O
the O
citral-treated O
HSCs O
in O
(A) O
. O

α-tubulin B-proteingene
was O
used O
as O
a O
loading O
control O
. O

The O
quantitative O
densitometric O
data O
are O
expressed O
as O
the O
percentage O
of O
untreated O
control O
and O
represent O
the O
means O
(SD) O
for O
three O
independent O
experiments O
. O

**P-value O
= O
0.002, O
paired O
t-test O
(compared O
to O
control) O
. O

Protein O
expression O
of O
ALDH1A1 B-proteingene
and O
ALDH1A2 B-proteingene
during O
the O
culture O
activation O
of O
HSCs O
. O

Cell O
lysates O
were O
prepared O
from O
HSCs O
at O
3 O
days O
after O
plating O
(HSCs-d3) O
and O
from O
HSCs O
after O
passage O
1 O
(P1), O
2 O
(P2), O
and O
3 O
(P3), O
and O
analyzed O
by O
Western O
blotting O
. O

Real-time O
PCR O
analysis O
for O
the O
expression O
levels O
of O
ALDH1A1 B-proteingene
and O
ALDH1A2 B-proteingene
during O
the O
culture O
activation O
of O
HSCs O
. O

The O
PCR O
data O
are O
expressed O
as O
the O
percentage O
of O
HSCs-d3 O
. O

**P-value, O
paired O
t-test O
(n O
= O
3) O
(compared O
to O
HSCs-d3), O
ALDH1A1/HSCs-P3: O
0.003, O
ALDH1A2/HSCs-P1: O
0.0018, O
ALDH1A2/HSCs-P3: O
0.001 O
. O

Effect O
of O
ALDH1A O
suppression O
on O
HSC O
activation O
. O

HSCs-P1 O
were O
transfected O
with O
non-targeting O
siRNA O
or O
siRNA O
specific O
to O
ALDH1A1 B-proteingene
and/or O
ALDH1A2, B-proteingene
and O
after O
48 O
h, O
whole-cell O
lysates O
were O
subjected O
to O
Western O
blotting O
. O

**P O
= O
0.0023, O
paired O
t-test O
(n O
= O
3) O
(siRNA-ALDH1A1/2 B-proteingene
compared O
to O
control) O
. O

Reverse-phase O
HPLC O
analysis O
of O
whole-cell O
lysates O
from O
the O
siRNA-ALDH1A-treated B-proteingene
HSCs O
in O
(E) O
. O

Typical O
chromatograms O
of O
all-trans O
retinoic O
acid O
and O
13-cis O
retinoic O
acid O
. O

The O
retention O
time O
is O
14 O
min O
for O
13-cis-RA O
and O
23 O
min O
for O
all-trans O
RA O
. O

Phenotypic O
changes O
of O
HSCs O
by O
RAR B-proteingene
antagonist O
. O

HSCs-d3 O
were O
incubated O
with O
AGN193109 O
(1 O
μM) O
± O
all-trans O
RA O
(10 O
μM) O
for O
3 O
days O
and O
subjected O
to O
Oil O
red O
Ostaining O
. O

Scale O
bar O
= O
10 O
μm O
. O

Western O
blot O
analysis O
of O
cell O
lysates O
from O
AGN193109 O
± O
RA-treated O
HSCs O
in O
(G) O
. O

**P O
= O
0.003, O
paired O
t-test O
(n O
= O
3) O
(AGN193109 O
compared O
to O
control) O
. O

Albumin B-proteingene
and O
R-III B-proteingene
downregulate O
RA O
signaling O
. O

HSCs-P1 O
were O
either O
transfected O
with O
RARE O
Cignal O
reporter O
and O
expression O
plasmid O
containing O
vehicle O
or O
albumin B-proteingene
(left O
panel) O
or O
treated O
with O
R-III B-proteingene
(25-250 O
nM) O
after O
transfection O
with O
RARE O
Cignal O
reporter O
(right O
panel) O
. O

After O
36 O
h, O
the O
transfected O
cells O
were O
harvested O
for O
luciferase O
assay O
. O

Renillaluciferase B-proteingene
activity O
was O
normalized O
to O
fireflyluciferase B-proteingene
activity O
. O

Ratios O
were O
normalized O
against O
the O
cells O
transfected O
with O
vehicle O
plasmid O
. O

**P-value, O
two-sample O
t-test O
(n O
= O
9) O
(compared O
to O
control), O
albumin: B-proteingene
0.0037, O
R-III B-proteingene
125 O
nM: O
0.0032 O
. O

Phenotypic O
changes O
of O
HSCs O
by O
the O
expression O
of O
albumin B-proteingene
and/or O
ALDH1A. O
HSCs-P1 O
were O
transfected O
with O
plasmids O
encoding O
albumin, B-proteingene
ALDH1A1, B-proteingene
and O
ALDH1A2, B-proteingene
either O
individually O
or O
in O
combination, O
and O
incubated O
in O
the O
presence O
of O
all-trans O
retinoic O
acid O
(50 O
nM) O
for O
18 O
h. O
Cells O
were O
analyzed O
by O
oil O
red O
O O
staining O
. O

Scale O
bar, O
20 O
μm O
. O

Western O
blot O
analysis O
of O
cell O
lysates O
from O
albumin- B-proteingene
and/or O
ALDH1A-transfected B-proteingene
HSCs O
as O
in O
(B) O
. O

**P O
= O
0.002, O
paired O
t-test O
(n O
= O
3) O
(albumin B-proteingene
compared O
to O
control) O
. O

Reverse-phase O
HPLC O
analysis O
of O
whole-cell O
lysates O
from O
albumin- B-proteingene
and/or O
ALDH1A-transfected B-proteingene
HSCs O
as O
in O
(B) O
. O

RAR B-proteingene
agonist O
counteracts O
R-III B-proteingene
action O
. O

HSCs-P1 O
were O
treated O
with O
His-tagged B-proteingene
R-III B-proteingene
(final O
concentration, O
0.15 O
μM) O
in O
the O
presence O
or O
absence O
of O
RAR B-proteingene
agonist O
(AGN191183, O
1 O
μM) O
for O
18 O
h O
and O
analyzed O
by O
Western O
blotting O
. O

**P O
= O
0.0024, O
paired O
t-test O
(n O
= O
3) O
(R-III B-proteingene
compared O
to O
control) O
. O

The O
separating O
lines O
demarcate O
bands O
that O
come O
from O
non-consecutive O
lanes O
of O
the O
same O
gel O
. O

Protein O
expression O
of O
STRA6 B-proteingene
during O
the O
culture O
activation O
of O
HSCs O
. O

Cell O
lysates O
were O
prepared O
from O
HSCs O
at O
3 O
days O
after O
plating O
(HSCs-3d), O
and O
from O
HSCs O
after O
passage O
1 O
(P1), O
2 O
(P2), O
and O
3 O
(P3), O
and O
analyzed O
by O
Western O
blotting O
. O

Lysates O
from O
NIH3T3 O
cells O
were O
used O
as O
a O
negative O
control O
. O

The O
separating O
lines O
demarcate O
bands O
that O
come O
from O
non-consecutive O
lanes O
of O
the O
same O
gel O
. O

Real-time O
PCR O
analysis O
for O
the O
expression O
level O
of O
STRA6 B-proteingene
during O
the O
culture O
activation O
of O
HSCs O
. O

The O
PCR O
data O
are O
expressed O
as O
the O
percentage O
of O
HSCs-3d O
. O

**P-value, O
paired O
t-test O
(n O
= O
3) O
(compared O
to O
HSCs-d3), O
HSCs-P2: O
0.002, O
HSCs-P3: O
0.0022 O
. O

R-IIIuptake B-proteingene
parallels O
STRA6 B-proteingene
level O
. O

HSCs O
at O
different O
stages O
of O
activation O
were O
incubated O
with O
His-tagged B-proteingene
R-III B-proteingene
(final O
concentration, O
0.15 O
μM) O
for O
30 O
min, O
washed, O
and O
subjected O
to O
Western O
blotting O
for O
R-IIIuptake B-proteingene
. O

STRA6-mediated B-proteingene
uptake O
of O
R-III. B-proteingene
HSCs-P1 O
were O
transfected O
with O
non-targeting O
siRNA O
or O
one O
of O
the O
two O
different O
STRA6-specific B-proteingene
siRNAs, O
and O
after O
48 O
h, O
cells O
were O
incubated O
with O
R-III B-proteingene
for O
30 O
min O
and O
analyzed O
by O
Western O
blotting O
. O

Representative O
macroscopic O
pictures O
of O
livers O
from O
control O
and O
CCl4-, O
CCl4/albumin-, B-proteingene
CCl4/RBP-, B-proteingene
and O
CCl4/R-III-treated B-proteingene
mice O
. O

Liver O
sections O
were O
stained O
with O
H&E O
and O
Sirius O
red, O
and O
also O
subjected O
to O
immunohistochemistry O
for O
type B-proteingene
I I-proteingene
collagen I-proteingene
. O

Scale O
bar, O
200 O
μm O
. O

Hydroxyproline O
content O
in O
the O
livers O
from O
control O
and O
CCl4-, O
CCl4/albumin-, B-proteingene
and O
CCl4/R-III-treated B-proteingene
mice O
(μg/g O
liver) O
. O

*P O
= O
0.037, O
two-sample O
t-test O
(n O
= O
10) O
(CCl4 O
+ O
R-III B-proteingene
compared O
to O
CCl4-treated O
mice) O
. O

Western O
blot O
analysis O
on O
liver O
extracts O
from O
the O
treated O
mice O
with O
antibody O
against O
type B-proteingene
I I-proteingene
collagen I-proteingene
. O

Immunohistochemical O
analysis O
of O
α-SMA B-proteingene
on O
representative O
liver O
sections O
from O
the O
treated O
mice O
. O

Scale O
bar, O
200 O
μm O
. O

Liver O
sections O
from O
control O
and O
CCl4- O
and O
CCl4/R-III-treated B-proteingene
mice O
were O
immunohistochemically O
stained O
for O
TGF-β B-proteingene
and O
F4/80 B-proteingene
. O

Scale O
bar, O
50 O
μm O
. O

Liver O
sections O
from O
treated O
mice O
were O
immunohistochemically O
stained O
for O
desmin, B-proteingene
His-tag, B-proteingene
and O
α-SMA. B-proteingene
His-positive B-proteingene
signals O
largely O
overlapped O
with O
desmin/α-SMA B-proteingene
staining O
. O

Scale O
bar, O
50 O
μm O
. O

Liver O
sections O
from O
control O
and O
CCl4- O
and O
CCl4/R-III-treated B-proteingene
mice O
were O
stained O
with O
Sirius O
red O
. O

Scale O
bar, O
200 O
μm O
. O

Hydroxyproline O
content O
in O
the O
livers O
(μg/g O
liver) O
. O

*P O
= O
0.034, O
two-sample O
t-test O
(n O
= O
10) O
(CCl4 O
+ O
R-III B-proteingene
compared O
to O
CCl4-treated O
mice) O
. O

Liver O
sections O
from O
control, O
BDL, O
and O
BDL/R-III-treated O
mice O
were O
stained O
with O
Sirius O
red O
. O

Scale O
bar, O
200 O
μm O
. O

. O

Hydroxyproline O
content O
in O
the O
livers O
(μg/g O
liver) O
. O

*P-value, O
two-sample O
t-test O
(n O
= O
10) O
(compared O
to O
BDL-treated O
mice); O
BDL O
+ O
R-III B-proteingene
(10 O
μg): O
0.031, O
BDL+R-III B-proteingene
(5 O
μg): O
0.026 O
. O

HumanAβ O
exhibits O
a O
biphasic O
profile O
in O
CSF O
of O
APP B-proteingene
transgenic O
mice O
A, O
B O
Aβ40 B-proteingene
and O
Aβ42 B-proteingene
concentrations O
in O
CSF O
of O
male O
APP23 B-proteingene
mice O
(heterozygous; O
3 O
(n O
= O
14), O
6 O
(n O
= O
12), O
8 O
(n O
= O
10), O
12 O
(n O
= O
11), O
19 O
(n O
= O
9), O
and O
25 O
(n O
= O
6) O
months O
of O
age) O
. O

CSFAβ40 B-proteingene
(F(1, O
56) O
= O
22.351, O
P O
< O
0.001) O
as O
well O
as O
CSFAβ42 B-proteingene
(F(1, O
56) O
= O
38.597, O
P O
< O
0.001) O
followed O
a O
significant O
quadratic O
trend O
. O

C O
Aβ42/40 B-proteingene
ratio O
in O
CSF O
of O
APP23 B-proteingene
mice O
showed O
a O
delayed O
decrease O
with O
age O
(F(1, O
56) O
= O
53.894, O
P O
< O
0.001) O
. O

D, O
E O
Aβ40 B-proteingene
and O
Aβ42 B-proteingene
concentrations O
in O
CSF O
of O
male O
and O
female O
APP24 B-proteingene
mice O
(homozygous; O
2 O
(n O
= O
13), O
3-4 O
(n O
= O
16), O
7-8 O
(n O
= O
15), O
18-19 O
(n O
= O
14), O
24 O
(n O
= O
16), O
and O
30 O
(n O
= O
18) O
months O
of O
age) O
. O

CSFAβ40 B-proteingene
followed O
a O
significant O
quadratic O
trend O
(F(1, O
86) O
= O
6.678, O
P O
= O
0.011) O
and O
CSFAβ42 B-proteingene
best O
fitted O
a O
cubic O
trend O
(F(1, O
86) O
= O
30.599, O
P O
< O
0.001) O
. O

F O
Aβ42/40 B-proteingene
ratio O
in O
CSF O
of O
APP24 B-proteingene
mice O
showed O
a O
delayed O
decrease O
with O
age O
(F(1, O
86) O
= O
64.936, O
P O
< O
0.001) O
. O

G, O
H O
Aβ40 B-proteingene
and O
Aβ42 B-proteingene
in O
the O
CSF O
of O
female O
APP51 B-proteingene
mice O
(heterozygous; O
3 O
(n O
= O
6), O
15 O
(n O
= O
8), O
and O
24 O
(n O
= O
8) O
months O
of O
age; O
22 O
mice O
in O
total) O
. O

CSFAβ40 B-proteingene
(F(1, O
19) O
= O
37.349, O
P O
< O
0.001) O
as O
well O
as O
CSFAβ42 B-proteingene
(F(1, O
19) O
= O
107.670, O
P O
< O
0.001) O
followed O
a O
significant O
quadratic O
trend O
. O

IAβ42/40 B-proteingene
ratio O
in O
CSF O
of O
APP51 B-proteingene
mice O
showed O
a O
delayed O
decrease O
with O
age O
(F(1, O
19) O
= O
26.367, O
P O
< O
0.001) O
. O

HumanAβ O
in O
CSF O
and O
brain O
of O
APP B-proteingene
transgenic O
mice O
A O
APP23CSFAβ40 B-proteingene
and O
Aβ42 B-proteingene
in O
the O
same O
animals O
as O
shown O
in O
Fig1 O
. O

CSFAβ42 B-proteingene
and O
Aβ40 B-proteingene
are O
expressed O
as O
percentages O
of O
levels O
measured O
in O
the O
youngest O
age O
group O
. O

B, O
C O
Aβ40 B-proteingene
and O
Aβ42 B-proteingene
(pmol/g O
wet O
brain) O
in O
the O
FA-soluble O
brain O
extract O
from O
the O
same O
APP23mice B-proteingene
showed O
a O
robust O
increase O
with O
age; O
ANOVA O
revealed O
a O
significant O
cubic O
trend O
(F(1, O
56) O
= O
221.114, O
P O
< O
0.001 O
and O
F(1, O
56) O
= O
370.947, O
P O
< O
0.001, O
respectively) O
. O

D O
APP24CSFAβ40 B-proteingene
and O
Aβ42 B-proteingene
in O
the O
same O
animals O
shown O
in O
Fig1 O
as O
percentage O
of O
the O
youngest O
age O
group O
. O

G O
APP51 O
CSFAβ40 B-proteingene
and O
Aβ42 B-proteingene
in O
the O
same O
animals O
shown O
in O
Fig1 O
as O
percentages O
of O
levels O
in O
the O
youngest O
age O
group O
. O

H, O
IAβ40 B-proteingene
and O
Aβ42 B-proteingene
(pmol/g O
wet O
brain) O
in O
the O
brain O
from O
the O
same O
APP51 B-proteingene
mice O
showed O
a O
robust O
increase O
with O
age; O
ANOVA O
revealed O
a O
significant O
quadratic O
trend O
(F(1, O
19) O
= O
12.960, O
P O
= O
0.002 O
and O
F(1, O
19) O
= O
19.366, O
P O
< O
0.001, O
respectively) O
. O

Aβplaque O
pathology O
in O
the O
brains O
of O
APP23mice O
Aβimmunostaining B-proteingene
(CN3 B-proteingene
antibody, O
dark O
blue) O
in O
25-μm O
sagittal O
brain O
sections O
shows O
only O
sparse O
Aβ B-proteingene
deposits O
primarily O
in O
the O
frontal O
cortex O
of O
6- O
to O
8-month-old O
APP23mice B-proteingene
. O

At O
12 O
months O
and O
thereafter, O
there O
is O
a O
progressive O
increase O
in O
plaque O
number O
and O
size O
and O
a O
progressive O
involvement O
of O
different O
brain O
regions O
. O

Insets O
highlight O
the O
plaque O
characteristics O
at O
the O
different O
ages O
. O

Scale O
bar, O
100 O
μm O
. O

The O
mean O
number O
of O
Aβ B-proteingene
plaques O
per O
section O
per O
hemibrain O
increased O
with O
age O
in O
3- O
to O
12-month-old O
mice O
. O

Only O
four O
mice O
were O
analyzed O
in O
the O
3-month-old O
age O
group, O
as O
APP23mice O
do O
not O
develop O
plaques O
at O
this O
age O
(Sturchler-Pierrat O
et O
al, O
1997) O
. O

The O
6-, O
8-, O
and O
12-month-old O
age O
groups O
included O
12, O
10, O
and O
11 O
mice, O
respectively O
(these O
are O
the O
same O
mice O
that O
were O
used O
for O
CSF O
and O
brainAβ B-proteingene
measurements) O
. O

Note O
that O
the O
Aβ B-proteingene
plaques O
became O
too O
numerous O
and O
often O
could O
no O
longer O
be O
individually O
distinguished O
in O
the O
age O
groups O
> O
12 O
months O
of O
age O
. O

Data O
are O
represented O
as O
group O
means O
± O
SEM O
. O

Brain O
sAPPβ B-proteingene
shows O
an O
age-related O
increase O
in O
APP23, B-proteingene
APP24, B-proteingene
and O
APP51 B-proteingene
mice O
sAPPβ B-proteingene
was O
measured O
in O
Triton O
X-100brain O
extracts O
from O
largely O
the O
same O
mice O
as O
analyzed O
in O
Figs1 O
and2 O
and O
is O
expressed O
as O
percentages O
of O
levels O
measured O
in O
the O
youngest O
age O
group O
. O

Swedish O
sAPPβ B-proteingene
showed O
an O
age-dependent O
increase O
in O
APP23mice B-proteingene
following O
a O
linear O
trend O
(F(1, O
83) O
= O
52.914, O
P O
< O
0.001); O
APP23 B-proteingene
from O
two O
independent O
batches O
were O
included O
in O
this O
analysis O
(see O
Materials O
and O
Methods O
and O
Supplementary O
Fig O
S2 O
for O
details) O
. O

Swedish O
sAPPβ B-proteingene
showed O
an O
age-dependent O
increase O
in O
APP24mice B-proteingene
following O
a O
linear O
trend O
(F(1, O
84) O
= O
11.264, O
P O
= O
0.001) O
. O

Human O
wild-type O
sAPPβ B-proteingene
showed O
an O
age-dependent O
increase O
in O
APP51 B-proteingene
following O
a O
quadratic O
trend O
(F(1, O
18) O
= O
68.980, O
P O
< O
0.001) O
. O

Data O
information: O
Post O
hoc O
Dunnett O
's O
test O
group O
comparisons O
were O
always O
conducted O
between O
the O
youngest O
group O
and O
all O
other O
groups O
. O

All O
data O
are O
represented O
as O
group O
means O
± O
SEM; O
*P O
< O
0.05; O
**P O
< O
0.01; O
and O
***P O
< O
0.001 O
. O

For O
absolute O
values, O
see O
Supplementary O
Fig O
S2 O
. O

Administration O
of O
corticosteroids O
promotes O
the O
persistence O
of O
H. O
influenzae O
in O
mice O
A-D O
C57BL/6 O
mice O
were O
infected O
with O
H. O
influenzae O
in O
PBS O
with O
or O
without O
supplementation O
with O
beclomethasone O
. O

Animals O
were O
killed O
at O
1, O
3, O
5 O
and O
7 O
days O
after O
infection, O
and O
10-fold O
serial O
dilutions O
of O
the O
lung O
homogenates O
(A) O
and O
spleen O
homogenates O
(B) O
were O
plated O
to O
determine O
the O
bacterial O
load O
. O

Airway O
inflammation O
represented O
by O
total O
and O
differential O
cell O
counts O
in O
bronchoalveolar O
lavage O
fluid O
(BALF) O
. O

The O
number O
of O
total O
leukocytes O
and O
in O
particular O
of O
neutrophils, O
monocytes O
and O
lymphocytes O
recruited O
in O
the O
airways O
was O
analyzed O
in O
BALF O
after O
day O
3 O
(C) O
and O
day O
7 O
(D) O
of O
infection O
. O

Data O
information: O
Values O
represent O
the O
mean O
± O
standard O
deviation O
(SD) O
. O

The O
data O
are O
pooled O
from O
three O
independent O
experiments O
. O

Statistical O
significance O
by O
two-tailed O
Student O
's O
t-test O
is O
indicated: O
*P O
< O
0.05, O
**P O
< O
0.01 O
. O

C, O
D O
Comparison O
of O
relative O
fold O
changes O
between O
RNA-seq O
and O
qRT-PCR O
results O
in O
vitro O
(C) O
and O
in O
vivo O
(D) O
in O
the O
presence O
of O
corticosteroids O
. O

All O
qRT-PCR O
results O
were O
normalized O
using O
the O
Cts O
obtained O
for O
the O
16S B-proteingene
rRNA I-proteingene
amplifications O
run O
in O
the O
same O
plate O
. O

The O
relative O
levels O
of O
gene O
transcripts O
are O
determined O
from O
standard O
curves O
. O

Values O
given O
are O
the O
mean O
and O
standard O
deviation O
of O
triplicate O
measurements O
(three O
biological O
and O
three O
technical O
replicates) O
. O

B, O
C O
Comparison O
of O
relative O
fold O
changes O
between O
RNA-seq O
and O
qRT-PCR O
results O
for O
rpoE B-proteingene
and O
mclA B-proteingene
mutants O
(B) O
and O
the O
rpoE B-proteingene
and O
the O
addition O
of O
corticosteroid O
to O
wild-type O
H. O
influenzae O
(C) O
. O

All O
qRT-PCR O
results O
were O
normalized O
using O
the O
Cts O
obtained O
for O
the O
16S B-proteingene
rRNA I-proteingene
amplifications O
run O
in O
the O
same O
plate O
. O

The O
relative O
levels O
of O
gene O
transcripts O
are O
determined O
from O
standard O
curves O
. O

Values O
given O
are O
the O
mean O
and O
standard O
deviation O
of O
triplicate O
measurements O
(three O
biological O
and O
three O
technical O
replicates) O
. O

Addition O
of O
corticosteroids O
affects O
biofilm O
formation O
and O
antibiotic O
tolerance O
of O
H. O
influenzae O
H. O
influenzaebiofilms O
were O
developed O
after O
24 O
h O
in O
μ-well O
chambers O
in O
sBHI O
medium O
with O
and O
without O
corticosteroid O
and O
were O
then O
treated O
with O
the O
antibioticazithromycin O
as O
specified O
. O

(i) O
H. O
influenzae O
wild-type O
with O
DMSO O
(solvent O
control); O
(ii) O
H. O
influenzae O
wild-type O
treated O
with O
1 O
μM O
beclomethasone O
(BEC); O
(iii) O
H. O
influenzae O
wild-type O
treated O
with O
150 O
μg/ml O
azithromycin O
(AZO); O
and O
(iv) O
H. O
influenzae O
wild-type O
treated O
with O
1 O
μM O
beclomethasone O
(BEC) O
and O
150 O
μg/ml O
azithromycin O
(AZO) O
. O

For O
these O
experiments, O
H. O
influenzae O
was O
visualized O
with O
SYTO9 O
(green O
strain), O
as O
described O
in O
Materials O
and O
Methods O
. O

Scale O
bars O
= O
20 O
μm O
. O

Images O
shown O
are O
representative O
of O
12 O
images O
from O
five O
independent O
experiments O
. O

The O
biofilm O
biomass O
after O
treatments O
was O
quantified O
using O
COMSTAT. O
Data O
are O
presented O
as O
the O
average O
of O
five O
replicates, O
with O
error O
bar O
representing O
the O
standard O
deviation O
of O
the O
data O
. O

Statistical O
significance O
by O
two-tailed O
Student O
's O
t-test O
is O
indicated: O
**P O
< O
0.01 O
. O

Mutation O
of O
genes O
encoding O
RpoE B-proteingene
(HI0628) B-proteingene
and O
MclA B-proteingene
(HI0629) B-proteingene
has O
similar O
effects O
on O
biofilm O
formation O
and O
antibiotic O
tolerance O
in O
H. O
influenzae O
Biofilms O
of O
different O
H. O
influenzae O
strains O
were O
developed O
after O
24 O
h O
in O
μ-well O
chambers O
in O
sBHI O
medium O
and O
were O
then O
treated O
with O
the O
antibioticazithromycin O
as O
specified O
. O

(i) O
H. O
influenzae O
wild-type; O
(ii) O
rpoE B-proteingene
(HI0628); B-proteingene
(iii) O
mclA B-proteingene
(HI0629); B-proteingene
(iv) O
H. O
influenzae O
wild-type O
treated O
with O
150 O
μg/ml O
azithromycin; O
(v) O
rpoE B-proteingene
(HI0628) B-proteingene
treated O
with O
150 O
μg/ml O
azithromycin; O
(vi) O
mclA B-proteingene
(HI0629) B-proteingene
treated O
with O
150 O
μg/ml O
azithromycin O
. O

For O
these O
experiments, O
H. O
influenzae O
was O
visualized O
with O
SYTO9 O
(green O
strain), O
as O
described O
in O
Materials O
and O
Methods O
. O

Scale O
bars O
= O
20 O
μm O
. O

Images O
shown O
are O
representative O
of O
12 O
images O
from O
five O
independent O
experiments O
. O

The O
biofilm O
biomass O
after O
treatments O
was O
quantified O
using O
COMSTAT. O
Data O
are O
presented O
as O
the O
average O
of O
five O
replicates, O
with O
error O
bars O
representing O
the O
standard O
deviation O
of O
the O
data O
. O

Statistical O
significance O
by O
two-tailed O
Student O
's O
t-test O
is O
indicated: O
**P O
< O
0.01 O
. O

Corticosteroid O
treatment O
affects O
H. O
influenzae O
clearance O
by O
antibiotic O
treatment O
in O
the O
mouse O
airway O
A, O
B O
Mice O
infected O
intranasally O
with O
1 O
× O
108 O
CFUH. O
influenzae O
and O
treated O
by O
inhaling O
PBS O
with O
or O
without O
50 O
μM O
beclomethasone O
. O

Azithromycin O
was O
administered O
at O
a O
concentration O
of O
100 O
mg/kg/24 O
h, O
daily O
for O
3 O
days O
after O
infection O
. O

On O
day O
3-4 O
after O
infection, O
the O
mice O
were O
harvested, O
and O
bacterial O
loads O
were O
determined O
in O
lung O
(A) O
and O
spleen O
(B) O
homogenates O
. O

Values O
represent O
the O
mean O
± O
standard O
deviation O
(SD) O
. O

The O
data O
are O
pooled O
from O
three O
independent O
experiments O
. O

Statistical O
significance O
by O
two-tailed O
Student O
's O
t-test O
is O
indicated: O
*P O
< O
0.05, O
**P O
< O
0.01 O
. O

(D) O
Representative O
immunoblots O
(n=3) O
showing O
phosphorylation O
state O
of O
Smad2 B-proteingene
and O
JNK B-proteingene
during O
TGF-β-induced B-proteingene
EMT O
in O
NMuMG O
cells O
. O

Lamin B-proteingene
B I-proteingene
serves O
as O
loading O
control O
. O

(E) O
Quantification O
of O
one O
set O
of O
representative O
immunoblots O
(in O
figure O
D) O
and O
its O
graphical O
representation O
showing O
dynamic O
of O
Smad2 B-proteingene
and O
JNK B-proteingene
activation O
during O
TGF-β-induced B-proteingene
EMT O
in O
NMuMG O
. O

(F) O
Representative O
immunohistochemistry O
image O
for O
pSmad2 B-proteingene
and O
pJNK B-proteingene
in O
non-invasive O
(n=34) O
and O
invasive O
(n=14) O
breast O
cancer O
samples O
. O

Scale O
bars O
for O
10X O
and O
40X O
images O
are O
200 O
µm O
and O
50 O
µm O
respectively O
. O

(H) O
Immunofluorescence O
microscopy O
for O
changes O
in O
the O
localization O
and O
expression O
levels O
of O
EMT O
markers O
in O
epithelialNMuMG O
cells O
(d0) O
and O
cells O
treated O
with O
TGF-β B-proteingene
for O
seven O
days O
in O
the O
presence O
of O
JNK B-proteingene
inhibitor O
(d7 O
JNKi) O
or O
control O
(d7 O
DMSO) O
. O

Staining O
was O
performed O
with O
antibodies O
against O
Fibronectin B-proteingene
1, I-proteingene
with O
Phalloidin O
to O
visualize O
the O
actin O
cytoskeleton O
and O
against O
Paxillin B-proteingene
to O
detect O
focal O
adhesion O
plaques O
. O

It O
is O
important O
to O
note O
that O
the O
untreated O
epithelial O
cells O
are O
highly O
proliferative O
and O
appear O
small O
in O
size, O
round O
in O
shape O
and O
adhere O
to O
surrounding O
cells O
whereas O
day O
7 O
TGF- B-proteingene
β-treated I-proteingene
(mesenchymal) O
cells O
are O
much O
bigger O
in O
size, O
elongated O
in O
shape O
and O
detached O
from O
the O
nearby O
cells O
. O

Scale O
bar, O
100 O
μm, O
63X O
magnification O
. O

(I) O
mRNA O
levels O
for O
classical O
EMT O
markers O
in O
cells O
treated O
as O
in O
(F) O
were O
measured O
by O
qRT-PCRs O
relative O
to O
Ctcf B-proteingene
and O
fold O
change O
as O
compare O
to O
untreated O
and O
plotted O
on O
the O
y-axis O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

(J) O
Transwell O
migration O
assay O
for O
NMuMG O
cells O
treated O
as O
in O
G. O
Plotted O
Mean O
± O
SEM O
of O
three O
biological O
replicates O
. O

* O
p<0.05, O
** O
p<0.01, O
*** O
p< O
0.001, O
Student O
's O
t-test O
. O

. O

(E) O
ChIP O
assay O
using O
H3K27me3-specific B-proteingene
antibody O
in O
epithelial O
cells O
(day O
0)) O
or O
NMuMG O
cells O
treated O
for O
seven O
days O
with O
TGF-β B-proteingene
(mesenchymal) O
and O
DMSO O
or O
JNKi O
. O

qRT-PCRs O
were O
performed O
for O
indicated O
gene O
promoters O
and O
enrichments O
are O
plotted O
on O
the O
right O
y-axis O
as O
ratio O
of O
precipitated O
DNA O
(bound) O
to O
total O
input O
DNA. O
On O
the O
left O
y-axis O
RNA O
levels O
of O
analyzed O
genes O
derived O
from O
RNA-seq O
data O
(fold O
change O
to O
untreated O
normalized O
tag O
counts O
) O
are O
plotted O
. O

Mean O
and O
SEM O
is O
plotted O
from O
two O
independent O
biological O
replicates O
. O

(F) O
FAIRE O
assay O
was O
performed O
in O
cells O
treated O
as O
in O
(D) O
and O
qRT-PCRs O
were O
performed O
for O
the O
same O
gene O
promoters O
and O
plotted O
as O
in O
(E) O
. O

(C) O
Representative O
bright O
field O
and O
immunofluorescence O
images O
for O
localization O
and O
expression O
levels O
of O
EMT O
marker O
proteins O
after O
four O
days O
(d4) O
of O
siRNA-mediated O
depletion O
of O
factors O
compared O
to O
non-targeting O
control O
(NTC) O
. O

Staining O
was O
performed O
with O
antibodies O
against O
epithelial O
markers O
E-cadherin B-proteingene
and O
ZO1, B-proteingene
mesenchymal O
markers O
Fibronectin B-proteingene
1, I-proteingene
with O
Phalloidin O
to O
visualize O
the O
actin O
cytoskeleton O
and O
against O
Paxillin B-proteingene
to O
detect O
focal O
adhesion O
plaques O
. O

Scale O
bar, O
100 O
μm, O
40X O
magnification O
. O

Plotted O
Mean O
± O
SEM O
of O
three O
biological O
replicates O
. O

* O
p<0.05, O
** O
p<0.01, O
*** O
p< O
0.001, O
Student O
's O
t-test O
. O

Depletion O
of O
Prkrir, B-proteingene
Pcbp4 B-proteingene
and O
Tsc22d1 B-proteingene
rescues O
TGF-β-induced B-proteingene
reduction O
in O
the O
rate O
of O
cell O
division O
. O

(A) O
Lineage O
trees O
tracked O
by O
live O
imaging O
under O
control, O
Non O
treated O
control O
(NTC) O
and O
siRNA-mediated O
depletion O
of O
factors O
(X= O
cell O
death/cells O
could O
not O
be O
tracked O
till O
the O
end) O
. O

PRKRIR, B-proteingene
PCBP4 B-proteingene
and O
TSC22D1 B-proteingene
are O
crucial O
for O
maintenance O
of O
the O
mesenchymal O
fate O
. O

(A) O
Scratch O
assay O
in O
MDA-MB-231 O
cells O
treated O
for O
four O
days O
with O
DMSO O
or O
JNKi O
. O

Scale O
bar, O
200 O
μm; O
20 O
X O
magnification O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

(B) O
mRNA O
levels O
for O
key O
EMT O
marker O
genes O
in O
MDA-MB-231 O
treated O
with O
DMSO O
or O
JNKi O
for O
4 O
days O
were O
measured O
by O
qRT-PCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O

(C) O
mRNA O
levels O
for O
transcription O
factors O
in O
isogenic O
epithelial O
(MDA-MB-361) O
and O
mesenchymal O
(MDA-MB-231) O
breast O
cancer O
cells O
were O
measured O
by O
qRT-PCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

(D) O
Scratch O
assay O
in O
MDA-MB-231 O
cells O
transfected O
with O
NTC O
or O
siRNA O
against O
PRKRIR, B-proteingene
NFIL3, B-proteingene
PCBP4 B-proteingene
and O
TSC22D1 B-proteingene
for O
4 O
days O
as O
in O
A. O
Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
as O
bar O
plot O
on O
right O
. O

(E) O
Invasion O
assay O
in O
MDA-MB-231 O
cells O
treated O
as O
in O
(D) O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

(F) O
mRNA O
levels O
of O
key O
EMT O
marker O
genes O
in O
MDA-MB-231 O
and O
MDA-MB-231 O
transfected O
with O
either O
empty O
vector O
or O
vector O
overexpressing O
PCBP4 B-proteingene
or O
TSC22D1 B-proteingene
for O
48 O
hours O
and O
then O
treated O
with O
the O
JNK B-proteingene
inhibitor O
(SP600125) O
for O
24 O
hours O
were O
measured O
by O
qRT-PCRs O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

Plotted O
Mean O
± O
SEM O
of O
three O
biological O
replicates O
. O

* O
p<0.05, O
** O
p<0.01, O
*** O
p< O
0.001, O
Student O
's O
t-test O
. O

(C) O
mRNA O
levels O
for O
representative O
genes O
highlighted O
in O
(A) O
for O
cells O
treated O
like O
in O
(Fig O
5D) O
were O
measured O
by O
qRT-PCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Mean O
and O
SEM O
is O
plotted O
from O
three O
independent O
biological O
replicates O
. O

F) O
Representative O
immunofluorescenceimages O
showing O
localization O
of O
Tsc22d1 B-proteingene
in O
NMuMG O
cells O
following O
transient O
expression O
of O
Flag-HA B-proteingene
tagged O
Tsc22d1 B-proteingene
and O
detection O
using O
an O
anti-Flag B-proteingene
antibody, O
Bar O
plot O
shows O
quantification O
of O
Tsc22d1 B-proteingene
localization O
with O
respect O
to O
DAPI O
density O
within O
the O
nucleus O
. O

Y-axis O
shows O
the O
percentage O
of O
total O
fluorescence O
intensity O
for O
Tsc22d1 B-proteingene
in O
DAPI O
dense O
and O
light O
regions O
. O

SEM O
is O
derived O
from O
independent O
biological O
replicates O
. O

(G) O
ChIP O
assay O
using O
anti-Flag B-proteingene
antibody O
following O
expression O
of O
Flag-HA B-proteingene
tagged O
TSC22D1 B-proteingene
in O
MDA-MB-231 O
cells O
. O

Quantitative O
PCRs O
were O
performed O
for O
indicated O
gene O
promoters O
and O
enrichments O
are O
plotted O
on O
the O
y-axis O
as O
ratio O
of O
precipitated O
DNA O
(bound) O
to O
total O
input O
DNA O
and O
then O
further O
divided O
by O
the O
same O
obtained O
in O
the O
empty O
vector O
transfected O
cells O
. O

SEM O
is O
derived O
from O
independent O
biological O
replicates O
. O

(H) O
mRNA O
levels O
for O
PRKRIR, B-proteingene
PCBP4, B-proteingene
TSC22D1 B-proteingene
in O
non-invasive O
(DCIS) O
(n=20) O
and O
invasive O
tumor O
(n=20) O
samples O
were O
measured O
by O
qRT O
PCRs O
relative O
to O
TBP B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

ZEB1 B-proteingene
was O
used O
as O
an O
established O
positive O
control O
for O
invasive O
tumors O
. O

Plotted O
Mean O
± O
SEM O
of O
three O
biological O
replicates O
. O

* O
p<0.05, O
** O
p<0.01, O
*** O
p< O
0.001, O
Student O
's O
t-test O
. O

Newly O
identified O
transcription O
factors O
are O
similarly O
upregulated O
during O
neurogenesis O
and O
function O
in O
neuronalmigration O
. O

(A) O
RT-qPCR O
analysis O
for O
key O
EMT O
markers O
in O
embryonic O
stem O
cells O
(ES), O
neuronal O
progenitors O
(NP) O
and O
terminally O
differentiated O
neurons O
(TN) O
. O

mRNA O
levels O
were O
measured O
by O
RT-qPCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Error O
bars O
represent O
SEM O
from O
independent O
biological O
replicates O
. O

(B) O
Western O
blot O
analyzing O
total O
JNK B-proteingene
and O
phospho-JNK B-proteingene
(p-JNK) B-proteingene
during O
neuronal O
differentiation O
of O
stem O
cells O
. O

β-actin B-proteingene
serve O
as O
a O
loading O
control O
. O

(C) O
RNA O
levels O
of O
Pcbp4, B-proteingene
Prkrir B-proteingene
and O
Tsc22d1 B-proteingene
during O
neuronal O
differentiation O
as O
shown O
in O
A, O
measured O
by O
RT-qPCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Error O
bars O
represent O
SEM O
from O
independent O
biological O
replicates O
. O

(D) O
RNA O
levels O
of O
Pcbp4, B-proteingene
Prkrir, B-proteingene
Tsc22d1, B-proteingene
represented O
by O
average O
counts O
derived O
from O
previously O
published O
microarray O
data O
of O
independent O
biological O
replicates O
from O
neurons O
treated O
with O
DMSO O
or O
JNK B-proteingene
inhibitor O
SP600125 O
(JNKi) O
for O
6 O
hours O
. O

(E) O
RNA O
levels O
of O
Tsc22d1 B-proteingene
and O
three O
Tsc22d1 B-proteingene
target O
genes O
during O
various O
stages O
of O
neuronal O
differentiation O
shown O
in O
(A), O
measured O
by O
RT-qPCR O
relative O
to O
Ctcf B-proteingene
and O
plotted O
on O
the O
y-axis O
. O

Error O
bars O
represent O
SEM O
from O
independent O
biological O
replicates O
. O

(F) O
RNA O
levels O
of O
Tsc22d1 B-proteingene
and O
the O
same O
three O
target O
genes O
is O
shown O
as O
average O
normalized O
tag O
counts O
derived O
from O
RNA-seq O
data O
from O
Ventricular O
Zone O
(VZ), O
Sub-Ventricular O
Zone O
(SVZ) O
and O
Cortical O
plate O
(CP) O
of O
E14.5mouseCortex O
. O

(G) O
RNA O
levels O
of O
genes O
shown O
in O
Figure O
(E), O
represented O
by O
average O
normalized O
tag O
counts O
derived O
from O
RNA-seq O
data O
of O
TGF-β-induced B-proteingene
EMT O
in O
NMuMG O
cells O
and O
plotted O
on O
the O
y-axis O
. O

Error O
bars O
represent O
SEM O
from O
three O
biological O
replicates O
. O

(I) O
A O
representative O
image O
from O
immunofluorescence O
analysis O
performed O
with O
anti-GFP B-proteingene
and O
anti-Tbr1 B-proteingene
antibody O
that O
shows O
retention O
of O
GFP B-proteingene
positive O
cells O
below O
the O
Tbr1 B-proteingene
layer O
in O
Tsc22d1 B-proteingene
knockdown O
brain O
as O
compared O
to O
the O
control O
brain O
. O

The O
bar O
plot O
on O
the O
right O
side O
shows O
quantification O
of O
migrated O
GFP B-proteingene
positive O
cells O
in O
control O
and O
Tsc22d1 B-proteingene
depleted O
mousebrain O
with O
respect O
to O
the O
Tbr1staining B-proteingene
. O

y O
axis O
represent O
percentage O
of O
cells O
above O
or O
below O
the O
Tbr1 B-proteingene
stain O
region O
. O

Error O
bars O
represent O
SEM O
from O
3 O
independent O
biological O
replicates O
. O

* O
p<0.05, O
** O
p<0.01, O
*** O
p< O
0.001, O
Student O
's O
t-test O
. O

A-D O
Progression O
of O
microglial O
infiltration O
in O
the O
ONL. O
Early O
in O
the O
course O
of O
rod O
degeneration O
at O
P18, O
few O
isolated O
apoptotic O
TUNEL-positive O
nuclei O
(red, O
inset) O
were O
present O
in O
the O
ONL, O
with O
Iba1+microglialsomata O
and O
processes O
(green) O
confined O
to O
the O
inner O
retina O
(A) O
. O

At O
P21, O
microglia O
in O
the O
outer O
plexiform O
layer O
(OPL) O
extended O
radial O
processes O
into O
the O
ONL O
(inset), O
with O
a O
concurrent O
increase O
in O
the O
number O
of O
TUNEL+nuclei O
(B) O
. O

At O
P30, O
retinalmicroglia O
infiltrated O
the O
entire O
depth O
of O
the O
markedly O
thinned O
ONL O
and O
the O
subretinal O
space O
(SRS) O
(inset) O
(C) O
. O

At O
P46, O
microglia O
became O
less O
dense O
in O
the O
ONL O
and O
reverted O
to O
a O
more O
ramified O
morphology O
(D) O
. O

Scale O
bar, O
50 O
μm O
. O

E-G O
Quantitative O
analyses O
demonstrate O
that O
ONL O
atrophy O
progression, O
characterized O
by O
ONL O
thickness O
(empty O
symbols) O
and O
number O
of O
rows O
of O
ONLnuclei O
(filled O
symbols) O
(E), O
occurred O
concurrently O
with O
the O
progression O
of O
ONL O
apoptosis, O
followed O
as O
the O
density O
of O
TUNEL+nuclei O
in O
the O
ONL O
(F), O
and O
microglia O
infiltration, O
followed O
as O
microglial O
density O
in O
the O
ONL O
(G) O
(n O
= O
3 O
animals O
at O
each O
time O
point) O
. O

Data O
points O
and O
error O
bars O
indicate O
mean O
± O
SEM. O
H-K O
Higher O
magnification O
images O
showing O
microglial O
process O
infiltration O
(H), O
phagosome O
formation O
in O
infiltrating O
processes O
(I), O
and O
microglial O
transformation O
into O
amoeboid O
morphologies O
containing O
multiple O
phagosomes O
(J,K) O
. O

A-C O
Microglia O
infiltrating O
the O
ONL O
demonstrate O
upregulation O
of O
the O
phagocytic O
molecule, O
CD68 B-proteingene
. O

Top O
images O
in O
(A) O
show O
composites O
of O
CD68 B-proteingene
(red), O
Iba1 B-proteingene
(green), O
and O
DAPI O
(blue) O
staining; O
bottom O
images O
show O
the O
same O
field O
with O
CD68 B-proteingene
staining O
only O
. O

At O
P18, O
non-infiltrating O
microglia O
expressed O
low O
or O
undetectable O
levels O
of O
CD68, B-proteingene
a O
lysosome-associated O
membrane O
protein O
. O

At O
P21-23, O
microglia O
infiltrating O
the O
ONL O
strongly O
upregulated O
CD68 B-proteingene
(arrowheads) O
. O

At O
P30, O
CD68 B-proteingene
immunopositivity O
in O
ONLmicroglia O
decreased O
and O
was O
mostly O
confined O
to O
amoeboid O
cells O
in O
the O
subretinal O
space O
. O

(B) O
Magnified O
view O
of O
inset O
in O
(A) O
demonstrates O
localization O
of O
CD68 B-proteingene
to O
microgliaphagosomes O
. O

(C) O
CD68 B-proteingene
expression O
(area O
of O
immunopositivity O
as O
a O
fraction O
of O
the O
ONL) O
demonstrated O
a O
peaked O
at O
P22 O
and O
decreased O
by O
P30 O
. O

Scale O
bar, O
20 O
μm O
. O

D-F O
Upregulation O
of O
MFG-E8, B-proteingene
a O
secreted O
glycoprotein O
that O
serves O
as O
a O
bridging O
molecule O
for O
phagocytosis O
receptors, O
in O
the O
ONL O
. O

(D) O
MFG-E8 B-proteingene
was O
low O
or O
absent O
in O
the O
ONL O
at O
P18, O
but O
emerged O
at O
P21-23, O
localizing O
to O
photoreceptorcell O
bodies O
in O
a O
column-like O
pattern O
(arrow) O
and O
as O
a O
punctate O
signal O
within O
infiltrating O
microglia O
(arrowhead), O
before O
decreasing O
throughout O
the O
ONL O
at O
P30 O
. O

(E) O
A O
magnified O
orthogonal O
view O
of O
the O
inset O
from O
(D) O
demonstrating O
punctate O
MFG-E8 B-proteingene
immunopositivity O
within O
ONLmicroglia O
. O

(F) O
Quantification O
of O
MFG-E8 B-proteingene
expression O
demonstrated O
a O
prominent O
emergence O
at O
P22 O
and O
a O
subsequent O
decrement O
by O
P30 O
. O

Scale O
bar, O
20 O
μm O
. O

G-K O
Increase O
in O
phosphatidylserine O
(PS) O
exposure O
in O
the O
ONL O
during O
photoreceptor O
degeneration O
. O

(G) O
At O
P18, O
PS O
immunopositivity O
is O
near O
absent O
in O
the O
ONL, O
but O
increased O
significantly O
in O
ONLsomata O
at O
P21-23, O
before O
decreasing O
at O
P30 O
. O

(H) O
Quantitation O
of O
PS O
exposure O
by O
image O
analysis O
(by O
fractional O
area O
of O
PS O
immunopositivity O
within O
the O
ONL O
(top), O
and O
the O
mean O
intensity O
of O
PS O
staining O
in O
the O
ONL O
(bottom)) O
demonstrated O
a O
transient O
increase O
at O
P22 O
. O

(I) O
Co-immunolabeling O
of O
rods O
with O
rhodopsin B-proteingene
at O
P22 O
demonstrates O
that O
PS O
exposure O
was O
present O
in O
a O
majority O
of O
rods O
(inset O
shows O
at O
high O
magnification O
the O
co-labeling O
of O
PS O
and O
rhodopsin B-proteingene
in O
multiple O
rodsomata) O
. O

(J) O
Conversely, O
immunolabeling O
of O
cones O
with O
conearrestin O
demonstrates O
the O
sparse O
co-localization O
of O
PS O
in O
cones O
(inset O
shows O
close O
juxtaposition O
but O
no O
colocalization O
of O
PS O
and O
arrestin B-proteingene
labeling) O
. O

(K) O
Scoring O
of O
rhodopsin+rods O
and O
arrestin+cones O
for O
PS O
co-labeling O
demonstrates O
that O
a O
large O
majority O
of O
rods, O
but O
only O
a O
small O
minority O
of O
cones, O
showed O
PS O
exposure O
(two-sided O
unpaired O
t-test, O
n O
= O
3 O
animals O
at O
P22) O
. O

Scale O
bars O
= O
20 O
μm O
. O

A-C O
Phagocytosis O
of O
rods O
by O
infiltrating O
microglia O
. O

(A) O
Representative O
example O
of O
a O
Iba1+microglial O
process O
extending O
into O
the O
ONL O
with O
a O
phagosome O
at O
its O
terminal O
end O
. O

Each O
phagosome O
contained O
a O
photoreceptornucleus O
(labeled O
with O
DAPI, O
arrow) O
that O
was O
identified O
as O
a O
rodphotoreceptor O
by O
rhodopsin B-proteingene
immunopositivity O
(superposition O
of O
Iba1+phagosome O
with O
rhodopsin+soma B-proteingene
in O
orthogonal O
views) O
. O

(B) O
Example O
of O
an O
amoeboid O
microglia O
in O
the O
ONL O
with O
multiple O
phagosomes O
containing O
both O
rhodopsin-positive B-proteingene
(arrowhead) O
and O
rhodopsin-negative B-proteingene
(arrow) O
nuclei O
. O

(C) O
Rhodopsin+nuclei O
can O
be O
localized O
within O
CD68-positive B-proteingene
phagosomes O
in O
infiltrating O
microglia, O
indicating O
phagocytic O
engulfment O
of O
rods O
. O

Scale O
bar, O
10 O
μm O
. O

D, O
E O
The O
peak O
of O
microglial O
phagocytic O
activity O
occurred O
around O
P21 O
and O
declined O
subsequently, O
as O
measured O
by O
the O
number O
of O
rods O
phagocytosed O
(D) O
and O
the O
number O
of O
photoreceptors O
phagocytosed O
per O
microglial O
cell O
(E) O
(n O
= O
3 O
animals O
at O
each O
time O
point) O
. O

F-J O
Infiltrating O
microglia O
phagocytose O
TUNEL-negative O
rods O
in O
the O
ONL O
. O

(F) O
Although O
the O
peaks O
of O
TUNEL O
positivity O
and O
microglial O
phagocytosis O
occurred O
concurrently, O
the O
majority O
of O
rodphotoreceptors O
undergoing O
microglial O
phagocytosis O
were O
non-apoptotic O
(arrows), O
while O
many O
apoptotic O
photoreceptors O
were O
not O
phagocytosed O
by O
microglia O
(arrowheads); O
representative O
example O
of O
a O
P21 O
retina O
demonstrates O
non-overlapping O
patterns O
of O
TUNEL O
positivity O
(red) O
and O
microglial O
phagocytosis O
(Iba1, B-proteingene
green) O
. O

(G) O
Confocal O
analysis O
of O
a O
representative O
amoeboid O
microglial O
cell O
demonstrates O
that O
while O
the O
photoreceptornuclei O
in O
phagosomes O
were O
rhodopsin-positive B-proteingene
(white), O
they O
were O
mostly O
TUNEL-negative O
. O

Only O
a O
small O
fraction O
of O
microglialphagosomes O
contained O
TUNEL+, O
rhodopsin+rods O
(example O
shown O
in O
H) O
. O

Scale O
bars, O
20 O
μm O
. O

(I) O
Quantitative O
analysis O
of O
photoreceptornuclei O
within O
microglialphagosomes O
according O
to O
rhodopsin B-proteingene
(black O
symbols), O
and O
TUNEL O
labeling O
(red O
symbols) O
at O
different O
times O
during O
rod O
degeneration O
. O

(J) O
Quantitative O
analysis O
of O
all O
photoreceptors O
undergoing O
either O
apoptosis O
or O
phagocytosis O
at O
P21-23 O
demonstrates O
that O
TUNEL+ O
apoptotic O
photoreceptors O
and O
phagocytosed O
photoreceptors O
consist O
of O
two O
distinct O
populations, O
indicating O
separate O
but O
parallel O
mechanisms O
of O
rod O
degeneration O
. O

Quantitative O
analyses O
involved O
retinal O
sections O
from O
n O
= O
3 O
animals O
at O
each O
age O
. O

A-C O
Evidence O
of O
microglial O
phagocytosis O
of O
photoreceptors O
in O
other O
mouse O
models O
of O
RP. O
Histological O
analysis O
of O
a O
rd1mouseretina O
(A) O
demonstrates O
microglial O
phagocytosis O
of O
photoreceptornuclei O
in O
vibratome O
sections O
(left) O
and O
in O
flat-mounted O
retina O
(right) O
. O

Phagocytosed O
nuclei O
were O
predominantly O
negative O
for O
TUNEL O
staining O
(arrows) O
. O

Similar O
findings O
were O
found O
in O
the O
retinas O
of O
the O
rd16mouse O
(loss-of-function O
mutation O
in O
the O
photoreceptor-expressed O
CEP290 B-proteingene
gene, O
1 O
month O
old) O
(B) O
and O
the O
RPGRIP-deficient B-proteingene
mouse O
(6 O
months O
old) O
(C) O
. O

Scale O
bar, O
20 O
μm O
. O

D-G O
Evidence O
of O
microglial O
phagocytosis O
of O
photoreceptors O
in O
other O
human O
histopathological O
specimens O
of O
RP O
. O

(D) O
Retinal O
section O
from O
a O
30-year-old O
male O
donor O
with O
autosomal O
recessive O
RP O
(AR O
RP) O
showing O
extensive O
microglial O
infiltration O
of O
the O
ONL; O
expanded O
inset O
(right) O
shows O
multiple O
photoreceptor O
nuclei O
in O
phagosomes O
that O
were O
predominantly O
negative O
for O
TUNEL O
staining O
. O

(E, O
F) O
Retinal O
sections O
from O
two O
separate O
donors O
with O
autosomal O
dominant O
RP O
(AD O
RP1 O
= O
68-year-old O
man, O
T17M O
rhodopsin B-proteingene
mutation, O
AD O
RP1 O
= O
50-year-old O
woman, O
Q-64-ter O
rhodopsin B-proteingene
mutation) O
showing O
similar O
evidence O
of O
microglial O
phagocytosis O
. O

(G) O
Retinal O
section O
from O
a O
46-year-old O
male O
donor O
with O
X-linked O
RP O
(XL O
RP) O
. O

Arrowheads O
indicate O
phagocytosed O
photoreceptor O
nuclei O
. O

Scale O
bars, O
20 O
μm O
. O

Time-lapse O
confocal O
imaging O
(at O
a O
rate O
of O
one O
image O
stack/min) O
was O
used O
to O
document O
dynamic O
behavior O
of O
ONLmicroglia O
in O
rd10retinal O
explants O
at O
ages O
P21-24 O
. O

Infiltrating O
microglia O
established O
rapid O
and O
transient O
physical O
contacts O
with O
nearby O
photoreceptorsomata O
(red O
and O
yellow O
circles) O
via O
their O
processes; O
these O
processes O
often O
terminated O
in O
a O
"cup"-like O
structure O
(arrow) O
that O
upon O
soma O
contact O
proceeded O
to O
extend O
across O
the O
entire O
soma O
(arrowhead, O
and O
red O
circle O
and O
*) O
to O
engulf O
it O
completely O
. O

The O
majority O
of O
microglia-photoreceptor O
contacts O
were O
transient O
with O
the O
microglial O
processes O
dynamically O
contacting O
and O
releasing O
photoreceptorsomata O
in O
repetitive O
cycles O
(e.g O
. O

yellow O
circle O
and O
*) O
(period O
≅10-15 O
min) O
. O

Time-lapse O
confocal O
imaging O
(at O
a O
rate O
of O
one O
image O
stack/min) O
was O
used O
to O
document O
dynamic O
behavior O
of O
ONLmicroglia O
in O
rd10retinal O
explants O
at O
ages O
P21-24 O
. O

Example O
in O
which O
the O
engulfment O
of O
photoreceptorsomata O
by O
microglialphagocytic O
cup O
was O
followed O
up O
by O
actual O
phagocytosis O
in O
which O
the O
engulfed O
cell O
(red O
*) O
is O
translocated O
intracellularly O
within O
the O
microglial O
cell O
toward O
the O
cell O
body O
. O

Phagocytosis O
of O
soma O
occurred O
simultaneously O
with O
"probing" O
of O
other O
somata O
by O
processes O
of O
the O
same O
microglial O
cell O
(yellow O
*) O
. O

Time-lapse O
confocal O
imaging O
(at O
a O
rate O
of O
one O
image O
stack/min) O
was O
used O
to O
document O
dynamic O
behavior O
of O
ONLmicroglia O
in O
rd10retinal O
explants O
at O
ages O
P21-24 O
. O

Phagocytosis O
of O
photoreceptorsomata O
occurred O
via O
flattened O
microgliallamellipodialmicroglial O
processes O
(arrow) O
that O
extended O
across O
somata O
(yellow O
*) O
to O
engulf O
them O
. O

Nuclei O
of O
phagocytosed O
photoreceptors O
within O
microglialphagosomes O
occasionally O
developed O
staining O
for O
propidium O
iodide O
(red O
arrow); O
these O
subsequently O
faded O
and O
disappeared O
over O
≅10 O
min, O
possibly O
representing O
intraphagosomal O
breakdown O
. O

Time-lapse O
confocal O
imaging O
(at O
a O
rate O
of O
one O
image O
stack/min) O
was O
used O
to O
document O
dynamic O
behavior O
of O
ONLmicroglia O
in O
rd10retinal O
explants O
at O
ages O
P21-24 O
. O

Amoeboid O
infiltrating O
microglia O
lacking O
extended O
processes O
were O
also O
observed O
to O
phagocytose O
photoreceptors O
via O
phagocytic O
cups O
formed O
at O
their O
cell O
body O
(red O
*) O
. O

Retinalmicroglia O
were O
depleted O
in O
rd10/CreDTAmice O
by O
the O
oral O
administration O
of O
tamoxifen O
(in O
corn O
oil) O
to O
activate O
microglia-specific O
Cre-mediated B-proteingene
recombination O
and O
diphtheria B-proteingene
toxin I-proteingene
expression; O
control O
CreDTA B-proteingene
littermates O
were O
administered O
corn O
oil O
without O
tamoxifen O
. O

A-D O
Depletion O
of O
retinalmicroglia O
in O
the O
rd10 O
retina O
. O

Representative O
retinal O
section O
from O
a O
P28 O
control O
animal O
demonstrates O
Iba1+microglia O
in O
the O
retina, O
including O
those O
infiltrating O
the O
ONL O
(A), O
while O
a O
tamoxifen-administered O
littermate O
(B) O
was O
substantially O
depleted O
of O
retinalmicroglia O
. O

Scale O
bar, O
40 O
μm O
. O

Microglial O
cell O
counts O
in O
the O
entire O
retina O
(C) O
and O
in O
the O
ONL O
only O
(D) O
confirmed O
efficient O
depletion O
of O
infiltrating O
microglia O
following O
tamoxifen O
administration O
(n O
= O
8 O
control O
and O
11 O
depleted O
animals O
from O
four O
litters, O
two-sided O
unpaired O
t-test) O
. O

E-J O
Effect O
of O
microglial O
depletion O
on O
retinal O
degeneration O
at O
P28-29 O
. O

ONL O
atrophy O
and O
thinning O
in O
control O
animals O
(E) O
was O
significantly O
more O
advanced O
relative O
to O
microglia-depleted O
littermates O
(F) O
. O

Scale O
bar, O
40 O
μm O
. O

Quantification O
of O
mean O
ONL O
thickness O
(G) O
and O
mean O
number O
of O
layers O
of O
ONLnuclei O
(H) O
at O
P28-29 O
demonstrate O
significantly O
greater O
ONL O
preservation O
in O
depleted O
retinas; O
the O
degree O
of O
ONL O
preservation O
correlated O
with O
the O
extent O
of O
microglia O
depletion O
(I) O
. O

(J) O
The O
mean O
density O
of O
TUNEL+nuclei O
in O
the O
ONL O
was O
not O
significantly O
decreased O
in O
depleted O
vs. O
control O
animals O
(n O
= O
8 O
control O
and O
11 O
depleted O
animals O
from O
four O
litters, O
two-sided O
unpaired O
t-test) O
. O

K-N O
Continuation O
of O
microglial O
depletion O
until O
P37-39 O
resulted O
in O
the O
persistence O
of O
morphological O
rescue O
(K-M), O
with O
a O
significant O
reduction O
in O
TUNEL+nuclei O
density O
(N) O
(n O
= O
6 O
control O
and O
nine O
depleted O
animals O
from O
two O
litters, O
two-sided O
unpaired O
t-test) O
. O

O-R O
Similar O
rescue O
effects O
as O
in O
(K-N) O
remained O
apparent O
when O
depletion O
was O
sustained O
until O
P50 O
(O-R), O
a O
time O
when O
rod O
degeneration O
in O
the O
rd10 O
model O
is O
relatively O
complete O
(n O
= O
9 O
control O
and O
10 O
depleted O
animals O
from O
three O
litters, O
two-sided O
unpaired O
t-test) O
. O

S, O
T O
Functional O
rescue O
of O
photoreceptors O
was O
evident O
following O
microglial O
depletion O
until O
P50 O
in O
significantly O
increased O
dark- O
(S) O
and O
light-adapted O
(T) O
responses O
in O
ERG O
testing O
in O
depleted O
animals O
(green O
lines) O
relative O
to O
control O
animals O
(black O
lines), O
in O
both O
a- O
and O
b-wave O
amplitudes O
across O
multiple O
flash O
intensities O
(n O
= O
9 O
control O
and O
nine O
depleted O
animals, O
*P O
< O
0.05 O
in O
one-way O
ANOVA O
with O
Sidak O
's O
multiple O
comparison O
test) O
. O

A, O
B O
Effect O
of O
phagocytosis O
inhibition O
on O
retinalmicroglia O
ex O
vivo O
. O

Retinal O
explants O
acutely O
isolated O
from O
P21-23 O
rd10/CX3CR1GFP/+mice O
were O
incubated O
in O
Ringer O
's O
solution O
(control), O
or O
Ringer O
's O
solution O
containing O
either O
the O
vitronectin B-proteingene
receptor I-proteingene
inhibitor O
cRGD B-proteingene
peptide O
or O
its O
inactive O
analog O
cRAD B-proteingene
(400 O
μM) O
for O
1 O
h. O
GFP-labeled B-proteingene
(green) O
ONLmicroglia O
in O
explants O
in O
cRGD B-proteingene
transitioned O
from O
amoeboid O
morphologies O
containing O
multiple O
phagosomes O
to O
more O
ramified O
morphologies O
with O
fewer O
phagosomes O
. O

No O
morphological O
changes O
were O
detected O
in O
microglia O
incubated O
in O
cRAD B-proteingene
(insets O
show O
morphologies O
at O
higher O
magnification) O
. O

Scale O
bar, O
40 O
μm O
. O

Quantifications O
of O
total O
number O
of O
phagosomes O
per O
40× O
field O
(left) O
and O
the O
mean O
number O
of O
phagosomes O
per O
microglia O
(right) O
demonstrate O
significant O
reductions O
in O
phagocytic O
activity O
of O
cRGD, B-proteingene
relative O
to O
cRAD, B-proteingene
exposure O
(n O
= O
8 O
imaging O
fields O
from O
in O
each O
condition) O
. O

C-N O
Structural O
effects O
of O
in O
vivo O
inhibition O
of O
microglial O
phagocytosis O
. O

P20 O
somatamice O
were O
injected O
intravitreally O
in O
one O
eye O
with O
the O
phagocytosis O
inhibitor O
cRGD, B-proteingene
and O
in O
the O
control O
contralateral O
eye O
with O
the O
inactive O
analogue, O
cRAD. B-proteingene
At O
P23, O
prominent O
microglia O
infiltration O
in O
the O
ONL O
observed O
in O
control-injected O
eyes O
(C) O
was O
decreased O
in O
the O
contralateral O
cRGD-injected B-proteingene
eyes O
(D) O
. O

ONLmicroglia O
in O
control O
eyes O
demonstrated O
more O
numerous O
phagosomes O
(inset, O
arrows) O
(E) O
compared O
with O
cRGD-injected B-proteingene
eyes O
(F) O
. O

Pairwise O
comparisons O
of O
control- O
vs. O
cRGD-injected B-proteingene
eyes O
demonstrated O
that O
phagocytosis O
inhibition O
significantly O
reduced O
the O
densities O
of O
infiltrating O
microglia O
(G) O
and O
microglialphagosomes O
(H), O
and O
mean O
phagosome O
number O
per O
microglia O
(I) O
. O

ONL O
atrophy O
in O
control O
eyes O
(J) O
was O
more O
advanced O
compared O
to O
cRGD-injected B-proteingene
eyes O
(K), O
with O
significantly O
greater O
mean O
ONL O
thickness O
(L), O
and O
ONLnuclear O
layers O
(M) O
in O
cRGD-injected B-proteingene
eyes O
. O

Mean O
density O
of O
TUNEL+ONLnuclei O
was O
lower, O
with O
marginal O
significance O
(N) O
(n O
= O
13 O
animals; O
measurements O
in O
cRGD-injected B-proteingene
eyes O
normalized O
to O
contralateral O
control O
eyes, O
two-sided O
paired O
t-test) O
. O

Scale O
bar, O
40 O
μm O
. O

O-T O
Functional O
effects O
of O
in O
vivo O
inhibition O
of O
microglial O
phagocytosis O
. O

Representative O
dark-adapted O
ERG O
recordings O
at O
P26 O
(following O
intravitreal O
injections O
at O
P20 O
and O
P23) O
in O
a O
cRGD-injected B-proteingene
eye O
(red) O
relative O
to O
the O
contralateral O
control O
eye O
(black) O
(O) O
showing O
that O
mean O
a- O
(P) O
and O
b-wave O
(Q) O
amplitudes O
were O
significantly O
greater O
in O
the O
cRGD-injected B-proteingene
vs. O
control O
eyes O
at O
higher O
flash O
intensities O
. O

Representative O
light-adapted O
responses O
(R) O
illustrating O
that O
while O
mean O
light-adapted O
a-wave O
amplitudes O
(S) O
were O
slightly O
but O
not O
significantly O
greater O
in O
cRGD-injected B-proteingene
eyes, O
mean O
b-wave O
amplitudes O
(T) O
were O
significantly O
greater O
at O
higher O
flash O
intensities O
(n O
= O
13 O
animals, O
two-sided O
paired O
t-test, O
*P O
< O
0.05, O
with O
exact O
values O
alongside) O
. O

Microglia O
infiltrating O
the O
rd10 O
retina O
upregulate O
IL-1β B-proteingene
expression O
during O
degeneration O
. O

Iba1+microglia O
(green) O
were O
immunonegative O
for O
IL-1β B-proteingene
(red) O
at O
P18 O
but O
become O
prominently O
IL-1β B-proteingene
immunopositive O
at O
P22 O
(arrows) O
. O

Scale O
bars, O
25 O
μm O
. O

Depletion O
of O
infiltrating O
microglia O
in O
the O
rd10retina O
decreases O
IL-1β B-proteingene
levels O
. O

Cytokine O
levels O
in O
rd10/CreDTAmouseretinas B-proteingene
were O
assayed O
following O
tamoxifen-induced O
microglial O
depletion O
(from O
P21 O
to O
P37-50, O
green O
bars; O
n O
= O
9 O
animals) O
and O
compared O
with O
their O
untreated O
littermate O
controls O
(white O
bars, O
n O
= O
8 O
animals; O
values O
normalized O
to O
control O
animals O
in O
the O
same O
litter) O
. O

IL-1β B-proteingene
protein O
levels O
were O
significantly O
lowered O
following O
microglial O
depletion, O
but O
IL-6, B-proteingene
CCL2, B-proteingene
or O
TNFα B-proteingene
were O
not O
significantly O
changed O
. O

Inhibition O
of O
microglial O
phagocytosis O
results O
in O
decreased O
microglialIL-1β O
expression O
. O

Eyes O
of O
rd10 O
animals O
were O
treated O
with O
intravitreal O
injections O
of O
cRGD B-proteingene
at O
P20, O
and O
analyzed O
at O
P23 O
by O
immunohistochemistry O
for O
Iba1 B-proteingene
(green) O
and O
IL-1β B-proteingene
(red), O
and O
compared O
to O
uninjected O
eyes O
and O
with O
eyes O
injected O
with O
inactive O
analog, O
cRAD B-proteingene
(n O
= O
3 O
eyes O
in O
each O
category) O
. O

Immunopositivity O
was O
high O
in O
infiltrating O
microglia O
(indicated O
by O
arrows) O
for O
untreated O
and O
cRAD-injected B-proteingene
control O
eyes O
and O
significantly O
reduced O
in O
microglia O
in O
cRGD-injected B-proteingene
eyes O
(upper O
panel), O
as O
demonstrated O
by O
the O
quantification O
of O
IL-1β B-proteingene
expression O
(area O
of O
immunopositivity O
as O
a O
fraction O
of O
the O
ONL) O
(lower O
left O
panel) O
. O

ONL O
thickness O
correlated O
negatively O
with O
the O
extent O
of O
IL-1β B-proteingene
immunopositivity O
(lower O
right O
panel) O
. O

Scale O
bar, O
25 O
μm O
. O

IL-1R B-proteingene
signaling O
during O
rod O
degeneration O
was O
inhibited O
by O
intravitreal O
injections O
of O
recombinant O
IL-1 O
receptor O
antagonist, O
anakinra B-proteingene
(from O
P20-22 O
to O
P26-27) O
in O
one O
eye O
of O
each O
rd10 O
animal, O
while O
the O
contralateral O
eye O
was O
injected O
with O
PBS O
as O
a O
control O
. O

Upper O
panels O
show O
representative O
retinal O
sections O
from O
control O
PBS-injected O
and O
IL-1RA-injected B-proteingene
eyes O
from O
the O
same O
animal O
. O

ONL O
atrophy O
in O
control O
eyes O
was O
more O
advanced O
compared O
to O
IL-1RA-injected B-proteingene
eyes, O
with O
greater O
mean O
ONL O
thickness O
and O
lower O
mean O
density O
of O
TUNEL+ONLnuclei O
in O
IL-1RA-injected B-proteingene
eyes O
(lower O
panels) O
(n O
= O
15 O
animals; O
measurements O
in O
IL-1RA-injected B-proteingene
eyes O
normalized O
to O
contralateral O
control O
eyes, O
paired O
t-test) O
. O

Scale O
bar, O
25 O
μm O
. O

About O
25 O
μg O
of O
membrane‐enriched O
lysate O
from O
the O
mass O
spectrometry O
experiments O
was O
immunoblotted O
with O
anti‐PINK1 B-proteingene
antibody O
. O

TOMM40 B-proteingene
and O
GAPDH B-proteingene
serve O
as O
markers O
for O
mitochondria O
and O
cytoplasm, O
respectively O
. O

A-C O
Confirmation O
by O
mass O
spectrometry O
that O
Rab8A B-proteingene
(A), O
Rab8B B-proteingene
(B) O
and O
Rab13 B-proteingene
(C) O
Ser111 O
is O
phosphorylated O
upon O
PINK1 B-proteingene
activation O
after O
CCCP O
treatment O
. O

Flp‐In O
T‐Rex O
HEK293 O
cells O
expressing O
empty‐FLAG, B-proteingene
WT O
PINK1‐FLAG B-proteingene
and O
KI O
(D384A) O
PINK1‐FLAG B-proteingene
were O
transfected O
either O
with O
HA‐Rab8A B-proteingene
(A), O
HA‐Rab8B B-proteingene
(B) O
or O
HA‐Rab13 B-proteingene
(C) O
induced O
with O
doxycycline O
and O
stimulated O
with O
10 O
μM O
of O
CCCP O
for O
3 O
h. O
Whole‐cell O
lysates O
(10 O
mg) O
were O
immunoprecipitated O
with O
anti‐HAagarose, O
resolved O
by O
SDS-PAGE O
and O
stained O
with O
colloidal O
Coomassie O
blue O
(second O
panel) O
. O

Coomassie‐stained O
bands O
migrating O
with O
expected O
molecular O
mass O
of O
HA‐Rabs B-proteingene
were O
excised, O
in‐gel O
digested O
with O
trypsin O
and O
subjected O
to O
high‐performance O
liquid O
chromatography O
with O
LC‐MS/MS O
on O
an O
LTQ‐Orbitrap O
mass O
spectrometer O
. O

Upper O
panel O
shows O
the O
extracted O
ion O
chromatogram O
(XIC) O
analysis O
of O
Ser111‐containing O
phosphopeptides O
(8A, O
NIEEHApSADVEK; O
8B, O
NIEEHApSSDVER; O
13, O
SIKENApSAGVER) O
with O
the O
combined O
signal O
intensity O
of O
the O
2+ O
and O
3+ O
forms O
of O
the O
peptide O
indicated O
on O
the O
y‐axis O
. O

Note O
that O
the O
Ser111 O
phosphopeptide O
was O
only O
detected O
in O
samples O
from O
WT O
PINK1‐FLAG‐expressing B-proteingene
cells O
following O
CCCP O
stimulation O
. O

D O
Characterisation O
of O
Rab8A, B-proteingene
Rab8B B-proteingene
and O
Rab13 B-proteingene
phospho‐Ser111 O
antibodies O
. O

Flp‐In O
T‐Rex O
HEK293 O
cells O
expressing O
empty‐FLAG, B-proteingene
WT O
PINK1‐FLAG B-proteingene
and O
KI O
(D384A) O
PINK1‐FLAG B-proteingene
were O
transfected O
with O
either O
WT O
or O
Ser111Ala‐mutant O
(S111A) O
HA‐Rab8A, B-proteingene
HA‐Rab8B B-proteingene
or O
HA‐Rab13, B-proteingene
induced O
with O
doxycycline O
and O
stimulated O
with O
10 O
μM O
of O
CCCP O
for O
3 O
h. O
Whole‐cell O
lysates O
(0.25 O
mg) O
were O
immunoprecipitated O
with O
anti‐HAagarose O
and O
immunoblotted O
with O
Rab8A, B-proteingene
Rab8B B-proteingene
or O
Rab13 B-proteingene
phospho‐Ser111 O
antibodies O
. O

Part O
of O
the O
immunoprecipitates O
was O
used O
to O
immunoblot O
for O
HA B-proteingene
antibody O
as O
loading O
controls O
. O

PINK1 B-proteingene
is O
essential O
for O
CCCP‐mediated O
Rab8A B-proteingene
Ser111 O
phosphorylation O
. O

WT O
and O
PINK1 B-proteingene
KO O
HeLa O
cells O
were O
transfected O
with O
either O
WT O
or O
Ser111Ala O
(S111A) O
mutant O
constructs O
of O
HA‐Rab8A, B-proteingene
HA‐Rab8B B-proteingene
or O
HA‐Rab13 B-proteingene
. O

Some O
PINK1 B-proteingene
KO O
HeLa O
cells O
were O
reintroduced O
with O
PINK1 B-proteingene
by O
transfection O
of O
WT O
PINK1‐3xFLAG B-proteingene
or O
KI O
(D384A) O
PINK1‐3xFLAG B-proteingene
as O
indicated O
. O

After O
transfection O
for O
at O
least O
24 O
h, O
cells O
were O
treated O
with O
DMSO O
as O
a O
vehicle O
control O
or O
CCCP O
for O
20 O
h. O
Whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐HA B-proteingene
agarose O
and O
immunoblotted O
with O
Rab8A, B-proteingene
Rab8B B-proteingene
or O
Rab13 B-proteingene
phospho‐Ser111 O
antibody O
. O

Part O
of O
the O
immunoprecipitates O
was O
used O
to O
immunoblot O
for O
HA B-proteingene
antibody O
as O
loading O
controls O
. O

For O
the O
lower O
panel, O
whole‐cell O
lysates O
(30 O
μg) O
were O
immunoblotted O
with O
total O
PINK1 B-proteingene
antibody O
to O
confirm O
PINK1 B-proteingene
expression O
and O
with O
GAPDH B-proteingene
as O
loading O
controls O
. O

Endogenous O
Rab8A B-proteingene
Ser111 O
phosphorylation O
is O
PINK1 B-proteingene
dependent O
. O

WT O
and O
PINK1 B-proteingene
KO O
HeLa O
cells O
were O
treated O
with O
DMSO O
as O
a O
vehicle O
control O
or O
CCCP O
for O
20 O
h. O
Some O
PINK1 B-proteingene
KO O
HeLa O
cells O
were O
reintroduced O
with O
PINK1 B-proteingene
by O
transfection O
of O
WT O
PINK1‐3xFLAG B-proteingene
or O
KI O
(D384A) O
PINK1‐3xFLAG B-proteingene
as O
indicated O
for O
at O
least O
24 O
h O
before O
CCCP O
treatment O
. O

Whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐Rab8A B-proteingene
pre‐bound O
with O
protein O
A O
agarose O
followed O
by O
immunoblot O
with O
Rab8A B-proteingene
phospho‐Ser111 O
antibody O
. O

Part O
of O
the O
immunoprecipitates O
was O
used O
to O
immunoblot O
with O
anti‐total O
Rab8A B-proteingene
antibody O
as O
loading O
controls O
. O

Absence O
of O
Rab8A B-proteingene
Ser111 O
phosphorylation O
in O
human O
mutant O
PINK1patientfibroblasts B-proteingene
. O

Primary O
skinfibroblasts O
were O
derived O
from O
a O
patient O
with O
homozygous O
PINK1 B-proteingene
Q456X O
mutation O
or O
unaffected O
control O
. O

Cells O
were O
incubated O
with O
DMSO O
or O
CCCP O
for O
20 O
h, O
and O
whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐Rab8A B-proteingene
antibody O
conjugated O
to O
protein O
A O
agarose O
and O
immunoblotted O
with O
total O
or O
Rab8A B-proteingene
phospho‐Ser111 O
antibody O
. O

Lysates O
(1 O
mg) O
were O
also O
subjected O
to O
immunoprecipitation O
with O
polyclonal O
anti‐PINK1 B-proteingene
antibody O
and O
immunoblotted O
with O
monoclonal O
PINK1 B-proteingene
antibody O
. O

Equal O
loading O
of O
protein O
extracts O
was O
confirmed O
by O
GAPDH B-proteingene
. O

Absence O
of O
Rab8A B-proteingene
Ser111 O
phosphorylation O
in O
PINK1 B-proteingene
knockout O
MEFs O
. O

MEFs O
were O
derived O
from O
PINK1 B-proteingene
knockout O
embryos O
or O
wild‐type O
controls O
(see O
Materials O
and O
Methods) O
. O

Cells O
were O
incubated O
with O
DMSO O
or O
CCCP O
for O
20 O
h, O
and O
whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐Rab8A B-proteingene
antibody O
conjugated O
to O
protein O
A O
agarose O
and O
immunoblotted O
with O
total O
or O
Rab8A B-proteingene
phospho‐Ser111 O
antibody O
. O

Lysates O
(1 O
mg) O
were O
also O
subjected O
to O
immunoprecipitation O
with O
a O
polyclonal O
anti‐mouse‐specific O
PINK1 B-proteingene
antibody O
and O
immunoblotted O
with O
a O
different O
anti‐mouse‐specific O
PINK1 B-proteingene
antibody O
. O

Equal O
loading O
of O
protein O
extracts O
was O
confirmed O
by O
GAPDH B-proteingene
. O

Rab8A B-proteingene
is O
not O
required O
for O
the O
activation O
of O
Parkin B-proteingene
E3 O
ligase O
activity O
at O
mitochondria O
in O
response O
to O
PINK1 B-proteingene
activation O
by O
CCCP O
Wild‐type O
(WT) O
or O
Rab8A B-proteingene
knockout O
(KO) O
HeLa O
cells O
were O
transfected O
with O
WT O
or O
Cys431Phe O
(C341F)‐mutant O
Parkin B-proteingene
. O

After O
transfection O
for O
24 O
h, O
cells O
were O
treated O
with O
DMSO O
as O
a O
vehicle O
control O
or O
10 O
μM O
CCCP O
for O
6 O
h. O
Mitochondrial O
enriched O
extracts O
(mitochondrial O
lysate) O
were O
incubated O
with O
ubiquitin‐binding O
resins O
derived O
from O
his‐halo‐ubiquilin1 B-proteingene
UBA O
domain O
tetramer O
(UBAUBQLN1) O
. O

Captured O
ubiquitylated O
proteins O
were O
subject O
to O
immunoblotting O
with O
anti‐CISD1 B-proteingene
and O
anti‐mitofusin B-proteingene
2 I-proteingene
antibodies O
. O

Mitochondrial O
lysate O
and O
total O
lysate O
were O
also O
subjected O
to O
immunoblotting O
with O
indicated O
antibodies O
for O
loading O
and O
protein O
expression O
controls O
. O

Phospho‐Ser111Rab8A B-proteingene
was O
detected O
after O
Rab8Aimmunoprecipitation B-proteingene
from O
200 O
μg O
of O
mitochondrial O
lysate O
with O
anti‐Rab8A B-proteingene
antibody O
. O

In O
vitro O
phosphorylation O
analysis O
of O
Rab8A B-proteingene
by O
PINK1 B-proteingene
. O

WT O
or O
S111A‐mutant O
Rab8A B-proteingene
(1.2 O
μg) O
was O
incubated O
in O
the O
presence O
of O
MBP‐fused B-proteingene
WT O
or O
KI O
(D359A) O
TcPINK1 B-proteingene
(1.1 O
μg) O
and O
Mg2+‐[γ‐32P] O
ATP O
for O
the O
indicated O
time O
. O

Samples O
were O
subjected O
to O
SDS-PAGE, O
and O
proteins O
were O
detected O
by O
colloidal O
Coomassie O
blue O
staining O
(lower O
panel) O
. O

The O
[γ‐32P] O
incorporation O
to O
substrate O
was O
detected O
by O
autoradiography O
(upper O
panel) O
. O

Cerenkov O
counting O
was O
used O
to O
calculate O
the O
stoichiometry O
of O
substrate O
phosphorylation O
as O
mol O
of O
[γ‐32P] O
incorporation/mol O
of O
substrate O
. O

Ubiquitin B-proteingene
was O
used O
as O
a O
positive O
control O
of O
the O
TcPINK1 B-proteingene
substrate O
. O

Time‐course O
comparison O
of O
PINK1‐mediated B-proteingene
Rab8A, B-proteingene
Rab8B B-proteingene
and O
Rab13 B-proteingene
Ser111 O
phosphorylation O
vs. O
Parkin B-proteingene
Ser65 O
phosphorylation O
. O

Flp‐In O
T‐Rex O
HEK293 O
cells O
expressing O
WT O
PINK1‐FLAG B-proteingene
were O
transfected O
with O
either O
WT O
or O
Ser111Ala‐(S111A) O
mutant O
HA‐Rab8A, B-proteingene
HA‐Rab8B B-proteingene
or O
HA‐Rab13, B-proteingene
induced O
with O
doxycycline O
and O
stimulated O
with O
CCCP O
for O
the O
indicated O
time O
. O

In O
parallel, O
Flp‐In O
T‐Rex O
HEK293 O
cells O
expressing O
WT O
PINK1‐FLAG B-proteingene
were O
transfected O
with O
either O
WT O
or O
Ser65 O
Ala O
(S65A)‐mutant O
Parkin B-proteingene
. O

Whole‐cell O
lysates O
(0.25 O
mg) O
were O
immunoprecipitated O
with O
anti‐HAagarose O
and O
immunoblotted O
with O
indicated O
phospho‐Ser111 O
antibodies O
. O

Part O
of O
the O
immunoprecipitates O
was O
used O
to O
immunoblot O
for O
HA B-proteingene
antibody O
as O
loading O
controls O
. O

For O
the O
lower O
panel, O
whole‐cell O
lysates O
(30 O
μg) O
were O
immunoblotted O
with O
indicated O
antibodies O
. O

Time‐course O
comparison O
of O
endogenous O
PINK1‐mediated B-proteingene
Rab8A, B-proteingene
Rab8B B-proteingene
and O
Rab13 B-proteingene
Ser111 O
phosphorylation O
vs. O
Parkin B-proteingene
Ser65 O
phosphorylation O
. O

HeLa O
cells O
were O
transfected O
with O
either O
WT O
or O
S111A‐mutant O
HA‐Rab8A, B-proteingene
HA‐Rab8B B-proteingene
or O
HA‐Rab13 B-proteingene
for O
at O
least O
24 O
h O
before O
CCCP O
treatment O
for O
the O
indicated O
time O
. O

Whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐HAagarose O
and O
immunoblotted O
with O
indicated O
phospho‐Ser111 O
antibodies O
. O

In O
parallel, O
HeLa O
cells O
were O
transfected O
with O
either O
WT O
or O
S65A‐mutant O
Parkin B-proteingene
and O
whole‐cell O
lysates O
(30 O
μg) O
were O
immunoblotted O
with O
indicated O
antibodies O
. O

Rabin8‐catalysed B-proteingene
mant‐GDP O
release O
from O
mant‐GDP O
loaded O
WT, O
S111A O
and O
S111E O
mutants O
of O
Rab8A. B-proteingene
The O
Rab O
proteins O
(1 O
μM) O
were O
incubated O
with O
100 O
μM O
GDP O
in O
buffer O
(20 O
mM O
HEPES O
pH O
7.5, O
50 O
mM O
NaCl, O
1 O
mM O
MgCl2, O
2 O
mM O
DTE), O
and O
the O
reaction O
was O
started O
by O
the O
addition O
of O
0.5 O
μM O
Rabin8 B-proteingene
. O

The O
decrease O
in O
mant O
fluorescence O
was O
used O
as O
a O
measure O
of O
mantGDP O
release O
. O

Rab8A B-proteingene
Ser111 O
phosphorylation O
impairs O
Rabin8 B-proteingene
interaction O
in O
cells O
. O

Rab8A B-proteingene
KO O
HeLa O
cells O
were O
transfected O
with O
wild‐type O
(WT), O
S111E O
or O
S111A O
HA‐Rab8A. B-proteingene
Whole‐cell O
lysates O
(1 O
mg) O
were O
immunoprecipitated O
with O
anti‐HAagarose O
and O
immunoblotted O
with O
Rabin8 B-proteingene
or O
anti‐HA B-proteingene
antibody O
. O

Lysates O
were O
immunoblotted O
with O
Rabin8 B-proteingene
or O
anti‐HA B-proteingene
antibody O
to O
confirm O
equivalent O
expression O
of O
Rabin8 B-proteingene
and O
WT O
and O
mutant O
HA‐Rab8A B-proteingene
in O
extracts O
. O

(A) O
GalNAc-T O
expression O
levels O
in O
humanliver O
(The O
body O
map O
data O
for O
humanliver O
was O
kindly O
provided O
by O
the O
"Gene O
Expression O
Applications O
research O
group O
at O
Illumina", O
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/) O
and O
HepG2 O
wild O
type O
cells O
quantified O
by O
RNAseq O
(n=2, O
bars O
representing O
mean O
with O
SD) O
. O

(B) O
VVAlectinimmunoblot B-proteingene
of O
secretomes O
from O
HepG2 O
SC, O
SCΔT1, B-proteingene
SCΔT2 B-proteingene
and O
SCΔT3 B-proteingene
. O

Histograms O
showing O
the O
distribution O
of O
M/L O
quantitation O
ratios O
of O
monoglycosylated O
peptides O
identified O
in O
(A) O
HepG2SCΔT1, O
(B) O
ΔT2 B-proteingene
and O
(C) O
+T3 B-proteingene
. O

Glycopeptides O
with O
M/L O
ratio O
< O
-1 O
are O
colored O
red O
and O
glycopeptides O
with O
a O
M/L O
ratio O
> O
+1 O
are O
colored O
green O
. O

(D) O
Venn O
diagram O
showing O
the O
distribution O
of O
candidates O
for O
isoform-specific O
sites O
among O
HepG2SCΔT1, O
T2 B-proteingene
and O
+T3 B-proteingene
applying O
a O
log10 O
(+/-1) O
cut-off O
(excluding O
sites O
identified O
in O
both O
TCL O
and O
SEC O
for O
each O
isoform), O
and O
(E) O
TCL O
alone O
and O
(F) O
SEC O
alone O
. O

Polygon O
distribution O
of O
biological O
tissues O
compared O
with O
Voronoi O
diagrams O
. O

A) O
Segmentation O
of O
a O
Drosophila O
prepupawing O
imaginal O
discepithelium O
(dWP) O
. O

B) O
Adult O
Biceps O
(BCA) O
biopsy O
stained O
with O
anti-collagen B-proteingene
VI I-proteingene
(green) O
and O
anti-Myosin O
Heavy O
Chain O
(red) O
antibodies O
. O

C) O
Segmentation O
of O
the O
image O
showed O
in O
(B) O
. O

D) O
Segmented O
image O
from O
a O
chickenembryoneural O
tubeepithelium O
(cNT) O
. O

E) O
Polygon O
distribution O
of O
the O
different O
biological O
tissues O
analysed O
. O

Two O
types O
of O
distribution O
can O
be O
distinguished: O
The O
Poisson O
Voronoi O
polygon O
distribution O
for O
Diagram O
1 O
(D1) O
and O
cNT, O
and O
the O
conserved O
polygon O
distribution O
for O
the O
rest O
of O
image O
categories O
. O

The O
CVT O
path O
matches O
the O
polygon O
distribution O
of O
natural O
tissues O
. O

A) O
Polygon O
distribution O
Voronoi O
diagrams O
resulting O
from O
the O
iterative O
application O
of O
Lloyd´s O
algorithm O
. O

B-E) O
Density O
plot O
showing O
the O
frequency O
of O
a O
value O
for O
four, O
five, O
seven O
and O
eight O
sided O
cells O
respectively, O
depending O
of O
the O
percentage O
of O
hexagons O
(P6) O
in O
the O
CVT O
diagrams O
. O

The O
darker O
region O
reflects O
the O
higher O
probability O
of O
a O
determine O
value O
. O

Coloured O
circles O
represent O
the O
average O
values O
of O
each O
polygon O
class O
for O
the O
different O
sets O
of O
images O
analysed O
in O
this O
study O
. O

dWL, O
Drosophila O
larvawing O
disc, O
light O
green O
. O

dMWP, O
Drosophila O
mutant O
wing O
disc, O
violet O
. O

EYE, O
Drosophila O
eye O
disc, O
orange O
. O

BCA, O
biceps O
control O
adult, O
dark O
green O
. O

BNA, O
biceps O
neurogenic O
atrophy, O
dark O
blue O
. O

Relationship O
between O
area O
and O
polygon O
distribution O
. O

A) O
Area O
distribution O
of O
several O
Voronoi O
diagrams O
along O
the O
CVT O
path O
. O

Cell O
areas O
became O
progressively O
more O
homogeneous O
after O
each O
Lloyd O
iteration O

B) O
Comparison O
of O
area O
distribution O
for O
proliferating O
epithelia O
cNT O
(blue), O
dWL O
(green) O
and O
dWP O
(red) O
. O

At O
the O
right O
of O
the O
image O
Biceps O
(green) O
and O
Diagram O
5 O
(grey) O
images O
. O

A) O
Segmentation O
of O
a O
prepupaleye O
imaginal O
disc O
from O
Drosophila O
(anterior O
to O
the O
left) O
. O

The O
analysed O
developing O
photoreceptors O
are O
labelled O
in O
green O
. O

The O
cells O
adjacent O
to O
the O
photoreceptors O
are O
labelled O
in O
blue O
(these O
are O
"cone O
cells" O
in O
the O
most O
posterior O
clusters) O
. O

B) O
Segmentation O
of O
a O
prepupawing O
imaginal O
discepithelium O
where O
myosin B-proteingene
II I-proteingene
levels O
have O
been O
reduced O

. O

C) O
Adult O
Biceps O
biopsy O
from O
a O
patient O
with O
neurogenic O
atrophy O
pathology O
. O

Fibres O
outlined O
with O
collagen B-proteingene
VI I-proteingene
antibody O
(green) O
. O

D) O
Segmentation O
of O
the O
image O
showed O
in O
(C) O
highlighting O
two O
atrophic O
elongated O
fibres O
that O
present O
seven O
neighbours O
. O

. O

A) O
Diagram O
resulting O
from O
a O
vertex O
model O
simulation O
that O
includes O
cell O
proliferation O
. O

B) O
Diagram O
resulting O
from O
a O
vertex O
model O
simulation O
that O
includes O
cell O
proliferation O
and O
heterogeneous O
reduction O
of O
line O
tension O
among O
the O
tissuecells O
. O

C) O
Diagram O
resulting O
from O
a O
vertex O
model O
simulation O
with O
heterogeneous O
reduction O
of O
line O
tension O
and O
an O
impairment O
of O
the O
cell O
division O
when O
tension O
value O
is O
under O
the O
30 O
percent O
of O
the O
initial O
value O
D) O
Similar O
simulation O
than O
in O
(C) O
with O
a O
threshold O
of O
40 O
percent O
. O

E-H) O
Density O
plot O
showing O
the O
frequency O
of O
a O
value O
for O
four, O
five, O
seven O
and O
eight O
sided O
cells O
respectively, O
depending O
of O
the O
percentage O
of O
hexagons O
(P6) O
in O
the O
CVT O
diagrams O
. O

The O
values O
for O
the O
individual O
myosin B-proteingene
mutant O
images O
(violet) O
and O
the O
individual O
diagrams O
of O
the O
four O
simulations O
(light O
grey, O
grey, O
light O
pink O
and O
pink) O
are O
shown O
in O
each O
plot O
. O

The O
average O
value O
for O
each O
simulation O
is O
shown O
with O
a O
black O
circumference O
. O

Computer O
simulations O
indicate O
that O
changes O
to O
homogeneous O
resting O
areas O
are O
able O
to O
alter O
cell O
topology O
. O

A) O
Diagram O
resulting O
from O
a O
vertex O
model O
simulation O
with O
homogeneous O
parameters O
for O
contractility, O
line O
tension O
and O
ideal O
area O
. O

B) O
Diagram O
resulting O
from O
a O
vertex O
model O
simulation O
where O
in O
ten O
percent O
of O
the O
cells O
(grey) O
the O
line O
tension O
and O
ideal O
area O
parameters O
were O
reduced O
C) O
Control O
diagram O
where O
in O
the O
ten O
percent O
of O
the O
cells O
(blue) O
only O
line O
tension O
parameter O
was O
reduced O

D) O
Comparison O
of O
polygon O
distribution O
for O
the O
10% O
smallest O
cells O
from O
BCA O
(green O
bar) O
and O
Control O
Simulation O
(grey O
bar) O
with O
the O
sick O
cells O
from O
BNA O
(light O
blue O
bar) O
and O
Atrophy O
Simulation O
(grey O
cells O
from O
(B), O
purple O
bar) O
. O

Figure O
1 O
. O

CHCHD10 B-proteingene
resides O
in O
the O
same O
complex O
than O
Mitofilin, B-proteingene
CHCHD3 B-proteingene
and O
CHCHD6 B-proteingene
. O

A. O
Second O
dimension O
of O
the O
Blue-Native O
(BN) O
PAGE O
showing O
that O
CHCHD10 B-proteingene
migrates O
with O
the O
MICOS O
protein O
subunits O
Mitofilin, B-proteingene
CHCHD3 B-proteingene
and O
CHCHD6 B-proteingene
in O
isolated O
mitochondria O
from O
mousebrain O

B. O
BN-PAGE O
of O
the O
MICOS O
and O
OXPHOS O
complexes O
in O
control O
(C) O
and O
patient O
(P1, O
P2) O
fibroblasts O
. O

Complexes O
I O
to O
IV O
of O
OXPHOS O
were O
detected O
with O
the O
39kDa O
subunit O
antibody O
(CI), O
70kDa O
subunit O
antibody O
(CII), O
core O
I O
antibody O
(CIII) O
and O
cytochrome B-proteingene
c I-proteingene
oxidase I-proteingene
subunit I-proteingene
I I-proteingene
antibody O
(CIV) O
. O

MICOS O
complex O
was O
detected O
with O
an O
anti-Mitofilin B-proteingene
antibody O
. O

C. O
Second O
dimension O
of O
the O
BN-PAGE O
showing O
that O
the O
steady-state O
levels O
of O
assembled O
CHCHD10 B-proteingene
in O
MICOS O
complex O
are O
decreased O
in O
patientfibroblasts O
. O

D. O
Analysis O
of O
OXPHOS O
supercomplexes O
in O
control O
and O
patientfibroblasts O
. O

BN-PAGE O
from O
isolated O
mitochondria O
permeabilized O
with O
6g/g O
(w/v) O
of O
digitoninimmunoblotted O
on O
PVDF O
membrane O
and O
incubated O
with O
the O
indicated O
antibodies O
. O

SC, O
supercomplexes O
I+III2+IVn O
. O

The O
dividing O
lines O
correspond O
to O
gels O
sections O
visible O
in O
the O
raw O
data O
file O
. O

Figure O
2 O
. O

Interaction O
of O
CHCHD10 B-proteingene
with O
components O
of O
MICOS O
complex O
. O

A. O
Co-immunonoprecipitation O
(IP) O
of O
endogenous O
mitofilin, B-proteingene
CHCHD10 B-proteingene
and O
CHCHD3 B-proteingene
in O
control O
and O
patientfibroblasts O
(1mg O
of O
total O
extracts O
were O
used O
for O
each O
IP O
(left O
lower O
panel) O
and O
200µg O
were O
used O
for O
the O
input O
(left O
upper O
panel)) O
. O

The O
same O
results O
were O
found O
in O
P2 O
fibroblasts O
(not O
shown) O
. O

Reverse O
co-IP O
experiment O
in O
HeLa O
cells O
with O
an O
antibody O
against O
CHCHD10 B-proteingene
(right O
lower O
panel) O
. O

1mg O
of O
total O
extracts O
were O
used O
for O
each O
IP O
and O
200µg O
were O
used O
for O
the O
input O
(right O
upper O
panel) O
. O

The O
dividing O
lines O
correspond O
to O
gels O
sections O
visible O
in O
the O
raw O
data O
file O
. O

B. O
Duolink O
proximity O
ligation O
assay O
between O
Mitofilin B-proteingene
and O
CHCHD10 B-proteingene
(upper O
panels) O
and, O
CHCHD10 B-proteingene
and O
CHCHD6 B-proteingene
(lower O
panels) O
in O
control O
and O
patientfibroblasts O
observed O
by O
confocal O
microscopy O
. O

Mitochondria O
were O
stained O
with O
Mitotracker O
. O

Duolink O
spots O
per O
cell O
were O
quantified O
for O
30 O
randomly-selected O
individual O
cells O
per O
each O
studied O
fibroblast O
cell O
line O
from O
2 O
independent O
experiments O
. O

Differences O
between O
the O
cell O
lines O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
extremely O
significant O
(***: O
p=0.0001) O
. O

Scale O
bar O
= O
10 O
µm O
. O

Figure O
3 O
. O

Decrease O
of O
nucleoid O
number O
without O
mtDNA O
depletion O
in O
patientfibroblasts O
. O

A. O
In O
control O
and O
patientfibroblasts, O
nucleoids O
were O
labeled O
with O
an O
antibody O
against O
DNA O
and O
mitochondria O
were O
stained O
with O
Mitotracker O
. O

Image O
analysis O
was O
performed O
by O
confocal O
microscopy O
. O

Scale O
bar: O
10 O
µm O
. O

B-C. O
The O
average O
number O
(B) O
and O
size O
(C) O
of O
nucleoids, O
labeled O
with O
antibodies O
against O
DNA O
shown O
in O
A, O
were O
quantified O
for O
35 O
randomly-selected O
individual O
cells O
per O
each O
studied O
fibroblast O
cell O
line O
from O
2 O
independent O
experiments O
. O

Differences O
between O
the O
cell O
lines O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
extremely O
significant O
(***: O
p<0.001) O
. O

Nucleoid O
number O
(B): O
patient O
1 O
versus O
control O
***: O
p=0.0001, O
patient O
2 O
versus O
control O
***: O
p=0.001 O
. O

Nucleoid O
size O
(C): O
patient O
1 O
versus O
control O
***: O
p=0.0001 O
. O

D. O
Mitochondrial O
DNA O
content O
in O
control O
and O
patientfibroblasts O
was O
quantified O
by O
real-time O
PCR. O
Data O
were O
expressed O
as O
ratio O
between O
mtDNA O
and O
nuclear O
DNA O
concentration O
. O

Results O
represent O
the O
mean O
of O
relative O
PCR O
± O
SD O
of O
3 O
independent O
experiments O
. O

Statistical O
analysis O
were O
performed O
by O
Student O
's O
t-test O
(two-sided) O
. O

Figure O
4 O
. O

Decrease O
of O
nucleoid O
number O
without O
mtDNA O
depletion O
in O
HeLa O
cells O
overexpressing O
the O
CHCHD10S59L B-proteingene
and O
CHCHD10P34S B-proteingene
alleles O
. O

A. O
Transfections O
were O
performed O
with O
empty O
vector O
(EV) O
or O
vectors O
encoding O
wild-type O
CHCHD10-FLAG B-proteingene
(WT), O
CHCHD10-FLAG B-proteingene
(S59L) O
or O
CHCHD10-FLAG B-proteingene
(P34S) O
mutants O
. O

Mitochondria O
were O
stained O
with O
Mitotracker O
. O

Cells O
overexpressing O
wild-type O
and O
mutant O
CHCHD10 B-proteingene
were O
labeled O
with O
FLAG B-proteingene
antibodies O
. O

Nucleoids O
were O
visualized O
with O
an O
antiserum O
against O
DNA. O
Image O
analysis O
was O
performed O
by O
confocal O
microscopy O
. O

Scale O
bar: O
10 O
µm O
. O

B-C. O
The O
average O
number O
(B) O
and O
size O
(C) O
of O
nucleoids, O
labeled O
with O
antibodies O
against O
DNA O
shown O
in O
A, O
were O
quantified O
for O
35 O
randomly-selected O
individual O
cells O
per O
each O
studied O
cell O
line O
from O
2 O
independent O
experiments O
. O

Differences O
between O
the O
cell O
lines O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
very O
significant O
(**: O
p=0.0280) O
or O
extremely O
significant O
(***: O
p=0.0001) O
. O

D. O
Mitochondrial O
DNA O
content O
was O
quantified O
by O
real-time O
PCR. O
Data O
were O
expressed O
as O
ratio O
between O
mtDNA O
and O
nDNA O
concentration O
. O

Results O
represent O
the O
mean O
of O
relative O
PCR O
± O
SD O
of O
3 O
independent O
experiments O
. O

Statistical O
analysis O
were O
performed O
by O
Student O
's O
t-test O
(two-sided) O
. O

Figure O
5 O
. O

Nucleoid O
disorganization O
in O
patientfibroblasts O
leading O
to O
a O
defect O
in O
mtDNA O
repair O
under O
conditions O
of O
oxidative O
stress O
. O

A. O
Total O
extracts O
from O
control O
(C) O
fibroblasts O
and O
intact O
isolated O
mitochondria O
from O
control O
and O
patientfibroblasts O
(P1, O
P2) O
were O
analyzed O
by O
immunoblotting O
using O
antibodies O
against O
PCNA B-proteingene
(nuclear O
protein), O
GAPDH B-proteingene
(cytosolic O
protein) O
or O
SMAC B-proteingene
(mitochondrial O
intermembrane O
space O
protein) O
(upper O
panel) O
. O

Mitochondria O
from O
patient O
and O
control O
fibroblasts O
were O
incubated O
with O
NP-40 O
and O
separated O
into O
pellets O
(P) O
and O
supernatants O
(S) O
. O

The O
fractions O
of O
each O
extraction O
were O
subjected O
to O
western O
blot O
analysis O
. O

VDAC B-proteingene
and O
SMAC B-proteingene
were O
used O
to O
identify O
behaviors O
of O
well O
defined O
mitochondrial O
proteins O
that O
are O
integral O
membrane O
and O
soluble O
proteins, O
respectively O
(middle O
panel) O
. O

Ratio O
of O
mtDNA O
amplified O
from O
supernatant/mtDNA O
amplified O
from O
pellet, O
by O
qPCR, O
was O
quantified O
in O
control O
and O
patientfibroblasts O
(lower O
panel) O
. O

B. O
Determination O
of O
the O
mtDNA O
copy O
number O
after O
H2O2 O
treatment O
. O

mtDNA/nDNA O
values O
in O
control, O
patient O
1 O
and O
patient O
2 O
fibroblasts O
. O

mtDNA O
: O
mitochondrial O
DNA, O
nDNA: O
nuclear O
DNA. O
C. O
mtDNA O
repair O
after O
H2O2 O
treatment O
. O

A O
long-range O
PCR O
was O
used O
to O
evaluate O
the O
oxidative O
damage, O
induced O
by O
H2O2 O
treatment, O
in O
mtDNA. O
The O
relative O
PCR O
amplification O
of O
a O
15.6kb O
mtDNA O
fragment O
was O
normalized O
to O
relative O
PCR O
copy O
number O
that O
was O
evaluated O
by O
PCR O
amplification O
of O
a O
172bp O
mtDNA O
fragment O
. O

mtDNA O
repair O
activity O
in O
control, O
patient O
1 O
and O
patient O
2 O
relative O
PCR. O
B-C. O
Cells O
were O
exposed O
to O
150µM O
H2O2 O
for O
30 O
min O
and O
either O
harvested O
immediately O
or O
allowed O
to O
recover O
in O
conditioned O
medium O
for O
the O
indicated O
times O
. O

Untreated O
control O
cultures O
were O
incubated O
in O
serum-free O
medium O
alone O
. O

Results O
represent O
the O
mean O
of O
relative O
PCR O
amplification O
± O
SD O
of O
three O
independent O
experiments O
in O
which O
three O
PCRs O
per O
point O
were O
performed O
. O

Values O
were O
normalized O
to O
untreated O
cells O
and O
differences O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
significant O
(*:0.05>p>0.01), O
very O
significant O
(**:0.01>p>0.001) O
. O

Patient O
1 O
versus O
control: O
*: O
p=0.015 O
(recovery O
1h), O
*: O
p=0.022 O
(recovery O
2h), O
**: O
p=0.003 O
(recovery O
4h) O
. O

Patient O
2 O
versus O
control: O
*: O
p=0.0230 O
(recovery O
2h), O
*: O
p=0.041 O
(recovery O
4h) O
. O

NT: O
cells O
not O
treated O
with O
H2O2 O

Figure O
6 O
. O

No O
autophagy O
inhibition O
(A-C) O
and O
no O
mitophagy O
defect O
(D-E) O
in O
patientfibroblasts O
. O

A. O
Immunoblot O
of O
LC3B-I/-II B-proteingene
expression O
in O
fibroblasts O
of O
patient O
2 O
(1,2), O
patient O
1 O
(3,4) O
and O
control O
individual O
(5,6) O
in O
absence O
(-) O
or O
presence O
(+) O
of O
chloroquine O
(CLQ) O
. O

B. O
Quantitative O
analysis O
of O
LC3B-II/β-tubulin B-proteingene
ratio O
from O
immunoblots O
(n=3) O
. O

C. O
Quantitative O
analysis O
of O
LC3B-II B-proteingene
+ O
CLQ/ O
LC3B-II B-proteingene
- O
CLQ O
ratio O
from O
immunoblots O
(n=3) O
. O

D. O
Confocal O
images O
of O
fibroblasts O
derived O
from O
a O
control, O
patient O
1 O
and O
patient O
2 O
. O

Boxed O
regions O
are O
enlarged O
. O

Scale O
bar: O
20µm O
. O

E. O
Bar O
graph O
showing O
ratios O
of O
fluorescent O
intensity O
of O
mitochondria O
delivered O
to O
lysosomes O
relative O
to O
that O
of O
mitochondria O
present O
in O
the O
cytosol O
(FL O
lyso/FL O
mito O
) O
. O

Statistical O
analysis O
were O
performed O
on O
mean O
± O
SEM O
using O
Student O
's O
t-test O
(two-sided) O
. O

Figure O
7 O
. O

CHCHD10 B-proteingene
mutant O
fibroblasts O
are O
less O
sensitive O
to O
apoptotic O
cell O
death O
compared O
to O
control O
fibroblasts O
. O

A. O
Control O
(C1, O
C2) O
and O
patient O
(P1, O
P2) O
fibroblasts O
were O
treated O
with O
1 O
μM O
of O
staurosporine O
(STS) O
for O
16 O
h. O
Cell O
death O
was O
determined O
by O
flow O
cytometry O
using O
Annexin O
V/DAPI O
staining O
. O

Three O
independent O
experiments O
were O
performed O
per O
condition O
with O
two O
points O
analyzed O
per O
experiment O
. O

Differences O
between O
the O
control O
and O
patientfibroblasts O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
significant O
(*: O
p=0.0116) O
or O
extremely O
significant O
(***: O
p=0.0001) O
. O

B-C. O
Fibroblasts O
were O
treated O
with O
1 O
μM O
STS O
for O
4, O
6 O
or O
16 O
h O
(O/N), O
and O
caspase O
activation O
was O
determined O
either O
by O
western O
blot O
(B) O
assessing O
the O
cleavage O
of O
PARP B-proteingene
and O
the O
caspase B-proteingene
3 I-proteingene
(actin B-proteingene
was O
used O
as O
a O
loading O
control) O

B-C. O
Fibroblasts O
were O
treated O
with O
1 O
μM O
STS O
for O
4, O
6 O
or O
16 O
h O
(O/N), O
and O
caspase O
activation O
was O
determined O
either O
by O
western O
blot O
(B) O
assessing O
the O
cleavage O
of O
PARP O
and O
the O
caspase B-proteingene
3 I-proteingene
(actin O
was O
used O
as O
a O
loading O
control) O
or O
by O
DEVDase O
activity O
measurement O
(C) O
. O

Two O
(B) O
or O
three O
(C) O
independent O
experiments O
were O
performed O
per O
condition O
. O

Differences O
between O
the O
control O
and O
patientfibroblasts O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
extremely O
significant O
(***: O
p=0.0001) O
. O

D-E. O
Mitochondrial O
membrane O
potential O
(ΔΨM) O
was O
measured O
by O
flow O
cytometry O
in O
control O
and O
patientfibroblasts O
after O
treatment O
of O
1μM O
STS O
for O
24 O
h O
(E) O
and O
quantified O
in O
D O
from O
two O
independent O
experiments O
. O

Differences O
between O
the O
control O
and O
patientfibroblasts O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
significant O
(*:0.05>p>0.01) O
. O

Patient O
1 O
(P1) O
versus O
control O
(C2): O
*: O
p=0.0414 O
(24h) O
. O

Patient O
2 O
(P2) O
versus O
control O
(C2): O
*: O
p=0.0461 O
(24h) O
. O

D-E. O
Mitochondrial O
membrane O
potential O
(ΔΨM) O
was O
measured O
by O
flow O
cytometry O
in O
control O
and O
patientfibroblasts O
after O
treatment O
of O
1μM O
STS O
for O
24 O
h O
(E) O
and O
quantified O
in O
D O
from O
two O
independent O
experiments O
. O

Differences O
between O
the O
control O
and O
patientfibroblasts O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
significant O
(*:0.05>p>0.01) O
. O

Patient O
1 O
(P1) O
versus O
control O
(C2): O
*: O
p=0.0414 O
(24h) O
. O

Patient O
2 O
(P2) O
versus O
control O
(C2): O
*: O
p=0.0461 O
(24h) O
. O

Figure O
8 O
. O

Overexpression O
of O
the O
CHCHD10 B-proteingene
mutant O
alleles O
in O
HeLa O
cells O
leads O
to O
inhibition O
of O
apoptotic O
cell O
death O
. O

Transfections O
were O
performed O
with O
empty O
vector O
(EV) O
or O
vectors O
encoding O
either O
wild-type O
CHCHD10-FLAG B-proteingene
(WT) O
or O
mutant O
CHCHD10-FLAG B-proteingene
(P34S O
and O
S59L) O
. O

A. O
Western O
blot O
on O
HeLa O
cells O
extracts O
using O
antibodies O
against O
FLAG B-proteingene
or O
Hsp90 B-proteingene
. O

B-D. O
HeLa O
cells O
transiently O
expressing O
the O
WT O
or O
mutated O
forms O
of O
CHCHD10-FLAG B-proteingene
(P34S O
or O
S59L) O
were O
treated O
with O
1 O
μM O
Actinomycine O
D O
(ActD) O
for O
4, O
6 O
or O
8 O
h O
with O
measurement O
of O
Annexin O
V/DAPI O
staining O
(B), O
DEVD-ase O
activity O
(C) O
from O
three O
independent O
experiments O
. O

Differences O
between O
the O
mutated O
and O
non O
mutated O
alleles O
were O
analyzed O
by O
Student O
's O
t-test O
(two-sided): O
significant O
(*:0.05>p>0.01) O
or O
very O
significant O
(**:0.01>p>0.001) O
. O

P34S O
versus O
WT: O
**: O
p=0.0055 O
(4h), O
*: O
p=0.0103 O
(8h) O
. O

S59L O
versus O
WT: O
*: O
p=0.0304 O
(4h), O
*: O
p=0.0129 O
(8h) O
. O

D. O
Mitochondrial O
outer O
membrane O
permeabilization O
was O
determined O
by O
western O
blot O
by O
assessing O
the O
degradation O
of O
Smac B-proteingene
. O

Hsp90 B-proteingene
was O
used O
as O
a O
loading O
control O
. O

B. O
The O
in O
vitro O
synthesized O
[35S]Met-labeled O
single-cysteine O
Bax B-proteingene
proteins O
were O
activated O
and O
targeted O
to O
the O
mitochondria O
that O
were O
pretreated O
with O
NEM O
to O
block O
the O
sulfhydryls O
of O
mitochondrial O
proteins O
. O

The O
resulting O
mitochondria O
were O
isolated O
and O
oxidized O
by O
CuPhe O
for O
30 O
min O
. O

NEM O
and O
EDTA O
were O
then O
added O
to O
stop O
the O
oxidation O
. O

For O
the O
"0 O
min" O
controls, O
NEM O
and O
EDTA O
were O
added O
before O
the O
addition O
of O
CuPhe O
. O

The O
resulting O
samples O
were O
analyzed O
by O
phosphor-imaging O
after O
non-reducing O
or O
reducing O
SDS-PAGE O
(see O
Appendix O
Figure O
S2A) O
. O

C. O
Oxidized O
mitochondria O
with O
the O
radioactive O
single-cysteine O
Bax B-proteingene
protein O
pair O
or O
double-cysteine O
Bax B-proteingene
protein O
were O
prepared O
and O
analyzed O
as O
in O
(B) O
. O

D. O
Oxidized O
mitochondria O
with O
the O
radioactive O
single-cysteine O
Bax B-proteingene
protein O
pair O
or O
double-cysteine O
Bax B-proteingene
protein O
were O
prepared O
as O
in O
(B) O
. O

After O
an O
aliquot O
was O
withdrawn O
as O
input, O
another O
aliquot O
was O
extracted O
by O
Na2CO3 O
(pH O
11.5) O
and O
centrifuged O
through O
a O
sucrose O
cushion O
to O
separate O
the O
integral O
proteins O
in O
the O
membrane O
pellet O
from O
the O
soluble O
and O
peripheral O
proteins O
in O
the O
supernatant O
. O

The O
input, O
pellet O
and O
supernatant O
were O
analyzed O
by O
non-reducing O
SDS-PAGE O
and O
phosphor-imaging O
. O

In O
a O
parallel O
control O
experiment, O
the O
pellet O
and O
supernatant O
were O
analyzed O
by O
reducing O
SDS-PAGE O
and O
immunoblotting O
with O
an O
antibody O
specific O
to O
PDHE1α, B-proteingene
a O
soluble O
mitochondrial O
matrix O
protein O
. O

A. O
The O
cytochrome B-proteingene
c I-proteingene
release O
by O
the O
indicated O
Bax B-proteingene
mutants O
was O
measured O
in O
two O
independent O
replicates, O
corrected O
and O
shown O
as O
in O
Figure O
9 O
. O

The O
amount O
of O
the O
Bax B-proteingene
mutants O
bound O
to O
the O
mitochondria O
in O
the O
assay O
was O
determined O
and O
the O
results O
are O
shown O
in O
Appendix O
Figure O
S1 O
. O

B. O
Purified O
wild-type O
(WT) O
or O
mutant O
(G179I O
or O
T182I) O
Bax B-proteingene
protein O
of O
the O
indicated O
concentration O
was O
incubated O
with O
the O
Bax-/-/Bak-/-mitochondria O
in O
the O
absence O
or O
presence O
of O
tBid B-proteingene
protein O
. O

The O
proteins O
released O
from O
and O
those O
remaining O
in O
the O
mitochondria O
were O
separated O
and O
analyzed O
by O
SDS-PAGE O
and O
immunoblotting O
with O
antibody O
specific O
to O
either O
cytochrome B-proteingene
c I-proteingene
or O
Smac B-proteingene
. O

n O
= O
2 O
. O

C. O
Purified O
wild-type O
or O
mutant O
Bax B-proteingene
protein O
of O
the O
indicated O
concentration O
alone O
or O
together O
with O
purified O
cBid B-proteingene
was O
incubated O
with O
the O
Bax-/-/Bak-/-mitochondria O
containing O
Smac-mCherry B-proteingene
protein O
. O

Release O
of O
Smac-mCherry B-proteingene
was O
detected O
by O
measuring O
the O
fluorescence O
in O
the O
supernatant O
after O
the O
mitochondria O
were O
pelleted O
by O
centrifugation O
. O

The O
dots O
are O
the O
fractions O
of O
Smac-mCherry B-proteingene
release O
from O
three O
independent O
replicates, O
and O
the O
lines O
are O
the O
means O
. O

D. O
The O
in O
vitro O
synthesized O
radioactive O
Bax B-proteingene
proteins O
with O
indicated O
mutations O
were O
targeted O
to O
the O
mitochondria O
in O
the O
absence O
or O
presence O
of O
purified O
tBid B-proteingene
protein, O
and O
then O
labeled O
with O
IASD, O
as O
in O
Figure O
2B. O
The O
IASD-labeled O
and O
unlabeled O
Bax B-proteingene
proteins O
were O
resolved O
using O
either O
gradient O
SDS-PAGE O
or O
IEF, O
detected O
by O
phosphor-imaging, O
and O
indicated O
by O
triangles O
and O
arrows, O
respectively O
. O

n O
= O
3 O
for O
A178C,G179I; O
2 O
for O
other O
mutants O
. O

E. O
The O
IASD O
labeling O
data O
in O
(D) O
and O
the O
similar O
data O
from O
the O
independent O
replicates O
were O
quantified O
to O
derive O
the O
membrane O
burial O
indices O
shown O
in O
Appendix O
Figure O
S7A, O
from O
which O
the O
relative O
membrane O
burial O
indices O
were O
obtained O
as O
described O
in O
Figure O
2C, O
and O
shown O
. O

B. O
The O
in O
vitro O
synthesized O
radioactive O
Bax B-proteingene
proteins, O
each O
with O
a O
single O
cysteine O
positioned O
in O
helix O
α2, O
α3, O
α4 O
or O
α5, O
were O
activated O
and O
targeted O
to O
the O
mitochondria O
. O

The O
resulting O
mitochondria O
were O
isolated O
and O
treated O
with O
IASD O
in O
the O
absence O
or O
presence O
of O
CHAPS, O
urea, O
or O
both O
. O

After O
30 O
min, O
the O
labeling O
reactions O
were O
stopped O
by O
mercaptoethanol O
. O

For O
the O
"0 O
min" O
controls, O
the O
samples O
were O
pretreated O
with O
mercaptoethanol O
before O
addition O
of O
IASD. O
The O
IASD-labeled O
radioactive O
Bax B-proteingene
proteins O
were O
resolved O
from O
the O
unlabeled O
ones O
using O
either O
isoelectric O
focusing O
(IEF; O
as O
indicated) O
or O
gradient O
SDS-PAGE O
and O
detected O
by O
phosphor-imaging O
. O

Triangles O
and O
arrows O
indicate O
the O
unlabeled O
and O
IASD-labeled O
Bax B-proteingene
proteins, O
respectively O
. O

n O
= O
3 O
for O
V111C, O
and O
K119C; O
4 O
for O
W107C, O
and O
A117C; O
2 O
for O
other O
mutants O
. O

C-D. O
The O
phosphor-imaging O
data O
for O
IASD O
labeling O
of O
Bax B-proteingene
mutants O
in O
(B) O
and O
the O
similar O
data O
from O
the O
independent O
replicates O
were O
quantified O
to O
derive O
the O
membrane O
or O
protein O
burial O
indices O
as O
described O
and O
shown O
in O
Appendix O
Figure O
S3 O
. O

The O
membrane O
burial O
indices O
were O
normalized O
by O
that O
of O
G179C O
in O
α9, O
a O
reference O
for O
the O
membrane-buried O
residues O
. O

The O
resulting O
relative O
membrane O
burial O
indices O
are O
shown O
in O
(C) O
. O

The O
residues O
with O
the O
relative O
membrane O
burial O
index O
≥ O
40% O
of O
that O
of O
Gly179 O
are O
considered O
as O
buried O
in O
the O
MOM. O
Similarly, O
the O
relative O
protein O
burial O
indices O
shown O
in O
(D) O
were O
obtained O
by O
using O
Y115C O
in O
α5 O
as O
a O
reference O
for O
the O
protein-buried O
residues O
. O

The O
residues O
with O
the O
relative O
protein O
burial O
index O
≥ O
40% O
of O
that O
of O
Tyr115 O
are O
considered O
as O
buried O
in O
the O
protein O
or O
its O
complex O
. O

A-B. O
Oxidized O
mitochondria O
with O
the O
radioactive O
single- O
or O
double-cysteine O
Bax B-proteingene
proteins, O
or O
the O
single-cysteine O
Bax B-proteingene
protein O
pairs O
were O
prepared O
and O
analyzed O
as O
in O
Figure O
1B O
. O

C. O
Oxidized O
mitochondria O
with O
the O
radioactive O
double-cysteine O
Bax B-proteingene
protein O
were O
prepared, O
subjected O
to O
Na2CO3 O
extraction O
and O
analyzed O
as O
in O
Figure O
1D O
. O

B O
and O
D. O
The O
radioactive O
single- O
or O
double-cysteine O
Bax B-proteingene
proteins O
with O
or O
without O
the O
indicated O
mutations O
were O
activated O
and O
targeted O
to O
the O
mitochondria O
that O
were O
either O
untreated O
(mito) O
or O
pretreated O
with O
NEM O
(NEM-mito), O
then O
oxidized O
and O
analyzed O
as O
in O
Figure O
1B. O
Protein O
standards, O
and O
monomers O
and O
disulfide-linked O
dimers O
of O
the O
Bax B-proteingene
proteins O
are O
indicated O
as O
in O
Figure O
1B. O
n O
= O
2 O
for O
all O
mutants O
. O

C. O
The O
in O
vitro O
synthesized O
[35S]Met-labeled O
Bax B-proteingene
E69C O
protein O
with O
or O
without O
the O
additional O
mutations O
(G108E O
and/or O
S184V) O
were O
activated O
by O
the O
in O
vitro O
synthesized O
[35S]Met-labeled O
tBid B-proteingene
L105C O
protein O
and O
targeted O
to O
the O
Bax-/-/Bak-/-mitochondria B-proteingene
that O
were O
pretreated O
with O
NEM. O
The O
resulting O
mitochondria O
were O
isolated O
and O
oxidized O
by O
CuPhe O
for O
0 O
or O
30 O
min O
. O

The O
resulting O
"0 O
min" O
samples O
(1 O
equivalent O
each) O
and O
"30 O
min" O
samples O
(1 O
equivalent O
each) O
were O
analyzed O
by O
non-reducing O
SDS-PAGE O
and O
phosphor-imaging O
. O

The O
remaining O
"30 O
min" O
samples O
(4 O
equivalent O
each) O
were O
immunoprecipitated O
(IP) O
by O
either O
Bax- B-proteingene
or O
tBid-specific B-proteingene
antibody, O
and O
then O
analyzed O
by O
non-reducing O
SDS-PAGE O
and O
phosphor-imaging O
. O

The O
identities O
of O
the O
four O
major O
products, O
indicated O
on O
the O
right O
side O
of O
the O
image, O
were O
based O
on O
their O
Mr O
and O
recognition O
by O
the O
respective O
antibody O
. O

n O
= O
2 O
. O

B O
and O
D. O
The O
radioactive O
single- O
or O
double-cysteine O
Bax B-proteingene
proteins O
with O
or O
without O
the O
indicated O
mutations O
were O
activated O
and O
targeted O
to O
the O
mitochondria O
that O
were O
either O
untreated O
(mito) O
or O
pretreated O
with O
NEM O
(NEM-mito), O
then O
oxidized O
and O
analyzed O
as O
in O
Figure O
1B. O
Protein O
standards, O
and O
monomers O
and O
disulfide-linked O
dimers O
of O
the O
Bax B-proteingene
proteins O
are O
indicated O
as O
in O
Figure O
1B. O
n O
= O
2 O
for O
all O
mutants O
. O

A. O
The O
in O
vitro O
synthesized O
radioactive O
Bax B-proteingene
proteins, O
each O
with O
a O
single O
cysteine O
positioned O
in O
α9, O
were O
activated O
and O
targeted O
to O
the O
mitochondria, O
and O
labeled O
with O
IASD O
as O
in O
Figure O
2B. O
The O
IASD-labeled O
and O
unlabeled O
Bax B-proteingene
proteins O
were O
resolved O
using O
gradient O
SDS-PAGE, O
detected O
by O
phosphor-imaging O
and O
indicated O
by O
triangles O
and O
arrows, O
respectively O
. O

For O
all O
mutants, O
n O
= O
2, O
except O
for O
A183C, O
n O
= O
3 O
. O

B-C. O
The O
IASD O
labeling O
data O
in O
(A) O
and O
the O
similar O
data O
from O
the O
independent O
replicates O
were O
quantified O
to O
derive O
the O
membrane O
or O
protein O
burial O
indices O
shown O
in O
Appendix O
Figure O
S5, O
from O
which O
the O
relative O
membrane O
(B) O
or O
protein O
(C) O
burial O
indices O
were O
obtained O
as O
described O
in O
Figure O
2C-D, O
and O
shown O
. O

D. O
The O
structure O
of O
α9 O
(extracted O
from O
the O
NMR O
structure O
of O
Bax B-proteingene
monomer, O
PDB O
entry O
1F16) O
is O
shown O
with O
the O
residues O
that O
are O
buried O
in O
the O
MOM O
or O
exposed O
to O
the O
aqueous O
milieu, O
as O
the O
IASD O
labeling O
data O
in O
(A-C) O
suggested, O
presented O
in O
yellow O
or O
cyan O
stick O
form, O
respectively O
. O

B O
and O
D. O
The O
oxidized O
mitochondria O
with O
radioactive O
single-cysteine O
Bax B-proteingene
proteins O
were O
prepared O
and O
analyzed O
as O
in O
Figure O
1B O
. O

C O
and O
E. O
The O
oxidized O
mitochondria O
with O
the O
radioactive O
single-cysteine O
Bax B-proteingene
proteins O
were O
prepared, O
subjected O
to O
Na2CO3 O
extraction, O
and O
analyzed O
as O
in O
Figure O
1D O
. O

B-D. O
The O
in O
vitro O
synthesized O
radioactive O
single O
or O
double-cysteine O
Bax B-proteingene
proteins O
with O
or O
without O
the O
indicated O
mutations O
were O
activated O
and O
targeted O
to O
the O
mitochondria, O
oxidized, O
and O
analyzed O
as O
in O
Figure O
1B. O
Protein O
standards, O
and O
monomers O
and O
disulfide-linked O
dimers O
of O
the O
Bax B-proteingene
proteins O
are O
indicated O
as O
in O
Figure O
1B. O
n O
= O
2 O
for O
all O
mutants O
. O

A. O
The O
oxidized O
mitochondria O
with O
radioactive O
single, O
double, O
or O
triple-cysteine O
Bax B-proteingene
proteins O
were O
prepared O
and O
analyzed O
by O
non-reducing O
or O
reducing O
SDS-PAGE O
as O
in O
Figure O
1B. O
Protein O
standards, O
Bax B-proteingene
monomers O
and O
disulfide-linked O
Bax B-proteingene
homodimers O
are O
also O
indicated O
as O
in O
Figure O
1B. O
Closed O
triangles O
indicate O
disulfide-linked O
higher O
order O
Bax B-proteingene
homo-oligomers O
. O

Open O
triangles O
indicate O
a O
background O
band O
that O
could O
not O
be O
reduced, O
and O
hence O
is O
not O
a O
disulfide-linked O
complex O
. O

B. O
The O
BMH-treated O
mitochondria O
with O
the O
radioactive O
single- O
and O
double-cysteine O
Bax B-proteingene
proteins O
were O
prepared O
and O
analyzed O
as O
in O
Figure O
EV3G, O
except O
that O
closed O
triangles O
indicate O
the O
BMH-linked O
Bax B-proteingene
oligomers O
. O

A-C. O
The O
single O
or O
double-cysteine O
Bax B-proteingene
proteins O
with O
or O
without O
the O
indicated O
mutations O
were O
synthesized O
in O
vitro, O
activated O
by O
tBid B-proteingene
protein O
and O
targeted O
to O
the O
Bax-/-/Bak-/- B-proteingene
mitochondria O
. O

Cytochrome B-proteingene
c I-proteingene
release O
from O
the O
mitochondria O
was O
measured O
using O
ELISA. O
The O
dots O
are O
the O
fractions O
of O
cytochrome B-proteingene
c I-proteingene
release O
from O
two O
independent O
replicates O
after O
they O
were O
corrected O
as O
described O
in O
Figure O
EV1B, O
and O
the O
lines O
are O
the O
means O
. O

The O
amount O
of O
the O
Bax B-proteingene
mutants O
bound O
to O
the O
mitochondria O
in O
the O
assay O
was O
determined O
and O
the O
results O
are O
shown O
in O
Appendix O
Figure O
S1 O
. O

A) O
GSTpulldown B-proteingene
used O
to O
analyse O
TBC1D14 B-proteingene
interactors O
. O

Recombinant O
GST B-proteingene
or O
GST-TBC1D14 B-proteingene
was O
incubated O
with O
or O
without O
HEK O
293A O
lysate O
. O

Bound O
proteins O
were O
eluted O
from O
the O
beads O
using O
Laemmli O
sample O
buffer O
and O
subjected O
to O
SDS-PAGE, O
with O
visible O
bands O
being O
excised O
from O
the O
gel O
and O
analysed O
by O
mass O
spectrometry O
. O

B) O
Lysates O
of O
HEK293A O
cells O
expressing O
either O
GFP B-proteingene
or O
GFP-TBC1D14 B-proteingene
were O
subjected O
to O
immunoprecipitation O
(IP) O
with O
GFP-Trap, O
and O
then O
immunoblotted O
for O
GFP, B-proteingene
TRAPPC12 B-proteingene
and O
TRAPPC4 B-proteingene
. O

C) O
Lysates O
of O
cells O
expressing O
GFP B-proteingene
or O
GFP-TRAPPC3 B-proteingene
were O
subjected O
to O
IP O
with O
GFP-Trap, O
and O
then O
immunoblotted O
for O
TRAPPC4, B-proteingene
GFP B-proteingene
and O
TBC1D14 B-proteingene
. O

D) O
Cells O
expressing O
GFP-TBC1D14, B-proteingene
generating O
a O
tubulated O
endosomal O
compartment, O
were O
fed O
Alexa647 O
labelled O
Transferrin B-proteingene
(white, O
blue O
in O
merge) O
for O
15 O
minutes O
in O
full O
medium, O
fixed, O
stained O
for O
endogenous O
TRAPPC4 B-proteingene
(red) O
and O
analysed O
by O
confocal O
microscopy O
. O

White O
arrowheads O
indicate O
transfected O
cells, O
yellow O
arrowheads O
depict O
regions O
of O
colocalisation O
in O
inset O
. O

Scale O
bars O
= O
10 O
μm O
. O

E) O
Cells O
treated O
as O
in O
D O
were O
stained O
for O
endogenous O
TRAPPC12 B-proteingene
(red) O
and O
analysed O
by O
confocal O
microscopy O
. O

Scale O
bars O
= O
10 O
μm O

F) O
Cells O
in O
complete O
medium O
were O
fixed, O
stained O
for O
endogenous O
TBC1D14 B-proteingene
(green), O
RAB1B B-proteingene
(red) O
and O
TRAPPC4 B-proteingene
(white, O
blue O
in O
merge) O
and O
analysed O
by O
confocal O
microscopy O
. O

Inset O
shows O
protein O
localisation O
in O
juxtanuclear O
area O
. O

Yellow O
arrowheads O
show O
regions O
of O
colocalisation O
Scale O
bars O
= O
10 O
μm O
. O

Data O
shown O
are O
representative O
from O
3 O
independent O
experiments O
. O

A) O
HEK293A O
cells O
transfected O
with O
GFP B-proteingene
(upper O
panels) O
or O
GFP-TBC1D14 B-proteingene
(lower O
panels) O
(green) O
were O
labelled O
with O
anti-RAB11A B-proteingene
(red) O
and O
anti-RAB1B B-proteingene
(white, O
blue O
in O
merge) O
antibodies O
. O

Arrows O
depict O
transfected O
cells O
. O

Inset: O
GFP-TBC1D14 B-proteingene
transfected O
cell O
showing O
triple O
co-localisation O
between O
GFP-TBC1D14, B-proteingene
RAB11A B-proteingene
and O
RAB1B B-proteingene
(white O
arrows) O
and O
double O
co-localisation O
between O
GFP-TBC1D14 B-proteingene
and O
RAB11A B-proteingene
(yellow O
arrows) O
. O

B) O
Co-localisation O
of O
GFP-TBC1D14, B-proteingene
TRAPPC4 B-proteingene
(red) O
and O
RAB11A B-proteingene
(white, O
blue O
in O
merge) O
. O

White O
arrowheads O
indicate O
regions O
of O
triple O
co-localisation O
. O

C) O
Co-localisation O
of O
GFP-TBC1D14, B-proteingene
TRAPPC4 B-proteingene
(red) O
and O
RAB1B B-proteingene
(white, O
blue O
in O
merge) O
. O

White O
arrowheads O
indicate O
regions O
of O
triple O
co-localisation, O
yellow O
arrowheads O
regions O
of O
double O
co-localisation O
between O
GFP-TBC1D14 B-proteingene
and O
TRAPPC4 B-proteingene
. O

All O
scale O
bars O
= O
20 O
μm O
. O

B) O
HEK O
293A O
cell O
lysates O
(from O
approximately O
8 O
× O
106 O
cells O
per O
construct) O
expressing O
the O
indicated O
GFP B-proteingene
fusions O
were O
subjected O
to O
IP O
and O
immunoblotting O
for O
GFP, B-proteingene
TRAPPC12 B-proteingene
and O
TRAPPC4 B-proteingene
. O

Data O
are O
representative O
of O
3 O
independent O
experiments O
. O

A) O
Cells O
expressing O
the O
indicated O
GFP-fusions B-proteingene
(green) O
were O
loaded O
with O
Alexa647-Transferrin B-proteingene
(red; O
arrowheads O
indicate O
transfected O
cells) O
for O
15 O
minutes, O
fixed O
and O
the O
morphology O
of O
the O
transferrin B-proteingene
positive O
recycling O
endosomes O
analysed O
by O
confocal O
microscopy O
. O

Scale O
bars O
= O
10 O
μm O
. O

Arrows O
in O
inset O
indicate O
the O
juxtanuclear O
ERC O

B) O
Cells O
transfected O
as O
in O
(A) O
were O
loaded O
with O
Alexa-647transferrin B-proteingene
for O
15 O
minutes O
and O
the O
fluorescent O
transferrin B-proteingene
chased O
out O
for O
the O
indicated O
time O
periods O
. O

At O
the O
end O
of O
the O
timecourse O
the O
cells O
were O
fixed O
and O
the O
transferrin B-proteingene
content O
of O
GFP B-proteingene
positive O
cells O
analysed O
by O
flow O
cytometry O
. O

Results O
are O
expressed O
as O
a O
percentage O
of O
Tfn O
fluorescence O
at O
t=0 O
and O
are O
the O
mean O
of O
3 O
independent O
experiments, O
± O
s.e.m O
. O

C) O
Cells O
transfected O
as O
in O
(A) O
were O
stained O
for O
the O
cis-Golgi O
marker O
GM130 B-proteingene
. O

Arrowheads O
depict O
transfected O
cells O
. O

Scale O
bars O
= O
10 O
μm O
. O

Bar O
chart O
is O
quantification O
of O
fragmented O
Golgi O
complex O
(> O
100 O
cells O
per O
condition O
from O
three O
independent O
experiments, O
± O
s.e.m O
. O

** O
p O
< O
0.01, O
one O
way O
ANOVA O
with O
Sidak O
's O
post-test) O
. O

D) O
HeLa O
C1 O
cells O
transfected O
with O
CFP B-proteingene
or O
CFP-TBR B-proteingene
were O
treated O
with O
D/D O
solubiliser O
(Clontech) O
or O
D/D O
solubiliser O
plus O
2.5 O
μg/ml O
Brefeldin O
A O
(BFA) O
for O
the O
indicated O
time O
periods, O
trypsinised, O
fixed O
and O
their O
GFP B-proteingene
content O
analysed O
by O
flow O
cytometry O
. O

Results O
are O
expressed O
as O
a O
percentage O
of O
GFP B-proteingene
levels O
at O
t=0, O
and O
the O
mean O
of O
3 O
independent O
experiments O
± O
s.e.m O
. O

A) O
HEK293A O
cells O
expressing O
GFP, B-proteingene
GFP-TBC1D14 B-proteingene
224-669 O
or O
GFP-TBR B-proteingene
were O
treated O
in O
duplicate O
with O
EBSS, O
EBSS O
plus O
100 O
nM O
BafA1 O
or O
not O
for O
two O
hours, O
lysed O
and O
subjected O
to O
immunoblotting O
for O
LC3B, B-proteingene
tubulin B-proteingene
and O
GFP. B-proteingene
The O
amount O
of O
LC3B/tubulin B-proteingene
for O
each O
condition O
from O
three O
independent O
experiments O
is O
shown O
on O
the O
bar O
graph, O
±s.e.m O
. O

* O
p<0.05, O
** O
p<0.01, O
one O
way O
ANOVA O
with O
Sidak O
's O
multiple O
comparison O
test O
. O

B) O
HEK293AGFP-LC3B B-proteingene
(2GL9) O
cells O
were O
transfected O
with O
mCherry B-proteingene
or O
mCherry-TBR, B-proteingene
treated O
with O
EBSS O
for O
two O
hours, O
fixed O
and O
analysed O
by O
confocal O
microscopy O
. O

C) O
HEK293A O
cells O
were O
treated O
as O
in O
(B), O
fixed, O
stained O
for O
WIPI2 B-proteingene
and O
analysed O
by O
confocal O
microscopy O
. O

D) O
HEK293A O
cells O
stably O
expressing O
GFP-DFCP1 B-proteingene
were O
treated O
as O
in O
(B), O
fixed O
and O
analysed O
by O
confocal O
microscopy O
. O

Scale O
bars O
= O
20 O
μm O
. O

For O
quantification O
of O
(B), O
(C) O
and O
(D), O
10 O
fields O
of O
view O
containing O
transfected O
cells O
were O
imaged O
for O
each O
of O
three O
experiments, O
and O
the O
number O
of O
GFP-LC3B, B-proteingene
WIPI2 O
or O
GFP-DFCP1 B-proteingene
puncta O
per O
cell O
enumerated O
using O
Imaris O
software O
(Bitplane) O
. O

B) O
Samples O
prepared O
according O
to O
(A) O
(8 O
× O
107HEK293A O
cells O
per O
transfection) O
were O
lysed O
in O
TNTE, O
split O
equally O
and O
denatured O
with O
1% O
SDS O
(D) O
or O
not O
(ND) O
and O
subjected O
to O
1 O
hour O
streptavidin O
resin O
pulldown O
at O
room O
temperature O
. O

The O
bound O
proteins O
were O
eluted O
in O
2x O
Laemmli O
sample O
buffer O
plus O
3 O
mM O
Biotin O
and O
immunoblotted O
for O
the O
indicated O
proteins O
. O

C) O
siRNA O
transfected O
control O
cells O
(RISC O
Free) O
or O
TRAPPC8 B-proteingene
knockdown O
(TRAPPC8) B-proteingene
(1x10cm O
plate O
per O
condition) O
were O
lysed O
in O
TNTE O
and O
used O
in O
pulldown O
assays O
with O
immobilised O
recombinant O
GST B-proteingene
or O
GST-TBR. B-proteingene
Bound O
proteins O
were O
subjected O
to O
immunoblot O
analysis O
using O
TRAPPC8, B-proteingene
TRAPPC4 B-proteingene
and O
tubulin B-proteingene
antibodies O
. O

Ponceau O
staining O
was O
used O
to O
verify O
loading O
of O
the O
GST B-proteingene
fusion O
proteins O
(GST-TBR B-proteingene
indicated O
with O
arrowhead) O
. O

The O
bar O
chart O
expresses O
the O
relative O
amount O
of O
TRAPPC4 B-proteingene
isolated O
from O
siTRAPPC8 B-proteingene
compared O
to O
siRISC O
Free O
control O
cells O
from O
three O
independent O
experiments, O
error O
bars O
are O
± O
s.e.m O
. O

** O
p<0.01, O
unpaired O
T-test O

D) O
HEK293T O
cells O
stably O
depleted O
of O
TRAPPC8 B-proteingene
(shC8) O
or O
not O
(shCtrl) O
were O
transfected O
with O
constructs O
encoding O
GFP B-proteingene
or O
GFP-TRAPPC3 B-proteingene
and O
subjected O
to O
GFPTrapIP. O
Precipitated O
proteins O
were O
immunoblotted O
for O
GFP, B-proteingene
TRAPPC4 B-proteingene
and O
TRAPPC8 B-proteingene
. O

Bar O
chart: O
the O
amount O
of O
TRAPPC4 B-proteingene
isolated O
was O
normalised O
to O
the O
amount O
of O
GFP-TRAPPC3 B-proteingene
precipitated O
from O
three O
independent O
experiments O
and O
plotted O
± O
s.e.m., O
ns O
= O
non-significant, O
unpaired O
T-test O
. O

A) O
HEK293A O
cells O
treated O
with O
transiently O
transfected O
with O
RISC O
free O
control O
siRNA O
or O
siRNA O
duplexes O
directed O
against O
TRAPPC8 B-proteingene
and O
RAB11A B-proteingene
and O
B O
(knockdown O
confirmed O
by O
immunoblot O
analysis) O
were O
fed O
with O
Alexa-647Transferrin B-proteingene
for O
15 O
minutes O
in O
full O
medium, O
and O
the O
fluorescent O
transferrin B-proteingene
chased O
out O
for O
the O
indicated O
time O
periods O
. O

At O
the O
end O
of O
the O
time O
course, O
cells O
were O
trypsinised, O
fixed O
and O
the O
Alexa-647 O
fluorescence O
analysed O
by O
flow O
cytometry O
. O

Results O
are O
plotted O
as O
percentage O
of O
transferrin B-proteingene
fluorescence O
at O
t=0 O
for O
the O
RISC O
free O
control O
cells, O
expressed O
as O
the O
mean O
of O
three O
independent O
experiments O
± O
s.e.m O
. O

B) O
Cells O
transiently O
transfected O
with O
RISC O
Free O
control O
siRNA, O
or O
siRNA O
duplexes O
directed O
against O
TRAPPC8 B-proteingene
or O
RAB1A B-proteingene
and O
B O
were O
stained O
for O
the O
cis-Golgi O
markers O
GM130 B-proteingene
or O
RAB1B B-proteingene
and O
analysed O
by O
confocal O
microscopy O
. O

Scale O
bars O
= O
20 O
μm O
in O
main O
panels, O
10 O
μm O
in O
inset O
panels O
. O

Bar O
graph: O
> O
100 O
cells O
per O
siRNA O
were O
scored O
for O
fragmented O
or O
normal O
juxtanuclear O
Golgi O
stacks O
from O
three O
independent O
experiments O
. O

Error O
bars O
± O
s.e.m., O
* O
p<0.05, O
** O
p<0.01, O
one O
way O
ANOVA O
with O
Sidak O
's O
multiple O
comparison O
test O
. O

C) O
HeLa O
C1 O
cells O
transiently O
transfected O
with O
RISC O
free O
control O
siRNA O
or O
siRNA O
duplexes O
directed O
against O
TRAPPC8 B-proteingene
or O
RAB1A B-proteingene
and O
B O
(knockdown O
confirmed O
by O
immunoblot O
analysis), O
were O
treated O
with O
D/D O
solubiliser O
for O
the O
indicated O
time O
periods, O
trypsinised, O
fixed O
and O
their O
GFP B-proteingene
content O
analysed O
by O
flow O
cytometry O
. O

The O
line O
graph O
shows O
the O
GFP B-proteingene
fluorescence O
as O
a O
percentage O
of O
t=0, O
± O
s.e.m O
. O

from O
three O
independent O
experiments O
. O

A) O
ATG9 B-proteingene
positive O
membranes O
were O
immunoisolated O
from O
approximately O
2 O
× O
107 O
fed O
(F) O
or O
starved O
(S) O
HEK293A O
cells O
using O
a O
monoclonal O
hamster O
anti-ATG9 B-proteingene
(ATG9) B-proteingene
or O
control O
hamster O
IgM O
and O
immunoblotted O
for O
ATG9 B-proteingene
using O
a O
rabbit O
polyclonal O
antibody, O
TRAPPC8, B-proteingene
TRAPPC4 B-proteingene
and O
actin B-proteingene
. O

B) O
HEK293A O
cells O
transfected O
with O
GFP B-proteingene
or O
GFP-TBR B-proteingene
(green) O
were O
stained O
for O
ATG9 B-proteingene
using O
hamster O
anti-ATG9 B-proteingene
(red) O
and O
analysed O
by O
confocal O
microscopy O
. O

Scale O
bar O
= O
20 O
μm O

C) O
HEK293A O
cells O
transiently O
transfected O
with O
RISC O
Free O
siRNA O
or O
siRNA O
against O
TRAPPC8 B-proteingene
were O
stained O
for O
RAB1B B-proteingene
(green) O
and O
ATG9 B-proteingene
using O
hamster O
anti-ATG9 B-proteingene
(red) O
and O
imaged O
using O
confocal O
microscopy O
. O

D) O
Stills O
at O
t O
= O
30 O
minutes O
from O
time O
lapse O
imaging O
of O
9B9 O
cells O
(stably O
expressing O
GFP-LC3 B-proteingene
and O
mRFP-ATG9) B-proteingene
expressing O
either O
CFP B-proteingene
or O
CFP-TBR B-proteingene
(blue) O
. O

Scale O
bars O
= O
20 O
μm O
. O

Inset O
panels O
show O
mRFP-ATG9 B-proteingene
and O
GFP-LC3 B-proteingene
contact O
events O
at O
the O
indicated O
time O
points O
. O

Bar O
chart O
shows O
number O
of O
times O
a O
GFP-LC3 B-proteingene
spot O
was O
within O
1 O
μm O
of O
an O
mRFP-ATG9 B-proteingene
spot O
(a O
contact O
event), O
expressed O
as O
total O
mRFP-ATG9 B-proteingene
contacts O
per O
GFP-LC3 B-proteingene
spot, O
n O
= O
18 O
cells O
per O
condition O
pooled O
from O
4 O
independent O
experiments O
. O

A) O
Cells O
depleted O
of O
ULK1 B-proteingene
(siULK1) B-proteingene
or O
not O
(RISC O
Free) O
were O
transfected O
with O
GFP B-proteingene
or O
GFP-TBR B-proteingene
(green), O
starved O
(EBSS) O
or O
not O
(-EBSS) O
and O
stained O
for O
ATG9 B-proteingene
using O
hamster O
anti-ATG9 B-proteingene
(red) O
. O

Arrows O
indicate O
transfected O
cells O
. O

Western O
blot O
indicates O
ULK1 B-proteingene
knockdown O
. O

Scale O
bars O
= O
20 O
μm O
. O

B) O
Cells O
depleted O
of O
ULK1 B-proteingene
(siULK1) B-proteingene
or O
not O
(RISC O
Free) O
were O
transfected O
with O
myc-RAB1B B-proteingene
or O
myc-RAB1B B-proteingene
(S22N) O
(green), O
starved O
(EBSS) O
or O
not O
(-EBSS) O
and O
stained O
for O
ATG9 B-proteingene
using O
hamster O
anti-ATG9 B-proteingene
(red) O
Arrows O
indicate O
transfected O
cells O
. O

Western O
blot O
indicates O
ULK1 B-proteingene
knockdown O
. O

Scale O
bars O
= O
20 O
μm O
. O

(A) O
Quantification O
of O
CXCR4+ B-proteingene
cells O
by O
flow O
cytometry O
and O
Sox17+ B-proteingene
cells O
by O
immunostaining O
at O
day O
7 O
following O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Average O
and O
standard O
deviation O
(SD) O
of O
eight O
independent O
experiments O
. O

(B) O
Gene O
expression O
profiling O
by O
RT-PCR O
at O
day O
7 O
differentiation O
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(C) O
Immunostaining O
for O
Ecadherin B-proteingene
(left) O
and O
FoxA2 B-proteingene
(right) O
at O
day O
7 O
of O
differentiation O
in O
presence O
of O
3 O
µM O
CH O
. O

(D) O
Quantification O
of O
CXCR4+ B-proteingene
by O
flow O
cytometry O
over O
a O
seven-day O
differentiation O
time O
course O
in O
the O
presence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(E) O
Immunostaining O
for O
Sox17 B-proteingene
at O
day O
4 O
to O
day O
7 O
of O
differentiation O
in O
the O
continuous O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Scale O
bars O
= O
200 O
µM O

(A) O
Assay O
of O
Tcf7l1 B-proteingene
mRNA O
by O
RT-PCR O
for O
the O
first O
4 O
days O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
μM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

Day2 O
*p= O
0.048, O
Day3 O
*p=0.036 O
. O

B) O
Immunoblot O
for O
Tcf7l1 B-proteingene
at O
day O
3 O
of O
differentiation O
in O
the O
presence O
(+) O
or O
absence O
(-) O
of O
3 O
μM O
CH O
. O

(C) O
Assay O
of O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
for O
the O
first O
3 O
days O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

**p=5x10-7 O
. O

(D) O
ChiP-seq O
data O
from O
a O
compendium O
of O
transcription O
factor O
ChIP-seq O
analyses O
(Sánchez-Castillo O
et O
al, O
2015) O
. O

Gene O
tracks O
represent O
binding O
of O
Tcf7l1 B-proteingene
at O
the O
FoxA2, B-proteingene
Nodal O
and O
Eomesodermin B-proteingene
(Eomes) B-proteingene
gene O
locus O
. O

Red O
lines O
indicate O
the O
regions O
analyzed O
by O
ChIP O
PCR O
for O
Tcf7l1 B-proteingene
. O

(E) O
ChIP O
for O
Tcf7l1 B-proteingene
followed O
by O
qPCR O
for O
the O
regions O
indicated O
in O
Fig O
. O

2D. O
Analysis O
was O
performed O
in O
wild-type O
ES O
cells O
in O
2i O
culture O
conditions O
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

Klf2 B-proteingene
*p=0.025, O
FoxA2 B-proteingene
*p=0.050, O
Eomes B-proteingene
*p=0.023 O
. O

(F) O
ChIP O
for O
Tcf7l1 B-proteingene
followed O
by O
qPCR. O
Analysis O
was O
performed O
in O
wild-type O
ES O
cells O
on O
day O
3 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

FoxA2 B-proteingene
*p O
= O
0.049 O
. O

(A) O
Assay O
of O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
in O
Tcf7l1 B-proteingene
null O
cells O
on O
day O
1 O
to O
4 O
of O
differentiation O
without O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(B) O
Gene O
expression O
analysis O
of O
endodermal O
associated O
genes O
by O
RT-PCR O
in O
control O
wild-type O
and O
Tcf7l1 B-proteingene
null O
cells O
on O
day O
4 O
of O
differentiation O
in O
the O
presence O
and O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(C) O
FoxA2 B-proteingene
(green) O
and O
Oct4 B-proteingene
(red) O
immunostaining O
of O
Tcf7l1 B-proteingene
null O
ES O
cells O
on O
day O
4 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
DAPI O
staining O
in O
blue O
. O

(D) O
Assay O
of O
CXCR4, B-proteingene
Hex B-proteingene
and O
Sox17 B-proteingene
mRNA O
by O
RT-PCR O
in O
control O
wild-type O
and O
Tcf7l1 B-proteingene
null O
cells O
on O
day O
6 O
of O
differentiation O
in O
the O
presence O
and O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(A) O
Assay O
of O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
in O
FoxA2-Tet B-proteingene
ES O
cell O
lines O
48 O
hr O
after O
treatment O
with O
the O
indicated O
dose O
of O
DOX. O
Average O
and O
SD O
of O
two O
independent O
experiments O
from O
2 O
independent O
lines O
. O

B) O
FoxA2immunostaining B-proteingene
of O
FoxA2-Tet B-proteingene
ES O
cells O
48 O
hr O
after O
DOX O
treatment O
. O

Left, O
no O
DOX O
control O
. O

Middle O
and O
right, O
10ng/ml O
DOX. O
DAPI O
staining O
shown O
in O
blue O
. O

Right O
panel O
shows O
middle O
image O
without O
DAPI O
signal O
. O

(C) O
Assay O
of O
FoxA2 B-proteingene
and O
CXCR4 B-proteingene
mRNA O
by O
RT-PCR O
on O
day O
3 O
of O
differentiation O
with O
DOX O
at O
the O
indicated O
dose O
. O

Average O
and O
SD O
of O
two O
experiments O
from O
two O
independent O
cell O
lines O
. O

(D) O
Assay O
of O
Sox17 B-proteingene
mRNA O
by O
RT-PCR O
on O
day O
7 O
of O
differentiation O
with O
addition O
of O
3 O
µM O
CH O
and/or O
10 O
ng/ml O
DOX O
at O
the O
indicated O
time O
points O
(in O
days) O
. O

Average O
and O
SD O
of O
two O
independent O
experiments O
from O
two O
independent O
cell O
lines O
. O

(E) O
Sox17immunostaining B-proteingene
of O
FoxA2-Tet B-proteingene
ES O
cells O
at O
day O
7 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
10 O
ng/ml O
DOX O
and O
the O
presence O
and O
absence O
of O
3 O
µM O
CH O
as O
indicated O
. O

Far O
right O
panel O
shows O
image O
to O
its O
left O
without O
DAPI O
. O

(A) O
TOPFlash O
reporter O
activity O
following O
differentiation O
for O
3 O
days O
in O
3 O
µM O
CH O
or O
100 O
ng/ml O
(W100) O
or O
200 O
ng/ml O
(W200) O
recombinant O
Wnt3a B-proteingene
plus O
500 O
ng/ml O
recombinant O
RSpondin1 B-proteingene
. O

Relative O
luciferase O
units O
are O
normalised O
to O
FOPflash O
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(B) O
Assay O
of O
Tcf7l1 B-proteingene
and O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
at O
day O
2 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH O
or O
recombinant O
Wnt3a B-proteingene
(200 O
ng/ml O
plus O
500 O
ng/ml O
RSpondin1(WR)) B-proteingene
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

** O
p<0.01 O
. O

(C) O
Assay O
of O
Tcf7l1 B-proteingene
and O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
in O
Ctnnb1 B-proteingene
null O
cells O
at O
day O
1 O
and O
3 O
of O
differentiation O
in O
the O
absence O
or O
presence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(D) O
Immunoblot O
for O
Tcf7l1 B-proteingene
in O
Ctnnb1 B-proteingene
null O
cells O
during O
the O
first O
3 O
days O
of O
differentiation O
in O
the O
absence O
(-) O
or O
presence O
(+) O
of O
3 O
µM O
CH. O
Results O
from O
two O
independent, O
clonally-derived O
Ctnnb1 B-proteingene
null O
ES O
cell O
lines O
are O
shown O
. O

Tubulin B-proteingene
was O
used O
as O
a O
loading O
control O
. O

(A) O
Assay O
of O
cMyc B-proteingene
mRNA O
by O
RT-PCR O
in O
wild-type O
ES O
cells O
at O
day O
1 O
to O
3 O
of O
differentiation O
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(B) O
Immunoblot O
for O
total O
cMyc B-proteingene
and O
phospho O
Ser62 O
(pSer62) O
cMyc B-proteingene
during O
the O
first O
3 O
days O
of O
differentiation O
in O
the O
absence O
(-) O
or O
presence O
(+) O
of O
3 O
µM O
CH O
. O

C,D) O
Immunoblot O
for O
the O
destabilized O
form O
of O
cMyc B-proteingene
protein O
(pThr58) O
during O
the O
first O
3 O
days O
of O
differentiation O
in O
the O
absence O
(-) O
or O
presence O
(+) O
of O
3 O
µM O
CH O
in O
wild-type O
and O
Ctnnb1 B-proteingene
null O
cells O
respectively O
. O

C,D) O
Immunoblot O
for O
the O
destabilized O
form O
of O
cMyc B-proteingene
protein O
(pThr58) O
during O
the O
first O
3 O
days O
of O
differentiation O
in O
the O
absence O
(-) O
or O
presence O
(+) O
of O
3 O
µM O
CH O
in O
wild-type O
and O
Ctnnb1 B-proteingene
null O
cells O
respectively O
. O

(E) O
Assay O
of O
Tcf7l1 B-proteingene
mRNA O
by O
RT-PCR O
in O
wild-type O
cells O
at O
day O
2 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
a O
small O
molecule O
inhibitor O
of O
cMyc B-proteingene
(cMyc O
Inhibitor O
II; O
Myci) O
. O

Treatment O
with O
Myc O
inhibitor O
10058-F4 O
(Sigma) O
generated O
similar O
results O
(data O
not O
shown) O
. O

Average O
and O
SD O
of O
three O
independent O
experiments O
. O

**p=0.0002 O
. O

(F) O
Assay O
of O
Tcf7l1 B-proteingene
and O
FoxA2 B-proteingene
mRNA O
by O
RT-PCR O
in O
cMyc B-proteingene
null/nMyc B-proteingene
heterozygous O
cells O
(C-/-;N+/-) O
and O
floxed O
parental O
cells O
(cMycfl/fl;nMycfl/fl B-proteingene
(control)) O
at O
day O
3 O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
four O
or O
six O
independent O
experiments O
. O

Tcf7l1 B-proteingene
*p=0.01, O
FoxA2 B-proteingene
*p=0.034 O
. O

(G) O
FoxA2immunostaining B-proteingene
of O
control O
and O
cMyc B-proteingene
null/nMyc B-proteingene
heterozygous O
(cMyc-/-;nMyc+/-) B-proteingene
cells O
at O
day O
3 O
of O
differentiation O
in O
the O
presence O
of O
3 O
µM O
CH O
. O

(H) O
Assay O
of O
cMyc B-proteingene
and O
Tcf7l1 B-proteingene
mRNA O
by O
RT-PCR O
in O
cMycT58A B-proteingene
inducible O
cell O
lines O
(icMycT58A) O
24 O
hr O
after O
DOX O
treatment O
. O

Average O
of O
2 O
independent O
experiments O
. O

(I) O
Assay O
of O
Tcf7l1 B-proteingene
mRNA O
by O
RT-PCR O
in O
icMycT58A B-proteingene
clone O
1 O
cell O
line O
at O
day O
3 O
of O
differentiation O
in O
the O
absence O
of O
3 O
µM O
CH O
following O
cMyc B-proteingene
induction O
with O
10 O
ng/ml O
DOX. O
Average O
and O
SD O
of O
3 O
independent O
experiments O
. O

**p=0.007 O
. O

(J) O
Immunoblot O
for O
cMyc B-proteingene
and O
Tcf7l1 B-proteingene
in O
icMycT58A B-proteingene
clonal O
cell O
line O
1 O
48 O
hr O
after O
DOX O
induction O
at O
10ng/ml O
. O

(B) O
ChIP O
for O
cMyc B-proteingene
performed O
in O
wild-type O
ES O
cells O
differentiated O
for O
2 O
days O
in O
the O
absence O
or O
presence O
of O
3 O
µM O
CH. O
qPCR O
was O
carried O
out O
for O
the O
regions O
indicated O
in O
Fig O
. O

7a O
. O

Average O
and O
SD O
for O
five O
independent O
experiments, O
*p=0.028 O
. O

(C) O
ChIP O
for O
cMyc B-proteingene
performed O
in O
wild-type O
ES O
cells O
differentiated O
for O
2 O
days O
in O
the O
presence O
of O
3 O
µM O
CH O
plus O
or O
minus O
Myc O
inhibitor O
10058-F4 O
. O

Average O
and O
SD O
for O
three O
independent O
experiments, O
*p=0.026 O
. O

(D) O
Assay O
for O
Miz1 B-proteingene
mRNA O
by O
RT-PCR O
for O
the O
first O
three O
days O
of O
differentiation O
in O
the O
presence O
or O
absence O
of O
3 O
µM O
CH. O
Average O
and O
SD O
of O
three O
independent O
experiments O
. O

(E) O
ChIP O
for O
Miz1 B-proteingene
or O
IgG B-proteingene
control O
performed O
in O
E14 O
ES O
cells O
differentiated O
for O
2 O
days O
in O
presence O
of O
3 O
µM O
CH. O
qPCR O
was O
carried O
out O
for O
the O
regions O
indicated O
in O
Fig O
. O

7a O
. O

Average O
and O
SD O
for O
five O
independent O
experiments, O
**p=0.0015 O
. O

(A) O
Left: O
qRT-PCR O
analysis O
of O
mRNA O
expression O
of O
MAPK12 B-proteingene
(p38gamma) O
and O
MAPK13 B-proteingene
(p38delta) O
in O
liver O
extracts O
prepared O
from O
obese O
patients O
with O
alcoholic O
fatty O
liver O
disease O
(NAFLD) O
and O
control O
individuals O
without O
NAFLD. O
mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA. O
Right: O
Representative O
H&E-stained O
liver O
sections O
. O

Scale O
Bar: O
50μm O
. O

(n= O
11-74) O

(B) O
Left: O
qRT-PCR O
analysis O
of O
mRNA O
expression O
of O
MAPK12 B-proteingene
(p38gamma) O
and O
MAPK13 B-proteingene
(p38delta) O
in O
liver O
extracts O
prepared O
from O
control O
patients O
with O
NAFLD/non-alcoholic O
steatohepatitis O
(NASH) O
and O
control O
individuals O
without O
NAFLD/NASH. O
mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA. O
Right: O
Representative O
H&E-stained O
liver O
sections O
. O

Scale O
Bar: O
50μm O
. O

(n= O
11-9) O

(C) O
Quantification O
of O
immunoblot O
analysis O
of O
p38δ B-proteingene
expression O
in O
liver O
extracts O
prepared O
from O
obese O
patients O
with O
NAFLD O
and O
individuals O
without O
NAFLD. O
Representative O
blots O
are O
shown O
. O

(n= O
7-40) O

(D) O
qRT-PCR O
analysis O
of O
Mapk12 B-proteingene
(p38gamma) O
and O
Mapk13 B-proteingene
(p38delta) O
mRNA O
expression O
in O
liver O
extracts O
prepared O
from O
wild-type O
mice O
(WT) O
fed O
a O
diet O
deficient O
in O
methionine O
and O
choline O
(MCD) O
or O
control O
diet O
(ND) O
for O
3 O
weeks; O
mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA O
. O

(n=5-10) O

(E) O
Immunoprecipitation O
analysis O
of O
activation O
and O
protein O
levels O
of O
p38γ B-proteingene
and O
δ O
isoforms O
in O
liver O
extracts O
prepared O
from O
WT O
fed O
a O
MCD O
or O
ND O
diet O
for O
the O
times O
indicated O
. O

(F) O
Immunoprecipitation O
analysis O
of O
activation O
and O
protein O
levels O
of O
p38γ B-proteingene
and O
δ O
isoforms O
in O
liver O
extracts O
prepared O
from O
WT O
fed O
a O
MCD O
or O
ND O
for O
3 O
weeks O
(n=5) O
. O

Western O
blot O
against O
vinculin B-proteingene
was O
used O
to O
assay O
the O
protein O
amount O
in O
the O
total O
lysate O
(TL) O
used O
for O
each O
IP. O
Protein O
expression O
was O
normalized O
to O
vinculin B-proteingene
. O

Data O
are O
means O
± O
SEM. O
*P<0.05; O
**P<0.01 O
. O

(Statistical O
significance O
by O
two-tailed O
Student O
's O
t O
test O
. O

Characteristics O
of O
patients O
and O
controls O
were O
compared O
by O
means O
of O
χ2 O
or O
Mann-Whitney O
U O
tests.) O

(A) O
Representative O
H&E O
and O
oil O
red-stained O
liver O
sections O
prepared O
from O
WT O
and O
p38γ/δ-/-mice B-proteingene
fed O
a O
ND O
or O
the O
MCD O
diet O
for O
3 O
weeks O
. O

Scale O
Bar: O
50μm O
. O

(B) O
Livertriglycerides O
and O
(C) O
plasma O
transaminase O
activity O
(ALT) B-proteingene
measured O
in O
WT O
and O
p38γ/δ-/-mice O
after O
3 O
weeks O
of O
MCD O
diet O
. O

(D) O
TBARS O
and O
hydrogen O
peroxide O
detected O
in O
liver O
samples O
from O
mice O
fasted O
overnight O
after O
the O
3-week O
MCD O
diet O
. O

(E) O
qRT-PCR O
analysis O
of O
Col1a1, B-proteingene
Acta2 B-proteingene
and O
Timp1 B-proteingene
mRNA O
expression O
. O

mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA O
. O

(F) O
Representative O
Masson O
's O
trichrome-stainedliver O
sections O
prepared O
from O
WT O
and O
p38γ/δ-/-mice O
fed O
a O
ND O
or O
the O
MCD O
diet O
for O
3 O
weeks O
. O

Scale O
Bar: O
50μm O
. O

Data O
are O
means O
± O
SEM O
(n=5-10) O
. O

*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
MCD O
diet O
for O
3 O
weeks O
. O

(A) O
Representative O
H&E O
and O
oil O
red O
stained O
liver O
sections O
. O

Scale O
Bar: O
50μm O
. O

(n=5-10) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
were O
fed O
a O
ND O
or O
a O
MCD O
diet O
for O
3 O
weeks O
. O

(B) O
Livertriglycerides O
(C) O
and O
plasmaALT B-proteingene
at O
the O
end O
of O
the O
diet O
period O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KO B-proteingene
mice O
were O
fed O
a O
ND O
or O
a O
MCD O
diet O
for O
3 O
weeks O
. O

(D) O
Measurement O
of O
plasmaTNF-α B-proteingene
and O
IL-6 B-proteingene
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KO B-proteingene
mice O
were O
fed O
a O
ND O
or O
a O
MCD O
diet O
for O
3 O
weeks O
. O

(E) O
qRT-PCR O
analysis O
of O
myeloid O
cell O
markers O
and O
cytokine O
mRNA O
expression O
from O
liver O
tissue; O
mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KO B-proteingene
mice O
were O
fed O
a O
ND O
or O
a O
MCD O
diet O
for O
3 O
weeks O
. O

(F) O
qRT-PCR O
analysis O
of O
M1 O
and O
M2 O
polarization O
cell O
markers O
from O
liver O
infiltrated O
macrophages O
. O

mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA. O
Data O
are O
means O
± O
SEM O
(n=5-10) O
. O

*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
high-fat O
diet O
(HFD) O
for O
10 O
weeks O
. O

(A) O
Body O
weight O
measured O
at O
the O
indicated O
times O
during O
HFD O
treatment O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
high-fat O
diet O
(HFD) O
for O
10 O
weeks O
. O

(B) O
Fat O
mass O
and O
lean O
mass O
determined O
by O
MRI O
at O
the O
end O
of O
the O
diet O
period O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
high-fat O
diet O
(HFD) O
for O
10 O
weeks O
. O

(C O
and O
D) O
Liver O
mass O
and O
white O
fat O
(WF) O
mass O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
high-fat O
diet O
(HFD) O
for O
10 O
weeks O
. O

(E) O
Respiratory O
exchange O
quotient, O
energy O
expenditure, O
and O
locomotor O
activity, O
detected O
in O
metabolic O
cages O
. O

Data O
are O
means O
± O
SEM O
. O

(n=5-10) O
*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
were O
fed O
a O
ND O
or O
a O
HFD O
for O
10 O
weeks O
. O

(A) O
Representative O
H&E O
and O
oil O
red O
stained O
liver O
sections O
(Scale O
Bar: O
50μm) O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
were O
fed O
a O
ND O
or O
a O
HFD O
for O
10 O
weeks O
. O

(B) O
livertriglycerides O
(n=5-10) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
were O
fed O
a O
ND O
or O
a O
HFD O
for O
10 O
weeks O
. O

(C) O
PlasmaALT O
at O
the O
end O
of O
the O
diet O
period O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
were O
fed O
a O
ND O
or O
a O
HFD O
for O
10 O
weeks O
. O

(D) O
Glucose O
tolerance O
measured O
at O
the O
end O
of O
the O
diet O
period O
. O

Bloodglucose O
concentration O
was O
measured O
in O
mice O
given O
an O
intraperitoneal O
glucose O
injection O
(1g/kg) O
after O
overnight O
fasting O
(n=5-10) O
. O

Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KO B-proteingene
mice O
were O
fed O
a O
ND O
or O
a O
HFD O
for O
10 O
weeks O
. O

(E) O
Basal O
bloodglucose O
in O
overnight-fasted O
ND O
and O
HFD-fed O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KO B-proteingene
mice O
(n=5-10) O
. O

Data O
are O
means O
± O
SEM O
. O

(n=5-10) O
*P<0.05; O
**P<0.01; O
***P<0.001 O
refers O
to O
p38γ/δLyzs-KO B-proteingene
versus O
Lyzs-Cre; B-proteingene
##P<0.01; O
###P<0.001 O
refers O
to O
ND O
versus O
HFD O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests O
or O
Newman-Keuls O
post O
test O
for O
liver O
triglycerides) O
. O

Lethally O
irradiated O
WT O
mice O
were O
reconstituted O
with O
BM O
from O
Lyzs-Cre B-proteingene
(Cx O
BMLyzs-Cre) B-proteingene
or O
p38γ/δLyzs-KOmice O
(Cx O
BMp38γ/δLyzs-KO) B-proteingene
. O

Two O
months O
after O
the O
transplant, O
mice O
were O
fed O
the O
HFD O
for O
10 O
weeks O
. O

(A) O
Freshly O
prepared O
CD45.2 B-proteingene
whole O
BM O
mononuclear O
cells O
(2 O
× O
107) O
were O
transplanted O
into O
lethally O
irradiated O
B6.SJL O
(CD45.1) B-proteingene
mice, O
and O
engraftment O
by O
CD45.2 B-proteingene
cells O
(%) O
was O
analyzed O
by O
antibody O
staining O
and O
FACS O
of O
peripheral O
blood O
and O
liverCD45+ B-proteingene
cells O
. O

Charts O
show O
CD45.1 B-proteingene
and O
CD45.2 B-proteingene
expression O
in O
blood O
cells O
(left) O
and O
liver O
cells O
(right) O
isolated O
from O
transplanted O
mice O
(n O
= O
3) O
. O

Representative O
FACS O
dot O
plots O
of O
CD45.1 B-proteingene
and O
CD45.2 B-proteingene
expression O
are O
shown O
beneath O
the O
charts O
. O

Lethally O
irradiated O
WT O
mice O
were O
reconstituted O
with O
BM O
from O
Lyzs-Cre B-proteingene
(Cx O
BMLyzs-Cre) B-proteingene
or O
p38γ/δLyzs-KOmice O
(Cx O
BMp38γ/δLyzs-KO) B-proteingene
. O

Two O
months O
after O
the O
transplant, O
mice O
were O
fed O
the O
HFD O
for O
10 O
weeks O
. O

(B) O
Representative O
H&E O
and O
oil O
red-stained O
liver O
sections O
. O

Scale O
bar: O
50 O
μm O
. O

Lethally O
irradiated O
WT O
mice O
were O
reconstituted O
with O
BM O
from O
Lyzs-Cre B-proteingene
(Cx O
BMLyzs-Cre) B-proteingene
or O
p38γ/δLyzs-KOmice O
(Cx O
BMp38γ/δLyzs-KO) B-proteingene
. O

Two O
months O
after O
the O
transplant, O
mice O
were O
fed O
the O
HFD O
for O
10 O
weeks O
. O

(C) O
Livertriglyceride O
content O
. O

Lethally O
irradiated O
WT O
mice O
were O
reconstituted O
with O
BM O
from O
Lyzs-Cre B-proteingene
(Cx O
BMLyzs-Cre) B-proteingene
or O
p38γ/δLyzs-KOmice O
(Cx O
BMp38γ/δLyzs-KO) B-proteingene
. O

Two O
months O
after O
the O
transplant, O
mice O
were O
fed O
the O
HFD O
for O
10 O
weeks O
. O

(D) O
Plasma O
transaminase O
ALT B-proteingene
activity O
. O

Lethally O
irradiated O
WT O
mice O
were O
reconstituted O
with O
BM O
from O
Lyzs-Cre B-proteingene
(Cx O
BMLyzs-Cre) B-proteingene
or O
p38γ/δLyzs-KOmice O
(Cx O
BMp38γ/δLyzs-KO) B-proteingene
. O

Two O
months O
after O
the O
transplant, O
mice O
were O
fed O
the O
HFD O
for O
10 O
weeks O
. O

(E) O
Fasted O
glucose, O
detected O
at O
the O
end O
of O
the O
diet O
period O
in O
overnight-fasted O
mice O
. O

Data O
are O
means O
± O
SEM O
. O

(n=5-10) O
*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

(A) O
Flow O
cytometry O
analysis O
of O
liver O
myeloid O
subsets O
(CD11b+ B-proteingene
Gr-1high, B-proteingene
CD11b+ B-proteingene
Gr-1intermediate, B-proteingene
CD11b+ B-proteingene
Gr-1-) B-proteingene
isolated O
from O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
fed O
a O
MCD O
for O
3 O
weeks O
or O
HFD O
for O
10 O
weeks O
. O

Representative O
dot O
plots O
are O
shown, O
and O
bar O
charts O
show O
the O
diet-induced O
increase O
in O
each O
population O
as O
a O
percentage O
of O
the O
total O
intra-hepatic O
CD11b+ B-proteingene
leukocyte O
population O
. O

Myeloid O
infiltrating O
cells O
isolated O
from O
livers O
were O
sorted O
by O
FACS O
and O
stain O
with O
H&E. O
Representative O
cells O
were O
shown O
next O
to O
the O
appropriate O
myeloid O
subsets O
. O

(B O
and O
C) O
Neutrophils O
and O
monocytes O
as O
a O
percentage O
of O
total O
circulating O
leukocytes, O
measured O
in O
total O
blood O
in O
animals O
fed O
the O
MCD O
diet O
for O
3 O
weeks O
(B) O
or O
the O
HFD O
for O
10 O
weeks O
(C) O
. O

(D O
and O
E) O
WT O
mice O
fed O
the O
MCD O
diet O
were O
i.v O
. O

injected O
with O
a O
1:1 O
mix O
of O
DiO-labeled O
Lyzs-Creneutrophil O
and O
DiD-labeled O
p38γ/δLyzs-KOneutrophils B-proteingene
(6x106 O
cells O
in O
total; O
n=10) O
. O

One O
hour O
after O
injection, O
liver-infiltrating O
neutrophils O
were O
assessed O
by O
flow O
cytometry O
(D) O
and O
fluorescence O
micrography O
on O
liver O
sections O
(E) O
. O

(F) O
Intravital O
microscopy O
quantification O
of O
the O
rolling O
and O
adhesion O
frequencies O
and O
rolling O
velocities O
of O
neutrophils O
recruited O
to O
venules O
irrigating O
inflamed O
(TNFα-injected) B-proteingene
cremaster O
muscle O
. O

Data O
are O
means O
± O
SEM O
. O

(n=5-10) O
. O

*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

Osmotic O
minipumps O
containing O
saline O
or O
Ly6G B-proteingene
antibody O
were O
implanted O
subcutaneously O
in O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
. O

These O
animals O
were O
fed O
a O
ND O
or O
MCD O
for O
3 O
weeks O
. O

(A) O
Neutrophils O
and O
monocytes O
as O
a O
percentage O
of O
circulating O
leukocytes, O
measured O
in O
total O
blood O
. O

Osmotic O
minipumps O
containing O
saline O
or O
Ly6G B-proteingene
antibody O
were O
implanted O
subcutaneously O
in O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
. O

These O
animals O
were O
fed O
a O
ND O
or O
MCD O
for O
3 O
weeks O
. O

(B) O
Representative O
H&E O
and O
oil O
red-stained O
liver O
sections O
after O
3 O
weeks O
of O
treatment O
. O

Scale O
Bar: O
50μm O
. O

Osmotic O
minipumps O
containing O
saline O
or O
Ly6G B-proteingene
antibody O
were O
implanted O
subcutaneously O
in O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
. O

These O
animals O
were O
fed O
a O
ND O
or O
MCD O
for O
3 O
weeks O
. O

(C) O
Livertriglyceride O
and O
(D) O
plasma O
transaminase O
activity O
(ALT) B-proteingene
at O
the O
end O
of O
the O
diet O
period O
. O

Osmotic O
minipumps O
containing O
saline O
or O
Ly6G B-proteingene
antibody O
were O
implanted O
subcutaneously O
in O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice B-proteingene
. O

These O
animals O
were O
fed O
a O
ND O
or O
MCD O
for O
3 O
weeks O
. O

(E) O
Total O
RNA O
was O
extracted O
from O
livers, O
and O
chemokine O
and O
cytokine O
mRNA O
levels O
were O
determined O
by O
qRT-PCR. O
mRNA O
expression O
was O
normalized O
to O
the O
amount O
of O
Gapdh B-proteingene
mRNA. O
Data O
are O
means O
± O
SEM O
. O

(n=5-10) O
. O

*P<0.05; O
**P<0.01; O
***P<0.001 O
(2-way O
ANOVA O
coupled O
to O
Bonferroni O
's O
post O
tests) O
. O

(A, O
B O
and O
C) O
Plasma O
levels O
of O
3-hydroxybutyrate O
in O
WT O
and O
p38γ/δ-/- B-proteingene
(A), O
Lyzs-Cre B-proteingene
and O
p38γ/δLyzs-KOmice O
(B) O
and O
Lyzs-CreLy6G B-proteingene
Ab O
treated O
after O
MCD O
diet O
(C) O
. O

(B) O
Overview O
of O
electroporated O
neocortices O
showing O
Cas9 B-proteingene
expression O
as O
revealed O
by O
PaprikaRFPfluorescence B-proteingene
(magenta) O
and O
the O
effects O
of O
Cas9 B-proteingene
expression, O
together O
with O
control O
gRNA B-proteingene
(top) O
or O
gGFP B-proteingene
(bottom), O
on O
GFP B-proteingene
expression O
(green, O
fluorescence) O
. O

Dotted O
lines O
indicate O
the O
electroporated O
area O
of O
the O
VZ. O
Single O
optical O
sections; O
scale O
bars, O
200 O
μm O
. O

(C) O
Higher O
magnification O
of O
the O
VZ O
and O
SVZ O
of O
the O
electroporated O
area O
shown O
in O
(B), O
with O
DAPI O
staining O
(blue) O
depicted O
in O
addition O
to O
PaprikaRFP B-proteingene
(Cas9) B-proteingene
and O
GFPfluorescence B-proteingene
. O

Boxes O
indicate O
areas O
shown O
at O
higher O
magnification O
in O
the O
insets O
(35 O
x O
35 O
μm) O
. O

Dotted O
lines O
indicate O
nuclei O
of O
progeny O
of O
electroporated O
aRGCs; O
note O
the O
presence O
of O
GFPfluorescence B-proteingene
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gGFP B-proteingene
electroporation O
(bottom) O
. O

Images O
are O
single O
optical O
sections O
. O

Scale O
bars, O
20 O
μm O
. O

(D) O
Quantification O
of O
the O
proportion O
of O
Cas9-positive B-proteingene
cells O
in O
the O
VZ O
plus O
SVZ O
that O
are O
GFP-positive B-proteingene
48 O
h O
after O
control O
(Con, O
white) O
or O
gGFP B-proteingene
(black) O
Cas9 B-proteingene
plasmid O
electroporation O
. O

Data O
are O
the O
mean O
of O
4 O
independent O
experiments O
(7 O
embryos O
per O
condition O
in O
total, O
from O
4 O
litters) O
. O

(F) O
Overview O
of O
electroporated O
areas O
of O
neocortices O
as O
revealed O
by O
mCherryfluorescence B-proteingene
(magenta) O
showing O
the O
effects O
of O
Cas9 B-proteingene
protein O
together O
with O
either O
control O
gRNA B-proteingene
(top) O
or O
gGFP B-proteingene
(bottom) O
on O
GFP B-proteingene
expression O
(green, O
fluorescence) O
. O

Dotted O
lines O
indicate O
the O
electroporated O
area O
of O
the O
VZ. O
Single O
optical O
sections; O
scale O
bars, O
200 O
μm O
. O

(G) O
Higher O
magnification O
of O
the O
VZ O
and O
SVZ O
of O
the O
electroporated O
area O
shown O
in O
(F), O
with O
DAPI O
staining O
(blue) O
depicted O
in O
addition O
to O
mCherry B-proteingene
and O
GFPfluorescence B-proteingene
. O

Boxes O
indicate O
areas O
shown O
at O
higher O
magnification O
in O
the O
insets O
(35 O
x O
35 O
μm) O
. O

Dotted O
lines O
indicate O
nuclei O
of O
progeny O
of O
electroporated O
aRGCs; O
note O
the O
presence O
of O
GFPfluorescence B-proteingene
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gGFP B-proteingene
electroporation O
(bottom) O
. O

Images O
are O
single O
optical O
sections O
. O

Scale O
bars, O
20 O
μm O
. O

H) O
Quantification O
of O
the O
proportion O
of O
mCherry-positive B-proteingene
cells O
in O
the O
VZ O
plus O
SVZ O
that O
are O
GFP-positive B-proteingene
48 O
h O
after O
control O
(Con, O
white) O
or O
gGFP B-proteingene
(black) O
Cas9 B-proteingene
protein O
electroporation O
. O

Data O
are O
the O
mean O
of O
4 O
independent O
experiments O
(5 O
embryos O
per O
condition O
in O
total, O
from O
4 O
litters) O
. O

(I) O
VZ O
and O
SVZ O
of O
the O
electroporated O
areas O
showing O
Cas9 B-proteingene
expression O
as O
revealed O
by O
PaprikaRFPfluorescence B-proteingene
(magenta) O
and O
the O
effects O
of O
Cas9 B-proteingene
expression, O
together O
with O
control O
gRNA B-proteingene
(top) O
or O
gGFP B-proteingene
(bottom), O
on O
GFP B-proteingene
expression O
(green, O
fluorescence); O
blue, O
DAPI O
staining O
. O

Boxes O
indicate O
areas O
shown O
at O
higher O
magnification O
in O
the O
insets O
(35 O
x O
35 O
μm) O
. O

Dotted O
lines O
indicate O
nuclei O
of O
progeny O
of O
electroporated O
aRGCs; O
note O
the O
presence O
of O
GFPfluorescence B-proteingene
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gGFP B-proteingene
electroporation O
(bottom) O
. O

Images O
are O
single O
optical O
sections O
. O

Scale O
bars, O
20 O
μm O
. O

(J) O
VZ O
and O
SVZ O
of O
the O
electroporated O
areas O
showing O
targeted O
cells O
as O
revealed O
by O
mCherryfluorescence B-proteingene
(magenta) O
and O
the O
effects O
of O
Cas9 B-proteingene
protein O
together O
with O
either O
control O
gRNA B-proteingene
(top) O
or O
gGFP B-proteingene
(bottom) O
on O
GFP B-proteingene
expression O
(green); O
blue, O
DAPI O
staining O
. O

Boxes O
indicate O
areas O
shown O
at O
higher O
magnification O
in O
the O
insets O
(35 O
x O
35 O
μm) O
. O

Dotted O
lines O
indicate O
nuclei O
of O
progeny O
of O
electroporated O
aRGCs; O
note O
the O
presence O
of O
GFPfluorescence B-proteingene
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gGFP B-proteingene
electroporation O
(bottom) O
. O

Images O
are O
single O
optical O
sections O
. O

Scale O
bars, O
20 O
μm O
. O

K) O
Quantification O
of O
the O
proportion O
of O
Cas9-positive B-proteingene
cells O
(left) O
and O
mCherry-positive B-proteingene
cells O
(right) O
in O
the O
VZ O
plus O
SVZ O
that O
are O
GFP-positive B-proteingene
24 O
h O
after O
control O
(Con, O
white) O
or O
gGFP B-proteingene
(black) O
Cas9 B-proteingene
plasmid O
(left) O
or O
protein O
(right) O
electroporation O
. O

Data O
are O
the O
mean O
of O
3 O
independent O
experiments O
each O
(3 O
embryos O
per O
condition O
in O
total, O
from O
3 O
litters) O
. O

(D, O
H, O
K) O
Controls O
were O
set O
to O
100% O
and O
the O
gGFP B-proteingene
conditions O
expressed O
relative O
to O
control O
(D, O
11%; O
H, O
24%; O
K O
left, O
40% O
K O
right, O
28%) O
. O

Error O
bars O
indicate O
SD; O
*, O
P<0.05; O
**, O
P<0.01; O
***, O
P<0.001 O
. O

(B) O
Daughter O
cells O
of O
single O
aRGCs O
microinjected O
with O
either O
Cas9/control B-proteingene
gRNA B-proteingene
(top) O
or O
Cas9/gGFP B-proteingene
(bottom) O
revealed O
by O
Dx-A555immunofluorescence O
(magenta); O
Cells O
1, O
aRGC O
daughter; O
Cells O
2, O
BP O
daughter O
. O

Dashed O
lines O
indicate O
ventricular O
surface O
. O

Images O
are O
maximum O
intensity O
projections O
of O
20 O
(Control) O
and O
24 O
(gGFP) B-proteingene
optical O
sections O
. O

Scale O
bars, O
20 O
µm O
. O

(C) O
Single O
optical O
sections O
of O
Cells O
1 O
and O
Cells O
2 O
depicted O
in O
(B), O
showing O
the O
effects O
of O
Cas9 B-proteingene
and O
control O
gRNA B-proteingene
(top) O
or O
gGFP B-proteingene
(bottom) O
on O
GFP B-proteingene
expression O
(as O
revealed O
by O
immunofluorescence, O
green) O
. O

Cells O
1 O
and O
Cells O
2 O
are O
indicated O
by O
dotted O
lines; O
note O
the O
presence O
of O
GFPimmunofluorescence B-proteingene
in O
the O
daughter O
cells O
in O
control O
and O
its O
absence O
upon O
Cas9/gGFP B-proteingene
microinjection O
. O

Scale O
bars, O
5 O
µm O
. O

(D) O
Quantification O
of O
the O
proportion O
of O
daughter O
cells O
(Dx-A555+) O
of O
microinjected O
cells O
that O
show O
GFP B-proteingene
expression O
24 O
h O
after O
control O
(Con, O
white) O
or O
gGFP B-proteingene
(black) O
microinjection O
. O

Control O
is O
set O
to O
100% O
and O
the O
gGFP B-proteingene
condition O
expressed O
relative O
to O
control O
(39%) O
. O

Data O
are O
the O
mean O
of O
two O
independent O
experiments O
(3 O
embryos O
and O
1 O
litter O
per O
experiment, O
total O
number O
of O
daughter O
cells O
scored: O
control O
142, O
gGFP B-proteingene
88); O
bars O
indicate O
the O
variation O
of O
the O
two O
individual O
values O
from O
the O
mean O
(P<0.05) O
. O

(A-D) O
Neocortex O
of O
mouseE13.5embryos O
was O
in O
utero O
electroporated O
with O
a O
plasmid O
encoding, O
under O
constitutive O
promoters, O
Cas9_T2A_PaprikaRFP B-proteingene
and O
gRNA B-proteingene
targeting O
either O
LacZ B-proteingene
(Control, O
Con) O
or O
Tbr2 B-proteingene
(Tbr2), O
followed O
by O
analysis O
at O
E15.5 O
. O

(A) O
Electroporated O
area O
showing O
the O
effects O
of O
Cas9 B-proteingene
expression O
(revealed O
by O
PaprikaRFPDAPI, B-proteingene
magenta) O
together O
with O
either O
control O
gRNA B-proteingene
(top) O
or O
gTbr2 B-proteingene
(bottom) O
on O
aRGCs O
expression O
(green, O
immunofluorescence); O
blue, O
Cas9 B-proteingene
staining O
. O

Boxes O
indicate O
areas O
shown O
at O
higher O
magnification O
in O
the O
insets O
(45 O
x O
45 O
μm) O
. O

Dotted O
lines O
indicate O
nuclei O
of O
progeny O
of O
electroporated O
Cas9; B-proteingene
note O
the O
presence O
of O
Tbr2 B-proteingene
immunoreactivity O
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gTbr2 B-proteingene
plasmid O
electroporation O
(bottom) O
. O

Scale O
bars, O
20 O
μm O
. O

(B) O
Quantification O
of O
the O
proportion O
of O
Cas9+ B-proteingene
cells O
that O
are O
Tbr2+ B-proteingene
48 O
h O
after O
control O
(Con, O
white) O
or O
gTbr2 B-proteingene
(black) O
plasmid O
electroporation O
. O

Data O
are O
the O
mean O
of O
4 O
independent O
experiments O
(6 O
embryos O
per O
condition, O
from O
4 O
litters) O
. O

(C) O
Electroporated O
area O
showing O
the O
effects O
of O
Cas9 B-proteingene
expression O
(revealed O
by O
PaprikaRFPfluorescence, B-proteingene
magenta) O
together O
with O
either O
control O
gRNA B-proteingene
(top) O
or O
gTbr2 B-proteingene
(bottom) O
on O
the O
abundance O
of O
mitotic O
progenitors O
as O
revealed O
by O
phosphohistone O
H3 B-proteingene
(PH3) O
immunofluorescence O
(green) O
. O

Apical O
and O
basal O
mitoses O
are O
indicated O
by O
arrows O
and O
arrowheads, O
respectively; O
note O
the O
reduction O
in O
mitotic O
Cas9+ B-proteingene
BPs O
upon O
Cas9/gTbr2 B-proteingene
plasmid O
electroporation O
. O

Scale O
bars, O
20 O
μm O
. O

(D) O
Quantification O
of O
apical O
and O
basal O
Cas9+ B-proteingene
mitoses O
(as O
revealed O
by O
PH3 O
immunofluorescence) O
in O
a O
unit O
area O
48 O
h O
after O
Cas9/gTbr2 B-proteingene
plasmid O
electroporation O
. O

Data O
are O
expressed O
as O
percentage O
of O
the O
data O
obtained O
upon O
control O
plasmid O
electroporation O
and O
are O
the O
mean O
of O
3 O
independent O
experiments O
(3 O
embryos O
per O
condition O
in O
total, O
from O
3 O
litters); O
note O
the O
reduction O
in O
basal O
(black, O
68%) O
but O
not O
apical O
(white) O
mitoses O
. O

(E-H) O
Single O
aRGCs O
in O
neocortex O
in O
organotypic O
slices O
of O
telencephalon O
of O
E14.5 O
mouseembryos O
were O
microinjected O
with O
recombinant O
Cas9 B-proteingene
protein O
together O
with O
gRNA B-proteingene
targeting O
either O
LacZ B-proteingene
(Control, O
Con) O
or O
Tbr2 B-proteingene
(gTbr2) B-proteingene
and O
with O
Dextran O
10,000-Alexa O
555 O
(Dx-A555), O
followed O
by O
analysis O
after O
48 O
h O
of O
culture O
. O

(E) O
Progeny O
of O
single O
microinjected O
aRGCs O
(revealed O
by O
Dx-A555immunofluorescence, O
magenta, O
dotted O
lines) O
showing O
the O
effects O
of O
Cas9 B-proteingene
together O
with O
either O
control O
gRNA B-proteingene
(top) O
or O
gTbr2 B-proteingene
(bottom) O
on O
Tbr2 B-proteingene
expression O
(green, O
immunofluorescence); O
blue, O
DAPI O
staining O
. O

Note O
the O
presence O
of O
Tbr2 B-proteingene
immunoreactivity O
in O
the O
control O
(top) O
and O
its O
absence O
upon O
Cas9/gTbr2 B-proteingene
(bottom) O
protein O
microinjection O
. O

Images O
are O
single O
optical O
sections O
. O

Scale O
bars, O
5 O
µm O
. O

(F) O
Quantification O
of O
the O
proportion O
of O
the O
progeny O
(Dx-A555+) O
of O
microinjected O
aRGCs O
that O
show O
Tbr2 B-proteingene
expression O
48 O
h O
after O
control O
(Con, O
white) O
or O
gTbr2 B-proteingene
(black) O
microinjection O
. O

Data O
are O
the O
mean O
of O
3 O
independent O
experiments O
(3 O
embryos O
per O
condition; O
total O
number O
of O
cells O
scored: O
control O
45, O
gTbr2 B-proteingene
41) O
. O

(G) O
Distribution O
across O
the O
cortical O
wall O
of O
the O
progeny O
(revealed O
by O
Dx-A555immunofluorescence, O
magenta; O
arrows, O
aRGC; O
arrowheads, O
BPs; O
open O
arrow, O
neuron) O
of O
single O
control O
(left) O
or O
gTbr2 B-proteingene
(right) O
microinjected O
aRGCs O
. O

Dashed O
lines O
indicate O
ventricular O
surface O
(bottom) O
and O
basal O
lamina O
(top) O
. O

Images O
are O
maximum O
intensity O
projections O
of O
67 O
(Control) O
and O
94 O
(gTbr2) B-proteingene
single O
optical O
sections O
. O

Scale O
bars, O
20 O
µm O
. O

(H) O
Quantification O
of O
the O
distribution O
of O
the O
progeny O
(Dx-A555+) O
of O
microinjected O
aRGCs O
in O
the O
VZ, O
SVZ O
and O
intermediate O
zone/cortical O
plate O
(CP+IZ) O
48 O
h O
after O
control O
(Con, O
white) O
or O
gTbr2 B-proteingene
(black) O
microinjection O
(total O
number O
of O
cells O
scored: O
control O
37, O
gTbr2 B-proteingene
51, O
pooled O
from O
at O
least O
3 O
independent O
experiments) O
. O

Note O
that O
upon O
gTbr2 B-proteingene
microinjection O
the O
distribution O
of O
cells O
across O
the O
various O
cortical O
zones O
is O
significantly O
different O
(VZ: O
control O
77%, O
gTbr2 B-proteingene
39: O
SVZ: O
control O
20%, O
gTbr2 B-proteingene
37%; O
IZ/CP: O
control O
3%, O
gTbr2 B-proteingene
24%, O
*, O
P<0.05) O
. O

(B, O
F) O
Controls O
were O
set O
to O
100% O
and O
the O
gTbr2 B-proteingene
conditions O
expressed O
relative O
to O
control O
(B, O
48%; O
F, O
50%) O
. O

(B, O
D, O
F) O
Error O
bars O
indicate O
SD O
(B, O
D, O
F); O
*, O
P<0.05; O
**, O
P<0.01 O
. O

Figure O
4 O
. O

Sequencing O
analysis O
of O
the O
CRISPR/Cas9-induced B-proteingene
disruption O
of O
the O
Tbr2 B-proteingene
locus O
. O

(A-C) O
Next-generation O
DNA O
sequencing O
analysis O
of O
amplicons O
containing O
the O
Tbr2 B-proteingene
locus O
and O
4 O
off-target O
loci O
generated O
from O
PaprikaRFP-expressing B-proteingene
cells O
isolated O
at O
E15.5 O
from O
neocortex O
of O
mouseembryos O
in O
utero O
electroporated O
at O
E13.5 O
with O
plasmids O
encoding O
Cas9_T2A_PaprikaRFP B-proteingene
and O
either O
gTbr2 B-proteingene
(black) O
or O
control O
gRNA B-proteingene
(Con, O
white) O
as O
in O
Fig O
3 O
A-D. O
(A) O
Quantification O
of O
the O
frequency O
of O
mismatches O
to O
the O
mouse O
genome O
sequence O
spanning O
30 O
bp O
upstream O
and O
downstream O
of O
the O
Tbr2 B-proteingene
target O
site O
and O
the O
off-target O
sites O
(OT1-4) B-proteingene
. O

Data O
are O
expressed O
as O
percentage O
of O
the O
total O
number O
of O
reads O
and O
are O
the O
mean O
of O
two O
independent O
experiments O
(8 O
and O
5 O
embryos O
per O
condition, O
respectively) O
. O

(B, O
C) O
Analysis O
of O
one O
of O
the O
experiments O
of O
(A) O
for O
deletions O
(B) O
and O
insertions O
(C) O
in O
the O
region O
spanning O
80 O
bp O
upstream O
and O
downstream O
of O
the O
Tbr2 B-proteingene
target O
site O
upon O
Cas9/gTbr2 B-proteingene
plasmid O
electroporation O
. O

(A) O
In O
a O
mixed O
population, O
flies O
reach O
the O
end O
of O
a O
"pre-mortality O
plateau O
phase" O
(PMP) O
at O
an O
age O
of O
four O
weeks, O
where O
90% O
of O
the O
flies O
are O
still O
alive O
. O

We O
define O
this O
age O
as O
their O
"midlife" O
point O
. O

At O
this O
stage, O
the O
rate O
of O
the O
population O
decline O
accelerates O
from O
1% O
(plateau) O
per O
day O
in O
the O
previous O
10 O
days O
to O
3.5% O
per O
day O
in O
the O
following O
10 O
days O
. O

Median O
survival=39 O
days, O
N=260 O
. O

(B) O
Oxygen O
consumption O
rates O
(OCR) O
quantification O
show O
a O
decreased O
OCR O
in O
old O
whole O
heads O
compared O
to O
young O
flies O
. O

Data O
were O
normalized O
to O
1-week-old O
flies O
(young O
flies) O
. O

and O
N=14 O
young O
versus O
N=12 O
old O
. O

(C) O
At O
midlife, O
flies O
show O
a O
reduced O
physical O
activity O
compared O
to O
young O
flies O
. O

(D) O
Oxygen O
consumption O
rates O
(OCR) O
quantification O
show O
an O
increased O
OCR O
in O
midlife O
whole O
heads O
compared O
to O
young O
flies O
. O

Data O
were O
normalized O
to O
1-week-old O
flies O
(young O
flies) O
. O

N=21 O
young O
versus O
N=24 O
midlife O
. O

(E) O
Metabolite O
levels O
show O
increased O
levels O
of O
acetyl-CoA B-proteingene
and O
citrate/isocitrate O
compound O
in O
midlife O
flies O
. O

N=6 O
per O
group O
. O

(F) O
Enzymatic O
activity O
of O
citrate B-proteingene
synthase I-proteingene
and O
ATPCL B-proteingene
is O
increased O
in O
midlife O
flies O
. O

CS, B-proteingene
citrate B-proteingene
synthase I-proteingene
(Kdn); B-proteingene
ATPCL, B-proteingene
ATPcitrate B-proteingene
lyase I-proteingene
. O

Data O
was O
normalized O
to O
young O
flies O
. O

N=8 O
young O
versus O
9 O
midlife O
for O
CS B-proteingene
and O
6 O
young O
versus O
7 O
midlife O
for O
ATPCL B-proteingene
. O

(*P<0.05, O
**P<0.01 O
***P<0.001) O
. O

Error O
bars O
indicate O
the O
S.E.M. O
in O
all O
the O
graphs O
. O

Unpaired O
two O
tailed O
t-tests O
were O
used O
for O
calculating O
the O
p-values O
in O
B-F. O
All O
male O
flies O
were O
collected O
from O
a O
mixed O
male/female O
population O
. O

(A) O
Representative O
western O
blot O
showing O
a O
mildly O
altered O
protein O
acetylation O
pattern O
(Anti O
AcK) O
between O
1 O
week O
(young) O
and O
4 O
week O
(midlife) O
old O
flies O
. O

Tubulin B-proteingene
served O
as O
a O
loading O
control O
. O

N=4-5 O
per O
group O
. O

Tub, B-proteingene
Tubulin B-proteingene
. O

(B) O
Heat O
map O
showing O
altered O
protein O
acetylation O
sites O
between O
young O
and O
midlife O
flies, O
based O
on O
the O
acetyl-lysine O
enriched O
peptide O
fractions O
analyzed O
by O
MS O
and O
after O
normalization O
to O
protein O
input O
(Detailed O
statistical O
method O
in O
extended O
'Methods') O
. O

N=5 O
per O
group O
. O

fc, O
fold O
change O
. O

(C) O
The O
lysine O
deacetylase O
inhibitor O
(KDACi) O
sodium O
butyrate O
(SB) O
induces O
a O
rapid O
increase O
in O
oxygen O
consumption O
in O
the O
heads O
of O
young O
flies, O
but O
this O
increase O
is O
milder O
in O
midlife O
flies O
. O

The O
dashed O
line O
indicates O
the O
addition O
of O
SB. O
Data O
was O
normalized O
to O
the O
measurement O
prior O
to O
addition O
of O
SB O
(100%) O
and O
collected O
after O
five O
cycles O
of O
measurements, O
corresponding O
to O
approximately O
33 O
minutes O
. O

N=9 O
young O
vehicle, O
8 O
young O
SB, O
9 O
midlife O
vehicle O
and O
7 O
midlife O
SB O
(**P<0.01, O
***P<0.001) O
. O

Error O
bars O
indicate O
the O
S.E.M O
. O

(D) O
High O
sodium O
butyrate O
(SB) O
treated O
flies O
reach O
the O
end O
of O
the O
pre-mortality O
plateau O
phase O
at O
earlier O
age O
of O
11 O
days O
. O

Survival O
90% O
control O
= O
26 O
days, O
15 O
mM O
SB O
= O
24 O
days, O
150 O
mM O
SB O
= O
11 O
days O
. O

Median O
survival O
for O
control O
= O
45 O
days, O
15 O
mM O
SB O
= O
41 O
days, O
150 O
mM O
SB O
= O
30 O
. O

N=357 O
(vehicle), O
294 O
(15 O
mM O
SB) O
and O
320 O
(150 O
mM O
SB) O
. O

SB O
15mM O
Log O
Rank O
Test, O
χ2 O
=14.83, O
p=0.0001 O
. O

SB O
150mM O
Log O
Rank O
Test, O
χ2 O
=151.1, O
p<0.0001 O
. O

Unpaired O
two O
tailed O
t-tests O
were O
used O
for O
calculating O
the O
p-values O
in O
C. O
All O
male O
flies O
were O
collected O
from O
a O
mixed O
male/female O
population O
. O

(A) O
Quantification O
of O
major O
acetylation O
sites O
on O
histones B-proteingene
H3 I-proteingene
and O
H4 B-proteingene
in O
young O
and O
midlife O
flies O
. O

Midlife O
flies O
display O
a O
transformed O
histone O
acetylation O
profile O
including O
elevation O
(H4K12, B-proteingene
H3K9, B-proteingene
H3K9/14 B-proteingene
and O
H3K23) B-proteingene
and O
reduction O
(H4K8 B-proteingene
and O
H3K18) B-proteingene
. O

Data O
were O
normalized O
to O
1-week-old O
(young) O
flies O
. O

N=15-22 O
(histone B-proteingene
4) I-proteingene
and O
12-19 O
(histone B-proteingene
3) I-proteingene
per O
group O
. O

Error O
bars O
indicate O
the O
S.E.M O
. O

(B) O
Male O
flies O
show O
a O
gradual O
increased O
lifespan O
and O
prolonged O
pre-mortality O
plateau O
phase O
at O
various O
length O
of O
exposure O
to O
18º O
C O
(cold) O
compared O
to O
the O
25º O
C O
(control) O
ambient O
temperature O
. O

Survival O
90% O
control=28 O
days, O
cold=58 O
days O
. O

Median O
survival; O
Control=38 O
days, O
cold=80 O
days O
. O

N=295 O
(control) O
and O
238 O
(cold) O
. O

Log O
Rank O
Test, O
χ2 O
=527.1, O
p<0.0001 O
. O

(C) O
Comparison O
of O
the O
activity O
of O
key O
metabolic O
enzymes O
between O
midlife O
flies O
grown O
at O
18ºC O
and O
25ºC. O
Midlife O
flies O
grown O
at O
25ºC O
have O
lower O
CS B-proteingene
and O
ATPCL B-proteingene
activity O
to O
midlife O
flies O
at O
25ºC. O
CS, B-proteingene
citrate B-proteingene
synthase; I-proteingene
ATPCL, B-proteingene
ATPcitrate B-proteingene
lyase I-proteingene
. O

N=9 O
midlife O
vs O
6 O
cold O
midlife O
for O
CS B-proteingene
and O
7 O
midlife O
vs O
6 O
cold O
midlife O
for O
ATPCL B-proteingene
. O

(D) O
Metabolite O
levels O
show O
reduced O
levels O
citrate O
and O
ATP O
in O
midlife O
flies O
at O
18ºC. O
The O
levels O
of O
acetyl-CoA B-proteingene
are O
not O
significantly O
different O
despite O
a O
trend O
of O
reduced O
levels O
in O
18ºC O
flies O
. O

N=6 O
midlife O
vs O
5 O
cold O
midlife O
. O

(E) O
Midlife O
flies O
grown O
at O
18ºC O
show O
a O
general O
reduction O
of O
histone O
acetylation O
states O
including O
acetylation O
states O
which O
are O
increased O
upon O
aging O
(Figure O
3A O
- O
H4K12, B-proteingene
H3K9, B-proteingene
H3K9/14 B-proteingene
and O
H3K23) B-proteingene
. O

Of O
note, O
H4K8 B-proteingene
is O
increased O
in O
midlife O
when O
flies O
are O
kept O
at O
18ºC. O
N=16-21 O
(histone B-proteingene
4) I-proteingene
and O
13-16 O
(histone B-proteingene
3) I-proteingene
per O
group O
. O

Data O
for O
the O
midlife O
flies O
were O
normalized O
to O
young O
flies O
as O
shown O
in O
panel O
A O
. O

(*P<0.05, O
**P<0.01, O
***P<0.001) O
. O

Error O
bars O
indicate O
the O
S.E.M. O
in O
all O
the O
graphs O
. O

Unpaired O
two O
tailed O
t-tests O
were O
used O
for O
calculating O
the O
p-values O
in O
A, O
C-E. O
All O
male O
flies O
were O
collected O
from O
a O
mixed O
male/female O
population O
. O

(A) O
ATPCL B-proteingene
mutant O
male O
flies O
show O
reduced O
ATPCL B-proteingene
activity O
at O
their O
4th O
week O
. O

N=7 O
per O
group O
. O

(B) O
Non-targeted O
metabolome O
reveals O
71 O
singinifcatly O
altered O
metabolites O
in O
young O
wild-type O
versus O
young O
+/atpcl B-proteingene
mutants, O
while O
439 O
metabolites O
are O
altered O
in O
the O
midlife O
groups O
out O
of O
1,658 O
metabolite O
compounds O
. O

N=6 O
per O
group O
. O

(C) O
Targeted O
metabolite O
measurements O
show O
decreased O
acetyl-CoA B-proteingene
and O
succinate O
in O
midlife O
+/atpcl B-proteingene
mutants O
. O

N=4-6 O
per O
measurement O
. O

(D) O
Quantification O
of O
histone O
H3 B-proteingene
and O
H4 B-proteingene
acetylation O
in O
+/atpcl B-proteingene
mutants O
at O
4 O
weeks O
old O
(midlife) O
. O

Age-associated O
hyper-acetylated O
histone O
states O
are O
reduced O
in O
+/atpcl B-proteingene
mutant O
flies O
(H4K12, B-proteingene
H3K14, B-proteingene
H3K9/14 B-proteingene
and O
H3K23) B-proteingene
. O

N=5-6 O
per O
group O
. O

(E) O
+/atpcl B-proteingene
male O
flies O
show O
an O
increased O
mean O
lifespan O
and O
slower O
mortality O
rates O
in O
midlife O
. O

Survival O
90% O
control O
= O
26 O
days, O
+/atpcl B-proteingene
= O
30 O
days, O
Median O
survival O
for O
control O
= O
38 O
days, O
+/atpcl B-proteingene
= O
50 O
days O
. O

N=220 O
(control), O
and O
202 O
(+/atpcl) B-proteingene
. O

Log O
Rank O
Test, O
χ2 O
=67.87, O
p<0.0001 O
. O

Error O
bars O
indicate O
the O
S.E.M. O
in O
all O
the O
graphs O
. O

Unpaired O
two O
tailed O
t-tests O
were O
used O
for O
calculating O
the O
p-values O
in O
A-D. O
All O
male O
flies O
were O
collected O
from O
a O
mixed O
male/female O
population O
. O

(A) O
The O
mutant O
chm B-proteingene
allele O
we O
used O
removes O
the O
catalytic, O
histone O
acetyltransferase O
MYST O
domain O
. O

The O
chm B-proteingene
mutants O
consistently O
display O
50% O
mRNA O
reduction O
in O
young O
(7 O
days) O
and O
midlife O
(22 O
days) O
when O
compared O
to O
wild-type O
flies O
. O

N=5 O
young O
wt, O
6 O
young O
chm B-proteingene
mutants, O
4 O
midlife O
wt O
and O
6 O
midlife O
chmmutants B-proteingene
. O

(B) O
MS-based O
quantification O
of O
histone O
H4 B-proteingene
and O
H3 B-proteingene
acetylation O
reveals O
a O
specific O
reduction O
of O
H4K12ac B-proteingene
in O
male O
chm B-proteingene
heterozygous O
mutants O
at O
22 O
days O
of O
age O
(midlife) O
. O

N=7 O
per O
group O
. O

(C) O
RNA-seq O
analysis O
reveals O
1,758 O
significantly O
altered O
genes O
during O
wild-type O
aging O
and O
1,319 O
altered O
genes O
during O
chm B-proteingene
aging O
process O
. O

920 O
genes O
are O
common O
to O
both O
aging O
processes O
. O

N=5 O
young O
wt, O
6 O
young O
chm B-proteingene
mutants, O
4 O
midlife O
wt O
and O
6 O
midlife O
chmmutants B-proteingene
. O

(D) O
Shared O
age-associated O
down O
regulated O
genes O
display O
similar O
fold-change O
response O
in O
wild-type O
and O
chm B-proteingene
aging O
. O

In O
contrast, O
the O
up O
regulated O
genes O
display O
higher O
fold O
change O
in O
wild-type O
aging O
compared O
with O
+/chm B-proteingene
aging O
. O

(E) O
Chm B-proteingene
male O
flies O
show O
increased O
mean O
lifespan O
and O
slower O
mortality O
rates O
in O
midlife O
. O

Survival O
90% O
control O
= O
20 O
days, O
chm B-proteingene
= O
22 O
days O
. O

Median O
survival O
for O
control O
= O
34 O
days, O
chm= B-proteingene
42 O
days, O
N O
= O
180 O
(control) O
and O
175 O
(chm) B-proteingene
. O

Log O
Rank O
Test, O
χ2 O
=37.15, O
p<0.0001 O
. O

(F) O
Midlife O
chm B-proteingene
mutants O
display O
increase O
activity O
compared O
to O
midlife O
control O
. O

(G) O
Double O
chm/atpcl B-proteingene
mutant O
display O
similar O
lifespan O
to O
+/atpcl B-proteingene
mutant O
. O

Survival O
90% O
+/atpcl B-proteingene
= O
39 O
days, O
chm/atpcl B-proteingene
= O
35 O
days O
. O

Median O
survival O
for O
+/atpcl B-proteingene
= O
57 O
days, O
chm/atpcl= B-proteingene
54 O
days, O
N O
= O
256 O
(+/atpcl) B-proteingene
and O
301 O
(chm/atpcl) B-proteingene
. O

Log O
Rank O
Test, O
χ2 O
=3.19 O
. O

(*P<0.05, O
**P<0.01, O
***P<0.001) O
. O

Error O
bars O
indicate O
the O
S.E.M. O
in O
all O
the O
graphs O
. O

Unpaired O
two O
tailed O
t-tests O
were O
used O
for O
calculating O
the O
p-values O
in O
A, O
B O
and O
F. O
All O
male O
flies O
were O
collected O
from O
a O
mixed O
male/female O
population O
. O

(b) O
Temperature-sensitive O
growth O
assay O
. O

Yeast O
strains O
(wild-type O
or O
deletion O
mutants, O
indicated O
on O
the O
left) O
were O
transformed O
with O
either O
an O
empty O
vector O
or O
a O
plasmid O
carrying O
an O
artificial O
guide O
RNA O
gene O
targeting O
U2 O
pseudouridylation O
at O
position O
42 O
and O
44 O
(indicated O
on O
the O
top), O
and O
grown O
at O
various O
temperatures O
(indicated O
at O
the O
bottom) O
. O

(c) O
Blockage O
of O
pseudouridylation O
by O
deletion O
of O
specific O
pseudouridylase O
genes O
. O

RNAs O
isolated O
from O
wild-type O
and O
pseudouridylase-deletion O
strains O
(indicated O
on O
the O
top) O
were O
used O
for O
U2 O
pseudouridylation O
assay O
(CMC O
modification O
followed O
by O
primer-extension) O
. O

Primer-extension O
pauses/stops O
correspond O
to O
ψ O
sites O
(indicated O
on O
the O
left O
and O
right) O
. O

Note: O
The O
above-background O
signal O
of O
ψ42 O
in O
the O
snr81Δ B-proteingene
lane O
(and O
to O
some O
extent, O
in O
the O
snr81Δ B-proteingene
pus7Δ B-proteingene
lane) O
is O
likely O
caused O
by O
the O
presence O
of O
strong O
ψ44 O
band O
. O

This O
is O
a O
primer-extension O
artifact, O
which O
often O
occurs O
when O
there O
is O
a O
strong O
ψ O
signal O
in O
the O
neighboring O
position O
. O

Alternatively, O
it O
is O
possible O
that O
having O
ψ O
at O
position O
44 O
allows O
for O
an O
unidentified O
enzyme O
other O
than O
snR81 B-proteingene
to O
modify O
U42 O
(albeit O
inefficiently) O
(Perhaps O
Pus1, B-proteingene
which O
is O
responsible O
for O
ψ44 O
formation, O
can O
be O
a O
bit O
"processive") O
. O

Lanes O
1-8 O
and O
lanes O
9-16 O
are O
from O
two O
separate O
gels O
. O

(d) O
Restoration O
of O
U2 O
pseudouridylation O
by O
an O
artificial O
box O
H/ACA O
RNA. O
RNAs O
isolated O
from O
various O
yeast O
strains O
(indicated O
on O
the O
top), O
including O
the O
snr81Δ B-proteingene
pusΔ O
strain O
that O
was O
transformed O
with O
an O
artificial O
guide O
RNA O
targeting O
positions O
42 O
and O
44 O
(lanes O
9 O
and O
10), O
were O
assayed O
for O
pseudouridylation O
[see O
legend O
to O
(c)] O
. O

(a) O
Growth O
assay O
using O
the O
ACT1-CUP1 B-proteingene
reporter O
system O
. O

Yeast O
cells O
carrying O
the O
ACT1-CUP1 B-proteingene
reporter O
were O
deleted O
of O
pseudouridylase O
genes O
(indicated O
on O
the O
left), O
and O
were O
then O
assayed O
for O
growth O
at O
30°C O
on O
media O
containing O
various O
concentrations O
of O
[Cu2+] O
(indicated O
at O
the O
bottom) O
. O

(b) O
Growth O
rescue O
by O
restoration O
of O
pseudouridylation O
. O

The O
wild-type O
strain O
[from O
(a)] O
or O
the O
snr81Δ B-proteingene
pusΔ O
strain O
[also O
from O
(a)], O
which O
exhibited O
the O
most O
severe O
growth-deficiency O
phenotype, O
was O
transformed O
with O
an O
empty O
vector O
or O
a O
plasmid O
carrying O
a O
pseudouridylation O
guide O
RNA O
gene O
targeting O
either O
position O
42, O
position O
44, O
or O
both O
(indicated) O
. O

The O
resulting O
cells O
were O
assayed O
for O
growth O
at O
30°C O
on O
media O
containing O
various O
concentrations O
of O
[Cu2+] O
(indicated O
at O
the O
bottom) O
. O

(d) O
Splicing O
assay O
using O
the O
wild-type O
and O
mutant O
ACT1-CUP1 B-proteingene
reporters O
. O

RNAs O
isolated O
from O
the O
wild-type O
and O
the O
snr81Δ B-proteingene
pusΔ O
strains O
(indicated O
on O
the O
top), O
which O
carry O
the O
wild-type O
ACT1-CUP1 B-proteingene
reporter O
pre-mRNA O
or O
any O
of O
the O
mutant O
ACT1-CUP1 B-proteingene
reporter O
pre-mRNAs O
[indicated, O
also O
see O
(c)], O
were O
used O
for O
splicing O
assay O
(primer-extension O
analysis) O
. O

The O
un-spliced O
pre-mRNA, O
lariat O
intermediate, O
and O
spliced O
mRNA O
are O
indicated O
. O

A O
primer O
complementary O
to O
U6 O
was O
also O
used O
(as O
an O
internal O
control) O
in O
the O
assay, O
and O
the O
U6 O
band O
is O
indicated O
as O
well O
. O

In O
addition, O
the O
growth O
phenotype O
of O
each O
strain O
(in O
various O
concentrations O
of O
[Cu2+]) O
is O
also O
shown O
. O

Lanes O
1-12, O
lanes O
13 O
and O
14, O
and O
lanes O
15 O
and O
16 O
are O
from O
separate O
gels O
. O

(e) O
Quantification O
of O
ACT1-CUP1mRNA O
levels O
. O

Spliced O
ACT1-CUP1mRNA O
levels O
were O
calculated O
relative O
to O
U6 O
in O
each O
lane O
. O

The O
quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(f) O
Relative O
improvement/reduction O
for O
the O
mutant O
reporters O
. O

Relative O
improvement O
or O
reduction O
in O
splicing O
was O
calculated O
by O
normalizing O
the O
splicing O
efficiency O
(mRNA/U6) O
of O
each O
mutant O
reporter O
to O
that O
of O
WT O
reporter O
(set O
at O
1) O
. O

Figure O
3 O
. O

Synthetic O
lethality O
assay O
. O

The O
Prp5 B-proteingene
domain O
structure, O
and O
the O
mutations O
in O
some O
of O
the O
domains O
(indicated) O
are O
schematized O
at O
the O
top O
. O

Each O
of O
these O
PRP5 B-proteingene
genes O
(wild-type O
or O
mutants, O
plasmid-borne) O
was O
used O
to O
replace O
the O
chromosomalPRP5 B-proteingene
. O

The O
numbers O
in O
parentheses O
are O
the O
relative O
ATPase O
activities O
of O
the O
wild-type O
(SAT) O
Prp5 B-proteingene
and O
some O
of O
the O
Prp5 B-proteingene
mutants O
tested O
before O
(Xu O
& O
Query, O
2007) O
. O

The O
U2 O
status, O
either O
containing O
Ψ42 O
and O
Ψ44 O
(WT-U2 O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
with O
pΨ42 O
or O
Ψ44) O
or O
lacking O
Ψ42 O
and O
Ψ44 O
(snR81Δ B-proteingene
pus1Δ), B-proteingene
is O
indicated O
(on O
the O
right) O
. O

Upon O
transformation O
with O
the O
plasmids O
carrying O
PRP5 B-proteingene
genes O
(wild-type O
or O
any O
of O
the O
mutants), O
cells O
were O
grown O
on O
the O
regular O
medium O
(-FOA) O
or O
on O
medium O
containing O
5-FOA O
(+FOA) O
. O

(a) O
Prp5-U2co-immunoprecipitation B-proteingene
(IP) O
. O

Wild-type O
(lanes O
1 O
and O
2) O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
(lane O
3) O
strains, O
each O
containing O
a O
FLAG-tagged B-proteingene
PRP5 B-proteingene
gene O
(indicated O
on O
the O
top), O
were O
used O
for O
anti-FLAGIP B-proteingene
in O
the O
absence O
(lane O
1) O
or O
presence O
(lanes O
2 O
and O
3) O
of O
ATP. O
The O
precipitated O
Prp5 B-proteingene
(WT O
Prp5-FLAG) B-proteingene
as O
well O
as O
co-precipitatedU1 O
and O
U2, O
detected O
by O
primer-extension, O
are O
indicated O
. O

(b) O
Quantification O
of O
co-precipitatedU2 O
snRNA. O
For O
each O
lane O
[the O
WT O
lane O
and O
the O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane, O
corresponding O
to O
lane O
2 O
and O
lane O
3 O
of O
(a), O
respectively], O
Prp5-co-precipitatedU2 B-proteingene
was O
normalized O
against O
co-precipitatedU1 O
[(intensity O
of O
the O
U2 O
band) O
/ O
(intensity O
of O
the O
U1 O
band)] O
. O

The O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane O
was O
then O
further O
normalized O
against O
the O
WT O
lane O
[(the O
value O
of O
normalized O
U2 O
from O
the O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane) O
/ O
(the O
value O
of O
normalized O
U2 O
from O
the O
WT O
lane)] O
. O

Quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(c) O
U2 O
expression O
level O
in O
wild-type O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
strains O
. O

Total O
RNA, O
isolated O
from O
the O
wild-type O
(lane O
1) O
or O
snR81Δ B-proteingene
pus1Δ B-proteingene
(lane O
2) O
strains, O
was O
used O
for O
primer-extension O
to O
measure O
the O
levels O
of O
U2 O
and O
U6 O
. O

The O
U2 O
and O
U6 O
bands O
are O
indicated O
. O

d) O
Depletion O
of O
Prp5 B-proteingene
. O

Wild-type O
(lanes O
1, O
3 O
and O
4) O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
(lanes O
2 O
and O
5) O
cells O
containing O
a O
FLAG-tagged B-proteingene
PRP5 B-proteingene
were O
lysed, O
and O
anti-FLAGIP B-proteingene
was O
performed O
at O
a O
high O
concentration O
of O
salt O
. O

Cell O
extracts, O
before O
(lanes O
1 O
and O
2), O
and O
after O
[lanes O
3 O
(mock), O
4 O
and O
5] O
anti-FLAGIP, B-proteingene
were O
used O
for O
western O
analysis O
using O
anti-FLAG. B-proteingene
The O
Prp5 B-proteingene
band O
is O
indicated O
. O

(e) O
IP O
of O
reconstituted O
Prp5 B-proteingene
(GAR)-U2 O
. O

An O
equal O
amount O
of O
FLAG-tagged B-proteingene
Prp5 B-proteingene
(GAR) O
was O
added O
to O
the O
wild-type O
(lane O
1) O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
(lane O
2) O
cell O
extracts O
depleted O
of O
endogenous O
Prp5 B-proteingene
[see O
(c)] O
. O

After O
the O
salt O
concentration O
was O
brought O
back O
to O
its O
original O
level, O
anti-FLAGIP B-proteingene
was O
carried O
out O
. O

The O
Prp5 B-proteingene
(GAR) O
band, O
detected O
by O
western, O
is O
indicated O
. O

The O
co-precipitatedU1 O
and O
U2 O
bands, O
detected O
by O
primer-extension, O
are O
also O
indicated O
. O

f) O
Quantification O
of O
U2 O
that O
is O
co-precipitated O
with O
mutant O
Prp5 B-proteingene
(GAR) O
. O

For O
each O
lane O
[including O
the O
WT O
lane O
and O
the O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane, O
corresponding O
to O
lane O
1 O
and O
lane O
2 O
of O
(e), O
respectively], O
U2co-precipitated O
with O
Prp5 B-proteingene
(GAR) O
was O
normalized O
against O
co-precipitatedU1 O
[(intensity O
of O
the O
U2 O
band) O
/ O
(intensity O
of O
the O
U1 O
band)] O
. O

The O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane O
was O
then O
further O
normalized O
against O
the O
WT O
lane O
[(the O
value O
of O
normalized O
U2 O
from O
the O
snr81Δ B-proteingene
pus1Δ B-proteingene
lane) O
/ O
(the O
value O
of O
normalized O
U2 O
from O
the O
WT O
lane)] O
. O

Quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(g) O
Prp5-U2-pre-mRNAco-IP. O
Reconstitution O
was O
carried O
out O
as O
described O
in O
(d) O
. O

Prior O
to O
IP, O
an O
equal O
amount O
of O
radiolabeled O
pre-mRNA O
was O
also O
added O
to O
each O
reaction O
. O

Anti-FLAGIP B-proteingene
was O
then O
performed O
in O
the O
presence O
of O
ATP. O
The O
precipitated O
Prp5 B-proteingene
(WT O
and O
GAR) O
band, O
detected O
by O
western, O
is O
indicated O
. O

The O
co-precipitatedpre-mRNA, O
directly O
visualized O
after O
electrophoresis, O
is O
also O
indicated O
. O

The O
pre-mRNA O
input O
is O
also O
shown O
. O

In O
lanes O
1 O
and O
2, O
wild-type O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
cell O
extracts, O
depleted O
of O
Prp5, B-proteingene
were O
reconstituted O
with O
the O
wild-type O
FLAG-Prp5 B-proteingene
. O

In O
lanes O
3 O
and O
4, O
wild-type O
and O
snR81Δ B-proteingene
pus1Δ B-proteingene
cell O
extracts, O
depleted O
of O
Prp5, B-proteingene
were O
reconstituted O
with O
mutant O
FLAG-Prp5 B-proteingene
(GAR) O
. O

(h) O
Quantification O
of O
pre-mRNAco-precipitated O
with O
Prp5 B-proteingene
and O
U2 O
. O

For O
each O
lane O
in O
(g), O
pre-mRNAco-precipitated O
with O
Prp5 B-proteingene
(Wild-type O
or O
GAR) O
was O
normalized O
against O
the O
Prp5 B-proteingene
(WT/GAR) O
band O
in O
the O
same O
lane O
(detected O
by O
Anti-FLAG) B-proteingene
[(intensity O
of O
pre-mRNA) O
/ O
(intensity O
of O
WT/GAR O
Prp5)] B-proteingene
. O

Lanes O
2,3,and O
4 O
(see O
(g)) O
were O
then O
further O
normalized O
against O
lane O
1 O
(see O
(g)) O
[(the O
value O
of O
normalized O
pre-mRNA O
from O
lane O
2, O
3 O
or O
4 O
in O
(g)) O
/ O
(the O
value O
of O
normalized O
pre-mRNA O
from O
lane O
1 O
in O
(g))] O
. O

The O
numbers O
at O
the O
bottom O
of O
(h) O
correspond O
to O
the O
lane O
numbers O
of O
(g) O
. O

Quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(a) O
Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
assay O
using O
synthetic O
U2 O
. O

The O
5' O
sequence O
of O
S. O
cerevisiae O
U2 O
is O
shown O
(top) O
. O

The O
three O
ψs O
(35, O
42 O
and O
44) O
as O
well O
as O
the O
branch O
site O
recognition O
sequence O
(underlined) O
are O
indicated O
. O

In O
the O
ATPase O
assay O
(bottom), O
no O
RNA O
(lane O
3), O
or O
an O
equal O
amount O
of O
LiCl-precipitated O
RNA O
(lane O
1) O
or O
tRNA O
(lane O
2), O
a O
short O
U2 O
fragment O
(nts O
1-76) O
(lane O
4), O
a O
fully O
pseudouridylated O
short O
U2 O
fragment O
(nts O
1-76) O
(lane O
5), O
a O
long O
U2 O
fragment O
(nts O
1-120) O
(lane O
6), O
or O
a O
fully O
pseudouridylated O
long O
U2 O
fragment O
(nts O
1-120) O
(lane O
7), O
was O
used O
. O

The O
un-hydrolyzed O
ATP O
and O
hydrolyzed O
product O
ADP O
are O
indicated O
. O

Lanes O
1 O
and O
2, O
lanes O
3-5, O
and O
lanes O
6 O
and O
7 O
are O
from O
separate O
gels O
. O

(b) O
Quantification O
of O
Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
activated O
by O
in O
vitro O
transcribed O
U2 O
. O

Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
shown O
in O
(a) O
was O
calculated O
using O
the O
formula O
(ADP) O
/ O
(ADT+ATP) O
. O

The O
numbers O
at O
the O
bottom O
of O
(b) O
correspond O
to O
the O
lane O
numbers O
of O
(a) O
. O

Quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(c) O
U2-Prp5 B-proteingene
binding O
assay O
. O

FLAG-Prp5 B-proteingene
and O
a O
radiolabeled O
short O
(nts O
1-76) O
(lanes O
1 O
and O
2) O
or O
long O
(nts O
1-120) O
(lanes O
5 O
and O
6) O
U2 O
fragment, O
or O
FLAG-Prp5 B-proteingene
and O
a O
radiolabeled O
fully O
pseudouridylated O
short O
(nts O
1-76) O
(lanes O
3 O
and O
4) O
or O
long O
(nts O
1-120) O
(lanes O
7 O
and O
8) O
U2 O
fragment, O
were O
incubated O
under O
the O
conditions O
used O
for O
ATPase O
activity O
assay O
. O

Anti-FLAGIP B-proteingene
was O
then O
carried O
out O
. O

Co-precipitated O
(lanes O
2, O
4, O
6 O
and O
8) O
and O
un-precipitated O
(lanes O
1, O
3, O
5 O
and O
7) O
U2 O
RNAs O
were O
analyzed O
by O
electrophoresis O
. O

The O
U2 O
band O
is O
indicated O
. O

(d) O
Quantification O
of O
Prp5-U2 B-proteingene
binding O
. O

Relative O
intensities O
of O
U2 O
bands O
shown O
in O
(c) O
were O
calculated O
[setting O
the O
un-precipitated O
uridine-containing O
U2 O
(lane O
1 O
and O
5) O
to O
1] O
. O

The O
numbers O
at O
the O
bottom O
of O
(d) O
correspond O
to O
the O
lane O
numbers O
of O
(c) O
. O

Quantification O
was O
based O
on O
three O
independent O
experiments O
. O

(e) O
Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
assay O
using O
cellular O
U2 O
. O

U2RNA O
isolated O
from O
the O
wild-type O
strain O
(lanes O
2 O
and O
4) O
or O
from O
the O
snR81Δ B-proteingene
pus1Δ B-proteingene
strain O
(lanes O
6 O
and O
8) O
was O
used O
for O
the O
ATPase O
activity O
assay O
. O

In O
odd-numbered O
lanes, O
no O
RNA O
was O
added O
. O

Both O
the O
wild-type O
Prp5 B-proteingene
(lanes O
1-4) O
and O
the O
mutant O
Prp5 B-proteingene
(GAR) O
(lanes O
5-8) O
were O
tested O
. O

(f) O
Quantification O
of O
Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
activated O
by O
U2 O
from O
cells O
. O

Prp5 B-proteingene
's I-proteingene
ATPase O
activity O
shown O
in O
(e) O
was O
calculated O
using O
the O
formula O
(ADP) O
/ O
(ADT+ATP) O
. O

The O
numbers O
at O
the O
bottom O
of O
(f) O
correspond O
to O
the O
lane O
numbers O
of O
(e) O
. O

Quantification O
was O
based O
on O
four O
independent O
experiments O
. O

(g) O
U2 O
level O
in O
the O
ATPase O
activity O
reactions O
. O

RNAs O
from O
lanes O
2 O
and O
4 O
in O
(c) O
were O
recovered, O
and O
U2 O
level O
was O
measured O
using O
primer-extension O
. O

Lanes O
1-5, O
a O
titration O
of O
U2 O
snRNA. O
Lane O
6, O
U2 O
from O
the O
wild-type O
strain O
[lane O
2 O
of O
(c)] O
. O

Lane O
7, O
U2 O
from O
the O
snR81Δ B-proteingene
pus1Δ B-proteingene
strain O
[lane O
4 O
of O
(c)] O
. O

(a) O
Native O
gel O
analysis O
of O
pre-splicing O
complexes O
. O

Pre-splicing O
complex O
assembly O
was O
carried O
out O
in O
the O
test O
tube O
with O
Prp5-reconstituted B-proteingene
cell O
extracts O
and O
labeled O
pre-mRNA. O
Lane O
1, O
Prp5-depleted B-proteingene
wild-type O
cell O
extract O
. O

Lane O
2, O
Prp5-depleted B-proteingene
wild-type O
cell O
extract, O
plus O
wild-type O
Prp5 B-proteingene
. O

Lane O
3, O
Prp5-depleted B-proteingene
snR81Δ B-proteingene
pus1Δ B-proteingene
cell O
extract, O
plus O
wild-type O
Prp5 B-proteingene
. O

Lane O
4, O
Prp5-depleted B-proteingene
wild-type O
cell O
extract, O
plus O
mutant O
Prp5 B-proteingene
(GAR) O
. O

Lane O
5, O
Prp5-depleted B-proteingene
snR81Δ B-proteingene
pus1Δ B-proteingene
cell O
extract, O
plus O
mutant O
Prp5 B-proteingene
(GAR) O
. O

The O
pre-splicing O
complexes O
A O
and O
B O
are O
indicated O
. O

(b) O
DMS O
in O
vivo O
probing O
. O

After O
being O
exposed O
to O
DMS, O
yeast O
cells O
were O
lysed, O
total O
RNA O
collected, O
and O
primer-extension O
analysis O
carried O
out O
(left O
panel) O
. O

Lane O
1, O
cells O
that O
were O
not O
exposed O
to O
DMS. O
Lane O
2, O
wild-type O
cells O
exposed O
to O
DMS. O
Lane O
3, O
snR81Δ B-proteingene
pus1Δ B-proteingene
cells O
exposed O
to O
DMS. O
Lane O
4, O
snR81Δ B-proteingene
pus1Δ B-proteingene
cells, O
transformed O
with O
a O
plasmid O
carrying O
an O
artificial O
guide O
RNA O
gene O
targeting O
positions O
42 O
and O
44, O
and O
exposed O
to O
DMS. O
Lane O
5, O
snR81Δ B-proteingene
pus1Δ B-proteingene
cells, O
transformed O
with O
a O
plasmid O
carrying O
a O
control O
guide O
RNA O
gene O
with O
random O
guide O
sequences, O
and O
exposed O
to O
DMS. O
The O
nucleotides O
in O
parentheses O
are O
DMS-modified O
C O
and O
A O
residues O
that O
are O
one O
nucleotide O
after O
the O
actual O
primer-extension O
stops O
(indicated O
by O
the O
arrows) O
. O

A O
partial O
U2 O
sequence O
(along O
with O
the O
BSL O
structure) O
is O
shown O
(right O
panel) O
. O

DMS-modified O
adenosine O
and O
cytosine O
in O
the O
BSL O
are O
also O
indicated O
. O

A. O
LN229 O
and O
U87 O
cells O
treated O
with O
Wnt B-proteingene
3a I-proteingene
(0, O
10, O
20, O
50, O
100 O
ng/ml) O
for O
4 O
hr O
. O

The O
indicated O
proteins O
were O
analyzed O
by O
Western O
blotting O
. O

B. O
LN229 O
cells O
treated O
with O
or O
without O
Wnt3a B-proteingene
(50 O
ng/ml) O
were O
pulsed O
with O
[35S] O
methionine O
for O
30 O
min O
and O
chased O
for O
the O
times O
indicated O
. O

Protein O
extracts O
were O
used O
for O
IP O
with O
FoxM1 B-proteingene
antibodies O
and O
subjected O
to O
SDS-PAGE O
and O
autoradiography O
. O

The O
intensities O
of O
the O
FoxM1 B-proteingene
bands O
in O
autoradiography O
were O
then O
quantified O
by O
using O
NIH O
Image O
software, O
and O
the O
densities O
of O
the O
FoxM1 B-proteingene
bands O
at O
time O
0 O
were O
set O
as O
100% O
. O

Values O
are O
mean O
± O
SD O
from O
two O
independent O
experiments O
. O

C. O
Levels O
of O
FoxM1 B-proteingene
were O
analyzed O
by O
Western O
blotting O
in O
LN229 O
and O
U87 O
cells O
treated O
with O
Wnt O
inhibitor O
DKK1 B-proteingene
(100 O
ng/ml) O
for O
indicated O
times O
. O

Noted O
that O
the O
basal O
levels O
of O
FoxM1 B-proteingene
and O
β-catenin B-proteingene
in O
(A) O
and O
(C) O
are O
similar O
but O
look O
different O
due O
to O
variations O
on O
the O
exposure O
time O
of O
the O
Western O
blots O
. O

D. O
FoxM1 B-proteingene
expression O
levels O
were O
determined O
in O
LN229 O
cells O
treated O
with O
or O
without O
GSK3 B-proteingene
inhibitor O
LiCl O
(10 O
mM) O
and O
CHX O
(100 O
µg/ml) O
for O
indicated O
times O
. O

E. O
GSK3 B-proteingene
wild-type O
(WT) O
and O
knockout O
(KO) O
cells O
were O
treated O
with O
CHX O
(100 O
µg/ml) O
for O
indicated O
times, O
and O
FoxM1 B-proteingene
and O
GSK3α/β B-proteingene
expression O
levels O
were O
determined O
by O
Western O
blotting O
. O

F. O
Flag-FoxM1 B-proteingene
and O
GSK3βKA B-proteingene
or O
GSK3βKD B-proteingene
plasmids O
were O
co-transfected O
into O
293T O
cells O
for O
48 O
hr O
. O

The O
cells O
were O
then O
treated O
with O
CHX O
(100 O
µg/ml) O
for O
indicated O
times O
. O

Exogenous O
Flag-FoxM1 B-proteingene
expression O
level O
was O
determined O
by O
Western O
blotting O
. O

B. O
Lysates O
from O
293T O
cells O
expressing O
Flag-FoxM1 B-proteingene
or O
its O
mutants O
were O
subjected O
to O
IP O
using O
mouse O
anti-Flag B-proteingene
antibody, O
followed O
by O
IB O
with O
GSK3α/β B-proteingene
antibody O
(upper O
panel) O
and O
rabbit O
anti-Flag B-proteingene
antibody O
(middle O
panel) O
. O

D. O
HA-ubiquitin B-proteingene
and O
Flag-tagged B-proteingene
FoxM1 B-proteingene
(WT) O
or O
mutants O
FoxM1S228A, B-proteingene
FoxM1T309A, B-proteingene
or O
Flag-FoxM1S474A B-proteingene
plasmid O
were O
co-transfected O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
25 O
nM O
MG132 O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
antibody, O
followed O
by O
IB O
with O
Flag B-proteingene
and O
HA B-proteingene
antibody O
. O

E. O
HA-ubiquitin B-proteingene
was O
co-transfected O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
25 O
nM O
MG132 O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
IgG O
or O
FoxM1 B-proteingene
phospho-S474 O
antibody, O
followed O
by O
IB O
with O
FoxM1 B-proteingene
and O
HA B-proteingene
antibody O
. O

F. O
HA-tagged B-proteingene
K48-only O
ubiquitin B-proteingene
or O
K63-only O
ubiquitin B-proteingene
construct O
was O
transfected O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
25 O
nM O
MG132 O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
IgG O
or O
FoxM1 B-proteingene
antibody, O
followed O
by O
IB O
with O
FoxM1 B-proteingene
and O
HA B-proteingene
antibody O
. O

G. O
GSK3βCA B-proteingene
or O
vector O
and O
Flag-tagged B-proteingene
FoxM1 B-proteingene
(WT), O
mutants O
S474A O
or O
S478A O
were O
co-transfected O
into O
293T O
cells O
. O

Lysates O
of O
the O
cells O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
antibody O
and O
followed O
by O
IB O
with O
FoxM1 B-proteingene
phospho-S474 O
antibody O
. O

A. O
Cell O
lysates O
of O
LN229 O
cells O
were O
subjected O
to O
IP O
using O
Axin B-proteingene
antibody O
or O
control O
IgG, O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

B. O
Axin B-proteingene
siRNA O
or O
control O
siRNA O
were O
transfected O
into O
LN229 O
cells, O
after O
36 O
hours, O
lysate O
of O
the O
cells O
was O
performed O
with O
co-IP O
using O
FoxM1 B-proteingene
antibody O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

C. O
Axin B-proteingene
siRNA O
or O
control O
siRNA O
were O
transfected O
into O
LN229 O
cells O
for O
36 O
hours O
. O

Lysates O
of O
the O
cells O
were O
subjected O
to O
IB O
with O
FoxM1 B-proteingene
phospho-S474 O
antibody O
. O

D. O
Cell O
lysates O
of O
LN229 O
cells O
with O
or O
without O
Wnt-3a B-proteingene
treatment O
for O
4 O
hours O
were O
subjected O
to O
IP O
using O
Axin B-proteingene
antibody O
or O
control O
IgG, O
followed O
by O
IB O
with O
FoxM1 B-proteingene
and O
Axin B-proteingene
antibodies. O
. O

E. O
Axin B-proteingene
siRNA O
or O
control O
siRNA O
with O
HA-Ubiquitin B-proteingene
were O
transfected O
into O
293T O
cells, O
after O
36 O
hours, O
cells O
were O
treated O
with O
MG132 O
with O
or O
without O
Wnt-3a B-proteingene
(50 O
ng/ml) O
for O
six O
hours O
. O

Then O
lysate O
of O
the O
cells O
was O
performed O
with O
IP O
using O
FoxM1 B-proteingene
antibody O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

F. O
Wild O
type O
Flag-FoxM1 B-proteingene
or O
S474A O
mutant O
was O
transfected O
into O
293T O
cells O
after O
36 O
hours, O
cells O
were O
treated O
with O
MG132 O
for O
six O
hours O
. O

Then O
lysate O
of O
the O
cells O
was O
performed O
with O
IP O
using O
Flag B-proteingene
antibody O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

G. O
HA-Ubiquitin B-proteingene
and/or O
FBXW7, B-proteingene
GSK3β B-proteingene
CA, O
Flag-FoxM1 B-proteingene
were O
co-transfected O
into O
293T O
cells, O
after O
36 O
hours, O
cells O
were O
treated O
with O
MG132 O
for O
six O
hours O
. O

Then O
lysate O
of O
the O
cells O
was O
performed O
with O
IP O
using O
Flag B-proteingene
antibody O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

H. O
FBXW7 B-proteingene
siRNA O
or O
control O
siRNA O
and O
HA-Ubiquitin B-proteingene
were O
transfected O
into O
293T O
cells, O
after O
36 O
hours, O
cells O
were O
treated O
with O
MG132 O
with O
or O
without O
Wnt-3a B-proteingene
(50 O
ng/ml) O
for O
six O
hours O
. O

Then O
lysate O
of O
the O
cells O
was O
performed O
with O
IP O
using O
FoxM1 B-proteingene
antibody O
followed O
by O
IB O
with O
indicated O
antibodies O
. O

A. O
293T O
cells O
were O
transfected O
with O
USPs O
cDNA O
or O
control O
plasmid O
. O

After O
36 O
hr O
of O
transfection, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
for O
4 O
hr O
. O

FoxM1protein B-proteingene
levels O
in O
the O
cells O
were O
then O
determined O
by O
Western O
blotting O
. O

B. O
293T O
cells O
were O
transfected O
with O
1 O
µg O
control O
plasmid O
or O
USP5 B-proteingene
cDNA O
in O
6-well O
plates O
. O

After O
36 O
hr O
of O
transfection, O
cells O
were O
treated O
with O
100 O
µg/ml O
CHX O
for O
0, O
2, O
4, O
or O
6 O
hr O
. O

FoxM1protein B-proteingene
levels O
in O
the O
cells O
were O
then O
determined O
by O
Western O
blotting O
. O

C. O
GSK3-β B-proteingene
CA, O
USP5, B-proteingene
or O
control O
plasmid O
was O
co-transfected O
with O
Flag-FoxM1 B-proteingene
into O
293T O
cells O
. O

After O
36 O
hr O
of O
transfection, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
or O
control O
PBS O
for O
4 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
USP5 B-proteingene
antibody O
and O
followed O
by O
IB O
with O
Flag B-proteingene
or O
USP5 B-proteingene
antibody O
. O

D. O
GSK3βCA, B-proteingene
USP5, B-proteingene
or O
control O
plasmid O
was O
co-transfected O
with O
Flag-FoxM1 B-proteingene
into O
293T O
cells O
. O

After O
36 O
hr O
of O
transfection, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
or O
control O
PBS O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
USP5 B-proteingene
with O
Flag B-proteingene
antibody O
and O
followed O
by O
USP5 O
with O
Flag B-proteingene
or O
USP5 B-proteingene
antibody O
. O

E. O
USP5 B-proteingene
and O
Flag-FoxM1 B-proteingene
(WT) O
or O
mutants O
Flag-FoxM1S474A B-proteingene
or O
Flag-FoxM1S474E B-proteingene
plasmids O
were O
co-transfected O
into O
293T O
cells O
for O
36 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
antibody O
and O
followed O
by O
IB O
with O
Flag B-proteingene
or O
USP5 B-proteingene
antibody O
. O

F. O
GSK3β B-proteingene
CA, O
USP5, B-proteingene
or O
control O
plasmid O
was O
co-transfected O
with O
Flag-FoxM1 B-proteingene
(WT) O
or O
mutants O
Flag-FoxM1S474A B-proteingene
into O
293T O
cells O
for O
36 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
antibody O
and O
followed O
by O
IB O
with O
Flag B-proteingene
or O
USP5 B-proteingene
antibody O
. O

G. O
HA-ubiquitin B-proteingene
and O
Flag-FoxM1 B-proteingene
were O
co-transfected O
with O
or O
without O
GSK3β B-proteingene
CA O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
25 O
nM O
MG132 O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
followed O
by O
IB O
with O
HA B-proteingene
or O
FoxM1 B-proteingene
antibody O
. O

H. O
HA-ubiquitin B-proteingene
and O
Flag-FoxM1 B-proteingene
were O
co-transfected O
with O
or O
without O
siUSP5into B-proteingene
U87 O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
and O
25 O
nM O
MG132 O
for O
6 O
hr O
. O

Cell O
lysates O
were O
subjected O
to O
IP O
with O
Flag B-proteingene
antibody O
followed O
by O
IB O
with O
HA B-proteingene
or O
FoxM1 B-proteingene
antibody O
. O

A. O
Expression O
of O
FoxM1 B-proteingene
and O
ICAT B-proteingene
was O
examined O
via O
IHC O
staining O
in O
30 O
GBM O
and O
paired O
adjacent O
normal O
tissues O
. O

Representative O
ICAT B-proteingene
and O
FoxM1 B-proteingene
expressions O
are O
shown O
in O
a O
section O
of O
a O
GBM O
tumor O
with O
adjacent O
normal O
brain O
. O

Scale O
bar: O
50 O
µm O
B. O
ICAT B-proteingene
stainings O
were O
scored O
as O
1-12 O
according O
to O
the O
intensity O
and O
percentage O
in O
the O
30 O
GBM O
and O
paired O
adjacent O
normal O
tissues O
. O

Boxes O
indicate O
interquartile O
range O
. O

Bars O
from O
each O
box O
extend O
to O
largest O
and O
smallest O
observations O
. O

C. O
FoxM1 B-proteingene
stainings O
were O
scored O
as O
1-12 O
according O
to O
the O
intensity O
and O
percentage O
in O
the O
30 O
GBM O
and O
paired O
adjacent O
normal O
tissues O
. O

Boxes O
indicate O
interquartile O
range O
. O

Bars O
from O
each O
box O
extend O
to O
largest O
and O
smallest O
observations O
. O

D. O
Increased O
amounts O
of O
FoxM1 B-proteingene
plasmids O
were O
transfected O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
for O
6 O
hr O
. O

Cell O
lysates O
were O
then O
subjected O
to O
IP O
with O
β-catenin B-proteingene
antibody, O
followed O
by O
IB O
with O
β-catenin, B-proteingene
ICAT, B-proteingene
FoxM1 B-proteingene
or O
IgG O
antibodies O
. O

E. O
Increased O
amounts O
of O
ICAT B-proteingene
plasmids O
were O
transfected O
into O
293T O
cells O
. O

After O
36 O
hr, O
cells O
were O
treated O
with O
50 O
ng/ml O
Wnt-3a B-proteingene
for O
6 O
hr O
. O

Cell O
lysates O
were O
then O
subjected O
to O
IP O
with O
β-catenin B-proteingene
antibody, O
followed O
by O
IB O
with O
β-catenin, B-proteingene
ICAT, B-proteingene
FoxM1 B-proteingene
or O
IgG O
antibodies O
. O

F. O
FoxM1 B-proteingene
siRNA O
or O
control O
siRNA O
was O
transfected O
into O
U87 O
cells, O
lysates O
were O
subjected O
to O
IP O
with O
β-catenin B-proteingene
antibody, O
followed O
by O
IB O
with O
β-catenin, B-proteingene
ICAT, B-proteingene
FoxM1 B-proteingene
or O
IgG O
antibodies O
. O

G. O
ICAT B-proteingene
siRNA O
or O
control O
siRNA O
was O
transfected O
into O
LN229 O
cells, O
lysates O
were O
subjected O
to O
IP O
with O
β-catenin B-proteingene
antibody, O
followed O
by O
IB O
with O
β-catenin, B-proteingene
ICAT, B-proteingene
FoxM1 B-proteingene
or O
IgG O
antibodies O
. O

H. O
ChIP O
analyses O
of O
endogenous O
β-catenin B-proteingene
binding O
at O
the O
TCF-binding O
site O
of O
the O
Axin2 B-proteingene
promoter O
were O
performed O
in O
vector-, O
FoxM1- B-proteingene
or/and O
ICAT B-proteingene
plasmid-transfected O
U87 O
cells O
. O

Fold O
was O
calculated O
relative O
to O
that O
in O
cells O
transfected O
with O
the O
vector, O
which O
was O
set O
as O
1 O
. O

I. O
ChIP O
analyses O
of O
endogenous O
β-catenin B-proteingene
binding O
at O
the O
TCF-binding O
site O
of O
the O
Axin2 B-proteingene
promoter O
were O
performed O
in O
FoxM1 B-proteingene
siRNA-, O
ICAT B-proteingene
siRNA-, O
control O
siRNA- O
or O
combination O
of O
FoxM1 B-proteingene
siRNA O
and O
ICAT B-proteingene
siRNA-transfected O
U87 O
cells O
as O
described O
in O
(H) O
. O

J. O
ChIP O
analyses O
of O
endogenous O
β-catenin B-proteingene
binding O
at O
the O
TCF-binding O
site O
of O
the O
Axin2 B-proteingene
promoter O
were O
performed O
in O
vector-, O
β-catenin-NLS-, B-proteingene
sh-FoxM1-, B-proteingene
FoxM1-shR- B-proteingene
and/or O
ICAT B-proteingene
plasmid-transfected O
U87 O
cells O
as O
described O
in O
(H) O
. O

A. O
FoxM1 B-proteingene
or/and O
ICAT B-proteingene
plasmids O
were O
co-transfected O
with O
Axin-2 B-proteingene
promoter O
luciferase B-proteingene
and O
TK-Renilla B-proteingene
plasmid O
into O
U87 O
cells O
. O

Luciferase O
activity O
was O
measured O
with O
the O
Dural O
Luciferase O
reporter O
assay, O
and O
relative O
luciferase B-proteingene
activity O
was O
normalized O
to O
that O
of O
the O
vector O
group O
. O

Values O
are O
mean O
± O
SD O
for O
triplicate O
samples O
. O

B. O
FoxM1 B-proteingene
siRNA#1, O
#2 O
or O
control O
siRNA O
were O
co-transfected O
to O
U87 O
cells O
with O
Axin-2 B-proteingene
promoter O
reporter O
. O

Luciferase O
activity O
was O
measured O
with O
the O
Dural O
Luciferase O
reporter O
assay, O
and O
relative O
luciferase B-proteingene
activity O
was O
normalized O
to O
that O
of O
the O
control O
siRNA O
group O
. O

Values O
are O
mean O
± O
SD O
for O
triplicate O
samples O
. O

C. O
ICAT B-proteingene
siRNA O
or O
control O
siRNA O
were O
co-transfected O
into O
LN229 O
cells O
with O
Axin-2 B-proteingene
promoter O
reporter O
. O

Luciferase B-proteingene
activity O
was O
measured O
as O
in O
(C) O
. O

D. O
FoxM1 B-proteingene
or/and O
ICAT B-proteingene
plasmids O
were O
co-transfected O
with O
TOP-Flash O
reporter O
and O
TK-Renilla B-proteingene
plasmids O
into O
U87 O
cells O
. O

Luciferase B-proteingene
activity O
of O
TOP-Flash B-proteingene
in O
the O
cells O
was O
measured O
as O
in O
A. O
Values O
are O
mean O
± O
SD O
for O
triplicate O
samples O
. O

E. O
ICAT, B-proteingene
FoxM1 B-proteingene
or O
FoxM1-∆FB B-proteingene
(FoxM1 B-proteingene
mutant O
lacking O
the O
forkhead O
box O
domain) O
plasmid O
or O
their O
combinations O
were O
co-transfected O
with O
TOP-Flash O
reporter O
and O
TK-Renilla B-proteingene
plasmids O
into O
LN229 O
cells O
. O

Luciferase B-proteingene
activity O
of O
TOP-Flash B-proteingene
in O
the O
cells O
was O
measured O
as O
in O
A. O
Values O
are O
mean O
± O
SD O
for O
triplicate O
samples O
. O

F. O
FoxM1 B-proteingene
siRNA O
and/or O
ICAT B-proteingene
siRNA O
were O
co-transfected O
with O
TOP-Flash B-proteingene
reporter O
and O
TK-Renilla B-proteingene
plasmids O
into O
LN229 O
cells, O
and O
the O
cells O
were O
treated O
with O
Wnt3a B-proteingene
(50 O
ng/ml) O
or O
control O
PBS. O
Luciferase B-proteingene
activity O
of O
TOP-Flash O
in O
the O
cells O
was O
measured O
as O
in O
A. O
Values O
are O
mean O
± O
SD O
for O
triplicate O
samples O
. O

G. O
Vector-, O
β-catenin-NLS-, B-proteingene
sh-FoxM1-, B-proteingene
FoxM1-shR- B-proteingene
and/or O
ICAT B-proteingene
plasmids O
were O
co-transfected O
with O
TOP-Flash O
reporter O
and O
TK-Renilla B-proteingene
plasmids O
into O
U87 O
cells O
. O

Luciferase B-proteingene
activity O
of O
TOP-Flash B-proteingene
in O
the O
cells O
was O
measured O
as O
in O
(A) O
. O

Values O
are O
mean O
± O
SD O
triplicate O
samples O
. O

H. O
Levels O
of O
Axin-2 B-proteingene
and O
cyclin B-proteingene
D1 I-proteingene
protein O
in O
LN229 O
cells O
transfected O
with O
FoxM1 B-proteingene
siRNA#1 O
or O
#2 O
were O
determined O
by O
Western O
blotting O
. O

I. O
Levels O
of O
Axin-2 B-proteingene
and O
cyclin B-proteingene
D1 I-proteingene
protein O
in O
LN229 O
cells O
transfected O
with O
ICAT B-proteingene
siRNA O
were O
determined O
by O
Western O
blotting O
. O

J. O
Levels O
of O
Axin-2 B-proteingene
and O
cyclin B-proteingene
D1 I-proteingene
protein O
in O
LN229 O
cells O
transfected O
with O
FoxM1 B-proteingene
or/and O
ICAT B-proteingene
plasmids O
were O
determined O
by O
Western O
blotting O
. O

A. O
A O
total O
of O
1 O
× O
104 O
LN229 O
cells O
were O
transfected O
with O
control O
vector, O
FoxM1, B-proteingene
and/or O
ICAT B-proteingene
plasmids O
and O
treated O
with O
Wnt3a B-proteingene
(50 O
ng/ml) O
and O
were O
then O
plated O
and O
counted O
48 O
hr O
after O
seeding O
. O

The O
proliferation O
percentage O
was O
calculated O
relative O
to O
that O
in O
cells O
transfected O
with O
the O
control O
vector, O
which O
was O
set O
as O
100% O
. O

Data O
represent O
the O
mean O
± O
SD O
of O
three O
independent O
experiments O
. O

B. O
LN229 O
cells O
were O
transfected O
with O
vector O
control, O
FoxM1, B-proteingene
FoxM1 B-proteingene
plus O
sh-β-catenin B-proteingene
or O
FoxM1 B-proteingene
plus O
ICAT B-proteingene
plasmid O
. O

The O
proliferation O
percentage O
was O
determined O
as O
described O
in O
(A) O
. O

C. O
LN229-shFoxM1 O
cells O
were O
transfected O
with O
FoxM1-shR B-proteingene
(siRNA-resistant O
FoxM1), B-proteingene
or O
FoxM1-shR B-proteingene
plus O
ICAT B-proteingene
plasmid O
. O

The O
cells O
were O
then O
treated O
with O
Wnt3a B-proteingene
(50 O
ng/ml) O
. O

The O
proliferation O
percentage O
was O
determined O
as O
described O
in O
(A) O
. O

D. O
LN229 O
cells O
were O
transfected O
with O
USP5 B-proteingene
and/or O
FoxM1 B-proteingene
siRNA. O
The O
proliferation O
percentage O
was O
determined O
as O
described O
in O
(A) O
. O

E. O
LN229 O
cells O
were O
transfected O
with O
USP5 B-proteingene
siRNA O
and/or O
FoxM1 B-proteingene
plasmid O
. O

The O
cells O
were O
then O
treated O
with O
Wnt3a B-proteingene
(50 O
ng/ml) O
. O

The O
proliferation O
percentage O
was O
determined O
as O
described O
in O
(A) O
. O

Data O
shown O
in O
(A)-(E) O
represent O
the O
mean O
± O
SD O
of O
three O
independent O
experiments O
. O

F-H. O
Expression O
of O
FoxM1, B-proteingene
Cyclin B-proteingene
D1 I-proteingene
and O
USP5 B-proteingene
proteins O
was O
examined O
via O
IHC O
staining O
in O
50 O
GBM O
specimens O
. O

Staining O
of O
FoxM1, B-proteingene
Cyclin B-proteingene
D1, I-proteingene
or O
USP5 B-proteingene
was O
scored O
as O
1-12 O
according O
to O
the O
intensity O
and O
percentage O
. O

The O
significance O
of O
the O
correlations O
was O
determined O
by O
Pearson O
's O
correlation O
test O
. O

I-J. O
Axin2 B-proteingene
mRNA O
levels O
in O
the O
above O
50 O
GBM O
specimens O
were O
examined O
through O
RNAscope O
technology O
. O

The O
staining O
was O
scored O
as O
1-12 O
according O
to O
the O
intensity O
and O
percentage O
. O

The O
significance O
of O
the O
correlations O
was O
determined O
by O
Pearson O
's O
correlation O
test O
. O

(A) O
Immunofluorescence O
staining O
of O
Lin-Sca-1+cKit+ B-proteingene
(LSK) O
cells O
using O
an O
antibody O
specific O
for O
phosphorylated O
STAT5 B-proteingene
(pSTAT5) B-proteingene
or O
total O
STAT5 B-proteingene
. O

Scale O
bars O
represent O
5μm O
. O

Bar O
graphs O
showing O
the O
quantification O
of O
nuclear O
localization O
presented O
as O
mean O
fluorescence O
intensity O
(MFI) O
. O

Data O
are O
shown O
as O
means O
± O
SD O
of O
three O
independent O
experiments O
. O

(C) O
Western O
blot O
analysis O
of O
HPC7 O
cells O
grown O
in O
the O
presence O
of O
SCF B-proteingene
demonstrates O
nuclear O
and O
cytoplasmic O
uSTAT5 B-proteingene
in O
the O
absence O
pSTAT5 B-proteingene
. O

K562 O
cell O
lysates O
were O
used O
as O
a O
positive O
control O
for O
pSTAT5 B-proteingene
. O

(D) O
Western O
blot O
analysis O
of O
HPC7 O
cells O
after O
TPO B-proteingene
stimulation O
(100ng/ml) O
at O
the O
indicated O
time O
points O
. O

(E) O
Western O
blot O
analysis O
was O
performed O
after O
immunoprecipitation O
of O
STAT5 B-proteingene
from O
unstimulated O
and O
TPO B-proteingene
stimulated O
cells O
using O
antibodies O
to O
total O
STAT5 B-proteingene
or O
to O
pSTAT5 B-proteingene
(pY694/p699) O
. O

1% O
(5μg) O
of O
lysate O
was O
loaded O
as O
input O
control O
. O

(A) O
Summary O
of O
ChIP-Seq O
results O
obtained O
using O
HPC7 O
cells O
and O
an O
antibody O
to O
total O
STAT5 B-proteingene
. O

For O
each O
STAT5 B-proteingene
occupied O
region, O
the O
occupancy O
of O
STAT5 B-proteingene
in O
unstimulated O
(T=0 O
mins) O
and O
in O
TPO B-proteingene
stimulated O
(T=30 O
mins) O
cells O
is O
indicated O
within O
a O
5-kb O
window O
centered O
on O
the O
total O
STAT5 B-proteingene
bound O
region O
. O

(B) O
Examples O
of O
loci O
containing O
ChIP-Seq O
peaks O
from O
Cluster O
1 O
(ie O
uSTAT5 B-proteingene
peaks) O
or O
Cluster O
2 O
(ie O
pSTAT5 B-proteingene
peaks) O
showing O
loss O
of O
the O
former O
and O
appearance O
of O
the O
latter O
following O
TPO B-proteingene
stimulation O
. O

(C O
and O
D) O
ChIP-Seq O
results O
were O
validated O
by O
ChIP-qPCR O
using O
antibodies O
against O
total O
STAT5 B-proteingene
or O
pSTAT5 B-proteingene
. O

Data O
represented O
as O
means O
± O
SD O
of O
3 O
independent O
experiments O
. O

(G) O
ChIP-Seq O
genome-browser O
views O
showing O
co-localization O
of O
uSTAT5 B-proteingene
binding O
with O
CTCF B-proteingene
. O

(H) O
Immunofluorescence O
analysis O
of O
STAT5 B-proteingene
wild O
type O
and O
knockout O
MEFs O
with O
4′,6-diamidino-2-phenylindole O
(DAPI) O
staining O
(blue) O
and O
anti-STAT5 B-proteingene
antibody O
(red) O
. O

Scale O
bars O
represent O
25μm O
. O

(I) O
Western O
blot O
analysis O
of O
cell O
lysates O
isolated O
from O
STAT5 B-proteingene
wild O
type O
and O
knockout O
MEFs O
. O

**, O
p<0.01; O
***, O
p<0.001 O
. O

(A) O
Western O
blot O
analysis O
showing O
efficient O
knock-down O
of O
uSTAT5 B-proteingene
in O
HPC7 O
cells O
on O
day O
3 O
after O
infection O
. O

(B) O
RNA O
microarray O
analysis O
following O
uSTAT5 B-proteingene
depletion O
by O
shRNA_7 O
in O
HPC7 O
cells O
grown O
in O
SCF. B-proteingene
The O
40 O
most O
upregulated O
genes O
following O
uSTAT5 O
knock-down O
are O
illustrated O
. O

Genes O
upregulated O
during O
megakaryopoiesis O
are O
indicated O
in O
red O
. O

(C) O
Gene O
set O
enrichment O
analysis O
showing O
significant O
enrichment O
of O
a O
megakaryocyte O
progenitor O
(MKP, O
Lin-Sca1-Kit+Itga2b+Slamf1+) O
signature O
in O
STAT5 B-proteingene
knockdown O
cells O
. O

CLP, O
common O
lymphoid O
progenitor O
(Lin-Sca1lowKitlowIL7r+Flk2+); O
preGM, O
pre-grenulocyte/macrophage O
progenitors O
(Lin-Sca1-Kit+Itga2b-FcgRlowSlamf1-Englow); O
NES, O
normalized O
enrichment O
score O
. O

(D) O
Quantitative O
RT-PCR O
confirmed O
upregulation O
of O
uSTAT5 B-proteingene
target O
genes O
following O
uSTAT5 B-proteingene
depletion O
. O

Relative O
RNA O
levels O
were O
normalized O
to O
18S B-proteingene
RNA. O
Bar O
graphs O
represent O
means O
± O
SD O
of O
three O
independent O
experiments O
. O

(E-F) O
Kinetics O
of O
the O
upregulation O
of O
uSTAT5(E) B-proteingene
and O
pSTAT5(F) B-proteingene
target O
genes O
following O
TPO B-proteingene
stimulation O
. O

Each O
data O
point O
represents O
a O
mean O
± O
SD. O
n=3; O
*, O
significant O
difference O
from O
time O
0 O
(p<0.05); O
*, O
p<0.05; O
**, O
p<0.01; O
***, O
p<0.001 O
. O

(B) O
Depletion O
of O
uSTAT5 B-proteingene
was O
accompanied O
by O
the O
appearance O
of O
large O
cells O
that O
stain O
positively O
for O
Acetylcholinesterase B-proteingene
(AchE) B-proteingene
. O

Scrambled O
shRNA O
(scr), O
shSTAT5_5 B-proteingene
(sh_5) O
or O
shSTAT5_7 B-proteingene
(sh_7) O
. O

(C) O
Increased O
percentage O
of O
polyploid O
cells O
following O
uSTAT5 B-proteingene
depletion O
. O

Bars O
represent O
means O
± O
SD O
from O
three O
independent O
experiments O
. O

(D) O
Increased O
percentage O
of O
cells O
expressing O
high O
levels O
of O
CD41 B-proteingene
and O
CD61 B-proteingene
following O
uSTAT5 B-proteingene
depletion O
. O

Bars O
represent O
means O
± O
SD O
from O
three O
independent O
experiments O
. O

(F) O
Western O
blot O
analysis O
of O
HPC7 O
cells O
expressing O
empty O
vector O
(EV), O
wild O
type O
STAT5B B-proteingene
(WT) O
or O
mutant O
STAT5B B-proteingene
(Y699F) O
. O

EV O
and O
Y699F O
expressing O
cells O
exhibit O
similar O
levels O
of O
STAT5 B-proteingene
phosphorylation O
following O
TPO B-proteingene
treatment O
(100ng/ml O
for O
30min) O
. O

(G) O
Expression O
of O
the O
Y699F O
mutant O
repressed O
the O
appearance O
of O
large O
cells O
that O
stained O
for O
acetylcholinesterase B-proteingene
(AchE) B-proteingene
. O

Scale O
bars O
represent O
25μm O
. O

(I) O
The O
Y699F O
mutant O
increased O
the O
percentage O
of O
cells O
expressing O
high O
levels O
of O
CD41 B-proteingene
and O
CD61 B-proteingene
. O

Bars O
represent O
means O
± O
SD O
from O
three O
independent O
experiments O
. O

(J) O
Quantitative O
RT-PCR O
showing O
that O
the O
Y699F O
mutant O
did O
not O
alter O
induction O
of O
pSTAT5 B-proteingene
target O
genes O
by O
endogenous O
pSTAT5 B-proteingene
following O
TPO B-proteingene
stimulation O
(100ng/ml O
for O
30 O
min) O
. O

Bars O
represent O
means O
± O
SDs O
from O
three O
independent O
experiments O
. O

(K) O
Quantitative O
RT-PCR O
showing O
that O
the O
Y699F O
mutant O
repressed O
induction O
of O
uSTAT5 O
target O
genes O
following O
TPO B-proteingene
treatment O
. O

Bar O
graphs O
represents O
means O
± O
SDs O
from O
three O
independent O
experiments O
. O

*, O
p<0.05; O
**, O
p<0.01; O
***, O
p<0.001 O
. O

(A) O
Heatmap O
showing O
hierarchical O
clustering O
of O
pairwise O
peak O
overlap O
of O
HPC7 O
ChIP-seq O
data, O
red O
representing O
positive O
Pearson O
's O
correlation O
coefficient O
values O
and O
blue O
representing O
negative O
correlation O
coefficients O
. O

(C) O
ChIP-reChIP O
experiment O
using O
HPC7 O
cells O
grown O
in O
SCF B-proteingene
containing O
media O
. O

An O
antibody O
to O
total O
STAT5 B-proteingene
or O
control O
IgG O
was O
used O
for O
the O
first O
pull-down O
and O
an O
antibody O
to O
CTCF B-proteingene
or O
ERG B-proteingene
was O
used O
for O
the O
second O
pull O
down O
. O

(D) O
ChIP-reChIP O
experiment O
using O
HPC7 O
cells O
grown O
in O
SCF B-proteingene
containing O
media O
. O

An O
antibody O
to O
ERG B-proteingene
or O
control O
IgG O
was O
used O
for O
the O
first O
pull-down O
and O
an O
antibody O
to O
CTCF B-proteingene
or O
STAT5 B-proteingene
was O
used O
for O
the O
second O
pull O
down O
. O

(E O
and O
G) O
ChIP-qPCR O
showing O
increased O
enrichment O
of O
ERG B-proteingene
binding O
sites O
at O
Mpl B-proteingene
or O
F2r B-proteingene
loci O
following O
STAT5 B-proteingene
knock-down O
(E) O
or O
stimulation O
with O
TPO(G) B-proteingene
. O

(F O
and O
H) O
ChIP-qPCR O
showing O
decreased O
uSTAT5 B-proteingene
binding O
at O
Mpl B-proteingene
and O
F2r B-proteingene
loci O
after O
STAT5 B-proteingene
knock-down O
(F) O
or O
following O
TPO B-proteingene
treatment O
(H) O
. O

All O
bar O
graphs O
represent O
means O
± O
SD; O
n O
= O
3; O
*, O
p<0.05; O
**, O
p<0.01 O
. O

(A) O
Proliferation O
assay O
of O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
cultured O
in O
N2B27-based O
2i O
media O
either O
in O
the O
presence O
or O
absence O
of O
LIF. B-proteingene
Cells O
were O
seeded O
and O
scored O
for O
four O
consecutive O
days O
. O

Scores O
were O
normalized O
to O
day1 O
. O

Mean O
and O
s.d O
. O

of O
three O
technical O
replicates O
. O

See O
also O
Appendix O
Figure O
S1A O
. O

(B) O
Cell O
cycle O
analysis O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
2i O
media O
without O
LIF B-proteingene
or O
with O
LIF B-proteingene
for O
several O
passages O
and O
Stat3-/- B-proteingene
cells O
in O
2i O
with O
LIF. B-proteingene
48hours O
after O
plating O
cells O
were O
detached, O
treated O
with O
Propidium O
Iodide O
and O
analysed O
by O
flow O
cytometry O
. O

Top: O
Cells O
cultured O
in O
presence O
of O
LIF B-proteingene
showed O
an O
increment O
in O
S/G2 O
and O
a O
decrease O
in O
G1 O
. O

Mean O
and O
s.e.m O
. O

of O
three O
technical O
replicates O
. O

Unpaired O
t-test: O
* O
P<0.05 O
. O

Bottom: O
representative O
plots O
. O

(C) O
Scatter O
plot O
showing O
RNA-seq O
data O
from O
Stat3+/+ B-proteingene
cells O
cultured O
in O
2i O
and O
stimulated O
with O
LIF B-proteingene
for O
1h O
(Martello O
et O
al, O
2013) O
. O

Absolute O
expression O
is O
shown O
in O
RPKM. O
Green O
dots O
indicate O
known O
LIF B-proteingene
targets O
that O
serve O
as O
positive O
controls O
. O

Mitochondrial O
encoded O
transcripts O
are O
represented O
as O
orange O
dots O
. O

Only O
genes O
with O
FC>1.7 O
and O
a O
p-value O
<0.05 O
are O
shown O
. O

(D) O
Heatmap O
showing O
mean O
normalised O
expression O
of O
13 O
mitochondrial O
transcripts O
encoding O
4 O
subunits O
of O
the O
mitochondrial O
respiratory O
chain O
. O

RNA-seq O
data O
are O
from O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
were O
expanded O
in O
2i O
media O
without O
LIF B-proteingene
and O
treated O
with O
LIF B-proteingene
for O
1hour O
or O
24 O
hours O
. O

(E) O
Gene O
expression O
analysis O
by O
RT-qPCR O
of O
Stat3+/+ B-proteingene
(blue) O
and O
Stat3-/- B-proteingene
(red) O
cells O
cultured O
in O
2i O
and O
treated O
with O
LIF B-proteingene
for O
1 O
hour, O
4 O
hours O
or O
4 O
days O
. O

Data O
are O
normalized O
to O
unstimulated O
2i O
cultures O
. O

Beta-actin B-proteingene
served O
as O
an O
internal O
control O
. O

Mean O
and O
s.e.m O
. O

of O
three O
independent O
experiments O
. O

Unpaired O
t-test: O
* O
P<0.05 O
** O
P<0.01 O
*** O
P<0.001 O
. O

See O
also O
Appendix O
Figure O
S1B O
. O

(B) O
Luciferase B-proteingene
assay O
on O
ES O
cells O
transfected O
with O
D-loop-Lux B-proteingene
reporter O
plasmid O
and O
Stat3 B-proteingene
in O
the O
presence O
or O
in O
the O
absence O
of O
LIF B-proteingene
for O
48 O
hours; O
p53 B-proteingene
was O
previously O
shown O
to O
activate O
a O
similar O
reporter O
construct O
(Heyne O
et O
al, O
2004) O
and O
therefore O
was O
used O
as O
positive O
control O
. O

Increased O
expression O
of O
Stat3 B-proteingene
enhances O
Luciferase B-proteingene
activity O
. O

Mean O
and O
sem O
of O
4 O
independent O
experiments O
. O

Unpaired O
t-test: O
* O
P<0.05 O
. O

(C) O
Luciferase B-proteingene
assay O
on O
EpiSCs O
transfected O
with O
D-loop-lux O
reporter O
plasmid O
and O
Stat3 B-proteingene
in O
the O
presence O
of O
LIF B-proteingene
for O
48 O
hours O
. O

Mean O
and O
sem O
of O
3 O
independent O
experiments O
. O

Unpaired O
t-test: O
* O
P<0.05 O
. O

(E) O
Chromatin O
immunoprecipitation O
(ChIP) O
was O
performed O
using O
anti-Stat3 B-proteingene
or O
a O
rabbit O
control O
IgG O
antibody O
in O
Rex1-GFP B-proteingene
cells O
cultured O
in O
LIF B-proteingene
and O
serum O
conditions O
in O
the O
presence O
of O
Blasticidin O
to O
reduce O
heterogeneity O
of O
the O
culture O
. O

ChIP-PCR O
was O
performed O
with O
primers O
located O
on O
three O
regions O
of O
the O
D-loop O
(A, O
B, O
C), O
as O
indicated O
in O
Figure O
2D. O
Mean O
and O
st.dev O
of O
two O
independent O
experiments O
are O
shown O
. O

(F) O
Representative O
confocalimages O
of O
Stat3+/+ B-proteingene
cells O
subjected O
to O
proximity-ligation-assay O
(PLA) O
by O
using O
anti-Stat3 B-proteingene
and O
anti-ATAD3 B-proteingene
antibodies O
(See O
Appendix O
Figure O
S2 O
for O
ATAD3 B-proteingene
localisation O
in O
nucleoids) O
. O

Only O
when O
the O
two O
proteins O
are O
close O
to O
each O
other O
an O
enzymatic O
reaction O
takes O
place, O
producing O
discrete O
fluorescent O
red O
dots O
in O
the O
nanometer O
range O
(bottom) O
. O

Anti-Stat3 B-proteingene
or O
anti-ATAD3 B-proteingene
alone O
were O
used O
to O
assess O
the O
assay O
specificity O
(top O
and O
centre O
respectively) O
. O

DAPI O
serves O
as O
a O
nuclear O
counterstain O
. O

Scale O
bar, O
10µm O
. O

(A) O
Oxygen O
consumption O
rate O
(OCR) O
measured O
by O
SeaHorse O
Extracellular O
Flux O
assay O
of O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
maintained O
in O
2i O
condition O
in O
the O
presence O
of O
LIF. B-proteingene
200nM O
FCCP O
treatment, O
a O
mitochondria O
uncoupler, O
resulted O
in O
higher O
OCR O
increase O
in O
Stat3+/+ B-proteingene
compared O
to O
Stat3-/- B-proteingene
cells, O
showing O
a O
higher O
level O
of O
maximal O
mitochondrial O
electron O
transport O
chain O
(ETC) O
activity O
in O
Stat3+/+ B-proteingene
cells O
. O

Injection O
of O
200nM O
Antimycin O
shows O
similar O
non-mitochondrial O
respiration O
rates O
for O
both O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
. O

Mean O
and O
s.e.m O
. O

of O
5 O
technical O
replicates O
is O
shown O
. O

(B) O
Oxygen O
consumption O
rate O
(OCR) O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
2i O
conditions O
without O
LIF B-proteingene
or O
with O
LIF B-proteingene
for O
several O
passages O
. O

200nM O
FCCP O
and O
200nM O
Antimycin O
were O
injected O
and O
resulted O
in O
a O
higher O
mitochondrial O
respiration O
activity O
in O
cells O
cultured O
in O
the O
presence O
of O
LIF. B-proteingene
Mean O
and O
s.e.m O
. O

of O
4 O
replicates O
is O
shown O
. O

See O
also O
Appendix O
Figure O
S3D O
. O

(C) O
Relative O
changes O
in O
oxygen O
consumption O
after O
200nM O
FCCP O
treatment O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
2i O
media O
in O
presence O
(dark O
blue O
bars) O
and O
absence O
of O
LIF B-proteingene
(light O
blue O
bars) O
. O

Mean O
and O
s.e.m O
. O

of O
>4 O
technical O
replicates O
of O
three O
independent O
experiments O
are O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
. O

(D) O
Western O
blot O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
presence O
or O
absence O
of O
LIF. B-proteingene
Note O
that O
protein O
levels O
of O
two O
mitochondrial O
markers O
(TOM20 B-proteingene
and O
TIMM23) B-proteingene
do O
not O
change O
in O
absence O
of O
LIF. B-proteingene
GAPDH B-proteingene
was O
used O
as O
a O
loading O
control O
. O

Relative O
mean O
intensity O
is O
shown O
below O
each O
band O
. O

(E) O
Mitochondrial O
DNA O
expression O
analysis O
of O
Stat3+/+ B-proteingene
cells O
maintained O
in O
2i O
in O
presence O
(dark O
blue O
bars) O
and O
absence O
(light O
blue O
bars) O
of O
LIF. B-proteingene
The O
abundance O
of O
3 O
mitochondrial O
genomic O
loci O
was O
measured O
and O
normalized O
to O
a O
nuclear O
genomic O
locus O
on O
chromosome O
3 O
. O

Mean O
and O
s.e.m O
of O
three O
independent O
biological O
replicates O
is O
shown O
. O

(F) O
BNGE O
analysis O
followed O
by O
Western O
Blot O
for O
a O
Complex-I O
protein O
(NDUFB8) B-proteingene
. O

ATPase B-proteingene
serves O
as O
a O
loading O
control O
. O

RCS= O
Respiratory O
Chain O
Supercomplexes O
. O

See O
also O
Appendix O
Figure O
S3E O
and O
S3F O
. O

(G) O
Quantification O
of O
the O
chemiluminescent O
RCS/ATPase O
signal O
ratio O
(left) O
and O
ComplexI/ATPase B-proteingene
signal O
ratio O
(right) O
. O

Unpaired O
t-test: O
* O
P<0.05 O
** O
P<0.01 O
*** O
P<0.001 O
. O

(A) O
Flow O
cytometry O
analysis O
after O
double O
staining O
with O
Annexin-V O
and O
Propidium O
Iodide O
in O
ES O
cells O
. O

The O
combination O
of O
Annexin O
V- O
FITC O
and O
Propidium O
Iodide O
allows O
the O
distinction O
between O
viable O
cells O
(unstained) O
bottom O
left O
quadrants, O
early O
apoptotic O
cells O
(Annexin O
V-FITC O
positive) O
bottom O
right O
quadrants, O
late O
apoptotic O
and/or O
necrotic O
cells O
(Annexin O
V-FITC O
and O
Propidium O
Iodide O
positive) O
top O
right O
quadrants O
. O

ES O
cells O
were O
treated O
with O
increasing O
concentrations O
of O
rotenone O
from O
50nM O
to O
200nM O
for O
48 O
hours O
. O

A O
slight O
increase O
in O
cell O
death O
could O
be O
observed O
only O
at O
a O
concentration O
of O
200nM O
of O
rotenone O
. O

In O
each O
quadrant O
the O
mean O
and O
s.e.m O
. O

of O
3 O
independent O
experiments O
is O
indicated O
. O

(B) O
Proliferation O
assay O
of O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
cultured O
in O
2i O
. O

Cells O
were O
seeded O
and O
treated O
for O
48 O
hours O
with O
LIF B-proteingene
and O
rotenone O
(orange O
bars), O
a O
Complex O
I O
inhibitor, O
as O
indicated O
. O

Scores O
were O
normalized O
to O
Stat3+/+ B-proteingene
cells O
treated O
with O
LIF B-proteingene
and O
DMSO. O
Proliferation O
was O
enhanced O
by O
LIF B-proteingene
treatment O
in O
Stat3+/+ B-proteingene
cells O
and O
reduced O
by O
rotenone O
treatment O
. O

Stat3-/- B-proteingene
cells O
resulted O
more O
sensitive O
to O
rotenone O
treatment O
. O

Mean O
and O
s.e.m O
. O

of O
at O
least O
2 O
independent O
experiments O
is O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
*** O
P<0.001 O
. O

n.s O
. O

:non O
significant O
. O

See O
also O
Appendix O
Figure O
S4A O
. O

(C) O
Gene O
expression O
analysis O
of O
Stat3+/+ B-proteingene
cells O
transfected O
with O
control O
shRNA O
(SCR, O
dark O
green), O
and O
two O
independent O
shRNAs O
for O
a O
Complex O
I O
subunity O
(NDUFS3) B-proteingene
(SH1 O
and O
SH2) O
. O

Note O
that O
shRNAs O
for O
NDUFS3 B-proteingene
downregulates O
gene O
expression O
of O
about O
70% O
. O

Mean O
and O
st.dev O
. O

of O
two O
independent O
experiments O
is O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
** O
P<0.01 O
. O

(D) O
Relative O
changes O
in O
oxygen O
consumption O
after O
200nM O
FCCP O
treatment O
of O
Stat3+/+ B-proteingene
cells O
transfected O
with O
control O
shRNA O
(dark O
green) O
and O
two O
different O
shRNAs O
for O
NDUFS3 B-proteingene
. O

Note O
that O
downregulation O
of O
the O
Complex O
I O
subunit O
results O
in O
decreased O
respiration O
. O

Mean O
and O
s.e.m O
. O

of O
>4 O
technical O
replicates O
are O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
*** O
P<0.001 O
. O

See O
also O
Appendix O
Figure O
S4D O
for O
full O
Seahorse O
profiles O
. O

(E) O
Proliferation O
assay O
of O
control O
shRNA O
cells O
(dark O
green) O
and O
cells O
with O
downregulation O
of O
NDUFS3 B-proteingene
. O

Note O
that O
downregulation O
of O
the O
Complex O
I O
subunit O
results O
in O
decreased O
proliferation O
. O

Mean O
and O
s.e.m O
. O

of O
three O
independent O
experiments O
is O
shown O
. O

(F) O
Proliferation O
assay O
of O
Stat3+/+ B-proteingene
and O
Stat3-/- B-proteingene
cells O
cultured O
in O
presence O
of O
LIF B-proteingene
showing O
the O
reduction O
of O
proliferation O
after O
48hours O
treatment O
with O
increasing O
concentrations O
of O
Antimycin O
A O
(50nM, O
100nM O
or O
200nM) O
. O

See O
also O
Appendix O
Figure O
S4F. O
Scores O
were O
normalized O
to O
WT O
cells O
treated O
with O
a O
vehicle O
(EtOH) O
. O

Mean O
and O
s.e.m O
. O

of O
two O
independent O
experiments O
is O
shown O
. O

Unpaired O
t-test: O
** O
P<0.01 O
. O

See O
also O
Appendix O
Figure O
S4E O
. O

(G) O
Proliferation O
assay O
showing O
the O
effect O
of O
long-term O
treatment O
of O
rotenone O
on O
cellproliferation O
. O

Stat3+/+ B-proteingene
cells O
cultured O
in O
2i O
and O
2i+LIF B-proteingene
with O
or O
without O
rotenone O
were O
scored O
for O
4 O
subsequent O
passages O
. O

The O
cumulative O
number O
of O
cells O
has O
been O
calculated O
and O
shown O
on O
log O
scale O
. O

Rotenone O
at O
50nM O
or O
100nM O
reduced O
the O
number O
of O
cells O
after O
4 O
passages O
by O
4.8 O
and O
16.7 O
times, O
respectively O
. O

Mean O
and O
st.dev O
of O
two O
technical O
replicates O
of O
a O
representative O
experiment O
is O
shown O
. O

See O
also O
Appendix O
Figure O
S6E O
. O

(H) O
Gene O
expression O
analysis O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
2i+LIF B-proteingene
(blue O
bars) O
and O
with O
50nM O
rotenone O
for O
48 O
hours O
(orange O
bars) O
showing O
that O
rotenone O
does O
not O
affect O
transcription O
of O
main O
LIF B-proteingene
targets O
in O
ES O
cells O
. O

Data O
were O
normalized O
to O
the O
highest O
value O
for O
each O
condition O
. O

Mean O
and O
st.dev O
. O

of O
2 O
biological O
replicates O
is O
shown O
. O

(I) O
Bright O
field O
images O
showing O
that O
long-term O
treatment O
with O
rotenone O
causes O
reduction O
in O
proliferation, O
shown O
by O
the O
reduced O
size O
of O
individual O
colonies, O
but O
does O
not O
cause O
differentiation O
in O
mES O
cells O
. O

Scale O
bar, O
50 O
µm O
. O

(B) O
Western O
blot O
of O
Stat3+/+ B-proteingene
cells O
cultured O
in O
presence O
or O
absence O
of O
LIF, B-proteingene
Stat3-/- B-proteingene
cells O
cultured O
in O
2i+LIF B-proteingene
and O
two O
clones O
of O
Stat3-/- B-proteingene
cells O
transfected O
with O
a O
full O
length O
form O
of O
Stat3 B-proteingene
cultured O
in O
2i+LIF. B-proteingene
Relative O
mean O
intensity O
is O
shown O
below O
each O
band O
. O

Note O
that O
Stat3protein B-proteingene
levels O
in O
clone O
A O
and O
B O
are O
comparable O
to O
the O
endogenous O
levels O
of O
the O
control O
. O

GAPDH B-proteingene
was O
used O
as O
a O
loading O
control O
. O

(C) O
Gene O
expression O
analysis O
of O
Stat3+/+ B-proteingene
cells, O
Stat3-/- B-proteingene
cells O
and O
two O
Stat3 B-proteingene
rescue O
clones O
(Stat3.A/B) B-proteingene
cultured O
in O
absence O
or O
presence O
of O
LIF. B-proteingene
Note O
that O
both O
clones O
respond O
to O
LIF B-proteingene
and O
activate O
Stat3 B-proteingene
direct O
target O
Socs3 B-proteingene
. O

(D) O
Proliferation O
assay O
of O
Stat3+/+ B-proteingene
cells, O
Stat3-/- B-proteingene
cells O
and O
Stat3.A/B B-proteingene
rescue O
clones O
cultured O
in O
the O
presence O
of O
LIF. B-proteingene
Cells O
were O
seeded O
and O
scored O
for O
four O
days O
. O

Scores O
were O
normalized O
to O
day1 O
. O

Mean O
and O
s.e.m O
. O

of O
two O
independent O
biological O
replicates O
of O
a O
representative O
experiment O
are O
shown O
. O

See O
also O
Appendix O
Figure O
S7A O
. O

(E) O
Western O
blot O
of O
total O
and O
mitochondrial O
fractions O
of O
Stat3+/+, B-proteingene
Stat3-/- B-proteingene
cells O
and O
two O
MLS-Stat3 B-proteingene
clones O
cultured O
in O
2i+LIF. B-proteingene
The O
nuclearprotein O
TRIM33 B-proteingene
and O
mitochondrial O
marker O
TOM20 B-proteingene
confirmed O
successful O
mitochondrial O
isolation O
. O

Note O
that O
MLS-Stat3 B-proteingene
is O
enriched O
in O
the O
mitochondrial O
fraction, O
suggesting O
correct O
localization O
of O
the O
fusion O
protein O
. O

See O
also O
Appendix O
Figure O
S7B O
. O

(F) O
Representative O
confocal O
images O
of O
Stat3-/- B-proteingene
and O
MLS-Stat3 B-proteingene
cells O
stained O
with O
anti-Stat3 B-proteingene
and O
anti-ATAD3 B-proteingene
antibodies O
. O

Merge O
image O
shows O
co-localization O
between O
Stat3 B-proteingene
and O
the O
nucleoids O
marker O
Atatd3 B-proteingene
(R=0.72 O
for O
MLS-Stat3 B-proteingene
cells, O
R=0.22 O
in O
Stat3-/-) B-proteingene
. O

DAPI O
serves O
as O
nuclear O
counterstain O
. O

Scale O
bar, O
10 O
μm O
. O

(G) O
Gene O
expression O
analysis O
of O
Stat3+/+, B-proteingene
Stat3-/- B-proteingene
cells O
and O
three O
MLS-Stat3 B-proteingene
clones O
cultured O
in O
the O
presence O
of O
LIF. B-proteingene
MLS-Stat3 B-proteingene
specifically O
induces O
expression O
of O
mitochondrial O
markers O
with O
negligible O
effects O
on O
the O
nuclear O
target O
Socs3 B-proteingene
. O

See O
also O
Appendix O
Figure O
S7E O
. O

(H) O
Chromatin O
immunoprecipitation O
(ChIP) O
performed O
using O
anti-Stat3 B-proteingene
or O
a O
rabbit O
control O
IgG O
antibody O
in O
Stat3-/- B-proteingene
and O
MLS-Stat3 B-proteingene
cells O
cultured O
in O
2i+LIF B-proteingene
conditions O
. O

ChIP-PCR O
was O
performed O
with O
primers O
located O
on O
three O
regions O
of O
the O
D-loop O
(A, O
B, O
C) O
. O

Note O
that O
2 O
D-loop O
regions O
are O
significantly O
enriched O
in O
MLS-Stat3 B-proteingene
compared O
to O
Stat3-/- B-proteingene
cells O
. O

Mean O
and O
s.e.m O
. O

of O
three O
independent O
experiments O
are O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
** O
P<0.01 O
. O

(I) O
Left: O
representative O
confocal O
images O
of O
Stat3-/- B-proteingene
and O
MLS-Stat3 B-proteingene
cells O
subjected O
to O
proximity-ligation-assay O
(PLA) O
by O
using O
anti-Stat3 B-proteingene
and O
anti-ATAD3 B-proteingene
antibodies O
. O

DAPI O
serves O
as O
a O
nuclear O
counterstain O
. O

Red O
dots O
indicates O
spacial O
proximity O
between O
Stat3 B-proteingene
and O
the O
nucleoids O
marker O
Atad3 B-proteingene
. O

Right: O
histogram O
showing O
quantification O
of O
PLA O
assay O
performed O
on O
Stat3+/+, B-proteingene
Stat3-/- B-proteingene
and O
MLS-Stat3 B-proteingene
cells O
. O

Number O
of O
red O
dots/cell O
are O
plotted O
. O

Note O
that O
double O
staining O
in O
MLS-Stat3 B-proteingene
cells O
results O
in O
increased O
number O
or O
red O
dots O
compared O
to O
Stat3-/- B-proteingene
cells O
Mean O
and O
s.e.m O
. O

of O
>15 O
cells O
for O
each O
sample O
are O
shown O
. O

Unpaired O
t-test: O
** O
P<0.01 O
*** O
P<0.001 O
. O

Scale O
bar, O
10µm O
. O

See O
also O
Appendix O
Figure O
S7D O
. O

(J) O
Proliferation O
assay O
of O
Stat3+/+, B-proteingene
Stat3-/- B-proteingene
cells O
and O
three O
MLS-Stat3 B-proteingene
clones O
cultured O
in O
the O
presence O
of O
LIF. B-proteingene
Cells O
were O
seeded O
and O
scored O
for O
four O
days O
. O

Mean O
and O
s.e.m O
. O

of O
two O
technical O
replicates O
of O
a O
representative O
experiment O
are O
shown O
. O

See O
also O
Appendix O
Figure O
S8A O
. O

(K) O
Proliferation O
assay O
of O
Stat3-/- B-proteingene
cells O
and O
three O
MLS-Stat3 B-proteingene
clones O
cultured O
in O
the O
presence O
of O
LIF. B-proteingene
Cells O
were O
seeded O
and O
treated O
with O
DMSO O
or O
with O
50nM O
or O
100nM O
of O
rotenone O
for O
48hours O
. O

MLS-Stat3 B-proteingene
clones O
also O
proliferated O
more O
than O
Stat3-/- B-proteingene
both O
basally O
and O
in O
the O
presence O
of O
rotenone O
. O

Mean O
and O
s.e.m O
. O

of O
two O
technical O
replicates O
of O
a O
representative O
experiment O
are O
shown O
. O

(L) O
Representative O
brightfield O
images O
of O
Stat3+/+, B-proteingene
Stat3-/- B-proteingene
and O
one O
MLS-Stat3 B-proteingene
clone O
cultured O
in O
2i+LIF B-proteingene
showing O
similar O
morphology O
but O
note O
smaller O
colony O
size O
for O
Stat3-/- B-proteingene
cells O
. O

Scale O
bar, O
100µm O
. O

(A) O
Gene O
expression O
analysis O
of O
EpiSCs O
(GOF18) O
cultured O
in O
FGF+Activin B-proteingene
(grey O
bars) O
and O
ES O
cells O
cultured O
in O
2i+LIF B-proteingene
(orange O
bars) O
shows O
a O
general O
reduction O
of O
both O
nuclearLIF B-proteingene
targets O
(Socs3, B-proteingene
Stat3) B-proteingene
and O
mitochondrial O
markers O
(Nd1, B-proteingene
Nd4, B-proteingene
Nd4l) B-proteingene
in O
EpiSCs O
. O

Data O
were O
normalized O
to O
EpiSCs O
in O
F/A O
and O
mean O
and O
s.e.m O
. O

of O
two O
technical O
replicates O
of O
two O
independent O
experiments O
(light O
and O
dark O
bars) O
is O
shown O
. O

(B) O
Experimental O
scheme O
for O
testing O
the O
effect O
of O
rotenone O
on O
EpiSCs O
reprogramming O
. O

EpiSCs O
were O
plated O
in O
FGF+Activin B-proteingene
(Day0) O
and O
cultured O
for O
24hours O
. O

Cells O
were O
then O
treated O
with O
or O
without O
LIF B-proteingene
and O
rotenone O
at O
different O
concentrations O
as O
indicated O
(Day1) O
. O

Cells O
were O
either O
harvested O
after O
48hours O
(Day3) O
for O
gene O
expression O
analysis O
or O
left O
in O
2i O
media O
and O
Oct4-GFP B-proteingene
positive O
colonies O
were O
scored O
at O
Day O
6 O
or O
8 O
. O

(C) O
Quantification O
of O
Oct4-GFP B-proteingene
positive O
iPS O
colonies O
at O
day7 O
of O
reprogramming O
generated O
from O
GOF18 O
EpiSCs O
subjected O
to O
48hours O
treatment O
(at O
D1-D3) O
with O
LIF B-proteingene
and O
two O
doses O
of O
rotenone O
. O

Note O
that O
rotenone O
treatment O
reduces O
the O
number O
of O
iPS O
colonies O
generated O
. O

Mean O
and O
s.e.m O
of O
two O
technical O
replicates O
of O
three O
independent O
experiments O
is O
shown O
. O

See O
also O
Appendix O
Figure O
S10B O
. O

(D) O
Left: O
number O
of O
Oct4-GFP B-proteingene
positive O
colonies O
at O
day8 O
of O
reprogramming O
upon O
48hours O
treatment O
with O
rotenone O
at O
day1-2 O
or O
at O
day5-6 O
. O

Note O
that O
rotenone O
treatment O
given O
at O
day5-6 O
does O
not O
reduce O
the O
number O
of O
iPS O
colonies O
. O

Mean O
and O
s.e.m O
of O
two O
technical O
replicates O
is O
shown O
. O

See O
also O
Appendix O
Figure O
S10C. O
Right: O
representative O
Alkaline O
Phosphatase O
(AP) O
staining O
of O
iPSc O
colonies O
generated O
from O
GOF18EpiSCs O
at O
day7 O
of O
reprogramming O
treated O
with O
DMSO O
(top) O
or O
with O
48h O
of O
rotenone O
at O
days O
1-2 O
(middle) O
or O
5-6 O
(bottom) O
. O

(E) O
Gene O
expression O
analysis O
of O
iPS O
cells O
generated O
from O
GOF18EpiSCs O
and O
cultured O
in O
2i+LIF B-proteingene
for O
at O
least O
2 O
passages O
. O

Note O
that O
iPS O
cells O
show O
high O
expression O
of O
naïve O
pluripotency O
markers O
(grey O
bars O
on O
left O
panel) O
and O
low O
expression O
of O
EpiSC O
markers O
(green O
bars O
on O
right O
panel) O
. O

Data O
were O
normalized O
to O
the O
highest O
value O
for O
each O
gene O
and O
mean O
and O
s.e.m O
of O
three O
technical O
replicates O
is O
shown O
. O

Right O
panel O
shows O
representative O
bright O
field O
and O
Pou5f1-GFP+images B-proteingene
of O
iPS O
colonies O
at O
day O
8 O
of O
reprogramming O
. O

Scale O
bar, O
50µm O
. O

(F) O
and O
(G) O
Gene O
expression O
analysis O
of O
GOF18EpiSCs O
cultured O
in O
FGF+Activin B-proteingene
or O
treated O
for O
48hours O
with O
2i+LIF B-proteingene
in O
absence O
or O
presence O
of O
decreasing O
concentrations O
of O
rotenone O
. O

Note O
that O
both O
nuclear O
(F) O
and O
mitochondrial O
(G) O
genes O
expression O
is O
induced O
upon O
LIF B-proteingene
treatment O
and O
rotenone O
did O
not O
impair O
LIF B-proteingene
effect O
. O

Data O
were O
normalized O
to O
F/A O
and O
mean O
and O
s.e.m O
of O
three O
independent O
experiments O
is O
shown O
. O

(H) O
Number O
of O
iPS O
colonies O
generated O
from O
GOF18EpiSCs O
transfected O
transiently O
with O
a O
piggyBac O
vector O
containing O
GFP B-proteingene
or O
Klf4 B-proteingene
and O
treated O
with O
LIF B-proteingene
for O
48hours O
and O
rotenone O
as O
indicated O
. O

Mean O
and O
s.e.m O
. O

of O
two O
technical O
replicates O
of O
a O
representative O
experiment O
is O
shown O
. O

Unpaired O
t-test: O
** O
P<0.01 O
*** O
P<0.001 O
. O

See O
also O
Appendix O
Figure O
S10H O
. O

(I) O
Left O
panel O
shows O
the O
number O
of O
GFP B-proteingene
positive O
iPS O
colonies O
generated O
from O
OEC2EpiSCs O
transiently O
transfected O
with O
a O
piggyBac O
vector O
containing O
Klf4 B-proteingene
(1st O
and O
2nd O
bar), O
Tfcp2l1 B-proteingene
(3rd O
and O
4th O
bar) O
or O
a O
combination O
of O
both O
(5th O
and O
6th O
bar) O
and O
treated O
with O
LIF B-proteingene
for O
48hours O
or O
rotenone O
as O
indicated O
. O

Note O
that O
rotenone O
abolished O
the O
effect O
of O
LIF B-proteingene
on O
iPS O
formation O
. O

Each O
bar O
shows O
the O
cumulative O
number O
of O
colonies O
from O
four O
independent O
experiments O
and O
mean O
and O
s.e.m O
. O

of O
two O
technical O
replicates O
for O
each O
experiment O
is O
shown O
. O

Unpaired O
t-test: O
* O
P<0.05 O
. O

Right O
panel O
shows O
representative O
Alkaline O
Phosphatase O
(AP) O
staining O
of O
iPSc O
colonies O
generated O
from O
OEC2EpiSCs O
at O
day7 O
of O
reprogramming O
transfected O
with O
a O
piggyBac O
vector O
containing O
Klf4 B-proteingene
and O
Tfcp2l1 B-proteingene
and O
treated O
with O
2i O
(top), O
2i+LIF B-proteingene
(middle) O
or O
with O
2i+LIF B-proteingene
and O
rotenone O
for O
48h O
at O
days O
1-2 O
(bottom) O
. O

(A) O
Western O
blot O
of O
SMC3-LAP B-proteingene
expressing O
HeLa O
cells O
treated O
with O
siRNA O
as O
indicated O
and O
synchronized O
in O
G2-phase O
. O

Efficiency O
of O
RNA O
interference O
and O
SMC3 B-proteingene
acetylation O
levels O
were O
analyzed O
from O
total O
extracts O
and O
after O
chromatin O
fractionation O
(asterisks O
indicate O
unspecific O
signals O
that O
were O
depleted O
from O
antibody O
dilutions O
used O
in O
later O
experiments, O
presumably O
by O
repeated O
usage O
of O
the O
antibody O
samples) O
. O

Note O
that O
ESCO1 B-proteingene
levels O
were O
increased O
on O
chromatin O
after O
depletion O
of O
ESCO2, B-proteingene
raising O
the O
possibility O
that O
a O
decrease O
in O
chromatin O
bound O
ESCO2 B-proteingene
might O
be O
compensated O
for O
by O
ESCO1 B-proteingene
recruitment O
to O
chromatin O
. O

(B) O
Still O
images O
of O
an O
inverse O
fluorescence O
recovery O
after O
photobleaching O
(iFRAP) O
experiment O
. O

Fluorescence O
intensities O
are O
false-colored O
as O
indicated O
. O

Size O
bar, O
5 O
μm O
. O

(C) O
Graph O
depicting O
the O
normalized O
intensity O
after O
photobleaching O
from O
two O
biological O
replicates O
to O
quantify O
chromatin O
dissociation O
kinetics O
. O

Error O
bars O
denote O
standard O
error O
of O
the O
mean O
(s.e.m O
. O

), O
n O
= O
10 O
cells O
per O
condition O
. O

(D) O
Quantification O
of O
the O
relative O
abundance O
of O
SMC3-LAP B-proteingene
in O
the O
stable O
chromatin O
binding O
mode O
. O

(A) O
Quantification O
of O
iFRAP O
experiments O
using O
HeLa O
cells O
expressing O
SMC3-LAP B-proteingene
in O
the O
wild-type O
form O
(wt) O
or O
with O
lysines O
105-106 O
mutated O
to O
glutamines O
(QQ) O
or O
arginines O
(RR) O
and O
synchronized O
in O
G1-phase O
. O

Error O
bars O
denote O
s.e.m., O
n O
> O
25 O
cells O
per O
condition O
. O

(B) O
Quantification O
of O
chromatin O
residence O
time O
of O
SMC3-LAP B-proteingene
alleles O
in O
G1-phase O
. O

(C) O
Quantification O
of O
iFRAP O
experiments O
using O
cells O
synchronized O
in O
G2-phase O
. O

Error O
bars O
denote O
s.e.m., O
n O
> O
26 O
cells O
per O
condition O
. O

(D) O
Quantification O
of O
stably O
bound O
SMC3-LAP B-proteingene
alleles O
in O
G2-phase O
. O

(E) O
Western O
blot O
of O
mousefibroblasts O
expressing O
SMC3-LAP B-proteingene
in O
the O
presence O
or O
absence O
of O
endogenous O
Smc3 B-proteingene
after O
gene O
deletion O
. O

Extracts O
were O
prepared O
after O
subculturing O
two O
times O
. O

Cells O
without O
SMC3-LAP B-proteingene
do O
not O
proliferate O
after O
deletion O
of O
Smc3 B-proteingene
. O

(F) O
Western O
blot O
showing O
HeLa O
cell O
extracts O
after O
treatment O
with O
siRNA O
as O
indicated O
and O
synchronized O
in O
G2-phase O
. O

Note O
that O
ESCO1immunoblot B-proteingene
signals O
were O
also O
reduced O
in O
sororin B-proteingene
depleted O
cells O
. O

We O
currently O
do O
not O
know O
if O
this O
is O
an O
effect O
of O
sororin B-proteingene
depletion, O
an O
off-target O
effect O
or O
an O
artefact O
of O
unequal O
sample O
loading O
. O

(G) O
iFRAP O
quantification O
of O
stably O
chromatin O
bound O
SMC3-LAP B-proteingene
after O
siRNA O
treatment O
using O
cells O
synchronized O
in O
G2-phase O
. O

Error O
bars O
denote O
s.e.m., O
n O
> O
11 O
cells O
per O
condition O
. O

(A) O
FACS O
profile O
of O
cells O
transfected O
with O
nondegradable O
KEN-box O
mutant O
sororin-FLAG B-proteingene
(sorKBM-FLAG) B-proteingene
after O
synchronization O
in O
G1-phase O
and O
propidium O
iodide O
staining O
. O

(B) O
Immunofluorescence O
microscopy O
experiment O
to O
determine O
transfection O
efficiency O
. O

(C) O
Western O
blot O
of O
fractionated O
lysates O
to O
detect O
sororinKBM-FLAG B-proteingene
. O

(D) O
Quantification O
of O
SMC3-LAP B-proteingene
residence O
time O
on O
chromatin O
after O
transfecting O
cells O
with O
sorKBM-FLAG B-proteingene
in O
G1-phase O
. O

Error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
15 O
cells O
per O
condition O
. O

(E-F) O
Analysis O
of O
cell O
cycle O
distribution O
and O
transfection O
efficiency O
using O
cells O
synchronized O
in O
G2-phase O
. O

(G) O
Quantification O
of O
stably O
chromatin-bound O
SMC3-LAP B-proteingene
from O
cells O
expressing O
nondegradable O
sororin B-proteingene
in O
G2-phase O
. O

Cells O
were O
treated O
with O
siRNA O
as O
indicated O
. O

(H) O
Western O
blot O
showing O
fractionated O
and O
nuclease O
digested O
chromatin O
from O
cells O
synchronized O
in O
G1 O
and O
G2-phase O
after O
immunoprecipitation O
with O
FLAG B-proteingene
antibodies O
. O

(A) O
Examples O
of O
sororin B-proteingene
(dotted O
arrows) O
and O
SMC3ChIP-seq B-proteingene
and O
BrdU O
DIP-seq O
data O
from O
early O
S-phase O
as O
compared O
to O
G2-phase O
using O
the O
Integrated O
Genome O
Browser O
(IGB; O
Nicol O
et O
al, O
2009) O
. O

(B) O
Alignment O
of O
sororin, B-proteingene
BrdU O
and O
BrdU-negative O
control O
sequencing O
bins O
in O
early O
S-phase O
to O
humanchromosome O
18 O
(GRCh37/hg19) O
. O

Bars O
correspond O
to O
called O
peaks, O
curves O
to O
read O
enrichments O
after O
smoothing O
(k=25 O
kbp) O
. O

(C) O
Quantification O
of O
the O
co-occupancy O
of O
BrdU O
incorporation O
and O
sororin B-proteingene
localization O
in O
early O
S-phase O
and O
sororin B-proteingene
in O
G2-phase O
depicted O
as O
p-value O
distributions O
calculated O
with O
IntervalStats O
(Chikina O
& O
Troyanskaya, O
2012) O
and O
compared O
to O
randomized O
controls O
. O

Sororin B-proteingene
peaks O
were O
identified O
as O
overlapping O
peaks O
of O
4 O
samples O
in O
early O
S-phase O
and O
2 O
samples O
in O
G2-phase, O
using O
only O
the O
common O
peaks O
. O

(D) O
Quantification O
of O
the O
co-occupancy O
of O
SMC3 B-proteingene
in O
early O
S-phase O
and O
in O
G2-phase O
with O
BrdU O
incorporation O
in O
early O
S-phase O
. O

(A) O
Schematic O
representation O
of O
wild-type O
(wt), O
targeted O
(flx) O
and O
deleted O
(Δ) O
Cdca5 B-proteingene
alleles O
(left) O
and O
Southern O
blot O
of O
mouse O
genomic O
DNA O
(right) O
. O

Red O
triangles, O
loxP O
sites O
. O

(B) O
Observed O
and O
expected O
genotype O
distribution O
among O
offspring O
of O
heterozygous O
Cdca5 B-proteingene
Δ/+ O
mice O
(newborn O
mice, O
n O
= O
136; O
E9.5, O
n O
= O
54) O
. O

(D) O
Western O
blot O
of O
cell O
extracts O
to O
analyze O
depletion O
of O
sororinprotein B-proteingene
from O
fibroblasts O
after O
tamoxifen-induced O
Cre B-proteingene
expression O
. O

Extracts O
were O
prepared O
either O
one O
or O
two O
days O
after O
release O
from O
the O
arrest O
as O
indicated O
. O

Chr, O
fractionated O
chromatin; O
sol, O
soluble O
proteins O
. O

(E) O
Proliferation O
curve O
of O
cells O
with O
the O
indicated O
genotype O
after O
tamoxifen O
treatment O
. O

(F) O
Observed O
cell O
cycle O
distribution O
of O
fibroblasts O
treated O
with O
tamoxifen O
under O
starvation O
and O
subcultured O
in O
rich O
medium O
. O

(G) O
Quantification O
of O
mitotic O
cells O
with O
misaligned O
chromosomes O
after O
Cdca5 B-proteingene
deletion O
and O
proliferation O
for O
36 O
to O
60 O
hours O
. O

Size O
bar, O
10 O
µm; O
error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
500 O
cells O
per O
condition O
. O

(H) O
Phenotypic O
classification O
of O
nuclear O
morphology O
after O
Cdca5 B-proteingene
deletion O
and O
proliferation O
for O
5 O
to O
7 O
days O
. O

Size O
bar, O
10 O
µm; O
error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
500 O
cells O
per O
condition O
. O

(I) O
Western O
blot O
showing O
protein O
depletion O
efficiency O
. O

Cre B-proteingene
expression O
was O
induced O
with O
tamoxifen O
for O
24 O
hours O
in O
proliferating O
Smc3 B-proteingene
and O
Cdca5 B-proteingene
conditional O
knockout O
immortalized O
fibroblasts O
. O

(J) O
Analysis O
of O
chromosome O
spreads O
after O
Smc3 B-proteingene
or O
Cdca5 B-proteingene
deletion O
and O
nocodazole O
treatment O
. O

Representative O
images O
from O
every O
category O
are O
shown; O
size O
bar, O
10 O
µm; O
error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
500 O
per O
genotype O
. O

(A) O
Schematic O
illustration O
of O
the O
LAP-AID-tag B-proteingene
integrated O
into O
the O
bacterial O
artificial O
chromosome O
containing O
the O
mouse O
Cdca5 B-proteingene
locus O
. O

(B) O
Immunofluorescence O
staining O
of O
cells O
expressing O
sor-LAP-AID B-proteingene
and O
the O
F-box O
helper O
protein O
after O
treatment O
with O
auxin O
. O

Antibodies O
against O
GFP B-proteingene
mark O
the O
fusion O
protein O
and O
Aurora B-proteingene
B I-proteingene
antibody O
stains O
cells O
in O
G2/M-phase O
. O

Scale O
bar, O
10 O
µm O
. O

(C) O
Quantification O
of O
immunofluorescence O
after O
treating O
cells O
with O
auxin O
. O

Error O
bars O
denote O
s.e.m O
. O

; O
a.u., O
arbitrary O
units O
. O

(D) O
Time O
course O
quantification O
of O
GFP B-proteingene
immunofluorescence O
signal O
decrease O
after O
auxin O
addition O
. O

(E) O
Analysis O
of O
chromosome O
spreads O
after O
auxin O
treatment O
. O

(F) O
Western O
blot O
showing O
cell O
extracts O
after O
treatment O
with O
auxin O
. O

(A) O
Cell O
cycle O
distribution O
of O
immortalized O
Cdca5 B-proteingene
Δ/Δ O
sor-LAP-AID B-proteingene
fibroblasts O
after O
24-hour O
incubation O
with O
aphidicolin O
and O
release O
. O

(B) O
Western O
blot O
showing O
cell O
extracts O
after O
incubation O
with O
aphidicolin O
and O
release O
. O

(C) O
Still O
images O
of O
a O
fluorescence O
recovery O
after O
photobleaching O
experiment O
. O

Size O
bar, O
5 O
μm O
. O

Bleach O
area O
radius, O
2 O
µm O
. O

(D) O
Graph O
depicting O
the O
normalized O
intensity O
after O
photobleaching O
to O
quantify O
turnover O
of O
sororin B-proteingene
(n O
= O
15) O
. O

(E) O
Quantification O
of O
the O
relative O
abundance O
of O
sororin-LAP-AID B-proteingene
on O
chromatin O
. O

Error O
bars O
denote O
s.e.m O
. O

(F) O
Quantification O
of O
the O
chromatin O
residence O
time O
of O
sor-LAP-AID B-proteingene
at O
different O
times O
. O

Error O
bars O
denote O
s.e.m O
. O

(B) O
Quantification O
of O
EdU-labeled O
prometaphase O
cells O
after O
treating O
cells O
with O
auxin O
and O
EdU O
at O
indicated O
time O
points O
. O

Error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
200 O
cells O
per O
condition O
. O

(C) O
Analysis O
of O
chromosome O
spreads O
after O
auxin O
and O
EdU O
treatment O
and O
Giemsa O
staining O
. O

(D) O
Representative O
picture O
of O
the O
most O
prominent O
phenotype O
class O
upon O
auxin O
and O
EdU O
treatment O
and O
immunofluorescence O
microscopy O
. O

Scale O
bar, O
10 O
µm O
. O

(E) O
Analysis O
of O
chromosome O
spreads O
after O
auxin O
treatment O
and O
EdU O
and O
DAPI O
labeling O
. O

Error O
bars O
denote O
s.e.m O
. O

; O
n O
> O
200 O
cells O
per O
condition O
. O

(A) O
Colony O
morphology O
and O
alkaline B-proteingene
phosphatase I-proteingene
(AP) B-proteingene
activity O
of O
ES O
cells O
upon O
KD O
of O
Yap1 B-proteingene
and O
Pou5f1 B-proteingene
. O

KD1 O
and O
KD2 O
indicate O
two O
different O
shRNA O
sequences O
tested O
. O

All O
the O
following O
cell O
morphology O
and O
AP O
staining O
pictures O
were O
taken O
two O
passages O
(4 O
days) O
after O
lentivirus O
infection O
unless O
otherwise O
stated O
. O

(B-C) O
mRNA O
expression O
levels O
of O
Pou5f1, B-proteingene
Nanog, B-proteingene
Sox2, B-proteingene
Esrrb B-proteingene
(B), O
and O
Yap1 B-proteingene
(C) O
upon O
KD O
of O
Yap1 B-proteingene
. O

All O
the O
following O
mRNA O
samples O
were O
harvested O
4 O
days O
after O
lentivirus O
infection O
while O
passaged O
every O
2 O
days O
unless O
otherwise O
stated O
. O

Data O
are O
represented O
as O
mean O
SD O
. O

(D) O
Protein O
levels O
of O
Yap1, B-proteingene
Pou5f1, B-proteingene
and O
Nanog B-proteingene
upon O
KD O
of O
Yap1 B-proteingene
. O

All O
the O
following O
protein O
samples O
were O
harvested O
4 O
days O
after O
lentivirus O
infection O
while O
passaged O
every O
2 O
days O
unless O
otherwise O
stated O
. O

(E) O
Colony O
morphology O
and O
AP B-proteingene
activity O
of O
mouse O
embryonic O
stem O
cells O
(ESC) O
and O
three O
Yap1 B-proteingene
KO O
clones O
(KO1-KO3) O
. O

(F) O
mRNA O
levels O
of O
Pou5f1, B-proteingene
Nanog, B-proteingene
Sox2, B-proteingene
and O
Esrrb B-proteingene
upon O
KO O
of O
Yap1 B-proteingene
. O

Data O
are O
represented O
as O
mean O
SD O
. O

(G) O
Protein O
levels O
of O
Yap1, B-proteingene
Pou5f1, B-proteingene
and O
Nanog B-proteingene
in O
Yap1 B-proteingene
KO O
clones O
. O

(H) O
A O
heatmap O
showing O
relative O
mRNA O
expression O
levels O
of O
3,605 O
genes O
differentially O
expressed O
(> O
2-fold) O
between O
ES O
cells O
and O
differentiating O
ES O
cells O
(dESC) O
. O

Genes O
were O
sorted O
by O
the O
fold O
changes O
of O
gene O
expression O
between O
dESC O
and O
ES O
cells O
. O

Corresponding O
gene O
expression O
profiles O
obtained O
from O
Yap1 B-proteingene
KO1, O
Yap1 B-proteingene
KO2, O
and O
Yap1 B-proteingene
KD O
cells O
are O
also O
shown O
. O

(I) O
mRNA O
expression O
levels O
of O
lineage-specific O
marker O
genes O
upon O
KD O
of O
Yap1 B-proteingene
. O

dESC O
were O
used O
as O
control O
cells O
. O

(J) O
A O
heatmap O
showing O
Pearson O
correlation O
coefficients O
of O
gene O
expression O
profiles O
obtained O
from O
ESC, O
control O
virus O
infected O
ES O
cells O
(Control), O
dESC, O
Yap1 B-proteingene
KD O
cells, O
and O
Yap1 B-proteingene
KO O
cells O
. O

(A) O
Colony O
morphology O
and O
AP B-proteingene
activity O
of O
ES O
cells O
upon O
KD O
of O
Yap1 B-proteingene
and O
Taz B-proteingene
. O

(B-D) O
mRNA O
expression O
levels O
of O
Yap1 B-proteingene
and O
Taz B-proteingene
(B), O
Pou5f1, B-proteingene
Nanog, B-proteingene
Sox2, B-proteingene
and O
Esrrb B-proteingene
(C), O
and O
lineage-specific O
marker O
genes O
upon O
KD O
of O
Yap1 B-proteingene
and O
Taz B-proteingene
. O

Data O
are O
represented O
as O
mean O
SD O
. O

(B-D) O
mRNA O
expression O
levels O
of O
lineage-specific O
marker O
genes O
upon O
KD O
of O
Yap1 B-proteingene
and O
Taz B-proteingene
. O

Data O
are O
represented O
as O
mean O
SD O
. O

(E) O
Colony O
morphology O
and O
AP B-proteingene
activity O
of O
ES O
cells O
upon O
KD O
of O
Tead B-proteingene
1/3/4 I-proteingene
. O

(F-G) O
mRNA O
expression O
levels O
of O
Tead1, B-proteingene
Tead3, B-proteingene
and O
Tead4 B-proteingene
(F) O
and O
Pou5f1, B-proteingene
Nanog, B-proteingene
Sox2, B-proteingene
and O
Esrrb B-proteingene
(G) O
upon O
KD O
of O
Tead B-proteingene
1/3/4 I-proteingene
. O

Data O
are O
represented O
as O
mean O
SD O
. O

(H) O
Protein O
levels O
of O
Tead1, B-proteingene
Tead3, B-proteingene
Tead4, B-proteingene
and O
Pou5f1 B-proteingene
upon O
KD O
of O
Tead B-proteingene
1/3/4 I-proteingene
. O

N.S. O
depicts O
non-specific O
. O

(I) O
mRNA O
expression O
levels O
of O
lineage-specific O
marker O
genes O
upon O
KD O
of O
Tead B-proteingene
1/3/4 I-proteingene
. O

(A) O
Relative O
mRNA O
levels O
of O
Yap1, B-proteingene
Pou5f1, B-proteingene
and O
Gata6 B-proteingene
during O
time-courseembryoid O
body O
(EB) O
differentiation O
. O

Gene O
expression O
data O
were O
obtained O
from O
GSE3749 O
. O

Pou5f1 B-proteingene
and O
Gata6 B-proteingene
serve O
as O
representative O
ES O
cell O
marker O
and O
lineage-specific O
marker, O
respectively O
. O

(B) O
Relative O
Yap1 B-proteingene
mRNA O
levels O
in O
ES O
cells O
(ESC) O
and O
differentiating O
ES O
cells O
(dESC) O
(LIF B-proteingene
withdrawal O
for O
4 O
days) O
and O
data O
are O
represented O
as O
mean O
SD. O
To O
differentiate O
ES O
cells, O
cells O
were O
incubated O
in O
LIF-withdrawn B-proteingene
medium O
for O
4 O
days O
. O

Both O
ESC O
and O
dESC O
were O
passaged O
every O
2 O
days O
. O

(C) O
Protein O
levels O
of O
Yap1 B-proteingene
and O
Pou5f1 B-proteingene
during O
time-course O
differentiation O
upon O
LIF B-proteingene
withdrawal O
. O

(D) O
Phospho-Yap1 B-proteingene
levels O
during O
time-course O
differentiation O
. O

Samples O
were O
normalized O
by O
total O
Yap1 B-proteingene
level O
. O

(E-G) O
Immunofluorescence O
(IF) O
images O
depicting O
localization O
of O
Yap1 B-proteingene
in O
J1 O
(D), O
CJ7 O
(E), O
and O
E14 O
(F) O
mouseESC O
(top) O
and O
dESC O
(bottom) O
. O

The O
white O
arrow O
indicates O
nucleolus O
. O

Bottom O
panels O
represent O
higher O
magnification O
of O
the O
above O
panels O
. O

Dashed O
circle O
indicates O
nucleus O
border O
. O

(H) O
A O
schematic O
diagram O
depicting O
a O
Yap1 B-proteingene
responsive O
luciferase B-proteingene
reporter O
(8xGTIIC) O
construct O
. O

(I) O
Luciferase O
reporter O
assay O
using O
Yap1 B-proteingene
responsive O
luciferase B-proteingene
reporter O
(8xGTIIC) O
upon O
transient O
overexpression O
(OE) O
Yap1 B-proteingene
in O
ES O
cells O
. O

P-values O
were O
calculated O
using O
Student O
's O
t-test O
. O

Two O
asterisks O
indicate O
P<0.01 O
. O

'Control' O
indicates O
ES O
cells O
infected O
with O
control O
virus O
not O
expressing O
any O
specific O
shRNA O
sequence O
and O
all O
RT-qPCR O
data O
are O
represented O
as O
mean O
SD O
(I-K) O
. O

(J) O
Relative O
activity O
of O
Yap1 B-proteingene
responsive O
luciferase B-proteingene
reporter O
gene O
in O
ESC O
and O
dESC. O
P-values O
were O
calculated O
using O
Student O
's O
t-test O
. O

(K) O
Relative O
Yap1 B-proteingene
mRNA O
levels O
in O
Control O
and O
Pou5f1 B-proteingene
KD O
ES O
cells O
. O

(L) O
IF O
images O
depicting O
localization O
of O
Yap1 B-proteingene
in O
Control O
and O
Pou5f1 B-proteingene
KD O
ES O
cells O
. O

(M) O
Relative O
activity O
of O
Yap1 B-proteingene
responsive O
luciferase B-proteingene
reporter O
gene O
upon O
Pou5f1 B-proteingene
KD O
in O
ES O
cells O
. O

P-values O
were O
calculated O
using O
Student O
's O
t-test O
. O

(A) O
Colony O
morphology O
and O
AP B-proteingene
activity O
of O
Control O
and O
Yap1 B-proteingene
KD O
ES O
cells O
upon O
differentiation O
. O

Morphology O
and O
AP O
staining O
pictures O
were O
taken O
2 O
days O
after O
differentiation O
. O

(B) O
A O
heatmap O
showing O
relative O
mRNA O
expression O
levels O
of O
1,995 O
genes O
differentially O
expressed O
(> O
2-fold) O
between O
Yap1 B-proteingene
KD O
ES O
cells O
and O
Control O
upon O
4 O
days O
of O
differentiation O
. O

Genes O
were O
sorted O
by O
the O
fold O
changes O
of O
gene O
expression O
between O
Yap1 B-proteingene
KD O
ES O
cells O
and O
Control O
(first O
column) O
. O

Corresponding O
gene O
expression O
profiles O
obtained O
from O
differentiating O
ES O
cells O
(dESC) O
are O
shown O
in O
the O
second O
column O
. O

(D) O
Colony O
morphology O
and O
AP B-proteingene
activity O
in O
Yap1 B-proteingene
OE O
cells O
. O

Two O
different O
Yap1 B-proteingene
OE O
clones O
(OE1 O
and O
OE2) O
and O
pool O
of O
Yap1 B-proteingene
OE O
(OE O
pool) O
were O
used O
. O

Cell O
morphology O
and O
AP O
staining O
pictures O
were O
taken O
3 O
weeks O
after O
electroporation O
. O

(E) O
A O
heatmap O
showing O
relative O
mRNA O
expression O
levels O
of O
2,137 O
genes O
differentially O
expressed O
(>2-fold) O
between O
Yap1 B-proteingene
OE O
ES O
cells O
and O
control O
ES O
cells O
. O

Genes O
were O
sorted O
by O
the O
fold O
changes O
of O
gene O
expression O
between O
Yap1 B-proteingene
OE O
ES O
cells O
and O
control O
ES O
cells O
(first O
column) O
and O
corresponding O
gene O
expression O
profiles O
obtained O
from O
dESC O
are O
shown O
. O

(A) O
miR-515-5p B-proteingene
expression O
increases O
the O
area O
of O
the O
tubulin O
cytoskeleton O
. O

Tubulin B-proteingene
(green) O
and O
cell O
nucleus O
(blue) O
. O

Objective O
x20 O
. O

Bar: O
200 O
µm O
. O

(B-C) O
miR-515-5p B-proteingene
inhibits O
random O
(B) O
and O
directed O
(C) O
cell O
migration O
. O

The O
indicated O
cell O
lines O
were O
transfected O
with O
miR-515-5p B-proteingene
for O
48 O
h O
before O
time-lapse O
imaging O
was O
performed O
for O
18 O
h O
(A) O
or O
transwell O
migration O
assays O
were O
performed O
for O
9 O
h O
(C) O
. O

(B-left O
panel) O
Plots O
show O
overlays O
of O
representative O
trajectories O
travelled O
. O

(B-right O
panel) O
The O
distance O
of O
migration O
was O
quantified O
and O
represented O
as O
the O
mean O
± O
SEM O
of O
values O
normalised O
to O
the O
respective O
control O
condition O
. O

(C-left O
panel) O
Representative O
field O
of O
view O
from O
the O
bottom O
of O
the O
transwell O
chambers O
. O

Scale O
bar O
is O
20 O
µm O
. O

(C-right O
panel) O
Data O
represent O
percentage O
of O
the O
average O
number O
migratory O
cells O
per O
field O
(n=5 O
fields O
per O
condition) O
. O

Data O
are O
mean O
of O
three O
experiments O
± O
SEM O
. O

(B-C) O
P O
values O
were O
calculated O
by O
t-test O
between O
miRNA O
(515-5p) O
values O
and O
their O
respective O
non-targeting O
control O
miR O
(NC) O
values O
(***, O
P<0.001) O
. O

All O
data O
shown O
are O
representative O
of O
experiments O
performed O
at O
least O
in O
triplicate O
. O

(A) O
RNA-seq O
of O
MCF7 O
and O
MDA-MB-231 O
transfected O
with O
miR-515-5p B-proteingene
revealed O
the O
down-regulation O
of O
five O
transcripts, O
NRAS, B-proteingene
FZD4, B-proteingene
CDC42BPA, B-proteingene
PIK3C2B B-proteingene
and O
MARK4 B-proteingene
. O

(B-D) O
The O
effect O
of O
miR-515-5p B-proteingene
overexpression O
on O
NRAS, B-proteingene
FZD4, B-proteingene
CDC42BPA, B-proteingene
PIK3C2B B-proteingene
and O
MARK4 B-proteingene
mRNA O
levels O
in O
MCF7 O
(B), O
MDA-MB-231(C), O
A549 O
and O
H1299 O
(D) O
was O
determined O
by O
qPCR O
48 O
h O
following O
transfection O
of O
the O
indicated O
cell O
line O
with O
non-targeting O
control O
miR O
(NC) O
or O
miR-515-5p B-proteingene
. O

Data O
is O
displayed O
as O
the O
normalised O
mean O
± O
SEM. O
P O
values O
were O
calculated O
by O
t-test O
between O
miRNA O
conditions O
and O
their O
respective O
NC O
conditions O
(*, O
P<0.05; O
**, O
P<0.01; O
***, O
P<0.001) O
. O

(E-F) O
miR-515-5p B-proteingene
directly O
interacts O
with O
NRAS, B-proteingene
MARK4 B-proteingene
and O
PI3KC2B B-proteingene
's I-proteingene
3'UTR. O
Relative O
luciferase O
activity O
levels O
were O
measured O
24 O
h O
after O
co-transfection O
of O
MCF-7 O
(E) O
and O
MDA-MB-231 O
(F) O
with O
3'UTR-luciferase B-proteingene
reporter O
constructs O
and O
either O
with O
miR-515-5p B-proteingene
or O
miR O
NC. O
Data O
shown O
are O
normalised O
mean O
of O
three O
independent O
experiments O
± O
SEM O
. O

(B-F) O
P O
values O
were O
calculated O
by O
t-test O
between O
miRNA O
conditions O
and O
their O
respective O
NC O
conditions O
(*, O
P<0.05; O
**, O
P<0.01; O
***, O
P<0.001) O
. O

MARK4 B-proteingene
siRNA-mediated O
silencing O
increases O
the O
tubulin O
cytoskeletal O
area O
(A) O
. O

(A) O
Data O
shown O
are O
representative O
of O
experiments O
performed O
in O
triplicate O
. O

Bar O
graph O
represents O
the O
average O
± O
SEM O
of O
n O
≥ O
50 O
per O
technical O
replicate O
with O
3 O
technical O
replicates O
per O
conditions O
. O

MARK4 B-proteingene
siRNA-mediated O
silencing O
reduces O
random O
(B) O
migration O
in O
MDA-MB-231 O
(MDA), O
A549 O
and O
H1299 O
cells.Cells O
were O
transfected O
either O
with O
siRNA O
targeting O
MARK4 B-proteingene
(M4) O
or O
a O
non-targeting O
control O
(NC) O
for O
48 O
h O
before O
time-lapse O
imaging O
was O
performed O
for O
18 O
h O
(B) O
. O

(B-top O
panel) O
Plots O
show O
overlays O
of O
representative O
trajectories O
described O
. O

(B-bottom O
panel) O
The O
migration O
distance O
was O
quantified O
and O
represented O
as O
the O
normalised O
mean O
± O
SEM O
. O

(C-top O
panel) O
Representative O
field O
of O
view O
from O
the O
bottom O
side O
of O
the O
transwell O
membrane O
. O

(C-bottom O
panel) O
Graphs O
indicate O
cell O
migration O
expressed O
as O
a O
percentage O
of O
the O
average O
of O
migratory O
cells O
per O
field O
(n=5 O
fields O
per O
condition) O
. O

(B-C) O
Data O
are O
mean O
of O
three O
experiments O
± O
SEM O
. O

(A-C) O
P O
values O
were O
calculated O
by O
t-test O
between O
the O
siRNA-transfected O
and O
the O
respective O
control O
condition O
(***P<0.001) O
. O

MARK4 B-proteingene
siRNA-mediated O
silencing O
reduces O
directed O
(C) O
migration O
in O
MDA-MB-231 O
(MDA), O
A549 O
and O
H1299 O
cells O
. O

(C-top O
panel) O
. O

Cells O
were O
transfected O
either O
with O
siRNA O
targeting O
MARK4 B-proteingene
(M4) O
or O
a O
non-targeting O
control O
(NC) O
for O
48 O
h O
before O
transwell O
assay O
for O
9h O
(C) O
. O

Representative O
field O
of O
view O
from O
the O
bottom O
side O
of O
the O
transwell O
membrane O
. O

(C-bottom O
panel) O
Graphs O
indicate O
cell O
migration O
expressed O
as O
a O
percentage O
of O
the O
average O
of O
migratory O
cells O
per O
field O
(n=5 O
fields O
per O
condition) O
. O

(B-C) O
Data O
are O
mean O
of O
three O
experiments O
± O
SEM O
. O

(A-C) O
P O
values O
were O
calculated O
by O
t-test O
between O
the O
siRNA-transfected O
and O
the O
respective O
control O
condition O
(***P<0.001) O
. O

(A-B) O
The O
indicated O
cell O
lines O
were O
transfected O
with O
either O
miR-515-5p B-proteingene
or O
a O
non-targeting O
miR O
(miR O
NC) O
together O
with O
a O
MARK4 B-proteingene
expressing O
or O
an O
empty O
vector O
(EV) O
plasmid O
DNA. O
MARK4 B-proteingene
over-expression O
rescues O
the O
inhibition O
by O
miR-515-5p B-proteingene
of O
random O
(A) O
and O
directed O
(B) O
migration O
of O
the O
indicated O
cell O
lines O
. O

(A-left O
panel) O
Plots O
show O
overlays O
of O
representative O
trajectories O
described O
for O
MDA-MB-231 O
cells O
(n=30) O
. O

(A-right O
panel) O
The O
migration O
distance O
was O
quantified O
and O
represented O
as O
the O
normalised O
mean O
± O
SEM O
. O

(B-left O
panel) O
Representative O
field O
of O
view O
from O
the O
bottom O
side O
of O
the O
transwell O
membrane O
for O
MDA-MB-231 O
. O

(B-right O
panel) O
Graphs O
indicate O
cell O
migration O
expressed O
as O
a O
percentage O
of O
the O
average O
of O
migratory O
cells O
per O
field O
(n=5 O
fields O
per O
condition) O
. O

Data O
are O
mean O
of O
three O
experiments O
± O
SEM O
. O

(A-C) O
P O
values O
were O
calculated O
by O
t-test O
between O
the O
transfected O
and O
the O
respective O
control O
condition O
(EV+miR-NC) O
(*,P<0.05; O
**,P<0.01; O
***,P<0.001) O
. O

(A-B) O
Overall O
survival O
of O
ER-negative O
metastatic O
breast O
cancer O
(n=226) O
(A) O
and O
lung O
adenocarcinoma O
(n=719) O
(B) O
patients O
according O
to O
MARK4 B-proteingene
mRNA O
levels O
found O
in O
their O
tumors O
was O
represented O
using O
the O
Kaplan O
Meier-plotter O
[25] O
. O

(C) O
A O
cDNA O
array O
for O
24 O
matched O
lung O
cancers O
and O
surrounding O
normal O
tissue O
was O
analysed O
for O
MARK4 B-proteingene
expression O
. O

Expression O
levels O
from O
tumors O
were O
normalised O
to O
their O
respective O
normal O
control O
and O
the O
percentage O
of O
cases O
for O
the O
indicated O
fold O
expression O
in O
the O
tumor O
represented O
as O
a O
pie-chart O
. O

(D-F) O
MARK4 B-proteingene
protein O
expression O
was O
determined O
by O
histoimmunochemistry O
in O
(D-E) O
a O
tissue O
microarray O
comprising O
90 O
lungtumor O
and O
10 O
normal O
lung O
samples O
or O
(F) O
a O
home-made O
tissue O
microarray O
comprising O
100 O
matched O
cases O
of O
primary O
and O
metastatic O
tumors O
. O

(D-E) O
The O
percentage O
of O
positivity O
for O
MARK4 B-proteingene
staining O
in O
lungtumors O
versus O
normal O
lung O
samples O
(D) O
or O
in O
lungtumors O
according O
to O
their O
histological O
subtypes O
(E) O
is O
represented O
. O

(F) O
The O
percentage O
of O
cases O
with O
increased, O
decreased O
or O
unchanged O
levels O
of O
MARK4 B-proteingene
in O
metastatic O
lesions O
as O
compared O
to O
the O
corresponding O
primary O
tumors O
is O
represented O
. O

(A-D) O
Low O
expression O
of O
miR-515-5p B-proteingene
is O
linked O
to O
survival O
in O
both O
Lung O
and O
Breast O
cancer O
. O

(A) O
Survival O
analysis O
of O
miR-515-5p B-proteingene
from O
195 O
lung O
adenocarcinoma O
samples O
from O
the O
TCGA O
. O

(B) O
Survival O
analysis O
of O
miR-515-p B-proteingene
from O
34 O
lung O
squamous O
cell O
carcinoma O
from O
the O
TCGA O
. O

(C) O
Survival O
analysis O
of O
miR-515-5p B-proteingene
from O
60 O
Breast O
cancer O
samples O
from O
the O
Lyng O
Ditzel O
Breast O
Study O
(GSE37405) O
. O

(D) O
Survival O
analysis O
of O
miR-515-5p B-proteingene
from O
33 O
Breast O
cancer O
from O
the O
GSE7405 O
Breast O
study O
. O

Analysis O
and O
plot O
were O
obtained O
with O
SurvMicro O
http://bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.jsp O
for O
(A-C) O
and O
with O
MIRUMIR O
for O
(D) O
. O

(E) O
Comparison O
of O
miR-515-5p B-proteingene
expression O
in O
18 O
primary O
and O
matched O
metastatic O
lesions O
from O
breast O
cancer O
patients O
. O

miR-515-5p B-proteingene
levels O
were O
quantified O
by O
TaqMan O
qRT-PCR. O
Absolute O
values O
were O
normalized O
to O
u6 B-proteingene
snRNA O
values O
and O
displayed O
as O
a O
dot-plot O
. O

Bar; O
Mean, O
Whiskers; O
SEM O
. O

(F) O
MDA-MB-231 O
cells O
were O
inoculated O
into O
the O
mammary O
fat O
pads O
of O
nude O
mice O
and O
allowed O
to O
form O
metastatic O
deposits O
[22] O
. O

miR-515-5p B-proteingene
and O
MARK4 B-proteingene
levels O
were O
then O
determined O
in O
the O
primary O
and O
indicated O
secondary O
lesions O
. O

Data O
are O
average O
± O
SEM O
of O
technical O
triplicates O
. O

(G) O
Luciferase-expressing B-proteingene
A549 O
cells O
overexpressing O
miR-515-5p B-proteingene
or O
a O
non-targeting O
control O
(miR-NC) O
were O
injected O
in O
the O
tail-vein O
of O
SCIDmice O
and O
the O
development O
of O
tumor O
burden O
monitored O
by O
whole O
animal-imaging O
in O
response O
to O
luciferin O
administration O
at O
week O
1 O
and O
4 O
following O
injection O
. O

(G-left O
panel) O
Representative O
imaging O
of O
the O
same O
animals O
for O
the O
indicated O
conditions O
at O
week O
1 O
and O
4 O
. O

(G-Right O
panel) O
The O
emitted O
photons O
were O
quantified O
and O
the O
signals O
normalised O
to O
the O
corresponding O
readings O
at O
week O
1 O
. O

Data O
represented O
are O
representative O
of O
three O
independent O
experiments O
. O

(E-G) O
P O
values O
were O
calculated O
by O
t-test O
(*, O
P<0.05; O
**, O
P<0.01; O
***, O
P<0.001) O
. O

A549-Luc O
cells O
transfected O
either O
with O
miR-515-5p B-proteingene
precursor O
(miR), O
siRNAs O
to O
MARK4 B-proteingene
(siMARK4) B-proteingene
or O
the O
corresponding O
control O
sequences O
(C O
and O
NT, O
respectively) O
were O
injected O
in O
Scidmice O
through O
the O
tail O
vein O
. O

4 O
weeks O
later, O
the O
mice O
were O
sacrificed, O
their O
lungs O
extracted O
and O
fixed O
prior O
to O
staining O
for O
Luciferase B-proteingene
expression O
. O

(A) O
Representative O
pictures O
showing O
the O
presence O
of O
A549-Luc B-proteingene
cells O
in O
the O
lungs O
of O
NT O
mice O
either O
as O
single O
cells O
(upper O
panel) O
or O
as O
a O
tumour O
mass O
(lower O
panel) O
. O

(B) O
Percentage O
of O
the O
area O
covered O
by O
tumour O
cells O
on O
randomly O
observed O
fields O
of O
views O
. O

Quantification O
was O
performed O
using O
Photoshop O
CS4 O
. O

Each O
spot O
corresponds O
to O
quantification O
of O
an O
individual O
1 O
mm O
x O
1.5 O
mm O
field O
. O

Transversal O
bar; O
Median O
. O

Statistics: O
Student O
t-test O
. O

*, O
p≤0.05 O
. O

C. O
SDS-PAGE O
showing O
a O
representative O
fraction O
of O
the O
purified O
spMis18N-terminal B-proteingene
Yippee-like B-proteingene
globular O
domain O
(amino O
acid O
residues O
1-120; O
spMis181-120) B-proteingene
. O

D. O
Cartoon O
representation O
of O
the O
crystal O
structure O
of O
spMis181-120 B-proteingene
in O
two O
different O
orientations, O
highlighting O
key O
residues O
within O
the O
putative O
substrate-binding O
pocket O
. O

E. O
Substrate-binding O
pocket O
mutations O
Y90A O
and O
Y74A/Y90A/T105A/S107K O
affect O
the O
ability O
of O
ectopically O
expressed O
spMis18fl B-proteingene
to O
rescue O
the O
temperature O
sensitivity O
of O
mis18-262 B-proteingene
cells O
to O
varying O
degrees O
. O

Five-fold O
serial O
dilutions O
of O
mis18-262 B-proteingene
cells O
transformed O
with O
plasmids O
harbouring O
the O
indicated O
spMis18fl B-proteingene
constructs, O
spotted O
on O
PMG O
- O
uracil O
+ O
Phloxine O
B O
media O
supplemented O
with O
(repressed) O
or O
without O
(expressed) O
thiamine, O
and O
incubated O
at O
the O
indicated O
temperatures; O
dead O
cells O
stain O
dark O
pink O
. O

A. O
Cartoon O
representation O
of O
the O
assembly O
of O
spMis18Yippee-like B-proteingene
domains O
(spMis181-120) B-proteingene
as O
observed O
in O
the O
crystal O
asymmetric O
unit O
. O

Close O
up O
views O
highlight O
the O
amino O
acid O
composition O
and O
interactions O
stabilizing O
the O
dimeric O
arrangements O
. O

Interface-II O
is O
composed O
of O
conserved O
residues O
and O
an O
extensive O
binding O
surface O
as O
compared O
to O
Interface-I O
(see O
text O
for O
details), O
suggesting O
Dimer-II O
to O
be O
a O
physiologically O
relevant O
dimer O
. O

Residues O
mutated O
in O
this O
study O
are O
highlighted O
with O
circles O
. O

B. O
Size O
Exclusion O
Chromatography O
(SEC) O
and O
SEC-MALS O
(SEC O
combined O
with O
Multi O
Angle O
Light O
scattering) O
analyses O
of O
the O
recombinant O
wild-type O
(wt) O
and O
dimer O
disrupting O
mutant O
(I31A) O
of O
spMis181-120 B-proteingene
. O

Measured O
molecular O
weights O
from O
SEC-MALS O
confirm O
that O
spMis181-120 B-proteingene
wt O
is O
a O
dimer O
in O
solution O
and O
spMis181-120 B-proteingene
I31A O
is O
a O
monomer O
. O

C. O
Evaluation O
of O
the O
ability O
of O
Yippee-like B-proteingene
domains O
of O
humanMis18 B-proteingene
proteins O
(hsMis18α77-187 B-proteingene
and O
hsMis18β56-183) B-proteingene
to O
form O
a O
heterodimer O
. O

SEC O
and O
SEC-MALS O
analyses O
demonstrate O
that O
while O
hsMis18α77-187 B-proteingene
elutes O
at O
15.5 O
ml O
as O
a O
dimer O
(31.3 O
kDa), O
hsMis18β56-183 B-proteingene
elutes O
at O
17.3 O
ml O
as O
a O
monomer O
(15 O
kDa) O
. O

Purified O
hsMis18α77-187 B-proteingene
and O
hsMis18β56-183 B-proteingene
when O
mixed O
together O
elute O
at O
15.4 O
ml O
as O
a O
heterodimer O
(27.5 O
kDa) O
. O

D. O
Cartoon O
representation O
of O
the O
structure O
of O
the O
homology-modelled O
humanMis18α77-187 B-proteingene
- O
Mis18β56-183 B-proteingene
heterodimer O
using O
the O
crystal O
structure O
of O
spMis181-120 B-proteingene
reported O
here O
as O
a O
template O
. O

Residues O
mutated O
in O
this O
study O
are O
highlighted O
with O
circles O
. O

Modelling O
was O
carried O
out O
using O
Phyre2 O
web O
server O
(<a O
href="http://www.sbg.bio.ic.ac.uk/phyre2/">www.sbg.bio.ic.ac.uk/phyre2/) O
. O

E. O
SDS-PAGE O
analysis O
of O
the O
GST-pull B-proteingene
down O
assay O
where O
wt O
and O
dimer O
disrupting O
mutants O
of O
hsMis18α77-187 B-proteingene
and O
hsMis18β56-183 B-proteingene
were O
co-expressed O
as O
His- B-proteingene
and O
GST-tagged B-proteingene
proteins, O
respectively O
in O
E. O
coli O
. O

While O
wt O
GST-hsMis18β56-183 B-proteingene
showed O
interaction O
with O
wt O
His-hsMis18α77-187, B-proteingene
hsMis18proteins B-proteingene
harbouring O
dimer-disrupting O
mutations, O
GST-hsMis18β56-183 B-proteingene
V77E/Y172D O
and O
His-hsMis18α77-187 B-proteingene
V82E/Y176D O
did O
not O
show O
noticeable O
interaction O
. O

The O
corresponding O
Ni-NTA O
pull O
downs O
showing O
the O
expression O
of O
His-tagged B-proteingene
proteins O
are O
shown O
in O
Fig O
EV2D O
. O

A O
& O
B. O
SEC-MALS O
analysis O
of O
His-GFP-spMis18fl B-proteingene
and O
His-spMis18ΔC, B-proteingene
respectively O
. O

Refractive O
index O
(RI, O
left O
Y-axis) O
and O
molecular O
mass O
(kDa, O
right O
Y-axis) O
profiles O
show O
that O
both O
His-GFP-spMis18fl B-proteingene
(predicted O
MW O
of O
a O
monomer O
is O
51.97 O
kDa) O
and O
His-spMis18ΔC B-proteingene
(Predicted O
MW O
of O
a O
monomer O
21.8 O
kDa) O
predominantly O
exist O
as O
tetramers O
(187.6 O
kDa O
and O
78.6 O
kDa, O
respectively) O
with O
a O
small O
population O
of O
dimer O
(128.5 O
kDa O
and O
45.8 O
kDa, O
respectively) O
. O

C. O
SEC O
profile O
of O
a O
sample O
containing O
an O
equimolar O
mixture O
of O
purified O
His-GFP-spMis18C-term-α B-proteingene
and O
His-spMis18MeDiY B-proteingene
(upper O
panel) O
and O
SDS-PAGE O
analysis O
of O
SEC-fractions O
(bottom O
panel) O
. O

His-GFP-spMis18C-term-α B-proteingene
and O
His-spMis18MeDiY B-proteingene
eluted O
separately O
at O
12.3 O
and O
15.3 O
ml, O
respectively, O
demonstrating O
the O
inability O
of O
these O
domains O
to O
interact O
with O
each O
other O
. O

D. O
SEC-MALS O
analysis O
of O
His-GFP-spMis18C-term-α B-proteingene
shows O
that O
it O
exists O
as O
a O
homotrimer O
with O
a O
measured O
molecular O
weight O
of O
119.8 O
kDa O
. O

(Theoretically O
calculated O
MW O
of O
a O
monomer O
is O
38.3 O
kDa) O
. O

A. O
spMis18fl-Mycco-immunoprecipitates B-proteingene
with O
both O
GFP-tagged B-proteingene
spMis18fl B-proteingene
and O
spMis18MeDiY, B-proteingene
but O
shows O
reduced O
association O
when O
MeDiY-mediated O
dimerization O
is O
disrupted O
in O
spMis18flI31A. B-proteingene
The O
asterisk O
(*) O
in O
the O
top O
panel O
denotes O
the O
IgG O
heavy O
chain O
. O

B O
& O
C. O
Dimer-II O
interface O
mutations O
I31A O
and O
Y114A O
affect O
the O
ability O
of O
ectopically O
expressed O
spMis18fl B-proteingene
to O
rescue O
the O
temperature O
sensitivity O
of O
mis18-818 B-proteingene
and O
mis18-262 B-proteingene
cells, O
while O
expression O
of O
spMis18MeDiY B-proteingene
alone O
confers O
a O
dominant O
negative O
effect O
on O
growth O
in O
a O
MeDiY O
dimerization-dependent O
manner O
. O

Five-fold O
serial O
dilutions O
of O
cells O
expressing O
the O
indicated O
spMis18 B-proteingene
constructs O
integrated O
at O
the O
leu1 O
locus O
in O
the O
genome, O
spotted O
on O
complete O
PMG O
+ O
Phloxine O
B O
media O
supplemented O
with O
(repressed) O
or O
without O
(expressed) O
thiamine, O
and O
incubated O
at O
the O
indicated O
temperatures; O
dead O
cells O
stain O
dark O
pink O
. O

D. O
Mutations O
that O
disrupt O
MeDiY O
dimerization O
lead O
to O
reduced O
levels O
of O
spMis18fl B-proteingene
association O
with O
centromeres O
. O

qChIP O
analyses O
of O
spMis18fl-GFP B-proteingene
association O
with O
centromere O
2 O
(cc2) O
in O
the O
indicated O
strains O
when O
grown O
in O
complete O
PMG O
media O
supplemented O
with O
(repressed) O
or O
without O
(expressed) O
thiamine O
. O

Error O
bars O
represent O
standard O
deviation O
between O
at O
least O
three O
biological O
replicates O
. O

A-B. O
Correlation O
of O
MCU B-proteingene
and O
MCUb B-proteingene
expression O
levels O
with O
breast O
cancer O
clinical O
stages O
. O

Median-centered O
log2 O
mRNA O
expression O
levels O
of O
MCU B-proteingene
and O
MCUb B-proteingene
were O
collected O
from O
the O
TCGA O
breast O
cancer O
dataset O
(http://tcga-data.nci.nih.gov/docs/publications/brca_2012/) O
. O

Data O
were O
plotted O
and O
analysed O
against O
tumor O
size O
(T1-T4) O
(A) O
and O
regional O
lymph O
node O
infiltration O
(N0-N3) O
(B), O
according O
to O
the O
AJCC O
Cancer O
Staging O
Manual O
(7th O
edition) O
. O

Linear O
regression O
analysis O
with O
different O
stages O
was O
implemented O
. O

Parameters O
of O
linear O
regression O
are O
shown O
. O

Number O
of O
samples O
for O
each O
stage O
are O
shown O
in O
parentheses O
. O

C-E. O
MCU O
silencing O
reduces O
Ca2+mit O
uptake O
in O
TNBC O
cells O
. O

Cells O
were O
transfected O
with O
siMCU O
or O
siControl O
. O

After O
48h, O
[Ca2+]mit O
uptake O
upon O
ATP O
(C, O
E) O
or O
Histamine O
(D) O
stimulation O
was O
measured O
(n=10) O
. O

P-values: O
***p= O
0.0008, O
***p<0.0001, O
***p= O
0.0001, O
respectively O
. O

F-H. O
MCU B-proteingene
silencing O
impairs O
TNBC O
cell O
migration O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

The O
day O
after O
transfection, O
a O
linear O
scratch O
was O
obtained O
on O
the O
cell O
monolayer O
through O
a O
vertically O
held O
P200 O
tip O
(time- O
point O
0h) O
. O

Cell O
migration O
into O
the O
scratched O
area O
was O
monitored O
48 O
hours O
later O
. O

The O
covered O
area O
was O
measured O
and O
expressed O
as O
a O
percentage O
relative O
to O
0-hour O
time-point O
(n=12) O
. O

P-value: O
***p<0.0001 O
. O

I-K O
. O

Cell O
proliferation O
is O
mainly O
unaffected O
by O
MCU O
depletion O
. O

Cells O
were O
transfected O
with O
siMCU O
or O
siControl O
. O

Cell O
number O
was O
counted O
every O
24 O
hours O
for O
3 O
days O
(the O
72-hour O
time O
point O
corresponds O
to O
the O
48-hour O
time-point O
of O
wound O
healing O
assay) O
. O

Results O
are O
expressed O
as O
ratio O
R/R0 O
where O
R0 O
is O
the O
number O
of O
cells O
at O
the O
time O
of O
transfection O
(0 O
hour O
time-point) O
(n=6) O
. O

P-value: O
*p=0.05 O
. O

A. O
Re-expression O
of O
mMCU O
rescues O
cell O
motility O
of O
MCU-silenced B-proteingene
cells O
. O

Cells O
were O
transfected O
with O
siMCU O
or O
siControl O
. O

Ad-mMCU O
was O
used O
to O
re-express O
MCU B-proteingene
(Ad-GFP O
was O
used O
as O
control) O
. O

MCU B-proteingene
protein O
expression O
was O
verified O
by O
western O
blot O
. O

The O
day O
after O
transduction O
a O
linear O
scratch O
was O
made O
(time-point O
0h) O
. O

Cell O
migration O
into O
the O
wounded O
area O
was O
monitored O
at O
48 O
hour O
time-point O
and O
the O
covered O
area O
was O
measured O
(n=12) O
. O

P-value: O
***p<0.0001 O
. O

B. O
MCU B-proteingene
silencing O
blunts O
cell O
invasiveness O
. O

Stable O
shMCU B-proteingene
and O
shControl-expressing O
spheroids O
were O
plated O
and O
let O
grow O
into O
collagen-I O
(0 O
hour O
time-point) O
. O

Spheroid O
area O
was O
measured O
at O
0-hour O
and O
48-hour O
(n=8) O
. O

Scale O
bar O
300 O
μm O
. O

P-value: O
***p=0.0003 O
. O

C. O
MCU B-proteingene
silencing O
reduces O
the O
clonogenic O
potential O
of O
MDA-MB-231 O
cells O
. O

Stable O
shMCU B-proteingene
and O
shControl-expressing O
cells O
were O
plated O
at O
low O
confluence O
(2x103/well O
of O
a O
6-well O
plate) O
. O

After O
7 O
days O
the O
number O
of O
colonies O
was O
counted O
(minimum O
30 O
cells/colony, O
n=8) O
. O

P-value: O
**p=0.0027 O
. O

D. O
MCU B-proteingene
depletion O
does O
not O
induce O
cell O
death O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

72 O
hours O
later, O
cell O
apoptosis O
and O
necrosis O
were O
measured O
by O
FITC-Annexin O
V O
and O
Propidium O
Iodide O
(PI) O
detection O
(Q1: O
PI O
positive, O
Q2: O
PI O
and O
FITC-Annexin O
V O
positive, O
Q3: O
PI O
and O
FITC-Annexin O
V O
negative, O
Q4: O
FITC-Annexin O
V O
positive O
. O

n=6) O
. O

E. O
MCU B-proteingene
depletion O
does O
not O
alter O
cell O
cycle O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

72 O
hours O
later, O
cell O
cycle O
distribution O
was O
monitored O
by O
Propidium O
Iodide O
(PI) O
detection O
(n=6) O
. O

A. O
Tumor O
mass O
volume O
was O
measured O
at O
specific O
time-points O
until O
the O
day O
of O
sacrifice O
(day O
39 O
post-injection O
for O
control, O
day O
46 O
and O
56 O
p.i O
. O

for O
MCU-/- B-proteingene
cl.1 O
and O
cl.2, O
respectively) O
. O

P-values: O
***p=0.0001, O
***p<0.0001 O
. O

B. O
left: O
in O
vivo O
metastasis O
at O
the O
homolateral O
axillary O
area O
of O
three O
representative O
mice O
per O
group O
at O
the O
time O
of O
sacrifice O
. O

Right: O
total O
flux O
analysis O
. O

P-values: O
**p=0.01, O
*p=0.02 O
. O

C. O
Lymph O
nodesweight O
at O
the O
time O
of O
sacrifice O
. O

P-values: O
***p=0.0010, O
**p=0.0014 O
. O

D. O
Human O
cytokeratin B-proteingene
7 I-proteingene
(CK7) B-proteingene
IHC O
staining O
of O
three O
representative O
lymph O
nodes O
per O
group O
. O

Scale O
bar= O
500 O
µm O
. O

E. O
Left: O
images O
of O
three O
representative O
lungs O
per O
group O
collected O
ex O
vivo O
at O
the O
time O
of O
sacrifice O
. O

Right: O
total O
flux O
analysis O
. O

P-values: O
**p=0.0031, O
***p= O
0.0004 O
. O

A-C. O
FLIM O
analysis O
of O
cellular O
NADH/NADPH O
levels O
. O

Fluorescence O
lifetimes O
of O
NAD(P)H O
autofluorescence O
in O
stable O
shControl O
and O
shMCU B-proteingene
expressing O
cells O
were O
imaged O
. O

Representative O
images O
of O
the O
distribution O
of O
τbound O
on O
an O
intensity O
weighted O
pseudocolored O
scale O
(2.2-2.5 O
ns) O
are O
shown O
. O

Scale O
bars O
= O
20 O
μm O
(A) O
. O

Mean O
+/- O
SE O
of O
τbound O
(B) O
and O
relative O
NADH O
and O
NADPH O
intensities O
(C) O
calculated O
from O
equation O
in O
(Blacker O
et O
al., O
2014) O
are O
shown O
(n=3) O
. O

P-values: O
**p=0.01, O
**p=0.002, O
respectively O
. O

D-E. O
Measurement O
of O
the O
redox O
state O
of O
the O
NADH/NAD+ O
couple O
. O

Representative O
measurements O
of O
NADH O
intensity O
at O
steady O
state O
and O
at O
minimal O
and O
maximal O
reduced O
state O
(D) O
. O

Percentage O
of O
the O
steady O
state O
redox O
state O
(E) O
(n=3) O
. O

F. O
MCU B-proteingene
depletion O
impairs O
the O
mitochondrial O
rate O
of O
ATP O
production O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

48 O
hours O
later, O
cells O
were O
treated O
with O
5.5 O
mM O
2-deoxy-D-glucose O
for O
1 O
hour O
and O
cellular O
ATP O
levels O
were O
quantified O
(n=6) O
. O

P-value: O
***p=0.0009 O
. O

A. O
Antioxidant O
treatments O
decrease O
cell O
migration O
. O

A O
linear O
scratch O
was O
obtained O
on O
cell O
monolayer O
through O
a O
vertically O
held O
P200 O
tip O
(time-point O
0h) O
. O

Cells O
were O
treated O
for O
48 O
hours O
with O
N-Acetylcysteine O
(NAC) O
or O
Dithioerythritol O
(DTE) O
. O

Cell O
migration O
into O
the O
wounded O
area O
was O
monitored O
at O
48-hour O
time-point O
and O
the O
covered O
area O
was O
measured O
(n=12) O
. O

P-values: O
**p=0.008, O
***p<0.0001, O
**p=0.005 O
. O

B. O
Scavenging O
of O
mitochondrial O
ROS O
decreases O
cell O
migration O
. O

A O
linear O
scratch O
was O
obtained O
on O
a O
cell O
monolayer O
through O
a O
vertically O
held O
P200 O
tip O
(time-point O
0h) O
. O

Cells O
were O
treated O
for O
48 O
hours O
with O
50 O
µM O
MitoTEMPO. O
Cell O
migration O
into O
the O
wounded O
area O
was O
monitored O
at O
48 O
hour O
time-point O
and O
the O
covered O
area O
was O
measured O
(n=12) O
. O

P-value: O
***p<0.0001 O
. O

C. O
MCU B-proteingene
silencing O
does O
not O
affect O
matrix O
pH. O
Cell O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
and O
SypHer2 O
probe O
. O

48 O
hours O
later, O
matrix O
pH O
was O
measured O
(n=22) O
. O

D-E. O
MitochondrialH2O2 O
levels O
are O
critically O
blunted O
after O
MCU B-proteingene
depletion O
. O

Cells O
were O
transfected O
with O
shMCU B-proteingene
or O
shControl, O
together O
with O
the O
ratiometric O
YFP-based B-proteingene
biosensor O
pHyper-dMito O
(D) O
or O
the O
mitochondrialH2O2-sensitive O
HyPerRed O
probe O
(E) O
. O

48 O
hours O
later, O
H2O2 O
production O
was O
measured O
(n=35) O
. O

P-values: O
*p=0.02, O
*p=0.05, O
respectively O
. O

F. O
Mitochondrialsuperoxide O
levels O
are O
critically O
blunted O
after O
MCU B-proteingene
silencing O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

48 O
hours O
later, O
cells O
were O
loaded O
with O
the O
red O
dye O
MitoSOXTM O
and O
superoxide O
anion O
levels O
were O
measured O
(n=25) O
. O

P-value: O
*p=0.04 O
. O

G. O
Mitochondrial O
GSSG/GSH O
ratio O
is O
critically O
reduced O
after O
MCU B-proteingene
silencing O
. O

Cells O
were O
transfected O
with O
shMCU B-proteingene
or O
shControl, O
together O
with O
the O
mitochondrial O
targeted O
mitGrx1-roGFP2 B-proteingene
probe O
. O

96 O
hours O
later, O
the O
glutathione O
redox O
potential O
(EGSH) O
was O
measured O
(n=46) O
. O

P-value: O
***p<0.0001 O
. O

A. O
MCU B-proteingene
silencing O
reduces O
HIF-1α B-proteingene
protein O
levels O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

HIF-1α B-proteingene
protein O
levels O
were O
detected O
48 O
hours O
later O
. O

B. O
MCU B-proteingene
silencing O
reduces O
MG132-mediated O
HIF-1α B-proteingene
and O
hydroxylated O
HIF-1α B-proteingene
protein O
accumulation O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

48 O
hours O
later, O
cells O
were O
treated O
with O
10 O
μM O
of O
the O
proteasome O
inhibitor O
MG132 O
. O

Left: O
Protein O
levels O
were O
revealed O
by O
western O
blot O
. O

Right: O
quantification O
by O
densitometry O
(n=5) O
. O

C. O
ROS O
increase O
HIF-1α B-proteingene
transcription O
. O

Cells O
were O
treated O
O/N O
with O
100 O
µM O
paraquat O
to O
induce O
ROS O
production O
. O

HIF-1α B-proteingene
mRNA O
levels O
were O
measured O
by O
RealTime-PCR O
(n=3) O
. O

P-value: O
**p=0.002 O
. O

D-J. O
MCU B-proteingene
silencing O
reduces O
mRNA O
levels O
of O
HIF-1α, B-proteingene
HIF-2α, B-proteingene
and O
HIF-1α B-proteingene
target O
genes O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

mRNA O
expression O
was O
measured O
by O
RealTime-PCR O
(n=3) O
. O

P-values: O
(HIF-1α) B-proteingene
**p=0.0031, O
**p=0.009, O
(HIF-2α)**p=0.01, B-proteingene
(LOX)***p=0.001, B-proteingene
***p=0.0005, O
(PDK1)*p=0.02, B-proteingene
**p=0.009, O
(G6PI)*p=0.02, B-proteingene
**p=0.005, O
(CA B-proteingene
IX)**p=0.0026, I-proteingene
**p=0.0022, O
(HK2) B-proteingene
**p=0.0024, O
*p=0.03 O
. O

K. O
HIF-1α B-proteingene
overexpression O
rescues O
siMCU-mediated B-proteingene
migration O
impairment O
. O

Cells O
were O
transfected O
with O
siMCU B-proteingene
or O
siControl O
. O

Wild O
type O
(wt) O
and O
constitutively O
active O
(ca) O
HIF-1α B-proteingene
were O
expressed O
by O
retroviral O
infection O
(pBABE O
was O
used O
as O
control) O
. O

The O
day O
after O
transduction, O
cells O
were O
scratched O
(time-point O
0h) O
. O

Cell O
migration O
into O
the O
wounded O
area O
was O
monitored O
at O
48 O
hour O
time-point O
and O
the O
covered O
area O
was O
measured O
(n=12) O
. O

P-values: O
***p<0.0001, O
*p=0.04 O
. O

L-M. O
MCU B-proteingene
expression O
levels O
correlate O
with O
HIF1α B-proteingene
(L) O
and O
HIF1α-regulated B-proteingene
genes O
(M) O
. O

A O
linear O
model O
(lm) O
to O
test O
the O
power O
of O
MCU B-proteingene
expression O
levels O
predicting O
the O
expression O
of O
HIF1α B-proteingene
and O
HIF1α-regulated B-proteingene
genes O
was O
calculated O
and O
plotted O
for O
each O
of O
the O
532 O
samples O
of O
the O
TCGA O
database O
(see O
Figure O
1) O
. O

Equation O
and O
R2 O
values O
of O
the O
linear O
regression O
and O
significance O
indicating O
deviation O
from O
0 O
are O
shown O
. O

The O
area O
of O
95% O
prediction O
limit O
is O
shaded O
below O
and O
above O
the O
linear O
regression O
line O
. O

The O
HIF1α-regulated B-proteingene
gene O
set O
was O
compiled O
from O
Broad O
Institute O
GSEA O
database O
(http://www.broadinstitute.org/gsea/msigdb/cards/V$HIF1_Q5.html, O
merged O
sets O
of O
V$HIF1_Q3 O
and O
V$HIF1_Q5) O
. O

(A) O
Silver O
staining O
of O
proteins O
extracted O
from O
N2Amouse O
neuronal O
cells O
expressing O
Flag-HA-tagged B-proteingene
C9ORF72 B-proteingene
and O
captured O
through O
consecutive O
anti-Flag B-proteingene
and O
anti-HA B-proteingene
affinity O
purification O
steps O
. O

(B) O
Immunoblot O
analysis O
of O
HA-immunoprecipitated B-proteingene
proteins O
and O
lysate O
of O
HEK293 O
cells O
co-expressing O
HA-tagged B-proteingene
C9ORF72 B-proteingene
and/ O
or O
Flag-tagged B-proteingene
SMCR8 B-proteingene
and/or O
Flag-tagged B-proteingene
WDR41 B-proteingene
. O

(C) O
Coomassie O
blue O
staining O
of O
Nickel-NTA O
affinity O
purification O
of O
HIS-C9ORF72, B-proteingene
SMCR8 B-proteingene
and O
WDR41 B-proteingene
co-expressed O
in O
baculovirus O
infected O
insect O
cells O
. O

(D) O
Immunoblot O
analysis O
of O
HA-immunoprecipitated B-proteingene
proteins O
and O
lysate O
of O
HEK293 O
cells O
co-expressing O
HA-tagged B-proteingene
C9ORF72 B-proteingene
and O
HA-tagged B-proteingene
SMCR8 B-proteingene
with O
various O
Flag-tagged B-proteingene
Rab O
GTPases O
. O

(E) O
Immunoblot O
against O
endogenous O
C9orf72, B-proteingene
Wdr41, B-proteingene
Rab8a, B-proteingene
Rab39b, B-proteingene
Rab5 B-proteingene
and O
Rab7 B-proteingene
of O
control O
(IgG O
alone) O
or O
endogenous O
Smcr8immunoprecipitated B-proteingene
from O
adult O
mousebrain O
. O

(F)αP32-radiolabelled O
GDP O
release O
from O
GST-tagged B-proteingene
purified O
RAB8a B-proteingene
as O
a O
function O
of O
increased O
concentration O
of O
either O
recombinant O
purified O
C9ORF72 B-proteingene
alone O
or O
in O
complex O
with O
SMCR8 B-proteingene
and O
WDR41 B-proteingene
. O

(G) O
Identical O
GDP O
release O
assay O
as O
in O
(F) O
but O
using O
recombinant O
purified O
GST-tagged B-proteingene
RAB39b B-proteingene
instead O
of O
RAB8a B-proteingene
. O

Error O
bars O
indicate O
s.e.m O
. O

Experiments O
were O
repeated O
3 O
times O
(n=3) O
. O

(A) O
Left O
panel, O
representative O
images O
of O
organotypic O
cultures O
of O
E18 O
mouse O
cortical O
neurons O
transfected O
with O
GFP-RFP-LC3B B-proteingene
and O
transduced O
with O
lentivirus O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
mRNA O
and O
treated O
or O
not O
with O
Torin O
. O

Right O
panel, O
quantification O
of O
LC3Bpuncta B-proteingene
. O

(B) O
Upper O
panel, O
immunoblot O
analysis O
of O
endogenous O
LC3B B-proteingene
(Map1lc3b), B-proteingene
C9orf72 B-proteingene
and O
control O
Actin B-proteingene
of O
E18 O
mouse O
cortical O
neurons O
transduced O
with O
lentivirus O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
mRNA O
and O
treated O
or O
not O
with O
Torin O
. O

Lower O
panel, O
real O
time O
RT-qPCR O
quantification O
of O
endogenous O
C9orf72 B-proteingene
mRNA O
expression O
relative O
to O
Rplp0 B-proteingene
mRNA O
. O

(C) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
endogenous O
P62 B-proteingene
(Sqstm1) B-proteingene
on O
organotypic O
cultures O
of O
E18 O
mouse O
cortical O
neurons O
transduced O
with O
lentiviral O
particles O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
. O

Right O
panel, O
quantification O
of O
P62 B-proteingene
aggregates O
. O

(D) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
transfected O
constructs O
(Green) O
and O
endogenous O
P62 B-proteingene
(Sqstm1, B-proteingene
red) O
on O
GT1-7neuronal O
cells O
transfected O
with O
siRNA O
targeting O
C9orf72 B-proteingene
and O
plasmids O
expressing O
control O
GFP, B-proteingene
HA B-proteingene
tagged O
wild O
type O
or O
mutant O
RAB39b B-proteingene
(CA, O
Q68L O
or O
CN, O
S22N), O
RAB8a B-proteingene
or O
RAB7 B-proteingene
. O

Right O
panel, O
quantification O
of O
P62 B-proteingene
aggregates O
. O

Scale O
bars, O
10 O
µm O
. O

Nuclei O
were O
counterstained O
with O
DAPI. O
Error O
bars O
indicate O
s.e.m O
. O

Student O
T-test, O
* O
indicates O
p<0.05, O
*** O
indicates O
p<0.001 O
. O

n=3 O
. O

(A) O
Immunoblot O
analysis O
of O
HA-immunoprecipitated B-proteingene
proteins O
and O
lysate O
of O
HEK293 O
cells O
co-expressing O
HA-tagged B-proteingene
C9ORF72 B-proteingene
and O
HA-tagged B-proteingene
SMCR8 B-proteingene
with O
Flag-tagged B-proteingene
TBK1, B-proteingene
NAP1, B-proteingene
TANK B-proteingene
or O
SINTBAD B-proteingene
. O

(B) O
ImmunoprecipitatedHA-tagged B-proteingene
C9ORF72, B-proteingene
HA-tagged B-proteingene
SMCR8 B-proteingene
and O
HA-tagged B-proteingene
WDR41 B-proteingene
expressed O
in O
HEK293 O
were O
subjected O
to O
in O
vitro O
TBK1 B-proteingene
kinase O
assay O
in O
the O
presence O
of O
γP32-radiolabelled O
ATP. O
Proteins O
were O
separated O
by O
SDS O
page O
migration O
and O
phosphorylation O
was O
detected O
by O
autoradiography O
(upper O
panel), O
while O
expression O
was O
detected O
by O
western O
blotting O
(lower O
panel) O
. O

(C) O
Mass O
spectrometry O
identification O
of O
SMCR8 B-proteingene
phosphorylation O
sites O
by O
in O
vitro O
TBK1 B-proteingene
kinase O
assay O
of O
HIS-tagged B-proteingene
C9ORF72:SMCR8:WDR41 B-proteingene
complex O
purified O
from O
baculovirus O
infected O
insect O
cells O
. O

(D) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
transfected O
constructs O
(Green) O
and O
endogenous O
P62 B-proteingene
(Sqstm1, B-proteingene
red) O
on O
GT1-7 O
neuronal O
cells O
transfected O
with O
siRNA O
targeting O
the O
3'UTR O
of O
Smcr8 B-proteingene
mRNA O
and O
plasmids O
expressing O
control O
GFP, B-proteingene
HA B-proteingene
tagged O
wild O
type O
or O
mutant O
SMCR8 B-proteingene
(TA, O
S402A O
and O
T796A; O
TD, O
S402D O
and O
T796D; O
UD, O
S400D, O
S492D, O
S562D O
and O
T666D) O
. O

Right O
panel, O
quantification O
of O
P62 B-proteingene
aggregates O
. O

(E) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
transfected O
constructs O
(Green) O
and O
endogenous O
P62 B-proteingene
(Sqstm1, B-proteingene
red) O
on O
GT1-7 O
neuronal O
cells O
transfected O
with O
siRNA O
targeting O
Tbk1 B-proteingene
and O
plasmids O
expressing O
control O
GFP, B-proteingene
HA B-proteingene
tagged O
wild O
type O
or O
mutant O
SMCR8 B-proteingene
or O
RAB39b B-proteingene
. O

Right O
panel, O
quantification O
of O
P62 B-proteingene
aggregates O
. O

Scale O
bars, O
10 O
µm O
. O

Nuclei O
were O
counterstained O
with O
DAPI. O
Error O
bars O
indicate O
s.e.m O
. O

Student O
T-test, O
* O
indicates O
p<0.05, O
*** O
indicates O
p<0.001 O
. O

n=3 O
. O

(A) O
Immunoblot O
analysis O
of O
endogenous O
Tdp-43, B-proteingene
C9orf72 B-proteingene
and O
control O
Gapdh B-proteingene
of O
E18 O
mousecortical O
neurons O
transduced O
with O
lentivirus O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
mRNA O
. O

(B) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
endogenous O
phosphorylated O
Ser409/410-Tdp-43 B-proteingene
on O
primary O
cultures O
of O
E18 O
mousecortical O
neurons O
transduced O
with O
lentiviral O
particles O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
. O

Right O
panel, O
quantification O
of O
cytoplasmic O
Tdp-43 B-proteingene
aggregates O
. O

(C) O
Left O
panel, O
representative O
images O
of O
immunofluorescence O
labeling O
of O
D169G O
mutant O
GFP-tagged B-proteingene
TDP-43 B-proteingene
on O
primary O
cultures O
of O
E18 O
mousecortical O
neurons O
transfected O
with O
either O
HA-tagged B-proteingene
control O
or O
HA-C9ORF72 B-proteingene
plasmid O
. O

Right O
panel, O
quantification O
of O
cells O
with O
cytoplasmic O
aggregates O
of O
TDP-43 B-proteingene
. O

Scale O
bars, O
10 O
µm O
. O

Nuclei O
were O
counterstained O
with O
DAPI. O
Error O
bars O
indicate O
s.e.m O
. O

Student O
T-test, O
*** O
indicates O
p<0.001 O
. O

n=3 O
. O

(A) O
Left O
panel, O
representative O
images O
of O
organotypic O
cultures O
of O
E18 O
mousecortical O
neurons O
co-transfected O
with O
HA-tagged B-proteingene
ATXN2 B-proteingene
with O
control O
(Q22x) O
or O
intermediate O
(Q30x) O
polyQ O
size O
and O
transduced O
with O
lentivirus O
expressing O
either O
control O
shRNA O
or O
shRNA O
targeting O
C9orf72 B-proteingene
mRNA. O
Right O
panel, O
quantification O
of O
ATXN2 B-proteingene
aggregates O
. O

Scale O
bars, O
10 O
µm O
. O

Nuclei O
were O
counterstained O
with O
DAPI O
. O

(B) O
Cell O
viability O
(tetrazolium O
assay) O
of O
GT1-7 O
neuronal O
cells O
co-transfected O
with O
HA-tagged B-proteingene
ATXN2 B-proteingene
with O
control O
(Q22x) O
or O
intermediate O
(Q30x) O
polyQ O
size O
and O
control O
siRNA O
or O
siRNA O
targeting O
C9orf72 B-proteingene
mRNA. O
Error O
bars O
indicate O
s.e.m O
. O

Student O
T-test, O
*** O
indicates O
p<0.001 O
. O

n=3 O
. O

(C) O
Tracing O
of O
the O
swimming O
trajectories O
of O
48 O
hours O
post-fertilization O
zebrafishlarvae O
following O
light O
touch O
. O

(D-F) O
Quantification O
of O
the O
touch-evoked O
swimming O
distance O
(D), O
average O
velocity O
(E), O
and O
maximum O
velocity O
attained O
(F) O
shows O
significant O
functional O
impairment O
of O
the O
zebrafish O
injected O
with O
HA-tagged B-proteingene
ATXN2 B-proteingene
with O
intermediate O
length O
of O
polyQ O
(Q30x) O
and O
antisense O
morpholino O
oligonucleotides O
(AMOs) O
against O
C9orf72 B-proteingene
compared O
to O
control O
HA-tagged B-proteingene
ATXN2 B-proteingene
(Q22x) O
or O
to O
the O
sole O
injection O
of O
AMO O
against O
C9orf72 B-proteingene
. O

(G) O
Representative O
images O
of O
motor O
neurons O
visualized O
with O
anti-Sv2immunohistochemistry B-proteingene
show O
severe O
axonopathy O
in O
fish O
injected O
with O
both O
ATXN2 B-proteingene
Q30x O
and O
AMO O
against O
C9orf72 B-proteingene
compared O
to O
zebrafish O
injected O
with O
control O
ATXN2 B-proteingene
Q22x O
or O
with O
AMO O
against O
C9orf72 B-proteingene
alone O
. O

(H) O
Quantification O
of O
the O
motor O
neuronaxonal O
length O
demonstrates O
a O
significant O
decrease O
of O
axonal O
length O
in O
48 O
hours O
post-fertilization O
zebrafishlarvae O
injected O
with O
both O
ATXN2 B-proteingene
Q30x O
and O
AMO O
against O
C9orf72 B-proteingene
compared O
to O
controls O
. O

Error O
bars O
indicate O
s.e.m O
. O

One-way O
ANOVA, O
** O
indicates O
p<0.01 O
. O

n=3 O
. O

A O
Analysis O
of O
MNase-digested O
chromatinDNA O
fragments O
from O
wild-type O
(WT, O
sizes O
indicated O
in O
black) O
and O
nap1Δ B-proteingene
(N, O
sizes O
indicated O
in O
red) O
cells O
by O
agarose O
gel O
electrophoresis O
. O

Diagram O
illustrating O
reduction O
of O
array O
length O
in O
nap1Δ B-proteingene
cells O
. O

B O
Frequency O
distribution O
of O
nucleosomalDNA O
size O
(WT O
in O
grey O
fill O
with O
nap1Δ B-proteingene
in O
blue O
traces) O
from O
H3ChIP-seq B-proteingene
. O

C O
Calculation O
of O
nucleosome O
fuzziness O
as O
the O
standard O
deviation O
of O
nucleosome O
(or O
tag) B-proteingene
positions O
. O

See O
also O
Appendix O
Fig O
S1 O
. O

B O
Ribbon O
view O
of O
the O
asymmetric O
crystallographic O
unit O
containing O
a O
(yNap1c2-H2AΔ14-H2BΔ28)6 B-proteingene
assembly O
. O

For O
clarity O
only O
layer O
1 O
of O
the O
complex O
is O
shown O
. O

Layer O
1 O
contains O
three O
protomers O
A-C O
that O
are O
related O
by O
two O
perpendicular O
non-crystallographic O
dyads O
() O
. O

C O
Side-view O
of O
the O
complex O
. O

The O
layer O
2 O
omitted O
from O
panel O
B O
is O
shown O
in O
grey O
. O

The O
yNap1 B-proteingene
dimer O
is O
shown O
in O
green O
and O
yellow, O
H2A B-proteingene
in O
red O
and O
H2B B-proteingene
in O
blue O
. O

See O
also O
Fig O
EV1 O
. O

D O
View O
of O
the O
yNap1-H2A-H2B B-proteingene
protomer O
complex O
with O
labeling O
of O
secondary O
structure O
elements O
. O

A O
Overview O
of O
the O
yNap1c2-H2AΔ14-H2BΔ28 B-proteingene
complex O
. O

B O
Residues O
R17, O
R20, O
R29, O
R32, O
R35 O
and O
K36 O
of O
H2A B-proteingene
make O
contacts O
with O
the O
acidic O
HBR1 O
in O
yNap1 B-proteingene
comprising O
residues O
D201, O
D205 O
and O
E310 O
. O

C O
Residues O
K75, O
R77 O
and O
R81 O
of O
H2A B-proteingene
make O
polar O
contacts O
with O
the O
HBR2 O
comprising O
residues O
E332, O
D333 O
and O
E339 O
in O
α8 O
of O
yNap1 B-proteingene
. O

D O
In O
vitro O
GST-pulldown O
assay O
showing O
the O
role O
of O
residues O
in O
the O
HBR O
interfaces O
in O
H2A-H2B B-proteingene
binding O
. O

The O
mutant O
labeled O
HBR1 O
(lane O
6) O
contains O
the O
triple O
mutation O
D201R, O
D205R, O
E310R O
and O
HBR2 O
(lane O
12) O
the O
triple O
mutations O
E332, O
D333, O
E336 O
. O

HBR1+2 O
(lane O
13) O
contains O
all O
six O
mutations O
. O

The O
mutant O
labeled O
HBR1+2A O
(lane O
14) O
has O
Alanine O
replacements O
in O
the O
six O
HBR B-proteingene
residues O
. O

Top O
panel: O
Bound O
. O

Bottom O
panel: O
Input O
. O

E O
Disruption O
of O
the O
Nap1-histone B-proteingene
interaction O
by O
H2A B-proteingene
mutation O
. O

Bottom O
panel: O
Inputs O
of O
the O
coexpressed O
proteins O
(soluble O
extract) O
and O
top O
panel O
the O
material O
bound O
to O
the O
glutathione O
affinity O
column O
were O
analyzed O
by O
SDS-PAGE O
and O
Coomassie O
staining O
. O

A O
EM O
analysis O
of O
the O
yNap1c2-H2AΔ14-H2BΔ28 B-proteingene
complex O
. O

Representative O
rawimage O
of O
negatively-stained O
particles O
. O

B O
Representative O
particles O
(1st O
row), O
class O
averages O
coming O
from O
the O
projection O
matching O
procedure O
(2nd O
row) O
and O
comparison O
of O
the O
class O
averages O
with O
projections O
from O
a O
final O
model O
generated O
after O
four O
projection O
matching O
cycles O
(3rd O
row) O
. O

C O
From O
left O
to O
right: O
Crystal O
structure O
of O
the O
(yNap1c2-H2A-H2B)6 B-proteingene
complex O
in O
two O
different O
orientations O
(brown); O
60 O
Å-filtered O
structure O
of O
the O
complex O
(magenta); O
3D O
reconstruction O
of O
the O
complex O
from O
negatively O
stained O
particles O
(green) O
and O
fit O
of O
the O
crystal O
structure O
into O
the O
EM O
map O
. O

D-I O
Mass O
spectra O
of O
yNap1 B-proteingene
variants O
in O
the O
absence O
and O
presence O
of O
H2A B-proteingene
-H2B. B-proteingene
yNap1 B-proteingene
in O
complex O
in O
the O
absence O
(D) O
or O
presence O
of O
H2A-H2B B-proteingene
(E) O
. O

yNap1c O
in O
the O
absence O
(F) O
or O
bound O
to O
H2A-H2B B-proteingene
(G) O
. O

The O
oligomerization O
mutant O
yNap1_IF1 B-proteingene
alone O
(H) O
or O
in O
complex O
with O
H2A_IF2Δ14-H2BΔ28 B-proteingene
(I) O
. O

yNap1 O
is O
shown O
in O
green O
circles O
and O
H2A-H2B B-proteingene
as O
red O
and O
blue O
asterisks O
. O

A O
Native O
PAGE O
gel O
showing O
the O
result O
of O
an O
affinity O
shift O
assay O
scanned O
to O
detect O
AF488- O
(left) O
or O
AF647-labeled O
DNA O
(right) O
. O

31 O
nM O
- O
4 O
µM O
of O
yNap1-H2A-H2B B-proteingene
(lanes O
6-13) O
were O
incubated O
with O
a O
mixture O
of O
0.8 O
µM O
AF488-labeled O
H3-H4-DNA O
tetrasome O
complexes O
and O
0.8 O
µM O
AF647-labeled O
DNA O
(lane O
5) O
. O

Lanes O
1-3 O
show O
migration O
of O
tetrasomes O
(tetra), O
nucleosomes O
(nucl) O
or O
free O
H2A-H2B B-proteingene
obtained O
by O
salt O
deposition O
onto O
AF647-labeled O
DNA O
. O

B O
Intensity O
of O
the O
nucleosome O
band O
(nucl) O
is O
plotted O
. O

The O
value O
at O
4 O
µM O
of O
yNap1-H2A-H2B B-proteingene
(lane O
13) O
was O
set O
to O
100% O
. O

For O
non-specific O
DNA O
binding, O
the O
value O
in O
the O
absence O
of O
H2A-H2B B-proteingene
(lane O
5) O
was O
set O
to O
100% O
intensity O
and O
disappearance O
of O
the O
free O
DNAAF647 O
band O
was O
plotted O
. O

Each O
curve O
is O
representative O
of O
three O
independent O
experiments O
performed O
on O
different O
days O
. O

Standard O
deviations O
are O
shown O
. O

C O
Analysis O
of O
MNase-digested O
chromatinDNA O
fragments O
from O
wild-type O
(BY4741), O
nap1Δ, B-proteingene
and O
nap1Δ B-proteingene
cells O
complemented O
with O
different O
yNap1 B-proteingene
expression O
plasmids O
. O

Total O
MNase O
units O
per O
50 O
ml O
of O
culture O
are O
indicated O
on O
the O
bottom O
of O
the O
lanes O
. O

Kb+: O
DNA O
Marker O
. O

A. O
NS1 B-proteingene
dimer O
with O
one O
subunit O
in O
grey O
and O
the O
other O
colored O
by O
domain O
(green, O
β-roll; O
orange, O
wing O
with O
magenta O
connector O
subdomain; O
blue, O
central O
β-ladder) O
. O

N-linked O
glycosylation O
sites O
are O
shown O
in O
sticks, O
and O
the O
glycans O
are O
shown O
in O
spheres O
. O

B. O
Topology O
diagram O
for O
the O
NS1 B-proteingene
monomer, O
colored O
as O
the O
pattern O
in O
(A) O
. O

Glycosylation O
sites O
are O
indicated O
with O
red O
hexagons O
and O
disulfide O
bonds O
with O
yellow O
circles O
. O

C. O
Side O
views O
of O
the O
NS1 B-proteingene
dimer O
from O
the O
wing O
(left) O
and O
the O
end O
of O
the O
β-ladder O
(right) O
. O

The O
β-roll O
(green), O
connector O
subdomain O
(orange) O
and O
the O
intertwined O
loop O
(yellow) O
of O
the O
wing O
domain O
form O
a O
discontinuous O
protrusion O
on O
one O
face O
of O
the O
β-ladder O
with O
the O
spaghetti O
loop O
(cyan) O
on O
the O
other O
face O
. O

The O
wing O
domain O
is O
omitted O
from O
the O
left O
image O
for O
clarity O
. O

The O
ZIKVNS1 B-proteingene
hexamer O
is O
modeled O
by O
using O
the O
full-length O
DENV2NS1 B-proteingene
structure O
(PDB O
code: O
4O6B) O
(Akey O
et O
al, O
2014) O
. O

Each O
monomer O
is O
colored O
by O
domains O
(green, O
β-roll; O
orange, O
wing; O
magenta, O
connector O
subdomain; O
blue, O
central O
β-ladder) O
. O

The O
intertwined O
loop O
"spike" O
of O
ZIKVNS1 B-proteingene
contributing O
to O
membrane O
association O
is O
colored O
in O
red O
and O
indicated O
by O
dotted O
lines O
. O

ABC. O
Electrostatic O
surface O
views O
of O
NS1 B-proteingene
from O
DENV2 O
(PDB: O
4O6B, O
A) O
and O
WNV O
(PDB: O
4O6C, O
B) O
(Akey O
et O
al, O
2014), O
as O
well O
as O
ZIKV©, O
showing O
diverse O
characteristics O
on O
certain O
regions O
. O

Surfaces O
are O
colored O
by O
electrostatic O
potential O
at O
neutral O
pH O
from O
-2 O
kT O
(red) O
to O
+2 O
kT O
(blue) O
using O
PyMOL O
(http://pymol.org/) O
. O

A. O
The O
NS1 B-proteingene
surface O
is O
colored O
using O
the O
ConSurf O
server O
(Ashkenazy O
et O
al, O
2016) O
according O
to O
sequence O
conservation O
from O
the O
most O
conserved O
(dark O
magenta) O
to O
the O
most O
divergent O
(dark O
cyan) O
based O
on O
an O
alignment O
of O
NS1 B-proteingene
sequences O
from O
73 O
flaviviruses O
. O

B. O
Models O
of O
intertwined O
loop O
"spike" O
interacting O
with O
the O
cellular O
membrane O
. O

The O
disordered O
"spike" O
regions O
are O
indicated O
by O
dash O
lines O
in O
DENV2 O
and O
WNVNS1 B-proteingene
structures, O
which O
consist O
of O
hydrophobic O
or O
positively O
charged O
amino O
acids O
. O

(B) O
Immunoblot O
analysis O
of O
the O
immunoprecipitatedHA-SOX9 B-proteingene
or O
FLAG- B-proteingene
FBW7α B-proteingene
and O
their O
pull-down O
products O
. O

The O
corresponding O
Western O
blotting O
from O
the O
whole O
cell O
extract O
(WCE) O
of O
the O
transfected O
HEK293 O
showed O
the O
levels O
of O
exogenous O
HA-SOX9 B-proteingene
or O
FLAG-FBW7α B-proteingene
proteins O
in O
the O
total O
input O
. O

Cells O
were O
treated O
with O
10 O
µM O
MG132 O
for O
4 O
hours O
prior O
to O
harvesting O
for O
the O
immunoprecipitation O
. O

Blots O
are O
representative O
from O
3 O
independent O
experiments O
. O

(C) O
FBW7α B-proteingene
immunoblot O
eluted O
from O
the O
agarose O
bead-bound O
peptide, O
which O
had O
been O
incubated O
with O
the O
recombinant O
SCF-FBW7α B-proteingene
for O
1 O
hour O
at O
37◦C. O
The O
agarose O
bead-bound O
peptide O
contains O
either O
the O
non-phosphorylated O
SOX9 B-proteingene
amino O
acid O
sequence O
spanning O
from O
residue O
number O
231 O
to O
245 O
(SOX9 B-proteingene
peptide), O
or O
those O
with O
the O
threonine O
corresponding O
to O
residue O
number O
236 O
and O
240 O
being O
phosphorylated O
(pSOX9 B-proteingene
peptide) O
. O

The O
input O
(10%) O
showed O
the O
level O
of O
the O
supplemented O
recombinant O
SCF-FBW7α B-proteingene
in O
the O
in O
vitro O
binding O
reaction O
. O

Shown O
blot O
is O
representative O
from O
2 O
independent O
experiments O
. O

(D) O
Representative O
Western O
blotting O
set O
from O
3 O
independent O
repeats O
of O
pT236-SOX9 B-proteingene
from O
lysates O
of O
HEK293 O
transfected O
with O
either O
HA-EV B-proteingene
or O
HA-SOX9 B-proteingene
. O

Each O
lysate O
were O
immediately O
divided O
and O
left O
untreated O
or O
subjected O
to O
lambda O
phosphatase O
(λ-PPase) B-proteingene
treatment O
for O
1 O
hour O
at O
37◦C O
prior O
to O
gel O
electrophoresis O
. O

SOX9 B-proteingene
blot O
showed O
the O
presence O
of O
SOX9 B-proteingene
protein O
in O
both O
the O
untreated O
and O
the O
phosphatase-treated O
SOX9-transfected B-proteingene
cell O
lysates O
. O

(E) O
Bead-immobilized O
in O
vitro O
translated O
(IVT) O
HA-SOX9 B-proteingene
wild O
type O
(WT) O
or O
T236/240 O
mutant O
were O
either O
untreated O
or O
subjected O
to O
in O
vitro O
GSK3 B-proteingene
kinase O
reaction O
for O
90 O
minutes O
at O
37◦C O
prior O
to O
elution O
and O
gel O
electrophoresis O
. O

The O
SOX9 B-proteingene
blot O
showed O
total O
SOX9 B-proteingene
protein O
eluted O
from O
the O
beads O
from O
each O
reaction O
. O

Shown O
immunoblots O
are O
single O
representative O
experiment O
from O
3 O
independent O
repeats O
. O

(F) O
GSK3-mediated B-proteingene
phosphorylation O
of O
threonine O
236 O
promoted O
SOX9 B-proteingene
interaction O
with O
recombinant O
SCF-FBW7α B-proteingene
in O
vitro O
. O

Bead-immobilized O
IVT O
HA-SOX9 B-proteingene
were O
either O
untreated O
or O
phosphorylated O
with O
GSK3 B-proteingene
as O
described O
in O
(E) O
prior O
to O
further O
incubation O
with O
recombinant O
SCF-FBW7α B-proteingene
for O
in O
vitro O
binding O
assay O
. O

Immunoblot O
showed O
FBW7α B-proteingene
protein O
in O
the O
in O
vitro O
binding O
reaction O
(input) O
as O
well O
as O
those O
which O
had O
been O
eluted O
from O
the O
untreated O
and O
GSK3-treated B-proteingene
immobilized O
SOX9 B-proteingene
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(A) O
Endogenous O
SOX9 B-proteingene
protein O
turnover O
in O
the O
presence O
of O
cycloheximide O
following O
RNAi O
depletion O
of O
FBW7α, B-proteingene
β O
or O
γ. O
HEK293 O
cells O
were O
transfected O
with O
20 O
nM O
of O
non-targeting O
scramble O
RNA O
or O
those O
specifically O
targeting O
FBW7α, B-proteingene
β O
or O
γ O
for O
72 O
hours O
prior O
to O
chase O
with O
addition O
of O
100 O
ng O
/mL O
cycloheximide O
. O

Immunoblot O
of O
Cyclin B-proteingene
E, I-proteingene
an O
established O
SCF-FBW7 B-proteingene
substrate, O
was O
used O
to O
assess O
the O
efficacy O
of O
RNAi-mediated O
depletion O
of O
FBW7 B-proteingene
protein O
with O
GAPDH B-proteingene
served O
as O
protein O
loading O
control O
. O

(B) O
Immunofluorescence O
staining O
of O
D324MEDmedulloblastoma O
cells O
showing O
nuclear O
co-localization O
of O
HA-SOX9 B-proteingene
WT O
(AlexaFluor O
568; O
Red) O
and O
FLAG-FBW7α B-proteingene
(AlexaFluor O
488; O
Green) O
. O

The O
cell O
nuclei O
were O
counter-stained O
with O
DAPI O
(blue) O
. O

Image O
set O
is O
representative O
for O
multiple O
image O
fields O
taken O
at O
40x O
objective O
magnification O
. O

Scale O
bar O
indicate O
20 O
µm O
. O

(C) O
Western O
blotting O
of O
HEK293 O
endogenous O
SOX9 B-proteingene
proteins O
24 O
hours O
following O
forced O
expression O
of O
100, O
250, O
500, O
and O
1000 O
ng O
of O
plasmid O
expressing O
FLAG-FBW7α B-proteingene
. O

Changes O
in O
SOX9 B-proteingene
protein O
level O
in O
the O
representative O
blots O
were O
analysed O
relative O
to O
GAPDH B-proteingene
using O
ImageJ. O
The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(D) O
Expression O
of O
FLAG-FBW7α B-proteingene
enhanced O
HA-SOX9-WT B-proteingene
protein O
turnover, O
which O
can O
be O
attenuated O
with O
addition O
of O
10 O
µM O
MG-132 O
(MG) O
in O
HEK293 O
cells O
. O

By O
contrast, O
forced O
expression O
of O
FLAG-FBW7α B-proteingene
did O
not O
enhance O
HA-SOX9-T236A B-proteingene
and O
-T236A/T240A O
protein O
turnover O
over O
the O
course O
of O
4 O
hours O
protein O
chase O
. O

Protein O
loading O
for O
each O
sample O
was O
indicated O
by O
the O
level O
of O
β-actin B-proteingene
protein O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
4 O
independent O
experiments O
. O

(E) O
Treatment O
of O
HEK293 O
cells O
with O
increasing O
concentration O
of O
BIO, O
a O
GSK3α/β B-proteingene
inhibitor, O
increased O
HA-SOX9-WT B-proteingene
protein O
level O
in O
dose-dependent O
manner O
. O

HA-SOX9-WT B-proteingene
and O
FLAG-FBW7α B-proteingene
were O
co-expressed O
in O
HEK293 O
overnight O
prior O
to O
treatment O
with O
various O
concentration O
of O
BIO O
for O
4 O
hours O
. O

Whole O
cell O
lysates O
were O
collected O
for O
Western O
blotting O
with O
protein O
loading O
for O
each O
sample O
adjusted O
to O
GAPDH B-proteingene
protein O
level O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
2 O
independent O
experiments O
. O

(F) O
The O
RNAi O
depletion O
of O
GSK3ß B-proteingene
decreased O
FBW7α-induced B-proteingene
HA-SOX9-WT B-proteingene
turnover O
in O
HEK293 O
cells O
. O

The O
HA-SOX9-WT B-proteingene
protein O
turnover O
was O
examined O
in O
the O
presence O
of O
100 O
ng/mL O
cycloheximide, O
48 O
hours O
following O
si-GSK3ß B-proteingene
(20 O
nM) O
transfection, O
24 O
hours O
after O
co-expression O
of O
HA-SOX9-WT B-proteingene
and O
FLAG-FBW7α B-proteingene
. O

Immunoblots O
of O
GSK3ß B-proteingene
demonstrated O
depletion O
of O
GSK3ß B-proteingene
protein O
with O
the O
siRNA. O
Changes O
in O
SOX9 B-proteingene
protein O
level O
in O
the O
representative O
blots O
were O
analysed O
relative O
to O
GAPDH B-proteingene
using O
ImageJ. O
The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(G) O
Forced O
FLAG-FBW7α-WT B-proteingene
expression O
promoted O
poly-ubiquitylation O
of O
endogenous O
SOX9 B-proteingene
in O
HEK293, O
which O
accumulated O
further O
in O
the O
presence O
of O
10 O
µM O
MG132 O
. O

Expression O
of O
non-functional O
FBW7α B-proteingene
lacking O
the O
F-box O
domain O
(ΔF), O
or O
those O
containing O
R465A O
mutation O
did O
not O
induce O
SOX9 B-proteingene
poly-ubiquitylation O
in O
vivo O
. O

Ubiquitylation O
assay O
was O
performed O
under O
denaturing O
condition O
to O
disrupt O
non-covalently O
linked O
ubiquitin B-proteingene
as O
described O
in O
the O
Materials O
& O
Methods O
. O

Expression O
of O
various O
FLAG-FBW7α B-proteingene
constructs O
and O
endogenous O
SOX9 B-proteingene
protein O
were O
examined O
in O
the O
whole O
cell O
extract O
(WCE) O
. O

GAPDH B-proteingene
protein O
was O
used O
to O
indicate O
total O
protein O
loading O
with O
protein O
loading O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
4 O
independent O
experiments O
. O

(H) O
Reconstitution O
of O
SOX9 B-proteingene
ubiquitylation O
reaction O
by O
FLAG-FBW7αin B-proteingene
vitro O
. O

Immobilized-IVT O
HA-SOX9 B-proteingene
WT O
were O
incubated O
with O
complete O
ubiquitylation O
reaction O
mixture O
containing O
either O
the O
eluted O
FLAG-FBW7α-WT B-proteingene
or O
the O
ΔF O
mutant O
for O
60 O
minutes O
at O
37◦C. O
Reaction O
mixture O
lacking O
the O
UbE1, B-proteingene
an O
E1 O
ubiquitin-activating B-proteingene
enzyme, O
or O
UbcH3, B-proteingene
an O
E2 O
ubiquiting-conjugating O
enzyme, O
served O
as O
negative O
control O
for O
the O
reaction O
. O

SOX9 B-proteingene
ubiquitylation O
was O
assessed O
following O
elution O
of O
the O
protein O
from O
the O
immobilized O
beads O
under O
denaturing O
condition O
as O
described O
in O
Materials O
& O
Methods O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(B) O
Immunoblotting O
of O
HA-SOX9-WT B-proteingene
protein O
following O
expression O
of O
various O
FLAG-FBW7α B-proteingene
constructs O
including O
wild O
type O
(WT), O
or O
those O
with O
R465A O
or O
R479A O
mutation O
in O
Daoy O
. O

The O
cells O
were O
transfected O
with O
equal O
amount O
of O
HA-SOX9-WT B-proteingene
and O
FLAG-FBW7α B-proteingene
and O
the O
whole O
cell O
lysates O
were O
collected O
24 O
hours O
following O
the O
transfection O
. O

GAPDH B-proteingene
proteins O
were O
shown O
to O
indicate O
total O
protein O
loading O
for O
each O
sample O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
2 O
independent O
experiments O
. O

(C) O
Co-immunoprecipitation O
of O
HA-SOX9 B-proteingene
with O
either O
wild O
type O
(WT) O
or O
R465A- O
FLAG-FBW7α B-proteingene
. O

Unlike O
the O
wild O
type O
protein, O
FLAG-FBW7α B-proteingene
containing O
arginine O
465 O
mutation O
did O
not O
significantly O
co-immunoprecipitate O
with O
HA-SOX9 B-proteingene
(IP O
with O
anti O
HA B-proteingene
antibody) O
and O
vice O
versa O
(IP O
with O
anti O
FLAG B-proteingene
antibody) O
. O

The O
expressions O
of O
HA-SOX9 B-proteingene
and O
FLAG- B-proteingene
FBW7α- B-proteingene
WT O
or O
R465A O
mutant O
were O
assessed O
in O
the O
whole O
cell O
extract O
(WCE) O
of O
the O
transfected O
HEK293 O
with O
GAPDH B-proteingene
protein O
used O
to O
indicate O
total O
protein O
loading O
. O

(D) O
Comparison O
of O
FBW7 B-proteingene
mRNA O
expression O
across O
the O
medulloblastoma O
subgroups O
(WNT, O
SHH, O
Group O
3, O
and O
4) O
in O
a O
cohort O
containing O
423 O
medulloblastoma O
cases O
. O

Expression O
of O
FBW7 B-proteingene
in O
both O
normal O
fetal O
(n= O
5) O
and O
adult O
cerebellum O
(n O
= O
13) O
were O
used O
for O
comparison O
against O
the O
medulloblastoma O
. O

(E) O
Overall O
survival O
analysis O
of O
medulloblastoma O
patient O
based O
upon O
FBW7 B-proteingene
expression O
level O
. O

Analysis O
was O
performed O
on O
383 O
out O
of O
the O
423 O
cases O
from O
which O
the O
survival O
data O
were O
available O
. O

Cohort O
was O
divided O
into O
high- O
(blue O
line) O
and O
low- O
FBW7 B-proteingene
(red O
line) O
expressing O
subgroup O
using O
FBW7 B-proteingene
median O
expression O
as O
group O
classifier O
. O

Statistical O
analysis O
was O
determined O
by O
using O
a O
LogRank O
test O
. O

(F) O
Correlation O
analysis O
between O
SOX9 B-proteingene
protein/mRNA O
and O
FBW7 B-proteingene
mRNA O
expression O
level O
from O
medulloblastoma O
tissue O
microarray O
consisting O
of O
142 O
tissue O
samples O
. O

SOX9 B-proteingene
protein O
level O
was O
scored O
following O
immunohistochemistry O
staining, O
while O
SOX9 B-proteingene
and O
FBW7 B-proteingene
mRNAs O
expression O
by O
the O
RNA O
Scope O
as O
described O
in O
Materials O
& O
Methods O
. O

A O
modest O
negative O
correlation O
was O
determined O
by O
Kendall O
's O
correlation O
test O
(τ O
= O
- O
0.223, O
p<0.001) O
between O
SOX9 B-proteingene
protein/mRNA O
and O
FBW7 B-proteingene
expression O
. O

Affiliation O
of O
samples O
with O
medulloblastoma O
subgroups O
was O
indicated O
by O
different O
colored O
circle O
(blue=WNT, O
red=SHH, O
yellow=Group O
3, O
green=Group O
4, O
grey=Undetermined) O
. O

(A) O
Overall O
survival O
analysis O
of O
mice O
bearing O
Daoy O
cell O
line O
expressing O
SOX9 B-proteingene
with O
doxycycline O
(dox) O
-inducible O
FBW7α B-proteingene
(Daoy-SOX9/T-FBW7α) B-proteingene
. O

The O
dox-preconditioned O
or O
the O
control O
cells O
(105cells) O
were O
orthotopically O
xenografted O
to O
the O
cerebellum O
of O
6-weeks O
old O
Athymic O
Nude-Foxn1nu B-proteingene
mice, O
which O
were O
continuously O
fed O
with O
either O
the O
dox-containing O
chow O
(red O
line) O
or O
the O
regular O
chow O
food O
(green O
line), O
respectively O
. O

Micexenografted O
with O
dox-preconditioned O
Daoy-SOX9/T-FBW7α B-proteingene
and O
fed O
continuously O
with O
dox-containing O
chow O
(red O
line) O
survived O
longer O
(p= O
0.0285) O
than O
the O
control O
group O
(green O
line) O

(B) O
Representative O
of O
Haemotoxylin O
& O
Eosin O
(H&E) O
staining O
of O
medulloblastomatumors O
arising O
from O
the O
orthotopic O
xenograft O
experiment O
described O
in O
(A) O
. O

Both O
the O
control O
(no O
dox-treated) O
and O
the O
dox-treated O
mice O
developed O
primary O
intracerebellar O
tumors O
(green O
and O
red O
arrows, O
respectively) O
. O

SOX9-expressing B-proteingene
Daoytumors O
disseminated O
to O
the O
spinal O
cord O
(3/4; O
green O
asterisks), O
while O
the O
group O
continuously O
receiving O
dox-containing O
chow O
showed O
no O
metastatic O
spread O
(0/4) O
. O

(C) O
Representative O
bright O
field O
images O
of O
migrating O
Daoy-SOX9/T-FBW7α B-proteingene
in O
the O
absence O
or O
presence O
of O
Dox O
. O

Daoy-SOX9/T-FBW7α B-proteingene
cells O
were O
either O
maintain O
in O
regular O
culture O
or O
pre-conditioned O
with O
dox O
prior O
to O
experiments O
. O

The O
cells O
(2 O
x O
105cells O
/ O
insert) O
were O
seeded O
and O
let O
to O
migrate O
across O
5 O
μm O
filter O
pore O
toward O
the O
laminin-coated B-proteingene
trans-well O
for O
4 O
hours O
prior O
to O
fixation O
and O
staining O
with O
crystal O
violet O
. O

Histogram O
quantification O
of O
cell O
migration O
were O
performed O
by O
measuring O
the O
crystal O
violet O
absorbance O
of O
the O
stained-migrating O
cells O
and O
presented O
as O
mean O
+ O
standard O
deviation O
from O
2 O
independent O
experiments O
each O
containing O
2 O
technical O
replicates O
. O

(D) O
Representative O
H&E O
staining O
of O
primary O
(arrow) O
and O
disseminated O
tumors O
(asterisk) O
arising O
from O
orthotopic O
xenograft O
of O
parental O
and O
SOX9-expressing B-proteingene
medulloblastoma O
initiating O
cells O
(MIC O
and O
MIC-Sox9, B-proteingene
respectively) O
. O

Quantification O
of O
primary O
and O
metastatic O
tumors O
arising O
from O
both O
of O
MIC O
(n=16) O
and O
MIC-SOX9 B-proteingene
(n=8) O
is O
shown O
in O
the O
histogram O
(p=0.0000136) O
. O

(E) O
Quantitative O
comparison O
of O
MIC O
and O
MIC-SOX9 O
cells O
to O
migrate O
across O
5 O
μm O
filter O
pore O
toward O
the O
laminin-coated B-proteingene
trans-well O
for O
4 O
hours O
. O

Quantification O
of O
cell O
migration O
were O
performed O
as O
described O
in O
(C) O
and O
presented O
as O
mean O
+ O
standard O
error O
mean O
from O
6 O
replicates O
. O

(F) O
Transwell O
migration O
of O
SOX9-expressing B-proteingene
MIC O
with O
dox-inducible O
FBW7α B-proteingene
or O
dominant O
negative O
∆F O
FBW7α B-proteingene
. O

The O
cells O
were O
either O
maintain O
in O
regular O
culture O
or O
pre-conditioned O
with O
dox O
prior O
to O
assessment O
of O
in O
vitro O
transwell O
migration O
as O
described O
in O
(C) O
. O

Data O
are O
mean O
+ O
standard O
deviation O
from O
2 O
independent O
experiments O
each O
containing O
2 O
technical O
replicates O
. O

(H) O
Correlation O
between O
clinical O
metastatic O
staging O
and O
SOX9 B-proteingene
protein O
across O
the O
TMA O
of O
142 O
cases O
of O
humanmedulloblastoma O
. O

The O
SOX9 B-proteingene
protein O
levels O
were O
determined O
by O
IHC O
in O
Figure O
3F. O
Tumors O
with O
SOX9 B-proteingene
protein O
level O
frequently O
presented O
(p=0.038, O
Fisher O
's O
exact O
test,) O
with O
the O
M3 O
metastatic O
staging, O
spread O
to O
the O
spinal O
cord O
(red O
bars) O
. O

Analysis O
was O
carried O
out O
by O
comparing O
patients O
with O
high O
SOX9 B-proteingene
protein O
rank O
(Rank O
5-7) O
versus O
patients O
with O
low O
SOX9 B-proteingene
protein O
rank O
(Rank O
1-3) O
. O

(A) O
Scatter O
plot O
depicting O
the O
relationship O
between O
transcriptional O
changes O
measured O
as O
log2 O
FC O
between O
EV O
to O
SOX9-WT B-proteingene
(x-axis) O
and O
EV O
to O
SOX9-T236/T240A B-proteingene
(y-axis) O
. O

Each O
dot O
represents O
one O
transcript, O
with O
colored O
dots O
indicating O
transcripts O
upregulated O
(log2 O
FC>0.585; O
p<0.05; O
red O
dots) O
or O
downregulated O
(log2 O
FC O

(B) O
Box-and-Whisker O
plot O
displaying O
the O
sample O
specific O
expression O
of O
three O
FBW7 O
isoforms; O
FBW7α B-proteingene
(NM_033632), O
FBW7β B-proteingene
(NM_018315) O
and O
FBW7γ(NM_001013415') B-proteingene
. O

Each O
box O
represents O
the O
expression O
distribution O
over O
three O
replicates O
. O

(D) O
Heat O
map O
of O
the O
row-wise O
z-scores O
of O
16 O
EMT O
hallmark O
genes O
in O
SOX9-WT B-proteingene
and O
-T236/T240A O
samples O
. O

Heat O
map O
was O
generated O
using O
the O
GenePattern O
software O
(Reich O
et O
al., O
2006) O
. O

(E) O
Quantitative O
PCR O
(qPCR) O
of O
SNAI2 B-proteingene
(SLUG), B-proteingene
VIM B-proteingene
and O
POU3F1 B-proteingene
(OCT6) B-proteingene
(normalized O
to O
GAPDH B-proteingene
levels) O
in O
MB002 O
cells O
stably O
transduced O
with O
EV O
(set O
to O
1), O
SOX9-WT B-proteingene
and O
SOX9-T236/240A. B-proteingene
Cells O
were O
induced O
for O
8 O
or O
24 O
hours O
with O
doxycycline O
. O

(F) O
Western O
blot O
of O
SOX9, B-proteingene
HA-SOX9, B-proteingene
pSOX9-T236, B-proteingene
SNAI2 B-proteingene
(SLUG), B-proteingene
VIM B-proteingene
and O
POU3F1 B-proteingene
(OCT6) B-proteingene
in O
MB002 O
cells O
stably O
transduced O
with O
EV, O
SOX9-WT B-proteingene
and O
SOX9-T236/240A. B-proteingene
Cells O
were O
induced O
for O
24 O
and O
48 O
hours O
with O
doxycycline O
and O
GAPDH B-proteingene
were O
used O
as O
a O
loading O
control O
. O

(G) O
Heat O
map O
of O
the O
row-wise O
z-scores O
of O
14 O
pro-metastasis O
genes O
differentially O
expressed O
between O
SOX9-WT B-proteingene
and O
-T236/T240A O
samples O
and O
previously O
identified O
as O
SOX9 B-proteingene
target O
genes O
(Kadaja O
et O
al., O
2014, O
Larsimont O
et O
al., O
2015, O
Oh O
et O
al., O
2014) O
. O

Heat O
map O
was O
generated O
using O
the O
GenePattern O
software O
(Reich O
et O
al., O
2006) O
. O

(A) O
Cisplatin O
dose O
response O
curves O
of O
(i) O
MB002, O
(ii) O
Daoy, O
and O
(iii) O
MIC O
in O
the O
absence O
(EV) O
or O
presence O
of O
SOX9 B-proteingene
by O
Alamar O
blue O
. O

Cells O
were O
pre-conditioned O
with O
doxycycline O
to O
induce O
expression O
of O
SOX9 B-proteingene
(or O
EV) O
prior O
to O
treatment O
with O
increasing O
concentrations O
of O
cisplatin O
. O

The O
IC50 O
were O
calculated O
following O
5 O
(MB002 O
and O
MIC) O
or O
3 O
days O
(Daoy) O
of O
treatment O
. O

Data O
are O
mean O
+ O
standard O
deviation O
from O
3 O
independent O
repeats, O
each O
containing O
5 O
technical O
replicates O
. O

(B) O
Cisplatin O
dose O
response O
curves O
of O
SOX9-expressing B-proteingene
(i) O
Daoy O
and O
(ii) O
MIC O
in O
the O
absence O
or O
presence O
of O
FBW7α B-proteingene
. O

Experiments O
and O
data O
analysis O
were O
performed O
as O
described O
in O
(A) O

(C) O
Overall O
survival O
analysis O
of O
mice O
bearing O
Daoy O
or O
Daoy-expressing O
dox-inducible O
SOX9 B-proteingene
treated O
with O
cisplatin O
. O

The O
dox-preconditioned O
cells O
(105 O
cells) O
were O
orthotopically O
xenografted O
to O
Nude-Foxn1nu B-proteingene
mice O
and O
left O
for O
1 O
week O
to O
prior O
to O
being O
treated O
with O
vehicle O
control O
or O
cisplatin O
(2mg/kg) O
intraperitoneally O
for O
every O
other O
day O
for O
a O
total O
of O
6 O
doses O
. O

(D) O
Heat O
map O
of O
the O
row-wise O
z-scores O
of O
11 O
genes O
associated O
with O
cisplatin O
resistance O
in O
MB002 O
expressing O
Sox9-WT B-proteingene
or O
Sox9-T236/T240A. B-proteingene
Heat O
map O
was O
generated O
using O
the O
GenePattern O
software O
. O

(E) O
Quantitative O
analysis O
of O
ATP7A, B-proteingene
DUSP2, B-proteingene
and O
TTK B-proteingene
mRNAs O
in O
MB002 O
following O
expression O
of O
SOX9-WT B-proteingene
or O
SOX9-T236/240A. B-proteingene
Total O
RNA O
were O
collected O
24 O
hours O
following O
doxycycline O
treatment, O
from O
which O
cDNA O
were O
generated O
for O
qPCR. O
Data O
are O
mean O
mRNA O
level O
(normalized O
to O
B2M B-proteingene
transcript) O
+ O
standard O
deviation O
from O
3 O
independent O
experiments O
with O
statistical O
significance O
were O
determined O
by O
Multiple O
comparisons O
2-way O
ANOVA O
with O
Bonferroni O
's O
post-test O
. O

(F) O
Time O
coursewestern O
blotting O
of O
HA-SOX9, B-proteingene
ATP7A, B-proteingene
DUSP2, B-proteingene
ERK1/2 B-proteingene
pThr202/Tyr204 O
and O
total O
ERK1/2 B-proteingene
in O
MB002 O
cells O
following O
doxycycline O
induction O
of O
either O
EV, O
SOX9-WT B-proteingene
or O
SOX9-T236/240A. B-proteingene
GAPDH B-proteingene
was O
used O
as O
a O
loading O
control O
. O

(A) O
Western O
blotting O
of O
pT236- O
and O
total O
SOX9 B-proteingene
following O
treatment O
of O
Daoy O
with O
a O
panel O
of O
inhibitors O
targeting O
PI3K/AKT/mTOR O
pathway O
. O

The O
whole O
cell O
lysates O
were O
collected O
for O
gel O
electrophoresis O
following O
6 O
hours O
treatment O
with O
1 O
μM O
of O
AZD5363, O
8186, O
or O
2014 O
. O

The O
set O
of O
blots O
shown O
is O
a O
representative O
from O
3 O
independent O
repeats O
. O

(B) O
Western O
blotting O
of O
endogenous O
SOX9 B-proteingene
protein O
turnover O
in O
the O
presence O
of O
PI3K/mTOR O
dual O
inhibitor, O
AZD2014 O
. O

Daoy O
were O
transfected O
with O
either O
siScr O
or O
siFBW7 B-proteingene
for O
48 O
hours O
prior O
to O
further O
treatment O
with O
1 O
µM O
AZD2014 O
. O

The O
cycloheximide O
chase O
of O
SOX9 B-proteingene
protein O
turnover O
was O
examined O
2 O
hours O
following O
the O
inhibitor O
treatment O
. O

Immunobloting O
of O
Cyclin B-proteingene
E I-proteingene
protein O
was O
used O
to O
indicate O
the O
efficacy O
of O
siFBW7 B-proteingene
transfection O
. O

Changes O
in O
SOX9 B-proteingene
protein O
level O
in O
the O
representative O
blots O
were O
analysed O
relative O
to O
GAPDH B-proteingene
using O
ImageJ. O
The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(C) O
Quantification O
of O
resazurin-based O
Daoy O
and O
MB002 O
cell O
viability O
following O
treatment O
with O
Cisplatin O
(blue O
bars), O
AZD2014 O
(red O
bars), O
or O
their O
combination O
(green O
bars) O
. O

Daoy O
were O
treated O
for O
72 O
hours, O
while O
MB002 O
were O
subjected O
to O
5 O
day O
course O
of O
treatment O
. O

The O
cellviability O
were O
calculated O
relative O
to O
the O
vehicle-treated O
cells O
. O

The O
synthetic O
lethality O
combination O
index O
(CI) O
for O
each O
treatment O
was O
calculated O
from O
the O
mean O
of O
3 O
independent O
experiments O
using O
the O
Compusyn O
software O
. O

Error O
bars O
indicate O
standard O
deviation O
. O

(D) O
Time O
coursewestern O
blotting O
of O
endogenous O
SOX9 B-proteingene
and O
apoptotic O
markers O
including O
cleaved O
PARP B-proteingene
and O
caspase B-proteingene
3 I-proteingene
following O
MB002 O
treatment O
with O
cisplatin, O
AZD2014, O
or O
their O
combination O
. O

β-actin B-proteingene
were O
used O
as O
a O
loading O
control O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(E) O
Western O
blotting O
profiling O
of O
MB002 O
expressing O
EV, O
SOX9-WT, B-proteingene
or O
SOX9-T236/240A B-proteingene
following O
48 O
hours O
treatment O
with O
cisplatin, O
AZD2014, O
and O
their O
combination O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
3 O
independent O
experiments O
. O

(F) O
Quantification O
of O
cell O
viability O
of O
MB002 O
expressing O
EV, O
SOX9-WT, B-proteingene
or O
SOX9-T236/240A B-proteingene
following O
5 O
days O
treatment O
with O
either O
of O
10 O
μM O
cisplatin O
(black O
bars), O
0.5 O
µM O
AZD2014 O
(blue O
bars), O
or O
their O
combination O
(red O
bars) O
. O

Data O
are O
mean O
+ O
standard O
deviation O
from O
3 O
independent O
experiments, O
from O
which O
statistical O
significance O
were O
analysed O
by O
2-way O
ANOVA O
multiple O
comparisons O
with O
Bonferroni O
's O
post-test O
. O

(G) O
Immunoblots O
of O
ATP7A B-proteingene
and O
DUSP2 B-proteingene
protein O
following O
doxycycline O
treatment O
of O
Daoy-SOX9/T-FBW7α B-proteingene
. O

The O
cells O
were O
either O
untreated O
or O
incubated O
with O
5 O
µg/mL O
doxycycline O
for O
72 O
hours O
prior O
to O
being O
harvested O
for O
gel O
electrophoresis O
. O

The O
set O
of O
blots O
shown O
is O
representative O
from O
2 O
independent O
experiments O
. O

A. O
Live-cell O
imaging O
assay O
to O
detect O
mitotic O
perturbations O
. O

HeLa O
cells O
stably O
expressing O
a O
chromatin O
marker O
(H2B-mCherry; B-proteingene
red) O
and O
a O
nuclear O
import O
substrate O
(IBB-eGFP; B-proteingene
green) O
were O
imaged O
by O
automated O
live-cell O
microscopy O
and O
the O
duration O
of O
mitosis O
from O
prometaphase O
to O
anaphase O
onset O
was O
automatically O
determined O
for O
each O
dividing O
cell O
based O
on O
the O
time O
from O
nuclear O
envelope O
breakdown O
(mitotic O
entry) O
until O
nuclear O
reassembly O
(mitotic O
exit) O
(Schmitz O
et O
al., O
2010) O
. O

B. O
miRNA O
mimic O
screen O
for O
miRNAs O
that O
regulate O
mitosis O
genes O
. O

miRNA-mimics O
from O
a O
library O
of O
all O
embryonic O
cortically O
expressed O
miRNAs O
were O
transfected O
individually O
into O
HeLa O
cells O
and O
prometaphase O
to O
anaphase O
onset O
duration O
was O
determined O
as O
in O
A. O
Individual O
points O
correspond O
to O
the O
mean O
z-score O
of O
the O
duration O
of O
prometaphase O
to O
anaphase O
onset O
determined O
in O
2 O
independent O
experimental O
replicates O
for O
a O
given O
miRNA-mimic O
. O

C. O
Cumulative O
histograms O
of O
mitotic O
progression O
for O
control O
cells O
and O
for O
cells O
transfected O
with O
miRNA O
mimics O
. O

Nuclear O
envelope O
breakdown O
is O
at O
t O
= O
0 O
min O
. O

(n O
≥ O
71 O
in O
all O
conditions) O
. O

D. O
Confocal O
time O
lapse O
microscopy O
images O
of O
HeLa O
cells O
stably O
expressing O
H2B-mCherry B-proteingene
(red) O
and O
a O
microtubule O
marker O
(α-Tub-eGFP; B-proteingene
green) O
48 O
h O
after O
transfection O
of O
miR-449a B-proteingene
mimic, O
or O
non-targeting O
control O
siRNA. O
Scale O
bar, O
10 O
μm O
. O

E. O
Quantification O
of O
spindle O
rotation O
and O
duration O
from O
prometaphase O
to O
anaphase O
onset O
in O
time-lapse O
movies O
as O
in O
D. O
miR-449a B-proteingene
mimic O
promotes O
spindle O
rotation O
. O

Duration O
from O
prometaphase O
to O
anaphase O
onset O
was O
defined O
as O
the O
time O
from O
nuclear O
envelope O
breakdown O
to O
anaphase O
onset O
. O

Spindle O
rotation O
during O
metaphase O
was O
measured O
as O
described O
in O
methods O
. O

Individual O
data O
points O
correspond O
to O
single O
cells O
(n O
≥ O
72 O
in O
all O
conditions) O
. O

Normality O
was O
tested O
with O
Kolmogorov-Smirnov O
test O
. O

Variance O
between O
samples O
was O
tested O
using O
F O
test O
. O

Significance O
was O
tested O
by O
Welch O
's O
t O
test: O
p-value O
= O
2.598e-06 O
comparing O
spindle O
rotation O
of O
negative O
control O
versus O
miR-449a B-proteingene
mimic-transfected O
cells O
(all O
data O
points O
are O
compared) O
. O

p-value O
= O
0.0005621 O
(for O
cells O
with O
prometaphase-anaphase O
onset O
duration O
lower O
than O
60 O
min O
. O

A. O
The O
expression O
levels O
of O
endogenous O
miR-34/449 O
family O
members O
were O
measured O
by O
RT-qPCR O
in O
ventricular O
zone O
samples O
derived O
by O
laser O
microdissection O
of O
mouse O
cortices O
at O
E14 O
. O

The O
levels O
of O
the O
different O
miR-34/449 O
family O
members O
and O
miR-7a-1, B-proteingene
a O
highly O
expressed O
miRNA O
relevant O
in O
cortical O
progenitor O
biology, O
were O
determined O
. O

All O
concentrations O
were O
normalized O
(norm.) O

using O
miR-7a-1 B-proteingene
concentration O
(n O
= O
8 O
cortices, O
2 O
different O
litters) O
. O

Error O
bars O
indicate O
standard O
error O
. O

B, O
C. O
Expression O
analysis O
of O
miR-34/449 O
by O
in O
situ O
hybridization O
using O
locked O
nucleic O
acid O
(LNA) O
probes O
in O
wild O
type O
cortices O
at O
E14 O
. O

Mature O
miR-449, B-proteingene
miR-34b B-proteingene
and O
miR-34c B-proteingene
are O
preferentially O
expressed O
in O
the O
subventricular O
(SVZ) O
and O
ventricular O
(VZ) O
zones O
of O
the O
neocortex O
. O

Scale O
bar, O
50 O
μm O
(A), O
10 O
μm O
(B) O
. O

B, O
C. O
Expression O
analysis O
of O
miR-34/449 O
by O
in O
situ O
hybridization O
using O
locked O
nucleic O
acid O
(LNA) O
probes O
in O
wild O
type O
cortices O
at O
E14 O
. O

Mature O
miR-449, B-proteingene
miR-34b B-proteingene
and O
miR-34c B-proteingene
are O
preferentially O
expressed O
in O
the O
subventricular O
(SVZ) O
and O
ventricular O
(VZ) O
zones O
of O
the O
neocortex O
. O

Scale O
bar, O
50 O
μm O
(B), O
10 O
μm O
(C) O
. O

D, O
E. O
Brains O
of O
adult O
mice O
(P23), O
and O
quantification O
of O
brain O
weight O
. O

Dots O
indicate O
individual O
brains; O
red O
line O
indicates O
median O
. O

Mice O
lacking O
miR-449abc B-proteingene
and O
miR-34bc B-proteingene
(DKO) O
or O
miR-449abc, B-proteingene
miR-34bc, B-proteingene
and O
miR-34a B-proteingene
(TKO) O
have O
significantly O
smaller O
brains O
compared O
to O
littermate O
controls O
(Het) O
. O

Significance O
was O
tested O
by O
Pairwaise O
t-test O
with O
Bonferroni O
correction; O
Het O
(n O
= O
6 O
brains, O
2 O
different O
litters) O
vs. O
DKO O
(n O
= O
4 O
brains, O
2 O
different O
litters) O
p-value O
= O
0.00215; O
Het O
(n O
= O
6 O
brains, O
2 O
different O
litters) O
vs. O
TKO O
(n O
= O
4 O
brains, O
2 O
different O
litters) O
p-value O
= O
0.00054 O
. O

Subfigure O
G O
was O
statistically O
tested O
as O
in O
E. O
* O
indicates O
p O
≤ O
0.05, O
** O
indicates O
p O
≤ O
0.01, O
*** O
indicates O
p O
≤ O
0.001 O
. O

F, O
G. O
Confocal O
images O
of O
coronal O
brain O
sections O
(P23) O
and O
quantification O
of O
cortex O
width O
from O
miR-34/449 O
DKO O
and O
TKO O
mice O
and O
littermate O
controls O
(Het) O
. O

Sections O
were O
stained O
with O
DAPI. O
DKO O
or O
TKO O
mice O
have O
significantly O
thinner O
cortices O
compared O
to O
littermate O
controls O
(Het) O
in O
adult O
mice O
(P23) O
. O

(n O
= O
6 O
brains, O
2 O
different O
litters) O
vs. O
DKO O
(n O
= O
4 O
brains, O
2 O
different O
litters) O
p-value O
= O
0.00084, O
Het O
(n O
= O
6 O
brains, O
2 O
different O
liters) O
vs. O
TKO O
(n O
= O
4 O
brains, O
2 O
different O
litters) O
p-value O
= O
0.00211 O
. O

Scale O
bar, O
500 O
μm O
. O

A. O
Confocal O
images O
of O
coronal O
sections O
from O
E16 O
brains O
of O
miR-34/449 B-proteingene
KO O
mice O
and O
littermate O
controls O
(Het), O
stained O
with O
anti-Satb2-antibody B-proteingene
to O
label O
neurons O
of O
layers O
II-IV O
(green) O
and O
DAPI O
to O
label O
all O
cell O
nuclei O
(blue) O
. O

Scale O
bars: O
50 O
μm O
. O

B. O
Quantification O
of O
the O
number O
of O
Satb2-positive B-proteingene
cells O
per O
100 O
μm O
ventricular O
zone O
surface O
. O

Bars O
indicate O
mean O
± O
SEM, O
as O
for O
all O
quantifications O
shown O
in O
this O
figure; O
n O
= O
3 O
brains O
per O
genotype O
group, O
from O
two O
independent O
litters O
. O

Data O
was O
normalized O
(norm.) O

to O
the O
ventricular O
zone O
surface O
analyzed O
(100 O
µm) O
and O
relativized O
to O
the O
heterozygous O
control O
average O
value O
. O

Significance O
was O
tested O
by O
Welch O
's O
t O
test: O
p-value O
= O
0.01146 O
(Het O
vs. O
KO) O
(n O
= O
4 O
cortices O
per O
genotype O
group, O
2 O
independent O
litters) O
. O

All O
subfigures O
were O
statistically O
tested O
as O
in O
B. O
* O
indicates O
p O
≤ O
0.05, O
** O
indicates O
p O
≤ O
0.01, O
*** O
indicates O
p O
≤ O
0.001 O
. O

C-J. O
Confocal O
images O
and O
cell O
density O
quantifications O
as O
in O
A O
using O
molecular O
markers O
for O
different O
cell O
types: O
C, O
D. O
E16 O
brains O
stained O
with O
anti-Ctip2 B-proteingene
antibody O
to O
label O
layer O
Vneurons O
(n O
= O
4 O
brains O
per O
genotype O
group, O
2 O
independent O
litters) O
. O

Scale O
bars: O
50 O
μm O
. O

Images O
in O
C O
were O
taken O
from O
same O
brain O
slices O
as O
shown O
in O
A. O
p-value O
= O
0.03224 O
(Het O
vs. O
KO) O
(immuno O
co-staining O
of O
Ctip2(red, B-proteingene
C)) O
. O

C-J. O
Confocal O
images O
and O
cell O
density O
quantifications O
as O
in O
A O
using O
molecular O
markers O
for O
different O
cell O
types: O
E, O
F. O
E14 O
brains O
stained O
with O
anti-Tbr1 B-proteingene
antibody O
to O
label O
layer O
IVneurons O
p-value O
= O
0.01392 O
(Het O
vs. O
KO) O
(n O
= O
3 O
and O
4 O
brains O
per O
genotype O
group O
from O
2 O
independent O
litters) O
. O

Scale O
bars: O
50 O
μm O
. O

C-J. O
Confocal O
images O
and O
cell O
density O
quantifications O
as O
in O
A O
using O
molecular O
markers O
for O
different O
cell O
types: O
G, O
H. O
E16 O
brains O
stained O
with O
anti-Tbr2 B-proteingene
antibody O
to O
label O
intermediate O
progenitors O
. O

p-value O
= O
0.01647 O
(Het O
vs. O
KO) O
(n O
= O
7 O
brains O
for O
each O
genotype O
group, O
5 O
independent O
litters) O
. O

Scale O
bars: O
50 O
μm O
. O

C-J. O
Confocal O
images O
and O
cell O
density O
quantifications O
as O
in O
A O
using O
molecular O
markers O
for O
different O
cell O
types: O
I, O
J. O
E16 O
brains O
stained O
with O
anti-Pax6 B-proteingene
antibody O
to O
label O
radial O
glia O
progenitors O
. O

p-value O
= O
0.002768 O
(n O
= O
5 O
brains O
per O
genotype O
group, O
3 O
independent O
litters) O
. O

Scale O
bars: O
50 O
μm O
. O

K. O
3D O
reconstruction O
of O
a O
dividing O
radial O
glial O
progenitor O
at O
early O
anaphase O
. O

A O
coronal O
section O
of O
an O
E14 O
brain O
of O
a O
heterozygous O
control O
mouse O
was O
stained O
with O
anti-phospho-Vimentin B-proteingene
antibody O
(red), O
anti-γ-tubulin B-proteingene
antibody O
(green/yellow), O
phalloidin O
(magenta), O
and O
DAPI O
(blue) O
and O
imaged O
by O
3D O
confocal O
microscopy O
. O

"s" O
indicates O
spindle O
axis, O
"α" O
indicates O
angle O
relative O
to O
ventricular O
surface O
plane, O
which O
was O
determined O
by O
a O
vector O
path O
as O
indicated O
by O
thin O
white O
lines O
located O
on O
the O
left O
side O
of O
the O
image O
. O

Yellow O
dots O
highlight O
the O
centrosomes O
of O
the O
spindle O
poles O
from O
the O
analyzed O
dividing O
cell O
. O

Scale O
bars: O
5 O
μm O
. O

L. O
Quantification O
of O
spindle O
orientation O
in O
radial O
glial O
cells O
as O
in O
K O
for O
E14 O
brains O
of O
miR-34/449 B-proteingene
KO O
and O
littermate O
controls O
(Het) O
. O

Each O
dot O
represents O
a O
single O
dividing O
cell; O
p-value O
= O
3.166e-05 O
(Het O
vs. O
KO) O
(n O
= O
131 O
vs. O
107 O
cells, O
n O
= O
4 O
brains O
per O
genotype O
group, O
2 O
independent O
litters) O
. O

A. O
Quantification O
of O
mRNA O
expression O
by O
RT-qPCR O
of O
candidate O
miR-34/449 B-proteingene
targets O
that O
might O
regulate O
spindle O
orientation O
in O
E14 O
cortex O
samples O
from O
miR-34/449 B-proteingene
KO O
mice O
compared O
with O
littermate O
controls O
(Het) O
. O

Expression O
was O
normlaized O
(norm.) O

to O
Phosphoglycerate O
kinase O
(PGK) B-proteingene
mRNA O
levels O
. O

Significance O
was O
tested O
by O
Welch O
's O
t O
test: O
p O
= O
0.009756 O
(JAM-A B-proteingene
(Het) O
vs. O
JAM-A B-proteingene
(KO)), O
all O
the O
rest O
Het O
vs. O
KO O
comparisons O
p=n.s O
. O

(n O
= O
4 O
cortices O
per O
genotype O
group, O
2 O
independent O
litters) O
. O

All O
subfigures O
were O
statistically O
tested O
as O
in O
A. O
* O
indicates O
p O
≤ O
0.05, O
** O
indicates O
p O
≤ O
0.01, O
*** O
indicates O
p O
≤ O
0.001 O
. O

Red O
bar O
indicates O
median O
. O

B. O
RT-qPCR O
quantification O
of O
JAM-A B-proteingene
mRNA O
expression O
in O
HeLa O
cells O
48 O
h O
after O
transfection O
of O
miR-449a B-proteingene
mimic O
compared O
to O
cells O
transfected O
with O
non-targeting O
negative O
control O
siRNA. O
JAM-A B-proteingene
mRNA O
Expression O
was O
normalized O
(norm.) O

to O
Glyceraldehyde O
3-phosphate O
dehydrogenase O
(GAPDH) B-proteingene
mRNA O
levels O
. O

p O
= O
0.0001218 O
(Neg O
. O

ctrol O
. O

vs. O
miR-449a B-proteingene
mimic) O
(n O
= O
9 O
measurements O
from O
3 O
independent O
replicates) O
. O

C, O
D. O
mouse O
J110 O
cells O
were O
transfected O
with O
either O
miR-449a B-proteingene
mimic O
or O
a O
negative O
control O
mimic O
. O

Whole O
cell O
extracts O
were O
subjected O
to O
immunoblot O
analysis O
to O
detect O
endogenous O
JAM-A B-proteingene
and O
ACTIN. B-proteingene
ACTIN B-proteingene
was O
used O
to O
normalize O
JAM-A B-proteingene
expression O
(norm.) O

as O
loading O
control O
. O

p O
= O
0.04454 O
(Neg O
. O

ctrol O
. O

vs. O
miR-449a B-proteingene
mimic) O
(n O
= O
4 O
independent O
wells, O
2 O
independent O
transfections) O
. O

E, O
F. O
HeLa O
cells O
were O
cotransfected O
with O
either O
miR-449a B-proteingene
mimic O
or O
a O
negative O
control O
mimic, O
together O
with O
JAM-A-GFP B-proteingene
fusion O
protein O
and O
GFP. B-proteingene
Whole O
cell O
extracts O
were O
subjected O
to O
immunoblot O
analysis O
to O
detect O
GFP. B-proteingene
GFP B-proteingene
was O
used O
to O
normalize O
(norm.) O

by O
transfection O
efficiency O
as O
loading O
control O
. O

p O
= O
0.001176 O
(JAM-A B-proteingene
WT O
Neg O
. O

ctrol O
. O

vs. O
miR-449a B-proteingene
mimic) O
(n O
= O
9 O
independent O
wells, O
4 O
independent O
transfections) O
. O

G, O
H. O
Confocal O
images O
of O
coronal O
sections O
from O
E14 O
brains O
of O
wild O
type O
mice O
stained O
with O
anti-JAM-A B-proteingene
antibody O
(green), O
phalloidin O
to O
label O
actin O
(gray) O
and O
DAPI O
to O
label O
cell O
nuclei O
(blue) O
. O

Scale O
bars: O
10 O
μm O
(G), O
5 O
μm O
(H) O
. O

I. O
Quantification O
of O
JAM-A B-proteingene
protein O
expression O
in O
the O
ventricular O
zone O
of O
E14 O
brain O
coronal O
sections O
from O
miR-34/449 B-proteingene
KO O
mice O
compared O
with O
littermate O
controls O
(Het) O
by O
immunofluorescence O
. O

ACTIN B-proteingene
(phalloidin O
signal) O
was O
used O
to O
normalize O
(norm.) O

the O
expresion O
levels O
of O
JAM-A. B-proteingene
p O
= O
0.04842 O
(n O
= O
5 O
(KO) O
or O
7 O
(het) O
cortices O
per O
genotype O
group, O
3 O
independent O
litters) O
. O

A, O
D. O
Confocal O
time O
lapse O
images O
of O
metaphase O
HeLa O
cells O
stably O
expressing O
a O
centriole O
marker O
(Centrin2-GFP; B-proteingene
green), O
the O
microtubule O
marker O
(α-tubulin-mRFP; B-proteingene
red) O
and O
no O
extra O
protein O
(A) O
or O
mouse O
JAM-A B-proteingene
(D), O
48 O
h O
after O
transfection O
of O
miR-449a B-proteingene
mimic, O
JAM-A B-proteingene
siRNA, O
or O
non-targeting O
negative O
control O
siRNA. O
Scale O
bar, O
10 O
μm O
. O

B, O
E. O
Quantification O
of O
spindle O
rotation O
for O
cells O
as O
shown O
in O
A O
and O
D. O
Each O
dot O
represents O
a O
single O
cell O
. O

Red O
bar O
indicates O
median O
. O

Significance O
was O
tested O
by O
Pairwise O
t-test O
with O
Bonferroni O
correction O
. O

p-value O
= O
2e-11 O
(Neg O
. O

control O
versus O
miR449 O
mimic), O
p-value O
= O
0.01928 O
(Neg O
. O

control O
versus O
JAM-A B-proteingene
siRNA), O
p-value O
= O
0.17492 O
(Neg O
. O

control O
versus O
miR449 O
mimic, O
under O
JAM-A B-proteingene
overexpression) O
. O

* O
indicates O
p O
≤ O
0.05; O
** O
p O
≤ O
0.01; O
p*** O
p O
≤ O
0.001 O
for O
all O
panels O
. O

C, O
F. O
Cumulative O
histograms O
of O
mitotic O
duration O
from O
nuclear O
envelope O
breakdown O
until O
anaphase O
onset, O
measured O
for O
cells O
as O
shown O
in O
A O
and O
D; O
n O
≥ O
20 O
cells O
for O
all O
conditions, O
2 O
independent O
replicates O
. O

(A) O
Western O
blot O
analysis O
of O
supernatants O
containing O
long O
and O
short O
mouse O
and O
human O
DNGR-1 B-proteingene
ECD O
proteins O
under O
reducing O
and O
non-reducing O
conditions O
. O

(B) O
Western O
blot O
analysis O
of O
supernatants O
after O
protein O
production O
of O
WT O
and O
C94S O
mutant O
long O
mouse O
DNGR-1 B-proteingene
ECD O
proteins O
under O
reducing O
and O
non-reducing O
conditions O
. O

C94S O
mutant-containing O
supernatant O
was O
200x O
concentrated O
before O
analysis O
. O

(C) O
Western O
blot O
analysis O
of O
supernatants O
containing O
the O
indicated O
DNGR-1 B-proteingene
ECD O
proteins O
after O
treatment O
with O
PNGase B-proteingene
F I-proteingene
overnight O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
of O
all O
proteins O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

(A) O
0.25 O
μg O
of O
purified O
long O
mouse O
DNGR-1 B-proteingene
ECD O
was O
diluted O
into O
10 O
mM O
Tris O
buffer O
of O
the O
indicated O
pH O
(left O
panel) O
or O
into O
10 O
mM O
Tris O
pH O
7.4 O
buffer O
supplemented O
with O
increasing O
amounts O
of O
NaCl O
(1 O
- O
250 O
mM; O
right O
panel), O
and O
reduction O
sensitivity O
of O
DNGR-1 B-proteingene
was O
assessed O
by O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

(B) O
0.25 O
μg O
of O
purified O
DNGR-1long B-proteingene
mouse O
ECD O
was O
diluted O
into O
buffers O
of O
different O
pH O
and O
ionic O
strength, O
and O
its O
reduction O
sensitivity O
was O
assessed O
by O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

The O
intensity O
of O
bands O
corresponding O
to O
dimer O
and O
monomer O
was O
determined O
densitometrically, O
and O
the O
ratio O
was O
plotted O
as O
a O
function O
of O
buffer O
ionic O
strength O
and O
pH O
. O

(C) O
0.25 O
μg O
of O
purified O
long O
mouse O
DNGR-1 B-proteingene
ECD O
was O
diluted O
into O
PBS O
or O
10 O
mM O
MES O
pH O
6.1 O
buffer, O
and O
its O
reduction O
sensitivity O
was O
tested O
under O
mildly O
(Laemmli O
buffer) O
or O
strongly O
denaturing O
(8 O
M O
urea) O
conditions O
by O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

(D) O
0.25 O
μg O
of O
purified O
long O
mouse O
DNGR-1 B-proteingene
ECD O
was O
diluted O
into O
PBS O
or O
10 O
mM O
MES O
pH O
6.1 O
buffers, O
and O
its O
reduction O
sensitivity O
after O
different O
lengths O
of O
heat-denaturation O
in O
Laemmli O
buffer O
was O
tested O
by O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
of O
all O
proteins O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

Reduction-resistant O
dimers O
are O
indicated O
with O
an O
* O
and O
reduction-sensitive O
protein O
with O
a O
+ O
. O

(A) O
1 O
μg O
of O
purified O
long O
mouse O
DNGR-1 B-proteingene
ECD O
was O
transferred O
into O
10mM O
MES O
pH O
6.1 O
and O
0.5 O
μg O
into O
PBS. O
Half O
of O
the O
MES O
sample O
and O
the O
whole O
PBS O
sample O
were O
dialyzed O
against O
2 O
l O
of O
PBS O
overnight O
at O
4°C. O
After O
dialysis, O
all O
samples O
were O
prepared O
for O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

(B) O
Supernatants O
after O
production O
of O
indicated O
proteins O
in O
293Fcells O
were O
harvested O
and O
diluted O
into O
indicated O
buffers O
at O
a O
2:3 O
ratio O
and O
analyzed O
using O
reducing O
SDS-PAGE O
and O
Western O
blot O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
of O
all O
proteins O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

Reduction-resistant O
dimers O
are O
indicated O
with O
an O
* O
and O
reduction-sensitive O
protein O
with O
a O
+ O
. O

(B) O
Supernatants O
containing O
ECD O
of O
long O
mouse O
DNGR-1, B-proteingene
Dectin-1 B-proteingene
and O
the O
chimeric O
receptor O
were O
prepared O
for O
SDS-PAGE O
and O
Western O
blot O
under O
non-reducing O
conditions O
. O

(C) O
Supernatants O
containing O
indicated O
proteins O
were O
diluted O
into O
PBS O
or O
pH O
6.1 O
MES O
buffer O
and O
analyzed O
using O
SDS-PAGE O
and O
Western O
blot O
under O
reducing O
conditions O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
of O
all O
proteins O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

Reduction-resistant O
dimers O
are O
indicated O
with O
an O
* O
and O
reduction O
sensitive O
protein O
with O
a O
+ O
. O

(A) O
Long O
mouse O
and O
human O
DNGR-1 B-proteingene
ECD O
proteins O
were O
diluted O
in O
PBS O
or O
10 O
mM O
MES O
pH O
6.1 O
buffer O
and O
20 O
independent O
far-UV O
spectra O
were O
acquired O
for O
each O
condition O
(red O
and O
black O
lines O
depict O
the O
composite O
curve O
for O
each O
condition) O

(B) O
Long O
mouse O
DNGR-1 B-proteingene
ECD O
was O
diluted O
in O
PBS O
or O
10 O
mM O
MES O
pH O
6.1 O
buffer O
and O
20 O
independent O
near-UV O
spectra O
were O
acquired O
for O
each O
condition O
(red O
and O
black O
lines O
depict O
the O
composite O
curve O
for O
each O
condition O
and O
the O
blue O
line O
shows O
the O
difference O
between O
the O
two) O
. O

(B) O
and O
(C) O
Supernatants O
containing O
the O
indicated O
ECD O
proteins O
(mouse, O
long O
isoform) O
were O
diluted O
1:2 O
into O
the O
indicated O
buffers O
and O
analyzed O
by O
SDS-PAGE O
and O
Western O
blot O
under O
reducing O
or O
non O
reducing O
conditions O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
of O
all O
proteins O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

Reduction-resistant O
dimers O
are O
indicated O
with O
an O
* O
and O
reduction-sensitive O
protein O
with O
a O
+ O
. O

(D) O
Phoenix O
cells O
expressing O
the O
indicated O
proteins O
were O
lysed O
in O
1% O
SDS O
in O
PBS O
or O
10mM O
MES O
pH O
6.1 O
buffers O
and O
the O
lysates O
were O
analyzed O
by O
SDS-PAGE O
and O
Western O
blot O
under O
reducing O
conditions O
. O

Anti-DNGR-1 B-proteingene
antibody O
(clone O
397) O
followed O
by O
HRP-conjugated B-proteingene
secondary O
anti-rat O
antibody O
was O
used O
for O
detection O
. O

Numbers O
on O
the O
side O
of O
blots O
indicate O
positions O
of O
molecular O
weight O
markers O
. O

Reduction-resistant O
dimers O
are O
indicated O
with O
an O
* O
and O
reduction-sensitive O
protein O
with O
a O
+ O
. O

(A) O
Decreasing O
amounts O
of O
F-actin B-proteingene
were O
spotted O
onto O
a O
nitrocellulose O
membrane O
and O
binding O
of O
indicated O
DNGR-1 B-proteingene
ECD O
(mouse, O
long O
isoform) O
proteins O
was O
tested O
in O
PBS O
or O
MES O
pH O
6.1 O
buffers O
. O

HRP-conjugated B-proteingene
anti-FLAG B-proteingene
antibody O
was O
used O
for O
detection O
. O

The O
signal O
was O
quantified O
by O
densitometry O
and O
quantitation O
of O
four O
independent O
experiments O
is O
shown O
. O

(B O
and O
C) O
B3Z-Syk B-proteingene
reporter O
cells O
expressing O
indicated O
mutant O
or O
WT O
DNGR-1 B-proteingene
receptors O
(mouse, O
long O
isoform) O
were O
incubated O
with O
UV-irradiated O
293T O
cells O
(ratio O
dead:reporter O
cells O
is O
indicated), O
or O
with O
plate-bound O
anti-DNGR-1 B-proteingene
antibody O
or O
medium O
alone O
at O
37°C O
overnight O
. O

Activation O
of O
the O
NFAT B-proteingene
reporter O
was O
measured O
at O
the O
end O
of O
the O
incubation O
period O
. O

Data O
are O
plotted O
as O
mean O
± O
SD O
of O
experimental O
duplicates O
. O

One O
representative O
of O
three O
experiments O
is O
shown O
. O

(B O
and O
C) O
B3Z-Syk B-proteingene
reporter O
cells O
expressing O
indicated O
mutant O
or O
WT O
DNGR-1 B-proteingene
receptors O
(mouse, O
long O
isoform) O
were O
incubated O
with O
UV-irradiated O
293T O
cells O
(ratio O
dead:reporter O
cells O
is O
indicated), O
or O
with O
plate-bound O
anti-DNGR-1 B-proteingene
antibody O
or O
medium O
alone O
at O
37°C O
overnight O
. O

Activation O
of O
the O
NFAT B-proteingene
reporter O
was O
measured O
at O
the O
end O
of O
the O
incubation O
period O
. O

Data O
are O
plotted O
as O
mean O
± O
SD O
of O
experimental O
duplicates O
. O

One O
representative O
of O
three O
experiments O
is O
shown O
. O

(D) O
Phoenix O
cells O
expressing O
indicated O
mutant O
or O
WT O
DNGR-1 B-proteingene
proteins O
(mouse, O
long O
isoform) O
were O
treated O
with O
F-actin, B-proteingene
F-actin B-proteingene
buffer, O
anti-DNGR-1 B-proteingene
antibody O
or O
isotype-matched O
antibody O
of O
irrelevant O
specificity O
for O
45 O
minutes, O
fixed O
in O
PFA, O
surface-stained O
for O
DNGR-1 B-proteingene
and O
analyzed O
by O
flow O
cytometry O
. O

One O
representative O
of O
three O
experiments O
is O
shown O
. O

(A) O
DNGR-1 B-proteingene
KO O
MuTu O
DCs O
were O
transduced O
to O
express O
indicated O
DNGR-1 B-proteingene
proteins, O
FACS-sorted O
and O
expanded O
. O

Surface O
(left O
panel) O
and O
total O
(right O
panel) O
DNGR-1 B-proteingene
expression O
was O
determined O
by O
flow O
cytometry O
. O

(B O
and O
C) O
Ovalbumin-expressing B-proteingene
mouse O
embryonic O
fibroblasts O
(bm1 O
T O
OVAMEFs) B-proteingene
were O
UV-irradiated, O
left O
to O
undergo O
secondary O
necrosis O
and O
incubated O
overnight O
with O
MuTu O
cells O
transduced O
with O
indicated O
WT O
or O
mutant O
DNGR-1 B-proteingene
proteins O
or O
an O
empty-vector O
control O
(ratio O
dead O
cells:MuTu O
cells O
is O
indicated) O
and O
OVA-specific B-proteingene
pre-activated O
OT-ICD8+T-lymphocytes O
. O

The O
amount O
of O
IFNγ B-proteingene
accumulating O
in O
the O
culture O
medium O
was O
assessed O
using O
ELISA. O
One O
representative O
of O
two O
(B) O
or O
four O
(C) O
experiments O
is O
shown O
. O

A O
HEK293T O
were O
transfected O
with O
NF-kBluciferase B-proteingene
reporter O
plasmid O
and O
FLAG-tagged B-proteingene
full-length O
CARD14 B-proteingene
(FL) O
or O
CARD14sh B-proteingene
(short) O
at O
the O
indicated O
concentrations O
and O
analyzed O
24 O
h O
later O
. O

(A) O
NF-kB B-proteingene
reporter O
gene O
expression O
. O

HEK293T O
were O
transfected O
with O
NF-kBluciferase B-proteingene
reporter O
plasmid O
and O
FLAG-tagged B-proteingene
full-length O
CARD14 B-proteingene
(FL) O
or O
CARD14sh B-proteingene
(short) O
at O
the O
indicated O
concentrations O
and O
analyzed O
24 O
h O
later O
. O

(B) O
IL-8 B-proteingene
secretion O
. O

Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

P-values O
are O
compared O
against O
empty O
vector O
treatment O
. O

Significance O
levels, O
ns O
P>0.05, O
*P<0.05, O
**P<0.01 O
and O
***P<0.001 O
by O
student O
t O
test O
. O

Unless O
otherwise O
stated, O
p-values O
are O
p<0.001 O
. O

HEK293T O
were O
transfected O
with O
NF-kBluciferase B-proteingene
reporter O
plasmid O
and O
FLAG-tagged B-proteingene
full-length O
CARD14 B-proteingene
(FL) O
or O
CARD14sh B-proteingene
(short) O
at O
the O
indicated O
concentrations O
and O
analyzed O
24 O
h O
later O
. O

(C) O
Immunoblotting O
for O
c-Jun, B-proteingene
phospho-c-Jun, B-proteingene
JNK, B-proteingene
phospho-JNK, B-proteingene
p38 B-proteingene
and O
phospho-p38 B-proteingene
as O
indicated O
. O

Actin B-proteingene
was O
used O
as O
a O
loading O
control O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

(A) O
MALT1 B-proteingene
interacts O
with O
CARD14sh B-proteingene
in O
a O
BCL10-dependent B-proteingene
manner O
. O

HEK293T O
cells O
were O
transfected O
with O
FLAG-CARD14sh, B-proteingene
Myc-MALT1 B-proteingene
and O
FLAG-BCL10 B-proteingene
as O
indicated O
. O

24 O
h O
later, O
MALT1 B-proteingene
was O
immunoprecipitated O
(IP) O
from O
cell O
lysates O
with O
anti-MALT1 B-proteingene
. O

CARD14sh B-proteingene
and O
BCL10co-immunoprecipitation B-proteingene
with O
MALT1 B-proteingene
was O
detected O
by O
immunoblotting O
with O
anti-FLAG. B-proteingene
Immunoprecipitated O
MALT1 B-proteingene
was O
detected O
by O
immunoblotting O
with O
anti-myc O
. O

The O
closed O
arrowhead O
shows O
the O
position O
of O
CARD14, B-proteingene
the O
double O
arrowhead O
shows O
the O
position O
of O
BCL10 B-proteingene
. O

The O
asterisk O
indicates O
a O
non-specific O
band O
. O

Total O
expression O
levels O
of O
transfected O
proteins O
are O
shown O
by O
immunoblotting O
of O
a O
fraction O
of O
the O
cell O
lysates O
with O
the O
indicated O
antibodies O
(bottom O
panel) O
. O

(B) O
MALT1 B-proteingene
co-expression O
potentiates O
CARD14sh-induced B-proteingene
JNK B-proteingene
and O
p38 B-proteingene
MAP O
kinase O
activation O
. O

HEK293T O
cells O
were O
transfected O
with O
the O
indicated O
concentrations O
of O
FLAG-tagged B-proteingene
CARD14sh, B-proteingene
with O
or O
without O
MALT1 B-proteingene
(30ng) O
. O

Transfection O
with O
FLAG-TRAF6 B-proteingene
and O
FLAG-CARD11(L232LI) B-proteingene
were O
used O
as O
a O
positive O
control O
. O

c-Jun B-proteingene
accumulation, O
JNK B-proteingene
and O
p38 B-proteingene
phosphorylation O
were O
analyzed O
by O
immunoblotting O
with O
the O
antibodies O
indicated O
. O

Actin B-proteingene
was O
used O
as O
a O
loading O
control O
. O

(C) O
MALT1 B-proteingene
co-expression O
potentiates O
NF-kB B-proteingene
activation O
by O
pathogenic O
CARD14 B-proteingene
mutants O
. O

HEK293T O
were O
transfected O
with O
NF-kB B-proteingene
reporter O
plasmid O
and O
wild-type O
(WT) O
FLAG-CARD14 B-proteingene
or O
the O
indicated O
psoriasis-associated O
CARD14 B-proteingene
mutants O
(15ng), O
with O
or O
without O
MALT1 B-proteingene
(15ng) O
. O

Luciferase O
activity O
in O
cell O
lysates O
was O
measured O
after O
24 O
h. O
Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Significance O
levels, O
*P<0.05, O
**P<0.01 O
and O
***P<0.001 O
by O
student O
t O
test O
. O

Expression O
of O
transfected O
proteins O
was O
verified O
by O
western O
blotting O
(bottom O
panel) O
. O

(D) O
CARD14(E138A) B-proteingene
mutation O
enhances O
MALT1 B-proteingene
binding O
. O

HEK293T O
cells O
were O
transfected O
with O
wild-type O
(WT) O
FLAG-CARD14sh B-proteingene
or O
the O
indicated O
CARD14sh B-proteingene
mutants O
and O
Myc-MALT1 B-proteingene
. O

24 O
h O
later, O
MALT1 B-proteingene
was O
immunoprecipitated O
(IP) O
from O
cell O
lysates O
with O
anti-MALT1 B-proteingene
and O
CARD14co-immunoprecipitation B-proteingene
was O
detected O
by O
immunoblotting O
with O
anti-FLAG. B-proteingene
Immunoprecipitated O
MALT1 B-proteingene
was O
detected O
by O
immunoblotting O
with O
anti-MALT1 B-proteingene
. O

The O
asterisk O
indicates O
a O
non-specific O
band O
. O

Immunoprecipitation O
with O
a O
non-relevant O
antibody O
(rIgG) O
was O
used O
as O
a O
negative O
control O
(first O
lane) O
. O

Total O
expression O
levels O
of O
transfected O
proteins O
are O
shown O
by O
immunoblotting O
of O
total O
cell O
lysates O
(bottom O
panel) O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

(A) O
MALT1 B-proteingene
expression O
is O
essential O
for O
CARD14sh-induced B-proteingene
NF-kB B-proteingene
activation O
. O

MALT1-deficient B-proteingene
HEK293T O
cells O
were O
transfected O
with O
NF-kB B-proteingene
reporter O
plasmid O
and O
the O
indicated O
expression O
plasmids O
. O

Luciferase O
activity O
in O
cell O
lysates O
was O
measured O
24 O
h O
later O
. O

CARD11(L232LI) B-proteingene
and O
TRAF6 B-proteingene
transfection O
were O
used O
as O
MALT1-dependent B-proteingene
and O
MALT1-independent B-proteingene
controls, O
respectively O
. O

Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Expression O
of O
the O
transfected O
plasmids O
was O
verified O
by O
immunoblotting O
(lower O
panel) O
. O

(B) O
MALT1 B-proteingene
expression O
is O
essential O
for O
CARD14sh-induced B-proteingene
JNK B-proteingene
activation O
. O

MALT1-deficient B-proteingene
HEK293T O
cells O
were O
transfected O
with O
FLAG-CARD14sh B-proteingene
(30ng) O
either O
alone O
or O
together O
with O
either O
wild-type O
(MALT1WT) B-proteingene
or O
catalytically O
inactive O
MALT1 B-proteingene
(MALT1C/A) B-proteingene
as O
indicated O
. O

c-Jun B-proteingene
accumulation O
and O
JNK B-proteingene
phosphorylation O
were O
analyzed O
by O
immunoblotting O
with O
the O
antibodies O
indicated O
. O

Actin B-proteingene
was O
used O
as O
a O
loading O
control O
. O

(C) O
MALT1 B-proteingene
deficiency O
inhibits O
CARD14-induced B-proteingene
gene O
expression O
in O
HaCaTkeratinocytes O
. O

HaCaT O
cells O
were O
transfected O
with O
scrambled O
(scr) O
or O
MALT1-targeting B-proteingene
siRNA O
prior O
to O
doxycycline-induced O
CARD14 B-proteingene
expression O
as O
described O
in O
materials O
and O
methods O
. O

IL-8 B-proteingene
and O
MCP-1 B-proteingene
concentration O
in O
the O
cell O
supernatants O
was O
measured O
8 O
h O
(IL-8) B-proteingene
or O
24 O
h O
(MCP-1) B-proteingene
later O
by O
ELISA. O
Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Doxycycline-induced O
CARD14 B-proteingene
expression O
and O
MALT1 B-proteingene
knock-down O
were O
verified O
by O
immunoblotting O
(right O
panel) O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

(A) O
CARD14 B-proteingene
signaling O
induces O
CYLD B-proteingene
and O
A20 B-proteingene
cleavage O
. O

HEK293T O
cells O
were O
transfected O
with O
different O
concentrations O
of O
FLAG-CARD14, B-proteingene
with O
or O
without O
MALT1 B-proteingene
as O
indicated O
. O

CARD11(L232LI) B-proteingene
transfection O
was O
used O
as O
a O
positive O
control O
. O

Endogenous O
CYLD B-proteingene
and O
A20 B-proteingene
processing O
was O
analyzed O
by O
immunoblotting O
. O

CYLD B-proteingene
and O
A20 B-proteingene
cleavage O
fragments O
are O
indicated O
by O
an O
arrow O
. O

(B) O
CARD14 B-proteingene
signaling O
induces O
CYLD B-proteingene
cleavage O
after O
R324 O
. O

HEK293T O
cells O
were O
transfected O
with O
different O
concentrations O
of O
FLAG-CARD14sh B-proteingene
and O
either O
wild-type O
(CYLDWT) B-proteingene
or O
non-cleavable O
CYLD B-proteingene
(CYLDR324A) B-proteingene
. O

CYLD B-proteingene
processing O
was O
analyzed O
by O
immunoblotting O
. O

The O
CYLD B-proteingene
cleavage O
fragment O
is O
indicated O
by O
an O
arrow O
. O

(C) O
Expression O
of O
catalytically O
active O
MALT1 B-proteingene
is O
necessary O
for O
CARD14-induced B-proteingene
CYLD B-proteingene
cleavage O
. O

MALT1-deficient B-proteingene
HEK293T O
cells O
in O
which O
MALT1 B-proteingene
expression O
was O
restored O
by O
transfection O
with O
different O
concentrations O
of O
either O
wild-type O
(MALT1WT) B-proteingene
or O
catalytically O
inactive O
MALT1 B-proteingene
(MALT1C/A), B-proteingene
were O
co-transfected O
with O
FLAG-CARD14sh B-proteingene
and O
CYLD B-proteingene
as O
indicated O
. O

CYLD B-proteingene
processing O
was O
analyzed O
by O
immunoblotting O
. O

The O
CYLD B-proteingene
cleavage O
fragment O
is O
indicated O
by O
an O
arrow O
. O

(D) O
Psoriasis-associated O
CARD14 B-proteingene
mutation O
enhances O
activation O
of O
MALT1 B-proteingene
proteolytic O
activity O
. O

HEK293T O
cells O
were O
transfected O
with O
wild-type O
(WT) O
FLAG-CARD14 B-proteingene
or O
different O
psoriasis-associated O
CARD14 B-proteingene
mutants O
(20ng), O
with O
or O
without O
MALT1 B-proteingene
(20 O
ng) O
as O
indicated O
. O

Endogenous O
CYLD B-proteingene
and O
A20 B-proteingene
processing, O
as O
well O
as O
IκBα B-proteingene
phosphorylation, O
were O
analyzed O
by O
immunoblotting O
. O

The O
CYLD B-proteingene
and O
A20 B-proteingene
cleavage O
fragments O
are O
indicated O
by O
an O
arrow O
. O

(E) O
Pharmacological O
inhibition O
of O
MALT1 B-proteingene
proteolytic O
activity O
prevents O
CARD14-induced B-proteingene
gene O
expression O
in O
HaCaTkeratinocytes O
. O

CARD14 B-proteingene
expression O
was O
induced O
by O
doxycycline O
(dox) O
treatment O
in O
the O
absence O
or O
presence O
of O
different O
concentrations O
of O
mepazine O
as O
indicated O
. O

The O
next O
morning, O
cell O
culture O
medium O
was O
refreshed O
and O
IL-8 B-proteingene
and O
MCP-1 B-proteingene
concentration O
in O
the O
cell O
supernatant O
was O
measured O
8 O
h O
later O
by O
ELISA. O
TNF B-proteingene
stimulation O
(MALT1-independent) B-proteingene
was O
used O
as O
a O
negative O
control O
. O

Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

Significance O
levels, O
*P<0.05, O
**P<0.001, O
***P<0.001 O
by O
student O
t O
test O
. O

(A-B) O
CYLD B-proteingene
and O
A20 B-proteingene
inhibit O
CARD14sh-induced B-proteingene
NF-kB B-proteingene
activation O
. O

HEK293T O
cells O
were O
transfected O
with O
NF-kB B-proteingene
reporter O
plasmid O
and O
FLAG-tagged B-proteingene
CARD14sh B-proteingene
(30ng), O
with O
or O
without O
the O
indicated O
concentrations O
of O
CYLD B-proteingene
(A) O
or O
A20 B-proteingene
(B) O
. O

Luciferase B-proteingene
activity O
in O
cell O
lysates O
was O
measured O
24 O
h O
later O
. O

Closed O
arrowheads O
indicate O
full O
length O
A20 B-proteingene
and O
CYLD; B-proteingene
arrows O
indicate O
cleaved O
A20 B-proteingene
and O
CYLD. B-proteingene
Data O
are O
representative O
of O
three O
independent O
experiments O
. O

(C) O
A20 B-proteingene
and O
ABIN-1 B-proteingene
inhibit O
CARD14-induced B-proteingene
NF-kB B-proteingene
activation O
. O

HEK293T O
cells O
were O
transfected O
with O
NF-kB B-proteingene
reporter O
plasmid, O
A20 B-proteingene
(3 O
ng) O
or O
ABIN1 B-proteingene
(15ng) O
and O
the O
indicated O
concentrations O
of O
FLAG-tagged B-proteingene
CARD14sh B-proteingene
. O

Luciferase B-proteingene
activity O
in O
cell O
lysates O
was O
measured O
24 O
h O
later O
. O

Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Protein O
expression O
of O
transfected O
plasmids O
was O
verified O
by O
western O
blot O
and O
is O
shown O
in O
the O
accompanying O
panels O
. O

(D) O
A20 B-proteingene
inhibits O
CARD14-induced B-proteingene
NF-kB B-proteingene
activation O
through O
its O
ZnF O
domains O
. O

HEK293T O
cells O
were O
transfected O
with O
NF-kB B-proteingene
reporter O
plasmid, O
FLAG-CARD14sh B-proteingene
(20ng) O
and O
wild-type O
(WT) O
or O
mutant O
A20 B-proteingene
expression O
plasmids O
(3ng) O
as O
indicated O
. O

Luciferase B-proteingene
activity O
in O
cell O
lysates O
was O
measured O
after O
24 O
h. O
CARD14 B-proteingene
and O
A20 B-proteingene
expression O
was O
measured O
by O
immunoblotting O
(bottom O
panel) O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

(A) O
CARD14(E138A) B-proteingene
induces O
cytokine O
and O
chemokine O
expression O
in O
human O
primary O
keratinocytes O
. O

Cells O
were O
transfected O
with O
empty O
vector O
(EV) O
or O
CARD14(E138A) B-proteingene
as O
indicated O
. O

24 O
h O
later, O
the O
secretion O
of O
36 O
different O
human O
cytokines, O
chemokines, O
and O
acute O
phase O
proteins O
was O
analyzed O
via O
a O
multiplex O
antibody O
array O
. O

Quantification O
was O
done O
using O
ImageJ O
software O
and O
is O
expressed O
as O
relative O
CARD14/EV B-proteingene
values O
for O
a O
selected O
number O
of O
proteins O
(bottom O
panel) O
. O

(B) O
MALT1 B-proteingene
deficiency O
inhibits O
CARD14(E138A)-induced B-proteingene
cytokine O
and O
chemokine O
expression O
in O
human O
primary O
keratinocytes O
. O

Cells O
were O
transfected O
with O
scrambled O
(scr) O
or O
MALT1-targeting B-proteingene
siRNA O
as O
indicated, O
48 O
h O
later O
followed O
by O
transfection O
with O
CARD14(E138A) B-proteingene
. O

After O
24 O
h, O
cytokine O
and O
chemokine O
expression O
was O
analyzed O
and O
is O
expressed O
as O
described O
in O
(A) O
. O

(C) O
Pathogenic O
CARD14 B-proteingene
mutation O
enhances O
MALT1-dependent B-proteingene
CARD14-induced B-proteingene
IL-8 B-proteingene
expression O
in O
human O
primary O
keratinocytes O
. O

Cells O
were O
transfected O
with O
scrambled O
(scr) O
or O
MALT1-targeting B-proteingene
siRNA O
as O
indicated, O
48 O
h O
later O
followed O
by O
transfection O
with O
CARD14 B-proteingene
wild-type O
(WT), O
CARD14(G117S) B-proteingene
or O
CARD14(E138A) B-proteingene
as O
indicated O
. O

TNF B-proteingene
treatment O
was O
used O
as O
a O
control O
. O

After O
24 O
h, O
IL-8 B-proteingene
concentration O
in O
the O
cell O
supernatant O
was O
analyzed O
via O
ELISA. O
Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Expression O
levels O
of O
MALT1 B-proteingene
and O
CARD14 B-proteingene
variants O
is O
verified O
by O
immunoblotting O
(bottom O
panel) O
. O

(D) O
Pharmacological O
inhibition O
of O
MALT1 B-proteingene
proteolytic O
activity O
inhibits O
CARD14-induced B-proteingene
IL-8 B-proteingene
production O
and O
A20 B-proteingene
processing O
in O
human O
primary O
keratinocytes O
. O

Cells O
were O
transfected O
with O
different O
CARD14 B-proteingene
variants O
in O
the O
presence O
or O
absence O
of O
mepazine O
as O
indicated O
. O

TNF B-proteingene
treatment O
was O
used O
as O
a O
control O
. O

24 O
h O
later, O
IL-8 B-proteingene
levels O
in O
the O
cell O
supernatant O
were O
measured O
by O
ELISA. O
Values O
are O
the O
mean O
of O
triplicates O
± O
s.e O
. O

Expression O
of O
different O
CARD14 B-proteingene
variants O
and O
CARD14-induced B-proteingene
processing O
of O
endogenous O
A20 B-proteingene
were O
analyzed O
by O
immunoblotting O
. O

Data O
are O
representative O
of O
two O
independent O
experiments O
. O

Significance O
levels, O
*P<0.05, O
**P<0.001, O
***P<0.001 O
by O
student O
t O
test O
. O

A) O
Representative O
nuclear O
spreads O
of O
wild-type O
pachytene O
and O
Rec8−/− B-proteingene
pachytene-like O
spermatocytes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
ACA. O
Magnified O
views O
are O
indicated O
by O
dashed O
areas O
. O

Schematic O
representation O
on O
magnified O
chromosomes O
represents O
tightly O
associated O
sister-AEs O
(separated O
for O
easier O
representation) O
in O
paired O
wild-type O
homologs, O
and O
the O
appearance O
of O
two O
distinguishable/separated O
sister-AEs O
once O
REC8-mediated B-proteingene
cohesion O
is O
lost O
in O
Rec8−/− B-proteingene
univalents O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

B) O
Representative O
nuclear O
spread O
of O
zygotene-like O
Stag3 B-proteingene
mutant O
spermatocytes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
ACA. O
Magnified O
views O
are O
indicated O
by O
dashed O
areas O
. O

Schematic O
representation O
on O
magnified O
univalents O
represents: O
separation O
of O
sister-AEs O
(centre) O
and O
close O
association O
of O
sister-AEs O
(right) O
. O

Bellow: O
graph O
showing O
the O
percentages O
of O
axes O
with: O
separation O
of O
AEs O
(dark O
grey O
area) O
and O
closely O
associated O
AEs O
(light O
grey O
area) O
. O

414 O
axes O
analysed, O
from O
11 O
nuclei O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

C) O
Magnified O
views O
of O
zygotene-like O
Stag3 B-proteingene
mutant O
univalents O
with O
LSAEs O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
ACA. O
Schematic O
representation O
indicates O
sites O
of O
LSAEs O
. O

Bellow: O
graph O
showing O
the O
percentages O
of O
axes O
with: O
LSAEs O
(red O
area), O
extensive O
separation O
of O
AEs O
(dark O
grey O
area) O
and O
closely O
associated O
AEs O
(light O
grey O
area) O
. O

414 O
axes O
analysed, O
from O
11 O
nuclei O
. O

Bars, O
1 O
μm O
. O

D) O
Representative O
nuclear O
spread O
of O
zygotene-like O
Smc1β−/− B-proteingene
spermatocytes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
ACA. O
Magnified O
views O
are O
indicated O
by O
dashed O
areas O
. O

Schematic O
representation O
on O
magnified O
univalents O
represents O
sites O
of O
LSAEs O
. O

Bellow: O
graph O
showing O
the O
percentages O
of O
axes O
with: O
LSAEs O
(red O
area), O
extensive O
separation O
of O
AEs O
(dark O
grey O
area) O
and O
closely O
associated O
AEs O
(light O
grey O
area) O
. O

404 O
axes O
analysed, O
from O
10 O
nuclei O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

E) O
STED O
images O
of O
representative O
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
displaying O
LSAEs O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
. O

Bars, O
1μm O
. O

F) O
Graph O
indicating O
the O
inter-axis O
distances O
measured O
in O
wild-type O
pachytene O
bivalents; O
pachytene-like O
Rec8−/− B-proteingene
and O
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
. O

Each O
measurement O
in O
wild-type O
and O
Rec8−/− B-proteingene
corresponds O
to O
the O
median O
of O
3 O
distances O
measured O
along O
one O
homolog O
(n=60) O
. O

Each O
measurement O
in O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
mutant O
axes O
correspond O
to O
1 O
distance O
measured O
at O
sites O
of O
local O
separation O
of O
AEs O
(n=40 O
and O
n=20, O
respectively) O
. O

Horizontal O
lines O
indicate O
median O
. O

G) O
Graph O
indicating O
the O
inter-axis O
distances O
measured O
at O
terminally O
and O
centrally O
located O
sites O
of O
LSAEs O
in O
zygotene-like O
Stag3 B-proteingene
mutant O
univalents O
. O

Each O
measurement O
corresponds O
to O
1 O
distance O
measured O
at O
terminally O
(n=20) O
and O
centrally O
(n=20) O
located O
sites O
of O
local O
separation O
of O
axial O
elements O
. O

Horizontal O
lines O
indicate O
median O
. O

A) O
Representative O
wild-type O
pachytene O
bivalents; O
pachytene-like O
Rec8−/−, B-proteingene
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP1, B-proteingene
SYCP3 B-proteingene
and O
ACA. O
Filled O
arrowheads O
indicate O
sites O
of O
LSAEs O
with O
detectable O
SYCP1 B-proteingene
. O

Bars, O
1 O
μm O
. O

Bellow: O
graphs O
showing O
the O
percentages O
of O
sites O
of O
LSAEs O
with O
detectable O
SC O
assembly O
along O
sister-AEs O
of O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
(n=120 O
and O
n=68, O
respectively) O
. O

B) O
Representative O
zygotene-like O
Stag3 B-proteingene
mutant O
univalents O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3, B-proteingene
ACA O
and: O
SYCE1, B-proteingene
SYCE2 B-proteingene
and O
TEX12 B-proteingene
. O

Filled O
arrowheads O
indicate O
SC O
assembly O
between O
sites O
of O
LSAEs O
. O

Bars, O
1 O
μm O

C) O
Quantification O
of O
signal O
distribution O
within O
sites O
of O
LSAEs, O
in O
Stag3 B-proteingene
mutant O
spermatocytes O
. O

Signal O
distribution O
measured O
for O
SYCP3 B-proteingene
and: O
SYCP1, B-proteingene
SYCE1, B-proteingene
SYCE2 B-proteingene
and O
TEX12 B-proteingene
. O

Empty O
arrowheads O
indicate O
signal O
intensity O
peaks O
that O
correspond O
to O
each O
of O
the O
two O
sister-chromatid O
axes, O
filled O
arrowheads O
indicate O
SYCP1 B-proteingene
peaks O
. O

A) O
Representative O
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3, B-proteingene
SYCE1 B-proteingene
and O
REC8 B-proteingene
. O

Bellow: O
graph O
showing O
the O
percentages O
of O
Stag3 B-proteingene
mutant O
axes O
with O
sites O
of O
LSAEs O
with O
and O
without O
flanking O
REC8 B-proteingene
foci O
. O

78 O
axes O
with O
LSAEs O
were O
analysed O
. O

Bars, O
1 O
μm O
. O

B) O
Representative O
pachytene-like O
Rec8−/−, B-proteingene
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3, B-proteingene
SYCE1 B-proteingene
and O
RAD21L. B-proteingene
Bars, O
1 O
μm O
. O

C) O
Representative O
zygotene-like O
Stag3 B-proteingene
mutant O
and O
Smc1β−/− B-proteingene
univalents O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3, B-proteingene
SYCE1 B-proteingene
and O
RAD21 B-proteingene
. O

Bars, O
1 O
μm O
. O

A) O
Representative O
wild-type O
pachytene O
sex O
chromosomes O
. O

Nuclear O
spreads O
of O
pachytene O
spermatocytes O
were O
immunostained O
for O
SYCP3 B-proteingene
. O

Filled O
arrowheads O
indicate O
the O
PAR. O
Dashed O
area O
indicated O
in O
centre O
panel O
corresponds O
to O
the O
magnified O
view O
on O
the O
right O
panel O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

B) O
Graph O
indicating O
the O
inter-axis O
distances O
measured O
at O
sites O
of O
local O
separation O
of O
axial O
elements O
in O
zygotene-like O
Stag3 B-proteingene
mutant O
univalents O
and O
along O
pachytene O
wild-type O
X-chromosomes O
. O

Each O
measurement O
in O
the O
X-chromosomes O
corresponds O
to O
the O
median O
of O
3 O
distances O
(according O
to O
the O
scheme O
in O
figure) O
(n=54) O
. O

Each O
measurement O
in O
Stag3 B-proteingene
mutant O
corresponds O
to O
1 O
distance O
measured O
at O
sites O
with O
local O
separation O
of O
axial O
elements O
(n=40) O
. O

Horizontal O
lines O
indicate O
median O
. O

p O
< O
0.0001, O
obtained O
with O
two-tailed O
Mann-Whitney O
test O
. O

Bellow: O
schematic O
representation O
of O
the O
XY O
pair: O
sister-AEs O
are O
coloured O
in O
black O
and O
grey O
for O
easier O
visualization O
. O

Filled O
arrowhead O
indicates O
PAR. O
Purple O
bars O
in O
scheme O
indicate O
regions O
where O
inter-axis O
distances O
are O
measured O
. O

C) O
Representative O
pachytene O
wild-type O
sex O
chromosomes O
. O

Nuclear O
spreads O
of O
pachytene O
spermatocytes O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
SYCE2 B-proteingene
. O

Dashed O
area O
indicated O
in O
centre O
panel O
corresponds O
to O
the O
magnified O
view O
on O
the O
right O
panel O
. O

Empty O
arrowhead O
indicates O
two O
discernable O
sister-AEs O
without O
SYCE2 B-proteingene
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

A) O
Analysis O
of O
REC8 B-proteingene
distribution O
in O
representative O
pachytene O
wild-type O
sex B-proteingene
chromosomes I-proteingene
. O

Nuclear O
spreads O
of O
pachytene O
spermatocytes O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
REC8 B-proteingene
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

Magnified O
XY O
pair O
is O
indicated O
by O
dashed O
area O
. O

Scatterplot O
showing O
the O
number O
of O
REC8 B-proteingene
foci O
per O
X-chromosome O
. O

225 O
foci O
identified O
in O
14 O
X-chromosomes B-proteingene
. O

Horizontal O
line O
indicates O
the O
mean, O
error O
bars O
indicate O
s.d O
. O

3.02 O
. O

B) O
Top: O
representative O
computationally O
straightened O
pachytene O
wild-type O
X-chromosomes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
REC8 B-proteingene
. O

Chromosomes O
were O
aligned O
at O
the O
PAR, O
and O
subdivided O
into O
25 O
regular O
intervals O
. O

Bar, O
1 O
μm O
. O

Bellow: O
histogram O
showing O
the O
distribution O
of O
the O
percentages O
of O
REC8 B-proteingene
foci O
(n=225) O
among O
25 O
regular O
intervals O
along O
14 O
X-chromosomes B-proteingene
. O

Dotted O
line O
indicates O
mean O
. O

C) O
Histogram O
showing O
the O
relative O
frequency O
of O
inter-REC8 B-proteingene
distances O
along O
X-chromosomes O
. O

211 O
inter-REC8 B-proteingene
distances O
from O
14 O
X-chromosomes O
. O

Grey O
area O
represents O
15% O
of O
the O
chromosome O
axis O
length O
. O

The O
respective O
cumulative O
distribution O
function O
is O
shown O
. O

D) O
Histogram O
showing O
the O
best O
fit O
of O
the O
observed O
inter-REC8 B-proteingene
distances O
to O
the O
gamma O
distribution O
. O

Green O
curve O
indicates O
the O
best O
fit O
of O
the O
observed O
inter-REC8 B-proteingene
distances O
. O

 O
indicates O
the O
value O
for O
which O
the O
best O
fit O
was O
obtained, O
with O
estimated O
standard O
error O
0.27 O
. O

E) O
Graph O
comparing O
the O
median O
distance O
of O
REC8 B-proteingene
foci O
with O
computationally O
predicted O
even O
and O
random O
distributions O
. O

Median O
distances O
between O
foci O
subdivided O
in O
three O
categories O
(11-14, O
15-18 O
and O
19-22 O
REC8 B-proteingene
foci O
per O
chromosome) O
. O

Purple O
asterisk O
indicates O
the O
median O
distance O
of O
all O
REC8 B-proteingene
foci O
. O

F) O
Scatterplot O
comparing O
inter-REC8 B-proteingene
distances O
along O
on O
X-chromosomes B-proteingene
with O
the O
distances O
between O
flanking O
REC8 B-proteingene
foci O
at O
sites O
of O
LSAEs O
in O
the O
Stag3 B-proteingene
mutant O
. O

211 O
inter-REC8 B-proteingene
distances O
measured O
along O
X-chromosomes B-proteingene
and O
10 O
distances O
measured O
between O
flanking O
REC8 B-proteingene
foci O
in O
Stag3 B-proteingene
mutant O
. O

Grey O
area O
represents O
15% O
of O
the O
chromosome O
axis O
length O
. O

Horizontal O
lines O
indicate O
the O
median O
. O

p O
< O
0.0001, O
obtained O
with O
two-tailed O
Mann-Whitney O
test O
. O

A) O
Representative O
yet-unsynapsed O
autosome O
from O
wild-type O
zygotene O
spermatocytes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3 B-proteingene
and O
SYCE2 B-proteingene
. O

Magnified O
autosome O
is O
indicated O
by O
dashed O
area O
. O

Filled O
arrowheads O
indicate O
yet-unsynapsed O
axes O
regions O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O

B) O
Representative O
unsynapsed O
autosome O
from O
wild-type O
zygotene O
spermatocytes O
. O

Nuclear O
spreads O
were O
immunostained O
for O
SYCP3, B-proteingene
REC8 B-proteingene
and O
ACA. O
Magnified O
autosome O
is O
indicated O
by O
dashed O
area O
. O

Bars, O
10 O
μm O
in O
spreads O
and O
1 O
μm O
on O
insets O
. O

C) O
Scatterplot O
comparing O
the O
average O
number O
of O
REC8 B-proteingene
foci O
along O
zygotene O
autosomes O
and O
X-chromosomes O
. O

Number O
of O
REC8 B-proteingene
foci O
were O
quantified O
along O
15 O
zygotene O
autosomes O
and O
14 O
X-chromosomes B-proteingene
. O

Each O
dot O
represents O
the O
number O
of O
REC8 B-proteingene
foci O
on O
each O
chromosome O
. O

Total O
number O
of O
foci O
identified: O
zygotene O
autosomes O
(343), O
X-chromosomes O
(225) O
. O

Horizontal O
lines O
indicate O
the O
mean, O
error O
bars O
indicate O
s.d O
. O

: O
7.42 O
and O
3.02 O
for O
zygotene O
autosomes O
and O
X-chromosomes, O
respectively O
. O

p O
= O
0.0060, O
obtained O
with O
two-tailed O
Mann-Whitney O
test O
. O

D) O
Histogram O
showing O
the O
relative O
frequency O
of O
inter-REC8 B-proteingene
distances O
along O
yet-unsynapsed O
zygotene O
autosomes O
. O

294 O
inter-REC8 B-proteingene
distances O
analyzed O
in O
14 O
chromosomes O
. O

Grey O
area O
represents O
15% O
of O
the O
chromosome O
axis O
length O
. O

The O
respective O
cumulative O
distribution O
function O
is O
shown O
. O

E) O
Scatterplot O
comparing O
the O
measured O
inter-REC8 B-proteingene
distances O
on O
yet-unsynapsed O
zygotene O
autosomes, O
X-chromosomes O
and O
sites O
of O
LSAEs O
in O
Stag3 B-proteingene
mutant O
. O

Number O
of O
inter-REC8 B-proteingene
distances O
for O
yet-unsynapsed O
zygotene O
autosomes, O
X-chromosomes O
and O
sites O
of O
local O
separation O
of O
axial O
elements O
in O
Stag3 B-proteingene
mutant, O
n=294, O
n=211 O
and O
n=10, O
respectively O
. O

Horizontal O
lines O
indicate O
the O
median O
. O

p O
< O
0.0001, O
obtained O
with O
two-tailed O
Mann-Whitney O
test O
. O

(A) O
Exomer O
components O
localize O
to O
different O
extent O
to O
the O
TGN O
and O
to O
the O
cytoplasm O
. O

Fluorescence O
images O
of O
cells O
expressing O
GFP-tagged B-proteingene
exomer O
components O
and O
TGN O
marker O
Sec7-DsRed B-proteingene
. O

The O
brightness O
and O
contrast O
were O
adjusted O
differently O
in O
the O
GFP B-proteingene
and O
merge O
images O
. O

Bar, O
5 O
µm O
. O

(B) O
Quantification O
of O
the O
relative O
TGN O
to O
cytoplasm O
concentration O
of O
the O
GFP-tagged B-proteingene
ChAPs O
in O
the O
cell O
. O

The O
mean O
fluorescence O
at O
the O
TGN O
and O
cytoplasm O
was O
determined O
using O
the O
Icy O
imaging O
software O
. O

20-30 O
individual O
cells O
were O
analysed O
. O

For O
statistical O
significance O
testing O
the O
Student O
's O
T O
test O
was O
used O
. O

(C) O
FCS O
measures O
the O
in O
vivo O
mobility O
of O
exomer O
components O
in O
the O
cytoplasm O
. O

FCS O
analysis O
was O
performed O
on O
the O
GFP, B-proteingene
Chs5-GFP B-proteingene
and O
GFP-tagged B-proteingene
ChAPs O
in O
the O
wild-type O
background O
(top) O
and O
on O
GFP-tagged B-proteingene
ChAPs O
in O
the O
Δchs5 B-proteingene
background O
(bottom) O
. O

10-20 O
FCS O
measurements O
were O
performed O
for O
each O
condition O
using O
different O
cells O
. O

The O
ACF O
of O
free O
GFP B-proteingene
is O
fitted O
with O
a O
one-component O
anomalous O
diffusion O
model O
. O

The O
ACF O
of O
Chs5 B-proteingene
in O
WT O
and O
ChAPs O
in O
WT O
and O
Δchs5 B-proteingene
background O
is O
fitted O
with O
a O
two-component O
diffusion O
model O
. O

Representative O
ACF O
curves O
(thin O
full O
lines) O
and O
fits O
(thick O
dashed O
lines) O
are O
shown O
. O

Estimated O
diffusion O
correlation O
times, O
diffusion O
coefficients O
and O
fractions O
are O
shown O
in O
Table O
1 O
. O

(D) O
Quantification O
of O
the O
Chs5 B-proteingene
independent O
fraction O
of O
ChAPs O
present O
in O
the O
cytoplasm O
based O
on O
the O
measurements O
shown O
in O
(C) O
. O

(E) O
Comparison O
of O
the O
residuals O
of O
the O
one-component O
and O
two-component O
fit O
(arrows) O
. O

(A) O
Comparison O
of O
the O
dynamic O
behavior O
of O
the O
GFP-tagged B-proteingene
Chs5 B-proteingene
and O
Bch1 B-proteingene
with O
the O
GFP-tagged B-proteingene
Sec28, B-proteingene
Cop1, B-proteingene
Clc1 B-proteingene
and O
Apm1 B-proteingene
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

(B) O
Binding O
kinetics O
of O
the O
GFP-tagged B-proteingene
Chs5 B-proteingene
and O
ChAPs O
at O
the O
TGN O
is O
different O
. O

Data O
processing O
was O
carried O
out O
as O
in O
(A) O
. O

(C) O
Quantification O
of O
the O
relative O
expression O
levels O
of O
the O
exomer O
components O
in O
GFP-tagged B-proteingene
strains O
. O

A O
representative O
immunoblot O
of O
yeast O
lysates O
is O
shown; O
Pgk1 B-proteingene
serves O
as O
loading O
control O
. O

The O
asterisks O
depict O
the O
analyzed O
bands O
. O

The O
plot O
shows O
average O
and O
SD O
of O
three O
independent O
biological O
experiments O
. O

The O
relative O
expression O
levels O
are O
normalized O
to O
Chs6 B-proteingene
(depicted O
by O
the O
red O
line) O
. O

(A) O
Chs5 B-proteingene
is O
necessary O
for O
recruitment O
and O
stable O
binding O
of O
ChAPs O
at O
the O
TGN. O
Differential O
centrifugation O
of O
cell O
lysates O
obtained O
from O
Chs6-GFP B-proteingene
WT O
and O
Δchs5 B-proteingene
strain O
. O

TCL, O
total O
cell O
lysate; O
S10, O
10,000 O
g O
supernatant; O
P10, O
10,000 O
g O
pellet; O
S100, O
100,000 O
g O
supernatant; O
P100, O
100,000 O
g O
pellet O
. O

Anp1 B-proteingene
serves O
as O
the O
Golgi O
marker O
and O
Pgk1 B-proteingene
as O
the O
cytoplasm O
marker O
. O

A O
representative O
immunoblot O
of O
three O
independent O
biological O
experiments O
is O
shown O
. O

(B) O
Diffusional O
behavior O
of O
GFP-tagged B-proteingene
ChAPs O
in O
the O
cytoplasm O
(open O
triangles, O
dashed O
line) O
and O
at O
the O
TGN O
(closed O
circles, O
full O
line) O
. O

The O
mean O
of O
10-20 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
diffusion O
coefficients O
are O
shown O
in O
Expanded O
View O
Table O
1 O
. O

(C) O
Chs5-GFP B-proteingene
displays O
reduced O
membrane O
association O
in O
the O
absence O
of O
ChAPs O
. O

Differential O
centrifugation O
of O
cell O
lysates O
obtained O
from O
Chs5GFP B-proteingene
WT O
and O
ΔΔΔΔ O
strains O
. O

TCL, O
total O
cell O
lysate; O
S10, O
10,000 O
g O
supernatant; O
P10, O
10,000 O
g O
pellet; O
S100, O
100,000 O
g O
supernatant; O
P100, O
100,000 O
g O
pellet O
. O

Anp1 B-proteingene
serves O
as O
the O
Golgi O
marker O
and O
Pgk1 B-proteingene
as O
the O
cytoplasm O
marker O
. O

A O
representative O
immunoblot O
of O
three O
independent O
biological O
experiments O
is O
shown O
. O

(D) O
Fluorescence O
images O
of O
cells O
expressing O
Chs5-GFP B-proteingene
and O
TGN O
marker O
Sec7-DsRed B-proteingene
in O
WT, O
ChAP O
and O
strains O
. O

Merged O
images O
depict O
the O
differences O
in O
Chs5-GFP B-proteingene
localization O
to O
the O
TGN, O
cytoplasm O
and O
distinct O
foci O
(arrows) O
in O
these O
strains O
. O

The O
brightness O
and O
contrast O
were O
adjusted O
differently O
in O
the O
merged O
images O
. O

Bar, O
5 O
µm O
. O

(E) O
Co-localization O
analysis O
of O
Chs5-GFP B-proteingene
and O
TGN O
marker O
Sec7-DsRed B-proteingene
in O
WT, O
ChAP O
and O
strains O
. O

Mander O
1 O
depicts O
the O
relative O
amount O
of O
the O
GFP B-proteingene
signal O
co-localizing O
with O
the O
overall O
DsRed B-proteingene
signal, O
and O
Mander O
2 O
vice O
versa O
. O

Manders O
coefficients O
were O
obtained O
using O
the O
JACoP O
plug-in O
for O
ImageJ O
after O
background O
subtraction O
(N O
= O
20) O
and O
are O
given O
in O
Expanded O
View O
Table O
2 O
. O

(F) O
Binding O
kinetics O
of O
Chs5-GFP B-proteingene
at O
the O
TGN O
in O
WT, O
ChAP O
and O
strains O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

The O
schematic O
cartoons O
depict O
the O
predicted O
majority O
of O
the O
analyzed O
complexes O
. O

The O
violet O
ovals O
represent O
Chs5 B-proteingene
dimer O
and O
circles O
represent O
ChAPs: O
green:Bch1, B-proteingene
red:Bud7, B-proteingene
dark O
blue:Bch2, B-proteingene
light O
blue:Chs6 B-proteingene
. O

(A-B) O
Overexpression O
of O
Bch2 B-proteingene
in O
absence O
of O
other O
ChAPs O
results O
in O
more O
efficient O
Chs5 B-proteingene
recruitment O
and O
stabilization O
at O
the O
TGN. O
Fluorescence O
images O
of O
cells O
expressing O
Chs5-GFP B-proteingene
(A) O
and O
binding O
kinetics O
of O
Chs5-GFP B-proteingene
at O
the O
TGN O
(B) O
in O
WT, O
BCH2 B-proteingene
and O
GPD-BCH2 B-proteingene
strains O
. O

Bar, O
5 O
µm O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

The O
schematic O
cartoons O
depict O
the O
predicted O
majority O
of O
the O
analyzed O
complexes; O
Chs5 B-proteingene
dimer:violet O
ovals, O
Bch2:dark B-proteingene
blue O
circles O
. O

(C-D) O
Overexpression O
of O
Chs6 B-proteingene
in O
absence O
of O
other O
ChAPs O
results O
in O
more O
efficient O
Chs5 B-proteingene
recruitment O
and O
stabilization O
at O
the O
TGN O
. O

(C) O
Fluorescence O
images O
of O
cells O
expressing O
Chs5-GFP B-proteingene
in O
WT, O
CHS6 B-proteingene
and O
GPD-CHS6 B-proteingene
strains O
. O

Bar, O
5 O
µm O
. O

(D) O
Binding O
kinetics O
of O
Chs5-GFP B-proteingene
at O
the O
TGN O
in O
WT, O
, O
CHS6 B-proteingene
and O
GPD-CHS6 B-proteingene
strains O
. O

Data O
processing O
was O
carried O
out O
as O
in O
(A-B) O
. O

The O
schematic O
cartoons O
depict O
the O
predicted O
majority O
of O
the O
analyzed O
complexes; O
Chs5 B-proteingene
dimer: O
violet O
ovals, O
Chs6: B-proteingene
light O
blue O
circles O
. O

(E-G) O
Overexpression O
of O
Chs6 B-proteingene
rescues O
Chs3 B-proteingene
export O
in O
absence O
of O
other O
ChAPs O
. O

(E) O
Fluorescence O
images O
of O
cells O
expressing O
Chs3-GFP B-proteingene
in O
WT, O
CHS6 B-proteingene
and O
GPD-CHS6 B-proteingene
strains O
. O

Arrows O
point O
to O
Chs3-GFP B-proteingene
signals O
at O
the O
bud O
neck O
. O

Bar, O
5 O
µm O
. O

The O
inset O
represents O
a O
twofold O
magnification O
. O

(F) O
Quantification O
of O
phenotypes O
in O
(E); O
100 O
small O
budded O
and O
100 O
large O
budded O
cells O
were O
quantified O
per O
experiment O
. O

Average O
and O
SD O
of O
three O
independent O
biological O
experiments O
is O
shown O
. O

(G) O
Chs3GFPGPD-CHS6 B-proteingene
strain O
was O
sensitive O
to O
calcofluor O
to O
a O
similar O
extent O
as O
the O
WT O
strain O
. O

Plates O
were O
incubated O
at O
30°C O
for O
2-3 O
days O
. O

A O
representative O
drop O
test O
of O
three O
independent O
biological O
experiments O
is O
shown O
. O

Fluorescence O
images O
of O
cells O
expressing O
Chs5-GFP B-proteingene
and O
TGN O
marker O
Sec7DsRed B-proteingene
(A) O
and O
binding O
kinetics O
of O
Chs5-GFP B-proteingene
at O
the O
TGN O
(B) O
in O
WT, O
CHS6 B-proteingene
and O
CHS6BUD7 B-proteingene
(A, O
B) O
The O
brightness O
and O
contrast O
were O
adjusted O
differently O
in O
the O
merged O
images O
. O

Bar, O
5 O
µm O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

Fluorescence O
images O
of O
cells O
expressing O
Chs5-GFP B-proteingene
and O
TGN O
marker O
Sec7DsRed B-proteingene
(C) O
and O
binding O
kinetics O
of O
Chs5-GFP B-proteingene
at O
the O
TGN O
(D) O
in O
WT, O
or O
CHS6BCH2 B-proteingene
(C, O
D) O
strains O
. O

The O
brightness O
and O
contrast O
were O
adjusted O
differently O
in O
the O
merged O
images O
. O

Bar, O
5 O
µm O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

(A-D) O
ChAPs O
are O
differently O
dependent O
on O
each O
other O
in O
terms O
of O
binding O
at O
the O
TGN. O
Binding O
kinetics O
of O
GFP-tagged B-proteingene
Chs6 B-proteingene
(A), O
Bud7 B-proteingene
(B), O
Bch2 B-proteingene
(C) O
and O
Bch1 B-proteingene
(D) O
at O
the O
TGN O
in O
the O
presence O
(WT) O
or O
absence O
of O
the O
other O
ChAPs O
() O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

(A-B) O
Overexpression O
of O
Bch1 B-proteingene
displaces O
Chs6 B-proteingene
from O
the O
TGN O
and O
impairs O
plasma O
membrane O
localization O
of O
Chs6-dependent B-proteingene
cargo O
Chs3 B-proteingene
. O

Fluorescence O
images O
of O
Chs6-GFP B-proteingene
(A) O
and O
Chs3-GFP B-proteingene
(B) O
in O
WT O
and O
GPD-BCH1 B-proteingene
strains O
. O

Bar, O
5 O
µm O
. O

Arrows O
point O
to O
Chs3-GFP B-proteingene
signals O
at O
the O
bud O
neck O
. O

The O
inset O
represents O
a O
twofold O
magnification O
. O

(D) O
Chitin O
production O
is O
reduced O
upon O
Bch1 B-proteingene
overexpression O
. O

Fluorescence O
images O
of O
chitin O
stained O
with O
calcofluor O
in O
Chs3-GFP B-proteingene
WT, O
chs5 B-proteingene
and O
GPD-BCH1 B-proteingene
strains O
. O

(E) O
Overexpression O
of O
Bch1 B-proteingene
does O
not O
impair O
plasma O
membrane O
localization O
of O
the O
Bch1-dependent B-proteingene
cargo O
Pin2 B-proteingene
. O

Fluorescence O
images O
of O
Pin2-GFP B-proteingene
in O
WT O
and O
GPD-BCH1 B-proteingene
strains O
. O

(F-I) O
Overexpression O
of O
Chs6 B-proteingene
displaces O
Bch1 B-proteingene
and O
Chs5 B-proteingene
from O
the O
TGN. O
Fluorescence O
images O
(F-G) O
and O
binding O
kinetics O
at O
the O
TGN O
(H-I) O
of O
cells O
expressing O
Bch1-GFP B-proteingene
(F, O
H) O
and O
Chs5-GFP B-proteingene
(G, O
I) O
upon O
overexpression O
of O
Chs6 B-proteingene
under O
GPD O
promoter O
from O
2μ O
plasmid O
. O

The O
insets O
in O
(F, O
G) O
represent O
two-fold O
magnifications O
. O

The O
arrows O
in O
(F) O
point O
to O
residual O
Bch1 B-proteingene
staining O
at O
the O
TGN. O
The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

Size O
bars O
represent O
5 O
µm O
. O

(A) O
Overexpression O
of O
Pin2 B-proteingene
enhances O
Chs5 B-proteingene
stabilization O
at O
the O
TGN. O
Binding O
kinetics O
of O
Chs5GFP B-proteingene
in O
WT, O
bud7bch1 B-proteingene
and O
bud7bch1 B-proteingene
strain O
expressing O
Bch2-dependent O
cargo O
Pin2 B-proteingene
from O
a O
centromeric O
or O
a O
2μ O
plasmid O
. O

The O
mean O
of O
20-30 O
FRAP O
measurements O
from O
different O
cells O
is O
shown O
. O

Calculated O
parameters O
are O
shown O
in O
Table O
2 O
. O

(B) O
Comparison O
of O
the O
expression O
levels O
of O
the O
endogenous O
Pin2 B-proteingene
with O
the O
levels O
of O
Pin2 B-proteingene
expressed O
from O
a O
centromeric O
or O
a O
2μ O
plasmid O
. O

Pgk1 B-proteingene
serves O
as O
loading O
control O
. O

A O
representative O
immunoblot O
of O
three O
independent O
biological O
experiments O
is O
shown O
. O
